22	22	NUM	CD	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
oxacalcitriol	oxacalcitriol	NOUN	NNS	9	I-Chemical
suppresses	suppress	VERB	VBZ	3	O
secondary	secondary	ADJ	JJ	9	B-Disease
hyperparathyroidism	hyperparathyroidism	NOUN	NN	5	I-Disease
without	without	ADP	IN	9	O
inducing	induce	VERB	VBG	3	O
low	low	ADJ	JJ	9	B-Disease
bone	bone	NOUN	NN	5	I-Disease
turnover	turnover	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Calcitriol	Calcitriol	PROPN	NNP	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
suppresses	suppress	VERB	VBZ	3	O
serum	serum	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
parathyroid	parathyroid	ADJ	JJ	9	O
hormone	hormone	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PTH	PTH	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
but	but	CCONJ	CC	9	O
has	have	VERB	VBZ	9	O
several	several	ADJ	JJ	9	O
drawbacks	drawback	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
marked	mark	VERB	VBN	9	O
suppression	suppression	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
bone	bone	NOUN	NN	5	I-Disease
turnover	turnover	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
adynamic	adynamic	ADJ	JJ	5	B-Disease
bone	bone	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
new	new	ADJ	JJ	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	NOUN	NN	9	I-Chemical
analogue	analogue	NOUN	NN	0	O
,	,	PUNCT	,	9	O
22	22	NUM	CD	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
oxacalcitriol	oxacalcitriol	NOUN	NNS	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
OCT	OCT	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
promising	promising	ADJ	JJ	5	O
characteristics	characteristic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
OCT	OCT	PROPN	NNP	5	B-Chemical
on	on	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
PTH	PTH	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
bone	bone	NOUN	NN	5	O
turnover	turnover	NOUN	NN	9	O
in	in	ADP	IN	5	O
states	state	NOUN	NNS	5	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Sixty	sixty	NUM	CD	5	O
dogs	dog	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
nephrectomized	nephrectomized	ADJ	JJ	0	O
(	(	PUNCT	-LRB-	9	O
Nx	Nx	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
N	N	PROPN	NNP	9	O
=	=	SYM	SYM	7	O
38	38	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
sham	sham	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
operated	operate	VERB	VBN	5	O
(	(	PUNCT	-LRB-	9	O
Sham	Sham	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
N	N	PROPN	NNP	9	O
=	=	SYM	SYM	7	O
22	22	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
supplemental	supplemental	ADJ	JJ	9	O
phosphate	phosphate	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
enhance	enhance	VERB	VB	9	O
PTH	PTH	PROPN	NNP	9	O
secretion	secretion	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Fourteen	fourteen	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
phosphate	phosphate	NOUN	NN	0	B-Chemical
supplementation	supplementation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
half	half	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Nx	Nx	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
Sham	Sham	PROPN	NNP	9	O
dogs	dog	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
OCT	OCT	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
per	per	ADP	IN	9	O
week	week	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
half	half	NOUN	NN	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
vehicle	vehicle	NOUN	NN	3	O
for	for	ADP	IN	5	O
60	60	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Thereafter	thereafter	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
modalities	modality	NOUN	NNS	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
subset	subset	NOUN	NN	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
crossed	cross	VERB	VBN	9	O
over	over	PART	RP	5	O
for	for	ADP	IN	5	O
an	an	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
eight	eight	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Biochemical	biochemical	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
hormonal	hormonal	ADJ	JJ	9	O
indices	index	NOUN	NNS	5	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
bone	bone	NOUN	NN	5	O
metabolism	metabolism	NOUN	NN	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
bone	bone	NOUN	NN	5	O
biopsies	biopsy	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
OCT	OCT	PROPN	NNP	5	B-Chemical
or	or	CCONJ	CC	5	O
vehicle	vehicle	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
crossover	crossover	NOUN	NN	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
Nx	Nx	PROPN	NNP	0	O
dogs	dog	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
OCT	OCT	PROPN	NNP	5	B-Chemical
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
serum	serum	ADJ	JJ	9	O
PTH	PTH	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
soon	soon	ADV	RB	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
standing	stand	VERB	VBG	5	O
secondary	secondary	ADJ	JJ	9	B-Disease
hyperparathyroidism	hyperparathyroidism	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
OCT	OCT	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
stabilized	stabilize	VERB	VBD	9	O
serum	serum	NOUN	NN	9	O
PTH	PTH	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Serum	Serum	PROPN	NNP	9	O
PTH	PTH	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
rose	rise	VERB	VBD	9	O
thereafter	thereafter	ADV	RB	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
rise	rise	NOUN	NN	9	O
was	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
pronounced	pronounce	VERB	VBN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
rise	rise	NOUN	NN	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
Nx	Nx	PROPN	NNP	0	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hyperphosphatemia	hyperphosphatemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
animals	animal	NOUN	NNS	9	O
with	with	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
OCT	OCT	PROPN	NNP	5	B-Chemical
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
transient	transient	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
PTH	PTH	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
sustained	sustain	VERB	VBN	5	O
with	with	ADP	IN	5	O
lowering	lower	VERB	VBG	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
Nx	Nx	PROPN	NNP	0	O
dogs	dog	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
OCT	OCT	PROPN	NNP	5	B-Chemical
reversed	reverse	VERB	VBD	9	O
abnormal	abnormal	ADJ	JJ	9	O
bone	bone	NOUN	NN	5	O
formation	formation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
woven	weave	VERB	VBN	5	B-Disease
osteoid	osteoid	VERB	VB	5	I-Disease
and	and	CCONJ	CC	5	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
alter	alter	VERB	VB	9	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
bone	bone	NOUN	NN	5	O
turnover	turnover	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
OCT	OCT	PROPN	NNP	5	B-Chemical
improved	improve	VERB	VBD	5	O
mineralization	mineralization	NOUN	NN	9	O
lag	lag	NOUN	NN	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
that	that	ADV	RB	5	O
is	is	ADV	RB	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
at	at	ADP	IN	9	O
which	which	DET	WDT	5	O
osteoid	osteoid	NOUN	NN	5	O
mineralizes	mineralize	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
Nx	Nx	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
Sham	Sham	PROPN	NNP	9	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
even	even	ADV	RB	5	O
though	though	ADP	IN	9	O
OCT	OCT	PROPN	NNP	5	B-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
completely	completely	ADV	RB	9	O
prevent	prevent	VERB	VB	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
secondary	secondary	ADJ	JJ	9	B-Disease
hyperparathyroidism	hyperparathyroidism	NOUN	NN	5	I-Disease
because	because	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
induce	induce	VERB	VB	3	O
low	low	ADJ	JJ	9	B-Disease
bone	bone	NOUN	NN	5	I-Disease
turnover	turnover	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
therefore	therefore	ADV	RB	5	O
,	,	PUNCT	,	9	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
adynamic	adynamic	ADJ	JJ	5	B-Disease
bone	bone	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Hypotension	Hypotension	PROPN	NNP	7	B-Disease
,	,	PUNCT	,	9	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
asystole	asystole	ADV	RB	5	B-Disease
after	after	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
intravenous	intravenous	ADJ	JJ	0	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
monitored	monitor	VERB	VBN	9	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
asystole	asystole	ADV	RB	5	B-Disease
after	after	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
73	73	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
electrocardiographic	electrocardiographic	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
ECG	ECG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
monitoring	monitor	VERB	VBG	5	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
episode	episode	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
cardiac	cardiac	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
9	9	NUM	CD	7	O
years	year	NOUN	NNS	5	O
earlier	earlier	ADV	RBR	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
renal	renal	NOUN	NN	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
hemoptysis	hemoptysis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
rapidly	rapidly	ADV	RB	9	O
progressive	progressive	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hypoxemia	hypoxemia	NOUN	NN	5	B-Disease
that	that	DET	WDT	5	O
required	require	VERB	VBD	9	O
mechanical	mechanical	ADJ	JJ	5	O
ventilation	ventilation	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
intensive	intensive	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
unit	unit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
advanced	advanced	ADJ	JJ	5	O
cardiopulmonary	cardiopulmonary	ADJ	JJ	5	O
resuscitation	resuscitation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
recovered	recover	VERB	VBD	9	O
cardiac	cardiac	ADJ	JJ	5	O
rhythm	rhythm	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ECG	ECG	PROPN	NNP	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
junctional	junctional	ADJ	JJ	9	O
rhythm	rhythm	NOUN	NN	5	O
without	without	ADP	IN	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmia	arrhythmia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
reviews	review	VERB	VBZ	5	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
proposed	propose	VERB	VBN	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sudden	sudden	ADJ	JJ	5	B-Disease
death	death	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
IVMP	IVMP	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
well	well	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
because	because	ADP	IN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
monitored	monitor	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
moment	moment	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
event	event	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Rapid	rapid	ADJ	JJ	9	O
infusion	infusion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
underlying	underlie	VERB	VBG	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
important	important	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
reported	report	VERB	VBN	9	O
here	here	ADV	RB	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
discount	discount	VERB	VBP	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmia	arrhythmia	NOUN	NN	5	I-Disease
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Worsening	worsen	VERB	VBG	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
by	by	ADP	IN	9	O
motor	motor	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mental	mental	ADJ	JJ	5	O
tasks	task	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ten	ten	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
disabling	disable	VERB	VBG	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
mental	mental	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
mental	mental	ADJ	JJ	5	O
calculation	calculation	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
motor	motor	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
flexion	flexion	NOUN	NN	5	O
/	/	SYM	SYM	9	O
extension	extension	NOUN	NN	9	O
of	of	ADP	IN	5	O
right	right	ADJ	JJ	5	O
fingers	finger	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
flexion	flexion	NOUN	NN	5	O
/	/	SYM	SYM	9	O
extension	extension	NOUN	NN	9	O
of	of	ADP	IN	5	O
left	left	ADJ	JJ	5	O
fingers	finger	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
flexion	flexion	NOUN	NN	5	O
/	/	SYM	SYM	9	O
extension	extension	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
neck	neck	NOUN	NN	5	O
,	,	PUNCT	,	9	O
speaking	speak	VERB	VBG	5	O
aloud	aloud	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
tasks	task	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
worsening	worsening	NOUN	NN	5	O
of	of	ADP	IN	5	O
peak	peak	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
score	score	NOUN	NN	5	O
at	at	ADP	IN	9	O
rest	rest	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
aggravation	aggravation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dyskinesia	dyskinesia	ADJ	JJ	5	B-Disease
score	score	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
during	during	ADP	IN	5	O
speaking	speak	VERB	VBG	5	O
aloud	aloud	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
movements	movement	NOUN	NNS	5	O
of	of	ADP	IN	5	O
right	right	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
left	leave	VERB	VBD	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
fingers	finger	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
movements	movement	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
neck	neck	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
mental	mental	ADJ	JJ	5	O
calculation	calculation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
activation	activation	NOUN	NN	3	O
tasks	task	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
"	"	PUNCT	``	5	O
speaking	speak	VERB	VBG	5	O
aloud	aloud	ADV	RB	5	O
"	"	PUNCT	''	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
objective	objective	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
dyskinesia	dyskinesia	ADJ	JJ	5	B-Disease
severity	severity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Urine	Urine	PROPN	NNP	9	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
acetyl	acetyl	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
D	d	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glucosaminidase	glucosaminidase	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
a	a	DET	DT	5	O
marker	marker	NOUN	NN	3	O
of	of	ADP	IN	5	O
tubular	tubular	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
?	?	PUNCT	.	5	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Although	although	ADP	IN	9	O
an	an	DET	DT	5	O
indicator	indicator	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
increased	increased	ADJ	JJ	9	O
urinary	urinary	ADJ	JJ	9	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
acetyl	acetyl	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
D	d	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glucosaminidase	glucosaminidase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
NAG	NAG	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
activity	activity	NOUN	NN	9	O
might	may	VERB	MD	9	O
reflect	reflect	VERB	VB	5	O
increased	increase	VERB	VBN	9	O
lysosomal	lysosomal	ADJ	JJ	3	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

METHODS	METHODS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Puromycin	Puromycin	PROPN	NNP	0	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
Sprague	Sprague	PROPN	NNP	9	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Total	total	ADJ	JJ	7	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
albumin	albumin	NOUN	NN	0	O
,	,	PUNCT	,	9	O
NAG	NAG	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
protein	protein	NOUN	NN	1	O
electrophoretic	electrophoretic	ADJ	JJ	0	O
pattern	pattern	NOUN	NN	9	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
urine	urine	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
for	for	ADP	IN	5	O
33	33	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
morphological	morphological	ADJ	JJ	9	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
kidneys	kidney	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
three	three	NUM	CD	9	O
,	,	PUNCT	,	9	O
four	four	NUM	CD	9	O
,	,	PUNCT	,	9	O
six	six	NUM	CD	9	O
,	,	PUNCT	,	9	O
eight	eight	NUM	CD	9	O
and	and	CCONJ	CC	5	O
thirty	thirty	NUM	CD	5	O
three	three	NUM	CD	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
NAG	NAG	PROPN	NNP	0	O
isoenzyme	isoenzyme	NOUN	NN	9	O
patterns	pattern	NOUN	NNS	5	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
zero	zero	NUM	CD	5	O
,	,	PUNCT	,	9	O
four	four	NUM	CD	9	O
,	,	PUNCT	,	9	O
eight	eight	NUM	CD	9	O
and	and	CCONJ	CC	5	O
thirty	thirty	NUM	CD	5	O
three	three	NUM	CD	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Following	follow	VERB	VBG	9	O
intravenous	intravenous	ADJ	JJ	0	O
PAN	PAN	PROPN	NNP	0	B-Chemical
urine	urine	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
NAG	NAG	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
by	by	ADP	IN	9	O
day	day	NOUN	NN	9	O
two	two	NUM	CD	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
by	by	ADP	IN	9	O
day	day	NOUN	NN	9	O
four	four	NUM	CD	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
day	day	NOUN	NN	9	O
four	four	NUM	CD	9	O
all	all	DET	DT	5	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
a	a	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
urine	urine	NOUN	NN	9	O
albumin	albumin	NOUN	NN	0	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
excretion	excretion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
NAG	NAG	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Electrophoresis	electrophoresis	NOUN	NN	0	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
generalised	generalised	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
middle	middle	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
molecular	molecular	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
urine	urine	NOUN	NN	9	O
proteins	protein	NOUN	NNS	1	O
from	from	ADP	IN	9	O
day	day	NOUN	NN	9	O
four	four	NUM	CD	9	O
onwards	onwards	ADV	RB	9	O
.	.	PUNCT	.	9	O

Protein	protein	NOUN	NN	9	O
droplets	droplet	NOUN	NNS	0	O
first	first	ADV	RB	9	O
appeared	appear	VERB	VBD	9	O
prominent	prominent	ADJ	JJ	9	O
in	in	ADP	IN	5	O
tubular	tubular	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
four	four	NUM	CD	9	O
.	.	PUNCT	.	9	O

Peak	peak	NOUN	NN	9	O
urine	urine	NOUN	NN	9	O
NAG	NAG	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
NAG	NAG	PROPN	NNP	0	O
isoenzyme	isoenzyme	NOUN	NN	9	O
pattern	pattern	NOUN	NN	9	O
coincided	coincide	VERB	VBD	9	O
with	with	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
peak	peak	NOUN	NN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
intracellular	intracellular	ADJ	JJ	3	O
protein	protein	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
NAG	NAG	PROPN	NNP	0	O
droplets	droplet	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
day	day	NOUN	NN	9	O
six	six	NUM	CD	9	O
onwards	onwards	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
demonstrates	demonstrate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
lysosomal	lysosomal	ADJ	JJ	3	O
turnover	turnover	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
hence	hence	ADV	RB	5	O
urine	urine	NOUN	NN	9	O
NAG	NAG	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
occurs	occur	VERB	VBZ	9	O
when	when	ADV	WRB	5	O
increased	increase	VERB	VBN	9	O
protein	protein	NOUN	NN	1	O
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
tubular	tubular	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Urine	Urine	PROPN	NNP	9	O
NAG	NAG	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
thus	thus	ADV	RB	9	O
a	a	DET	DT	5	O
measure	measure	NOUN	NN	5	O
of	of	ADP	IN	5	O
altered	altered	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
tubules	tubule	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
not	not	ADV	RB	5	O
simply	simply	ADV	RB	5	O
an	an	DET	DT	5	O
indicator	indicator	NOUN	NN	9	O
of	of	ADP	IN	5	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cauda	Cauda	PROPN	NNP	7	B-Disease
equina	equina	VERB	VBD	4	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
with	with	ADP	IN	5	O
hyperbaric	hyperbaric	ADJ	JJ	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
lignocaine	lignocaine	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
six	six	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cauda	cauda	NOUN	NN	9	B-Disease
equina	equina	NOUN	NN	4	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
reported	report	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Swedish	Swedish	PROPN	NNP	5	O
Pharmaceutical	Pharmaceutical	PROPN	NNP	2	O
Insurance	Insurance	PROPN	NNP	5	O
1993	1993	NUM	CD	2	O
-	-	SYM	SYM	7	O
1997	1997	NUM	CD	2	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cauda	cauda	NOUN	NN	9	B-Disease
equina	equina	NOUN	NN	4	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
varying	vary	VERB	VBG	5	O
severity	severity	NOUN	NN	5	O
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Swedish	Swedish	PROPN	NNP	5	O
Pharmaceutical	Pharmaceutical	PROPN	NNP	2	O
Insurance	Insurance	PROPN	NNP	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
period	period	NOUN	NN	5	O
1993	1993	NUM	CD	2	O
-	-	SYM	SYM	7	O
1997	1997	NUM	CD	2	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
using	use	VERB	VBG	9	O
hyperbaric	hyperbaric	ADJ	JJ	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
lignocaine	lignocaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
shot	shot	NOUN	NN	5	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
one	one	PRON	PRP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
repeat	repeat	NOUN	NN	9	O
spinal	spinal	NOUN	NN	5	O
anaesthetic	anaesthetic	ADJ	JJ	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
inadequate	inadequate	ADJ	JJ	5	O
block	block	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
hyperbaric	hyperbaric	ADJ	JJ	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
lignocaine	lignocaine	NOUN	NN	0	B-Chemical
administered	administer	VERB	VBD	9	O
ranged	range	VERB	VBN	9	O
from	from	ADP	IN	9	O
60	60	NUM	CD	9	O
to	to	ADP	IN	5	O
120	120	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
most	most	ADV	RBS	9	O
likely	likely	ADV	RB	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
direct	direct	ADJ	JJ	9	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
hyperbaric	hyperbaric	ADJ	JJ	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
lignocaine	lignocaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
3	3	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
direct	direct	ADJ	JJ	9	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
probable	probable	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
unfortunately	unfortunately	ADV	RB	5	O
radiological	radiological	ADJ	JJ	5	O
investigations	investigation	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
done	do	VERB	VBN	9	O
to	to	PART	TO	5	O
definitely	definitely	ADV	RB	5	O
exclude	exclude	VERB	VB	9	O
a	a	DET	DT	5	O
compressive	compressive	ADJ	JJ	5	O
aetiology	aetiology	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
cases	case	NOUN	NNS	5	O
sustained	sustain	VERB	VBD	5	O
permanent	permanent	ADJ	JJ	5	O
neurological	neurological	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
recommend	recommend	VERB	VBP	5	O
that	that	DET	DT	5	O
hyperbaric	hyperbaric	ADJ	JJ	5	O
lignocaine	lignocaine	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
concentrations	concentration	NOUN	NNS	0	O
not	not	ADV	RB	5	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
preferably	preferably	ADV	RB	5	O
not	not	ADV	RB	5	O
exceeding	exceed	VERB	VBG	9	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Systemic	systemic	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
following	follow	VERB	VBG	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
formerly	formerly	ADV	RB	4	O
rapamycin	rapamycin	NOUN	NN	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
psoriasis	psoriasis	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
association	association	NOUN	NN	9	O
of	of	ADP	IN	5	O
capillary	capillary	ADJ	JJ	0	B-Disease
leak	leak	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
apoptosis	apoptosis	NOUN	NN	3	O
of	of	ADP	IN	5	O
lesional	lesional	ADJ	JJ	3	O
lymphocytes	lymphocyte	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Sirolimus	Sirolimus	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
formerly	formerly	ADV	RB	4	O
rapamycin	rapamycin	NOUN	NN	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
that	that	DET	WDT	5	O
interferes	interfere	VERB	VBZ	9	O
with	with	ADP	IN	5	O
T	T	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
2	2	NUM	CD	9	O
individuals	individual	NOUN	NNS	5	O
with	with	ADP	IN	5	O
psoriasis	psoriasis	NOUN	NN	9	B-Disease
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
capillary	capillary	ADJ	JJ	0	B-Disease
leak	leak	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
lesional	lesional	ADJ	JJ	3	O
skin	skin	NOUN	NN	5	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
activated	activate	VERB	VBN	3	O
peripheral	peripheral	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
for	for	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
apoptosis	apoptosis	NOUN	NN	3	O
.	.	PUNCT	.	9	O

OBSERVATIONS	observation	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
keratome	keratome	NOUN	NN	5	O
skin	skin	NOUN	NN	5	O
specimen	speciman	NOUN	NNS	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
capillary	capillary	ADJ	JJ	0	B-Disease
leak	leak	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	PUNCT	:	7	O
fold	fold	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
apoptotic	apoptotic	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
to	to	ADP	IN	5	O
48	48	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
unaffected	unaffected	ADJ	JJ	9	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
psoriasis	psoriasis	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Activated	activate	VERB	VBN	3	O
peripheral	peripheral	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
T	t	NOUN	NN	3	O
cells	cell	VERB	VBZ	3	O
from	from	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
psoriasis	psoriasis	NOUN	NN	9	B-Disease
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
exhibit	exhibit	VERB	VB	9	O
greater	great	ADJ	JJR	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
apoptosis	apoptosis	NOUN	NN	3	O
than	than	ADP	IN	5	O
did	do	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
T	T	PROPN	NNP	3	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Severe	severe	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
include	include	VERB	VBP	5	O
fever	fever	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
anemia	anemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
capillary	capillary	ADJ	JJ	0	B-Disease
leak	leak	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
apoptosis	apoptosis	NOUN	NN	3	O
of	of	ADP	IN	5	O
lesional	lesional	ADJ	JJ	3	O
leukocytes	leukocyte	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
activated	activate	VERB	VBN	3	O
T	T	PROPN	NNP	3	O
lymphocytes	lymphocyte	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
possibly	possibly	ADV	RB	9	O
release	release	VERB	VB	9	O
of	of	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
mediators	mediator	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
psoriasis	psoriasis	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
develop	develop	VERB	VB	5	O
capillary	capillary	ADJ	JJ	0	B-Disease
leak	leak	NOUN	NN	5	I-Disease
from	from	ADP	IN	9	O
various	various	ADJ	JJ	9	O
systemic	systemic	ADJ	JJ	9	O
therapies	therapy	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
clinical	clinical	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
advisable	advisable	ADJ	JJ	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
immune	immune	ADJ	JJ	3	O
modulators	modulator	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
maintenance	maintenance	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
on	on	ADP	IN	5	O
thyroid	thyroid	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
parathyroid	parathyroid	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
changes	change	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
maintenance	maintenance	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
thyroid	thyroid	NOUN	NN	9	O
,	,	PUNCT	,	9	O
parathyroid	parathyroid	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ion	ion	NOUN	NN	0	O
alterations	alteration	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
family	family	NOUN	NN	9	O
history	history	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
whether	whether	ADP	IN	9	O
or	or	CCONJ	CC	5	O
not	not	ADV	RB	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
degree	degree	NOUN	NN	5	O
relative	relative	NOUN	NN	9	O
with	with	ADP	IN	5	O
thyroid	thyroid	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

SETTING	set	VERB	VBG	2	O
:	:	PUNCT	:	9	O
Affective	Affective	PROPN	NNP	5	O
Disorders	Disorders	PROPN	NNPS	2	O
Clinic	Clinic	PROPN	NNP	2	O
at	at	ADP	IN	9	O
St	St	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

Mary	Mary	PROPN	NNP	6	O
'	'	PUNCT	''	9	O
s	s	PROPN	NNP	9	O
Hospital	Hospital	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Montreal	Montreal	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
One	one	NUM	CD	5	O
hundred	hundred	NUM	CD	5	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
28	28	NUM	CD	7	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
73	73	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
receiving	receiving	NOUN	NN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
maintenance	maintenance	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
ranging	range	VERB	VBG	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
to	to	ADP	IN	5	O
32	32	NUM	CD	7	O
years	year	NOUN	NNS	5	O
'	'	PART	POS	9	O
duration	duration	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
82	82	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
or	or	CCONJ	CC	5	O
endocrinological	endocrinological	ADJ	JJ	5	O
diagnoses	diagnosis	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
out	out	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
patient	patient	ADJ	JJ	5	O
clinics	clinic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OUTCOME	OUTCOME	PROPN	NNP	2	O
MEASURES	MEASURES	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Laboratory	laboratory	NOUN	NN	2	O
analyses	analysis	NOUN	NNS	9	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
thyroid	thyroid	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
stimulating	stimulate	VERB	VBG	9	O
hormone	hormone	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
performed	perform	VERB	VBN	9	O
before	before	ADP	IN	9	O
beginning	begin	VERB	VBG	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
biannual	biannual	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Hypothyroidism	hypothyroidism	NOUN	NN	7	B-Disease
developed	develop	VERB	VBD	5	O
in	in	ADP	IN	5	O
40	40	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
excluding	exclude	VERB	VBG	9	O
8	8	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
hypothyroid	hypothyroid	ADJ	JJ	9	B-Disease
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
having	have	VERB	VBG	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
degree	degree	NOUN	NN	5	O
relatives	relative	NOUN	NNS	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
thyroid	thyroid	NOUN	NN	9	B-Disease
illness	illness	NOUN	NN	5	I-Disease
had	have	VERB	VBD	9	O
accelerated	accelerate	VERB	VBN	9	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypothyroidism	hypothyroidism	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
years	year	NOUN	NNS	5	O
after	after	ADP	IN	9	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
a	a	DET	DT	5	O
family	family	NOUN	NN	9	O
history	history	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
years	year	NOUN	NNS	5	O
after	after	ADP	IN	9	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Women	woman	NOUN	NNS	5	O
over	over	ADP	IN	5	O
60	60	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
often	often	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
hypothyroidism	hypothyroidism	NOUN	NN	5	B-Disease
than	than	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
under	under	ADP	IN	9	O
60	60	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
34	34	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
31	31	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Magnesium	magnesium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
were	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
either	either	CCONJ	CC	9	O
baseline	baseline	NOUN	NN	5	O
levels	level	NOUN	NNS	3	O
or	or	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
counteracted	counteract	VERB	VBD	9	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
aging	age	VERB	VBG	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Familial	familial	ADJ	JJ	9	O
thyroid	thyroid	NOUN	NN	9	B-Disease
illness	illness	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
hypothyroidism	hypothyroidism	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
immune	immune	ADJ	JJ	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
cefotetan	cefotetan	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
obstetric	obstetric	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
gynecologic	gynecologic	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
cephalosporins	cephalosporin	NOUN	NNS	5	B-Chemical
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
cefotetan	cefotetan	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
increasingly	increasingly	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
sometimes	sometimes	ADV	RB	5	O
fatal	fatal	ADJ	JJ	5	O
immune	immune	ADJ	JJ	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
noticed	notice	VERB	VBD	9	O
that	that	ADP	IN	5	O
10	10	NUM	CD	9	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
35	35	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cefotetan	cefotetan	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemias	anemia	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
cefotetan	cefotetan	NOUN	NN	0	B-Chemical
prophylactically	prophylactically	ADV	RB	5	O
for	for	ADP	IN	5	O
obstetric	obstetric	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
gynecologic	gynecologic	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
immune	immune	ADJ	JJ	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
are	be	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
on	on	ADP	IN	5	O
hemostasis	hemostasis	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
aneurysmal	aneurysmal	ADJ	JJ	5	B-Disease
subarachnoid	subarachnoid	NOUN	NN	5	I-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Platelet	platelet	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
impaired	impair	VERB	VBN	9	O
by	by	ADP	IN	9	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
NSAIDs	nsaid	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
prominent	prominent	ADJ	JJ	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
properties	property	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Their	-PRON-	DET	PRP$	5	O
safety	safety	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
intracranial	intracranial	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
under	under	ADP	IN	9	O
debate	debate	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
aneurysmal	aneurysmal	ADJ	JJ	5	B-Disease
subarachnoid	subarachnoid	NOUN	NN	5	I-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SAH	SAH	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
either	either	CCONJ	CC	9	O
ketoprofen	ketoprofen	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
a	a	DET	DT	5	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ketoprofen	ketoprofen	PROPN	NNP	0	B-Chemical
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
weak	weak	ADJ	JJ	9	O
NSAID	NSAID	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
g	g	NOUN	NN	0	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
a	a	DET	DT	5	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
starting	start	VERB	VBG	9	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
aneurysmal	aneurysmal	ADJ	JJ	5	B-Disease
SAH	SAH	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
continued	continue	VERB	VBN	9	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
postoperatively	postoperatively	ADV	RB	5	O
.	.	PUNCT	.	9	O

Test	test	NOUN	NN	5	O
blood	blood	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
before	before	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
surgery	surgery	NOUN	NN	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
third	third	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
fifth	fifth	ADJ	JJ	9	O
postoperative	postoperative	ADJ	JJ	5	O
mornings	morning	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Maximal	maximal	ADJ	JJ	9	O
platelet	platelet	NOUN	NN	9	B-Disease
aggregation	aggregation	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
6	6	NUM	CD	9	O
microM	microM	PROPN	NNP	0	O
of	of	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
diphosphate	diphosphate	NOUN	NN	0	I-Chemical
decreased	decrease	VERB	VBD	9	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
ketoprofen	ketoprofen	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Aggregation	aggregation	NOUN	NN	0	O
was	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ketoprofen	ketoprofen	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
just	just	ADV	RB	5	O
before	before	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
postoperative	postoperative	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
maximal	maximal	ADJ	JJ	9	O
platelet	platelet	NOUN	NN	9	B-Disease
aggregation	aggregation	NOUN	NN	9	I-Disease
increased	increase	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
postoperative	postoperative	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
pretreatment	pretreatment	ADJ	JJ	0	O
platelet	platelet	NOUN	NN	9	B-Disease
aggregation	aggregation	NOUN	NN	9	I-Disease
results	result	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ketoprofen	ketoprofen	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
postoperative	postoperative	ADJ	JJ	5	O
intracranial	intracranial	ADJ	JJ	5	O
hematoma	hematoma	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Coagulation	coagulation	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
prothrombin	prothrombin	NOUN	NN	9	O
time	time	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
PT	PT	PROPN	NNP	9	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
activated	activate	VERB	VBD	3	O
partial	partial	ADJ	JJ	9	O
thromboplastin	thromboplastin	NOUN	NN	5	O
time	time	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
APPT	APPT	PROPN	NNP	5	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
fibrinogen	fibrinogen	NOUN	NN	0	O
concentration	concentration	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
antithrombin	antithrombin	NOUN	NN	9	O
III	III	PROPN	NNP	9	O
[	[	PUNCT	-LRB-	9	O
AT	at	ADP	IN	9	O
III	III	PROPN	NNP	9	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Ketoprofen	Ketoprofen	PROPN	NNP	0	B-Chemical
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
impaired	impair	VERB	VBN	9	O
platelet	platelet	NOUN	NN	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
SAH	SAH	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

If	if	ADP	IN	5	O
ketoprofen	ketoprofen	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
before	before	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
on	on	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	B-Disease
aneurysms	aneurysm	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
pose	pose	VERB	VB	5	O
an	an	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
synthase	synthase	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
lead	lead	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
recently	recently	ADV	RB	9	O
showed	show	VERB	VBD	9	O
elevated	elevated	ADJ	JJ	9	O
reactive	reactive	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
species	specie	NOUN	NNS	4	O
(	(	PUNCT	-LRB-	9	O
ROS	ROS	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
reduced	reduce	VERB	VBD	9	O
urinary	urinary	ADJ	JJ	9	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
NO	no	DET	DT	9	B-Chemical
metabolites	metabolite	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
NOx	NOx	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
NO	no	DET	DT	9	B-Chemical
sequestration	sequestration	NOUN	NN	9	O
as	as	ADP	IN	5	O
nitrotyrosine	nitrotyrosine	NOUN	NN	3	B-Chemical
in	in	ADP	IN	5	O
various	various	ADJ	JJ	9	O
tissues	tissue	NOUN	NNS	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
lead	lead	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
discern	discern	VERB	VB	5	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
NOx	NOx	NOUN	NNS	0	O
in	in	ADP	IN	5	O
lead	lead	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
part	part	NOUN	NN	9	O
,	,	PUNCT	,	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
depressed	depressed	ADJ	JJ	5	O
NO	no	DET	DT	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
NOS	NOS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
lead	lead	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
given	give	VERB	VBN	5	O
lead	lead	NOUN	NN	5	B-Chemical
acetate	acetate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
ppm	ppm	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
drinking	drinking	NOUN	NN	5	O
water	water	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
regular	regular	ADJ	JJ	5	O
rat	rat	NOUN	NN	3	O
chow	chow	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
given	give	VERB	VBN	5	O
lead	lead	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
-	-	ADJ	JJ	7	O
fortified	fortified	ADJ	JJ	5	O
chow	chow	NOUN	NN	0	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
given	give	VERB	VBN	5	O
either	either	CCONJ	CC	9	O
regular	regular	ADJ	JJ	5	O
food	food	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
water	water	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
-	-	ADJ	JJ	7	O
fortified	fortify	VERB	VBN	5	O
food	food	NOUN	NN	5	O
for	for	ADP	IN	5	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Tail	tail	NOUN	NN	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
urinary	urinary	ADJ	JJ	9	O
NOx	NOx	NOUN	NNS	0	O
excretion	excretion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
plasma	plasma	NOUN	NN	9	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
MDA	MDA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
endothelial	endothelial	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
inducible	inducible	ADJ	JJ	3	O
NOS	NOS	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
eNOS	eNOS	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
iNOS	iNOS	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
isotypes	isotype	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
aorta	aorta	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
kidney	kidney	NOUN	NN	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
lead	lead	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
exhibited	exhibit	VERB	VBD	9	O
a	a	DET	DT	5	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
plasma	plasma	VERB	VB	9	O
MDA	MDA	PROPN	NNP	9	B-Chemical
concentration	concentration	NOUN	NN	0	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
NOx	NOx	NOUN	NNS	0	O
excretion	excretion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
paradoxical	paradoxical	ADJ	JJ	5	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
vascular	vascular	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
eNOS	eNOS	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
iNOS	iNOS	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
supplementation	supplementation	NOUN	NN	0	O
ameliorated	ameliorate	VERB	VBD	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
lowered	lower	VERB	VBN	9	O
plasma	plasma	NOUN	NN	9	O
MDA	MDA	PROPN	NNP	9	B-Chemical
concentration	concentration	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
raised	raise	VERB	VBD	9	O
urinary	urinary	ADJ	JJ	9	O
NOx	NOx	NOUN	NNS	0	O
excretion	excretion	NOUN	NN	0	O
while	while	ADP	IN	9	O
significantly	significantly	ADV	RB	9	O
lowering	lower	VERB	VBG	9	O
vascular	vascular	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
renal	renal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
tissue	tissue	VERB	VB	9	O
eNOS	eNOS	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
iNOS	iNOS	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
supplementation	supplementation	NOUN	NN	0	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
either	either	DET	DT	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
plasma	plasma	VERB	VB	9	O
MDA	MDA	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
NOS	NOS	PROPN	NNP	9	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
also	also	ADV	RB	9	O
revealed	reveal	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
NOS	NOS	PROPN	NNP	9	O
enzymatic	enzymatic	ADJ	JJ	0	O
activity	activity	NOUN	NN	9	O
by	by	ADP	IN	9	O
lead	lead	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
cell	cell	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
preparations	preparation	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
lead	lead	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
compensatory	compensatory	ADJ	JJ	5	O
upregulation	upregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
vascular	vascular	ADJ	JJ	5	O
eNOS	eNOS	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
iNOS	iNOS	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
part	part	NOUN	NN	9	O
,	,	PUNCT	,	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
ROS	ROS	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
NO	no	DET	DT	9	B-Chemical
inactivation	inactivation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
lead	lead	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
NOS	NOS	PROPN	NNP	9	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
perhaps	perhaps	ADV	RB	5	O
stimulatory	stimulatory	ADJ	JJ	3	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
shear	shear	ADJ	JJ	5	O
stress	stress	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Glyceryl	glyceryl	NOUN	NN	0	B-Chemical
trinitrate	trinitrate	NOUN	NN	0	I-Chemical
induces	induce	VERB	VBZ	3	O
attacks	attack	NOUN	NNS	5	O
of	of	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	I-Disease
aura	aura	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
sufferers	sufferer	NOUN	NNS	5	O
of	of	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	I-Disease
aura	aura	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Migraine	migraine	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	I-Disease
aura	aura	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
migraine	migraine	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	I-Disease
aura	aura	NOUN	NN	5	I-Disease
have	have	VERB	VBP	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
pain	pain	NOUN	NN	5	B-Disease
phase	phase	NOUN	NN	5	O
,	,	PUNCT	,	9	O
thus	thus	ADV	RB	9	O
indicating	indicate	VERB	VBG	9	O
that	that	DET	DT	5	O
migraine	migraine	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	I-Disease
aura	aura	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
migraine	migraine	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	I-Disease
aura	aura	NOUN	NN	5	I-Disease
share	share	VERB	VB	5	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
pathway	pathway	NOUN	NN	3	O
of	of	ADP	IN	5	O
nociception	nociception	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
recent	recent	ADJ	JJ	5	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
increasing	increase	VERB	VBG	9	O
evidence	evidence	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
messenger	messenger	NOUN	NN	9	O
molecule	molecule	NOUN	NN	3	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NO	no	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	I-Disease
aura	aura	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
clarify	clarify	VERB	VB	9	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
is	be	VERB	VBZ	5	O
true	true	ADJ	JJ	5	O
for	for	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	I-Disease
aura	aura	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
headache	headache	NOUN	NN	5	B-Disease
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
glyceryl	glyceryl	NOUN	NN	0	B-Chemical
trinitrate	trinitrate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
GTN	GTN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
for	for	ADP	IN	5	O
20	20	NUM	CD	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
12	12	NUM	CD	9	O
sufferers	sufferer	NOUN	NNS	5	O
of	of	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	I-Disease
aura	aura	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
aim	aim	NOUN	NN	5	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
elucidate	elucidate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
an	an	DET	DT	5	O
aura	aura	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
an	an	DET	DT	5	O
attack	attack	NOUN	NN	5	O
of	of	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	I-Disease
aura	aura	NOUN	NN	5	I-Disease
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
induced	induce	VERB	VBN	3	O
.	.	PUNCT	.	9	O

Fourteen	fourteen	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
served	serve	VERB	VBD	9	O
as	as	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Aura	aura	NOUN	NN	2	O
symptoms	symptom	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
elicited	elicit	VERB	VBN	9	O
in	in	ADP	IN	5	O
any	any	DET	DT	5	O
subject	subject	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Headache	Headache	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
severe	severe	ADJ	JJ	5	O
in	in	ADP	IN	5	O
migraineurs	migraineur	NOUN	NNS	5	B-Disease
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
controls	control	NOUN	NNS	9	O
during	during	ADP	IN	5	O
and	and	CCONJ	CC	5	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
GTN	GTN	PROPN	NNP	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
037	037	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
11	11	NUM	CD	7	O
h	h	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
008	008	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
GTN	GTN	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
headache	headache	NOUN	NN	5	B-Disease
gradually	gradually	ADV	RB	9	O
disappeared	disappear	VERB	VBD	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
in	in	ADP	IN	5	O
migraineurs	migraineur	NOUN	NNS	5	B-Disease
peak	peak	NOUN	NN	9	O
headache	headache	NOUN	NN	5	B-Disease
intensity	intensity	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
240	240	NUM	CD	9	O
min	min	NOUN	NN	0	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
this	this	DET	DT	5	O
time	time	NOUN	NN	5	O
the	the	DET	DT	5	O
induced	induced	ADJ	JJ	3	O
headache	headache	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
migraineurs	migraineur	NOUN	NNS	5	B-Disease
fulfilled	fulfil	VERB	VBD	5	O
the	the	DET	DT	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	I-Disease
aura	aura	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
International	International	PROPN	NNP	2	O
Headache	Headache	PROPN	NNP	7	B-Disease
Society	Society	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
therefore	therefore	ADV	RB	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
NO	no	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pain	pain	NOUN	NN	5	B-Disease
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	I-Disease
aura	aura	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
cortical	cortical	ADJ	JJ	5	O
spreading	spread	VERB	VBG	9	O
depression	depression	NOUN	NN	5	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
liberate	liberate	VERB	VB	0	O
NO	NO	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
finding	finding	NOUN	NN	9	O
may	may	VERB	MD	5	O
help	help	VERB	VB	5	O
our	-PRON-	DET	PRP$	5	O
understanding	understanding	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
coupling	coupling	NOUN	NN	9	O
between	between	ADP	IN	5	O
cortical	cortical	NOUN	NN	5	O
spreading	spread	VERB	VBG	9	O
depression	depression	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
headache	headache	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	I-Disease
aura	aura	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Rapid	rapid	ADJ	JJ	9	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
diltiazem	diltiazem	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
tetany	tetany	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
tetany	tetany	ADJ	JJ	5	B-Disease
with	with	ADP	IN	5	O
sudden	sudden	ADJ	JJ	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
diltiazem	diltiazem	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
rapidly	rapidly	ADV	RB	9	O
resolved	resolve	VERB	VBD	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
tetany	tetany	ADJ	JJ	5	B-Disease
with	with	ADP	IN	5	O
prompt	prompt	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
averting	avert	VERB	VBG	5	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
more	more	ADV	RBR	5	O
aggressive	aggressive	ADJ	JJ	5	O
airway	airway	NOUN	NN	5	O
management	management	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
ventilatory	ventilatory	NOUN	NN	5	O
support	support	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
physician	physician	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
that	that	ADP	IN	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
tetany	tetany	NOUN	NN	5	B-Disease
may	may	VERB	MD	5	O
accompany	accompany	VERB	VB	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
diltiazem	diltiazem	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
effective	effective	ADJ	JJ	5	O
remedy	remedy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitor	inhibitor	NOUN	NN	3	O
therapy	therapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
results	result	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
left	left	ADJ	JJ	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
SOLVD	SOLVD	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Although	although	ADP	IN	9	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitor	inhibitor	NOUN	NN	3	O
therapy	therapy	NOUN	NN	5	O
reduces	reduce	VERB	VBZ	9	O
mortality	mortality	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
CHF	CHF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
also	also	ADV	RB	9	O
cause	cause	VERB	VB	5	O
decreased	decrease	VERB	VBN	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Little	little	ADJ	JJ	9	O
information	information	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
available	available	ADJ	JJ	5	O
to	to	PART	TO	5	O
predict	predict	VERB	VB	5	O
which	which	DET	WDT	5	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
at	at	ADP	IN	9	O
highest	high	ADJ	JJS	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
quantify	quantify	VERB	VB	9	O
specific	specific	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
reduction	reduction	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
CHF	CHF	PROPN	NNP	9	B-Disease
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
prescribed	prescribe	VERB	VBN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitor	inhibitor	NOUN	NN	3	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
analyzed	analyze	VERB	VBD	9	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
Studies	Studies	PROPN	NNPS	9	O
of	of	ADP	IN	5	O
Left	Left	PROPN	NNP	9	B-Disease
Ventricular	Ventricular	PROPN	NNP	5	I-Disease
Dysfunction	Dysfunction	PROPN	NNP	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SOLVD	SOLVD	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
enalapril	enalapril	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
CHF	CHF	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
3379	3379	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	PART	TO	5	O
enalapril	enalapril	VERB	VB	0	B-Chemical
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
median	median	ADJ	JJ	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
974	974	NUM	CD	7	O
days	day	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
3379	3379	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	PART	TO	5	O
placebo	placebo	VERB	VB	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
967	967	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Decreased	decrease	VERB	VBN	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
>	>	X	XX	0	O
/	/	SYM	SYM	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
44	44	NUM	CD	7	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
used	use	VERB	VBD	5	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
event	event	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
potential	potential	ADJ	JJ	9	O
predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
including	include	VERB	VBG	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
baseline	baseline	NOUN	NN	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
baseline	baseline	NOUN	NN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
low	low	ADJ	JJ	9	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
100	100	NUM	CD	0	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
diabetes	diabetes	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
antiplatelet	antiplatelet	NOUN	NN	5	O
,	,	PUNCT	,	9	O
diuretic	diuretic	ADJ	JJ	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocker	blocker	NOUN	NN	0	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBD	5	O
to	to	PART	TO	5	O
enalapril	enalapril	VERB	VB	0	B-Chemical
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
33	33	NUM	CD	7	O
%	%	NOUN	NN	9	O
greater	great	ADJ	JJR	5	O
likelihood	likelihood	NOUN	NN	5	O
of	of	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
than	than	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
003	003	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
multivariate	multivariate	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
enalapril	enalapril	ADJ	JJ	0	B-Chemical
groups	group	NOUN	NNS	9	O
older	old	ADJ	JJR	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
diuretic	diuretic	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
diabetes	diabete	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocker	blocker	NOUN	NN	0	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
were	be	VERB	VBD	9	O
renoprotective	renoprotective	ADJ	JJ	3	O
.	.	PUNCT	.	9	O

Older	old	ADJ	JJR	5	O
age	age	NOUN	NN	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
decreased	decrease	VERB	VBN	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
so	so	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
enalapril	enalapril	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
enalapril	enalapril	VERB	VB	0	B-Chemical
:	:	PUNCT	:	9	O
risk	risk	NOUN	NN	5	O
ratio	ratio	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
]	]	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
42	42	NUM	CD	7	O
per	per	ADP	IN	9	O
10	10	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
]	]	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
32	32	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
52	52	NUM	CD	7	O
with	with	ADP	IN	5	O
enalapril	enalapril	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
placebo	placebo	NOUN	NN	9	O
:	:	PUNCT	:	9	O
RR	RR	PROPN	NNP	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
18	18	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
12	12	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Diuretic	diuretic	ADJ	JJ	7	B-Chemical
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
likewise	likewise	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
enalapril	enalapril	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
89	89	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
70	70	NUM	CD	9	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
08	08	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
09	09	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
66	66	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Conversely	conversely	ADV	RB	9	O
,	,	PUNCT	,	9	O
enalapril	enalapril	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
renoprotective	renoprotective	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
33	33	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
13	13	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
53	53	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
96	96	NUM	CD	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
57	57	NUM	CD	7	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
44	44	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
diabetes	diabete	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
lower	low	ADJ	JJR	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
with	with	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocker	blocker	NOUN	NN	0	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
70	70	NUM	CD	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
57	57	NUM	CD	7	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
85	85	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
baseline	baseline	NOUN	NN	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
93	93	NUM	CD	7	O
per	per	ADP	IN	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
increment	increment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
91	91	NUM	CD	7	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
96	96	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Enalapril	Enalapril	PROPN	NNP	0	B-Chemical
use	use	NOUN	NN	5	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
33	33	NUM	CD	7	O
%	%	NOUN	NN	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
CHF	CHF	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Diuretic	diuretic	ADJ	JJ	7	B-Chemical
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
advanced	advanced	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
increased	increase	VERB	VBD	9	O
this	this	DET	DT	5	O
risk	risk	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Diabetes	diabete	NOUN	NNS	7	B-Disease
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
CHF	CHF	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
this	this	DET	DT	5	O
risk	risk	NOUN	NN	5	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
enalapril	enalapril	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

beta	beta	NOUN	NN	9	O
-	-	PUNCT	:	7	O
Blocker	blocker	NOUN	NN	0	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
were	be	VERB	VBD	9	O
renoprotective	renoprotective	ADJ	JJ	3	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
regardless	regardless	ADV	RB	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hypomania	Hypomania	PROPN	NNP	7	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
syndrome	syndrome	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
female	female	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
not	not	ADV	RB	5	O
otherwise	otherwise	ADV	RB	9	O
specified	specify	VERB	VBN	5	O
psychotic	psychotic	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
DSM	DSM	PROPN	NNP	4	O
-	-	PUNCT	HYPH	7	O
IV	IV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
hypomania	hypomania	NOUN	NN	5	B-Disease
shortly	shortly	ADV	RB	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
introduction	introduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
olanzapine	olanzapine	ADJ	JJ	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Acetazolamide	acetazolamide	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
Gerstmann	Gerstmann	PROPN	NNP	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
confusion	confusion	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
acetazolamide	acetazolamide	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
well	well	ADV	RB	9	O
known	know	VERB	VBN	9	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
reaction	reaction	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acetazolamide	acetazolamide	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
Gerstmann	Gerstmann	PROPN	NNP	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
highlight	highlight	VERB	VB	5	O
predisposing	predispose	VERB	VBG	5	O
factors	factor	NOUN	NNS	9	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
frequently	frequently	ADV	RB	5	O
overlooked	overlook	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Vasopressin	vasopressin	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
milrinone	milrinone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
phosphodiesterase	phosphodiesterase	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
milrinone	milrinone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
frequently	frequently	ADV	RB	5	O
restricted	restrict	VERB	VBN	9	O
because	because	ADP	IN	5	O
they	-PRON-	PRON	PRP	5	O
cause	cause	VERB	VBP	5	O
vasodilation	vasodilation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
decompensated	decompensated	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
milrinone	milrinone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
low	low	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
vasopressin	vasopressin	NOUN	NN	9	B-Chemical
restored	restore	VERB	VBN	3	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
without	without	ADP	IN	9	O
inhibiting	inhibit	VERB	VBG	3	O
the	the	DET	DT	5	O
inotropic	inotropic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
milrinone	milrinone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
by	by	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
to	to	PART	TO	5	O
cyclosporine	cyclosporine	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
tacrolimus	tacrolimus	ADJ	JJ	0	B-Chemical
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
persist	persist	VERB	VBP	5	O
despite	despite	ADP	IN	9	O
dose	dose	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
conversion	conversion	NOUN	NN	9	O
to	to	PART	TO	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
immunosuppression	immunosuppression	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CyA	CyA	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
necessary	necessary	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
characterized	characterize	VERB	VBD	9	O
tacrolimus	tacrolimus	VERB	VBP	0	B-Chemical
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
that	that	DET	WDT	5	O
warranted	warrant	VERB	VBD	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
outcomes	outcome	NOUN	NNS	5	O
after	after	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
388	388	NUM	CD	7	O
liver	liver	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
immunosuppression	immunosuppression	NOUN	NN	5	O
,	,	PUNCT	,	9	O
70	70	NUM	CD	9	O
required	require	VERB	VBN	9	O
conversion	conversion	NOUN	NN	9	O
to	to	ADP	IN	5	O
CyA	CyA	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
recorded	record	VERB	VBD	5	O
indication	indication	NOUN	NN	5	O
for	for	ADP	IN	5	O
conversion	conversion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
whether	whether	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
was	be	VERB	VBD	9	O
early	early	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
late	late	ADJ	JJ	9	O
after	after	ADP	IN	9	O
transplantation	transplantation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
trough	trough	VERB	VB	9	O
blood	blood	NOUN	NN	9	O
level	level	NOUN	NN	9	O
at	at	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
rejection	rejection	NOUN	NN	5	O
after	after	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Conversion	conversion	NOUN	NN	9	O
was	be	VERB	VBD	9	O
early	early	ADJ	JJ	9	O
in	in	ADP	IN	5	O
29	29	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
41	41	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
late	late	ADV	RB	9	O
in	in	ADP	IN	5	O
41	41	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
58	58	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Indications	indication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
early	early	ADJ	JJ	9	O
conversion	conversion	NOUN	NN	9	O
were	be	VERB	VBD	9	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	B-Disease
insulin	insulin	NOUN	NN	3	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
dependent	dependent	ADJ	JJ	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
IDDM	IDDM	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
(	(	PUNCT	-LRB-	9	I-Disease
GI	GI	PROPN	NNP	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
late	late	ADJ	JJ	9	O
conversion	conversion	NOUN	NN	9	O
were	be	VERB	VBD	9	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
IDDM	IDDM	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
GI	GI	PROPN	NNP	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
post	post	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
transplant	transplant	ADJ	JJ	9	I-Disease
lmphoproliferate	lmphoproliferate	NOUN	NN	_	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PTLD	PTLD	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pruritus	pruritus	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
early	early	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
conversion	conversion	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
improvement	improvement	NOUN	NN	5	O
/	/	SYM	SYM	9	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
late	late	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
conversion	conversion	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
37	37	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
90	90	NUM	CD	9	O
.	.	NOUN	NN	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
improvement	improvement	NOUN	NN	5	O
/	/	SYM	SYM	9	O
resolution	resolution	NOUN	NN	5	O
;	;	PUNCT	:	9	O
in	in	ADP	IN	5	O
4	4	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
persisted	persist	VERB	VBD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
rejection	rejection	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Sixty	sixty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
88	88	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
alive	alive	ADJ	JJ	9	O
with	with	ADP	IN	5	O
functioning	function	VERB	VBG	5	O
grafts	graft	NOUN	NNS	5	O
686	686	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
362	362	NUM	CD	7	O
days	day	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
154	154	NUM	CD	7	O
-	-	SYM	SYM	7	O
1433	1433	NUM	CD	7	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
tacrolimus	tacrolimus	ADJ	JJ	0	B-Chemical
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
unresponsive	unresponsive	ADJ	JJ	9	O
to	to	PART	TO	5	O
dose	dose	VERB	VB	9	O
reduction	reduction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
conversion	conversion	NOUN	NN	9	O
to	to	ADP	IN	5	O
CyA	CyA	PROPN	NNP	0	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
accomplished	accomplish	VERB	VBN	5	O
safely	safely	ADV	RB	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
rejection	rejection	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
excellent	excellent	ADJ	JJ	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
outcome	outcome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ocular	ocular	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
juvenile	juvenile	NOUN	NN	4	B-Disease
rheumatoid	rheumatoid	ADJ	JJ	9	I-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
followed	follow	VERB	VBD	9	O
210	210	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
juvenile	juvenile	NOUN	NN	4	B-Disease
rheumatoid	rheumatoid	ADJ	JJ	9	I-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
closely	closely	ADV	RB	9	O
for	for	ADP	IN	5	O
eleven	eleven	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
210	210	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBN	5	O
iridocyclitis	iridocyclitis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Iridocyclitis	Iridocyclitis	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
most	most	ADV	RBS	9	O
frequently	frequently	ADV	RB	5	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
female	female	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
to	to	PART	TO	5	O
4	4	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
monoarticular	monoarticular	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
pauciatricular	pauciatricular	ADJ	JJ	_	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
arthritis	arthritis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
uveitis	uveitis	ADJ	JJ	5	B-Disease
after	after	ADP	IN	9	O
16	16	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
61	61	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
noncontributory	noncontributory	ADJ	JJ	5	O
ocular	ocular	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
on	on	ADP	IN	5	O
entry	entry	NOUN	NN	9	O
,	,	PUNCT	,	9	O
42	42	NUM	CD	7	O
%	%	NOUN	NN	9	O
had	have	VERB	VBD	9	O
active	active	ADJ	JJ	9	O
uveitis	uveitis	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
entry	entry	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
approach	approach	NOUN	NN	5	O
was	be	VERB	VBD	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
detecting	detect	VERB	VBG	9	O
uveitis	uveitis	ADJ	JJ	5	B-Disease
in	in	ADP	IN	5	O
new	new	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
exacerbations	exacerbation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
uveitis	uveitis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
established	establish	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
uveitis	uveitis	PROPN	NNP	5	B-Disease
had	have	VERB	VBD	9	O
one	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
identifiable	identifiable	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
red	red	ADJ	JJ	9	O
eye	eye	NOUN	NN	5	O
,	,	PUNCT	,	9	O
ocular	ocular	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	B-Disease
visual	visual	ADJ	JJ	5	I-Disease
acuity	acuity	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
photophobia	photophobia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
of	of	ADP	IN	5	O
decreasing	decrease	VERB	VBG	9	O
frequency	frequency	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Even	even	ADV	RB	5	O
after	after	ADP	IN	9	O
early	early	ADJ	JJ	9	O
detection	detection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
prompt	prompt	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
41	41	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
uveitis	uveitis	NOUN	NN	5	B-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
respond	respond	VERB	VB	5	O
to	to	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
intensive	intensive	ADJ	JJ	5	O
topical	topical	ADJ	JJ	0	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
and	and	CCONJ	CC	5	O
mydriatics	mydriatic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
this	this	DET	DT	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
dramatic	dramatic	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
blinding	blind	VERB	VBG	5	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
uveitis	uveitis	ADJ	JJ	5	B-Disease
cited	cite	VERB	VBN	5	O
in	in	ADP	IN	5	O
earlier	early	ADJ	JJR	9	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Cataract	cataract	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
band	band	NOUN	NN	9	B-Disease
keratopathy	keratopathy	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
only	only	ADV	RB	9	O
22	22	NUM	CD	7	O
and	and	CCONJ	CC	5	O
13	13	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
used	use	VERB	VBD	5	O
chloroquine	chloroquine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
hydroxychloroquine	hydroxychloroquine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
173	173	NUM	CD	7	O
of	of	ADP	IN	5	O
210	210	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
found	find	VERB	VBD	9	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
chorioretinopathy	chorioretinopathy	ADJ	JJ	5	B-Disease
attributable	attributable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Systemically	systemically	ADV	RB	3	O
administered	administer	VERB	VBN	9	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
75	75	NUM	CD	9	O
of	of	ADP	IN	5	O
210	210	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
posterior	posterior	ADJ	JJ	5	O
subcapsular	subcapsular	ADJ	JJ	5	O
cataracts	cataract	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Typical	typical	ADJ	JJ	9	O
keratoconjunctivitis	keratoconjunctivitis	NOUN	NN	5	B-Disease
sicca	sicca	NOUN	NN	4	O
developed	develop	VERB	VBD	5	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
uveitis	uveitis	ADJ	JJ	5	B-Disease
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
uveitis	uveitis	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
JRA	JRA	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
noted	note	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
.	.	PUNCT	.	9	O

Surgical	surgical	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
cataracts	cataract	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
band	band	NOUN	NN	9	B-Disease
keratopathy	keratopathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
achieved	achieve	VERB	VBN	5	O
uniformly	uniformly	ADV	RB	9	O
discouraging	discouraging	ADJ	JJ	5	O
results	result	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Cyclophosphamide	Cyclophosphamide	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
freely	freely	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
moving	move	VERB	VBG	5	O
conscious	conscious	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
behavioral	behavioral	ADJ	JJ	5	O
approach	approach	NOUN	NN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
visceral	visceral	ADJ	JJ	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
develop	develop	VERB	VB	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
visceral	visceral	ADJ	JJ	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
approach	approach	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cyclophosphamide	Cyclophosphamide	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CP	CP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
antitumoral	antitumoral	ADJ	JJ	3	O
agent	agent	NOUN	NN	9	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
wall	wall	NOUN	NN	5	O
through	through	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
main	main	ADJ	JJ	5	O
toxic	toxic	ADJ	JJ	0	O
metabolite	metabolite	NOUN	NN	0	O
acrolein	acrolein	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
CP	CP	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
and	and	CCONJ	CC	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
to	to	ADP	IN	5	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
behavior	behavior	NOUN	NN	5	O
observed	observe	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
scored	score	VERB	VBD	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
to	to	PART	TO	5	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
CP	CP	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
behavioral	behavioral	ADJ	JJ	5	O
modifications	modification	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
administered	administer	VERB	VBD	9	O
alone	alone	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
s	s	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
90	90	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
CP	CP	PROPN	NNP	9	B-Chemical
injection	injection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
that	that	ADV	RB	5	O
is	is	ADV	RB	5	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
was	be	VERB	VBD	9	O
removed	remove	VERB	VBN	9	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
for	for	ADP	IN	5	O
histological	histological	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
show	show	VERB	VB	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
essential	essential	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
CP	CP	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
behavioral	behavioral	ADJ	JJ	5	O
modifications	modification	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
also	also	ADV	RB	9	O
received	receive	VERB	VBD	9	O
CP	CP	PROPN	NNP	9	B-Chemical
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
intravesical	intravesical	ADJ	JJ	5	O
route	route	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
acrolein	acrolein	VERB	VB	0	B-Chemical
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
intravesical	intravesical	ADJ	JJ	5	O
route	route	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
CP	cp	NOUN	NN	9	B-Chemical
dose	dose	NOUN	NN	9	O
-	-	PUNCT	:	7	O
relatedly	relatedly	ADV	RB	5	O
induced	induce	VERB	VBN	3	O
marked	mark	VERB	VBN	9	O
behavioral	behavioral	ADJ	JJ	5	O
modifications	modification	NOUN	NNS	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
breathing	breathing	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
decrease	decrease	NOUN	NN	9	O
,	,	PUNCT	,	9	O
closing	closing	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
eyes	eye	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
specific	specific	ADJ	JJ	9	O
postures	posture	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Morphine	morphine	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
-	-	PUNCT	:	7	O
dependently	dependently	ADV	RB	3	O
reversed	reverse	VERB	VBD	9	O
these	these	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
almost	almost	ADV	RB	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
score	score	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
CP	CP	PROPN	NNP	9	B-Chemical
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
histological	histological	ADJ	JJ	9	O
modifications	modification	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
wall	wall	NOUN	NN	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
chorionic	chorionic	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
muscle	muscle	NOUN	NN	9	O
layer	layer	NOUN	NN	9	O
edema	edema	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
CP	CP	PROPN	NNP	9	B-Chemical
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
produced	produce	VERB	VBD	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
marked	mark	VERB	VBN	9	O
behavioral	behavioral	ADJ	JJ	5	O
modifications	modification	NOUN	NNS	9	O
as	as	ADP	IN	5	O
those	those	DET	DT	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Administered	administer	VERB	VBN	2	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
intravesically	intravesically	ADV	RB	0	O
,	,	PUNCT	,	9	O
CP	CP	PROPN	NNP	9	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
produce	produce	VERB	VB	9	O
any	any	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
acrolein	acrolein	VERB	VBP	0	B-Chemical
at	at	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
intravesically	intravesically	ADV	RB	0	O
induced	induce	VERB	VBN	3	O
behavioral	behavioral	ADJ	JJ	5	O
modifications	modification	NOUN	NNS	9	O
identical	identical	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
under	under	ADP	IN	9	O
CP	CP	PROPN	NNP	9	B-Chemical
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
maximal	maximal	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Conversely	conversely	ADV	RB	9	O
,	,	PUNCT	,	9	O
acrolein	acrolein	NOUN	NN	0	B-Chemical
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
produce	produce	VERB	VB	9	O
any	any	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
at	at	ADV	RB	9	O
all	all	ADV	RB	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Overall	overall	ADV	RB	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
CP	CP	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
interesting	interesting	ADJ	JJ	9	O
new	new	ADJ	JJ	5	O
behavioral	behavioral	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
visceral	visceral	ADJ	JJ	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
allowing	allow	VERB	VBG	5	O
a	a	DET	DT	5	O
better	well	ADJ	JJR	5	O
understanding	understanding	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
painful	painful	ADJ	JJ	5	B-Disease
syndromes	syndrome	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
thus	thus	ADV	RB	9	O
a	a	DET	DT	5	O
better	better	ADV	RBR	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
approach	approach	NOUN	NN	5	O
to	to	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
.	.	PUNCT	.	9	O

Prednisolone	Prednisolone	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
muscle	muscle	NOUN	NN	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
caused	cause	VERB	VBN	9	O
more	more	ADJ	JJR	5	O
by	by	ADP	IN	9	O
atrophy	atrophy	NOUN	NN	5	B-Disease
than	than	ADP	IN	5	O
by	by	ADP	IN	9	O
altered	alter	VERB	VBN	9	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Large	large	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
glucocorticoids	glucocorticoid	NOUN	NNS	9	O
can	can	VERB	MD	5	O
alter	alter	VERB	VB	9	O
muscle	muscle	NOUN	NN	9	O
physiology	physiology	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
neuromuscular	neuromuscular	ADJ	JJ	5	O
blocking	block	VERB	VBG	3	O
drugs	drug	NOUN	NNS	5	O
by	by	ADP	IN	9	O
mechanisms	mechanism	NOUN	NNS	9	O
not	not	ADV	RB	5	O
clearly	clearly	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
moderate	moderate	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
large	large	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
prednisolone	prednisolone	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
pharmacology	pharmacology	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
relationship	relationship	NOUN	NN	5	O
to	to	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	O
size	size	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
AChR	AChR	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
institutional	institutional	ADJ	JJ	5	O
approval	approval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
35	35	NUM	CD	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
allocated	allocate	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
daily	daily	ADJ	JJ	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
prednisolone	prednisolone	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
P10	P10	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
prednisolone	prednisolone	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
P100	p100	NOUN	NN	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
an	an	DET	DT	5	O
equal	equal	ADJ	JJ	9	O
volume	volume	NOUN	NN	9	O
of	of	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
S	S	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
fourth	fourth	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
pair	pair	NOUN	NN	9	O
fed	feed	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
food	food	NOUN	NN	5	O
restricted	restrict	VERB	VBN	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
P100	P100	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
FR	FR	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
Day	day	NOUN	NN	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
nerve	nerve	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
evoked	evoke	VERB	VBN	5	O
peak	peak	NOUN	NN	9	O
twitch	twitch	NOUN	NN	5	O
tensions	tension	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
tetanic	tetanic	ADJ	JJ	5	B-Disease
tensions	tension	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
fatigability	fatigability	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
curves	curve	NOUN	NNS	5	O
of	of	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tubocurarine	tubocurarine	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
tibialis	tibialis	NOUN	NN	4	O
cranialis	cranialis	NOUN	NN	4	O
muscle	muscle	NOUN	NN	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	O
mass	mass	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
AChRs	AChRs	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

Rate	rate	NOUN	NN	5	O
of	of	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
gain	gain	NOUN	NN	5	O
was	be	VERB	VBD	9	O
depressed	depress	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
P100	P100	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
FR	FR	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
P10	P10	PROPN	NNP	9	O
groups	group	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
S	S	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Tibialis	Tibialis	PROPN	NNP	7	O
muscle	muscle	NOUN	NN	9	O
mass	mass	NOUN	NN	9	O
was	be	VERB	VBD	9	O
smaller	small	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
P100	P100	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
P10	P10	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
S	S	PROPN	NNP	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
evoked	evoked	ADJ	JJ	5	O
peak	peak	NOUN	NN	9	O
twitch	twitch	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
tetanic	tetanic	ADJ	JJ	5	B-Disease
tensions	tension	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
P100	P100	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
P10	P10	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
S	S	PROPN	NNP	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
tension	tension	NOUN	NN	5	O
per	per	ADP	IN	9	O
milligram	milligram	NOUN	NN	0	O
of	of	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	O
mass	mass	NOUN	NN	9	O
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
P100	P100	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
S	S	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
effective	effective	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tubocurarine	tubocurarine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
tibialis	tibialis	NOUN	NN	4	O
muscle	muscle	NOUN	NN	9	O
was	be	VERB	VBD	9	O
smaller	small	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
P10	P10	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
S	S	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
61	61	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
P100	P100	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
71	71	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

AChR	AChR	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
was	be	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
P10	P10	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
S	S	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
evoked	evoked	ADJ	JJ	5	O
tensions	tension	NOUN	NNS	5	O
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	O
mass	mass	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
=	=	VERB	VBZ	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
32	32	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
not	not	ADV	RB	5	O
with	with	ADP	IN	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
AChR	AChR	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
effective	effective	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
d	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tubocurarine	tubocurarine	NOUN	NN	0	I-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
correlate	correlate	VERB	VB	9	O
with	with	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	O
mass	mass	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
AChR	AChR	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
neuromuscular	neuromuscular	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
prednisolone	prednisolone	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
derives	derive	VERB	VBZ	5	O
primarily	primarily	ADV	RB	9	O
from	from	ADP	IN	9	O
muscle	muscle	NOUN	NN	9	B-Disease
atrophy	atrophy	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
derives	derive	VERB	VBZ	5	O
less	less	ADV	RBR	5	O
so	so	ADV	RB	5	O
from	from	ADP	IN	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
AChR	AChR	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

IMPLICATIONS	implications	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
chronic	chronic	ADJ	JJ	5	O
glucocorticoid	glucocorticoid	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
alters	alter	NOUN	NNS	9	O
neuromuscular	neuromuscular	ADJ	JJ	5	O
physiology	physiology	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
pharmacology	pharmacology	NOUN	NN	5	O
are	be	VERB	VBP	5	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
observed	observed	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
derive	derive	VERB	VBP	5	O
primarily	primarily	ADV	RB	9	O
from	from	ADP	IN	9	O
muscle	muscle	NOUN	NN	9	B-Disease
atrophy	atrophy	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
derive	derive	VERB	VB	5	O
less	less	ADJ	JJR	5	O
from	from	ADP	IN	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Apomorphine	apomorphine	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
underutilized	underutilize	VERB	VBN	5	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Apomorphine	Apomorphine	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
ever	ever	ADV	RB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
powerful	powerful	ADJ	JJ	5	O
antiparkinsonian	antiparkinsonian	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
observed	observe	VERB	VBN	9	O
as	as	ADV	RB	5	O
early	early	ADV	RB	9	O
as	as	ADP	IN	5	O
1951	1951	NUM	CD	2	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
treating	treat	VERB	VBG	5	O
fluctuating	fluctuate	VERB	VBG	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
only	only	ADV	RB	9	O
recently	recently	ADV	RB	9	O
become	become	VERB	VBN	5	O
the	the	DET	DT	5	O
subject	subject	NOUN	NN	5	O
of	of	ADP	IN	5	O
systematic	systematic	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
small	small	ADJ	JJ	9	O
scale	scale	NOUN	NN	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
unequivocally	unequivocally	ADV	RB	9	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
intermittent	intermittent	ADJ	JJ	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
apomorphine	apomorphine	ADJ	JJ	0	B-Chemical
injections	injection	NOUN	NNS	9	O
produce	produce	VERB	VBP	9	O
antiparkinsonian	antiparkinsonian	ADJ	JJ	5	O
benefit	benefit	NOUN	NN	5	O
close	close	ADV	RB	5	O
if	if	ADP	IN	5	O
not	not	ADV	RB	5	O
identical	identical	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
seen	see	VERB	VBN	9	O
with	with	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
apomorphine	apomorphine	ADJ	JJ	0	B-Chemical
rescue	rescue	NOUN	NN	3	O
injections	injection	NOUN	NNS	9	O
can	can	VERB	MD	5	O
reliably	reliably	ADV	RB	5	O
revert	revert	VERB	VB	9	O
off	off	PART	RP	5	O
-	-	PUNCT	HYPH	7	O
periods	period	NOUN	NNS	5	O
even	even	ADV	RB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
complex	complex	ADJ	JJ	9	O
on	on	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
off	off	PART	RP	5	O
motor	motor	NOUN	NN	5	O
swings	swing	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Continuous	continuous	ADJ	JJ	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
infusions	infusion	NOUN	NNS	9	O
can	can	VERB	MD	5	O
reduce	reduce	VERB	VB	5	O
daily	daily	ADV	RB	5	O
off	off	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
by	by	ADP	IN	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
stronger	strong	ADJ	JJR	9	O
effect	effect	NOUN	NN	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
generally	generally	ADV	RB	5	O
seen	see	VERB	VBN	9	O
with	with	ADP	IN	5	O
add	add	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
on	on	PART	RP	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
agonists	agonist	NOUN	NNS	3	O
or	or	CCONJ	CC	5	O
COMT	COMT	PROPN	NNP	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Extended	extend	VERB	VBN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
8	8	NUM	CD	9	O
years	year	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
demonstrated	demonstrate	VERB	VBN	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
persistence	persistence	NOUN	NN	9	O
of	of	ADP	IN	5	O
apomorphine	apomorphine	ADJ	JJ	0	B-Chemical
efficacy	efficacy	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
convincing	convince	VERB	VBG	9	O
clinical	clinical	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
that	that	DET	DT	5	O
monotherapy	monotherapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
infusions	infusion	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
marked	marked	ADJ	JJ	9	O
reductions	reduction	NOUN	NNS	9	O
of	of	ADP	IN	5	O
preexisting	preexist	VERB	VBG	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
apomorphine	apomorphine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
are	be	VERB	VBP	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
cutaneous	cutaneous	ADJ	JJ	5	O
tolerability	tolerability	NOUN	NN	5	O
problems	problem	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
sedation	sedation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	O
play	play	VERB	VBP	9	O
a	a	DET	DT	5	O
lesser	less	ADJ	JJR	9	O
role	role	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
the	the	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
apomorphine	apomorphine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
fluctuating	fluctuate	VERB	VBG	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
approach	approach	NOUN	NN	5	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
deserve	deserve	VERB	VB	5	O
more	more	ADV	RBR	5	O
widespread	widespread	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Probing	probe	VERB	VBG	9	O
peripheral	peripheral	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
central	central	ADJ	JJ	5	O
cholinergic	cholinergic	NOUN	NN	3	O
system	system	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
act	act	VERB	VBP	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
cholinergic	cholinergic	NOUN	NN	3	O
system	system	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
iris	iris	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
predict	predict	VERB	VB	5	O
deficits	deficit	NOUN	NNS	5	O
in	in	ADP	IN	5	O
central	central	ADJ	JJ	5	O
cholinergic	cholinergic	NOUN	NN	3	O
functioning	functioning	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
diseases	disease	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
yet	yet	CCONJ	CC	9	O
correlations	correlation	NOUN	NNS	5	O
between	between	ADP	IN	5	O
central	central	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
properly	properly	ADV	RB	5	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
assessed	assess	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
aging	aging	NOUN	NN	5	O
on	on	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
tropicamide	tropicamide	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
pupil	pupil	NOUN	NN	5	O
diameter	diameter	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
with	with	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Scopolamine	Scopolamine	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
control	control	NOUN	NN	9	O
to	to	PART	TO	5	O
detect	detect	VERB	VB	9	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
central	central	ADJ	JJ	5	O
cholinergic	cholinergic	NOUN	NN	3	O
functioning	functioning	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Randomized	randomize	VERB	VBN	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PARTICIPANTS	participant	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Ten	ten	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
elderly	elderly	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
70	70	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
9	9	NUM	CD	7	O
young	young	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
33	33	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
volunteers	volunteer	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

INTERVENTIONS	intervention	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Pupil	pupil	NOUN	NN	5	O
diameter	diameter	NOUN	NN	9	O
was	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
computerized	computerized	ADJ	JJ	5	O
infrared	infrared	ADJ	JJ	0	O
pupillometer	pupillometer	NOUN	NN	5	O
over	over	ADP	IN	5	O
4	4	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
involved	involve	VERB	VBD	9	O
4	4	NUM	CD	9	O
sessions	session	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
1	1	NUM	CD	9	O
session	session	NOUN	NN	5	O
,	,	PUNCT	,	9	O
tropicamide	tropicamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
microL	microL	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
one	one	NUM	CD	5	O
eye	eye	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
another	another	DET	DT	9	O
session	session	NOUN	NN	5	O
,	,	PUNCT	,	9	O
tropicamide	tropicamide	VERB	VB	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
microL	microL	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
both	both	DET	DT	9	O
eyes	eye	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBD	9	O
23	23	NUM	CD	7	O
minutes	minute	NOUN	NNS	0	O
later	later	ADV	RB	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
microL	microL	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
one	one	NUM	CD	5	O
eye	eye	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
eye	eye	NOUN	NN	5	O
drops	drop	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
randomized	randomized	ADJ	JJ	5	O
order	order	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
2	2	NUM	CD	9	O
separate	separate	ADJ	JJ	9	O
sessions	session	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
intravenously	intravenously	ADV	RB	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
word	word	NOUN	NN	5	O
recall	recall	NOUN	NN	5	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
Buschke	Buschke	PROPN	NNP	6	O
Selective	Selective	PROPN	NNP	9	O
Reminding	Reminding	PROPN	NNP	5	O
Test	test	NOUN	NN	5	O
over	over	ADP	IN	5	O
2	2	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

OUTCOME	OUTCOME	PROPN	NNP	2	O
MEASURES	MEASURES	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Pupil	pupil	NOUN	NN	5	O
size	size	NOUN	NN	9	O
at	at	ADP	IN	9	O
time	time	NOUN	NN	5	O
points	point	NOUN	NNS	5	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
tropicamide	tropicamide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
impairment	impairment	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	I-Disease
word	word	NOUN	NN	5	I-Disease
recall	recall	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
young	young	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
in	in	ADP	IN	5	O
pupillary	pupillary	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
to	to	PART	TO	5	O
tropicamide	tropicamide	VERB	VB	0	B-Chemical
at	at	ADP	IN	9	O
any	any	DET	DT	5	O
time	time	NOUN	NN	5	O
point	point	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
net	net	ADJ	JJ	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
pupil	pupil	NOUN	NN	5	O
size	size	NOUN	NN	9	O
85	85	NUM	CD	9	O
,	,	PUNCT	,	9	O
125	125	NUM	CD	9	O
,	,	PUNCT	,	9	O
165	165	NUM	CD	7	O
and	and	CCONJ	CC	5	O
215	215	NUM	CD	7	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
young	young	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
young	young	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
impairment	impairment	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	I-Disease
word	word	NOUN	NN	5	I-Disease
recall	recall	NOUN	NN	5	I-Disease
60	60	NUM	CD	9	O
,	,	PUNCT	,	9	O
90	90	NUM	CD	9	O
and	and	CCONJ	CC	5	O
120	120	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
pupillary	pupillary	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
to	to	PART	TO	5	O
pilocarpine	pilocarpine	VERB	VB	0	B-Chemical
that	that	DET	DT	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
found	find	VERB	VBN	9	O
with	with	ADP	IN	5	O
tropicamide	tropicamide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
variations	variation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
central	central	ADJ	JJ	5	O
cholinergic	cholinergic	NOUN	NN	3	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Pain	pain	NOUN	NN	5	B-Disease
responses	response	NOUN	NNS	5	O
in	in	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
maintained	maintain	VERB	VBN	9	O
opioid	opioid	NOUN	NN	5	O
abusers	abuser	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Providing	provide	VERB	VBG	5	O
pain	pain	NOUN	NN	5	B-Disease
management	management	NOUN	NN	5	O
for	for	ADP	IN	5	O
known	know	VERB	VBN	9	O
opioid	opioid	NOUN	NN	5	O
abusers	abuser	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
challenging	challenging	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
task	task	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
part	part	NOUN	NN	9	O
because	because	ADP	IN	5	O
little	little	ADJ	JJ	9	O
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
about	about	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
pain	pain	NOUN	NN	5	B-Disease
experience	experience	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
analgesic	analgesic	ADJ	JJ	5	O
requirements	requirement	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
describe	describe	VERB	VB	5	O
pain	pain	NOUN	NN	5	B-Disease
tolerance	tolerance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
analgesic	analgesic	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
sample	sample	NOUN	NN	9	O
of	of	ADP	IN	5	O
opioid	opioid	NOUN	NN	5	B-Disease
addicts	addict	NOUN	NNS	5	I-Disease
stabilized	stabilize	VERB	VBN	9	O
in	in	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
maintenance	maintenance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
MM	MM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
60	60	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
to	to	ADP	IN	5	O
matched	match	VERB	VBN	9	O
nondependent	nondependent	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
60	60	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
way	way	NOUN	NN	5	O
factorial	factorial	ADJ	JJ	5	O
design	design	NOUN	NN	5	O
,	,	PUNCT	,	9	O
tolerance	tolerance	NOUN	NN	9	O
to	to	ADP	IN	5	O
cold	cold	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
pressor	pressor	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CP	CP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
pain	pain	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
,	,	PUNCT	,	9	O
both	both	CCONJ	CC	9	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
common	common	ADJ	JJ	5	O
opioid	opioid	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
hydromorphone	hydromorphone	NOUN	NN	0	B-Chemical
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
ketorolac	ketorolac	NOUN	NN	0	B-Chemical
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
analgesic	analgesic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Results	result	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
MM	MM	PROPN	NNP	9	O
individuals	individual	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADV	RBR	5	O
tolerant	tolerant	ADJ	JJ	9	O
of	of	ADP	IN	5	O
CP	CP	PROPN	NNP	9	O
pain	pain	NOUN	NN	5	B-Disease
than	than	ADP	IN	5	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
replicating	replicate	VERB	VBG	9	O
previous	previous	ADJ	JJ	9	O
work	work	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Analgesic	analgesic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
neither	neither	CCONJ	CC	9	O
for	for	ADP	IN	5	O
medication	medication	NOUN	NN	5	O
nor	nor	CCONJ	CC	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
MM	MM	PROPN	NNP	9	O
opioid	opioid	VERB	VBP	5	O
abusers	abuser	NOUN	NNS	5	O
represent	represent	VERB	VBP	9	O
a	a	DET	DT	5	O
pain	pain	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
intolerant	intolerant	ADJ	JJ	9	I-Disease
subset	subset	NOUN	NN	9	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Their	-PRON-	DET	PRP$	5	O
complaints	complaint	NOUN	NNS	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
evaluated	evaluate	VERB	VBN	9	O
seriously	seriously	ADV	RB	5	O
and	and	CCONJ	CC	5	O
managed	manage	VERB	VBN	5	O
aggressively	aggressively	ADV	RB	5	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
do	do	VERB	VB	5	O
more	more	ADJ	JJR	5	O
harm	harm	NOUN	NN	5	O
for	for	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	B-Disease
cord	cord	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
National	National	PROPN	NNP	2	O
Acute	Acute	PROPN	NNP	5	O
Spinal	Spinal	PROPN	NNP	9	B-Disease
Cord	Cord	PROPN	NNP	9	I-Disease
Injury	Injury	PROPN	NNP	5	I-Disease
Studies	Studies	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
NASCIS	NASCIS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
became	become	VERB	VBD	9	O
the	the	DET	DT	5	O
standard	standard	NOUN	NN	5	O
of	of	ADP	IN	5	O
care	care	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
spinal	spinal	ADJ	JJ	5	B-Disease
cord	cord	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
NASCIS	NASCIS	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
mention	mention	NOUN	NN	5	O
regarding	regard	VERB	VBG	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
corticosteroid	corticosteroid	NOUN	NN	5	B-Chemical
myopathy	myopathy	NOUN	NN	9	B-Disease
that	that	DET	WDT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
recommended	recommend	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
NASCIS	NASCIS	PROPN	NNP	5	O
3	3	NUM	CD	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
ever	ever	ADV	RB	5	O
being	be	VERB	VBG	5	O
used	use	VERB	VBN	5	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
period	period	NOUN	NN	5	O
for	for	ADP	IN	5	O
any	any	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
condition	condition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
hypothesize	hypothesize	VERB	VBP	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
some	some	DET	DT	5	O
damage	damage	NOUN	NN	9	B-Disease
to	to	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
muscle	muscle	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	B-Disease
cord	cord	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Further	further	ADV	RB	9	O
,	,	PUNCT	,	9	O
steroid	steroid	VERB	VB	9	B-Chemical
myopathy	myopathy	ADJ	JJ	9	B-Disease
recovers	recover	NOUN	NNS	5	O
naturally	naturally	ADV	RB	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
neurological	neurological	ADJ	JJ	5	O
improvement	improvement	NOUN	NN	5	O
shown	show	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
NASCIS	NASCIS	PROPN	NNP	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
just	just	ADV	RB	5	O
a	a	DET	DT	5	O
recording	recording	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
natural	natural	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
recovery	recovery	NOUN	NN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
myopathy	myopathy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
instead	instead	ADV	RB	5	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
protection	protection	NOUN	NN	9	O
that	that	ADP	IN	5	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
offers	offer	VERB	VBZ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
spinal	spinal	ADJ	JJ	5	B-Disease
cord	cord	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
discussion	discussion	NOUN	NN	5	O
considering	consider	VERB	VBG	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
recommended	recommend	VERB	VBN	5	O
by	by	ADP	IN	9	O
NASCIS	NASCIS	PROPN	NNP	5	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
acute	acute	ADJ	JJ	9	O
corticosteroid	corticosteroid	ADJ	JJ	5	B-Chemical
myopathy	myopathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Conversion	conversion	NOUN	NN	9	O
to	to	PART	TO	5	O
rapamycin	rapamycin	VERB	VB	3	B-Chemical
immunosuppression	immunosuppression	NOUN	NN	5	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
experience	experience	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
RAPA	RAPA	PROPN	NNP	3	B-Chemical
conversion	conversion	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CsA	CsA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Tac	Tac	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Twenty	twenty	NUM	CD	9	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
switched	switch	VERB	VBN	9	O
to	to	ADP	IN	5	O
fixed	fix	VERB	VBN	9	O
dose	dose	NOUN	NN	9	O
rapamycin	rapamycin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
RAPA	RAPA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
204	204	NUM	CD	7	O
months	month	NOUN	NNS	5	O
posttransplant	posttransplant	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	O
monitoring	monitoring	NOUN	NN	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
initially	initially	ADV	RB	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
adjust	adjust	VERB	VB	5	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
indications	indication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
switch	switch	NOUN	NN	9	O
were	be	VERB	VBD	9	O
chronic	chronic	ADJ	JJ	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
Tac	Tac	PROPN	NNP	3	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
acute	acute	ADJ	JJ	9	O
CsA	CsA	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
Tac	Tac	PROPN	NNP	3	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
severe	severe	ADJ	JJ	5	O
facial	facial	ADJ	JJ	5	B-Disease
dysmorphism	dysmorphism	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
posttransplant	posttransplant	ADJ	JJ	5	B-Disease
lymphoproliferative	lymphoproliferative	ADJ	JJ	3	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PTLD	PTLD	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
remission	remission	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O

Follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
7	7	NUM	CD	9	O
to	to	PART	TO	5	O
24	24	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
the	the	DET	DT	5	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
switched	switch	VERB	VBN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
[	[	PUNCT	-LRB-	9	O
233	233	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
34	34	NUM	CD	7	O
to	to	ADP	IN	5	O
210	210	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
56	56	NUM	CD	7	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
liter	liter	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
]	]	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Facial	facial	ADJ	JJ	5	B-Disease
dysmorphism	dysmorphism	NOUN	NN	5	I-Disease
improved	improve	VERB	VBD	5	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
relapse	relapse	NOUN	NN	5	O
of	of	ADP	IN	5	O
PTLD	PTLD	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
pneumonia	pneumonia	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
two	two	NUM	CD	5	O
Pneumocystis	Pneumocystis	PROPN	NNP	9	B-Disease
carinii	carinii	NOUN	NN	9	I-Disease
pneumonia	pneumonia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
infectious	infectious	ADJ	JJ	5	B-Disease
mononucleosis	mononucleosis	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
polyclonal	polyclonal	ADJ	JJ	3	O
PTLD	PTLD	PROPN	NNP	5	B-Disease
lung	lung	NOUN	NN	9	O
infiltrate	infiltrate	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
had	have	VERB	VBD	9	O
bronchiolitis	bronchiolitis	NOUN	NN	5	B-Disease
obliterans	obliteran	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
deaths	death	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RAPA	RAPA	PROPN	NNP	3	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
pneumonia	pneumonia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
,	,	PUNCT	,	9	O
PTLD	PTLD	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
oral	oral	ADJ	JJ	9	O
aphtous	aphtous	ADJ	JJ	5	B-Disease
ulcers	ulcer	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
.	.	PUNCT	.	9	O

RAPA	RAPA	PROPN	NNP	3	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
15	15	NUM	CD	9	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
of	of	ADP	IN	5	O
13	13	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
54	54	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
RAPA	RAPA	PROPN	NNP	3	B-Chemical
conversion	conversion	NOUN	NN	9	O
provides	provide	VERB	VBZ	5	O
adequate	adequate	ADJ	JJ	5	O
immunosuppression	immunosuppression	NOUN	NN	5	O
to	to	PART	TO	5	O
enable	enable	VERB	VB	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
converting	convert	VERB	VBG	9	O
patients	patient	NOUN	NNS	5	O
to	to	ADP	IN	5	O
RAPA	RAPA	PROPN	NNP	3	B-Chemical
drug	drug	NOUN	NN	5	O
levels	level	NOUN	NNS	3	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
monitored	monitor	VERB	VBN	9	O
to	to	PART	TO	5	O
avoid	avoid	VERB	VB	5	O
over	over	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
immunosuppression	immunosuppression	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
adequate	adequate	ADJ	JJ	5	O
antiviral	antiviral	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
Pneumocystis	Pneumocystis	PROPN	NNP	9	B-Disease
carinii	carinii	NOUN	NN	9	I-Disease
pneumonia	pneumonia	NOUN	NN	5	I-Disease
prophylaxis	prophylaxis	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
given	give	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Electro	electro	NOUN	NN	2	O
-	-	PUNCT	HYPH	7	O
oculography	oculography	NOUN	NN	5	O
,	,	PUNCT	,	9	O
electroretinography	electroretinography	NOUN	NN	5	O
,	,	PUNCT	,	9	O
visual	visual	ADJ	JJ	5	O
evoked	evoke	VERB	VBN	5	O
potentials	potential	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
multifocal	multifocal	ADJ	JJ	5	O
electroretinography	electroretinography	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
vigabatrin	vigabatrin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
attributed	attribute	VERB	VBN	9	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
constriction	constriction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Symptomatic	symptomatic	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
constriction	constriction	NOUN	NN	5	I-Disease
thought	think	VERB	VBD	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
vigabatrin	vigabatrin	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
visual	visual	ADJ	JJ	5	O
fields	field	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
visual	visual	ADJ	JJ	5	O
electrophysiology	electrophysiology	NOUN	NN	5	O
of	of	ADP	IN	5	O
eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
known	know	VERB	VBN	9	O
vigabatrin	vigabatrin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
attributed	attribute	VERB	VBN	9	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
loss	loss	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
no	no	ADV	RB	9	O
longer	longer	ADV	RBR	5	O
receiving	receive	VERB	VBG	9	O
vigabatrin	vigabatrin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	O
fields	field	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
Humphrey	Humphrey	PROPN	NNP	6	O
Visual	Visual	PROPN	NNP	5	O
Field	Field	PROPN	NNP	9	O
Analyzer	Analyzer	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

Full	full	ADJ	JJ	9	O
visual	visual	ADJ	JJ	5	O
electrophysiology	electrophysiology	NOUN	NN	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
flash	flash	NOUN	NN	5	O
electroretinography	electroretinography	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ERG	ERG	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
pattern	pattern	NOUN	NN	9	O
electroretinography	electroretinography	NOUN	NN	5	O
,	,	PUNCT	,	9	O
multifocal	multifocal	ADJ	JJ	5	O
ERG	ERG	PROPN	NNP	3	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
VERIS	VERIS	PROPN	NNP	5	O
system	system	NOUN	NN	5	O
,	,	PUNCT	,	9	O
electro	electro	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
oculography	oculography	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
flash	flash	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
pattern	pattern	VERB	VB	9	O
visual	visual	ADJ	JJ	5	O
evoked	evoke	VERB	VBN	5	O
potentials	potential	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Seven	seven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
marked	mark	VERB	VBN	9	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
constriction	constriction	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
some	some	DET	DT	5	O
sparing	sparing	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
temporal	temporal	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
eighth	eighth	ADJ	JJ	5	O
exhibited	exhibit	VERB	VBN	9	O
concentric	concentric	ADJ	JJ	5	O
constriction	constriction	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Most	Most	ADJ	JJS	5	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
usually	usually	ADV	RB	5	O
just	just	ADV	RB	5	O
within	within	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
limits	limit	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
subnormal	subnormal	ADJ	JJ	5	O
Arden	Arden	PROPN	NNP	6	O
electro	electro	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
oculography	oculography	NOUN	NN	5	O
indices	index	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
an	an	DET	DT	5	O
abnormally	abnormally	ADV	RB	9	O
delayed	delay	VERB	VBN	9	O
photopic	photopic	NOUN	NN	5	O
b	b	PUNCT	LS	9	O
wave	wave	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
delayed	delay	VERB	VBN	9	O
30	30	NUM	CD	9	O
-	-	SYM	SYM	7	O
Hz	hz	NOUN	NN	5	O
flicker	flicker	NOUN	NN	5	O
b	b	NOUN	NN	9	O
waves	wave	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
seven	seven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
delayed	delay	VERB	VBN	9	O
oscillatory	oscillatory	ADJ	JJ	5	O
potentials	potential	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Multifocal	multifocal	ADJ	JJ	7	O
ERG	ERG	PROPN	NNP	3	O
showed	show	VERB	VBD	9	O
abnormalities	abnormality	NOUN	NNS	9	O
that	that	ADP	IN	5	O
sometimes	sometimes	ADV	RB	5	O
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
visual	visual	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
appearance	appearance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
confirmed	confirm	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
deficit	deficit	NOUN	NN	5	O
occurs	occur	VERB	VBZ	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
retinal	retinal	ADJ	JJ	5	O
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Marked	mark	VERB	VBN	9	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
constriction	constriction	NOUN	NN	5	I-Disease
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
vigabatrin	vigabatrin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
field	field	NOUN	NN	5	O
defects	defect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
some	some	DET	DT	5	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
abnormalities	abnormality	NOUN	NNS	9	O
persist	persist	VERB	VBP	5	O
when	when	ADV	WRB	5	O
vigabatrin	vigabatrin	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
withdrawn	withdraw	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
during	during	ADP	IN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
stress	stress	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Dobutamine	dobutamine	NOUN	NN	0	B-Chemical
stress	stress	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
DSE	DSE	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
safe	safe	ADJ	JJ	5	O
provocation	provocation	NOUN	NN	5	O
test	test	NOUN	NN	5	O
for	for	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Until	until	ADP	IN	5	O
now	now	ADV	RB	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
focused	focus	VERB	VBN	5	O
only	only	ADV	RB	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
organic	organic	ADJ	JJ	0	O
lesion	lesion	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
positive	positive	ADJ	JJ	9	O
DSE	DSE	PROPN	NNP	9	O
has	have	VERB	VBZ	9	O
indicated	indicate	VERB	VBN	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
fixed	fix	VERB	VBN	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
is	be	VERB	VBZ	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
performed	perform	VERB	VBD	9	O
DSE	DSE	PROPN	NNP	9	O
on	on	ADP	IN	5	O
51	51	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
spastic	spastic	ADJ	JJ	5	I-Disease
angina	angina	NOUN	NN	5	I-Disease
but	but	CCONJ	CC	9	O
without	without	ADP	IN	9	O
significant	significant	ADJ	JJ	9	O
fixed	fix	VERB	VBN	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
anginal	anginal	ADJ	JJ	5	B-Disease
attacks	attack	NOUN	NNS	5	O
at	at	ADP	IN	9	O
rest	rest	NOUN	NN	5	O
with	with	ADP	IN	5	O
ST	ST	PROPN	NNP	9	O
elevation	elevation	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
variant	variant	ADJ	JJ	1	B-Disease
angina	angina	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Coronary	coronary	ADJ	JJ	5	O
spasm	spasm	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
intracoronary	intracoronary	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
fixed	fix	VERB	VBN	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
documented	document	VERB	VBN	9	O
on	on	ADP	IN	5	O
angiograms	angiogram	NOUN	NNS	5	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

DSE	DSE	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
infusion	infusion	NOUN	NN	0	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
incremental	incremental	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
40	40	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
every	every	DET	DT	5	O
5	5	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
51	51	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
asynergy	asynergy	ADV	RB	5	O
with	with	ADP	IN	5	O
ST	ST	PROPN	NNP	9	O
elevation	elevation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
7	7	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
asynergy	asynergy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
both	both	DET	DT	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
electrocardiographic	electrocardiographic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
preceded	precede	VERB	VBN	9	O
by	by	ADP	IN	9	O
asynergy	asynergy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
can	can	VERB	MD	5	O
provoke	provoke	VERB	VB	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
spastic	spastic	ADJ	JJ	5	I-Disease
angina	angina	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
DSE	DSE	PROPN	NNP	9	O
is	be	VERB	VBZ	5	O
performed	perform	VERB	VBN	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
not	not	ADV	RB	5	O
only	only	ADV	RB	9	O
fixed	fix	VERB	VBN	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
also	also	ADV	RB	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
genesis	genesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
asynergy	asynergy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
intravenous	intravenous	ADJ	JJ	0	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
plus	plus	CCONJ	CC	9	O
glucagon	glucagon	NOUN	NN	3	O
on	on	ADP	IN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

STUDY	study	NOUN	NN	2	O
OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
stress	stress	NOUN	NN	9	O
testing	testing	NOUN	NN	5	O
with	with	ADP	IN	5	O
technetium	technetium	NOUN	NN	0	B-Chemical
-	-	PUNCT	:	7	I-Chemical
99m	99m	NOUN	NNS	0	I-Chemical
sestamibi	sestamibi	VERB	VBP	0	I-Chemical
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
photon	photon	NOUN	NN	5	O
emission	emission	NOUN	NN	0	O
computed	compute	VERB	VBD	5	O
tomography	tomography	NOUN	NN	5	O
imaging	image	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
ST	ST	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
segment	segment	NOUN	NN	9	O
monitoring	monitoring	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
impact	impact	NOUN	NN	5	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
glucagon	glucagon	NOUN	NN	3	O
on	on	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

SETTING	setting	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Community	community	NOUN	NN	2	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
known	know	VERB	VBN	9	O
reversible	reversible	ADJ	JJ	9	O
perfusion	perfusion	NOUN	NN	5	O
defects	defect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

INTERVENTION	intervention	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
underwent	undergo	VERB	VBD	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
stress	stress	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
per	per	ADP	IN	9	O
standard	standard	ADJ	JJ	5	O
protocol	protocol	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Before	before	ADP	IN	9	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
begun	begin	VERB	VBN	5	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
visit	visit	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
on	on	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
visits	visit	NOUN	NNS	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
plus	plus	CCONJ	CC	9	O
glucagon	glucagon	ADJ	JJ	3	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Metoprolol	Metoprolol	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
dosed	dose	VERB	VBN	0	O
to	to	PART	TO	5	O
achieve	achieve	VERB	VB	5	O
a	a	DET	DT	5	O
resting	rest	VERB	VBG	5	O
predobutamine	predobutamine	NOUN	NN	_	B-Chemical
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
below	below	ADP	IN	9	O
65	65	NUM	CD	7	O
beats	beat	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
minute	minute	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
total	total	ADJ	JJ	9	O
intravenous	intravenous	ADJ	JJ	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

MEASUREMENTS	measurement	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
MAIN	main	ADJ	JJ	2	O
RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Metoprolol	Metoprolol	PROPN	NNP	0	B-Chemical
reduced	reduce	VERB	VBD	9	O
maximum	maximum	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
31	31	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
summed	sum	VERB	VBN	5	O
stress	stress	NOUN	NN	9	O
scores	score	VERB	VBZ	5	O
29	29	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
summed	sum	VERB	VBN	5	O
difference	difference	NOUN	NN	9	O
scores	score	VERB	VBZ	5	O
43	43	NUM	CD	7	O
%	%	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Metoprolol	Metoprolol	PROPN	NNP	0	B-Chemical
plus	plus	CCONJ	CC	9	O
glucagon	glucagon	NOUN	NN	3	O
also	also	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
29	29	NUM	CD	7	O
%	%	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Summed	sum	VERB	VBN	5	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
summed	sum	VERB	VBN	5	O
difference	difference	NOUN	NN	9	O
scores	score	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
18	18	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
lower	low	ADJ	JJR	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
than	than	ADP	IN	5	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
any	any	DET	DT	5	O
parameter	parameter	NOUN	NN	5	O
between	between	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
glucagon	glucagon	NOUN	NN	3	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
During	during	ADP	IN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
stress	stress	NOUN	NN	9	O
testing	testing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
attenuates	attenuate	NOUN	NNS	3	O
or	or	CCONJ	CC	5	O
eliminates	eliminate	VERB	VBZ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Glucagon	Glucagon	PROPN	NNP	0	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
somewhat	somewhat	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
correct	correct	VERB	VB	5	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
administered	administer	VERB	VBN	9	O
clinically	clinically	ADV	RB	5	O
.	.	PUNCT	.	9	O

Evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
functional	functional	ADJ	JJ	9	O
somatotopy	somatotopy	NOUN	NN	5	O
in	in	ADP	IN	5	O
GPi	GPi	NOUN	NNS	5	O
from	from	ADP	IN	9	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
explore	explore	VERB	VB	5	O
the	the	DET	DT	5	O
functional	functional	ADJ	JJ	9	O
anatomy	anatomy	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
globus	globus	ADJ	JJ	5	O
pallidus	pallidus	NOUN	NN	4	O
internus	internus	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
GPi	GPi	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
by	by	ADP	IN	9	O
studying	study	VERB	VBG	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
unilateral	unilateral	ADJ	JJ	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
on	on	ADP	IN	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
'	'	PUNCT	``	9	O
off	off	PART	RP	5	O
'	'	PUNCT	``	9	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
LID	LID	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
positive	positive	ADJ	JJ	9	O
correlations	correlation	NOUN	NNS	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
preoperative	preoperative	ADJ	JJ	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
responsiveness	responsiveness	NOUN	NN	9	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
responsiveness	responsiveness	NOUN	NN	9	O
of	of	ADP	IN	5	O
scores	score	NOUN	NNS	5	O
in	in	ADP	IN	5	O
timed	time	VERB	VBN	5	O
tests	test	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
Core	Core	PROPN	NNP	9	O
Assessment	Assessment	PROPN	NNP	5	O
Program	Program	PROPN	NNP	2	O
for	for	ADP	IN	5	O
Intracerebral	Intracerebral	PROPN	NNP	5	O
Transplantations	Transplantations	PROPN	NNPS	2	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
contralateral	contralateral	ADJ	JJ	5	O
limbs	limb	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
scores	score	NOUN	NNS	5	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
correlation	correlation	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
LID	LID	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
also	also	ADV	RB	9	O
found	find	VERB	VBD	9	O
a	a	DET	DT	5	O
highly	highly	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
:	:	PUNCT	:	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
,	,	PUNCT	,	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
volume	volume	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ventral	ventral	ADJ	JJ	5	O
lesion	lesion	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
GPi	GPi	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
LID	LID	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
contralateral	contralateral	ADJ	JJ	5	O
limbs	limb	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
ventral	ventral	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
'	'	PUNCT	``	9	O
off	off	PART	RP	5	O
'	'	PUNCT	``	9	O
signs	sign	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
volumes	volume	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
lesion	lesion	NOUN	NN	5	O
cylinder	cylinder	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
dorsal	dorsal	ADJ	JJ	5	O
lesion	lesion	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
correlate	correlate	VERB	VB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
outcome	outcome	NOUN	NN	5	O
of	of	ADP	IN	5	O
either	either	CCONJ	CC	9	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
or	or	CCONJ	CC	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
'	'	PUNCT	''	9	O
off	off	PART	RP	5	O
'	'	PUNCT	``	9	O
signs	sign	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
predictive	predictive	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
responsiveness	responsiveness	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
outcome	outcome	NOUN	NN	5	O
of	of	ADP	IN	5	O
parkinsonian	parkinsonian	NOUN	NN	5	B-Disease
'	'	PUNCT	``	9	O
off	off	PART	RP	5	O
'	'	PUNCT	``	9	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
LID	LID	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
different	different	ADJ	JJ	9	O
correlations	correlation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ventral	ventral	ADJ	JJ	5	O
lesion	lesion	NOUN	NN	5	O
volume	volume	NOUN	NN	9	O
with	with	ADP	IN	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
'	'	PUNCT	''	9	O
off	off	PART	RP	5	O
'	'	PUNCT	''	9	O
signs	sign	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	DET	DT	5	O
different	different	ADJ	JJ	9	O
anatomical	anatomical	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
pathophysiological	pathophysiological	ADJ	JJ	5	O
substrates	substrate	NOUN	NNS	0	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
generation	generation	NOUN	NN	9	O
of	of	ADP	IN	5	O
parkinsonian	parkinsonian	NOUN	NN	5	B-Disease
'	'	PUNCT	``	9	O
off	off	PART	RP	5	O
'	'	PUNCT	``	9	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Whereas	whereas	ADP	IN	9	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
wider	wide	ADJ	JJR	5	O
area	area	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
GPi	GPi	NOUN	NNS	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
parkinsonism	parkinsonism	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
ventral	ventral	ADJ	JJ	5	O
GPi	GPi	NOUN	NNS	5	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
crucial	crucial	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
manifestation	manifestation	NOUN	NN	5	O
of	of	ADP	IN	5	O
LID	LID	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
observations	observation	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
additional	additional	ADJ	JJ	9	O
proof	proof	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
functional	functional	ADJ	JJ	9	O
somatotopy	somatotopy	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
systems	system	NOUN	NNS	5	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
GPi	GPi	NOUN	NNS	5	O
that	that	DET	WDT	5	O
mediate	mediate	VERB	VBP	3	O
parkinsonism	parkinsonism	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
along	along	ADP	IN	9	O
the	the	DET	DT	5	O
dorsoventral	dorsoventral	ADJ	JJ	5	O
trajectory	trajectory	NOUN	NN	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
outcome	outcome	NOUN	NN	5	O
of	of	ADP	IN	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
lesion	lesion	NOUN	NN	5	O
involves	involve	VERB	VBZ	5	O
the	the	DET	DT	5	O
ventral	ventral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
dorsal	dorsal	ADJ	JJ	5	O
GPi	GPi	NOUN	NNS	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
net	net	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
alteration	alteration	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
pathways	pathway	NOUN	NNS	9	O
which	which	DET	WDT	5	O
mediate	mediate	VERB	VBP	3	O
different	different	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hence	hence	ADV	RB	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
variable	variable	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Screening	screen	VERB	VBG	9	O
for	for	ADP	IN	5	O
stimulant	stimulant	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
positive	positive	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
drug	drug	NOUN	NN	5	O
screening	screen	VERB	VBG	5	O
for	for	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
evaluated	evaluate	VERB	VBD	9	O
consecutive	consecutive	ADJ	JJ	5	O
eligible	eligible	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
sample	sample	NOUN	NN	9	O
collected	collect	VERB	VBN	9	O
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
clinical	clinical	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Plasma	Plasma	PROPN	NNP	0	O
was	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
for	for	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
metabolite	metabolite	NOUN	NN	0	O
benzoylecgonine	benzoylecgonine	NOUN	NN	0	B-Chemical
using	use	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
immunoassay	immunoassay	NOUN	NN	0	O
methodology	methodology	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Plasma	plasma	NOUN	NN	0	O
samples	sample	NOUN	NNS	9	O
with	with	ADP	IN	5	O
benzoylecgonine	benzoylecgonine	NOUN	NN	0	B-Chemical
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
150	150	NUM	CD	0	O
ng	ng	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
an	an	DET	DT	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
500	500	NUM	CD	0	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
mL	mL	PROPN	NNP	0	O
were	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
positive	positive	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Patient	patient	ADJ	JJ	5	O
demographics	demographic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
underlying	underlie	VERB	VBG	5	O
drug	drug	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
seizure	seizure	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	O
,	,	PUNCT	,	9	O
estimated	estimate	VERB	VBN	5	O
time	time	NOUN	NN	5	O
from	from	ADP	IN	9	O
seizure	seizure	NOUN	NN	5	B-Disease
to	to	PART	TO	5	O
sample	sample	NOUN	NN	9	O
collection	collection	NOUN	NN	5	O
,	,	PUNCT	,	9	O
history	history	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
suspicion	suspicion	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	I-Disease
amphetamine	amphetamine	NOUN	NN	5	I-Disease
abuse	abuse	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
urine	urine	NOUN	NN	9	O
testing	testing	NOUN	NN	5	O
for	for	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
of	of	ADP	IN	5	O
abuse	abuse	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
assay	assay	ADJ	JJ	3	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
without	without	ADP	IN	9	O
patient	patient	ADJ	JJ	5	O
identifiers	identifier	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Fourteen	fourteen	NUM	CD	9	O
of	of	ADP	IN	5	O
248	248	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
plasma	plasma	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
by	by	ADP	IN	9	O
immunoassay	immunoassay	NOUN	NN	0	O
testing	testing	NOUN	NN	5	O
for	for	ADP	IN	5	O
benzoylecgonine	benzoylecgonine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
samples	sample	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
for	for	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Positive	positive	ADJ	JJ	7	O
test	test	NOUN	NN	5	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
in	in	ADP	IN	5	O
patient	patient	ADJ	JJ	5	O
visits	visit	NOUN	NNS	5	O
where	where	ADV	WRB	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
suspicion	suspicion	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	I-Disease
amphetamine	amphetamine	NOUN	NN	5	I-Disease
abuse	abuse	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0005	0005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
During	during	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
routine	routine	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
screening	screen	VERB	VBG	5	O
for	for	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
amphetamines	amphetamine	NOUN	NNS	5	B-Chemical
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
seizure	seizure	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
yield	yield	NOUN	NN	9	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
,	,	PUNCT	,	9	O
routine	routine	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
screening	screening	NOUN	NN	5	O
would	would	VERB	MD	5	O
yield	yield	VERB	VB	9	O
few	few	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
stimulant	stimulant	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
neither	neither	CCONJ	CC	9	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
nor	nor	CCONJ	CC	9	O
suspicion	suspicion	NOUN	NN	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Contribution	contribution	NOUN	NN	6	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
valproate	valproate	NOUN	NN	0	I-Chemical
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
inappropriate	inappropriate	ADJ	JJ	5	I-Disease
secretion	secretion	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	I-Disease
antidiuretic	antidiuretic	ADJ	JJ	5	I-Disease
hormone	hormone	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
62	62	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
valproate	valproate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
VPA	VPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
who	who	PRON	WP	5	O
subsequently	subsequently	ADV	RB	9	O
developed	develop	VERB	VBD	5	O
the	the	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
inappropriate	inappropriate	ADJ	JJ	5	I-Disease
secretion	secretion	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	I-Disease
antidiuretic	antidiuretic	ADJ	JJ	5	I-Disease
hormone	hormone	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
SIADH	SIADH	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
taking	take	VERB	VBG	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
idiopathic	idiopathic	ADJ	JJ	5	O
generalized	generalize	VERB	VBN	5	O
tonic	tonic	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
clonic	clonic	NOUN	NN	5	I-Disease
convulsions	convulsion	NOUN	NNS	5	I-Disease
since	since	ADP	IN	9	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
56	56	NUM	CD	7	O
years	year	NOUN	NNS	5	O
old	old	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
substituting	substitute	VERB	VBG	9	O
VPA	VPA	PROPN	NNP	9	B-Chemical
with	with	ADP	IN	5	O
zonisamide	zonisamide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
consider	consider	VERB	VBP	5	O
this	this	DET	DT	5	O
episode	episode	NOUN	NN	5	O
of	of	ADP	IN	5	O
SIADH	SIADH	PROPN	NNP	5	B-Disease
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
factors	factor	NOUN	NNS	9	O
including	include	VERB	VBG	9	O
a	a	DET	DT	5	O
weakness	weakness	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
central	central	ADJ	JJ	5	I-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Association	association	NOUN	NN	2	O
of	of	ADP	IN	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
production	production	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
apoptosis	apoptosis	NOUN	NN	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
recent	recent	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
increased	increase	VERB	VBD	9	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NO	no	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
apoptosis	apoptosis	NOUN	NN	3	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
various	various	ADJ	JJ	9	O
pathological	pathological	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
studied	study	VERB	VBN	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
NO	no	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
apoptosis	apoptosis	NOUN	NN	3	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
alteration	alteration	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
NO	no	DET	DT	9	B-Chemical
pathway	pathway	NOUN	NN	3	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
measuring	measure	VERB	VBG	9	O
nitrite	nitrite	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
/	/	SYM	SYM	9	O
urine	urine	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
evaluating	evaluate	VERB	VBG	5	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
vascular	vascular	ADJ	JJ	5	O
reactivity	reactivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
isolated	isolate	VERB	VBN	9	O
perfused	perfused	ADJ	JJ	0	O
rat	rat	NOUN	NN	3	O
kidney	kidney	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
IPRK	IPRK	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
stratified	stratify	VERB	VBN	5	O
into	into	ADP	IN	9	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	ADJ	JJ	9	B-Disease
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
:	:	PUNCT	:	9	O
group	group	NOUN	NN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
animals	animal	NOUN	NNS	9	O
receiving	receive	VERB	VBG	9	O
saline	saline	NOUN	NN	0	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
group	group	NOUN	NN	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
animals	animal	NOUN	NNS	9	O
receiving	receive	VERB	VBG	9	O
aminoguanidine	aminoguanidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
AG	AG	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
inducible	inducible	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
NO	no	NOUN	NN	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
21	21	NUM	CD	7	O
,	,	PUNCT	,	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
sacrificed	sacrifice	VERB	VBN	3	O
after	after	ADP	IN	9	O
obtaining	obtain	VERB	VBG	5	O
material	material	NOUN	NN	5	O
for	for	ADP	IN	5	O
biochemical	biochemical	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Histopathological	histopathological	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
kidneys	kidney	NOUN	NNS	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
revealed	reveal	VERB	VBD	9	O
focal	focal	ADJ	JJ	5	O
areas	area	NOUN	NNS	5	O
of	of	ADP	IN	5	O
mesangial	mesangial	ADJ	JJ	3	B-Disease
proliferation	proliferation	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
mild	mild	ADJ	JJ	9	O
tubulointerstitial	tubulointerstitial	ADJ	JJ	3	B-Disease
inflammation	inflammation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
had	have	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Urine	urine	ADJ	JJ	9	O
nitrite	nitrite	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
IPRK	IPRK	PROPN	NNP	_	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
related	related	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
impaired	impair	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Apoptosis	apoptosis	NOUN	NN	3	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
numerous	numerous	ADJ	JJ	9	O
apoptotic	apoptotic	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
tubulointerstitial	tubulointerstitial	ADJ	JJ	3	O
areas	area	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Double	double	ADJ	JJ	9	O
staining	staining	NOUN	NN	3	O
revealed	reveal	VERB	VBD	9	O
numerous	numerous	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	O
apoptotic	apoptotic	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
to	to	PART	TO	5	O
stain	stain	VERB	VB	3	O
for	for	ADP	IN	5	O
ED1	ED1	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
marker	marker	NOUN	NN	3	O
for	for	ADP	IN	5	O
monocytes	monocyte	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
macrophages	macrophage	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
AG	AG	PROPN	NNP	9	B-Chemical
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
impairment	impairment	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
bed	bed	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBD	9	O
both	both	DET	DT	9	O
urine	urine	ADJ	JJ	9	O
nitrite	nitrite	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
apoptosis	apoptosis	NOUN	NN	3	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
interactions	interaction	NOUN	NNS	9	O
between	between	ADP	IN	5	O
NO	no	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
apoptosis	apoptosis	NOUN	NN	3	O
are	be	VERB	VBP	5	O
important	important	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrosis	nephrosis	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

Dual	dual	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
on	on	ADP	IN	5	O
barbiturate	barbiturate	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
narcosis	narcosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Melatonin	Melatonin	PROPN	NNP	0	B-Chemical
affects	affect	VERB	VBZ	9	O
the	the	DET	DT	5	O
circadian	circadian	ADJ	JJ	9	O
sleep	sleep	NOUN	NN	5	O
/	/	SYM	SYM	9	O
wake	wake	NOUN	NN	5	O
cycle	cycle	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
clear	clear	ADJ	JJ	9	O
whether	whether	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
influence	influence	VERB	VB	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
narcosis	narcosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Sodium	sodium	NOUN	NN	0	B-Chemical
thiopenthal	thiopenthal	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
into	into	ADP	IN	9	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
pre	pre	VERB	VBN	9	O
-	-	VERB	VBN	7	O
treated	treated	ADJ	JJ	3	O
with	with	ADP	IN	5	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Melatonin	Melatonin	PROPN	NNP	0	B-Chemical
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	NOUN	NN	9	O
affected	affect	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dual	dual	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
barbiturate	barbiturate	NOUN	NN	0	B-Chemical
narcosis	narcosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
correlation	correlation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
particular	particular	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
low	low	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
latency	latency	NOUN	NN	5	O
to	to	ADP	IN	5	O
and	and	CCONJ	CC	5	O
prolonged	prolong	VERB	VBD	9	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
barbiturate	barbiturate	NOUN	NN	0	B-Chemical
narcosis	narcosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
paradoxical	paradoxical	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
latency	latency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
sustained	sustained	ADJ	JJ	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
narcosis	narcosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
mortality	mortality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Melatonin	Melatonin	PROPN	NNP	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
influenced	influence	VERB	VBD	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
the	the	DET	DT	5	O
latency	latency	NOUN	NN	5	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
narcosis	narcosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
dual	dual	ADJ	JJ	9	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
on	on	ADP	IN	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
narcosis	narcosis	NOUN	NN	5	B-Disease
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
specific	specific	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
barbiturate	barbiturate	NOUN	NN	0	B-Chemical
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Reduced	reduce	VERB	VBN	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
preserved	preserve	VERB	VBD	9	O
antitumor	antitumor	CCONJ	CC	3	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
liposome	liposome	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
encapsulated	encapsulate	VERB	VBN	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
conventional	conventional	ADJ	JJ	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
randomized	randomized	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
multicenter	multicenter	NOUN	NN	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
Myocet	Myocet	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
liposome	liposome	ADV	RB	0	O
-	-	PUNCT	HYPH	7	O
encapsulated	encapsulate	VERB	VBN	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
The	the	DET	DT	5	O
Liposome	Liposome	PROPN	NNP	0	O
Company	Company	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Elan	Elan	PROPN	NNP	2	O
Corporation	Corporation	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Princeton	Princeton	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
NJ	NJ	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
significantly	significantly	ADV	RB	9	O
reduces	reduce	VERB	VBZ	9	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
while	while	ADP	IN	9	O
providing	provide	VERB	VBG	9	O
comparable	comparable	ADJ	JJ	9	O
antitumor	antitumor	CCONJ	CC	3	O
efficacy	efficacy	NOUN	NN	9	O
in	in	ADP	IN	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
MBC	MBC	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
hundred	hundred	NUM	CD	5	O
ninety	ninety	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
seven	seven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
MBC	MBC	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
prior	prior	ADJ	JJ	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
disease	disease	NOUN	NN	5	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
either	either	CCONJ	CC	9	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
Myocet	Myocet	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
M	M	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
conventional	conventional	ADJ	JJ	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
600	600	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
C	C	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
every	every	DET	DT	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
until	until	ADP	IN	5	O
disease	disease	NOUN	NN	5	O
progression	progression	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
unacceptable	unacceptable	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Cardiotoxicity	Cardiotoxicity	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
by	by	ADP	IN	9	O
reductions	reduction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
left	left	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
ventricular	ventricular	ADJ	JJ	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
serial	serial	ADJ	JJ	9	O
multigated	multigate	VERB	VBN	5	O
radionuclide	radionuclide	ADJ	JJ	5	O
angiography	angiography	ADJ	JJ	5	O
scans	scan	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
CHF	CHF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Antitumor	Antitumor	PROPN	NNP	0	O
efficacy	efficacy	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
objective	objective	ADJ	JJ	5	O
tumor	tumor	NOUN	NN	3	B-Disease
response	response	NOUN	NN	9	O
rates	rate	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
World	World	PROPN	NNP	5	O
Health	Health	PROPN	NNP	2	O
Organization	Organization	PROPN	NNP	2	O
criteria	criterion	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
progression	progression	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
survival	survival	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Six	six	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
MC	MC	PROPN	NNP	9	O
patients	patient	NOUN	NNS	5	O
versus	versus	ADP	IN	9	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
including	include	VERB	VBG	9	O
five	five	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
CHF	CHF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
AC	AC	PROPN	NNP	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
0002	0002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
cumulative	cumulative	ADJ	JJ	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
at	at	ADP	IN	9	O
onset	onset	NOUN	NN	5	O
was	be	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
220	220	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
MC	MC	PROPN	NNP	9	O
versus	versus	ADP	IN	9	O
480	480	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
AC	AC	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
,	,	PUNCT	,	9	O
hazard	hazard	NOUN	NN	5	O
ratio	ratio	NOUN	NN	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

MC	MC	PROPN	NNP	9	O
patients	patient	NOUN	NNS	5	O
also	also	ADV	RB	9	O
experienced	experience	VERB	VBD	5	O
less	less	ADJ	JJR	5	O
grade	grade	NOUN	NN	9	O
4	4	NUM	CD	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Antitumor	Antitumor	PROPN	NNP	0	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
MC	MC	PROPN	NNP	9	O
versus	versus	ADP	IN	9	O
AC	AC	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
:	:	PUNCT	:	9	O
objective	objective	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rates	rate	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
43	43	NUM	CD	7	O
%	%	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
43	43	NUM	CD	7	O
%	%	NOUN	NN	9	O
;	;	PUNCT	,	9	O
median	median	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
progression	progression	NOUN	NN	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
months	month	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
median	median	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
failure	failure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
versus	versus	ADP	IN	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
median	median	ADJ	JJ	9	O
survival	survival	NOUN	NN	9	O
,	,	PUNCT	,	9	O
19	19	NUM	CD	7	O
versus	versus	ADP	IN	9	O
16	16	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Myocet	Myocet	PROPN	NNP	0	B-Chemical
improves	improve	VERB	VBZ	5	O
the	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
index	index	NOUN	NN	5	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
by	by	ADP	IN	9	O
significantly	significantly	ADV	RB	9	O
reducing	reduce	VERB	VBG	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
grade	grade	NOUN	NN	9	O
4	4	NUM	CD	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
provides	provide	VERB	VBZ	5	O
comparable	comparable	ADJ	JJ	9	O
antitumor	antitumor	CCONJ	CC	3	O
efficacy	efficacy	NOUN	NN	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
MBC	MBC	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
nitrergic	nitrergic	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
in	in	ADP	IN	5	O
lidocaine	lidocaine	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsion	convulsion	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mouse	mouse	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitro	nitro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
L	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
ester	ester	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NAME	NAME	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
a	a	DET	DT	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NO	no	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
synthase	synthase	NOUN	NN	1	O
inhibitor	inhibitor	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
NO	no	DET	DT	9	B-Chemical
precursor	precursor	NOUN	NN	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
on	on	ADP	IN	5	O
lidocaine	lidocaine	ADV	RBR	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
experiment	experiment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
four	four	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
received	receive	VERB	VBD	9	O
physiological	physiological	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NAME	NAME	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
these	these	DET	DT	5	O
injections	injection	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
mice	mouse	NOUN	NNS	3	O
received	receive	VERB	VBD	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
experiment	experiment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
four	four	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
received	receive	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
experiment	experiment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
these	these	DET	DT	5	O
injections	injection	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
mice	mouse	NOUN	NNS	3	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NAME	name	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
significantly	significantly	ADV	RB	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
may	may	VERB	MD	5	O
suggest	suggest	VERB	VB	9	O
that	that	ADP	IN	5	O
NO	no	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
proconvulsant	proconvulsant	ADJ	JJ	0	O
mediator	mediator	NOUN	NN	9	O
in	in	ADP	IN	5	O
lidocaine	lidocaine	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Erythropoietin	erythropoietin	NOUN	NN	9	O
restores	restore	VERB	VBZ	3	O
the	the	DET	DT	5	O
anemia	anemia	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
cytotoxicity	cytotoxicity	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
tumors	tumor	NOUN	NNS	3	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
impact	impact	NOUN	NN	5	O
of	of	ADP	IN	5	O
anemia	anemia	NOUN	NN	9	B-Disease
prevention	prevention	NOUN	NN	5	O
by	by	ADP	IN	9	O
recombinant	recombinant	ADJ	JJ	3	O
human	human	ADJ	JJ	3	O
erythropoietin	erythropoietin	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
rHuEPO	rhuepo	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
cytotoxicity	cytotoxicity	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
solid	solid	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
tumors	tumor	NOUN	NNS	3	B-Disease
.	.	PUNCT	.	9	O

Anemia	Anemia	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
lasting	last	VERB	VBG	5	O
reduction	reduction	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
concentration	concentration	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
anemia	anemia	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
rHuEPO	rhuepo	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
1000	1000	NUM	CD	9	O
IU	IU	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
administered	administer	VERB	VBD	9	O
s	s	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
week	week	NOUN	NN	9	O
starting	start	VERB	VBG	9	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
before	before	ADP	IN	9	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
application	application	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
carboplatin	carboplatin	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
tumors	tumor	NOUN	NNS	3	B-Disease
(	(	PUNCT	-LRB-	9	O
DS	DS	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
sarcoma	sarcoma	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
implanted	implant	VERB	VBN	9	O
s	s	PART	POS	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
onto	onto	ADP	IN	0	O
the	the	DET	DT	5	O
hind	hind	NOUN	NN	4	O
food	food	NOUN	NN	5	O
dorsum	dorsum	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neither	neither	DET	DT	9	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
nor	nor	CCONJ	CC	9	O
rHuEPO	rhuepo	NOUN	NN	0	O
treatment	treatment	NOUN	NN	9	O
influenced	influence	VERB	VBN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
growth	growth	NOUN	NN	3	O
rate	rate	NOUN	NN	9	O
per	per	ADP	IN	9	O
se	se	X	FW	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
tumors	tumor	NOUN	NNS	3	B-Disease
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
implantation	implantation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
growth	growth	NOUN	NN	3	O
delay	delay	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
subsequent	subsequent	ADJ	JJ	9	O
regrowth	regrowth	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
tumors	tumor	NOUN	NNS	3	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
anemia	anemia	NOUN	NN	9	B-Disease
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
growth	growth	NOUN	NN	3	O
delay	delay	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
shorter	short	ADJ	JJR	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
nonanemic	nonanemic	ADJ	JJ	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
versus	versus	ADP	IN	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
where	where	ADV	WRB	5	O
anemia	anemia	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
rHuEPO	rhuepo	NOUN	NN	0	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
growth	growth	NOUN	NN	3	O
delay	delay	NOUN	NN	5	O
was	be	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
with	with	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
nonanemic	nonanemic	ADJ	JJ	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	DET	DT	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anemia	anemia	NOUN	NN	9	B-Disease
reduces	reduce	VERB	VBZ	9	O
cytotoxicity	cytotoxicity	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
tumors	tumor	NOUN	NNS	3	B-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
correction	correction	NOUN	NN	5	O
of	of	ADP	IN	5	O
anemia	anemia	NOUN	NN	9	B-Disease
by	by	ADP	IN	9	O
rHuEPO	rhuepo	NOUN	NN	0	O
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
epoetin	epoetin	NOUN	NN	0	O
alpha	alpha	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
sensitivity	sensitivity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
probably	probably	ADV	RB	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
improved	improve	VERB	VBN	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
supply	supply	NOUN	NN	5	O
to	to	PART	TO	5	O
tumor	tumor	NOUN	NN	3	B-Disease
tissue	tissue	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Fatal	Fatal	PROPN	NNP	5	O
haemorrhagic	haemorrhagic	ADJ	JJ	5	B-Disease
myocarditis	myocarditis	NOUN	NN	9	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	PART	TO	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Haemorrhagic	haemorrhagic	ADJ	JJ	2	B-Disease
myocarditis	myocarditis	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
important	important	ADJ	JJ	9	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Echocardiographic	echocardiographic	ADJ	JJ	5	O
identification	identification	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
disorder	disorder	NOUN	NN	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
made	make	VERB	VBN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
believe	believe	VERB	VBP	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
ultrasound	ultrasound	NOUN	NN	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
disorder	disorder	NOUN	NN	5	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
determinants	determinant	NOUN	NNS	5	O
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Atrial	atrial	ADJ	JJ	7	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
remodeling	remodeling	NOUN	NN	9	O
promotes	promote	VERB	VBZ	3	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
maintenance	maintenance	NOUN	NN	9	O
of	of	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AF	AF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
decreases	decrease	VERB	VBZ	9	O
L	l	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
Ca	ca	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
current	current	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
also	also	ADV	RB	9	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
suggestion	suggestion	NOUN	NN	9	O
that	that	DET	WDT	5	O
acute	acute	ADJ	JJ	9	O
L	l	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
Ca	ca	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
channel	channel	NOUN	NN	9	O
blockade	blockade	NOUN	NN	3	O
can	can	VERB	MD	5	O
promote	promote	VERB	VB	3	O
AF	AF	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
AF	AF	PROPN	NNP	9	B-Disease
promoting	promote	VERB	VBG	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
channel	channel	NOUN	NN	9	O
inhibition	inhibition	NOUN	NN	3	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
AF	AF	PROPN	NNP	9	B-Disease
promotion	promotion	NOUN	NN	5	O
by	by	ADP	IN	9	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
administered	administer	VERB	VBD	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
chloralose	chloralose	ADJ	JJ	0	B-Chemical
anesthetized	anesthetized	ADJ	JJ	0	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Diltiazem	Diltiazem	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
comparison	comparison	NOUN	NN	9	O
drug	drug	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
autonomic	autonomic	ADJ	JJ	5	O
blockade	blockade	NOUN	NN	3	O
with	with	ADP	IN	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
nadolol	nadolol	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
applied	apply	VERB	VBN	5	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
experiments	experiment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Epicardial	epicardial	ADJ	JJ	5	O
mapping	mapping	NOUN	NN	5	O
with	with	ADP	IN	5	O
240	240	NUM	CD	9	O
epicardial	epicardial	ADJ	JJ	5	O
electrodes	electrode	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
activation	activation	NOUN	NN	3	O
during	during	ADP	IN	5	O
AF	AF	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Verapamil	Verapamil	PROPN	NNP	0	B-Chemical
caused	cause	VERB	VBD	9	O
AF	AF	PROPN	NNP	9	B-Disease
promotion	promotion	NOUN	NN	5	O
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
increasing	increase	VERB	VBG	9	O
mean	mean	ADJ	JJ	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
AF	AF	PROPN	NNP	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
burst	burst	NOUN	NN	5	O
pacing	pacing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
from	from	ADP	IN	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
s	s	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	ADJ	JJ	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
S	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O
E	e	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
95	95	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
39	39	NUM	CD	7	O
s	s	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
control	control	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
loading	loading	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
228	228	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
101	101	NUM	CD	7	O
s	s	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0005	0005	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
control	control	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Underlying	underlie	VERB	VBG	5	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
detail	detail	NOUN	NN	5	O
in	in	ADP	IN	5	O
five	five	NUM	CD	9	O
additional	additional	ADJ	JJ	9	O
dogs	dog	NOUN	NNS	5	O
under	under	ADP	IN	9	O
control	control	NOUN	NN	9	O
conditions	condition	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
higher	high	ADJ	JJR	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
these	these	DET	DT	5	O
experiments	experiment	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
shortened	shorten	VERB	VBN	9	O
mean	mean	ADJ	JJ	5	O
effective	effective	ADJ	JJ	5	O
refractory	refractory	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ERP	ERP	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
122	122	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
to	to	ADP	IN	5	O
114	114	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
ms	ms	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
cycle	cycle	NOUN	NN	9	O
length	length	NOUN	NN	9	O
of	of	ADP	IN	5	O
300	300	NUM	CD	0	O
ms	m	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
ERP	ERP	PROPN	NNP	5	O
heterogeneity	heterogeneity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
15	15	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
10	10	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
heterogeneously	heterogeneously	ADV	RB	9	O
accelerated	accelerate	VERB	VBD	9	O
atrial	atrial	ADJ	JJ	5	O
conduction	conduction	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
cycle	cycle	NOUN	NN	9	O
length	length	NOUN	NN	9	O
of	of	ADP	IN	5	O
AF	AF	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
94	94	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
to	to	ADP	IN	5	O
84	84	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
ms	ms	NOUN	NN	5	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
005	005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Diltiazem	Diltiazem	PROPN	NNP	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
ERP	ERP	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
AF	AF	PROPN	NNP	9	B-Disease
cycle	cycle	NOUN	NN	9	O
length	length	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
AF	AF	PROPN	NNP	9	B-Disease
duration	duration	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
produced	produce	VERB	VBD	9	O
conduction	conduction	NOUN	NN	5	O
acceleration	acceleration	NOUN	NN	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
verapamil	verapamil	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
autonomic	autonomic	ADJ	JJ	5	O
blockade	blockade	NOUN	NN	3	O
,	,	PUNCT	,	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
promote	promote	VERB	VB	3	O
AF	AF	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
,	,	PUNCT	,	9	O
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
decreasing	decrease	VERB	VBG	9	O
,	,	PUNCT	,	9	O
refractoriness	refractoriness	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neither	neither	DET	DT	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
nor	nor	CCONJ	CC	9	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
affected	affected	ADJ	JJ	9	O
atrial	atrial	ADJ	JJ	5	O
conduction	conduction	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
autonomic	autonomic	ADJ	JJ	5	O
blockade	blockade	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Epicardial	epicardial	ADJ	JJ	5	O
mapping	mapping	NOUN	NN	5	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
promoted	promote	VERB	VBN	3	O
AF	AF	PROPN	NNP	9	B-Disease
by	by	ADP	IN	9	O
increasing	increase	VERB	VBG	9	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
simultaneous	simultaneous	ADJ	JJ	5	O
wavefronts	wavefront	NOUN	NNS	5	O
reflected	reflect	VERB	VBN	5	O
by	by	ADP	IN	9	O
separate	separate	ADJ	JJ	9	O
zones	zone	NOUN	NNS	5	O
of	of	ADP	IN	5	O
reactivation	reactivation	NOUN	NN	9	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
cycle	cycle	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Verapamil	Verapamil	PROPN	NNP	0	B-Chemical
promotes	promote	VERB	VBZ	3	O
AF	AF	PROPN	NNP	9	B-Disease
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
dogs	dog	NOUN	NNS	5	O
by	by	ADP	IN	9	O
promoting	promote	VERB	VBG	9	O
multiple	multiple	ADJ	JJ	5	O
circuit	circuit	NOUN	NN	5	O
reentry	reentry	NOUN	NN	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
effect	effect	NOUN	NN	9	O
dependent	dependent	ADJ	JJ	9	O
on	on	ADP	IN	5	O
intact	intact	ADJ	JJ	9	O
autonomic	autonomic	ADJ	JJ	5	O
tone	tone	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
not	not	ADV	RB	5	O
shared	share	VERB	VBN	5	O
by	by	ADP	IN	9	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

Calcitonin	calcitonin	ADJ	JJ	0	O
gene	gene	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
peptide	peptide	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
during	during	ADP	IN	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
headache	headache	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
tension	tension	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
type	type	NOUN	NN	9	I-Disease
headache	headache	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
proposed	propose	VERB	VBN	5	O
that	that	ADP	IN	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NO	NO	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
induced	induced	ADJ	JJ	3	O
headache	headache	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
primary	primary	ADJ	JJ	9	B-Disease
headaches	headache	NOUN	NNS	5	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
calcitonin	calcitonin	ADJ	JJ	3	O
gene	gene	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
peptide	peptide	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
CGRP	CGRP	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
aimed	aim	VERB	VBD	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
plasma	plasma	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
CGRP	CGRP	NOUN	NNS	3	O
during	during	ADP	IN	5	O
headache	headache	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
NO	no	DET	DT	9	B-Chemical
donor	donor	NOUN	NN	9	O
glyceryl	glyceryl	NOUN	NN	0	B-Chemical
trinitrate	trinitrate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
GTN	GTN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
16	16	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
tension	tension	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
type	type	NOUN	NN	9	I-Disease
headache	headache	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
16	16	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
allocated	allocate	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
GTN	GTN	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
over	over	ADP	IN	5	O
20	20	NUM	CD	9	O
min	min	NOUN	NN	0	O
on	on	ADP	IN	5	O
two	two	NUM	CD	5	O
headache	headache	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
and	and	CCONJ	CC	5	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
controls	control	NOUN	NNS	9	O
developed	develop	VERB	VBD	5	O
significantly	significantly	ADV	RB	9	O
stronger	strong	ADJ	JJR	9	O
immediate	immediate	ADJ	JJ	5	O
headache	headache	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
GTN	GTN	PROPN	NNP	0	B-Chemical
day	day	NOUN	NN	9	O
than	than	ADP	IN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
day	day	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
headache	headache	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
pronounced	pronounced	ADJ	JJ	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
area	area	NOUN	NN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
CGRP	CGRP	PROPN	NNP	3	O
curve	curve	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
AUCCGRP	AUCCGRP	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
GTN	GTN	PROPN	NNP	0	B-Chemical
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
placebo	placebo	NOUN	NN	9	O
day	day	NOUN	NN	9	O
in	in	ADP	IN	5	O
either	either	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
65	65	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
48	48	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
AUCCGRP	auccgrp	NOUN	NN	_	O
recorded	record	VERB	VBD	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
GTN	GTN	PROPN	NNP	0	B-Chemical
day	day	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
between	between	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
36	36	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
CGRP	CGRP	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
changed	change	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
over	over	ADP	IN	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
GTN	GTN	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
days	day	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
NO	no	ADV	RB	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
immediate	immediate	ADJ	JJ	5	O
headache	headache	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
CGRP	CGRP	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

Fluconazole	fluconazole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
present	present	VERB	VB	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
fluconazole	fluconazole	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TDP	TDP	PROPN	NNP	0	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
discuss	discuss	VERB	VB	5	O
fluconazole	fluconazole	NOUN	NN	9	B-Chemical
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
causing	cause	VERB	VBG	9	O
TDP	tdp	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
68	68	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
white	white	ADJ	JJ	9	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
Candida	Candida	PROPN	NNP	4	O
glabrata	glabrata	NOUN	NN	4	O
isolated	isolate	VERB	VBD	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
presacral	presacral	ADJ	JJ	5	O
abscess	abscess	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
TDP	tdp	NOUN	NN	0	B-Disease
eight	eight	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
commencing	commence	VERB	VBG	5	O
oral	oral	ADJ	JJ	9	O
fluconazole	fluconazole	NOUN	NN	9	B-Chemical
The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
TDP	TDP	PROPN	NNP	0	B-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
cardiomyopathy	cardiomyopathy	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
electrolyte	electrolyte	NOUN	NN	0	O
abnormalities	abnormality	NOUN	NNS	9	O
There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
temporal	temporal	ADJ	JJ	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
fluconazole	fluconazole	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
TDP	tdp	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
TDP	tdp	NOUN	NN	0	B-Disease
resolved	resolve	VERB	VBD	9	O
when	when	ADV	WRB	5	O
fluconazole	fluconazole	NOUN	NN	9	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
continued	continue	VERB	VBD	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
premature	premature	ADJ	JJ	9	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
contractions	contraction	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
nonsustained	nonsustaine	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
NSVT	NSVT	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
until	until	ADP	IN	5	O
six	six	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
cessation	cessation	NOUN	NN	5	O
DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Naranjo	Naranjo	PROPN	NNP	6	O
probability	probability	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
indicates	indicate	VERB	VBZ	9	O
a	a	DET	DT	5	O
probable	probable	ADJ	JJ	9	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
fluconazole	fluconazole	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
TDP	TDP	PROPN	NNP	0	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
depression	depression	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
rapidly	rapidly	ADV	RB	9	O
activating	activate	VERB	VBG	3	O
delayed	delay	VERB	VBN	9	O
rectifier	rectifi	ADJ	JJR	0	O
potassium	potassium	NOUN	NN	0	B-Chemical
currents	current	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
etiology	etiology	NOUN	NN	9	O
identified	identify	VERB	VBD	9	O
that	that	DET	WDT	5	O
could	could	VERB	MD	9	O
explain	explain	VERB	VB	9	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	O
TDP	tdp	NOUN	NN	0	B-Disease
The	the	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
disappearance	disappearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
NSVT	NSVT	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	O
premature	premature	ADJ	JJ	9	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
contractions	contraction	NOUN	NNS	5	I-Disease
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
normalization	normalization	NOUN	NN	5	O
of	of	ADP	IN	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
strongly	strongly	ADV	RB	9	O
suggests	suggest	VERB	VBZ	9	O
fluconazole	fluconazole	NOUN	NN	9	B-Chemical
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
etiology	etiology	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Clinicians	clinician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
that	that	DET	DT	5	O
fluconazole	fluconazole	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
at	at	ADP	IN	9	O
low	low	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
prolongation	prolongation	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
QT	QT	PROPN	NNP	5	I-Disease
interval	interval	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
TDP	TDP	PROPN	NNP	0	B-Disease
.	.	PUNCT	.	9	O

Serial	serial	ADJ	JJ	9	O
electrocardiographic	electrocardiographic	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
when	when	ADV	WRB	5	O
fluconazole	fluconazole	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Cutaneous	cutaneous	ADJ	JJ	5	B-Disease
leucocytoclastic	leucocytoclastic	ADJ	JJ	5	I-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
oxacillin	oxacillin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
67	67	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
oxacillin	oxacillin	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
one	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
Staphylococcus	Staphylococcus	PROPN	NNP	4	B-Disease
aureus	aureus	NOUN	NN	9	I-Disease
bacteremia	bacteremia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
developed	develop	VERB	VBN	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
diffuse	diffuse	NOUN	NN	5	O
,	,	PUNCT	,	9	O
symmetric	symmetric	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
palpable	palpable	ADJ	JJ	5	O
purpuric	purpuric	ADJ	JJ	5	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
on	on	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
feet	foot	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Necrotic	necrotic	ADJ	JJ	3	B-Disease
blisters	blister	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
on	on	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
fingers	finger	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Skin	skin	NOUN	NN	9	O
biopsies	biopsy	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
findings	finding	NOUN	NNS	9	O
diagnostic	diagnostic	ADJ	JJ	5	O
of	of	ADP	IN	5	O
leucocytoclastic	leucocytoclastic	ADJ	JJ	5	B-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Oxacillin	Oxacillin	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
patient	patient	ADJ	JJ	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rash	rash	NOUN	NN	5	B-Disease
disappeared	disappear	VERB	VBD	9	O
after	after	ADP	IN	9	O
three	three	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Leucocytoclastic	leucocytoclastic	ADJ	JJ	9	B-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
presents	present	VERB	VBZ	5	O
as	as	ADP	IN	5	O
palpable	palpable	ADJ	JJ	5	O
purpura	purpura	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lower	low	ADJ	JJR	9	O
extremities	extremity	NOUN	NNS	5	O
often	often	ADV	RB	5	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
abdominal	abdominal	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
arthralgia	arthralgia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
involvement	involvement	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Etiologic	etiologic	ADJ	JJ	2	O
factors	factor	NOUN	NNS	9	O
or	or	CCONJ	CC	5	O
associated	associate	VERB	VBN	9	O
disorders	disorder	NOUN	NNS	5	O
include	include	VERB	VBP	5	O
infections	infection	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
medications	medication	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
collagen	collagen	NOUN	NN	3	B-Disease
vascular	vascular	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
neoplasia	neoplasia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
half	half	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
no	no	DET	DT	9	O
etiologic	etiologic	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
identified	identify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Usually	usually	ADV	RB	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
limited	limit	VERB	VBN	5	O
disorder	disorder	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
corticosteroid	corticosteroid	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
needed	need	VERB	VBN	5	O
in	in	ADP	IN	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
cases	case	NOUN	NNS	5	O
since	since	ADP	IN	9	O
early	early	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
in	in	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
can	can	VERB	MD	5	O
prevent	prevent	VERB	VB	5	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Oxacillin	Oxacillin	PROPN	NNP	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
included	include	VERB	VBN	5	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
leucocytoclastic	leucocytoclastic	ADJ	JJ	5	B-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
pathology	pathology	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetes	diabetes	NOUN	NN	5	B-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetes	diabetes	NOUN	NN	5	B-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
necropsy	necropsy	ADJ	JJ	9	O
microscopy	microscopy	NOUN	NN	9	O
shoed	shoed	NOUN	NN	9	O
unique	unique	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
extensive	extensive	ADJ	JJ	5	O
damage	damage	NOUN	NN	9	O
to	to	ADP	IN	5	O
cells	cell	NOUN	NNS	3	O
lining	line	VERB	VBG	9	O
the	the	DET	DT	5	O
distal	distal	ADJ	JJ	9	O
nephron	nephron	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
changes	change	NOUN	NNS	9	O
represent	represent	VERB	VBP	9	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
toxic	toxic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
reported	report	VERB	VBN	9	O
here	here	ADV	RB	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cholestatic	cholestatic	ADJ	JJ	7	B-Disease
jaundice	jaundice	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
jaundice	jaundice	NOUN	NN	5	I-Disease
shortly	shortly	ADV	RB	9	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Ultrasound	Ultrasound	PROPN	NNP	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
abdominal	abdominal	ADJ	JJ	5	O
CT	CT	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
ERCP	ERCP	PROPN	NNP	5	O
showed	show	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
biliary	biliary	ADJ	JJ	5	O
anatomy	anatomy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
percutaneous	percutaneous	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
showing	show	VERB	VBG	9	O
marked	marked	ADJ	JJ	9	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
portal	portal	ADJ	JJ	5	O
edema	edema	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
ductular	ductular	ADJ	JJ	3	O
proliferation	proliferation	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	O
inflammation	inflammation	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Metformin	metformin	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
jaundice	jaundice	NOUN	NN	5	B-Disease
resolved	resolve	VERB	VBN	9	O
slowly	slowly	ADV	RB	5	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
several	several	ADJ	JJ	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
jaundice	jaundice	NOUN	NN	5	B-Disease
2	2	NUM	CD	9	O
wk	wk	ADV	RB	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
believe	believe	VERB	VBP	5	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
represents	represent	VERB	VBZ	9	O
an	an	DET	DT	5	O
example	example	NOUN	NN	5	O
of	of	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
such	such	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
reported	report	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Systemic	systemic	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
resuscitation	resuscitation	NOUN	NN	5	O
in	in	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
ropivacaine	ropivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
infused	infuse	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
compared	compare	VERB	VBD	9	O
the	the	DET	DT	5	O
systemic	systemic	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
ropivacaine	ropivacaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
anesthetized	anesthetized	ADJ	JJ	0	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
also	also	ADV	RB	9	O
compared	compare	VERB	VBD	9	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
resuscitate	resuscitate	VERB	VB	5	O
rats	rat	NOUN	NNS	9	O
after	after	ADP	IN	9	O
lethal	lethal	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
local	local	ADJ	JJ	5	O
anesthetics	anesthetic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Bupivacaine	bupivacaine	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
ropivacaine	ropivacaine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
infused	infuse	VERB	VBN	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

kg	kg	X	FW	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

min	min	X	FW	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
while	while	ADP	IN	9	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
,	,	PUNCT	,	9	O
electroencephalogram	electroencephalogram	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
were	be	VERB	VBD	9	O
continuously	continuously	ADV	RB	5	O
monitored	monitor	VERB	VBN	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
asystole	asystole	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
,	,	PUNCT	,	9	O
drug	drug	NOUN	NN	5	O
infusion	infusion	NOUN	NN	0	O
was	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
resuscitation	resuscitation	NOUN	NN	5	O
sequence	sequence	NOUN	NN	1	O
was	be	VERB	VBD	9	O
begun	begin	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Epinephrine	Epinephrine	PROPN	NNP	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	PROPN	NNP	0	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
min	min	NOUN	NN	0	O
intervals	interval	NOUN	NNS	5	O
while	while	ADP	IN	9	O
external	external	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	O
compressions	compression	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
applied	apply	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Resuscitation	resuscitation	NOUN	NN	5	O
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
successful	successful	ADJ	JJ	5	O
when	when	ADV	WRB	5	O
a	a	DET	DT	5	O
systolic	systolic	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
100	100	NUM	CD	0	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
was	be	VERB	VBD	9	O
achieved	achieve	VERB	VBN	5	O
within	within	ADP	IN	9	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
ropivacaine	ropivacaine	NOUN	NN	0	B-Chemical
that	that	DET	WDT	5	O
produced	produce	VERB	VBD	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
larger	large	ADJ	JJR	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
that	that	DET	WDT	5	O
produced	produce	VERB	VBD	9	O
dysrhythmias	dysrhythmia	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
asystole	asystole	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
smaller	small	ADJ	JJR	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
corresponding	correspond	VERB	VBG	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
ropivacaine	ropivacaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
larger	large	ADJ	JJR	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
successful	successful	ADJ	JJ	5	O
resuscitations	resuscitation	NOUN	NNS	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
among	among	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
smaller	small	ADJ	JJR	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
required	require	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Ropivacaine	Ropivacaine	PROPN	NNP	0	B-Chemical
group	group	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
systemic	systemic	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
intermediate	intermediate	ADJ	JJ	9	O
between	between	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
ropivacaine	ropivacaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
that	that	DET	DT	5	O
ropivacaine	ropivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
more	more	ADV	RBR	5	O
susceptible	susceptible	ADJ	JJ	9	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
levobupivacaine	levobupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Amphotericin	Amphotericin	PROPN	NNP	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
patent	patent	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
amphotericin	amphotericin	NOUN	NN	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
46	46	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
African	african	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
American	american	ADJ	JJ	9	O
man	man	NOUN	NN	5	O
experienced	experience	VERB	VBD	5	O
recurrent	recurrent	ADJ	JJ	5	O
grand	grand	ADJ	JJ	5	B-Disease
mal	mal	NOUN	NN	2	I-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
during	during	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
amphotericin	amphotericin	PROPN	NNP	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
then	then	ADV	RB	9	O
petit	petit	VERB	VBZ	2	O
mal	mal	NOUN	NN	2	O
seizures	seizure	NOUN	NNS	5	B-Disease
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
was	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
concentrations	concentration	NOUN	NNS	0	O
decreased	decrease	VERB	VBD	9	O
with	with	ADP	IN	5	O
time	time	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
concurrent	concurrent	ADJ	JJ	5	O
medications	medication	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
didanosine	didanosine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
hydroxyzine	hydroxyzine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
promethazine	promethazine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
hydrocortisone	hydrocortisone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
prochlorperazine	prochlorperazine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
lorazepam	lorazepam	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
persisted	persist	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
occurred	occur	VERB	VBD	9	O
only	only	ADV	RB	9	O
during	during	ADP	IN	5	O
amphotercin	amphotercin	NOUN	NN	0	B-Chemical
B	b	NOUN	NN	9	I-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
AIDS	aids	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
cryptococcal	cryptococcal	ADJ	JJ	5	B-Disease
meningitis	meningitis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
,	,	PUNCT	,	9	O
can	can	VERB	MD	5	O
potentially	potentially	ADV	RB	5	O
cause	cause	VERB	VB	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
;	;	PUNCT	:	9	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
intake	intake	NOUN	NN	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
can	can	VERB	MD	5	O
also	also	ADV	RB	9	O
cause	cause	VERB	VB	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Didanosine	Didanosine	PROPN	NNP	7	B-Chemical
also	also	ADV	RB	9	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
potential	potential	NOUN	NN	9	O
for	for	ADP	IN	5	O
inducing	induce	VERB	VBG	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
other	other	ADJ	JJ	5	O
potential	potential	ADJ	JJ	9	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
ruled	rule	VERB	VBN	9	O
out	out	PART	RP	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
events	event	NOUN	NNS	5	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
amphotericin	amphotericin	PROPN	NNP	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Amphotericin	Amphotericin	PROPN	NNP	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
probable	probable	ADJ	JJ	9	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
date	date	NOUN	NN	5	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
three	three	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
amphotericin	amphotericin	ADJ	JJ	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
healthcare	healthcare	NOUN	NN	5	O
providers	provider	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Sirolimus	sirolimus	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
mycophenolate	mycophenolate	NOUN	NN	0	B-Chemical
mofetil	mofetil	NOUN	NN	0	I-Chemical
for	for	ADP	IN	5	O
calcineurin	calcineurin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
immunosuppression	immunosuppression	NOUN	NN	5	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Calcineurin	calcineurin	NOUN	NN	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
available	available	ADJ	JJ	5	O
for	for	ADP	IN	5	O
almost	almost	ADV	RB	9	O
20	20	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
highly	highly	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
represent	represent	VERB	VB	9	O
the	the	DET	DT	5	O
mainstay	mainstay	NOUN	NN	5	O
of	of	ADP	IN	5	O
transplant	transplant	NOUN	NN	9	O
immunosuppression	immunosuppression	NOUN	NN	5	O
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
are	be	VERB	VBP	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
occurs	occur	VERB	VBZ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
after	after	ADP	IN	9	O
transplantation	transplantation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
leads	lead	VERB	VBZ	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
dialysis	dialysis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
eventually	eventually	ADV	RB	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
graft	graft	NOUN	NN	5	O
loss	loss	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Acute	Acute	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
becoming	become	VERB	VBG	5	O
more	more	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
marginal	marginal	ADJ	JJ	5	O
kidneys	kidney	NOUN	NNS	9	O
for	for	ADP	IN	5	O
transplantation	transplantation	NOUN	NN	9	O
increases	increase	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
recently	recently	ADV	RB	9	O
available	available	ADJ	JJ	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
mycophenolate	mycophenolate	NOUN	NN	0	B-Chemical
mofetil	mofetil	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
rapamycin	rapamycin	NOUN	NN	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
no	no	DET	DT	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
has	have	VERB	VBZ	9	O
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
new	new	ADJ	JJ	5	O
paradigms	paradigms	NOUN	NN	5	O
of	of	ADP	IN	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
paper	paper	NOUN	NN	5	O
reviews	review	VERB	VBZ	5	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
that	that	DET	WDT	5	O
have	have	VERB	VBP	5	O
investigated	investigate	VERB	VBN	9	O
these	these	DET	DT	5	O
new	new	ADJ	JJ	5	O
approaches	approach	NOUN	NNS	5	O
to	to	ADP	IN	5	O
immunosuppression	immunosuppression	NOUN	NN	5	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
nimesulide	nimesulide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
NSAID	NSAID	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
urticaria	urticaria	NOUN	NN	5	B-Disease
/	/	SYM	SYM	9	O
angioedema	angioedema	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
tolerance	tolerance	NOUN	NN	9	O
of	of	ADP	IN	5	O
nimesulide	nimesulide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cutaneous	cutaneous	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
respiratory	respiratory	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
anaphylactoid	anaphylactoid	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	B-Chemical
anti	anti	ADJ	JJ	3	I-Chemical
-	-	ADJ	JJ	7	I-Chemical
inflammatory	inflammatory	ADJ	JJ	3	I-Chemical
drugs	drug	NOUN	NNS	5	I-Chemical
(	(	PUNCT	-LRB-	9	O
NSAIDs	nsaid	NOUN	NNS	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
tolerability	tolerability	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
reliability	reliability	NOUN	NN	5	O
of	of	ADP	IN	5	O
nimesulide	nimesulide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
very	very	ADV	RB	5	O
large	large	ADJ	JJ	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
exclusive	exclusive	ADJ	JJ	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
documented	document	VERB	VBN	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
NSAID	NSAID	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
urticaria	urticaria	NOUN	NN	5	B-Disease
/	/	SYM	SYM	9	O
angioedema	angioedema	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
evaluated	evaluate	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
some	some	DET	DT	5	O
factors	factor	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
the	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
to	to	PART	TO	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
reaction	reaction	NOUN	NN	9	O
to	to	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
nimesulide	nimesulide	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
oral	oral	ADJ	JJ	9	O
challenge	challenge	NOUN	NN	9	O
procedure	procedure	NOUN	NN	5	O
with	with	ADP	IN	5	O
nimesulide	nimesulide	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
applied	apply	VERB	VBN	5	O
to	to	ADP	IN	5	O
829	829	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
NSAID	NSAID	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
urticaria	urticaria	NOUN	NN	5	B-Disease
/	/	SYM	SYM	9	O
angioedema	angioedema	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
75	75	NUM	CD	9	O
/	/	SYM	SYM	9	O
829	829	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
reactions	reaction	NOUN	NNS	9	O
to	to	PART	TO	5	O
nimesulide	nimesulide	VERB	VB	0	B-Chemical
or	or	CCONJ	CC	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
715	715	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
tested	test	VERB	VBN	9	O
with	with	ADP	IN	5	O
nimesulide	nimesulide	NOUN	NN	0	B-Chemical
62	62	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
of	of	ADP	IN	5	O
114	114	NUM	CD	7	O
subjects	subject	NOUN	NNS	5	O
submitted	submit	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
challenge	challenge	NOUN	NN	9	O
with	with	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
13	13	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
tolerate	tolerate	VERB	VB	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
28	28	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
urticaria	urticaria	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
NSAID	NSAID	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
urticaria	urticaria	NOUN	NN	5	B-Disease
/	/	SYM	SYM	9	O
angioedema	angioedema	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
angioedema	angioedema	NOUN	NN	5	B-Disease
alone	alone	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
urticaria	urticaria	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
resulted	result	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
intolerant	intolerant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
alternative	alternative	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Taken	take	VERB	VBN	9	O
together	together	ADV	RB	9	O
,	,	PUNCT	,	9	O
our	-PRON-	DET	PRP$	5	O
results	result	NOUN	NNS	9	O
confirm	confirm	VERB	VBP	9	O
the	the	DET	DT	5	O
good	good	ADJ	JJ	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
nimesulide	nimesulide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
experienced	experience	VERB	VBD	5	O
urticaria	urticaria	NOUN	NN	5	B-Disease
/	/	SYM	SYM	9	O
angioedema	angioedema	NOUN	NN	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
NSAIDs	nsaid	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
reaction	reaction	NOUN	NN	9	O
to	to	ADP	IN	5	O
these	these	DET	DT	5	O
alternative	alternative	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
drugs	drug	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
statistically	statistically	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
urticaria	urticaria	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
above	above	ADP	IN	9	O
all	all	DET	DT	5	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
NSAID	NSAID	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
angioedema	angioedema	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
aqueous	aqueous	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
gellan	gellan	VERB	VB	0	O
ophthalmic	ophthalmic	ADJ	JJ	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
response	response	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Topical	topical	ADJ	JJ	0	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocker	blocker	NOUN	NN	0	O
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
routine	routine	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Therapy	therapy	NOUN	NN	5	O
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
absorption	absorption	NOUN	NN	0	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
resting	rest	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
peak	peak	NOUN	NN	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
quantified	quantify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
trial	trial	NOUN	NN	5	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
aqueous	aqueous	ADJ	JJ	0	O
timolol	timolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
timolol	timolol	NOUN	NN	0	B-Chemical
solution	solution	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
timolol	timolol	NOUN	NN	0	B-Chemical
suspension	suspension	NOUN	NN	0	O
that	that	DET	WDT	5	O
forms	form	VERB	VBZ	9	O
a	a	DET	DT	5	O
gel	gel	NOUN	NN	0	O
on	on	ADP	IN	5	O
application	application	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
conjunctiva	conjunctiva	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
timolol	timolol	NOUN	NN	0	B-Chemical
gellan	gellan	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
currently	currently	ADV	RB	5	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
to	to	PART	TO	5	O
quantify	quantify	VERB	VB	9	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
Caucasian	caucasian	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
open	open	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
angle	angle	NOUN	NN	5	I-Disease
glaucoma	glaucoma	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
ocular	ocular	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
63	63	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
years	year	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
crossed	cross	VERB	VBD	9	O
over	over	PART	RP	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
masked	mask	VERB	VBN	5	O
manner	manner	NOUN	NN	9	O
to	to	ADP	IN	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
morning	morning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
evening	evening	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
eyes	eye	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
timolol	timolol	NOUN	NN	0	B-Chemical
solution	solution	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
morning	morning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
evening	evening	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
eyes	eye	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
gellan	gellan	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
morning	morning	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
eyes	eye	NOUN	NNS	5	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
evening	evening	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
13th	13th	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
continuously	continuously	ADV	RB	5	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
typical	typical	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
ambulant	ambulant	ADJ	JJ	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Both	both	DET	DT	9	O
timolol	timolol	NOUN	NN	0	B-Chemical
solution	solution	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
gellan	gellan	NOUN	NN	0	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
this	this	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
most	most	ADV	RBS	9	O
pronounced	pronounce	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
daytime	daytime	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
-	-	PUNCT	:	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
beats	beat	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Timolol	Timolol	PROPN	NNP	7	B-Chemical
gellan	gellan	NOUN	NN	0	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
numerically	numerically	ADV	RB	5	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
smaller	small	ADJ	JJR	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
solution	solution	NOUN	NN	0	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
night	night	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
on	on	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
gellan	gellan	NOUN	NN	0	O
were	be	VERB	VBD	9	O
both	both	DET	DT	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
on	on	ADP	IN	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
solution	solution	NOUN	NN	0	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
solution	solution	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
gellan	gellan	NOUN	NN	0	O
treatments	treatment	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Both	both	DET	DT	9	O
timolol	timolol	NOUN	NN	0	B-Chemical
solution	solution	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
gellan	gellan	NOUN	NN	0	O
decrease	decrease	NOUN	NN	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
most	most	ADV	RBS	9	O
pronounced	pronounce	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
active	active	ADJ	JJ	9	O
daytime	daytime	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
quantify	quantify	VERB	VBP	9	O
the	the	DET	DT	5	O
modest	modest	ADJ	JJ	9	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
ophthalmic	ophthalmic	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocker	blocker	NOUN	NN	0	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
typical	typical	ADJ	JJ	9	O
patient	patient	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
on	on	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
exercise	exercise	NOUN	NN	5	O
performance	performance	NOUN	NN	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
trial	trial	NOUN	NN	5	O
,	,	PUNCT	,	9	O
reductions	reduction	NOUN	NNS	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
magnitude	magnitude	NOUN	NN	5	O
should	should	VERB	MD	5	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
substantial	substantial	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
consequences	consequence	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Management	management	NOUN	NN	5	O
strategies	strategy	NOUN	NNS	5	O
for	for	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
C	C	PROPN	NNP	9	I-Disease
:	:	PUNCT	:	9	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
economic	economic	ADJ	JJ	5	O
implications	implication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Recently	recently	ADV	RB	9	O
published	publish	VERB	VBN	9	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
demonstrated	demonstrate	VERB	VBN	9	O
increased	increase	VERB	VBN	9	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cost	cost	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effectiveness	effectiveness	NOUN	NN	5	O
of	of	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
interferon	interferon	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2b	2b	NOUN	NN	9	O
/	/	SYM	SYM	9	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
interferon	interferon	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
monotherapy	monotherapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
C	C	PROPN	NNP	9	I-Disease
(	(	PUNCT	-LRB-	9	O
CHC	CHC	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
clinically	clinically	ADV	RB	5	O
important	important	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
:	:	PUNCT	:	9	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
RIHA	RIHA	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
health	health	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
care	care	NOUN	NN	5	O
costs	cost	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
RIHA	RIHA	PROPN	NNP	9	B-Disease
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
CHC	CHC	PROPN	NNP	9	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
setting	setting	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
systematic	systematic	ADJ	JJ	5	O
literature	literature	NOUN	NN	5	O
review	review	NOUN	NN	5	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
to	to	PART	TO	5	O
synthesize	synthesize	VERB	VB	9	O
information	information	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
RIHA	RIHA	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Decision	decision	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
analytic	analytic	ADJ	JJ	5	O
techniques	technique	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
estimate	estimate	VERB	VB	5	O
the	the	DET	DT	5	O
cost	cost	NOUN	NN	5	O
of	of	ADP	IN	5	O
treating	treat	VERB	VBG	5	O
RIHA	RIHA	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Uncertainty	uncertainty	NOUN	NN	5	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
using	use	VERB	VBG	9	O
sensitivity	sensitivity	NOUN	NN	9	O
analyses	analysis	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
RIHA	RIHA	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
to	to	ADP	IN	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
,	,	PUNCT	,	9	O
occurs	occur	VERB	VBZ	9	O
in	in	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
standard	standard	NOUN	NN	5	O
of	of	ADP	IN	5	O
care	care	NOUN	NN	5	O
for	for	ADP	IN	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
RIHA	RIHA	PROPN	NNP	9	B-Disease
is	be	VERB	VBZ	5	O
reduction	reduction	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
dosage	dosage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
estimated	estimate	VERB	VBD	5	O
the	the	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
cost	cost	NOUN	NN	5	O
of	of	ADP	IN	5	O
treating	treat	VERB	VBG	5	O
clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
RIHA	RIHA	PROPN	NNP	9	B-Disease
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
170	170	NUM	CD	9	O
per	per	ADP	IN	9	O
patient	patient	NOUN	NN	5	O
receiving	receive	VERB	VBG	9	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
per	per	ADP	IN	9	O
48	48	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
course	course	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VB	9	O
68	68	NUM	CD	7	O
-	-	SYM	SYM	7	O
692	692	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
one	one	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
way	way	NOUN	NN	5	O
sensitivity	sensitivity	NOUN	NN	9	O
analyses	analysis	NOUN	NNS	9	O
ranged	range	VERB	VBD	9	O
from	from	ADP	IN	9	O
57	57	NUM	CD	7	O
to	to	ADP	IN	5	O
317	317	NUM	CD	7	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
comparison	comparison	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
cost	cost	NOUN	NN	5	O
of	of	ADP	IN	5	O
48	48	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
16	16	NUM	CD	9	O
,	,	PUNCT	,	9	O
459	459	NUM	CD	7	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
cost	cost	NOUN	NN	5	O
of	of	ADP	IN	5	O
treating	treat	VERB	VBG	5	O
clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
RIHA	RIHA	PROPN	NNP	9	B-Disease
is	be	VERB	VBZ	5	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
170	170	NUM	CD	9	O
/	/	SYM	SYM	9	O
16	16	NUM	CD	9	O
,	,	PUNCT	,	9	O
459	459	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
costs	cost	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Questions	question	NOUN	NNS	5	O
remain	remain	VERB	VBP	9	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
optimal	optimal	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
RIHA	RIHA	PROPN	NNP	9	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
real	real	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
world	world	NOUN	NN	5	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
these	these	DET	DT	5	O
uncertainties	uncertainty	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
cost	cost	NOUN	NN	5	O
of	of	ADP	IN	5	O
treating	treat	VERB	VBG	5	O
RIHA	RIHA	PROPN	NNP	9	B-Disease
provides	provide	VERB	VBZ	5	O
an	an	DET	DT	5	O
estimate	estimate	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cost	cost	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
management	management	NOUN	NN	5	O
implications	implication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
clinically	clinically	ADV	RB	5	O
important	important	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Preliminary	preliminary	ADJ	JJ	9	O
efficacy	efficacy	NOUN	NN	9	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
American	american	ADJ	JJ	9	O
formulation	formulation	NOUN	NN	5	O
of	of	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Preclinical	preclinical	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
suggest	suggest	VERB	VBP	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
chronic	chronic	ADJ	JJ	5	I-Disease
pain	pain	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
preliminary	preliminary	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
in	in	ADP	IN	5	O
volunteers	volunteer	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
Swedish	swedish	ADJ	JJ	5	O
formulation	formulation	NOUN	NN	5	O
of	of	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
suggests	suggest	VERB	VBZ	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
states	state	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
noxious	noxious	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
screen	screen	VERB	VB	5	O
for	for	ADP	IN	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
different	different	ADJ	JJ	9	O
formulation	formulation	NOUN	NN	5	O
of	of	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
marketed	market	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
US	US	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
both	both	DET	DT	9	O
acute	acute	ADJ	JJ	9	O
noxious	noxious	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
evoked	evoke	VERB	VBN	5	O
mechanical	mechanical	ADJ	JJ	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Following	follow	VERB	VBG	9	O
Food	Food	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Drug	Drug	PROPN	NNP	5	O
Administration	Administration	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
institutional	institutional	ADJ	JJ	5	O
review	review	NOUN	NN	5	O
board	board	NOUN	NN	5	O
approval	approval	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
written	write	VERB	VBN	5	O
informed	informed	ADJ	JJ	5	O
consent	consent	NOUN	NN	5	O
,	,	PUNCT	,	9	O
65	65	NUM	CD	7	O
volunteers	volunteer	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
trials	trial	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
,	,	PUNCT	,	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
escalating	escalate	VERB	VBG	5	O
trial	trial	NOUN	NN	5	O
with	with	ADP	IN	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Cerebrospinal	cerebrospinal	ADJ	JJ	9	O
fluid	fluid	NOUN	NN	5	O
was	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
for	for	ADP	IN	5	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
ratings	rating	NOUN	NNS	5	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
heat	heat	NOUN	NN	9	O
stimuli	stimulus	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
areas	area	NOUN	NNS	5	O
of	of	ADP	IN	5	O
mechanical	mechanical	ADJ	JJ	5	B-Disease
hyperalgesia	hyperalgesia	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
allodynia	allodynia	ADJ	JJ	5	B-Disease
after	after	ADP	IN	9	O
intradermal	intradermal	ADJ	JJ	9	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Adenosine	adenosine	NOUN	NN	0	B-Chemical
produced	produce	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
report	report	NOUN	NN	5	O
to	to	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
noxious	noxious	ADJ	JJ	5	O
thermal	thermal	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
chemical	chemical	ADJ	JJ	0	O
stimulation	stimulation	NOUN	NN	3	O
but	but	CCONJ	CC	9	O
reduced	reduce	VERB	VBD	9	O
mechanical	mechanical	ADJ	JJ	5	B-Disease
hyperalgesia	hyperalgesia	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
allodynia	allodynia	ADJ	JJ	5	B-Disease
from	from	ADP	IN	9	O
intradermal	intradermal	ADJ	JJ	9	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
for	for	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
residence	residence	NOUN	NN	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
cerebrospinal	cerebrospinal	ADJ	JJ	9	O
fluid	fluid	NOUN	NN	5	O
was	be	VERB	VBD	9	O
short	short	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
4	4	NUM	CD	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
selective	selective	ADJ	JJ	9	O
inhibition	inhibition	NOUN	NN	3	O
by	by	ADP	IN	9	O
intrathecal	intrathecal	ADJ	JJ	3	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
presumed	presume	VERB	VBN	9	O
to	to	PART	TO	5	O
reflect	reflect	VERB	VB	5	O
central	central	ADJ	JJ	5	O
sensitization	sensitization	NOUN	NN	9	O
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
after	after	ADP	IN	9	O
peripheral	peripheral	ADJ	JJ	9	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
lasting	last	VERB	VBG	5	O
effect	effect	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
that	that	DET	DT	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
preliminary	preliminary	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
residence	residence	NOUN	NN	5	O
of	of	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
cerebrospinal	cerebrospinal	ADJ	JJ	9	O
fluid	fluid	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Delayed	delay	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
onset	onset	NOUN	NN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Heparin	Heparin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
presents	present	NOUN	NNS	5	O
5	5	NUM	CD	9	O
to	to	PART	TO	5	O
12	12	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
heparin	heparin	ADJ	JJ	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
arterial	arterial	ADJ	JJ	5	B-Disease
or	or	CCONJ	CC	5	I-Disease
venous	venous	ADJ	JJ	5	I-Disease
thromboemboli	thromboemboli	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Delayed	delay	VERB	VBN	5	O
recognition	recognition	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
contribute	contribute	VERB	VBP	9	O
to	to	ADP	IN	5	O
poor	poor	ADJ	JJ	5	O
patient	patient	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
describe	describe	VERB	VB	5	O
and	and	CCONJ	CC	5	O
increase	increase	VERB	VB	9	O
awareness	awareness	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
scenario	scenario	NOUN	NN	5	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
manifestations	manifestation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
are	be	VERB	VBP	5	O
delayed	delay	VERB	VBN	9	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Retrospective	retrospective	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
series	series	NOUN	NN	5	O
.	.	PUNCT	.	9	O

SETTING	set	VERB	VBG	2	O
:	:	PUNCT	:	9	O
Three	three	NUM	CD	9	O
large	large	ADJ	JJ	5	O
urban	urban	ADJ	JJ	5	O
hospitals	hospital	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
with	with	ADP	IN	5	O
active	active	ADJ	JJ	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
programs	program	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
14	14	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
seen	see	VERB	VBN	9	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
period	period	NOUN	NN	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
became	become	VERB	VBD	9	O
apparent	apparent	ADJ	JJ	9	O
on	on	ADP	IN	5	O
delayed	delay	VERB	VBN	9	O
presentation	presentation	NOUN	NN	5	O
with	with	ADP	IN	5	O
thromboembolic	thromboembolic	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

MEASUREMENTS	measurement	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Platelet	platelet	ADJ	JJ	9	O
counts	count	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
objectively	objectively	ADV	RB	5	O
determined	determine	VERB	VBN	9	O
thromboembolism	thromboembolism	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
platelet	platelet	NOUN	NN	9	O
factor	factor	NOUN	NN	9	O
4	4	NUM	CD	9	O
antibody	antibody	NOUN	NN	3	O
tests	test	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
outcomes	outcome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
went	go	VERB	VBD	5	O
home	home	ADV	RB	5	O
after	after	ADP	IN	9	O
hospitalizations	hospitalization	NOUN	NNS	5	O
that	that	DET	WDT	5	O
had	have	VERB	VBD	9	O
included	include	VERB	VBN	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
-	-	PUNCT	:	7	O
-	-	PUNCT	HYPH	7	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
recognized	recognize	VERB	VBN	9	O
-	-	PUNCT	:	7	O
-	-	PUNCT	HYPH	7	O
only	only	ADV	RB	9	O
to	to	PART	TO	5	O
return	return	VERB	VB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
median	median	NOUN	NN	9	O
,	,	PUNCT	,	9	O
day	day	NOUN	NN	9	O
14	14	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
thromboembolic	thromboembolic	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Thromboemboli	Thromboemboli	PROPN	NNP	9	B-Disease
were	be	VERB	VBD	9	O
venous	venous	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
with	with	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
emboli	emboli	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
arterial	arterial	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
both	both	DET	DT	9	O
.	.	PUNCT	.	9	O

Platelet	platelet	ADJ	JJ	9	O
counts	count	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
mildly	mildly	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
but	but	ADP	IN	9	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
second	second	ADJ	JJ	9	O
presentation	presentation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
readmission	readmission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
worsened	worsen	VERB	VBD	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
clinical	clinical	ADJ	JJ	5	O
condition	condition	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
11	11	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
platelet	platelet	NOUN	NN	9	O
count	count	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
at	at	ADP	IN	9	O
readmission	readmission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
143	143	NUM	CD	7	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
;	;	PUNCT	:	9	O
mean	mean	VERB	VB	5	O
nadir	nadir	NOUN	NN	9	O
after	after	ADP	IN	9	O
heparin	heparin	ADJ	JJ	0	B-Chemical
re	re	NOUN	NN	5	O
-	-	NOUN	NN	7	O
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
39	39	NUM	CD	7	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
serologic	serologic	ADJ	JJ	9	O
tests	test	NOUN	NNS	5	O
for	for	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
antibodies	antibody	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Subsequent	subsequent	ADJ	JJ	9	O
treatments	treatment	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
alternative	alternative	ADJ	JJ	5	O
anticoagulants	anticoagulant	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
thrombolytic	thrombolytic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
inferior	inferior	ADJ	JJ	5	O
vena	vena	NOUN	NN	5	O
cava	cava	NOUN	NN	5	O
filters	filter	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
eventually	eventually	ADV	RB	5	O
,	,	PUNCT	,	9	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
died	die	VERB	VBD	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Delayed	delayed	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
onset	onset	NOUN	NN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
increasingly	increasingly	ADV	RB	5	O
being	be	VERB	VBG	5	O
recognized	recognize	VERB	VBN	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
avoid	avoid	VERB	VB	5	O
disastrous	disastrous	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
physicians	physician	NOUN	NNS	5	O
must	must	VERB	MD	5	O
consider	consider	VERB	VB	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
whenever	whenever	ADV	WRB	5	O
a	a	DET	DT	5	O
recently	recently	ADV	RB	9	O
hospitalized	hospitalize	VERB	VBN	5	O
patient	patient	ADJ	JJ	5	O
returns	return	NOUN	NNS	5	O
with	with	ADP	IN	5	O
thromboembolism	thromboembolism	NOUN	NN	5	B-Disease
;	;	PUNCT	:	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
alternative	alternative	ADJ	JJ	5	O
anticoagulants	anticoagulant	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
not	not	ADV	RB	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
initiated	initiate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
agonist	agonist	NOUN	NN	3	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Risperidone	Risperidone	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
antagonist	antagonist	NOUN	NN	3	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
serotonergic	serotonergic	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
5HT2A	5ht2a	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
D2	D2	PROPN	NNP	9	O
receptors	receptor	NOUN	NNS	3	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Chronically	chronically	ADV	RB	5	O
elevated	elevated	ADJ	JJ	9	O
prolactin	prolactin	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
prolactinomas	prolactinoma	NOUN	NNS	5	B-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
arrested	arrest	VERB	VBN	3	O
growth	growth	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
development	development	NOUN	NN	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
either	either	DET	DT	9	O
delayed	delay	VERB	VBN	9	B-Disease
puberty	puberty	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
short	short	ADJ	JJ	5	O
stature	stature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
possibilities	possibility	NOUN	NNS	5	O
stress	stress	VERB	VBP	9	O
the	the	DET	DT	5	O
importance	importance	NOUN	NN	5	O
of	of	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
a	a	DET	DT	5	O
safe	safe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
effective	effective	ADJ	JJ	5	O
approach	approach	NOUN	NN	5	O
to	to	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
youth	youth	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
successful	successful	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
cabergoline	cabergoline	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
youth	youth	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
undertook	undertake	VERB	VBD	9	O
a	a	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
cabergoline	cabergoline	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Four	four	NUM	CD	9	O
males	male	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
age	age	NOUN	NN	5	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
Diagnostic	Diagnostic	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Statistical	Statistical	PROPN	NNP	5	O
Manual	Manual	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Mental	Mental	PROPN	NNP	5	B-Disease
Disorders	Disorders	PROPN	NNP	2	I-Disease
(	(	PUNCT	-LRB-	9	O
fourth	fourth	ADJ	JJ	9	O
edition	edition	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
psychoses	psychosis	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
elevations	elevation	NOUN	NNS	9	O
in	in	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
prolactin	prolactin	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
57	57	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
129	129	NUM	CD	9	O
ng	ng	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
normal	normal	ADJ	JJ	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
15	15	NUM	CD	9	O
ng	ng	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
cabergoline	cabergoline	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
dose	dose	NOUN	NN	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
13	13	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
09	09	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
week	week	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
serum	serum	ADJ	JJ	9	O
prolactin	prolactin	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
normalized	normalize	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
four	four	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
cabergoline	cabergoline	NOUN	NN	5	B-Chemical
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
week	week	NOUN	NN	9	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
cabergoline	cabergoline	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
523	523	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
129	129	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
788	788	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
162	162	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Cabergoline	Cabergoline	PROPN	NNP	7	B-Chemical
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
without	without	ADP	IN	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Cabergoline	Cabergoline	PROPN	NNP	7	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
youth	youth	NOUN	NN	5	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
further	further	ADJ	JJ	9	O
research	research	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
needed	need	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
following	follow	VERB	VBG	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
inhalational	inhalational	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
70	70	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
healthy	healthy	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
from	from	ADP	IN	9	O
Iraq	Iraq	PROPN	NNP	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
repair	repair	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
rotator	rotator	NOUN	NN	5	O
cuff	cuff	NOUN	NN	5	O
under	under	ADP	IN	9	O
general	general	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
viral	viral	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
autoimmune	autoimmune	NOUN	NN	3	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
metabolic	metabolic	ADJ	JJ	9	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
medications	medication	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
involved	involve	VERB	VBN	9	O
except	except	ADP	IN	9	O
for	for	ADP	IN	5	O
dipyrone	dipyrone	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
analgesia	analgesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
alanine	alanine	NOUN	NN	1	B-Chemical
aminotransferase	aminotransferase	NOUN	NN	7	O
was	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
peak	peak	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
1533	1533	NUM	CD	7	O
U	U	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
reached	reach	VERB	VBD	9	O
a	a	DET	DT	5	O
peak	peak	NOUN	NN	9	O
of	of	ADP	IN	5	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
slow	slow	ADJ	JJ	5	O
improvement	improvement	NOUN	NN	5	O
over	over	ADP	IN	5	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Accidental	accidental	ADJ	JJ	5	O
reexposure	reexposure	NOUN	NN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
to	to	ADP	IN	5	O
dipyrone	dipyrone	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
uneventful	uneventful	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
histologic	histologic	ADJ	JJ	9	O
picture	picture	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
resembles	resemble	VERB	VBZ	9	O
halothane	halothane	NOUN	NN	0	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
mortality	mortality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Isoflurane	Isoflurane	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
severe	severe	ADJ	JJ	5	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Torsade	Torsade	PROPN	NNP	2	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
metoclopramide	metoclopramide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
preexisting	preexist	VERB	VBG	9	O
complete	complete	ADJ	JJ	9	O
left	left	ADJ	JJ	5	B-Disease
bundle	bundle	ADJ	JJ	5	I-Disease
branch	branch	NOUN	NN	5	I-Disease
block	block	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
growing	grow	VERB	VBG	9	O
list	list	NOUN	NN	5	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
acquired	acquire	VERB	VBN	5	O
long	long	ADJ	JJ	5	B-Disease
QT	QT	PROPN	NNP	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
torsadogenic	torsadogenic	ADJ	JJ	5	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
metoclopramide	metoclopramide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
antiemetic	antiemetic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
prokinetic	prokinetic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
,	,	PUNCT	,	9	O
despite	despite	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
chemical	chemical	NOUN	NN	0	O
similarity	similarity	NOUN	NN	5	O
to	to	ADP	IN	5	O
procainamide	procainamide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
92	92	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
preexisting	preexist	VERB	VBG	9	O
complete	complete	ADJ	JJ	9	O
left	left	ADJ	JJ	5	B-Disease
bundle	bundle	ADJ	JJ	5	I-Disease
branch	branch	NOUN	NN	5	I-Disease
block	block	NOUN	NN	9	I-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
after	after	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
metoclopramide	metoclopramide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
also	also	ADV	RB	9	O
developed	develop	VERB	VBD	5	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
when	when	ADV	WRB	5	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
erythromycin	erythromycin	ADV	RB	0	B-Chemical
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
simultaneously	simultaneously	ADV	RB	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
two	two	NUM	CD	5	O
episodes	episode	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
suppressed	suppress	VERB	VBN	3	O
successfully	successfully	ADV	RB	5	O
after	after	ADP	IN	9	O
discontinuing	discontinue	VERB	VBG	5	O
the	the	DET	DT	5	O
offending	offend	VERB	VBG	5	O
drugs	drug	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
administering	administer	VERB	VBG	9	O
class	class	NOUN	NN	9	O
IB	ib	NOUN	NN	9	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
documentation	documentation	NOUN	NN	5	O
that	that	DET	WDT	5	O
metoclopramide	metoclopramide	VERB	VBP	0	B-Chemical
provokes	provoke	NOUN	NNS	9	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
clinically	clinically	ADV	RB	5	O
.	.	PUNCT	.	9	O

Metoclopramide	Metoclopramide	PROPN	NNP	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
cautiously	cautiously	ADV	RB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Dopamine	dopamine	NOUN	NN	0	B-Chemical
D2	d2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
signaling	signal	VERB	VBG	3	O
controls	control	VERB	VBZ	9	O
neuronal	neuronal	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
death	death	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
muscarinic	muscarinic	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
glutamatergic	glutamatergic	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Dopamine	Dopamine	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DA	DA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
through	through	ADP	IN	9	O
D1	D1	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
D2	d2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
signaling	signaling	NOUN	NN	3	O
,	,	PUNCT	,	9	O
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
arising	arise	VERB	VBG	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
limbic	limbic	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Excitotoxicity	excitotoxicity	NOUN	NN	3	B-Disease
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
neuronal	neuronal	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
death	death	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
affected	affect	VERB	VBN	9	O
areas	area	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
consequence	consequence	NOUN	NN	5	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
cellular	cellular	ADJ	JJ	3	O
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
respect	respect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
little	little	ADJ	JJ	9	O
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
DA	DA	PROPN	NNP	9	B-Chemical
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neuronal	neuronal	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
death	death	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
analyze	analyze	VERB	VBP	9	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
D2R	D2R	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
cholinergic	cholinergic	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
compared	compare	VERB	VBD	9	O
these	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
previously	previously	ADV	RB	9	O
obtained	obtain	VERB	VBN	9	O
with	with	ADP	IN	5	O
kainic	kainic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
KA	KA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
agonist	agonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Importantly	importantly	ADV	RB	9	O
,	,	PUNCT	,	9	O
D2R	D2R	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
develop	develop	VERB	VBP	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
epileptogenic	epileptogenic	ADJ	JJ	5	O
for	for	ADP	IN	5	O
WT	wt	NOUN	NN	3	O
littermates	littermate	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
show	show	VERB	VB	9	O
greater	great	ADJ	JJR	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
result	result	VERB	VBP	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
widespread	widespread	ADJ	JJ	5	O
neuronal	neuronal	ADJ	JJ	3	O
death	death	NOUN	NN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
WT	WT	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
D2R	D2R	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
brains	brain	NOUN	NNS	9	O
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
to	to	ADP	IN	5	O
KA	KA	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
D2R	D2R	PROPN	NNP	3	O
lowers	lower	VERB	VBZ	9	O
the	the	DET	DT	5	O
threshold	threshold	NOUN	NN	5	O
for	for	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
both	both	DET	DT	9	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neurodegeneration	neurodegeneration	NOUN	NN	3	B-Disease
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
distinct	distinct	ADJ	JJ	9	O
interactions	interaction	NOUN	NNS	9	O
of	of	ADP	IN	5	O
D2R	D2R	PROPN	NNP	3	O
signaling	signal	VERB	VBG	3	O
with	with	ADP	IN	5	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
neurotransmitters	neurotransmitter	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Steroid	steroid	VERB	VB	9	B-Chemical
structure	structure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
properties	property	NOUN	NNS	9	O
determine	determine	VERB	VBP	9	O
the	the	DET	DT	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
amnesic	amnesic	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
pregnenolone	pregnenolone	NOUN	NN	0	B-Chemical
sulphate	sulphate	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Pregnenolone	pregnenolone	NOUN	NN	7	B-Chemical
sulphate	sulphate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PREGS	pregs	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
generated	generate	VERB	VBN	9	O
interest	interest	NOUN	NN	5	O
as	as	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
potent	potent	ADJ	JJ	3	O
memory	memory	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
enhancing	enhance	VERB	VBG	9	O
neurosteroids	neurosteroid	NOUN	NNS	0	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
rodent	rodent	ADJ	JJ	9	O
learning	learning	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
particular	particular	ADJ	JJ	5	O
importance	importance	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ageing	ageing	NOUN	NN	5	O
process	process	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
this	this	DET	DT	5	O
endogenous	endogenous	ADJ	JJ	3	O
steroid	steroid	NOUN	NN	9	B-Chemical
enhances	enhance	NOUN	NNS	3	O
memory	memory	NOUN	NN	5	O
formation	formation	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
hypothesized	hypothesize	VERB	VBN	9	O
to	to	PART	TO	5	O
involve	involve	VERB	VB	5	O
actions	action	NOUN	NNS	5	O
on	on	ADP	IN	5	O
glutamatergic	glutamatergic	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
GABAergic	GABAergic	PROPN	NNP	3	O
systems	system	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
stems	stem	VERB	VBZ	4	O
from	from	ADP	IN	9	O
findings	finding	NOUN	NNS	9	O
that	that	DET	WDT	5	O
PREGS	pregs	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
positive	positive	ADJ	JJ	9	O
modulator	modulator	NOUN	NN	9	O
of	of	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
d	d	VERB	VBN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
receptors	receptor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
NMDARs	NMDARs	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
negative	negative	ADJ	JJ	9	O
modulator	modulator	NOUN	NN	9	O
of	of	ADP	IN	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminobutyric	aminobutyric	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
receptors	receptor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
Rs	r	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
PREGS	pregs	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
reverse	reverse	VERB	VB	9	O
the	the	DET	DT	5	O
amnesic	amnesic	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
NMDAR	NMDAR	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
R	r	NOUN	NN	9	O
ligands	ligand	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
investigate	investigate	VERB	VB	9	O
this	this	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
memory	memory	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
altering	alter	VERB	VBG	9	O
abilities	ability	NOUN	NNS	5	O
of	of	ADP	IN	5	O
structural	structural	ADJ	JJ	9	O
analogs	analog	NOUN	NNS	0	O
of	of	ADP	IN	5	O
PREGS	PREGS	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
differ	differ	VERB	VBP	9	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
NMDAR	NMDAR	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
R	r	NOUN	NN	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
analogs	analog	NOUN	NNS	0	O
tested	test	VERB	VBN	9	O
were	be	VERB	VBD	9	O
:	:	PUNCT	:	9	O
11	11	NUM	CD	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ketopregnenolone	ketopregnenolone	NOUN	NN	_	I-Chemical
sulphate	sulphate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
an	an	DET	DT	5	O
agent	agent	NOUN	NN	9	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
inactive	inactive	ADJ	JJ	9	O
at	at	ADP	IN	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
Rs	r	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
NMDARs	NMDARs	PROPN	NNPS	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
epipregnanolone	epipregnanolone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
3beta	3beta	NUM	CD	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxy	hydroxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5beta	5beta	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pregnan	pregnan	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
20	20	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
one	one	NUM	CD	5	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
sulphate	sulphate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
Rs	r	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
NMDARs	NMDARs	PROPN	NNPS	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
newly	newly	ADV	RB	9	O
synthesized	synthesize	VERB	VBN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
PREGS	pregs	NOUN	NN	0	B-Chemical
enantiomer	enantiomer	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
identical	identical	ADJ	JJ	9	O
to	to	ADP	IN	5	O
PREGS	pregs	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
Rs	r	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
NMDARs	NMDARs	PROPN	NNPS	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
memory	memory	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
enhancing	enhance	VERB	VBG	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
PREGS	PREGS	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
analogs	analog	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
PREGS	pregs	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
enantiomer	enantiomer	NOUN	NN	0	O
blocked	block	VERB	VBD	3	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
unlike	unlike	ADP	IN	9	O
PREGS	PREGS	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
11	11	NUM	CD	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ketopregnenolone	ketopregnenolone	NOUN	NN	_	I-Chemical
sulphate	sulphate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
epipregnanolone	epipregnanolone	NOUN	NN	0	B-Chemical
sulphate	sulphate	NOUN	NN	0	I-Chemical
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
block	block	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
altering	alter	VERB	VBG	9	O
the	the	DET	DT	5	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptors	receptor	NOUN	NNS	3	O
diminishes	diminish	VERB	VBZ	9	O
the	the	DET	DT	5	O
memory	memory	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
enhancing	enhance	VERB	VBG	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
PREGS	pregs	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
enantioselectivity	enantioselectivity	NOUN	NN	0	O
was	be	VERB	VBD	9	O
demonstrated	demonstrate	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
natural	natural	ADJ	JJ	5	O
PREGS	pregs	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
order	order	NOUN	NN	5	O
of	of	ADP	IN	5	O
magnitude	magnitude	NOUN	NN	5	O
more	more	ADV	RBR	5	O
effective	effective	ADJ	JJ	5	O
than	than	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
synthetic	synthetic	ADJ	JJ	0	O
enantiomer	enantiomer	NOUN	NN	0	O
in	in	ADP	IN	5	O
reversing	reverse	VERB	VBG	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
identify	identify	VERB	VBP	9	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
neuropharmacological	neuropharmacological	ADJ	JJ	5	O
site	site	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
processes	process	NOUN	NNS	5	O
by	by	ADP	IN	9	O
neuroactive	neuroactive	ADJ	JJ	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
.	.	PUNCT	.	9	O

Activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
poly	poly	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
ADP	ADP	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ribose	ribose	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
polymerase	polymerase	NOUN	NN	1	O
contributes	contribute	NOUN	NNS	9	O
to	to	ADP	IN	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
nuclear	nuclear	ADJ	JJ	3	O
enzyme	enzyme	ADJ	JJ	0	O
poly	poly	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
ADP	ADP	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ribose	ribose	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
polymerase	polymerase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
PARP	PARP	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
by	by	ADP	IN	9	O
oxidant	oxidant	ADJ	JJ	0	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
DNA	dna	NOUN	NN	9	O
damage	damage	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
pathway	pathway	NOUN	NN	3	O
of	of	ADP	IN	5	O
cell	cell	NOUN	NN	3	O
dysfunction	dysfunction	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tissue	tissue	NOUN	NN	9	O
injury	injury	NOUN	NN	9	O
in	in	ADP	IN	5	O
conditions	condition	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
antitumor	antitumor	CCONJ	CC	3	O
anthracycline	anthracycline	ADJ	JJ	9	B-Chemical
antibiotic	antibiotic	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
hypothesized	hypothesize	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
PARP	PARP	PROPN	NNP	3	O
may	may	VERB	MD	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
dual	dual	ADJ	JJ	9	O
approach	approach	NOUN	NN	5	O
of	of	ADP	IN	5	O
PARP	PARP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
suppression	suppression	NOUN	NN	9	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
genetic	genetic	ADJ	JJ	5	O
deletion	deletion	NOUN	NN	1	O
or	or	CCONJ	CC	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
inhibition	inhibition	NOUN	NN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
phenanthridinone	phenanthridinone	NOUN	NN	9	O
PARP	PARP	PROPN	NNP	3	O
inhibitor	inhibitor	NOUN	NN	3	O
PJ34	PJ34	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
now	now	ADV	RB	5	O
demonstrate	demonstrate	VERB	VBP	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
PARP	PARP	PROPN	NNP	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

PARP	PARP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
+	+	NOUN	NN	9	O
/	/	SYM	SYM	9	O
+	+	CCONJ	CC	9	O
and	and	CCONJ	CC	5	O
PARP	PARP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
performance	performance	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
depressed	depress	VERB	VBN	5	O
in	in	ADP	IN	5	O
PARP	PARP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
+	+	NOUN	NN	9	O
/	/	SYM	SYM	9	O
+	+	CCONJ	CC	9	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
only	only	ADV	RB	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
smaller	small	ADJ	JJR	5	O
extent	extent	NOUN	NN	9	O
in	in	ADP	IN	5	O
PARP	PARP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
ones	one	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Similar	similar	ADJ	JJ	9	O
experiments	experiment	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
in	in	ADP	IN	5	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
c	c	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
PJ34	PJ34	PROPN	NNP	3	B-Chemical
or	or	CCONJ	CC	5	O
vehicle	vehicle	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
PJ34	PJ34	PROPN	NNP	3	B-Chemical
significantly	significantly	ADV	RB	9	O
improved	improve	VERB	VBD	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
survival	survival	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
PJ34	PJ34	PROPN	NNP	3	B-Chemical
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
lactate	lactate	NOUN	NN	0	B-Chemical
dehydrogenase	dehydrogenase	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
creatine	creatine	NOUN	NN	0	B-Chemical
kinase	kinase	NUM	CD	3	O
activities	activity	NOUN	NNS	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
metalloproteinase	metalloproteinase	VERB	VB	3	O
activation	activation	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
PARP	PARP	PROPN	NNP	3	O
activation	activation	NOUN	NN	3	O
contributes	contribute	VERB	VBZ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

PARP	parp	NOUN	NN	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
may	may	VERB	MD	5	O
exert	exert	VERB	VB	9	O
protective	protective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Spironolactone	spironolactone	NOUN	NN	7	B-Chemical
:	:	PUNCT	:	9	O
is	be	VERB	VBZ	5	O
it	-PRON-	PRON	PRP	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
amphotericin	amphotericin	PROPN	NNP	0	B-Chemical
B	b	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
?	?	PUNCT	.	5	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Nephrotoxicity	nephrotoxicity	NOUN	NN	0	B-Disease
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
amphotericin	amphotericin	NOUN	NN	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
AmB	AmB	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
often	often	ADV	RB	5	O
limiting	limit	VERB	VBG	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
full	full	ADJ	JJ	5	O
dosage	dosage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Selective	selective	ADJ	JJ	9	O
distal	distal	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	O
epithelial	epithelial	ADJ	JJ	3	O
toxicity	toxicity	NOUN	NN	9	B-Disease
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
profound	profound	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
wasting	wasting	NOUN	NN	5	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
AmB	AmB	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Potassium	potassium	NOUN	NN	0	B-Chemical
depletion	depletion	NOUN	NN	3	O
also	also	ADV	RB	9	O
potentiates	potentiate	VERB	VBZ	3	O
the	the	DET	DT	5	O
tubular	tubular	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
AmB	AmB	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
spironolactone	spironolactone	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
requirements	requirement	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
neutropenic	neutropenic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
AmB	amb	DET	DT	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
26	26	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
various	various	ADJ	JJ	9	O
hematological	hematological	ADJ	JJ	9	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
either	either	CCONJ	CC	9	O
intravenous	intravenous	ADJ	JJ	0	O
AmB	amb	CCONJ	CC	0	B-Chemical
alone	alone	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
AmB	amb	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
oral	oral	ADJ	JJ	9	O
spironolactone	spironolactone	NOUN	NN	0	B-Chemical
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
twice	twice	ADV	RB	9	O
daily	daily	ADV	RB	5	O
when	when	ADV	WRB	5	O
developing	develop	VERB	VBG	5	O
a	a	DET	DT	5	O
proven	prove	VERB	VBN	5	O
or	or	CCONJ	CC	5	O
suspected	suspect	VERB	VBN	5	O
fungal	fungal	ADJ	JJ	4	B-Disease
infection	infection	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
concomitant	concomitant	ADJ	JJ	9	O
AmB	AmB	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
spironolactone	spironolactone	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
plasma	plasma	NOUN	NN	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
receiving	receive	VERB	VBG	9	O
AmB	amb	CCONJ	CC	0	B-Chemical
alone	alone	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0027	0027	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Those	those	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
AmB	amb	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
spironolactone	spironolactone	NOUN	NN	0	B-Chemical
required	require	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADJ	JJR	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
supplementation	supplementation	NOUN	NN	0	O
to	to	PART	TO	5	O
maintain	maintain	VERB	VB	5	O
their	-PRON-	DET	PRP$	5	O
plasma	plasma	NOUN	NN	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
range	range	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
022	022	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
urinary	urinary	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
losses	loss	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADV	RBR	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
AmB	amb	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
spironolactone	spironolactone	NOUN	NN	0	B-Chemical
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
receiving	receive	VERB	VBG	9	O
AmB	amb	CCONJ	CC	0	B-Chemical
alone	alone	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
040	040	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
spironolactone	spironolactone	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
reduce	reduce	VERB	VB	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
requirements	requirement	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
prevent	prevent	VERB	VB	5	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
reducing	reduce	VERB	VBG	9	O
urinary	urinary	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
loss	loss	NOUN	NN	9	O
in	in	ADP	IN	5	O
neutropenic	neutropenic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
AmB	amb	DET	DT	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Erectile	erectile	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
occurs	occur	VERB	VBZ	9	O
following	follow	VERB	VBG	9	O
substantia	substantia	ADJ	JJ	9	O
nigra	nigra	NOUN	NN	4	O
lesions	lesion	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Erectile	erectile	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
uni	uni	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
bilateral	bilateral	ADJ	JJ	5	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxydopamine	hydroxydopamine	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
substantia	substantia	ADJ	JJ	9	O
nigra	nigra	NOUN	NN	4	O
nucleus	nucleus	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Behavioral	behavioral	ADJ	JJ	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
penile	penile	NOUN	NN	5	O
erections	erection	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
uni	uni	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
bilateral	bilateral	ADJ	JJ	5	O
lesioned	lesione	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Intracavernous	intracavernous	ADJ	JJ	9	O
pressures	pressure	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
following	follow	VERB	VBG	9	O
electrical	electrical	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cavernous	cavernous	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
in	in	ADP	IN	5	O
lesioned	lesione	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Lesions	lesion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
substantia	substantia	NOUN	NN	9	O
nigra	nigra	NOUN	NN	4	O
were	be	VERB	VBD	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
histology	histology	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
metabolites	metabolite	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
of	of	ADP	IN	5	O
substantia	substantia	NOUN	NN	9	O
nigra	nigra	NOUN	NN	4	O
lesioned	lesione	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Lesions	lesion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
substantia	substantia	NOUN	NN	9	O
nigra	nigra	NOUN	NN	4	O
are	be	VERB	VBP	5	O
therefore	therefore	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
erectile	erectile	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
serve	serve	VERB	VB	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
erectile	erectile	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Nicotine	nicotine	NOUN	NN	0	B-Chemical
potentiation	potentiation	NOUN	NN	3	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Morphine	morphine	NOUN	NN	0	B-Chemical
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
response	response	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
potentiated	potentiate	VERB	VBN	3	O
by	by	ADP	IN	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Intraperitoneal	intraperitoneal	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
mecamylamine	mecamylamine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hexamethonium	hexamethonium	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
reduced	reduce	VERB	VBN	9	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Intracerebroventricular	intracerebroventricular	ADJ	JJ	3	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
hexamethonium	hexamethonium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
also	also	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
plus	plus	CCONJ	CC	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Intraperitoneal	intraperitoneal	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
intraperitoneal	intraperitoneal	ADJ	JJ	0	O
or	or	CCONJ	CC	5	O
intracerebroventricular	intracerebroventricular	ADJ	JJ	3	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
hexamethonium	hexamethonium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
catalepsy	catalepsy	NOUN	NN	5	B-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
elicited	elicit	VERB	VBN	9	O
by	by	ADP	IN	9	O
opioid	opioid	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cholinergic	cholinergic	NOUN	NN	3	O
receptors	receptor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
potentiation	potentiation	NOUN	NN	3	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
also	also	ADV	RB	9	O
be	be	VERB	VB	5	O
mediated	mediate	VERB	VBN	3	O
through	through	ADP	IN	9	O
cholinergic	cholinergic	ADJ	JJ	3	O
receptor	receptor	NOUN	NN	3	O
mechanisms	mechanism	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Force	force	NOUN	NN	5	O
overflow	overflow	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
assessed	assess	VERB	VBD	9	O
force	force	NOUN	NN	5	O
coordination	coordination	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hand	hand	NOUN	NN	5	O
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
relationship	relationship	NOUN	NN	5	O
to	to	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
to	to	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
LID	LID	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
+	+	CCONJ	CC	9	O
LID	LID	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
23	23	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	O
LID	LID	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
matched	match	VERB	VBN	9	O
healthy	healthy	ADJ	JJ	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
motor	motor	NOUN	NN	5	O
score	score	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Unified	Unified	PROPN	NNP	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
Disease	Disease	PROPN	NNP	2	I-Disease
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
dyskinesia	dyskinesia	ADJ	JJ	5	B-Disease
score	score	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
force	force	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
grip	grip	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
lift	lift	NOUN	NN	5	O
paradigm	paradigm	NOUN	NN	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
ON	ON	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
OFF	OFF	PROPN	NNP	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
pathological	pathological	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
forces	force	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
ON	ON	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
state	state	NOUN	NN	5	O
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
+	+	CCONJ	CC	9	O
LID	LID	PROPN	NNP	5	B-Disease
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
+	+	CCONJ	CC	9	O
LID	LID	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
force	force	NOUN	NN	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
pressing	press	VERB	VBG	5	O
down	down	PART	RP	9	O
the	the	DET	DT	5	O
object	object	NOUN	NN	5	O
before	before	ADP	IN	9	O
lifting	lifting	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
by	by	ADP	IN	9	O
61	61	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
overshooting	overshooting	NOUN	NN	5	O
of	of	ADP	IN	5	O
peak	peak	NOUN	NN	9	O
grip	grip	NOUN	NN	5	O
force	force	NOUN	NN	5	O
by	by	ADP	IN	9	O
51	51	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
static	static	ADJ	JJ	5	O
grip	grip	NOUN	NN	5	O
force	force	NOUN	NN	5	O
by	by	ADP	IN	9	O
45	45	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ON	ON	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
OFF	OFF	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
condition	condition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
excessive	excessive	ADJ	JJ	5	O
force	force	NOUN	NN	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PUNCT	HYPH	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	O
LID	lid	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Peak	peak	VERB	VB	9	O
grip	grip	NOUN	NN	5	O
force	force	NOUN	NN	5	O
in	in	ADP	IN	5	O
ON	ON	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
state	state	NOUN	NN	5	O
was	be	VERB	VBD	9	O
140	140	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
+	+	CCONJ	CC	9	O
LID	lid	NOUN	NN	5	B-Disease
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PUNCT	HYPH	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	O
LID	lid	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
static	static	ADJ	JJ	5	O
grip	grip	NOUN	NN	5	O
force	force	NOUN	NN	5	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
138	138	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
peak	peak	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
strongly	strongly	ADV	RB	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
grip	grip	ADJ	JJ	5	O
force	force	NOUN	NN	5	O
in	in	ADP	IN	5	O
ON	ON	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
state	state	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
79	79	NUM	CD	7	O
with	with	ADP	IN	5	O
peak	peak	NOUN	NN	9	O
force	force	NOUN	NN	5	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
correlation	correlation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
forces	force	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
motor	motor	NOUN	NN	5	O
score	score	NOUN	NN	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Force	force	NOUN	NN	5	O
excess	excess	NOUN	NN	9	O
was	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
LID	LID	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	O
motor	motor	NOUN	NN	5	O
fluctuations	fluctuation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
close	close	ADJ	JJ	5	O
relationship	relationship	NOUN	NN	5	O
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
overshooting	overshooting	NOUN	NN	5	O
of	of	ADP	IN	5	O
forces	force	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ON	ON	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
condition	condition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
postulate	postulate	VERB	VBP	9	O
that	that	ADP	IN	5	O
both	both	CCONJ	CC	9	O
LID	LID	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	O
grip	grip	NOUN	NN	5	O
force	force	NOUN	NN	5	O
excess	excess	ADJ	JJ	9	O
share	share	NOUN	NN	5	O
common	common	ADJ	JJ	5	O
pathophysiological	pathophysiological	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
fluctuations	fluctuation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	NUM	CD	7	I-Chemical
on	on	ADP	IN	5	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dizocilpine	dizocilpine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
noncompetitive	noncompetitive	ADJ	JJ	0	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
(	(	PUNCT	-LRB-	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
on	on	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
behaviors	behavior	NOUN	NNS	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
treatments	treatment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
focuses	focus	VERB	VBZ	5	O
on	on	ADP	IN	5	O
behavioral	behavioral	ADJ	JJ	5	O
syndromes	syndrome	NOUN	NNS	5	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
models	model	NOUN	NNS	5	O
for	for	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
tardive	tardive	ADJ	JJ	5	B-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
response	response	NOUN	NN	9	O
after	after	ADP	IN	9	O
glutamatergic	glutamatergic	ADJ	JJ	3	O
blockage	blockage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Reserpine	Reserpine	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
administered	administer	VERB	VBD	9	O
once	once	ADV	RB	5	O
every	every	DET	DT	5	O
other	other	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
produced	produce	VERB	VBD	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
orofacial	orofacial	ADJ	JJ	5	B-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
tongue	tongue	NOUN	NN	5	O
protrusion	protrusion	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
vacuous	vacuous	ADJ	JJ	5	O
chewing	chewing	NOUN	NN	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
are	be	VERB	VBP	5	O
signs	sign	NOUN	NNS	5	O
indicative	indicative	ADJ	JJ	9	O
of	of	ADP	IN	5	O
tardive	tardive	ADJ	JJ	5	B-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Reserpine	Reserpine	PROPN	NNP	0	B-Chemical
also	also	ADV	RB	9	O
produced	produce	VERB	VBD	9	O
tremor	tremor	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
are	be	VERB	VBP	5	O
signs	sign	NOUN	NNS	5	O
suggestive	suggestive	ADJ	JJ	9	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
administered	administer	VERB	VBD	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
observation	observation	NOUN	NN	9	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
vacuous	vacuous	ADJ	JJ	5	O
chewing	chewing	NOUN	NN	5	O
movements	movement	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
tongue	tongue	NOUN	NN	5	O
protrusions	protrusion	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	NUM	CD	7	I-Chemical
injection	injection	NOUN	NN	9	O
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
tremor	tremor	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Reserpine	Reserpine	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
administered	administer	VERB	VBD	9	O
90	90	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
apomophine	apomophine	NOUN	NN	_	B-Chemical
injection	injection	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
produce	produce	VERB	VB	9	O
oral	oral	ADJ	JJ	9	B-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
induced	induced	ADJ	JJ	3	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
tremor	tremor	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
tremor	tremor	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
with	with	ADP	IN	5	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
observation	observation	NOUN	NN	9	O
test	test	NOUN	NN	5	O
produced	produce	VERB	VBD	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
vacuous	vacuous	ADJ	JJ	5	O
chewing	chewing	NOUN	NN	5	O
movements	movement	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
tongue	tongue	NOUN	NN	5	O
protrusion	protrusion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
tremor	tremor	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
injection	injection	NOUN	NN	9	O
90	90	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
reversed	reverse	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
produces	produce	VERB	VBZ	9	O
different	different	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
abnormal	abnormal	ADJ	JJ	9	B-Disease
movements	movement	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
are	be	VERB	VBP	5	O
related	relate	VERB	VBN	9	O
to	to	PART	TO	5	O
dose	dose	VERB	VB	9	O
and	and	CCONJ	CC	5	O
schedule	schedule	NOUN	NN	5	O
employed	employ	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
as	as	ADP	IN	5	O
parkinsonian	parkinsonian	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
tardive	tardive	ADJ	JJ	5	B-Disease
dsykinesia	dsykinesia	NOUN	NN	_	I-Disease
signs	sign	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
glutamatergic	glutamatergic	ADJ	JJ	3	O
blockage	blockage	NOUN	NN	9	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
can	can	VERB	MD	5	O
restore	restore	VERB	VB	9	O
these	these	DET	DT	5	O
signs	sign	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
vacuous	vacuous	ADJ	JJ	5	O
chewing	chewing	NOUN	NN	5	O
movements	movement	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
tongue	tongue	NOUN	NN	5	O
protrusions	protrusion	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
tremor	tremor	NOUN	NN	5	B-Disease
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
employed	employ	VERB	VBN	5	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Risperidone	risperidone	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
benign	benign	ADJ	JJ	5	O
transient	transient	ADJ	JJ	9	O
visual	visual	ADJ	JJ	5	B-Disease
disturbances	disturbance	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
schizophrenic	schizophrenic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
past	past	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
LSD	LSD	PROPN	NNP	9	B-Chemical
abuse	abuse	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
schizophrenic	schizophrenic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
prior	prior	ADJ	JJ	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
LSD	LSD	PROPN	NNP	9	B-Chemical
abuse	abuse	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
previously	previously	ADV	RB	9	O
developed	develop	VERB	VBN	5	O
EPS	EPS	PROPN	NNP	9	B-Disease
with	with	ADP	IN	5	O
classic	classic	ADJ	JJ	5	O
antipsychotics	antipsychotic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
successfully	successfully	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
both	both	DET	DT	9	O
reported	report	VERB	VBD	9	O
short	short	ADJ	JJ	5	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
visual	visual	ADJ	JJ	5	B-Disease
disturbances	disturbance	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
appeared	appear	VERB	VBD	9	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
starting	start	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
imagery	imagery	NOUN	NN	5	O
resembled	resemble	VERB	VBD	9	O
visual	visual	ADJ	JJ	5	B-Disease
disturbances	disturbance	NOUN	NNS	5	I-Disease
previously	previously	ADV	RB	9	O
experienced	experience	VERB	VBD	5	O
as	as	ADP	IN	5	O
"	"	PUNCT	``	5	O
flashbacks	flashback	NOUN	NNS	5	O
"	"	PUNCT	''	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
LSD	LSD	PROPN	NNP	9	B-Chemical
consumption	consumption	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Risperidone	risperidone	NOUN	NN	7	B-Chemical
administration	administration	NOUN	NN	9	O
was	be	VERB	VBD	9	O
continued	continue	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
visual	visual	ADJ	JJ	5	B-Disease
disturbances	disturbance	NOUN	NNS	5	I-Disease
gradually	gradually	ADV	RB	9	O
wore	wear	VERB	VBD	5	O
off	off	PART	RP	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
a	a	DET	DT	5	O
six	six	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
visual	visual	ADJ	JJ	5	B-Disease
disturbances	disturbance	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
phenomenon	phenomenon	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
interpreted	interpret	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
benign	benign	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
which	which	DET	WDT	5	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
contraindicate	contraindicate	VERB	VB	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
interfere	interfere	VERB	VB	9	O
with	with	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Conclusions	conclusion	NOUN	NNS	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
two	two	NUM	CD	5	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
taken	take	VERB	VBN	5	O
with	with	ADP	IN	5	O
appropriate	appropriate	ADJ	JJ	5	O
caution	caution	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Topiramate	topiramate	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrolithiasis	nephrolithiasis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Topiramate	topiramate	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
recently	recently	ADV	RB	9	O
developed	develop	VERB	VBN	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
becoming	become	VERB	VBG	5	O
more	more	ADV	RBR	5	O
widely	widely	ADV	RB	5	O
prescribed	prescribe	VERB	VBN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
efficacy	efficacy	NOUN	NN	9	O
in	in	ADP	IN	5	O
treating	treat	VERB	VBG	5	O
refractory	refractory	NOUN	NN	9	B-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Urologists	urologist	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
medication	medication	NOUN	NN	5	O
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
metabolic	metabolic	ADJ	JJ	9	B-Disease
acidosis	acidosis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
carbonic	carbonic	ADJ	JJ	0	O
anhydrase	anhydrase	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
distal	distal	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	O
acidification	acidification	NOUN	NN	9	O
defect	defect	NOUN	NN	9	O
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
,	,	PUNCT	,	9	O
thus	thus	ADV	RB	9	O
impairing	impair	VERB	VBG	9	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
compensatory	compensatory	NOUN	NN	5	O
drop	drop	NOUN	NN	9	O
in	in	ADP	IN	5	O
urine	urine	NOUN	NN	9	O
pH	pH	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
factors	factor	NOUN	NNS	9	O
can	can	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
phosphate	phosphate	NOUN	NN	0	I-Chemical
nephrolithiasis	nephrolithiasis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
topiramate	topiramate	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrolithiasis	nephrolithiasis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
urologic	urologic	ADJ	JJ	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ketamine	ketamine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
war	war	NOUN	NN	5	O
/	/	SYM	SYM	9	O
tropical	tropical	ADJ	JJ	4	O
surgery	surgery	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
a	a	DET	DT	5	O
final	final	ADJ	JJ	9	O
tribute	tribute	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
racemic	racemic	NOUN	NN	0	O
mixture	mixture	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
technique	technique	NOUN	NN	5	O
of	of	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
intravenous	intravenous	ADJ	JJ	0	O
anaesthesia	anaesthesia	NOUN	NN	5	O
with	with	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
successfully	successfully	ADV	RB	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
Somalia	Somalia	PROPN	NNP	4	O
civil	civil	ADJ	JJ	5	O
war	war	NOUN	NN	5	O
in	in	ADP	IN	5	O
1994	1994	NUM	CD	2	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
north	north	ADJ	JJ	4	O
Uganda	Uganda	PROPN	NNP	5	O
in	in	ADP	IN	5	O
1999	1999	NUM	CD	2	O
for	for	ADP	IN	5	O
64	64	NUM	CD	7	O
operations	operation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
62	62	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
aged	age	VERB	VBN	9	O
from	from	ADP	IN	9	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
to	to	ADP	IN	5	O
70	70	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
undergoing	undergo	VERB	VBG	9	O
limb	limb	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
abdominal	abdominal	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
including	include	VERB	VBG	9	O
caesarian	caesarian	ADJ	JJ	5	O
sections	section	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
interventions	intervention	NOUN	NNS	5	O
in	in	ADP	IN	5	O
neonates	neonate	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Operations	operation	NOUN	NNS	2	O
lasting	last	VERB	VBG	5	O
up	up	PART	RP	5	O
to	to	ADP	IN	5	O
2h	2h	PRON	PRP	0	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
sophisticated	sophisticated	ADJ	JJ	5	O
equipment	equipment	NOUN	NN	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
pulse	pulse	NOUN	NN	5	O
oximeters	oximeter	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
ventilators	ventilator	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
ventilation	ventilation	NOUN	NN	5	O
breathing	breathing	NOUN	NN	5	O
air	air	NOUN	NN	5	O
/	/	SYM	SYM	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
premedication	premedication	NOUN	NN	5	O
with	with	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
glycopyrrolate	glycopyrrolate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
local	local	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
induction	induction	NOUN	NN	3	O
with	with	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
maintenance	maintenance	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
proved	prove	VERB	VBD	9	O
safe	safe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
effective	effective	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Emphasis	emphasis	NOUN	NN	5	O
was	be	VERB	VBD	9	O
placed	place	VERB	VBN	5	O
on	on	ADP	IN	5	O
bedside	bedside	NOUN	NN	5	O
clinical	clinical	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
,	,	PUNCT	,	9	O
relying	rely	VERB	VBG	5	O
heavily	heavily	ADV	RB	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Diazepam	Diazepam	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
unless	unless	ADP	IN	9	O
contraindicated	contraindicated	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
risky	risky	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
remains	remain	VERB	VBZ	9	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
necessary	necessary	ADJ	JJ	5	O
complementary	complementary	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
to	to	PART	TO	5	O
ketamine	ketamine	VERB	VB	0	B-Chemical
as	as	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
buffers	buffer	VERB	VBZ	0	O
its	-PRON-	DET	PRP$	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
decreases	decrease	VERB	VBZ	9	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
intensity	intensity	NOUN	NN	5	O
of	of	ADP	IN	5	O
operative	operative	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
postoperative	postoperative	ADJ	JJ	5	O
hallucinations	hallucination	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Local	local	ADJ	JJ	5	O
anaesthetic	anaesthetic	ADJ	JJ	5	O
blocks	block	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
decreasing	decrease	VERB	VBG	9	O
the	the	DET	DT	5	O
requirement	requirement	NOUN	NN	9	O
for	for	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	O
analgesia	analgesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
antisialogue	antisialogue	NOUN	NN	9	O
was	be	VERB	VBD	9	O
usually	usually	ADV	RB	5	O
unnecessary	unnecessary	ADJ	JJ	5	O
in	in	ADP	IN	5	O
operations	operation	NOUN	NNS	5	O
lasting	last	VERB	VBG	5	O
up	up	PART	RP	5	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
glycopyrrolate	glycopyrrolate	NOUN	NN	0	B-Chemical
being	be	VERB	VBG	5	O
the	the	DET	DT	5	O
best	good	ADJ	JJS	5	O
choice	choice	NOUN	NN	5	O
for	for	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
lowest	low	ADJ	JJS	9	O
psychotropic	psychotropic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
chronotropic	chronotropic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
hot	hot	ADJ	JJ	5	O
climate	climate	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Experience	experience	NOUN	NN	5	O
in	in	ADP	IN	5	O
war	war	NOUN	NN	5	O
/	/	SYM	SYM	9	O
tropical	tropical	ADJ	JJ	4	O
settings	setting	NOUN	NNS	5	O
suggests	suggest	VERB	VBZ	9	O
this	this	DET	DT	5	O
technique	technique	NOUN	NN	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
civilian	civilian	ADJ	JJ	5	O
contexts	contexts	NOUN	NN	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
outdoor	outdoor	ADJ	JJ	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
saving	save	VERB	VBG	5	O
emergency	emergency	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
mass	mass	ADJ	JJ	9	O
casualties	casualty	NOUN	NNS	5	O
where	where	ADV	WRB	5	O
,	,	PUNCT	,	9	O
e	e	NOUN	NN	9	O
.	.	PUNCT	.	9	O
g	g	NOUN	NN	0	O
.	.	PUNCT	.	9	O
amputation	amputation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
rapid	rapid	ADJ	JJ	5	O
extrication	extrication	NOUN	NN	5	O
were	be	VERB	VBD	9	O
required	require	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
immunocompromised	immunocompromise	VERB	VBN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Adenovirus	Adenovirus	PROPN	NNP	3	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
morbidity	morbidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
immunocompromised	immunocompromise	VERB	VBN	5	O
host	host	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
pediatrics	pediatric	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
increasing	increase	VERB	VBG	9	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
growing	grow	VERB	VBG	9	O
numbers	number	NOUN	NNS	9	O
of	of	ADP	IN	5	O
immunocompromised	immunocompromised	ADJ	JJ	5	O
children	child	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
where	where	ADV	WRB	5	O
case	case	NOUN	NN	5	O
fatality	fatality	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
as	as	ADV	RB	5	O
high	high	ADJ	JJ	9	O
as	as	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
80	80	NUM	CD	9	O
%	%	NOUN	NN	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
no	no	DET	DT	9	O
approved	approve	VERB	VBN	2	O
antiviral	antiviral	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
with	with	ADP	IN	5	O
proven	prove	VERB	VBN	5	O
efficacy	efficacy	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
nor	nor	CCONJ	CC	9	O
are	be	VERB	VBP	5	O
there	there	ADV	EX	5	O
any	any	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
controlled	control	VERB	VBN	5	O
trials	trial	NOUN	NNS	5	O
of	of	ADP	IN	5	O
potentially	potentially	ADV	RB	5	O
useful	useful	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
adenovirus	adenovirus	ADJ	JJ	3	O
therapies	therapy	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Apparent	apparent	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
success	success	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
limited	limit	VERB	VBN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
small	small	ADJ	JJ	9	O
series	series	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Experience	experience	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
greatest	great	ADJ	JJS	9	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
cidofovir	cidofovir	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Ribavirin	Ribavirin	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
guanosine	guanosine	NOUN	NN	0	B-Chemical
analogue	analogue	NOUN	NN	0	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
broad	broad	ADJ	JJ	5	O
antiviral	antiviral	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
against	against	ADP	IN	9	O
both	both	DET	DT	9	O
RNA	RNA	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
DNA	dna	NOUN	NN	9	O
viruses	virus	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
documented	document	VERB	VBN	9	O
activity	activity	NOUN	NN	9	O
against	against	ADP	IN	9	O
adenovirus	adenovirus	NOUN	NN	3	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
.	.	PUNCT	.	9	O

Ribavirin	Ribavirin	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
licensed	license	VERB	VBN	5	O
in	in	ADP	IN	5	O
aerosol	aerosol	NOUN	NN	5	O
form	form	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
syncytial	syncytial	ADJ	JJ	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
infection	infection	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
orally	orally	ADV	RB	0	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
interferon	interferon	NOUN	NN	3	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
C	C	PROPN	NNP	9	I-Disease
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
choice	choice	NOUN	NN	5	O
for	for	ADP	IN	5	O
infection	infection	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	I-Disease
hemorrhagic	hemorrhagic	ADJ	JJ	5	I-Disease
fever	fever	NOUN	NN	5	I-Disease
viruses	virus	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
reversible	reversible	ADJ	JJ	9	O
mild	mild	ADJ	JJ	9	O
anemia	anemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
cidofovir	cidofovir	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
infection	infection	NOUN	NN	9	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
limited	limit	VERB	VBN	5	O
by	by	ADP	IN	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
significant	significant	ADJ	JJ	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
our	-PRON-	DET	PRP$	5	O
experience	experience	NOUN	NN	5	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
immunocompromised	immunocompromise	VERB	VBN	5	O
children	child	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
review	review	VERB	VB	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

DESIGN	DESIGN	PROPN	NNP	2	O
/	/	SYM	SYM	9	O
METHODS	METHODS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
retrospectively	retrospectively	ADV	RB	5	O
reviewed	review	VERB	VBD	9	O
the	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
records	record	NOUN	NNS	5	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
children	child	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
documented	document	VERB	VBN	9	O
severe	severe	ADJ	JJ	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
adenovirus	adenovirus	ADJ	JJ	3	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
cardiac	cardiac	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplants	transplant	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplant	transplant	NOUN	NN	9	O
patient	patient	NOUN	NN	5	O
also	also	ADV	RB	9	O
received	receive	VERB	VBD	9	O
intravenous	intravenous	ADJ	JJ	0	O
cidofovir	cidofovir	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	O
disseminated	disseminate	VERB	VBN	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
3	3	NUM	CD	9	O
children	child	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
pneumonia	pneumonia	NOUN	NN	5	I-Disease
;	;	PUNCT	:	9	O
2	2	NUM	CD	9	O
were	be	VERB	VBD	9	O
neonates	neonate	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
had	have	VERB	VBD	9	O
partial	partial	ADJ	JJ	9	O
DiGeorge	DiGeorge	PROPN	NNP	1	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
infant	infant	NOUN	NN	5	O
had	have	VERB	VBD	9	O
recently	recently	ADV	RB	9	O
undergone	undergo	VERB	VBN	5	O
a	a	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
transplant	transplant	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
compassionate	compassionate	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
use	use	NOUN	NN	5	O
protocol	protocol	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Complete	complete	VERB	VB	9	O
clinical	clinical	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
followed	follow	VERB	VBD	9	O
later	later	ADV	RB	9	O
by	by	ADP	IN	9	O
viral	viral	ADJ	JJ	9	O
clearance	clearance	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
children	child	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
transplant	transplant	NOUN	NN	9	O
recipient	recipient	NOUN	NN	9	O
with	with	ADP	IN	5	O
adenovirus	adenovirus	ADJ	JJ	3	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
immunocompetent	immunocompetent	ADJ	JJ	5	O
neonate	neonate	NOUN	NN	9	O
with	with	ADP	IN	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
pneumonia	pneumonia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
3	3	NUM	CD	9	O
children	child	NOUN	NNS	5	O
died	die	VERB	VBD	9	O
of	of	ADP	IN	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Use	Use	PROPN	NNP	5	O
of	of	ADP	IN	5	O
cidofovir	cidofovir	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
child	child	NOUN	NN	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
representative	representative	ADJ	JJ	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
spectrum	spectrum	NOUN	NN	9	O
of	of	ADP	IN	5	O
immunocompromised	immunocompromised	ADJ	JJ	5	O
children	child	NOUN	NNS	5	O
at	at	ADP	IN	9	O
greatest	great	ADJ	JJS	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
namely	namely	ADV	RB	9	O
solid	solid	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
organ	organ	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
neonates	neonate	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
immunodeficiency	immunodeficiency	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
for	for	ADP	IN	5	O
all	all	DET	DT	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
series	series	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
,	,	PUNCT	,	9	O
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
unlikely	unlikely	ADJ	JJ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
benefit	benefit	NOUN	NN	5	O
if	if	ADP	IN	5	O
begun	begin	VERB	VBN	5	O
late	late	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
infection	infection	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Early	early	ADJ	JJ	9	O
identification	identification	NOUN	NN	9	O
,	,	PUNCT	,	9	O
eg	eg	NOUN	NN	5	O
by	by	ADP	IN	9	O
polymerase	polymerase	NOUN	NN	1	O
chain	chain	NOUN	NN	9	O
reaction	reaction	NOUN	NN	9	O
of	of	ADP	IN	5	O
those	those	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
disseminated	disseminate	VERB	VBN	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
permit	permit	VERB	VB	5	O
earlier	earlier	ADV	RBR	9	O
antiviral	antiviral	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
better	well	ADJ	JJR	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
recovered	recover	VERB	VBD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
availability	availability	NOUN	NN	5	O
of	of	ADP	IN	5	O
newer	new	ADJ	JJR	5	O
rapid	rapid	ADJ	JJ	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
techniques	technique	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
polymerase	polymerase	NOUN	NN	1	O
chain	chain	NOUN	NN	9	O
reaction	reaction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
make	make	VERB	VB	5	O
earlier	earlier	ADV	RBR	9	O
,	,	PUNCT	,	9	O
more	more	ADV	RBR	5	O
effective	effective	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
adenovirus	adenovirus	ADJ	JJ	3	B-Disease
infection	infection	NOUN	NN	9	I-Disease
possible	possible	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
the	the	DET	DT	5	O
seriousness	seriousness	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
increasing	increase	VERB	VBG	9	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
adenovirus	adenovirus	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
hosts	host	NOUN	NNS	4	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
children	child	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
large	large	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
multicenter	multicenter	NOUN	NN	5	O
clinical	clinical	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
potentially	potentially	ADV	RB	5	O
useful	useful	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
adenoviral	adenoviral	ADJ	JJ	3	O
therapies	therapy	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
clearly	clearly	ADV	RB	9	O
required	require	VERB	VBN	9	O
to	to	PART	TO	5	O
demonstrate	demonstrate	VERB	VB	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
effective	effective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
least	least	ADJ	JJS	9	O
toxic	toxic	ADJ	JJ	0	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Delayed	delay	VERB	VBN	5	O
asystolic	asystolic	VERB	VBP	5	B-Disease
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
after	after	ADP	IN	9	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
;	;	PUNCT	:	9	O
resuscitation	resuscitation	NOUN	NN	5	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
intravenous	intravenous	ADJ	JJ	0	O
calcium	calcium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
51	51	NUM	CD	7	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
took	take	VERB	VBD	5	O
a	a	DET	DT	5	O
mixed	mixed	ADJ	JJ	9	O
overdose	overdose	NOUN	NN	0	B-Disease
including	include	VERB	VBG	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
g	g	NOUN	NN	0	O
of	of	ADP	IN	5	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
aspirin	aspirin	ADJ	JJ	9	B-Chemical
,	,	PUNCT	,	9	O
isosorbide	isosorbide	ADJ	JJ	0	B-Chemical
nitrate	nitrate	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
initially	initially	ADV	RB	9	O
presented	present	VERB	VBD	5	O
to	to	ADP	IN	5	O
hospital	hospital	NOUN	NN	5	O
after	after	ADP	IN	9	O
six	six	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
with	with	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
activated	activate	VERB	VBN	3	O
charcoal	charcoal	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
intravenous	intravenous	ADJ	JJ	0	O
fluids	fluid	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Eighteen	eighteen	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
overdose	overdose	NOUN	NN	0	B-Disease
he	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
two	two	NUM	CD	5	O
generalised	generalise	VERB	VBN	5	O
tonic	tonic	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
clonic	clonic	NOUN	NN	5	I-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
remained	remain	VERB	VBD	9	O
unresponsive	unresponsive	ADJ	JJ	9	O
with	with	ADP	IN	5	O
junctional	junctional	ADJ	JJ	9	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
unrecordable	unrecordable	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
became	become	VERB	VBD	9	O
asystolic	asystolic	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
resuscitated	resuscitate	VERB	VBN	5	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
g	g	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
intravenous	intravenous	ADJ	JJ	0	O
calcium	calcium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
required	require	VERB	VBD	9	O
inotropic	inotropic	ADJ	JJ	5	O
support	support	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
temporary	temporary	ADJ	JJ	5	O
pacing	pacing	NOUN	NN	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
next	next	ADJ	JJ	9	O
48	48	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
for	for	ADP	IN	5	O
aggressive	aggressive	ADJ	JJ	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
intravenous	intravenous	ADJ	JJ	0	O
calcium	calcium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
asystole	asystole	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
early	early	ADV	RB	9	O
in	in	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
after	after	ADP	IN	9	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
case	case	NOUN	NN	5	O
also	also	ADV	RB	9	O
highlights	highlight	VERB	VBZ	5	O
the	the	DET	DT	5	O
problems	problem	NOUN	NNS	5	O
with	with	ADP	IN	5	O
delayed	delay	VERB	VBN	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
when	when	ADV	WRB	5	O
whole	whole	ADJ	JJ	9	O
bowel	bowel	NOUN	NN	5	O
irrigation	irrigation	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
administered	administer	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Low	low	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
molecular	molecular	ADJ	JJ	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
weight	weight	NOUN	NN	9	I-Chemical
heparin	heparin	NOUN	NN	0	I-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
mechanical	mechanical	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
valves	valve	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
interruption	interruption	NOUN	NN	5	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
anticoagulant	anticoagulant	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
OAC	OAC	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
sometimes	sometimes	ADV	RB	5	O
indicated	indicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
mechanical	mechanical	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
valves	valve	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
mainly	mainly	ADV	RB	9	O
before	before	ADP	IN	9	O
noncardiac	noncardiac	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
surgical	surgical	ADJ	JJ	5	O
interventions	intervention	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pregnancy	pregnancy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Unfractionated	unfractionated	ADJ	JJ	0	B-Chemical
heparin	heparin	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
UH	UH	PROPN	NNP	2	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
currently	currently	ADV	RB	5	O
the	the	DET	DT	5	O
substitute	substitute	NOUN	NN	9	O
for	for	ADP	IN	5	O
selected	select	VERB	VBN	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Low	low	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
molecular	molecular	ADJ	JJ	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
weight	weight	NOUN	NN	9	I-Chemical
heparin	heparin	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
LMWH	LMWH	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
offers	offer	VERB	VBZ	5	O
theoretical	theoretical	ADJ	JJ	5	O
advantages	advantage	NOUN	NNS	5	O
over	over	ADP	IN	5	O
UH	UH	PROPN	NNP	2	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
currently	currently	ADV	RB	5	O
considered	consider	VERB	VBN	5	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
guidelines	guideline	NOUN	NNS	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
alternative	alternative	NOUN	NN	5	O
to	to	ADP	IN	5	O
UH	UH	PROPN	NNP	2	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
prosthetic	prosthetic	ADJ	JJ	5	O
valves	valve	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

HYPOTHESIS	hypothesis	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
review	review	VERB	VB	5	O
the	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
accumulated	accumulate	VERB	VBN	9	O
so	so	ADV	RB	5	O
far	far	ADV	RB	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
LMWH	LMWH	PROPN	NNP	5	B-Chemical
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
discuss	discuss	VERB	VB	5	O
its	-PRON-	DET	PRP$	9	O
applicability	applicability	NOUN	NN	5	O
in	in	ADP	IN	5	O
common	common	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
For	for	ADP	IN	9	O
this	this	DET	DT	5	O
paper	paper	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
literature	literature	NOUN	NN	5	O
on	on	ADP	IN	5	O
LMWH	LMWH	PROPN	NNP	5	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
mechanical	mechanical	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
valves	valve	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
extensively	extensively	ADV	RB	9	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
eight	eight	NUM	CD	9	O
series	series	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
six	six	NUM	CD	9	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
studies	study	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
was	be	VERB	VBD	9	O
prospective	prospective	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
to	to	PART	TO	5	O
establish	establish	VERB	VB	5	O
the	the	DET	DT	5	O
thromboembolic	thromboembolic	ADJ	JJ	5	B-Disease
risk	risk	NOUN	NN	5	O
were	be	VERB	VBD	9	O
incomplete	incomplete	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
excluding	exclude	VERB	VBG	9	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
constructed	construct	VERB	VBN	9	O
:	:	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
a	a	DET	DT	5	O
)	)	PUNCT	-RRB-	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
valve	valve	NOUN	NN	5	O
insertion	insertion	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
212	212	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
b	b	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
,	,	PUNCT	,	9	O
perioperative	perioperative	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
noncardiac	noncardiac	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
periprocedural	periprocedural	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
114	114	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
c	c	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
,	,	PUNCT	,	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
intolerance	intolerance	NOUN	NN	5	O
to	to	ADP	IN	5	O
OAC	OAC	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
16	16	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
d	d	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
thromboembolism	thromboembolism	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
studies	study	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
a	a	DET	DT	5	O
,	,	PUNCT	,	9	O
b	b	NOUN	NN	9	O
,	,	PUNCT	,	9	O
c	c	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
d	d	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
;	;	PUNCT	:	9	O
for	for	ADP	IN	5	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
respective	respective	ADJ	JJ	9	O
groups	group	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
mechanical	mechanical	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
valves	valve	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
LMWH	lmwh	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
compares	compare	VERB	VBZ	5	O
favorably	favorably	ADV	RB	5	O
with	with	ADP	IN	5	O
UH	UH	PROPN	NNP	2	B-Chemical
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
mid	mid	PROPN	NNP	9	O
-	-	NOUN	NN	7	O
and	and	CCONJ	CC	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
LMWH	lmwh	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
sparse	sparse	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
randomized	randomize	VERB	VBN	5	O
studies	study	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
confirm	confirm	VERB	VB	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
precise	precise	ADJ	JJ	5	O
indications	indication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
LMWH	LMWH	PROPN	NNP	5	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
mechanical	mechanical	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
valves	valve	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
after	after	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
metoclopramide	metoclopramide	NOUN	NN	0	B-Chemical
-	-	PUNCT	,	7	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
five	five	NUM	CD	9	O
repeated	repeat	VERB	VBN	5	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
metoclopramide	metoclopramide	NOUN	NN	0	B-Chemical
causing	cause	VERB	VBG	9	O
five	five	NUM	CD	9	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
where	where	ADV	WRB	5	O
intravenous	intravenous	ADJ	JJ	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
metoclopramide	metoclopramide	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
immediately	immediately	ADV	RB	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
asystole	asystole	NOUN	NN	5	B-Disease
repeatedly	repeatedly	ADV	RB	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
received	receive	VERB	VBD	9	O
metoclopramide	metoclopramide	NOUN	NN	0	B-Chemical
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
five	five	NUM	CD	9	O
times	time	NOUN	NNS	5	O
during	during	ADP	IN	5	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
interviewing	interview	VERB	VBG	5	O
the	the	DET	DT	5	O
attending	attend	VERB	VBG	5	O
nurses	nurse	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
reviewing	review	VERB	VBG	5	O
the	the	DET	DT	5	O
written	write	VERB	VBN	5	O
documentation	documentation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
clear	clear	ADJ	JJ	9	O
that	that	ADP	IN	5	O
every	every	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
metoclopramide	metoclopramide	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
immediately	immediately	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
within	within	ADP	IN	9	O
s	s	PRON	PRP	9	O
)	)	PUNCT	-RRB-	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
asystole	asystole	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
asystole	asystole	NOUN	NN	5	B-Disease
lasted	last	VERB	VBD	5	O
15	15	NUM	CD	9	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
s	s	NOUN	NN	9	O
on	on	ADP	IN	5	O
four	four	NUM	CD	9	O
occasions	occasion	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
one	one	NUM	CD	5	O
occasion	occasion	NOUN	NN	5	O
it	-PRON-	PRON	PRP	5	O
lasted	last	VERB	VBD	5	O
2	2	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
received	receive	VERB	VBD	9	O
atropine	atropine	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
chest	chest	NOUN	NN	5	O
compressions	compression	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
before	before	ADP	IN	9	O
sinus	sinus	NOUN	NN	5	O
rhythm	rhythm	NOUN	NN	5	O
again	again	ADV	RB	9	O
took	take	VERB	VBD	5	O
over	over	PART	RP	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
interpret	interpret	VERB	VBP	5	O
this	this	DET	DT	5	O
as	as	ADP	IN	5	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
metoclopramide	metoclopramide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
via	via	ADP	IN	9	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
venous	venous	ADJ	JJ	5	O
route	route	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
concomitant	concomitant	ADJ	JJ	9	O
tapering	tapering	NOUN	NN	5	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
infusion	infusion	NOUN	NN	0	O
might	may	VERB	MD	9	O
have	have	VERB	VB	5	O
contributed	contribute	VERB	VBN	9	O
in	in	ADP	IN	5	O
precipitating	precipitate	VERB	VBG	9	O
the	the	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
reaction	reaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Immunohistochemical	immunohistochemical	ADJ	JJ	3	O
study	study	NOUN	NN	9	O
on	on	ADP	IN	5	O
inducible	inducible	ADJ	JJ	3	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
iNOS	iNOS	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
basic	basic	ADJ	JJ	5	O
fibroblast	fibroblast	NOUN	NN	3	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
bFGF	bFGF	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
tumor	tumor	NOUN	NN	3	B-Disease
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
beta1	beta1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
TGF	TGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
beta1	beta1	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
arteritis	arteritis	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
by	by	ADP	IN	9	O
fenoldopam	fenoldopam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
vasodilators	vasodilator	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Arteritis	Arteritis	PROPN	NNP	2	B-Disease
induced	induce	VERB	VBD	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
by	by	ADP	IN	9	O
vasodilators	vasodilator	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
fenoldopam	fenoldopam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
immunohistochemically	immunohistochemically	ADV	RB	3	O
for	for	ADP	IN	5	O
expressions	expression	NOUN	NNS	9	O
of	of	ADP	IN	5	O
inducible	inducible	ADJ	JJ	3	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
synthase	synthase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
iNOS	iNOS	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
basic	basic	ADJ	JJ	5	O
fibroblast	fibroblast	NOUN	NN	3	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
bFGF	bFGF	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
tumor	tumor	NOUN	NN	3	B-Disease
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
beta1	beta1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
TGF	TGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
beta1	beta1	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
fenoldopam	fenoldopam	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
by	by	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
following	follow	VERB	VBG	9	O
repeated	repeat	VERB	VBN	5	O
daily	daily	ADJ	JJ	5	O
oral	oral	ADJ	JJ	9	O
administrations	administration	NOUN	NNS	5	O
of	of	ADP	IN	5	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Irrespective	irrespective	ADV	RB	5	O
of	of	ADP	IN	5	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
iNOS	iNOS	PROPN	NNP	3	O
antigens	antigen	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
remarkably	remarkably	ADV	RB	9	O
abundant	abundant	ADJ	JJ	9	O
in	in	ADP	IN	5	O
ED	ED	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
post	post	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
fenoldopam	fenoldopam	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
infusion	infusion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
DPI	DPI	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
bFGF	bFGF	NOUN	NNS	3	O
antigens	antigen	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
remarkably	remarkably	ADV	RB	9	O
abundant	abundant	ADJ	JJ	9	O
in	in	ADP	IN	5	O
ED	ED	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
on	on	ADP	IN	5	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
DPI	DPI	PROPN	NNP	0	O
;	;	PUNCT	:	9	O
TGF	TGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
beta1	beta1	PROPN	NNP	3	O
antigens	antigen	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
ED	ED	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
on	on	ADP	IN	5	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
5	5	NUM	CD	9	O
DPI	dpi	NOUN	NN	0	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
peak	peak	NOUN	NN	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
iNOS	iNOS	PROPN	NNP	3	O
antigen	antigen	NOUN	NN	3	O
was	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
bFGF	bFGF	PROPN	NNP	3	O
antigen	antigen	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
bFGF	bFGF	PROPN	NNP	3	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
suppressive	suppressive	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
iNOS	iNOS	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
rat	rat	NOUN	NN	3	O
arteritis	arteritis	NOUN	NN	5	B-Disease
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
TGF	TGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
beta1	beta1	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
considered	consider	VERB	VBN	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
suppressive	suppressive	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
iNOS	iNOS	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
target	target	NOUN	NN	9	O
for	for	ADP	IN	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
rigor	rigor	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
antagonist	antagonist	NOUN	NN	3	O
of	of	ADP	IN	5	O
mGluR1	mGluR1	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
an	an	DET	DT	5	O
agonist	agonist	NOUN	NN	3	O
of	of	ADP	IN	5	O
group	group	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
metabotropic	metabotropic	ADJ	JJ	3	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
find	find	VERB	VB	5	O
out	out	PART	RP	9	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
metabotropic	metabotropic	ADJ	JJ	3	O
receptor	receptor	NOUN	NN	3	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
mGluR1	mGluR1	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
group	group	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
mGluRs	mglurs	NUM	CD	3	O
,	,	PUNCT	,	9	O
localized	localize	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
antiparkinsonian	antiparkinsonian	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Haloperidol	Haloperidol	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
ip	ip	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
induced	induce	VERB	VBD	3	O
parkinsonian	parkinsonian	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
measured	measure	VERB	VBN	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
resistance	resistance	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
'	'	PUNCT	``	9	O
s	s	PART	POS	9	O
hind	hind	NOUN	NN	4	O
foot	foot	NOUN	NN	5	O
to	to	ADP	IN	5	O
passive	passive	ADJ	JJ	5	O
flexion	flexion	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
extension	extension	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
ankle	ankle	NOUN	NN	5	O
joint	joint	NOUN	NN	5	O
.	.	PUNCT	.	9	O

(	(	PUNCT	-LRB-	9	B-Chemical
RS	RS	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminoindan	aminoindan	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dicarboxylic	dicarboxylic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
AIDA	AIDA	PROPN	NNP	9	B-Chemical
;	;	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
15	15	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
selective	selective	ADJ	JJ	9	O
mGluR1	mGluR1	PROPN	NNP	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	B-Chemical
2R	2r	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4R	4R	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminopyrrolidine	aminopyrrolidine	NOUN	NN	_	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
dicarboxylate	dicarboxylate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
2R	2r	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
4R	4r	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
APDC	apdc	ADJ	JJ	5	I-Chemical
;	;	PUNCT	:	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
15	15	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
agonist	agonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
bilaterally	bilaterally	ADV	RB	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

AIDA	AIDA	NOUN	NNS	9	B-Chemical
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
15	15	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
diminished	diminish	VERB	VBD	9	O
the	the	DET	DT	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
2R	2r	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
4R	4r	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
APDC	apdc	ADJ	JJ	5	I-Chemical
injections	injection	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
ineffective	ineffective	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
may	may	VERB	MD	5	O
suggest	suggest	VERB	VB	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
mGluR1	mGluR1	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
the	the	DET	DT	5	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
group	group	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
mGluRs	mglurs	NUM	CD	3	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
ameliorate	ameliorate	VERB	VB	9	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
metastatic	metastatic	ADJ	JJ	3	O
renal	renal	ADJ	JJ	9	B-Disease
cell	cell	NOUN	NN	3	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
metastatic	metastatic	ADJ	JJ	3	O
renal	renal	ADJ	JJ	9	B-Disease
cell	cell	NOUN	NN	3	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
measure	measure	VERB	VB	5	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
one	one	NUM	CD	5	O
angiogenic	angiogenic	ADJ	JJ	3	O
factor	factor	NOUN	NN	9	O
,	,	PUNCT	,	9	O
vascular	vascular	ADJ	JJ	5	O
endothelial	endothelial	ADJ	JJ	3	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
VEGF	VEGF	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
165	165	NUM	CD	7	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
29	29	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
using	use	VERB	VBG	9	O
an	an	DET	DT	5	O
intra	intra	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
patient	patient	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
escalation	escalation	NOUN	NN	5	O
schedule	schedule	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
began	begin	VERB	VBD	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
escalated	escalate	VERB	VBN	5	O
as	as	ADP	IN	5	O
tolerated	tolerate	VERB	VBN	9	O
to	to	ADP	IN	5	O
1200	1200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
by	by	ADP	IN	9	O
day	day	NOUN	NN	9	O
54	54	NUM	CD	7	O
.	.	PUNCT	.	9	O

Fifty	fifty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
had	have	VERB	VBN	9	O
previous	previous	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
52	52	NUM	CD	7	O
%	%	NOUN	NN	9	O
were	be	VERB	VBD	9	O
performance	performance	NOUN	NN	5	O
status	status	NOUN	NN	9	O
2	2	NUM	CD	9	O
or	or	CCONJ	CC	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

Systemic	systemic	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
VEGF165	vegf165	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
dual	dual	ADJ	JJ	9	O
monoclonal	monoclonal	ADJ	JJ	3	O
ELISA	ELISA	PROPN	NNP	3	O
in	in	ADP	IN	5	O
8	8	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
24	24	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
evaluable	evaluable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
response	response	NOUN	NN	9	O
with	with	ADP	IN	5	O
one	one	NUM	CD	5	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
of	of	ADP	IN	5	O
11	11	NUM	CD	7	O
months	month	NOUN	NNS	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
metastases	metastasis	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
minor	minor	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
stable	stable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
over	over	ADP	IN	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Somnolence	somnolence	NOUN	NN	7	B-Disease
and	and	CCONJ	CC	5	O
constipation	constipation	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
prominent	prominent	ADJ	JJ	9	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
most	most	ADJ	JJS	9	O
patients	patient	NOUN	NNS	5	O
could	could	VERB	MD	9	O
not	not	ADV	RB	5	O
tolerate	tolerate	VERB	VB	5	O
the	the	DET	DT	5	O
1200	1200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Systemic	systemic	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
VEGF165	vegf165	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
with	with	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
cell	cell	NOUN	NN	3	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
over	over	ADP	IN	5	O
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
was	be	VERB	VBD	9	O
difficult	difficult	ADJ	JJ	5	O
to	to	PART	TO	5	O
achieve	achieve	VERB	VB	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
practical	practical	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
relationship	relationship	NOUN	NN	5	O
,	,	PUNCT	,	9	O
if	if	ADP	IN	5	O
any	any	DET	DT	5	O
,	,	PUNCT	,	9	O
of	of	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
cell	cell	NOUN	NN	3	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
is	be	VERB	VBZ	5	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Can	Can	VERB	MD	5	O
lidocaine	lidocaine	ADV	RB	0	B-Chemical
reduce	reduce	VERB	VB	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
induced	induce	VERB	VBN	3	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
myalgia	myalgia	NOUN	NN	5	I-Disease
?	?	PUNCT	.	5	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	ADJ	JJR	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
on	on	ADP	IN	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
myalgia	myalgia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
general	general	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
for	for	ADP	IN	5	O
gynecological	gynecological	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
hundred	hundred	NUM	CD	5	O
and	and	CCONJ	CC	5	O
thirty	thirty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomized	ADJ	JJ	5	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Group	Group	PROPN	NNP	9	O
PS	PS	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
received	receive	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
x	x	X	XX	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
Group	Group	PROPN	NNP	9	O
LS	LS	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
x	x	X	XX	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
x	x	X	XX	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
Group	Group	PROPN	NNP	9	O
PR	PR	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
rocuronium	rocuronium	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
x	x	X	XX	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Morphine	Morphine	PROPN	NNP	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
x	x	X	XX	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
iv	iv	PRON	PRP	9	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
for	for	ADP	IN	5	O
premedication	premedication	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
noninvasive	noninvasive	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
monitor	monitor	NOUN	NN	5	O
,	,	PUNCT	,	9	O
ECG	ECG	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
pulse	pulse	VERB	VB	5	O
oximetry	oximetry	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Anesthesia	Anesthesia	PROPN	NNP	2	O
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
with	with	ADP	IN	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
thiopental	thiopental	ADJ	JJ	0	B-Chemical
iv	iv	NOUN	NN	9	O
.	.	PUNCT	.	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
Group	Group	PROPN	NNP	9	O
PS	PS	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
LS	LS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
rocuronium	rocuronium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Group	Group	PROPN	NNP	9	O
PR	PR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
tracheal	tracheal	NOUN	NN	9	O
intubation	intubation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
fasciculation	fasciculation	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
visually	visually	ADV	RB	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
four	four	NUM	CD	9	O
point	point	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
by	by	ADP	IN	9	O
one	one	NUM	CD	5	O
investigator	investigator	NOUN	NN	5	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
blinded	blind	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
administered	administer	VERB	VBD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
patient	patient	NOUN	NN	5	O
were	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
on	on	ADP	IN	5	O
nine	nine	NUM	CD	9	O
occasions	occasion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
any	any	DET	DT	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
experienced	experience	VERB	VBD	5	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
structured	structured	ADJ	JJ	5	O
questionaire	questionaire	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
graded	grade	VERB	VBN	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
four	four	NUM	CD	9	O
point	point	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
by	by	ADP	IN	9	O
one	one	NUM	CD	5	O
investigator	investigator	NOUN	NN	5	O
blinded	blind	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
intraoperative	intraoperative	ADJ	JJ	5	O
management	management	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	DET	DT	5	O
muscle	muscle	NOUN	NN	9	B-Disease
fasciculation	fasciculation	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
PR	PR	PROPN	NNP	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
LS	LS	PROPN	NNP	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	B-Disease
fasciculation	fasciculation	NOUN	NN	5	I-Disease
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
PS	PS	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
p	p	PROPN	NNP	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
PS	PS	PROPN	NNP	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
LS	LS	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
PR	PR	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
correlation	correlation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
found	find	VERB	VBN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	B-Disease
fasciculation	fasciculation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
systolic	systolic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
diastolic	diastolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
where	where	ADV	WRB	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
,	,	PUNCT	,	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
proven	prove	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
pretreatment	pretreatment	ADJ	JJ	0	O
agent	agent	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
myalgia	myalgia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Reduced	reduce	VERB	VBN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
density	density	NOUN	NN	9	O
,	,	PUNCT	,	9	O
altered	alter	VERB	VBD	9	O
voltage	voltage	NOUN	NN	5	O
dependence	dependence	NOUN	NN	5	O
of	of	ADP	IN	5	O
inactivation	inactivation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
lacking	lack	VERB	VBG	1	O
sodium	sodium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
beta	beta	NOUN	NN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
subunits	subunit	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

Sodium	sodium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
subunits	subunit	NOUN	NNS	1	O
modulate	modulate	ADJ	JJ	9	O
channel	channel	NOUN	NN	9	O
gating	gating	NOUN	NN	5	O
,	,	PUNCT	,	9	O
assembly	assembly	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cell	cell	NOUN	NN	3	O
surface	surface	NOUN	NN	9	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
heterologous	heterologous	ADJ	JJ	1	O
cell	cell	NOUN	NN	3	O
systems	system	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
generated	generate	VERB	VBD	9	O
beta2	beta2	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
beta2	beta2	NOUN	NN	5	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
density	density	NOUN	NN	9	O
,	,	PUNCT	,	9	O
localization	localization	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Measurements	measurement	NOUN	NNS	9	O
of	of	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
H	h	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
saxitoxin	saxitoxin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
STX	STX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
binding	binding	NOUN	NN	1	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
membrane	membrane	NOUN	NN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
channels	channel	NOUN	NNS	9	O
in	in	ADP	IN	5	O
beta2	beta2	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
neurons	neuron	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
beta2	beta2	NOUN	NN	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
negative	negative	ADJ	JJ	9	O
shifts	shift	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
voltage	voltage	NOUN	NN	5	O
dependence	dependence	NOUN	NN	5	O
of	of	ADP	IN	5	O
inactivation	inactivation	NOUN	NN	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
current	current	ADJ	JJ	5	O
density	density	NOUN	NN	9	O
in	in	ADP	IN	5	O
acutely	acutely	ADV	RB	9	O
dissociated	dissociate	VERB	VBN	3	O
hippocampal	hippocampal	ADJ	JJ	3	O
neurons	neuron	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
integral	integral	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
compound	compound	NOUN	NN	0	O
action	action	NOUN	NN	5	O
potential	potential	NOUN	NN	9	O
in	in	ADP	IN	5	O
optic	optic	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
threshold	threshold	NOUN	NN	5	O
for	for	ADP	IN	5	O
action	action	NOUN	NN	5	O
potential	potential	ADJ	JJ	9	O
generation	generation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
functional	functional	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
membrane	membrane	NOUN	NN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
channels	channel	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
conduction	conduction	NOUN	NN	5	O
velocity	velocity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
size	size	NOUN	NN	9	O
of	of	ADP	IN	5	O
axons	axon	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
optic	optic	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
localization	localization	NOUN	NN	3	O
of	of	ADP	IN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
v	v	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
channels	channel	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
nodes	node	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Ranvier	Ranvier	PROPN	NNP	5	O
were	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

beta2	beta2	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
displayed	display	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
indicated	indicate	VERB	VBN	9	O
by	by	ADP	IN	9	O
reduced	reduced	ADJ	JJ	9	O
latency	latency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
threshold	threshold	NOUN	NN	5	O
for	for	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
seemed	seem	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
in	in	ADP	IN	5	O
other	other	ADJ	JJ	5	O
neurological	neurological	ADJ	JJ	5	O
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
observations	observation	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
beta2	beta2	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
subunits	subunit	NOUN	NNS	1	O
play	play	VERB	VBP	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
density	density	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
are	be	VERB	VBP	5	O
required	require	VERB	VBN	9	O
for	for	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
action	action	NOUN	NN	5	O
potential	potential	ADJ	JJ	9	O
generation	generation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
excitability	excitability	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
concurrent	concurrent	ADJ	JJ	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
carbimazole	carbimazole	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
possibly	possibly	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
concurrent	concurrent	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
carbimazole	carbimazole	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
41	41	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Chinese	chinese	ADJ	JJ	9	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
hyperthyroidism	hyperthyroidism	NOUN	NN	5	B-Disease
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
carbimazole	carbimazole	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
past	past	ADJ	JJ	5	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
aid	aid	NOUN	NN	5	O
for	for	ADP	IN	5	O
smoking	smoking	NOUN	NN	5	O
cessation	cessation	NOUN	NN	5	O
10	10	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
presentation	presentation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
rapid	rapid	ADJ	JJ	5	O
deterioration	deterioration	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
nonspecific	nonspecific	ADJ	JJ	3	O
drug	drug	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
induced	induce	VERB	VBN	3	I-Disease
acute	acute	ADJ	JJ	9	I-Disease
liver	liver	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

His	-PRON-	DET	PRP$	9	O
condition	condition	NOUN	NN	5	O
was	be	VERB	VBD	9	O
further	further	ADV	RB	9	O
complicated	complicate	VERB	VBN	5	O
by	by	ADP	IN	9	O
sepsis	sepsis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
coagulopathy	coagulopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Death	death	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
19	19	NUM	CD	7	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
likelihood	likelihood	NOUN	NN	5	O
that	that	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
induced	induce	VERB	VBD	3	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
possible	possible	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
Naranjo	Naranjo	PROPN	NNP	6	O
probability	probability	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Although	although	ADP	IN	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
increasing	increase	VERB	VBG	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
fatality	fatality	NOUN	NN	5	O
that	that	DET	WDT	5	O
could	could	VERB	MD	9	O
have	have	VERB	VB	5	O
resulted	result	VERB	VBN	9	O
from	from	ADP	IN	9	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	ADJ	JJ	5	O
receiving	receive	VERB	VBG	9	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
while	while	ADP	IN	9	O
on	on	ADP	IN	5	O
concomitant	concomitant	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
carbimazole	carbimazole	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Clinicians	clinician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
insult	insult	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
given	give	VERB	VBN	5	O
concurrently	concurrently	ADV	RB	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
hepatotoxic	hepatotoxic	ADJ	JJ	0	B-Disease
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Pyeloureteral	pyeloureteral	ADJ	JJ	_	O
filling	filling	NOUN	NN	5	O
defects	defect	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
anticoagulation	anticoagulation	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
etiology	etiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
pyeloureteritis	pyeloureteritis	NOUN	NN	9	B-Disease
cystica	cystica	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
long	long	ADV	RB	5	O
been	be	VERB	VBN	9	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
infection	infection	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
inflammation	inflammation	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
that	that	ADP	IN	5	O
is	be	VERB	VBZ	5	O
unique	unique	ADJ	JJ	9	O
in	in	ADP	IN	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
onset	onset	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
pyeloureteral	pyeloureteral	ADJ	JJ	5	O
filling	filling	NOUN	NN	5	O
defects	defect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
were	be	VERB	VBD	9	O
documented	document	VERB	VBN	9	O
by	by	ADP	IN	9	O
radiography	radiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
antecedent	antecedent	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
concurrent	concurrent	ADJ	JJ	5	O
infection	infection	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
disease	disease	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
subsequent	subsequent	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
suspected	suspect	VERB	VBN	5	O
pelvic	pelvic	ADJ	JJ	5	O
thrombophlebitis	thrombophlebitis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
cleared	clear	VERB	VBD	9	O
rapidly	rapidly	ADV	RB	9	O
subsequent	subsequent	ADJ	JJ	9	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
discontinuation	discontinuation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
radiographic	radiographic	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
helpful	helpful	ADJ	JJ	6	O
in	in	ADP	IN	5	O
distinguishing	distinguish	VERB	VBG	5	O
between	between	ADP	IN	5	O
true	true	ADJ	JJ	5	O
pyeloureteritis	pyeloureteritis	NOUN	NN	9	B-Disease
cystica	cystica	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
submucosal	submucosal	NOUN	NN	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Nephrotoxic	nephrotoxic	ADJ	JJ	0	B-Disease
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
angiography	angiography	ADV	RB	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
iodinated	iodinate	VERB	VBN	0	O
contrast	contrast	NOUN	NN	9	O
medium	medium	NOUN	NN	0	O
can	can	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Whether	whether	ADP	IN	9	O
iso	iso	ADJ	JJ	0	O
-	-	PUNCT	HYPH	7	O
osmolar	osmolar	NOUN	NN	0	O
contrast	contrast	NOUN	NN	9	O
medium	medium	NOUN	NN	0	O
is	be	VERB	VBZ	5	O
less	less	ADV	RBR	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
than	than	ADP	IN	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
osmolar	osmolar	NOUN	NN	0	O
contrast	contrast	NOUN	NN	9	O
medium	medium	NOUN	NN	0	O
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
uncertain	uncertain	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
multicenter	multicenter	NOUN	NN	5	O
study	study	NOUN	NN	9	O
comparing	compare	VERB	VBG	9	O
the	the	DET	DT	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
iso	iso	ADJ	JJ	0	O
-	-	PUNCT	HYPH	7	O
osmolar	osmolar	NOUN	NN	0	O
,	,	PUNCT	,	9	O
dimeric	dimeric	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
nonionic	nonionic	ADJ	JJ	0	O
contrast	contrast	NOUN	NN	9	O
medium	medium	NOUN	NN	0	O
,	,	PUNCT	,	9	O
iodixanol	iodixanol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
osmolar	osmolar	NOUN	NN	0	O
,	,	PUNCT	,	9	O
nonionic	nonionic	ADJ	JJ	0	O
,	,	PUNCT	,	9	O
monomeric	monomeric	ADJ	JJ	0	O
contrast	contrast	NOUN	NN	9	O
medium	medium	NOUN	NN	0	O
,	,	PUNCT	,	9	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
involved	involve	VERB	VBD	9	O
129	129	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
diabetes	diabete	NOUN	NNS	5	B-Disease
with	with	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
deciliter	deciliter	NOUN	NN	0	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
coronary	coronary	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
aortofemoral	aortofemoral	ADJ	JJ	5	O
angiography	angiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
end	end	NOUN	NN	9	O
point	point	NOUN	NN	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
peak	peak	NOUN	NN	9	O
increase	increase	NOUN	NN	9	O
from	from	ADP	IN	9	O
base	base	NOUN	NN	5	O
line	line	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
angiography	angiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
end	end	NOUN	NN	9	O
points	point	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
deciliter	deciliter	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
deciliter	deciliter	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
from	from	ADP	IN	9	O
day	day	NOUN	NN	9	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
day	day	NOUN	NN	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
increased	increase	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADV	RBR	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
iodixanol	iodixanol	ADV	RB	0	B-Chemical
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
day	day	NOUN	NN	9	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
day	day	NOUN	NN	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
peak	peak	NOUN	NN	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
13	13	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
deciliter	deciliter	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
iodixanol	iodixanol	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
55	55	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
deciliter	deciliter	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
with	with	ADP	IN	5	O
iodixanol	iodixanol	NOUN	NN	0	B-Chemical
minus	minus	CCONJ	CC	9	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
with	with	ADP	IN	5	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
42	42	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
deciliter	deciliter	NOUN	NN	0	O
[	[	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
73	73	NUM	CD	7	O
to	to	PART	TO	5	O
-	-	PUNCT	HYPH	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
22	22	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
64	64	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
iodixanol	iodixanol	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
deciliter	deciliter	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
17	17	NUM	CD	7	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
65	65	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
26	26	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
;	;	PUNCT	:	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
for	for	ADP	IN	5	O
such	such	DET	PDT	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
iodixanol	iodixanol	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
09	09	NUM	CD	7	O
[	[	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
41	41	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
patient	patient	NOUN	NN	5	O
receiving	receive	VERB	VBG	9	O
iodixanol	iodixanol	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
deciliter	deciliter	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
from	from	ADP	IN	9	O
day	day	NOUN	NN	9	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
day	day	NOUN	NN	9	O
7	7	NUM	CD	9	O
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
07	07	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
deciliter	deciliter	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
iodixanol	iodixanol	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
24	24	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
deciliter	deciliter	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
003	003	NUM	CD	2	O
;	;	PUNCT	:	9	O
value	value	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
iodixanol	iodixanol	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
minus	minus	ADP	IN	9	O
the	the	DET	DT	5	O
value	value	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
17	17	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
deciliter	deciliter	NOUN	NN	0	O
[	[	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
34	34	NUM	CD	7	O
to	to	PART	TO	5	O
-	-	PUNCT	HYPH	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
07	07	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Nephropathy	Nephropathy	PROPN	NNP	7	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
medium	medium	NOUN	NN	0	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
less	less	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
when	when	ADV	WRB	5	O
iodixanol	iodixanol	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
osmolar	osmolar	NOUN	NN	0	O
,	,	PUNCT	,	9	O
nonionic	nonionic	ADJ	JJ	0	O
contrast	contrast	NOUN	NN	9	O
medium	medium	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
edaravone	edaravone	NOUN	NN	0	B-Chemical
against	against	ADP	IN	9	O
streptomycin	streptomycin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
vestibulotoxicity	vestibulotoxicity	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
guinea	guinea	NOUN	NN	9	O
pig	pig	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
investigated	investigate	VERB	VBD	9	O
alleviation	alleviation	NOUN	NN	5	O
of	of	ADP	IN	5	O
streptomycin	streptomycin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
vestibulotoxicity	vestibulotoxicity	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
edaravone	edaravone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
guinea	guinea	NOUN	NN	9	O
pigs	pig	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Edaravone	Edaravone	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
free	free	ADJ	JJ	9	O
radical	radical	ADJ	JJ	0	O
scavenger	scavenger	NOUN	NN	0	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
potent	potent	ADJ	JJ	3	O
free	free	ADJ	JJ	9	O
radical	radical	ADJ	JJ	0	O
quenching	quenching	NOUN	NN	0	O
action	action	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Streptomycin	Streptomycin	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
inner	inner	ADJ	JJ	9	O
ear	ear	NOUN	NN	5	O
by	by	ADP	IN	9	O
osmotic	osmotic	ADJ	JJ	0	O
pump	pump	NOUN	NN	0	O
for	for	ADP	IN	5	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
edaravone	edaravone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
injected	inject	VERB	VBN	3	O
once	once	ADV	RB	5	O
a	a	DET	DT	5	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
observed	observe	VERB	VBD	9	O
horizontal	horizontal	ADJ	JJ	5	O
vestibulo	vestibulo	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
ocular	ocular	ADJ	JJ	5	O
reflex	reflex	NOUN	NN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
marker	marker	NOUN	NN	3	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	O
vestibular	vestibular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
injected	inject	VERB	VBD	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
showed	show	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
smaller	small	ADJ	JJR	5	O
gains	gain	NOUN	NNS	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
edaravone	edaravone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
edaravone	edaravone	NOUN	NN	0	B-Chemical
suppresses	suppress	VERB	VBZ	3	O
streptomycin	streptomycin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
vestibulotoxicity	vestibulotoxicity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Levodopa	Levodopa	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
oromandibular	oromandibular	ADJ	JJ	5	O
dystonia	dystonia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	B-Disease
supranuclear	supranuclear	NOUN	NN	5	I-Disease
palsy	palsy	ADJ	JJ	5	I-Disease
.	.	PUNCT	.	9	O

Levodopa	Levodopa	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
multiple	multiple	ADJ	JJ	5	B-Disease
system	system	NOUN	NN	5	I-Disease
atrophy	atrophy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Cranial	cranial	ADJ	JJ	5	O
dystonias	dystonia	NOUN	NNS	5	B-Disease
are	be	VERB	VBP	5	O
rare	rare	ADJ	JJ	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	B-Disease
supranuclear	supranuclear	NOUN	NN	5	I-Disease
palsy	palsy	ADJ	JJ	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PSP	PSP	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
report	report	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
describe	describe	VERB	VBP	5	O
an	an	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
reversible	reversible	ADJ	JJ	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
Oromandibular	Oromandibular	PROPN	NNP	5	B-Disease
dystonia	dystonia	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
OMD	OMD	PROPN	NNP	7	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
PSP	PSP	PROPN	NNP	9	B-Disease
patient	patient	NOUN	NN	5	O
to	to	PART	TO	5	O
highlight	highlight	VERB	VB	5	O
the	the	DET	DT	5	O
importance	importance	NOUN	NN	5	O
of	of	ADP	IN	5	O
recognizing	recognize	VERB	VBG	9	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
related	relate	VERB	VBN	9	O
complication	complication	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
PSP	PSP	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
discuss	discuss	VERB	VB	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
underlying	underlying	ADJ	JJ	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Dexatrim	Dexatrim	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
Phenylpropanolamine	Phenylpropanolamine	PROPN	NNP	7	B-Chemical
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Phenylpropanolamine	Phenylpropanolamine	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
PPA	PPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
amine	amine	NOUN	NN	0	B-Chemical
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
over	over	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
the	the	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
counter	counter	NOUN	NN	5	O
cold	cold	ADJ	JJ	9	O
remedies	remedy	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
weight	weight	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
preparations	preparation	NOUN	NNS	9	O
worldwide	worldwide	ADV	RB	5	O
.	.	PUNCT	.	9	O

Its	-PRON-	DET	PRP$	5	O
use	use	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
episodes	episode	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
strokes	stroke	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
younger	young	ADJ	JJR	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Several	several	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
linked	link	VERB	VBN	9	O
the	the	DET	DT	5	O
abuse	abuse	NOUN	NN	5	O
of	of	ADP	IN	5	O
PPA	PPA	PROPN	NNP	9	B-Chemical
with	with	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
when	when	ADV	WRB	5	O
overdose	overdose	NOUN	NN	0	B-Disease
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
here	here	ADV	RB	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
Dexatrim	Dexatrim	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
PPA	PPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
young	young	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
using	use	VERB	VBG	9	O
it	-PRON-	PRON	PRP	5	O
at	at	ADP	IN	9	O
recommended	recommend	VERB	VBN	5	O
doses	dose	NOUN	NNS	0	O
for	for	ADP	IN	5	O
weight	weight	NOUN	NN	9	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
review	review	VERB	VBP	5	O
the	the	DET	DT	5	O
7	7	NUM	CD	9	O
other	other	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
PPA	PPA	PROPN	NNP	9	B-Chemical
related	relate	VERB	VBN	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
that	that	DET	WDT	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
so	so	ADV	RB	5	O
far	far	ADV	RB	5	O
.	.	PUNCT	.	9	O

Physicians	physician	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
alert	alert	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
PPA	PPA	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
generally	generally	ADV	RB	5	O
considered	consider	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
safe	safe	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Differential	differential	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
creatine	creatine	NOUN	NN	0	B-Chemical
kinase	kinase	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	B-Disease
lupus	lupus	NOUN	NN	9	I-Disease
erythematosus	erythematosus	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
bioptic	bioptic	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
57	57	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
chloroquine	chloroquine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
myopathy	myopathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
1989	1989	NUM	CD	2	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
systemic	systemic	ADJ	JJ	9	B-Disease
lupus	lupus	NOUN	NN	9	I-Disease
erythematosus	erythematosus	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
SLE	SLE	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
involvement	involvement	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
undergone	undergone	ADJ	JJ	5	O
periods	period	NOUN	NNS	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Additional	additional	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
chloroquine	chloroquine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CQ	CQ	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
started	start	VERB	VBN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
arthralgia	arthralgia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
slightly	slightly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
creatine	creatine	NOUN	NN	0	B-Chemical
kinase	kinase	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
CK	ck	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Myositis	Myositis	PROPN	NNP	2	B-Disease
was	be	VERB	VBD	9	O
suspected	suspect	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
CK	CK	PROPN	NNP	9	O
increase	increase	NOUN	NN	9	O
persisted	persist	VERB	VBD	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
she	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
progressive	progressive	ADJ	JJ	5	O
muscular	muscular	ADJ	JJ	5	B-Disease
weakness	weakness	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
muscular	muscular	ADJ	JJ	5	B-Disease
atrophy	atrophy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Routine	Routine	PROPN	NNP	5	O
controls	control	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
elevated	elevate	VERB	VBN	9	O
CK	CK	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
700	700	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
l	l	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
neurological	neurological	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
typical	typical	ADJ	JJ	9	O
of	of	ADP	IN	5	O
myositis	myositis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
muscle	muscle	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
deltoid	deltoid	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
exclude	exclude	VERB	VB	9	O
polymyositis	polymyositis	NOUN	NN	9	B-Disease
or	or	CCONJ	CC	5	O
toxic	toxic	ADJ	JJ	0	O
myopathy	myopathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
revealed	reveal	VERB	VBD	9	O
chloroquine	chloroquine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
myopathy	myopathy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
medication	medication	NOUN	NN	5	O
was	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Discriminating	discriminate	VERB	VBG	5	O
between	between	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
SLE	SLE	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
affection	affection	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
musculoskeletal	musculoskeletal	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
important	important	ADJ	JJ	9	O
for	for	ADP	IN	5	O
appropriate	appropriate	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
SLE	SLE	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Seizure	Seizure	PROPN	NNP	5	B-Disease
associated	associate	VERB	VBD	9	O
with	with	ADP	IN	5	O
sleep	sleep	NOUN	NN	5	B-Disease
deprivation	deprivation	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
sustained	sustain	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
describes	describe	VERB	VBZ	5	O
a	a	DET	DT	5	O
generalized	generalized	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
sustained	sustain	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
sleep	sleep	NOUN	NN	5	B-Disease
deprivation	deprivation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
subject	subject	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
31	31	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
female	female	ADJ	JJ	9	O
smoker	smoker	NOUN	NN	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
participating	participate	VERB	VBG	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
evaluating	evaluate	VERB	VBG	5	O
an	an	DET	DT	5	O
investigational	investigational	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
for	for	ADP	IN	5	O
smoking	smoking	NOUN	NN	5	O
cessation	cessation	NOUN	NN	5	O
that	that	DET	WDT	5	O
used	use	VERB	VBD	5	O
sustained	sustained	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
active	active	ADJ	JJ	9	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
5	5	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
subject	subject	NOUN	NN	5	O
experienced	experience	VERB	VBD	5	O
a	a	DET	DT	5	O
generalized	generalized	ADJ	JJ	5	O
tonic	tonic	NOUN	NN	5	O
clonic	clonic	NOUN	NN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
staying	stay	VERB	VBG	5	O
up	up	PART	RP	5	O
nearly	nearly	ADV	RB	9	O
all	all	DET	DT	5	O
night	night	NOUN	NN	5	O
packing	pack	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
moving	move	VERB	VBG	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
residence	residence	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
sleep	sleep	NOUN	NN	5	B-Disease
deprivation	deprivation	NOUN	NN	9	I-Disease
may	may	VERB	MD	5	O
add	add	VERB	VB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Postoperative	postoperative	ADJ	JJ	5	B-Disease
myalgia	myalgia	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
:	:	PUNCT	:	9	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
an	an	DET	DT	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
origin	origin	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
common	common	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
myalgia	myalgia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
unclear	unclear	ADJ	JJ	9	O
;	;	PUNCT	:	9	O
inflammation	inflammation	NOUN	NN	9	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
suggested	suggest	VERB	VBN	9	O
but	but	CCONJ	CC	9	O
without	without	ADP	IN	9	O
convincing	convince	VERB	VBG	9	O
evidence	evidence	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
designed	design	VERB	VBD	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
an	an	DET	DT	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
reaction	reaction	NOUN	NN	9	O
contributes	contribute	NOUN	NNS	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
myalgia	myalgia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
64	64	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
before	before	ADP	IN	9	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
32	32	NUM	CD	7	O
for	for	ADP	IN	5	O
each	each	DET	DT	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Incidence	incidence	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
15	15	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
18	18	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
saline	saline	NOUN	NN	0	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
by	by	ADP	IN	9	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
not	not	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
still	still	ADV	RB	5	O
suffered	suffer	VERB	VBD	5	O
from	from	ADP	IN	9	O
myalgia	myalgia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
not	not	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
interleukin	interleukin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
6	6	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
early	early	ADJ	JJ	9	O
marker	marker	NOUN	NN	3	O
of	of	ADP	IN	5	O
inflammation	inflammation	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
subgroup	subgroup	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
6	6	NUM	CD	9	O
for	for	ADP	IN	5	O
only	only	ADV	RB	9	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
reported	report	VERB	VBD	9	O
myalgia	myalgia	NOUN	NN	5	B-Disease
;	;	PUNCT	:	9	O
no	no	DET	DT	9	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
myalgia	myalgia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
6	6	NUM	CD	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
an	an	DET	DT	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
origin	origin	NOUN	NN	9	O
of	of	ADP	IN	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
myalgia	myalgia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

IMPLICATIONS	implications	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
before	before	ADP	IN	9	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
decreasing	decrease	VERB	VBG	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
myalgia	myalgia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
myalgia	myalgia	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
interleukin	interleukin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
6	6	NUM	CD	9	O
concentrations	concentration	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
marker	marker	NOUN	NN	3	O
of	of	ADP	IN	5	O
inflammation	inflammation	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
with	with	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
justified	justified	ADJ	JJ	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
myalgia	myalgia	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
cytochrome	cytochrome	DET	PDT	0	O
P450s	P450s	PROPN	NNP	1	O
and	and	CCONJ	CC	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
P450	P450	PROPN	NNP	1	O
modulation	modulation	NOUN	NN	9	O
in	in	ADP	IN	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
induced	induced	ADJ	JJ	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
P450	P450	PROPN	NNP	1	O
dependent	dependent	ADJ	JJ	9	O
7	7	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
ethoxyresorufin	ethoxyresorufin	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
O	o	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
deethylase	deethylase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
EROD	EROD	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
pentoxyresorufin	pentoxyresorufin	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
O	o	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dealkylase	dealkylase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
PROD	PROD	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitrosodimethylamine	nitrosodimethylamine	NOUN	NN	0	I-Chemical
demethylase	demethylase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
NDMA	NDMA	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
d	d	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
brain	brain	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hepatic	hepatic	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
P450	P450	PROPN	NNP	1	O
monooxygenases	monooxygenase	NOUN	NNS	0	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
exposure	exposure	NOUN	NN	9	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
from	from	ADP	IN	9	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
to	to	ADP	IN	5	O
15	15	NUM	CD	9	O
or	or	CCONJ	CC	5	O
21	21	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
different	different	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
magnitude	magnitude	NOUN	NN	5	O
of	of	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
P450	P450	PROPN	NNP	1	O
monooxygenases	monooxygenase	NOUN	NNS	0	O
was	be	VERB	VBD	9	O
several	several	ADJ	JJ	9	O
fold	fold	VERB	VB	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
microsomes	microsome	NOUN	NNS	0	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Western	western	ADJ	JJ	3	O
blotting	blotting	NOUN	NN	3	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
indicated	indicate	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
P450	P450	PROPN	NNP	1	O
enzymes	enzyme	NOUN	NNS	1	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
P450	P450	PROPN	NNP	1	O
1A1	1a1	NUM	CD	0	O
/	/	SYM	SYM	9	O
1A2	1a2	NUM	CD	0	O
,	,	PUNCT	,	9	O
2B1	2b1	NUM	CD	0	O
/	/	SYM	SYM	9	O
2B2	2b2	NUM	CD	0	O
and	and	CCONJ	CC	5	O
2E1	2e1	NUM	CD	0	O
isoenzymes	isoenzyme	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vitro	vitro	X	FW	3	O
studies	study	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
organic	organic	ADJ	JJ	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
specific	specific	ADJ	JJ	9	O
for	for	ADP	IN	5	O
individual	individual	ADJ	JJ	5	O
P450	P450	PROPN	NNP	1	O
isoenzymes	isoenzyme	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
antibody	antibody	NOUN	NN	3	O
inhibition	inhibition	NOUN	NN	3	O
experiments	experiment	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
further	further	ADV	RB	9	O
demonstrated	demonstrate	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
PROD	PROD	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
EROD	EROD	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
NDMA	NDMA	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
d	d	PROPN	NNP	9	O
are	be	VERB	VBP	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
P450	P450	PROPN	NNP	1	O
2B1	2B1	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
2B2	2b2	NUM	CD	0	O
,	,	PUNCT	,	9	O
1A1	1a1	NUM	CD	0	O
/	/	SYM	SYM	9	O
1A2	1a2	NUM	CD	0	O
and	and	CCONJ	CC	5	O
2E1	2e1	NUM	CD	0	O
isoenzymes	isoenzyme	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Induction	induction	NOUN	NN	3	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
further	further	ADV	RB	9	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
while	while	ADP	IN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylcholanthrene	methylcholanthrene	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
MC	MC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
inducer	inducer	NOUN	NN	3	O
of	of	ADP	IN	5	O
P4501A1	P4501A1	PROPN	NNP	1	O
/	/	SYM	SYM	9	O
1A2	1a2	NUM	CD	0	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
produce	produce	VERB	VB	9	O
any	any	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
lindane	lindane	ADJ	JJ	0	B-Chemical
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PB	PB	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
inducer	inducer	NOUN	NN	3	O
of	of	ADP	IN	5	O
P450	P450	PROPN	NNP	1	O
2B1	2B1	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
2B2	2b2	NUM	CD	0	O
or	or	CCONJ	CC	5	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
inducer	inducer	NOUN	NN	3	O
of	of	ADP	IN	5	O
P450	P450	PROPN	NNP	1	O
2E1	2e1	NUM	CD	0	O
catalysed	catalyse	VERB	VBN	0	O
reactions	reaction	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
lindane	lindane	ADJ	JJ	0	B-Chemical
induced	induced	ADJ	JJ	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
P450	P450	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
metabolism	metabolism	NOUN	NN	9	O
of	of	ADP	IN	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
cobalt	cobalt	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
indicating	indicate	VERB	VBG	9	O
that	that	DET	DT	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
per	per	X	FW	9	O
se	se	X	FW	9	O
or	or	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
metabolites	metabolite	NOUN	NNS	0	O
formed	form	VERB	VBN	9	O
by	by	ADP	IN	9	O
PB	PB	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
inducible	inducible	ADJ	JJ	3	O
P450	P450	PROPN	NNP	1	O
isoenzymes	isoenzyme	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
neurobehavioral	neurobehavioral	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Absolute	absolute	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
attributable	attributable	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
on	on	ADP	IN	5	O
combined	combined	ADJ	JJ	9	O
cyproterone	cyproterone	NOUN	NN	0	B-Chemical
acetate	acetate	ADJ	JJ	0	I-Chemical
and	and	CCONJ	CC	5	O
ethinylestradiol	ethinylestradiol	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
achieve	achieve	VERB	VB	5	O
absolute	absolute	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
estimates	estimate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
VTE	VTE	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
among	among	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
on	on	ADP	IN	5	O
cyproterone	cyproterone	NOUN	NN	0	B-Chemical
acetate	acetate	ADJ	JJ	0	I-Chemical
plus	plus	CCONJ	CC	9	O
ethinylestradiol	ethinylestradiol	NOUN	NNS	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CPA	CPA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
EE	EE	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
among	among	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
on	on	ADP	IN	5	O
combined	combine	VERB	VBN	9	B-Chemical
oral	oral	ADJ	JJ	9	I-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
(	(	PUNCT	-LRB-	9	O
COCs	COCs	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
From	from	ADP	IN	5	O
the	the	DET	DT	5	O
Danish	Danish	PROPN	NNP	5	O
National	National	PROPN	NNP	2	O
Register	Register	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Patients	Patients	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
NRP	NRP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
1996	1996	NUM	CD	2	O
to	to	ADP	IN	5	O
1998	1998	NUM	CD	2	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
records	record	NOUN	NNS	5	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
million	million	NUM	CD	5	O
Danish	danish	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
ages	age	VERB	VBZ	5	O
15	15	NUM	CD	9	O
to	to	PART	TO	5	O
44	44	NUM	CD	7	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
searched	search	VERB	VBN	9	O
for	for	ADP	IN	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

COC	COC	PROPN	NNP	9	B-Chemical
use	use	NOUN	NN	5	O
was	be	VERB	VBD	9	O
ascertained	ascertain	VERB	VBN	9	O
through	through	ADP	IN	9	O
mailed	mail	VERB	VBN	5	O
questionnaires	questionnaire	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Sales	sale	NOUN	NNS	2	O
statistics	statistic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
COCs	coc	NOUN	NNS	9	B-Chemical
and	and	CCONJ	CC	5	O
CPA	CPA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
EE	EE	PROPN	NNP	9	B-Chemical
were	be	VERB	VBD	9	O
provided	provide	VERB	VBN	9	O
through	through	ADP	IN	9	O
Danish	Danish	PROPN	NNP	5	O
Drug	Drug	PROPN	NNP	5	O
Statistics	Statistics	PROPN	NNPS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
During	during	ADP	IN	5	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
frame	frame	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
330	330	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
had	have	VERB	VBN	9	O
VTE	VTE	PROPN	NNP	5	B-Disease
while	while	ADP	IN	9	O
on	on	ADP	IN	5	O
COCs	coc	NOUN	NNS	9	B-Chemical
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
these	these	DET	DT	5	O
women	woman	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
67	67	NUM	CD	7	O
were	be	VERB	VBD	9	O
on	on	ADP	IN	5	O
levonorgestrel	levonorgestrel	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
COCs	COCs	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Eleven	eleven	NUM	CD	9	O
were	be	VERB	VBD	9	O
on	on	ADP	IN	5	O
CPA	CPA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
EE	ee	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
corresponding	correspond	VERB	VBG	9	O
absolute	absolute	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	PUNCT	LS	9	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
per	per	ADP	IN	9	O
10	10	NUM	CD	9	O
000	000	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
years	year	NOUN	NNS	5	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
women	woman	NOUN	NNS	5	O
on	on	ADP	IN	5	O
COCs	COCs	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	PUNCT	LS	9	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
per	per	ADP	IN	9	O
10	10	NUM	CD	9	O
000	000	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
years	year	NOUN	NNS	5	O
among	among	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
on	on	ADP	IN	5	O
levonorgestrel	levonorgestrel	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
COCs	COCs	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
per	per	ADP	IN	9	O
10	10	NUM	CD	9	O
000	000	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
years	year	NOUN	NNS	5	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
women	woman	NOUN	NNS	5	O
on	on	ADP	IN	5	O
CPA	CPA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
EE	ee	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
the	the	DET	DT	5	O
absolute	absolute	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
among	among	ADP	IN	5	O
Danish	danish	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
on	on	ADP	IN	5	O
COCs	COCs	PROPN	NNP	9	B-Chemical
is	be	VERB	VBZ	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
among	among	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
CPA	CPA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
EE	ee	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
developmental	developmental	ADJ	JJ	9	O
toxicology	toxicology	NOUN	NN	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
acetylsalicylic	acetylsalicylic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
selected	select	VERB	VBN	9	O
dosing	dose	VERB	VBG	9	O
paradigms	paradigms	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
for	for	ADP	IN	5	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
NSAIDs	nsaid	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
developmental	developmental	ADJ	JJ	9	B-Disease
anomalies	anomaly	NOUN	NNS	5	I-Disease
occurs	occur	VERB	VBZ	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
NSAIDs	nsaid	NOUN	NNS	5	O
on	on	ADP	IN	5	O
specific	specific	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
during	during	ADP	IN	5	O
organogenesis	organogenesis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Aspirin	Aspirin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
acetylsalicylic	acetylsalicylic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
[	[	PUNCT	-LRB-	9	O
ASA	ASA	PROPN	NNP	9	B-Chemical
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
irreversible	irreversible	ADJ	JJ	9	O
cyclooxygenase	cyclooxygenase	NOUN	NN	0	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
induces	induce	VERB	VBZ	3	O
developmental	developmental	ADJ	JJ	9	B-Disease
anomalies	anomaly	NOUN	NNS	5	I-Disease
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
on	on	ADP	IN	5	O
gestational	gestational	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
GD	GD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
11	11	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
Kimmel	Kimmel	PROPN	NNP	6	O
CA	CA	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
Wilson	Wilson	PROPN	NNP	6	O
JG	JG	PROPN	NNP	6	O
,	,	PUNCT	,	9	O
Schumacher	Schumacher	PROPN	NNP	6	O
HJ	HJ	PROPN	NNP	6	O
.	.	PUNCT	.	9	O
Teratology	teratology	NOUN	NN	2	O
4	4	NUM	CD	9	O
:	:	PUNCT	:	9	O
15	15	NUM	CD	9	O
-	-	SYM	SYM	7	O
24	24	NUM	CD	9	O
,	,	PUNCT	,	9	O
1971	1971	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
no	no	DET	DT	9	O
published	publish	VERB	VBN	9	O
ASA	ASA	PROPN	NNP	9	B-Chemical
studies	study	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
multiple	multiple	ADJ	JJ	5	O
dosing	dose	VERB	VBG	9	O
paradigm	paradigm	NOUN	NN	5	O
of	of	ADP	IN	5	O
GDs	gd	NOUN	NNS	5	O
6	6	NUM	CD	9	O
to	to	ADP	IN	5	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O

Objectives	objective	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
were	be	VERB	VBD	9	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
results	result	NOUN	NNS	9	O
between	between	ADP	IN	5	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
SD	SD	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Wistar	Wistar	PROPN	NNP	9	O
strains	strain	NOUN	NNS	1	O
when	when	ADV	WRB	5	O
ASA	ASA	PROPN	NNP	9	B-Chemical
is	be	VERB	VBZ	5	O
administered	administer	VERB	VBN	9	O
on	on	ADP	IN	5	O
GD	GD	PROPN	NNP	9	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
11	11	NUM	CD	7	O
;	;	PUNCT	:	9	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
malformation	malformation	NOUN	NN	5	O
patterns	pattern	NOUN	NNS	5	O
following	follow	VERB	VBG	9	O
single	single	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
multiple	multiple	ADJ	JJ	5	O
dosings	dosing	NOUN	NNS	0	O
during	during	ADP	IN	5	O
organogenesis	organogenesis	NOUN	NN	9	O
in	in	ADP	IN	5	O
SD	SD	PROPN	NNP	7	O
rats	rat	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
test	test	VERB	VB	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
maternal	maternal	ADJ	JJ	9	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
confounds	confound	VERB	VBZ	5	O
the	the	DET	DT	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
malformations	malformation	NOUN	NNS	5	B-Disease
with	with	ADP	IN	5	O
ASA	ASA	PROPN	NNP	9	B-Chemical
when	when	ADV	WRB	5	O
a	a	DET	DT	5	O
multiple	multiple	ADJ	JJ	5	O
dosing	dose	VERB	VBG	9	O
paradigm	paradigm	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
ASA	ASA	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
on	on	ADP	IN	5	O
GD	GD	PROPN	NNP	9	O
9	9	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
250	250	NUM	CD	0	O
,	,	PUNCT	,	9	O
500	500	NUM	CD	0	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
625	625	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
500	500	NUM	CD	0	O
,	,	PUNCT	,	9	O
625	625	NUM	CD	7	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
750	750	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
11	11	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
500	500	NUM	CD	0	O
,	,	PUNCT	,	9	O
750	750	NUM	CD	0	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
1000	1000	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
from	from	ADP	IN	9	O
GD	GD	PROPN	NNP	9	O
6	6	NUM	CD	9	O
to	to	ADP	IN	5	O
GD	GD	PROPN	NNP	9	O
17	17	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
50	50	NUM	CD	0	O
,	,	PUNCT	,	9	O
125	125	NUM	CD	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
250	250	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
a	a	DET	DT	5	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
multiple	multiple	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
study	study	NOUN	NN	9	O
to	to	ADP	IN	5	O
SD	SD	PROPN	NNP	7	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
killed	kill	VERB	VBN	9	O
on	on	ADP	IN	5	O
GD	GD	PROPN	NNP	9	O
21	21	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
fetuses	fetus	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
viscerally	viscerally	ADV	RB	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
evaluation	evaluation	NOUN	NN	5	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
NSAIDs	nsaid	NOUN	NNS	5	O
induce	induce	VERB	VBP	3	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
septal	septal	ADJ	JJ	5	I-Disease
defects	defect	NOUN	NNS	9	I-Disease
(	(	PUNCT	-LRB-	9	O
VSDs	vsd	NOUN	NNS	5	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
midline	midline	NOUN	NN	5	B-Disease
defects	defect	NOUN	NNS	9	I-Disease
(	(	PUNCT	-LRB-	9	O
MDs	md	NOUN	NNS	5	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
diaphragmatic	diaphragmatic	ADJ	JJ	5	B-Disease
hernia	hernia	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
DH	DH	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
MDs	md	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
VSDs	vsd	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
rabbits	rabbit	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
Cook	Cook	PROPN	NNP	6	O
JC	JC	PROPN	NNP	2	O
et	et	PROPN	NNP	6	O
al	al	PROPN	NNP	6	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
2003	2003	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
hence	hence	ADV	RB	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
focused	focus	VERB	VBD	5	O
on	on	ADP	IN	5	O
these	these	DET	DT	5	O
malformations	malformation	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
though	though	ADP	IN	9	O
ASA	ASA	PROPN	NNP	9	B-Chemical
induces	induce	VERB	VBZ	3	O
several	several	ADJ	JJ	9	O
other	other	ADJ	JJ	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
incidence	incidence	NOUN	NN	5	O
malformations	malformation	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
DH	DH	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
MD	MD	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
VSD	VSD	PROPN	NNP	5	B-Disease
were	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
on	on	ADP	IN	5	O
GDs	gd	NOUN	NNS	5	O
9	9	NUM	CD	7	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O

VSD	VSD	PROPN	NNP	5	B-Disease
also	also	ADV	RB	9	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
following	follow	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
GD	GD	PROPN	NNP	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
DH	DH	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
MD	MD	PROPN	NNP	9	B-Disease
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
multiple	multiple	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
study	study	NOUN	NN	9	O
design	design	NOUN	NN	5	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
VSD	VSD	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
across	across	ADP	IN	5	O
all	all	DET	DT	5	O
dose	dose	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
High	high	ADJ	JJ	9	O
concordance	concordance	NOUN	NN	9	O
in	in	ADP	IN	5	O
major	major	ADJ	JJ	9	O
developmental	developmental	ADJ	JJ	9	B-Disease
anomalies	anomaly	NOUN	NNS	5	I-Disease
between	between	ADP	IN	5	O
Wistar	Wistar	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
SD	SD	PROPN	NNP	7	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
exception	exception	NOUN	NN	9	O
of	of	ADP	IN	5	O
VSD	VSD	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
SD	sd	NOUN	NN	7	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
hydrocephalus	hydrocephalus	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Variations	variation	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
malformations	malformation	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
when	when	ADV	WRB	5	O
ASA	ASA	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
organogenesis	organogenesis	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
GDs	gd	NOUN	NNS	5	O
6	6	NUM	CD	9	O
to	to	ADP	IN	5	O
17	17	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
evident	evident	ADJ	JJ	9	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
titrating	titrate	VERB	VBG	0	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
to	to	PART	TO	5	O
achieve	achieve	VERB	VB	5	O
a	a	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
tolerated	tolerate	VERB	VBN	9	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
malformations	malformation	NOUN	NNS	5	B-Disease
that	that	DET	WDT	5	O
normally	normally	ADV	RB	9	O
occur	occur	VERB	VBP	5	O
at	at	ADP	IN	9	O
low	low	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
reported	report	VERB	VBN	9	O
from	from	ADP	IN	9	O
previous	previous	ADJ	JJ	9	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
could	could	VERB	MD	9	O
also	also	ADV	RB	9	O
be	be	VERB	VB	5	O
induced	induce	VERB	VBN	3	O
with	with	ADP	IN	5	O
ASA	ASA	PROPN	NNP	9	B-Chemical
given	give	VERB	VBN	5	O
at	at	ADP	IN	9	O
multiple	multiple	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
benzodiazepine	benzodiazepine	ADJ	JJ	5	B-Chemical
effects	effect	NOUN	NNS	9	O
by	by	ADP	IN	9	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
after	after	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
conscious	conscious	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
with	with	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
opioids	opioid	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
multicenter	multicenter	NOUN	NN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Flumazenil	Flumazenil	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
Intravenous	Intravenous	PROPN	NNP	0	O
Conscious	Conscious	PROPN	NNP	5	O
Sedation	Sedation	PROPN	NNP	5	O
with	with	ADP	IN	5	O
Diazepam	Diazepam	PROPN	NNP	0	B-Chemical
Multicenter	Multicenter	PROPN	NNP	2	O
Study	Study	PROPN	NNP	5	O
Group	Group	PROPN	NNP	9	O
II	II	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
benzodiazepine	benzodiazepine	NOUN	NN	5	B-Chemical
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
multicenter	multicenter	NOUN	NN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Flumazenil	Flumazenil	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
76	76	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
intravenously	intravenously	ADV	RB	0	O
to	to	ADP	IN	5	O
130	130	NUM	CD	9	O
and	and	CCONJ	CC	5	O
67	67	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
given	give	VERB	VBN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
conjunction	conjunction	NOUN	NN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
opioid	opioid	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
meperidine	meperidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
maintenance	maintenance	NOUN	NN	9	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
conscious	conscious	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
for	for	ADP	IN	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
surgical	surgical	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
group	group	NOUN	NN	9	O
assessable	assessable	ADJ	JJ	5	O
for	for	ADP	IN	5	O
efficacy	efficacy	NOUN	NN	9	O
comprised	comprise	VERB	VBN	9	O
122	122	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
64	64	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
given	give	VERB	VBN	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
5	5	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
80	80	NUM	CD	9	O
/	/	SYM	SYM	9	O
115	115	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
70	70	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
21	21	NUM	CD	7	O
/	/	SYM	SYM	9	O
63	63	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
awake	awake	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
alert	alert	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
indicated	indicate	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
score	score	NOUN	NN	5	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
Observer	Observer	PROPN	NNP	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
Assessment	Assessment	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Alertness	Alertness	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
Sedation	Sedation	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Ninety	ninety	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
group	group	NOUN	NN	9	O
who	who	PRON	WP	5	O
attained	attain	VERB	VBD	9	O
a	a	DET	DT	5	O
score	score	NOUN	NN	5	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
assessment	assessment	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
alertness	alertness	NOUN	NN	5	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
180	180	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
assessment	assessment	NOUN	NN	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Flumazenil	Flumazenil	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
also	also	ADV	RB	9	O
performed	perform	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
better	better	ADV	RBR	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
Finger	Finger	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
Nose	nose	NOUN	NN	2	O
Test	Test	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
recall	recall	NOUN	NN	5	O
of	of	ADP	IN	5	O
pictures	picture	NOUN	NNS	5	O
shown	show	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
assessment	assessment	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Flumazenil	Flumazenil	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
17	17	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
one	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
adverse	adverse	ADJ	JJ	5	O
experiences	experience	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
nausea	nausea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
nausea	nausea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
injection	injection	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
site	site	NOUN	NN	9	O
pain	pain	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Flumazenil	Flumazenil	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
promptly	promptly	ADV	RB	5	O
reverse	reverse	VERB	VB	9	O
sedation	sedation	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
opioids	opioid	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Methylphenidate	methylphenidate	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
obsessive	obsessive	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
compulsive	compulsive	ADJ	JJ	5	I-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
82	82	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
resistant	resistant	ADJ	JJ	9	I-Disease
depression	depression	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
early	early	ADJ	JJ	9	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
started	start	VERB	VBN	5	O
on	on	ADP	IN	5	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
.	.	PUNCT	.	9	O

Significant	significant	ADJ	JJ	9	O
obsessive	obsessive	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
compulsive	compulsive	ADJ	JJ	5	I-Disease
behavior	behavior	NOUN	NN	5	I-Disease
ensued	ensue	VERB	VBN	5	O
but	but	CCONJ	CC	9	O
diminished	diminish	VERB	VBN	9	O
over	over	ADP	IN	5	O
several	several	ADJ	JJ	9	O
weeks	week	NOUN	NNS	9	O
when	when	ADV	WRB	5	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
was	be	VERB	VBD	9	O
replaced	replace	VERB	VBN	9	O
by	by	ADP	IN	9	O
fluvoxamine	fluvoxamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
prior	prior	ADJ	JJ	9	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
history	history	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
he	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
sister	sister	NOUN	NN	4	O
with	with	ADP	IN	5	O
obsessive	obsessive	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
compulsive	compulsive	ADJ	JJ	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
appears	appear	VERB	VBZ	9	O
that	that	ADP	IN	5	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
precipitated	precipitate	VERB	VBD	0	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
pathological	pathological	ADJ	JJ	5	O
behavior	behavior	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ciprofloxacin	Ciprofloxacin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
autoimmune	autoimmune	ADJ	JJ	3	B-Disease
hemolytic	hemolytic	ADJ	JJ	0	I-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Ciprofloxacin	Ciprofloxacin	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
several	several	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
including	include	VERB	VBG	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
extremely	extremely	ADV	RB	5	O
rare	rare	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
report	report	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
ciprofloxacin	ciprofloxacin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
autoimmune	autoimmune	ADJ	JJ	3	B-Disease
hemolytic	hemolytic	ADJ	JJ	0	I-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
improved	improve	VERB	VBN	5	O
after	after	ADP	IN	9	O
stopping	stop	VERB	VBG	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Unfortunately	unfortunately	ADV	RB	5	O
,	,	PUNCT	,	9	O
acute	acute	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
irreversible	irreversible	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBN	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Potential	potential	ADJ	JJ	5	O
deleterious	deleterious	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
furosemide	furosemide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
radiocontrast	radiocontrast	NOUN	NN	5	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
furosemide	furosemide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
fluids	fluid	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
radiocontrast	radiocontrast	NOUN	NN	5	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

18	18	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
referred	refer	VERB	VBD	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
radiocontrast	radiocontrast	NOUN	NN	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
considered	consider	VERB	VBN	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
preexisting	preexist	VERB	VBG	9	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
,	,	PUNCT	,	9	O
performed	perform	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
secondary	secondary	ADJ	JJ	9	O
care	care	NOUN	NN	5	O
center	center	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
bed	bed	NOUN	NN	5	O
private	private	ADJ	JJ	5	O
university	university	NOUN	NN	5	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
fluids	fluid	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
group	group	NOUN	NN	9	O
received	receive	VERB	VBD	9	O
furosemide	furosemide	ADV	RB	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
dose	dose	NOUN	NN	9	O
110	110	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
intravenously	intravenously	ADV	RB	0	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
material	material	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
received	receive	VERB	VBD	9	O
fluids	fluid	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
3	3	NUM	CD	9	O
liters	liter	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Radiological	radiological	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
mostly	mostly	ADV	RB	9	O
angiographies	angiography	NOUN	NNS	5	O
performed	perform	VERB	VBN	9	O
with	with	ADP	IN	5	O
both	both	CCONJ	CC	9	O
ionic	ionic	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
ionic	ionic	ADJ	JJ	0	O
contrast	contrast	NOUN	NN	9	O
material	material	NOUN	NN	5	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
average	average	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
245	245	NUM	CD	7	O
ml	ml	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	B-Disease
function	function	NOUN	NN	9	I-Disease
significantly	significantly	ADV	RB	9	I-Disease
deteriorated	deteriorate	VERB	VBN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
furosemide	furosemide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
005	005	NUM	CD	7	O
by	by	ADP	IN	9	O
ANOVA	ANOVA	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
from	from	ADP	IN	9	O
145	145	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
13	13	NUM	CD	7	O
to	to	PART	TO	5	O
182	182	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
16	16	NUM	CD	9	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
l	l	NOUN	NN	0	O
at	at	ADP	IN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
141	141	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
to	to	ADP	IN	5	O
142	142	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
l	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
weight	weight	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
furosemide	furosemide	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Furosemide	furosemide	ADV	RB	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
deleterious	deleterious	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
radiocontrast	radiocontrast	NOUN	NN	5	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Progestational	progestational	ADJ	JJ	0	O
agents	agent	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	B-Disease
coagulation	coagulation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

VII	VII	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Thromboembolic	thromboembolic	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptive	contraceptive	ADJ	JJ	5	I-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
relationship	relationship	NOUN	NN	5	O
to	to	ADP	IN	5	O
pretreatment	pretreatment	ADJ	JJ	0	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	B-Disease
coagulation	coagulation	NOUN	NN	5	I-Disease
factors	factor	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
summary	summary	NOUN	NN	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
ten	ten	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
a	a	DET	DT	5	O
ten	ten	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
348	348	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
877	877	NUM	CD	7	O
patient	patient	ADJ	JJ	5	O
months	month	NOUN	NNS	5	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
separate	separate	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
relating	relate	VERB	VBG	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
to	to	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
hematologic	hematologic	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Significant	significant	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
factors	factor	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	B-Disease
coagulation	coagulation	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
fibrinolysin	fibrinolysin	NOUN	NN	0	O
systems	system	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
factors	factor	NOUN	NNS	9	O
I	-PRON-	PRON	PRP	9	O
,	,	PUNCT	,	9	O
II	II	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
VII	VII	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
VIII	VIII	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
IX	IX	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
X	x	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
plasminogen	plasminogen	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treated	treated	ADJ	JJ	3	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
complications	complication	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
four	four	NUM	CD	9	O
had	have	VERB	VBD	9	O
an	an	DET	DT	5	O
abnormal	abnormal	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	B-Disease
coagulation	coagulation	NOUN	NN	5	I-Disease
profile	profile	NOUN	NN	9	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
"	"	PUNCT	``	5	O
hypercoagulability	hypercoagulability	NOUN	NN	5	B-Disease
"	"	PUNCT	''	5	O
before	before	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Some	some	DET	DT	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
represented	represent	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
extreme	extreme	ADJ	JJ	5	O
abnormalities	abnormality	NOUN	NNS	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
some	some	DET	DT	5	O
increased	increase	VERB	VBD	9	O
further	further	ADV	RB	9	O
during	during	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
before	before	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
any	any	DET	DT	5	O
medication	medication	NOUN	NN	5	O
,	,	PUNCT	,	9	O
shortly	shortly	ADV	RB	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
base	base	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
values	value	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
retinopathy	retinopathy	ADJ	JJ	5	B-Disease
19	19	NUM	CD	7	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
she	-PRON-	PRON	PRP	5	O
began	begin	VERB	VBD	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
another	another	DET	DT	9	O
developed	develop	VERB	VBN	5	O
thrombophlebitis	thrombophlebitis	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
27	27	NUM	CD	7	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
fourth	fourth	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBN	5	O
thrombophlebitis	thrombophlebitis	NOUN	NN	5	B-Disease
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
contraceptive	contraceptive	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
A	a	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
AB	AB	PROPN	NNP	9	O
blood	blood	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
suggested	suggest	VERB	VBD	9	O
the	the	DET	DT	5	O
possiblility	possiblility	NOUN	NN	9	O
of	of	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
propensity	propensity	NOUN	NN	5	O
for	for	ADP	IN	5	O
thromboembolic	thromboembolic	ADJ	JJ	5	B-Disease
episodes	episode	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
possessing	possess	VERB	VBG	9	O
the	the	DET	DT	5	O
A	A	PROPN	NNP	9	O
antigen	antigen	NOUN	NN	3	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
appears	appear	VERB	VBZ	9	O
from	from	ADP	IN	9	O
these	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
that	that	DET	WDT	5	O
hematologic	hematologic	ADJ	JJ	5	O
work	work	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
ups	up	NOUN	NNS	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
about	about	ADJ	JJ	5	O
to	to	PART	TO	5	O
start	start	VERB	VB	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptive	contraceptive	NOUN	NN	5	I-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Orthostatic	orthostatic	ADJ	JJ	5	B-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
occurs	occur	VERB	VBZ	9	O
following	follow	VERB	VBG	9	O
alpha	alpha	NOUN	NN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
blockade	blockade	NOUN	NN	3	O
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
pretreated	pretreate	VERB	VBN	3	O
conscious	conscious	ADJ	JJ	5	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

1	1	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
alters	alter	NOUN	NNS	9	O
the	the	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
function	function	NOUN	NN	9	O
for	for	ADP	IN	5	O
orthostatic	orthostatic	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
SHR	SHR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

2	2	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Conscious	conscious	ADJ	JJ	5	O
SHR	SHR	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
male	male	ADJ	JJ	9	O
300	300	NUM	CD	0	O
-	-	SYM	SYM	7	O
350	350	NUM	CD	9	O
g	g	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
90	90	NUM	CD	9	O
degrees	degree	NOUN	NNS	5	O
head	head	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
tilts	tilt	NOUN	NNS	5	O
for	for	ADP	IN	5	O
60	60	NUM	CD	9	O
s	s	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
acute	acute	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
rauwolscine	rauwolscine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Orthostatic	orthostatic	ADJ	JJ	5	B-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
decrease	decrease	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MAP	MAP	PROPN	NNP	9	O
femoral	femoral	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
60	60	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
s	s	NOUN	NN	9	O
tilt	tilt	NOUN	NN	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
basal	basal	NOUN	NN	3	O
MAP	MAP	PROPN	NNP	9	O
of	of	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
SHR	SHR	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
extent	extent	NOUN	NN	9	O
by	by	ADP	IN	9	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
23	23	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
MAP	MAP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
rauwolscine	rauwolscine	VERB	VB	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
16	16	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
33	33	NUM	CD	7	O
%	%	NOUN	NN	9	O
MAP	MAP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
head	head	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
tilt	tilt	NOUN	NN	5	O
induced	induce	VERB	VBD	3	O
orthostatic	orthostatic	ADJ	JJ	5	B-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
SHR	SHR	PROPN	NNP	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
16	16	NUM	CD	9	O
%	%	NOUN	NN	9	O
MAP	MAP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
SHR	SHR	PROPN	NNP	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
rauwolscine	rauwolscine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
+	+	SYM	SYM	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
MAP	MAP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

3	3	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Conscious	conscious	ADJ	JJ	5	O
SHR	SHR	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
with	with	ADP	IN	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
day	day	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
for	for	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
alpha	alpha	NOUN	NN	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
blockade	blockade	NOUN	NN	3	O
.	.	PUNCT	.	9	O

MAP	MAP	PROPN	NNP	9	O
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
SHR	SHR	PROPN	NNP	9	O
after	after	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
14	14	NUM	CD	7	O
%	%	NOUN	NN	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
untreated	untreated	ADJ	JJ	3	O
SHR	SHR	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Head	Head	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
tilts	tilt	NOUN	NNS	5	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
produce	produce	VERB	VB	9	O
orthostatic	orthostatic	ADJ	JJ	5	B-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
when	when	ADV	WRB	5	O
performed	perform	VERB	VBN	9	O
either	either	CCONJ	CC	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
or	or	CCONJ	CC	5	O
after	after	ADP	IN	9	O
acute	acute	ADJ	JJ	9	O
dosing	dosing	NOUN	NN	9	O
of	of	ADP	IN	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Conversely	conversely	ADV	RB	9	O
,	,	PUNCT	,	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
rauwolscine	rauwolscine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
treated	treat	VERB	VBD	3	O
SHR	SHR	PROPN	NNP	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
basal	basal	NOUN	NN	3	O
MAP	MAP	PROPN	NNP	9	O
by	by	ADP	IN	9	O
12	12	NUM	CD	9	O
-	-	SYM	SYM	7	O
31	31	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
tilts	tilt	NOUN	NNS	5	O
induced	induce	VERB	VBD	3	O
further	further	ADJ	JJ	9	O
drops	drop	NOUN	NNS	0	O
of	of	ADP	IN	5	O
MAP	MAP	PROPN	NNP	9	O
by	by	ADP	IN	9	O
19	19	NUM	CD	7	O
-	-	SYM	SYM	7	O
23	23	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

4	4	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
agonist	agonist	NOUN	NN	3	O
cirazoline	cirazoline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
agonist	agonist	NOUN	NN	3	O
Abbott	Abbott	PROPN	NNP	2	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
53693	53693	NUM	CD	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
SHR	SHR	PROPN	NNP	9	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
the	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cirazoline	cirazoline	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
abolished	abolish	VERB	VBN	3	O
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
treated	treat	VERB	VBD	3	O
SHR	SHR	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
untreated	untreated	ADJ	JJ	3	O
SHR	SHR	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Abbott	Abbott	PROPN	NNP	2	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
53693	53693	NUM	CD	_	I-Chemical
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
SHR	SHR	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
accompanying	accompany	VERB	VBG	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
in	in	ADP	IN	5	O
SHR	SHR	PROPN	NNP	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
than	than	ADP	IN	5	O
without	without	ADP	IN	9	O
such	such	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
that	that	DET	WDT	5	O
accompanied	accompany	VERB	VBD	9	O
the	the	DET	DT	5	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
pressor	pressor	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
SHR	SHR	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
despite	despite	ADP	IN	9	O
a	a	DET	DT	5	O
47	47	NUM	CD	7	O
-	-	SYM	SYM	7	O
71	71	NUM	CD	7	O
%	%	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
alpha	alpha	NOUN	NN	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
blocked	block	VERB	VBN	3	O
SHR	SHR	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
400	400	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Hemolytic	hemolytic	ADJ	JJ	0	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
uremic	uremic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
ingestion	ingestion	NOUN	NN	9	O
of	of	ADP	IN	5	O
quinine	quinine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Hemolytic	hemolytic	ADJ	JJ	0	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
uremic	uremic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
quinine	quinine	NOUN	NN	0	B-Chemical
ingestion	ingestion	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
newly	newly	ADV	RB	9	O
described	describe	VERB	VBN	9	O
phenomenon	phenomenon	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
just	just	ADV	RB	5	O
two	two	NUM	CD	5	O
previous	previous	ADJ	JJ	9	O
descriptions	description	NOUN	NNS	5	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
5th	5th	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
reaction	reaction	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
antibodies	antibody	NOUN	NNS	3	O
reactive	reactive	ADJ	JJ	9	O
against	against	ADP	IN	9	O
platelets	platelet	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
quinine	quinine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
included	include	VERB	VBN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
exchange	exchange	NOUN	NN	9	O
,	,	PUNCT	,	9	O
prednisone	prednisone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
all	all	DET	DT	5	O
regained	regain	VERB	VBN	5	O
some	some	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
unclear	unclear	ADJ	JJ	9	O
whether	whether	ADP	IN	9	O
pharmacological	pharmacological	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
resolution	resolution	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Quinine	Quinine	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
uremic	uremic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
probably	probably	ADV	RB	9	O
occurs	occur	VERB	VBZ	9	O
more	more	ADV	RBR	5	O
often	often	ADV	RB	5	O
than	than	ADP	IN	5	O
is	be	VERB	VBZ	5	O
recognized	recognize	VERB	VBN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
important	important	ADJ	JJ	9	O
to	to	PART	TO	5	O
recognize	recognize	VERB	VB	9	O
this	this	DET	DT	5	O
reaction	reaction	NOUN	NN	9	O
when	when	ADV	WRB	5	O
it	-PRON-	PRON	PRP	5	O
occurs	occur	VERB	VBZ	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
avoid	avoid	VERB	VB	5	O
further	further	ADJ	JJ	9	O
quinine	quinine	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
since	since	ADP	IN	9	O
the	the	DET	DT	5	O
reaction	reaction	NOUN	NN	9	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
recurrent	recurrent	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Amnestic	amnestic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
an	an	DET	DT	5	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
subacute	subacute	NOUN	NN	5	O
dementia	dementia	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
manifestations	manifestation	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
impairment	impairment	NOUN	NN	5	O
of	of	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
accounted	account	VERB	VBD	5	O
for	for	ADP	IN	5	O
virtually	virtually	ADV	RB	9	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
abnormalities	abnormality	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
evidence	evidence	NOUN	NN	9	O
that	that	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
to	to	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
can	can	VERB	MD	5	O
exhibit	exhibit	VERB	VB	9	O
patterns	pattern	NOUN	NNS	5	O
that	that	DET	WDT	5	O
suggest	suggest	VERB	VBP	9	O
highly	highly	ADV	RB	9	O
selective	selective	ADJ	JJ	9	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
functional	functional	ADJ	JJ	9	O
subdivisions	subdivision	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cefotetan	Cefotetan	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
immune	immune	ADJ	JJ	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Immune	Immune	PROPN	NNP	9	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
adsorption	adsorption	NOUN	NN	0	O
mechanism	mechanism	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
primarily	primarily	ADV	RB	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
penicillins	penicillin	NOUN	NNS	0	B-Chemical
and	and	CCONJ	CC	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
cephalosporins	cephalosporin	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
anemia	anemia	NOUN	NN	9	B-Disease
while	while	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
intravenous	intravenous	ADJ	JJ	0	O
cefotetan	cefotetan	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Cefotetan	cefotetan	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
antibodies	antibody	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
serum	serum	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
eluate	eluate	NOUN	NN	0	O
prepared	prepare	VERB	VBN	0	O
from	from	ADP	IN	9	O
his	-PRON-	DET	PRP$	5	O
red	red	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
eluate	eluate	NOUN	NN	0	O
also	also	ADV	RB	9	O
reacted	react	VERB	VBD	0	O
weakly	weakly	ADV	RB	9	O
with	with	ADP	IN	5	O
red	red	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
cefotetan	cefotetan	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
the	the	DET	DT	5	O
concomitant	concomitant	ADJ	JJ	9	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
warm	warm	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
reactive	reactive	ADJ	JJ	9	O
autoantibodies	autoantibody	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
observations	observation	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
conjunction	conjunction	NOUN	NN	9	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
extravascular	extravascular	ADJ	JJ	5	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
involving	involve	VERB	VBG	5	O
both	both	CCONJ	CC	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
adsorption	adsorption	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
autoantibody	autoantibody	NOUN	NN	3	O
formation	formation	NOUN	NN	9	O
mechanisms	mechanism	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
emphasizes	emphasize	VERB	VBZ	5	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
awareness	awareness	NOUN	NN	5	O
of	of	ADP	IN	5	O
hemolytic	hemolytic	ADJ	JJ	0	O
reactions	reaction	NOUN	NNS	9	O
to	to	ADP	IN	5	O
all	all	DET	DT	5	O
cephalosporins	cephalosporin	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

Use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Hemorrhagic	hemorrhagic	ADJ	JJ	9	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
HC	HC	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
limiting	limit	VERB	VBG	9	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
IFS	IFS	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
presented	present	VERB	VBN	5	O
here	here	ADV	RB	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
IFS	IFS	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
HC	HC	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Male	Male	PROPN	NNP	7	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
150	150	NUM	CD	0	O
-	-	SYM	SYM	7	O
200	200	NUM	CD	0	O
g	g	NOUN	NN	0	O
;	;	PUNCT	:	9	O
6	6	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
per	per	ADP	IN	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
(	(	PUNCT	-LRB-	9	O
v	v	X	XX	0	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
IFS	IFS	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
or	or	CCONJ	CC	5	O
three	three	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
replaced	replace	VERB	VBN	9	O
with	with	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
alone	alone	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
with	with	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
plus	plus	CCONJ	CC	9	O
mesna	mesna	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Cystitis	Cystitis	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
induction	induction	NOUN	NN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
wet	wet	ADJ	JJ	5	O
weight	weight	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
macroscopic	macroscopic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
microscopic	microscopic	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
replacement	replacement	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
two	two	NUM	CD	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
wet	wet	ADJ	JJ	5	O
weight	weight	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
IFS	IFS	PROPN	NNP	9	B-Chemical
by	by	ADP	IN	9	O
84	84	NUM	CD	7	O
.	.	PUNCT	.	9	O
79	79	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
89	89	NUM	CD	7	O
.	.	PUNCT	.	9	O
13	13	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
almost	almost	ADV	RB	9	O
abolished	abolish	VERB	VBD	3	O
the	the	DET	DT	5	O
macroscopic	macroscopic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
microscopic	microscopic	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
IFS	IFS	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
two	two	NUM	CD	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
efficient	efficient	ADJ	JJ	5	O
than	than	ADP	IN	5	O
three	three	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
when	when	ADV	WRB	5	O
evaluated	evaluate	VERB	VBN	9	O
microscopically	microscopically	ADV	RB	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
efficient	efficient	ADJ	JJ	5	O
in	in	ADP	IN	5	O
blocking	block	VERB	VBG	3	O
IFS	IFS	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
HC	HC	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
replacement	replacement	NOUN	NN	9	O
of	of	ADP	IN	5	O
last	last	ADJ	JJ	5	O
two	two	NUM	CD	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
doses	dose	VERB	VBZ	0	O
with	with	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
prevent	prevent	VERB	VB	5	O
HC	HC	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
trans	trans	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
retinoic	retinoic	ADJ	JJ	3	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
erythema	erythema	NOUN	NN	5	B-Disease
nodosum	nodosum	NOUN	NN	4	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
promyelocytic	promyelocytic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Erythema	Erythema	PROPN	NNP	2	B-Disease
nodosum	nodosum	NOUN	NN	4	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
all	all	DET	DT	5	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
trans	trans	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
retinoic	retinoic	ADJ	JJ	3	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
ATRA	ATRA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
promyelocytic	promyelocytic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
APL	APL	PROPN	NNP	3	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
very	very	ADV	RB	5	O
rare	rare	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
classic	classic	ADJ	JJ	5	O
APL	APL	PROPN	NNP	3	B-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
erythema	erythema	NOUN	NN	5	B-Disease
nodosum	nodosum	NOUN	NN	4	I-Disease
during	during	ADP	IN	5	O
ATRA	ATRA	PROPN	NNP	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Fever	fever	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
multiple	multiple	ADJ	JJ	5	O
painful	painful	ADJ	JJ	5	B-Disease
erythematous	erythematous	ADJ	JJ	5	B-Disease
nodules	nodule	NOUN	NNS	9	I-Disease
over	over	ADP	IN	5	O
extremities	extremity	NOUN	NNS	5	O
developed	develop	VERB	VBN	5	O
on	on	ADP	IN	5	O
D11	D11	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
D16	D16	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
D17	D17	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
D19	D19	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
ATRA	ATRA	PROPN	NNP	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
skin	skin	NOUN	NN	5	O
biopsy	biopsy	NOUN	NN	5	O
taken	take	VERB	VBN	5	O
from	from	ADP	IN	9	O
each	each	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
erythema	erythema	NOUN	NN	5	B-Disease
nodosum	nodosum	NOUN	NN	4	I-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
short	short	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
.	.	PUNCT	.	9	O

Fever	fever	NOUN	NN	9	B-Disease
subsided	subside	VERB	VBD	5	O
rapidly	rapidly	ADV	RB	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
skin	skin	NOUN	NN	5	O
lesions	lesion	NOUN	NNS	5	O
regressed	regress	VERB	VBN	5	O
completely	completely	ADV	RB	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
achieved	achieve	VERB	VBD	5	O
complete	complete	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
without	without	ADP	IN	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
ATRA	ATRA	PROPN	NNP	3	B-Chemical
.	.	PUNCT	.	9	O

ATRA	ATRA	PROPN	NNP	3	B-Chemical
seemed	seem	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
possible	possible	ADJ	JJ	5	O
etiology	etiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
erythema	erythema	NOUN	NN	5	B-Disease
nodosum	nodosum	NOUN	NN	4	I-Disease
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
very	very	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
ATRA	ATRA	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
erythema	erythema	NOUN	NN	5	B-Disease
nodosum	nodosum	NOUN	NN	4	I-Disease
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
some	some	DET	DT	5	O
convulsants	convulsant	NOUN	NNS	0	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
loreclezole	loreclezole	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
combinations	combination	NOUN	NNS	9	O
with	with	ADP	IN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
clonazepam	clonazepam	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
amygdala	amygdala	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
kindled	kindle	VERB	VBN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Loreclezole	Loreclezole	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
exerted	exert	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
protective	protective	ADJ	JJ	9	O
action	action	NOUN	NN	5	O
in	in	ADP	IN	5	O
amygdala	amygdala	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
kindled	kindle	VERB	VBN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
reducing	reduce	VERB	VBG	9	O
both	both	DET	DT	9	O
seizure	seizure	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
afterdischarge	afterdischarge	ADJ	JJ	5	O
durations	duration	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
combinations	combination	NOUN	NNS	9	O
of	of	ADP	IN	5	O
loreclezole	loreclezole	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
clonazepam	clonazepam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
applied	apply	VERB	VBN	5	O
at	at	ADP	IN	9	O
their	-PRON-	DET	PRP$	5	O
subprotective	subprotective	ADJ	JJ	_	O
doses	dose	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
also	also	ADV	RB	9	O
exhibited	exhibit	VERB	VBD	9	O
antiseizure	antiseizure	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
two	two	NUM	CD	5	O
first	first	ADJ	JJ	9	O
combinations	combination	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
pharmacodynamic	pharmacodynamic	ADJ	JJ	5	O
nature	nature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
several	several	ADJ	JJ	9	O
chemoconvulsants	chemoconvulsant	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
bicuculline	bicuculline	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartic	aspartic	ADJ	JJ	1	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
BAY	BAY	PROPN	NNP	0	B-Chemical
k	k	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8644	8644	NUM	CD	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
the	the	DET	DT	5	O
opener	opener	NOUN	NN	0	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
channels	channel	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
reversed	reverse	VERB	VBD	9	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
loreclezole	loreclezole	NOUN	NN	3	B-Chemical
alone	alone	ADV	RB	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
bicuculline	bicuculline	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
aminophylline	aminophylline	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
BAY	BAY	PROPN	NNP	0	B-Chemical
k	k	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
8644	8644	NUM	CD	0	I-Chemical
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
anticonvulsive	anticonvulsive	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
loreclezole	loreclezole	NOUN	NN	3	B-Chemical
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
clonazepam	clonazepam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
support	support	VERB	VBP	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
loreclezole	loreclezole	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
combinations	combination	NOUN	NNS	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
antiepileptics	antiepileptic	NOUN	NNS	5	O
may	may	VERB	MD	5	O
involve	involve	VERB	VB	5	O
potentiation	potentiation	NOUN	NN	3	O
of	of	ADP	IN	5	O
GABAergic	GABAergic	PROPN	NNP	3	O
neurotransmission	neurotransmission	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channels	channel	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Mitochondrial	mitochondrial	ADJ	JJ	9	O
DNA	DNA	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
respiratory	respiratory	ADJ	JJ	5	O
chain	chain	NOUN	NN	9	O
products	product	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
defective	defective	ADJ	JJ	1	O
in	in	ADP	IN	5	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
nephrosis	nephrosis	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Doxorubicin	Doxorubicin	PROPN	NNP	0	B-Chemical
induces	induce	VERB	VBZ	3	O
a	a	DET	DT	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
perpetuating	perpetuate	VERB	VBG	5	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
early	early	ADJ	JJ	9	O
glomerular	glomerular	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
late	late	ADJ	JJ	9	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
onset	onset	NOUN	NN	5	I-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
lesions	lesion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
week	week	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
sacrificed	sacrifice	VERB	VBN	3	O
either	either	CCONJ	CC	9	O
1	1	NUM	CD	9	O
week	week	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
'	'	PUNCT	``	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
'	'	PUNCT	''	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
30	30	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
'	'	PUNCT	``	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
'	'	PUNCT	''	9	O
)	)	PUNCT	-RRB-	9	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Additional	additional	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
either	either	CCONJ	CC	9	O
6	6	NUM	CD	9	O
days	day	NOUN	NNS	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
euthanasia	euthanasia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
killed	kill	VERB	VBN	9	O
at	at	ADP	IN	9	O
48	48	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Glomerular	glomerular	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
correlated	correlate	VERB	VBD	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	O
chain	chain	NOUN	NN	9	O
components	component	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
quantified	quantify	VERB	VBD	9	O
both	both	CCONJ	CC	9	O
nuclear	nuclear	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
DNA	DNA	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
mtDNA	mtDNA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
superoxide	superoxide	ADJ	JJ	0	B-Chemical
production	production	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
4834	4834	NUM	CD	7	O
base	base	NOUN	NN	5	O
pair	pair	NOUN	NN	9	O
'	'	PUNCT	''	9	O
common	common	ADJ	JJ	5	O
'	'	PUNCT	''	9	O
mtDNA	mtdna	ADJ	JJ	9	O
deletion	deletion	NOUN	NN	1	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
'	'	PUNCT	``	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
'	'	PUNCT	''	9	O
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
glomerular	glomerular	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
depressed	depressed	ADJ	JJ	5	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mtDNA	mtDNA	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
encoded	encode	VERB	VBN	1	O
NADH	NADH	PROPN	NNP	0	O
dehydrogenase	dehydrogenase	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
cytochrome	cytochrome	ADJ	JJ	0	O
-	-	PUNCT	HYPH	7	O
c	c	NOUN	NN	9	O
oxidase	oxidase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
COX	COX	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
citrate	citrate	NOUN	NN	0	B-Chemical
synthase	synthase	NOUN	NN	1	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mtDNA	mtDNA	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
encoded	encode	VERB	VBN	1	O
COX	COX	PROPN	NNP	9	O
subunit	subunit	NOUN	NN	1	O
I	-PRON-	PRON	PRP	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
mtDNA	mtdna	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
'	'	PUNCT	``	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
'	'	PUNCT	''	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
fewer	few	ADJ	JJR	5	O
tubular	tubular	ADJ	JJ	9	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
similar	similar	ADJ	JJ	9	O
numbers	number	NOUN	NNS	9	O
of	of	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
all	all	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
glomerular	glomerular	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
were	be	VERB	VBD	9	O
inversely	inversely	ADV	RB	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
mtDNA	mtdna	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
mtDNA	mtDNA	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
encoded	encode	VERB	VBN	1	O
respiratory	respiratory	ADJ	JJ	5	O
chain	chain	NOUN	NN	9	O
activities	activity	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mtDNA	mtDNA	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
encoded	encode	VERB	VBN	1	O
respiratory	respiratory	ADJ	JJ	5	O
chain	chain	NOUN	NN	9	O
subunit	subunit	NOUN	NN	1	O
COX	COX	PROPN	NNP	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
.	.	PUNCT	.	9	O

Injury	Injury	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
positively	positively	ADV	RB	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
superoxide	superoxide	ADJ	JJ	0	B-Chemical
production	production	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nucleus	nucleus	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
encoded	encode	VERB	VBN	1	O
mitochondrial	mitochondrial	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
enzymes	enzyme	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

Kidneys	kidney	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
'	'	PUNCT	``	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
'	'	PUNCT	''	9	O
group	group	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
mtDNA	mtdna	ADJ	JJ	9	O
deletions	deletion	NOUN	NNS	1	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
'	'	PUNCT	``	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
'	'	PUNCT	''	9	O
animals	animal	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
these	these	DET	DT	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
for	for	ADP	IN	5	O
quantitative	quantitative	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
qualitative	qualitative	ADJ	JJ	5	O
mtDNA	mtdna	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
mtDNA	mtDNA	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
encoded	encode	VERB	VBN	1	O
respiratory	respiratory	ADJ	JJ	5	O
chain	chain	NOUN	NN	9	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
randomized	randomized	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
crossover	crossover	NOUN	NN	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
SSRI	SSRI	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
female	female	ADJ	JJ	9	O
sexual	sexual	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
agonist	agonist	NOUN	NN	3	O
previously	previously	ADV	RB	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
enhance	enhance	VERB	VB	9	O
genital	genital	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
beneficial	beneficial	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
reversing	reverse	VERB	VBG	5	O
antidepressant	antidepressant	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
sexual	sexual	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Nineteen	nineteen	NUM	CD	9	O
sexually	sexually	ADV	RB	5	B-Disease
dysfunctional	dysfunctional	ADJ	JJ	9	I-Disease
women	woman	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
either	either	CCONJ	CC	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
sertraline	sertraline	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
paroxetine	paroxetine	NOUN	NN	0	B-Chemical
participated	participate	VERB	VBD	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
eight	eight	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
over	over	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
report	report	NOUN	NN	5	O
measures	measure	NOUN	NNS	5	O
of	of	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
desire	desire	NOUN	NN	5	O
,	,	PUNCT	,	9	O
arousal	arousal	NOUN	NN	5	O
,	,	PUNCT	,	9	O
orgasm	orgasm	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sexual	sexual	ADJ	JJ	5	O
satisfaction	satisfaction	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
improvements	improvement	NOUN	NNS	5	O
relative	relative	ADJ	JJ	9	O
to	to	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
in	in	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
desire	desire	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
orgasm	orgasm	VERB	VB	5	O
intensity	intensity	NOUN	NN	5	O
/	/	SYM	SYM	9	O
pleasure	pleasure	NOUN	NN	5	O
on	on	ADP	IN	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
1	1	NUM	CD	9	O
-	-	PUNCT	:	7	O
hr	hr	INTJ	UH	0	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
significant	significant	ADJ	JJ	9	O
improvements	improvement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
measures	measure	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
arousal	arousal	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
orgasmic	orgasmic	ADJ	JJ	5	O
ability	ability	NOUN	NN	9	O
also	also	ADV	RB	9	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
highlight	highlight	VERB	VBP	5	O
the	the	DET	DT	5	O
importance	importance	NOUN	NN	5	O
of	of	ADP	IN	5	O
conducting	conduct	VERB	VBG	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
trials	trial	NOUN	NNS	5	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
condition	condition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Does	do	VERB	VBZ	5	O
hormone	hormone	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
detrimental	detrimental	ADJ	JJ	9	B-Disease
effect	effect	NOUN	NN	9	I-Disease
on	on	ADP	IN	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
cognition	cognition	NOUN	NN	5	I-Disease
?	?	PUNCT	.	5	O

A	a	DET	DT	9	O
pilot	pilot	NOUN	NN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
pilot	pilot	NOUN	NN	5	O
study	study	NOUN	NN	9	O
examines	examine	NOUN	NNS	5	O
whether	whether	ADP	IN	9	O
hormone	hormone	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
affects	affect	VERB	VBZ	9	O
cognition	cognition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
participating	participate	VERB	VBG	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
randomised	randomise	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
anastrozole	anastrozole	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
tamoxifen	tamoxifen	ADV	RB	9	B-Chemical
alone	alone	ADV	RB	9	O
or	or	CCONJ	CC	5	O
combined	combined	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
ATAC	ATAC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
94	94	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
without	without	ADP	IN	9	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
35	35	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
completed	complete	VERB	VBD	5	O
a	a	DET	DT	5	O
battery	battery	NOUN	NN	5	O
of	of	ADP	IN	5	O
neuropsychological	neuropsychological	ADJ	JJ	5	O
measures	measure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
impaired	impair	VERB	VBN	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
processing	processing	NOUN	NN	5	O
speed	speed	NOUN	NN	5	O
task	task	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	X	XX	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
032	032	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
measure	measure	NOUN	NN	5	O
of	of	ADP	IN	5	O
immediate	immediate	ADJ	JJ	5	O
verbal	verbal	ADJ	JJ	5	O
memory	memory	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
026	026	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
controlling	control	VERB	VBG	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
hormone	hormone	NOUN	NN	9	O
replacement	replacement	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Patient	patient	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
performance	performance	NOUN	NN	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
length	length	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
measures	measure	NOUN	NNS	5	O
of	of	ADP	IN	5	O
psychological	psychological	ADJ	JJ	5	O
morbidity	morbidity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
specific	specific	ADJ	JJ	9	O
impairments	impairment	NOUN	NNS	5	O
in	in	ADP	IN	5	O
processing	process	VERB	VBG	5	O
speed	speed	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
verbal	verbal	ADJ	JJ	5	O
memory	memory	NOUN	NN	5	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
hormonal	hormonal	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Verbal	verbal	ADJ	JJ	5	O
memory	memory	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
especially	especially	ADV	RB	5	O
sensitive	sensitive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
oestrogen	oestrogen	NOUN	NN	3	B-Chemical
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
finding	finding	NOUN	NN	9	O
commonly	commonly	ADV	RB	5	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hormone	hormone	NOUN	NN	9	O
replacement	replacement	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
view	view	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
hormone	hormone	NOUN	NN	9	O
therapies	therapy	NOUN	NNS	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
adjuvant	adjuvant	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
preventative	preventative	ADJ	JJ	5	O
setting	set	VERB	VBG	5	O
their	-PRON-	DET	PRP$	5	O
impact	impact	NOUN	NN	5	O
on	on	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	O
functioning	functioning	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
investigated	investigate	VERB	VBN	9	O
more	more	ADV	RBR	5	O
thoroughly	thoroughly	ADV	RB	9	O
.	.	PUNCT	.	9	O

Expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
p300	p300	PROPN	NNP	3	O
protects	protect	VERB	VBZ	3	O
cardiac	cardiac	ADJ	JJ	5	O
myocytes	myocyte	NOUN	NNS	3	O
from	from	ADP	IN	9	O
apoptosis	apoptosis	NOUN	NN	3	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Doxorubicin	Doxorubicin	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
tumor	tumor	ADJ	JJ	3	B-Disease
agent	agent	NOUN	NN	9	O
that	that	DET	WDT	5	O
represses	repress	VERB	VBZ	1	O
cardiac	cardiac	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
induces	induce	VERB	VBZ	3	O
myocardial	myocardial	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
apoptosis	apoptosis	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Doxorubicin	Doxorubicin	PROPN	NNP	0	B-Chemical
depletes	deplete	VERB	VBZ	3	O
cardiac	cardiac	ADJ	JJ	5	O
p300	p300	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
transcriptional	transcriptional	ADJ	JJ	1	O
coactivator	coactivator	NOUN	NN	1	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
required	require	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
maintenance	maintenance	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
differentiated	differentiated	ADJ	JJ	3	O
phenotype	phenotype	NOUN	NN	3	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
myocytes	myocyte	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
p300	p300	PROPN	NNP	3	O
in	in	ADP	IN	5	O
protection	protection	NOUN	NN	9	O
against	against	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
apoptosis	apoptosis	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Transgenic	transgenic	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
overexpressing	overexpresse	VERB	VBG	3	O
p300	p300	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
transgenic	transgenic	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
exhibited	exhibit	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
survival	survival	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
more	more	ADV	RBR	5	O
preserved	preserve	VERB	VBN	9	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
sarcomeric	sarcomeric	ADJ	JJ	3	O
actin	actin	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Doxorubicin	Doxorubicin	PROPN	NNP	0	B-Chemical
induced	induce	VERB	VBD	3	O
myocardial	myocardial	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
apoptosis	apoptosis	NOUN	NN	3	O
in	in	ADP	IN	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
transgenic	transgenic	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
p300	p300	PROPN	NNP	3	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
bcl	bcl	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
mdm	mdm	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
p53	p53	NOUN	NN	3	O
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
members	member	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
bcl	bcl	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
family	family	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	DET	DT	5	O
overexpression	overexpression	NOUN	NN	3	O
of	of	ADP	IN	5	O
p300	p300	PROPN	NNP	3	O
protects	protect	VERB	VBZ	3	O
cardiac	cardiac	ADJ	JJ	5	O
myocytes	myocyte	NOUN	NNS	3	O
from	from	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
apoptosis	apoptosis	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Methimazole	Methimazole	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
jaundice	jaundice	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Methimazole	Methimazole	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
generally	generally	ADV	RB	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
tolerated	tolerate	VERB	VBN	9	O
antithyroid	antithyroid	ADJ	JJ	0	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
43	43	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
had	have	VERB	VBD	9	O
severe	severe	ADJ	JJ	5	O
jaundice	jaundice	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
itching	itching	NOUN	NN	5	B-Disease
1	1	NUM	CD	9	O
month	month	NOUN	NN	5	O
after	after	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
methimazole	methimazole	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
tid	tid	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
tid	tid	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
hyperthyroidism	hyperthyroidism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
continued	continue	VERB	VBN	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
another	another	DET	DT	9	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
jaundice	jaundice	NOUN	NN	5	B-Disease
until	until	ADP	IN	5	O
she	-PRON-	PRON	PRP	5	O
finished	finish	VERB	VBD	5	O
both	both	DET	DT	9	O
medications	medication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
seen	see	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
still	still	ADV	RB	5	O
had	have	VERB	VBD	9	O
severe	severe	ADJ	JJ	5	O
icterus	icterus	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
pruritus	pruritus	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hyperbilirubinemia	hyperbilirubinemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
formed	form	VERB	VBN	9	O
mainly	mainly	ADV	RB	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
conjugated	conjugate	VERB	VBN	0	O
fraction	fraction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Methimazole	Methimazole	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
resumed	resume	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Over	over	ADP	IN	5	O
the	the	DET	DT	5	O
following	following	ADJ	JJ	9	O
9	9	NUM	CD	7	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
improved	improve	VERB	VBD	5	O
and	and	CCONJ	CC	5	O
plasma	plasma	NOUN	NN	9	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
after	after	ADP	IN	9	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
without	without	ADP	IN	9	O
methimazole	methimazole	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
rare	rare	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
few	few	ADJ	JJ	5	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
severe	severe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
reversible	reversible	ADJ	JJ	9	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
jaundice	jaundice	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Physicians	physician	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
so	so	ADP	IN	5	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
upon	upon	ADP	IN	9	O
occurrence	occurrence	NOUN	NN	5	O
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
discontinue	discontinue	VERB	VB	5	O
methimazole	methimazole	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
avoid	avoid	VERB	VB	5	O
unnecessary	unnecessary	ADJ	JJ	5	O
invasive	invasive	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Atrial	atrial	ADJ	JJ	7	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
stage	stage	NOUN	NN	9	O
IIIE	IIIE	PROPN	NNP	9	O
diffuse	diffuse	VERB	VBP	5	O
large	large	ADJ	JJ	5	O
B	b	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
gastric	gastric	NOUN	NN	9	B-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
myotonic	myotonic	ADJ	JJ	5	B-Disease
dystrophy	dystrophy	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
Steinert	Steinert	PROPN	NNP	6	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
diffuse	diffuse	NOUN	NN	5	O
B	b	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
gastric	gastric	ADJ	JJ	9	B-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
myotonic	myotonic	ADJ	JJ	5	B-Disease
dystrophy	dystrophy	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
muscular	muscular	ADJ	JJ	5	B-Disease
dystrophy	dystrophy	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sudden	sudden	ADJ	JJ	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
one	one	NUM	CD	5	O
cycle	cycle	NOUN	NN	9	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Atrial	atrial	ADJ	JJ	7	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
are	be	VERB	VBP	5	O
unusual	unusual	ADJ	JJ	9	O
complications	complication	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
intrinsically	intrinsically	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
aggressive	aggressive	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
employed	employ	VERB	VBN	5	O
could	could	VERB	MD	9	O
function	function	VERB	VB	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
triggering	trigger	VERB	VBG	9	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
predisposed	predispose	VERB	VBN	5	O
myocardium	myocardium	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
immune	immune	ADJ	JJ	3	O
reaction	reaction	NOUN	NN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
for	for	ADP	IN	5	O
dilevalol	dilevalol	NOUN	NN	_	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
lymphocyte	lymphocyte	ADJ	JJ	3	O
reactivity	reactivity	NOUN	NN	9	O
to	to	PART	TO	5	O
dilevalol	dilevalol	VERB	VB	_	B-Chemical
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
serum	serum	ADV	RB	9	O
containing	contain	VERB	VBG	0	O
putative	putative	ADJ	JJ	1	O
ex	ex	NOUN	NN	9	O
vivo	vivo	NOUN	NNS	3	O
dilevalol	dilevalol	VERB	VBP	_	B-Chemical
antigens	antigen	NOUN	NNS	3	O
or	or	CCONJ	CC	5	O
metabolites	metabolite	NOUN	NNS	0	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
dilevalol	dilevalol	NOUN	NN	_	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
liver	liver	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

PATIENT	PATIENT	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
58	58	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
dilevalol	dilevalol	NOUN	NN	_	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
liver	liver	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Peripheral	peripheral	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
mononuclear	mononuclear	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
collected	collect	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
were	be	VERB	VBD	9	O
cultured	culture	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
solution	solution	NOUN	NN	0	O
of	of	ADP	IN	5	O
dilevalol	dilevalol	NOUN	NN	_	B-Chemical
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
with	with	ADP	IN	5	O
sera	sera	NOUN	NN	3	O
collected	collect	VERB	VBN	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
volunteer	volunteer	NOUN	NN	5	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
dilevalol	dilevalol	NOUN	NN	_	B-Chemical
intake	intake	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
similar	similar	ADJ	JJ	9	O
protocol	protocol	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
with	with	ADP	IN	5	O
lymphocytes	lymphocyte	NOUN	NNS	3	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
healthy	healthy	ADJ	JJ	5	O
subject	subject	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
No	no	DET	DT	9	O
lymphocyte	lymphocyte	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
either	either	CCONJ	CC	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
healthy	healthy	ADJ	JJ	5	O
volunteer	volunteer	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
dilevalol	dilevalol	NOUN	NN	_	B-Chemical
solutions	solution	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
proliferative	proliferative	ADJ	JJ	3	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
serum	serum	ADV	RB	9	O
collected	collect	VERB	VBN	9	O
after	after	ADP	IN	9	O
dilevalol	dilevalol	NOUN	NN	_	B-Chemical
intake	intake	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
proliferative	proliferative	ADJ	JJ	3	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	NOUN	NN	9	O
collected	collect	VERB	VBN	9	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
intake	intake	NOUN	NN	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
reactivity	reactivity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
when	when	ADV	WRB	5	O
lymphocytes	lymphocyte	NOUN	NNS	3	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
healthy	healthy	ADJ	JJ	5	O
subject	subject	NOUN	NN	5	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
under	under	ADP	IN	9	O
similar	similar	ADJ	JJ	9	O
conditions	condition	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
methodology	methodology	NOUN	NN	5	O
used	use	VERB	VBD	5	O
allowed	allow	VERB	VBN	9	O
the	the	DET	DT	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
lymphocyte	lymphocyte	ADJ	JJ	3	O
sensitization	sensitization	NOUN	NN	9	O
to	to	ADP	IN	5	O
sera	sera	NOUN	NN	3	O
containing	contain	VERB	VBG	0	O
ex	ex	NOUN	NN	9	O
vivo	vivo	NOUN	NNS	3	O
-	-	PUNCT	HYPH	7	O
prepared	prepare	VERB	VBN	0	O
dilevalol	dilevalol	NOUN	NN	_	B-Chemical
antigens	antigen	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
the	the	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
immunologic	immunologic	ADJ	JJ	9	O
mechanism	mechanism	NOUN	NN	9	O
in	in	ADP	IN	5	O
dilevalol	dilevalol	NOUN	NN	_	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
liver	liver	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
apical	apical	ADJ	JJ	9	O
targeting	targeting	NOUN	NN	3	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
ENaC	ENaC	PROPN	NNP	3	O
subunits	subunit	NOUN	NNS	1	O
in	in	ADP	IN	5	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Nephrotic	nephrotic	ADJ	JJ	2	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
often	often	ADV	RB	5	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
retention	retention	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
generalized	generalize	VERB	VBN	5	O
edema	edema	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
basis	basis	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
decreased	decrease	VERB	VBN	9	O
renal	renal	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
excretion	excretion	NOUN	NN	0	O
remains	remain	VERB	VBZ	9	O
undefined	undefined	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
hypothesized	hypothesize	VERB	VBD	9	O
that	that	ADP	IN	5	O
epithelial	epithelial	ADJ	JJ	3	O
Na	Na	PROPN	NNP	0	B-Chemical
channel	channel	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ENaC	ENaC	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
subunit	subunit	NOUN	NN	1	O
dysregulation	dysregulation	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
retention	retention	NOUN	NN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
;	;	PUNCT	:	9	O
180	180	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
iv	iv	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
received	receive	VERB	VBD	9	O
only	only	ADJ	JJ	9	O
vehicle	vehicle	NOUN	NN	3	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
induced	induce	VERB	VBD	3	O
significant	significant	ADJ	JJ	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
hypoalbuminemia	hypoalbuminemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
urinary	urinary	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
excretion	excretion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
extensive	extensive	ADJ	JJ	5	O
ascites	ascite	NOUN	NNS	3	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
protein	protein	NOUN	NN	1	O
abundance	abundance	NOUN	NN	9	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ENaC	enac	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ENaC	ENaC	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
inner	inner	ADJ	JJ	9	O
stripe	stripe	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
outer	outer	ADJ	JJ	9	O
medulla	medulla	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ISOM	ISOM	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
inner	inner	ADJ	JJ	9	O
medulla	medulla	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
IM	IM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
altered	alter	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

gamma	gamma	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ENaC	enac	ADJ	JJ	3	O
abundance	abundance	NOUN	NN	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
ISOM	ISOM	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
IM	IM	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Immunoperoxidase	Immunoperoxidase	PROPN	NNP	3	O
brightfield	brightfield	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
laser	laser	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
scanning	scan	VERB	VBG	5	O
confocal	confocal	ADJ	JJ	3	O
fluorescence	fluorescence	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
demonstrated	demonstrate	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
targeting	targeting	NOUN	NN	3	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ENaC	enac	NOUN	NN	3	O
,	,	PUNCT	,	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ENaC	enac	NUM	CD	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
gamma	gamma	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ENaC	ENaC	PROPN	NNP	3	O
subunits	subunit	NOUN	NNS	1	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
apical	apical	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
membrane	membrane	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
distal	distal	ADJ	JJ	9	O
convoluted	convoluted	ADJ	JJ	9	O
tubule	tubule	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
DCT2	DCT2	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
connecting	connect	VERB	VBG	5	O
tubule	tubule	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cortical	cortical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
medullary	medullary	ADJ	JJ	5	O
collecting	collect	VERB	VBG	5	O
duct	duct	NOUN	NN	5	O
segments	segment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Immunoelectron	immunoelectron	ADJ	JJ	3	O
microscopy	microscopy	NOUN	NN	9	O
further	further	ADV	RB	9	O
revealed	reveal	VERB	VBD	9	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
labeling	labeling	NOUN	NN	3	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ENaC	enac	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
apical	apical	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
membrane	membrane	NOUN	NN	9	O
of	of	ADP	IN	5	O
cortical	cortical	ADJ	JJ	5	O
collecting	collect	VERB	VBG	5	O
duct	duct	NOUN	NN	5	O
principal	principal	ADJ	JJ	5	O
cells	cell	NOUN	NNS	3	O
of	of	ADP	IN	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
enhanced	enhance	VERB	VBN	3	O
apical	apical	ADJ	JJ	9	O
targeting	targeting	NOUN	NN	3	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ENaC	enac	NUM	CD	3	O
subunits	subunit	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
protein	protein	NOUN	NN	1	O
abundances	abundance	NOUN	NNS	4	O
of	of	ADP	IN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
H	h	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
exchanger	exchanger	NOUN	NN	0	O
type	type	NOUN	NN	9	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
NHE3	NHE3	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
Na	Na	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
2Cl	2cl	NUM	CD	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
cotransporter	cotransporter	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
BSC	BSC	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
thiazide	thiazide	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
Na	Na	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
Cl	cl	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
cotransporter	cotransporter	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
TSC	TSC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
abundance	abundance	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
subunit	subunit	NOUN	NN	1	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Na	Na	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
K	K	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
ATPase	ATPase	PROPN	NNP	1	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cortex	cortex	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
ISOM	ISOM	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
it	-PRON-	PRON	PRP	5	O
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
IM	IM	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
or	or	CCONJ	CC	5	O
sustained	sustain	VERB	VBN	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
ENaC	enac	NUM	CD	3	O
subunits	subunit	NOUN	NNS	1	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
apical	apical	ADJ	JJ	9	O
targeting	targeting	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
DCT2	DCT2	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
connecting	connect	VERB	VBG	5	O
tubule	tubule	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
collecting	collect	VERB	VBG	5	O
duct	duct	NOUN	NN	5	O
are	be	VERB	VBP	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
play	play	VERB	VB	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
retention	retention	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
decreased	decrease	VERB	VBN	9	O
abundance	abundance	NOUN	NN	9	O
of	of	ADP	IN	5	O
NHE3	NHE3	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
BSC	BSC	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
TSC	TSC	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Na	Na	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
K	K	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
ATPase	ATPase	PROPN	NNP	1	O
may	may	VERB	MD	5	O
play	play	VERB	VB	9	O
a	a	DET	DT	5	O
compensatory	compensatory	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
to	to	PART	TO	5	O
promote	promote	VERB	VB	3	O
sodium	sodium	NOUN	NN	0	B-Chemical
excretion	excretion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Pallidal	pallidal	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
alternative	alternative	NOUN	NN	5	O
to	to	ADP	IN	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
?	?	PUNCT	.	5	O

A	a	DET	DT	9	O
resurgence	resurgence	NOUN	NN	5	O
of	of	ADP	IN	5	O
interest	interest	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
surgical	surgical	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	PD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
came	come	VERB	VBD	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
rediscovery	rediscovery	NOUN	NN	5	O
of	of	ADP	IN	5	O
posteroventral	posteroventral	ADJ	JJ	4	O
pallidotomy	pallidotomy	NOUN	NN	5	O
by	by	ADP	IN	9	O
Laitinen	Laitinen	PROPN	NNP	6	O
in	in	ADP	IN	5	O
1985	1985	NUM	CD	2	O
.	.	PUNCT	.	9	O

Laitinen	laitinen	NOUN	NN	6	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
procedure	procedure	NOUN	NN	5	O
improved	improve	VERB	VBD	5	O
most	most	ADJ	JJS	9	O
symptoms	symptom	NOUN	NNS	5	O
in	in	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
resistant	resistant	ADJ	JJ	9	O
PD	pd	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
engendered	engender	VERB	VBD	5	O
wide	wide	ADJ	JJ	5	O
interest	interest	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
neurosurgical	neurosurgical	ADJ	JJ	5	O
community	community	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Another	another	DET	DT	5	O
lesioning	lesione	VERB	VBG	5	O
procedure	procedure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
ventrolateral	ventrolateral	ADJ	JJ	5	O
thalamotomy	thalamotomy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
become	become	VERB	VBN	5	O
a	a	DET	DT	5	O
powerful	powerful	ADJ	JJ	5	O
alternative	alternative	NOUN	NN	5	O
to	to	PART	TO	5	O
stimulate	stimulate	VERB	VB	3	O
the	the	DET	DT	5	O
nucleus	nucleus	NOUN	NN	9	O
ventralis	ventralis	X	FW	4	O
intermedius	intermedius	NOUN	NN	4	O
,	,	PUNCT	,	9	O
producing	produce	VERB	VBG	9	O
high	high	ADJ	JJ	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
success	success	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
morbidity	morbidity	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Pallidal	Pallidal	PROPN	NNP	5	O
stimulation	stimulation	NOUN	NN	3	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
met	meet	VERB	VBN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
success	success	NOUN	NN	5	O
.	.	PUNCT	.	9	O

According	accord	VERB	VBG	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
improves	improve	VERB	VBZ	5	O
the	the	DET	DT	5	O
"	"	PUNCT	``	5	O
on	on	ADP	IN	5	O
"	"	PUNCT	``	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
PD	PD	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
"	"	PUNCT	``	5	O
off	off	ADP	IN	5	O
"	"	PUNCT	``	5	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
bradykinesia	bradykinesia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
off	off	PART	RP	5	O
fluctuations	fluctuation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Pallidal	pallidal	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
improves	improve	VERB	VBZ	5	O
bradykinesia	bradykinesia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
minor	minor	ADJ	JJ	9	O
extent	extent	NOUN	NN	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
its	-PRON-	DET	PRP$	9	O
strength	strength	NOUN	NN	5	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
in	in	ADP	IN	5	O
improving	improve	VERB	VBG	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Stimulation	stimulation	NOUN	NN	3	O
often	often	ADV	RB	5	O
produces	produce	VERB	VBZ	9	O
an	an	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hyper	hyper	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
or	or	CCONJ	CC	5	I-Disease
dyskinetic	dyskinetic	ADJ	JJ	5	I-Disease
upper	upper	ADJ	JJ	9	O
limbs	limb	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
"	"	PUNCT	``	5	O
freezing	freezing	ADJ	JJ	5	O
"	"	PUNCT	''	5	O
phenomenon	phenomenon	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lower	low	ADJ	JJR	9	O
limbs	limb	NOUN	NNS	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Considering	consider	VERB	VBG	9	O
the	the	DET	DT	5	O
small	small	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
independence	independence	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
costs	cost	NOUN	NNS	5	O
of	of	ADP	IN	5	O
bilateral	bilateral	ADJ	JJ	5	O
implants	implant	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
difficulty	difficulty	NOUN	NN	5	O
most	most	ADJ	JJS	9	O
patients	patient	NOUN	NNS	5	O
experience	experience	VERB	VBP	5	O
in	in	ADP	IN	5	O
handling	handle	VERB	VBG	5	O
the	the	DET	DT	5	O
devices	device	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
question	question	NOUN	NN	5	O
arises	arise	VERB	VBZ	5	O
as	as	ADP	IN	5	O
to	to	ADP	IN	5	O
whether	whether	ADP	IN	9	O
bilateral	bilateral	ADJ	JJ	5	O
pallidal	pallidal	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
real	real	ADJ	JJ	5	O
alternative	alternative	NOUN	NN	5	O
to	to	ADP	IN	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cyclooxygenase	cyclooxygenase	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
specific	specific	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
valdecoxib	valdecoxib	NOUN	NN	0	B-Chemical
versus	versus	ADP	IN	9	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
antiinflammatory	antiinflammatory	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
on	on	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
events	event	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
arthritis	arthritis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
concerns	concern	NOUN	NNS	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
events	event	NOUN	NNS	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
higher	high	ADJ	JJR	9	O
with	with	ADP	IN	5	O
cyclooxygenase	cyclooxygenase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
COX	COX	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
than	than	ADP	IN	5	O
nonselective	nonselective	ADJ	JJ	0	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
antiinflammatory	antiinflammatory	NOUN	NN	9	O
drugs	drug	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
NSAIDs	nsaid	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
evaluated	evaluate	VERB	VBD	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
data	datum	NOUN	NNS	5	O
for	for	ADP	IN	5	O
valdecoxib	valdecoxib	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
COX	COX	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
in	in	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
8000	8000	NUM	CD	0	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
osteoarthritis	osteoarthritis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
rheumatoid	rheumatoid	VERB	VB	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
agent	agent	NOUN	NN	9	O
in	in	ADP	IN	5	O
randomized	randomize	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
events	event	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
cardiac	cardiac	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
cerebrovascular	cerebrovascular	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	O
vascular	vascular	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
arterial	arterial	ADJ	JJ	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
analyzing	analyze	VERB	VBG	9	O
pooled	pool	VERB	VBN	9	O
valdecoxib	valdecoxib	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
nonselective	nonselective	ADJ	JJ	0	O
NSAID	NSAID	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
bid	bid	NOUN	NN	5	O
,	,	PUNCT	,	9	O
ibuprofen	ibuprofen	VERB	VB	0	B-Chemical
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
tid	tid	NOUN	NN	0	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
naproxen	naproxen	ADJ	JJ	0	B-Chemical
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
bid	bid	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
10	10	NUM	CD	9	O
randomized	randomize	VERB	VBN	5	O
osteoarthritis	osteoarthritis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
rheumatoid	rheumatoid	VERB	VB	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
trials	trial	NOUN	NNS	5	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
52	52	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
in	in	ADP	IN	5	O
duration	duration	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
7934	7934	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
325	325	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
1051	1051	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
nonusers	nonuser	NOUN	NNS	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	NOUN	NNS	7	O
6883	6883	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Crude	crude	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
exposure	exposure	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adjusted	adjust	VERB	VBN	9	O
incidences	incidence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
for	for	ADP	IN	5	O
valdecoxib	valdecoxib	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
NSAIDs	nsaid	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
events	event	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
similar	similar	ADJ	JJ	9	O
for	for	ADP	IN	5	O
each	each	DET	DT	5	O
valdecoxib	valdecoxib	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thrombotic	thrombotic	ADJ	JJ	5	B-Disease
risk	risk	NOUN	NN	5	O
was	be	VERB	VBD	9	O
consistently	consistently	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
for	for	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	ADJ	JJ	9	B-Chemical
users	user	NOUN	NNS	5	O
than	than	ADP	IN	5	O
nonusers	nonuser	NOUN	NNS	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
;	;	PUNCT	,	9	O
valdecoxib	valdecoxib	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
NSAIDs	nsaid	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
events	event	NOUN	NNS	5	O
in	in	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
for	for	ADP	IN	5	O
all	all	DET	DT	5	O
3	3	NUM	CD	9	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
across	across	ADP	IN	5	O
valdecoxib	valdecoxib	NOUN	NN	0	B-Chemical
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Short	Short	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
intermediate	intermediate	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
or	or	CCONJ	CC	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
supratherapeutic	supratherapeutic	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
or	or	CCONJ	CC	5	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
valdecoxib	valdecoxib	NOUN	NN	0	B-Chemical
doses	dose	NOUN	NNS	0	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
events	event	NOUN	NNS	5	O
relative	relative	ADJ	JJ	9	O
to	to	ADP	IN	5	O
nonselective	nonselective	ADJ	JJ	0	O
NSAIDs	nsaid	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
in	in	ADP	IN	5	O
osteoarthritis	osteoarthritis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
rheumatoid	rheumatoid	VERB	VB	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
controlled	control	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
myocarditis	myocarditis	NOUN	NN	9	B-Disease
complicating	complicate	VERB	VBG	5	O
hypertrophic	hypertrophic	ADJ	JJ	3	B-Disease
cardiomyopathy	cardiomyopathy	ADJ	JJ	5	I-Disease
heart	heart	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
report	report	NOUN	NN	5	O
describes	describe	VERB	VBZ	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
eosinophilic	eosinophilic	NOUN	NN	5	B-Disease
myocarditis	myocarditis	NOUN	NN	9	I-Disease
complicating	complicate	VERB	VBG	5	O
hypertrophic	hypertrophic	ADJ	JJ	3	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
47	47	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
female	female	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
hypertrophic	hypertrophic	ADJ	JJ	3	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
with	with	ADP	IN	5	O
biventricular	biventricular	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
managed	manage	VERB	VBD	5	O
aggressively	aggressively	ADV	RB	5	O
with	with	ADP	IN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
infusion	infusion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
while	while	ADP	IN	9	O
being	be	VERB	VBG	5	O
assessed	assess	VERB	VBN	9	O
for	for	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
transthoracic	transthoracic	NOUN	NN	5	O
echocardiogram	echocardiogram	NOUN	NN	5	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
moderate	moderate	ADJ	JJ	9	O
left	leave	VERB	VBN	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
regional	regional	ADJ	JJ	5	O
variability	variability	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
moderate	moderate	ADJ	JJ	9	O
mitral	mitral	ADJ	JJ	5	B-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
recipient	recipient	NOUN	NN	9	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
heart	heart	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
the	the	DET	DT	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
apical	apical	ADJ	JJ	9	O
hypertrophic	hypertrophic	ADJ	JJ	3	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
myocarditis	myocarditis	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
abundant	abundant	ADJ	JJ	9	O
eosinophils	eosinophil	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Myocarditis	Myocarditis	PROPN	NNP	7	B-Disease
is	be	VERB	VBZ	5	O
rare	rare	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
eosinophilic	eosinophilic	ADJ	JJ	5	B-Disease
myocarditis	myocarditis	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
rarer	rare	ADJ	JJR	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
likely	likely	ADJ	JJ	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
eosinophilic	eosinophilic	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
myocarditis	myocarditis	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
related	relate	VERB	VBN	9	O
to	to	PART	TO	5	O
dobutamine	dobutamine	VERB	VB	5	B-Chemical
infusion	infusion	NOUN	NN	0	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Eosinophilic	eosinophilic	ADJ	JJ	2	B-Disease
myocarditis	myocarditis	NOUN	NN	9	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
explanted	explante	VERB	VBN	9	O
hearts	heart	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
multidrug	multidrug	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Time	time	NOUN	NN	9	O
trends	trend	NOUN	NNS	5	O
in	in	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
annual	annual	ADJ	JJ	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
bleeding	bleeding	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
Brigham	Brigham	PROPN	NNP	6	O
and	and	CCONJ	CC	5	O
Women	Women	PROPN	NNP	5	O
'	'	PART	POS	9	O
s	s	PROPN	NNP	9	O
Hospital	Hospital	PROPN	NNP	2	O
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
97	97	NUM	CD	7	O
/	/	SYM	SYM	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
patient	patient	ADJ	JJ	5	O
admissions	admission	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
period	period	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
January	January	PROPN	NNP	2	O
1995	1995	NUM	CD	2	O
to	to	ADP	IN	5	O
October	October	PROPN	NNP	2	O
1998	1998	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
19	19	NUM	CD	7	O
/	/	SYM	SYM	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
patient	patient	ADJ	JJ	5	O
admissions	admission	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
period	period	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
November	November	PROPN	NNP	2	O
1998	1998	NUM	CD	2	O
to	to	ADP	IN	5	O
August	August	PROPN	NNP	2	O
2002	2002	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
proportion	proportion	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
major	major	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
intracranial	intracranial	ADJ	JJ	5	B-Disease
bleeding	bleeding	NOUN	NN	5	I-Disease
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
to	to	ADP	IN	5	O
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Yohimbine	yohimbine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	B-Disease
side	side	NOUN	NN	5	I-Disease
effects	effect	NOUN	NNS	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
blockers	blocker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Preclinical	preclinical	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
facilitates	facilitate	VERB	VBZ	9	O
sexual	sexual	ADJ	JJ	5	O
behavior	behavior	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
helpful	helpful	ADJ	JJ	6	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
male	male	ADJ	JJ	9	B-Disease
impotence	impotence	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
single	single	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
the	the	DET	DT	5	O
sexual	sexual	ADJ	JJ	5	B-Disease
side	side	NOUN	NN	5	I-Disease
effects	effect	NOUN	NNS	9	I-Disease
of	of	ADP	IN	5	O
clomipramine	clomipramine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
evaluated	evaluate	VERB	VBD	9	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
sexual	sexual	ADJ	JJ	5	B-Disease
side	side	NOUN	NN	5	I-Disease
effects	effect	NOUN	NNS	9	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
blockers	blocker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
obsessive	obsessive	ADJ	JJ	5	B-Disease
compulsive	compulsive	ADJ	JJ	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
trichotillomania	trichotillomania	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
anxiety	anxiety	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
affective	affective	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
who	who	PRON	WP	5	O
suffered	suffer	VERB	VBD	5	O
sexual	sexual	ADJ	JJ	5	B-Disease
side	side	NOUN	NN	5	I-Disease
effects	effect	NOUN	NNS	9	I-Disease
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
blockers	blocker	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
r	r	NOUN	NN	9	O
.	.	PUNCT	.	9	O
n	n	ADV	RB	9	O
.	.	PUNCT	.	9	O
basis	basis	NOUN	NN	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
open	open	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Various	various	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
ideal	ideal	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
for	for	ADP	IN	5	O
each	each	DET	DT	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Five	five	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
improved	improve	VERB	VBN	5	O
sexual	sexual	ADJ	JJ	5	O
functioning	functioning	NOUN	NN	5	O
after	after	ADP	IN	9	O
taking	take	VERB	VBG	5	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
comply	comply	VERB	VB	5	O
with	with	ADP	IN	5	O
yohimbine	yohimbine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
included	include	VERB	VBD	5	O
excessive	excessive	ADJ	JJ	5	O
sweating	sweating	NOUN	NN	5	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBN	9	O
anxiety	anxiety	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
wound	wound	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
feeling	feeling	NOUN	NN	5	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
sexual	sexual	ADJ	JJ	5	B-Disease
side	side	NOUN	NN	5	I-Disease
effects	effect	NOUN	NNS	9	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
blockers	blocker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Future	future	NOUN	NN	5	O
controlled	control	VERB	VBN	5	O
studies	study	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
further	further	ADV	RB	9	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
effectiveness	effectiveness	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
indication	indication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hemorrhagic	hemorrhagic	ADJ	JJ	9	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
complicating	complicate	VERB	VBG	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Hemorrhagic	hemorrhagic	ADJ	JJ	9	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
serious	serious	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
administered	administer	VERB	VBN	9	O
before	before	ADP	IN	9	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
standard	standard	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
at	at	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
institution	institution	NOUN	NN	5	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
scheduled	schedule	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
a	a	DET	DT	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplant	transplant	NOUN	NN	9	O
are	be	VERB	VBP	5	O
treated	treat	VERB	VBN	3	O
prophylactically	prophylactically	ADV	RB	5	O
with	with	ADP	IN	5	O
forced	force	VERB	VBN	5	O
hydration	hydration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
bladder	bladder	NOUN	NN	9	O
irrigation	irrigation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
an	an	DET	DT	5	O
attempt	attempt	NOUN	NN	5	O
to	to	PART	TO	5	O
obviate	obviate	VERB	VB	5	O
the	the	DET	DT	5	O
inconvenience	inconvenience	NOUN	NN	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
irrigation	irrigation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
feasibility	feasibility	NOUN	NN	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
uroprophylaxis	uroprophylaxis	NOUN	NN	_	O
with	with	ADP	IN	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
neutralizes	neutralize	VERB	VBZ	3	O
the	the	DET	DT	5	O
hepatic	hepatic	ADJ	JJ	9	O
metabolite	metabolite	NOUN	NN	0	O
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
that	that	DET	WDT	5	O
causes	cause	VERB	VBZ	9	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
97	97	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
standard	standard	ADJ	JJ	5	O
prophylaxis	prophylaxis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
had	have	VERB	VBD	9	O
symptomatic	symptomatic	ADJ	JJ	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
mesna	mesna	ADJ	JJ	0	B-Chemical
uroprophylaxis	uroprophylaxis	ADJ	JJ	_	O
before	before	ADP	IN	9	O
allogeneic	allogeneic	ADJ	JJ	3	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
had	have	VERB	VBD	9	O
severe	severe	ADJ	JJ	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
for	for	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
suboptimal	suboptimal	ADJ	JJ	9	O
result	result	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
resumed	resume	VERB	VBD	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
irrigation	irrigation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
forced	force	VERB	VBN	5	O
hydration	hydration	NOUN	NN	0	O
to	to	PART	TO	5	O
minimize	minimize	VERB	VB	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Consensus	consensus	NOUN	NN	9	O
statement	statement	NOUN	NN	5	O
concerning	concern	VERB	VBG	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
occurring	occur	VERB	VBG	9	O
during	during	ADP	IN	5	O
haematopoietic	haematopoietic	ADJ	JJ	3	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
autoimmune	autoimmune	ADJ	JJ	3	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
special	special	ADJ	JJ	5	O
reference	reference	NOUN	NN	9	O
to	to	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	B-Disease
sclerosis	sclerosis	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
multiple	multiple	ADJ	JJ	5	B-Disease
sclerosis	sclerosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Autologous	autologous	ADJ	JJ	3	O
haematopoietic	haematopoietic	ADJ	JJ	3	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
now	now	ADV	RB	5	O
a	a	DET	DT	5	O
feasible	feasible	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
effective	effective	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
selected	select	VERB	VBN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
autoimmune	autoimmune	ADJ	JJ	3	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Worldwide	worldwide	ADV	RB	5	O
,	,	PUNCT	,	9	O
over	over	ADP	IN	5	O
650	650	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
transplanted	transplant	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
context	context	NOUN	NN	5	O
of	of	ADP	IN	5	O
phase	phase	NOUN	NN	5	O
I	I	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
II	II	PROPN	NNP	9	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
encouraging	encourage	VERB	VBG	5	O
enough	enough	ADV	RB	5	O
to	to	PART	TO	5	O
begin	begin	VERB	VB	5	O
randomised	randomise	VERB	VBN	5	O
phase	phase	NOUN	NN	5	O
III	iii	NUM	CD	9	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
predicted	predict	VERB	VBN	9	O
,	,	PUNCT	,	9	O
significant	significant	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
morbidity	morbidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
primarily	primarily	ADV	RB	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
complications	complication	NOUN	NNS	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
either	either	CCONJ	CC	9	O
the	the	DET	DT	5	O
stage	stage	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
disease	disease	NOUN	NN	5	O
at	at	ADP	IN	9	O
transplant	transplant	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
infections	infection	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
deaths	death	NOUN	NNS	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
low	low	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
caution	caution	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
required	require	VERB	VBN	9	O
when	when	ADV	WRB	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
anthracyclines	anthracycline	NOUN	NNS	0	B-Chemical
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
mitoxantrone	mitoxantrone	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
underlying	underlie	VERB	VBG	5	O
heart	heart	NOUN	NN	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
example	example	NOUN	NN	5	O
,	,	PUNCT	,	9	O
systemic	systemic	ADJ	JJ	9	B-Disease
sclerosis	sclerosis	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
November	November	PROPN	NNP	2	O
2002	2002	NUM	CD	2	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
meeting	meeting	NOUN	NN	5	O
was	be	VERB	VBD	9	O
held	hold	VERB	VBN	5	O
in	in	ADP	IN	5	O
Florence	Florence	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
bringing	bring	VERB	VBG	5	O
together	together	ADV	RB	9	O
a	a	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
experts	expert	NOUN	NNS	5	O
in	in	ADP	IN	5	O
various	various	ADJ	JJ	9	O
fields	field	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
rheumatology	rheumatology	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cardiology	cardiology	NOUN	NN	5	O
,	,	PUNCT	,	9	O
neurology	neurology	NOUN	NN	5	O
,	,	PUNCT	,	9	O
pharmacology	pharmacology	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
transplantation	transplantation	NOUN	NN	9	O
medicine	medicine	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
object	object	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
meeting	meeting	NOUN	NN	5	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
analyse	analyse	VERB	VB	9	O
existing	exist	VERB	VBG	5	O
data	datum	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
both	both	CCONJ	CC	9	O
published	publish	VERB	VBN	9	O
or	or	CCONJ	CC	5	O
available	available	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
European	European	PROPN	NNP	5	O
Group	Group	PROPN	NNP	9	O
for	for	ADP	IN	5	O
Blood	Blood	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
Marrow	Marrow	PROPN	NNP	2	O
Transplantation	Transplantation	PROPN	NNP	2	O
autoimmune	autoimmune	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
database	database	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
propose	propose	VERB	VB	9	O
a	a	DET	DT	5	O
safe	safe	ADJ	JJ	5	O
approach	approach	NOUN	NN	5	O
to	to	ADP	IN	5	O
such	such	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
full	full	ADJ	JJ	5	O
cardiological	cardiological	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
transplant	transplant	NOUN	NN	9	O
emerged	emerge	VERB	VBD	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
recommendation	recommendation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Does	do	VERB	VBZ	5	O
supplemental	supplemental	ADJ	JJ	9	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
C	c	NOUN	NN	9	I-Chemical
increase	increase	VERB	VBP	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
risk	risk	NOUN	NN	5	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
diabetes	diabete	NOUN	NNS	5	B-Disease
?	?	PUNCT	.	5	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Vitamin	vitamin	NOUN	NN	0	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
acts	act	VERB	VBZ	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
antioxidant	antioxidant	NOUN	NN	0	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
also	also	ADV	RB	9	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
prooxidant	prooxidant	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
glycate	glycate	ADJ	JJ	0	O
protein	protein	NOUN	NN	1	O
under	under	ADP	IN	9	O
certain	certain	ADJ	JJ	5	O
circumstances	circumstance	NOUN	NNS	5	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
observations	observation	NOUN	NNS	9	O
led	lead	VERB	VBD	9	O
us	-PRON-	PRON	PRP	5	O
to	to	PART	TO	5	O
hypothesize	hypothesize	VERB	VB	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
intake	intake	NOUN	NN	5	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
C	c	NOUN	NN	9	I-Chemical
in	in	ADP	IN	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
persons	person	NOUN	NNS	5	O
might	may	VERB	MD	9	O
promote	promote	VERB	VB	3	O
atherosclerosis	atherosclerosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
relation	relation	NOUN	NN	5	O
between	between	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
C	c	NOUN	NN	9	I-Chemical
intake	intake	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
from	from	ADP	IN	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
relation	relation	NOUN	NN	5	O
between	between	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
C	c	NOUN	NN	9	I-Chemical
intake	intake	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
from	from	ADP	IN	9	O
total	total	ADJ	JJ	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
281	281	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
175	175	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
stroke	stroke	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
57	57	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
1923	1923	NUM	CD	4	O
postmenopausal	postmenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
reported	report	VERB	VBD	9	O
being	be	VERB	VBG	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Diet	Diet	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
food	food	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
frequency	frequency	NOUN	NN	5	O
questionnaire	questionnaire	NOUN	NN	5	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
subjects	subject	NOUN	NNS	5	O
initially	initially	ADV	RB	9	O
free	free	ADJ	JJ	9	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
prospectively	prospectively	ADV	RB	5	O
followed	follow	VERB	VBN	9	O
for	for	ADP	IN	5	O
15	15	NUM	CD	9	O
y	y	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
After	after	ADP	IN	9	O
adjustment	adjustment	NOUN	NN	5	O
for	for	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
diabetes	diabetes	NOUN	NN	5	B-Disease
medication	medication	NOUN	NN	5	O
used	use	VERB	VBN	5	O
,	,	PUNCT	,	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
diabetes	diabetes	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
intakes	intake	NOUN	NNS	5	O
of	of	ADP	IN	5	O
folate	folate	ADJ	JJ	9	B-Chemical
,	,	PUNCT	,	9	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carotene	carotene	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
adjusted	adjust	VERB	VBN	9	O
relative	relative	ADJ	JJ	9	O
risks	risk	NOUN	NNS	5	O
of	of	ADP	IN	5	O
total	total	ADJ	JJ	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
mortality	mortality	NOUN	NN	5	O
were	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
97	97	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
11	11	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
47	47	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
84	84	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
for	for	ADP	IN	5	O
trend	trend	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
across	across	ADP	IN	5	O
quintiles	quintile	NOUN	NNS	5	O
of	of	ADP	IN	5	O
total	total	ADJ	JJ	9	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
C	c	NOUN	NN	9	I-Chemical
intake	intake	NOUN	NN	5	O
from	from	ADP	IN	9	O
food	food	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
supplements	supplement	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Adjusted	adjusted	ADJ	JJ	5	O
relative	relative	ADJ	JJ	9	O
risks	risk	NOUN	NNS	5	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
81	81	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
99	99	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
26	26	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
91	91	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
for	for	ADP	IN	5	O
trend	trend	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
stroke	stroke	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
52	52	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
23	23	NUM	CD	7	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
22	22	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
57	57	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
for	for	ADP	IN	5	O
trend	trend	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
dietary	dietary	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
supplemental	supplemental	ADJ	JJ	9	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
C	c	NOUN	NN	9	I-Chemical
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
separately	separately	ADV	RB	9	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
supplemental	supplemental	ADJ	JJ	9	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
C	c	NOUN	NN	9	I-Chemical
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
mortality	mortality	NOUN	NN	5	O
endpoints	endpoint	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Vitamin	vitamin	NOUN	NN	0	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
intake	intake	NOUN	NN	5	O
was	be	VERB	VBD	9	O
unrelated	unrelated	ADJ	JJ	9	O
to	to	ADP	IN	5	O
mortality	mortality	NOUN	NN	5	O
from	from	ADP	IN	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
nondiabetic	nondiabetic	ADJ	JJ	9	O
subjects	subject	NOUN	NNS	5	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
high	high	ADJ	JJ	9	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
C	c	NOUN	NN	9	I-Chemical
intake	intake	NOUN	NN	5	O
from	from	ADP	IN	9	O
supplements	supplement	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
mortality	mortality	NOUN	NN	5	O
in	in	ADP	IN	5	O
postmenopausal	postmenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
diabetes	diabete	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Optical	optical	ADJ	JJ	0	O
coherence	coherence	NOUN	NN	5	O
tomography	tomography	NOUN	NN	5	O
can	can	VERB	MD	5	O
measure	measure	VERB	VB	5	O
axonal	axonal	ADJ	JJ	3	O
loss	loss	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
map	map	VERB	VB	5	O
and	and	CCONJ	CC	5	O
identify	identify	VERB	VB	9	O
the	the	DET	DT	5	O
pattern	pattern	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
of	of	ADP	IN	5	O
axonal	axonal	ADJ	JJ	3	B-Disease
degeneration	degeneration	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
using	use	VERB	VBG	9	O
optical	optical	ADJ	JJ	5	O
coherence	coherence	NOUN	NN	5	O
tomography	tomography	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
OCT	OCT	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Ethambutol	Ethambutol	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
antimycobacterial	antimycobacterial	ADJ	JJ	0	O
agent	agent	NOUN	NN	9	O
often	often	ADV	RB	5	O
used	use	VERB	VBD	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
tuberculosis	tuberculosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
serious	serious	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
impairs	impair	VERB	VBZ	9	O
visual	visual	ADJ	JJ	5	O
acuity	acuity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
contrast	contrast	NOUN	NN	9	O
sensitivity	sensitivity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
color	color	NOUN	NN	5	O
vision	vision	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
early	early	ADV	RB	9	O
on	on	ADV	RB	5	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
mild	mild	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
partly	partly	ADV	RB	9	O
reversible	reversible	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
funduscopic	funduscopic	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
often	often	ADV	RB	5	O
subtle	subtle	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
easy	easy	ADJ	JJ	5	O
to	to	PART	TO	5	O
miss	miss	VERB	VB	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Three	three	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
EMB	EMB	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
intermediate	intermediate	ADJ	JJ	9	O
-	-	PUNCT	:	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
visual	visual	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
a	a	DET	DT	5	O
full	full	ADJ	JJ	5	O
neuro	neuro	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ophthalmologic	ophthalmologic	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
including	include	VERB	VBG	9	O
visual	visual	ADJ	JJ	5	O
acuity	acuity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
color	color	NOUN	NN	5	O
vision	vision	NOUN	NN	5	O
,	,	PUNCT	,	9	O
contrast	contrast	NOUN	NN	9	O
sensitivity	sensitivity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
fundus	fundus	NOUN	NN	5	O
examination	examination	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
OCT	OCT	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
OCT	OCT	PROPN	NNP	5	O
3000	3000	NUM	CD	0	O
,	,	PUNCT	,	9	O
Humphrey	Humphrey	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Zeiss	Zeiss	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
Dublin	Dublin	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
CA	CA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
both	both	DET	DT	9	O
eyes	eye	NOUN	NNS	5	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
subject	subject	NOUN	NN	5	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
retinal	retinal	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
fiber	fiber	NOUN	NN	5	O
layer	layer	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
RNFL	RNFL	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
analysis	analysis	NOUN	NN	9	O
protocol	protocol	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OCT	OCT	PROPN	NNP	5	O
interpolates	interpolate	VERB	VBZ	5	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
100	100	NUM	CD	0	O
points	point	NOUN	NNS	5	O
around	around	ADP	IN	5	O
the	the	DET	DT	5	O
optic	optic	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
to	to	PART	TO	5	O
effectively	effectively	ADV	RB	5	O
map	map	VERB	VB	5	O
out	out	PART	RP	9	O
the	the	DET	DT	5	O
RNFL	RNFL	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
calculated	calculated	ADJ	JJ	5	O
average	average	ADJ	JJ	5	O
RNFL	rnfl	NOUN	NN	5	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
eyes	eye	NOUN	NNS	5	O
accumulated	accumulate	VERB	VBN	9	O
from	from	ADP	IN	9	O
four	four	NUM	CD	9	O
prior	prior	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
OCT	OCT	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
661	661	NUM	CD	7	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
all	all	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
with	with	ADP	IN	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
EMB	EMB	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
72	72	NUM	CD	9	O
%	%	NOUN	NN	9	O
nerve	nerve	NOUN	NN	5	O
fiber	fiber	NOUN	NN	5	O
layer	layer	NOUN	NN	9	O
thickness	thickness	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
temporal	temporal	ADJ	JJ	5	O
quadrant	quadrant	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
patient	patient	NOUN	NN	5	O
A	a	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
eventual	eventual	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
visual	visual	ADJ	JJ	5	O
acuity	acuity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
fields	field	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
58	58	NUM	CD	7	O
%	%	NOUN	NN	9	O
loss	loss	NOUN	NN	9	O
;	;	PUNCT	:	9	O
patient	patient	NOUN	NN	5	O
B	b	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
intermediate	intermediate	ADJ	JJ	9	O
visual	visual	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
68	68	NUM	CD	7	O
%	%	NOUN	NN	9	O
loss	loss	NOUN	NN	9	O
;	;	PUNCT	:	9	O
patient	patient	NOUN	NN	5	O
C	C	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
loss	loss	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
average	average	ADJ	JJ	5	O
mean	mean	ADJ	JJ	5	O
optic	optic	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
thickness	thickness	NOUN	NN	5	O
of	of	ADP	IN	5	O
26	26	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
16	16	NUM	CD	9	O
microm	microm	NOUN	NN	0	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
combined	combine	VERB	VBN	9	O
mean	mean	ADJ	JJ	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
46	46	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
fibers	fiber	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
superior	superior	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
inferior	inferior	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
nasal	nasal	NOUN	NN	5	O
quadrants	quadrant	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
(	(	PUNCT	-LRB-	9	O
six	six	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
eyes	eye	NOUN	NNS	5	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
three	three	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
average	average	ADJ	JJ	5	O
thickness	thickness	NOUN	NN	5	O
of	of	ADP	IN	5	O
55	55	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
29	29	NUM	CD	7	O
microm	microm	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
both	both	DET	DT	9	O
sets	set	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
four	four	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
eyes	eye	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
with	with	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
patients	patient	NOUN	NNS	5	O
B	B	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
C	C	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
an	an	DET	DT	5	O
average	average	ADJ	JJ	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
79	79	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
nerve	nerve	NOUN	NN	5	O
fiber	fiber	NOUN	NN	5	O
thickness	thickness	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
temporal	temporal	ADJ	JJ	5	O
quadrant	quadrant	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
OCT	OCT	PROPN	NNP	5	O
results	result	VERB	VBZ	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
EMB	EMB	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
show	show	VERB	VBP	9	O
considerable	considerable	ADJ	JJ	5	O
loss	loss	NOUN	NN	9	O
especially	especially	ADV	RB	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
temporal	temporal	ADJ	JJ	5	O
fibers	fiber	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
histopathological	histopathological	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
that	that	DET	WDT	5	O
show	show	VERB	VBP	9	O
predominant	predominant	ADJ	JJ	9	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
parvo	parvo	NOUN	NNS	5	O
-	-	PUNCT	HYPH	7	O
cellular	cellular	ADJ	JJ	3	O
axons	axon	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
or	or	CCONJ	CC	5	O
small	small	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
caliber	caliber	NOUN	NN	5	O
axons	axon	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
papillo	papillo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
macular	macular	ADJ	JJ	5	O
bundle	bundle	NOUN	NN	5	O
in	in	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	O
or	or	CCONJ	CC	5	O
hereditary	hereditary	ADJ	JJ	5	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathies	neuropathy	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

OCT	OCT	PROPN	NNP	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
valuable	valuable	ADJ	JJ	5	O
tool	tool	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
quantitative	quantitative	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathies	neuropathy	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
EMB	EMB	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
important	important	ADJ	JJ	9	O
to	to	PART	TO	5	O
properly	properly	ADV	RB	5	O
manage	manage	VERB	VB	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
dosing	dose	VERB	VBG	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
achieve	achieve	VERB	VB	5	O
proper	proper	ADJ	JJ	5	O
transition	transition	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
maintenance	maintenance	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
once	once	ADV	RB	5	O
an	an	DET	DT	5	O
appropriate	appropriate	ADJ	JJ	5	O
loading	loading	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reached	reach	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Hypoxia	hypoxia	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
glomerular	glomerular	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
the	the	DET	DT	5	O
increasing	increase	VERB	VBG	9	O
need	need	NOUN	NN	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
and	and	CCONJ	CC	5	O
quantify	quantify	VERB	VB	9	O
tissue	tissue	NOUN	NN	9	O
oxygenation	oxygenation	NOUN	NN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
cellular	cellular	ADJ	JJ	3	O
level	level	NOUN	NN	9	O
,	,	PUNCT	,	9	O
relatively	relatively	ADV	RB	5	O
few	few	ADJ	JJ	5	O
methods	method	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
available	available	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
hypoxia	hypoxia	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	O
responsive	responsive	ADJ	JJ	9	O
reporter	reporter	NOUN	NN	1	O
vector	vector	NOUN	NN	1	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
hypoxia	hypoxia	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	O
responsive	responsive	ADJ	JJ	9	O
element	element	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
'	'	PUNCT	``	9	O
vascular	vascular	ADJ	JJ	5	O
endothelial	endothelial	ADJ	JJ	3	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
untranslated	untranslated	ADJ	JJ	1	O
region	region	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
generated	generate	VERB	VBD	9	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
hypoxia	hypoxia	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	O
sensing	sense	VERB	VBG	5	O
transgenic	transgenic	ADJ	JJ	3	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
then	then	ADV	RB	9	O
applied	apply	VERB	VBD	5	O
this	this	DET	DT	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
tubulointerstitial	tubulointerstitial	ADJ	JJ	3	O
hypoxia	hypoxia	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
diseased	diseased	ADJ	JJ	5	B-Disease
kidney	kidney	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
diffuse	diffuse	VERB	VB	5	O
cortical	cortical	ADJ	JJ	5	O
hypoxia	hypoxia	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
focal	focal	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
segmental	segmental	ADJ	JJ	5	O
hypoxia	hypoxia	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
remnant	remnant	ADJ	JJ	9	O
kidney	kidney	NOUN	NN	9	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hypoxia	hypoxia	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	O
responsive	responsive	ADJ	JJ	9	O
transgene	transgene	NOUN	NN	3	O
increased	increase	VERB	VBD	9	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
observation	observation	NOUN	NN	9	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
reaching	reach	VERB	VBG	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	PUNCT	LS	9	O
-	-	PUNCT	:	7	O
fold	fold	VERB	VB	9	O
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
model	model	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
-	-	NOUN	NN	7	O
fold	fold	VERB	VB	9	O
at	at	ADP	IN	9	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
remnant	remnant	ADJ	JJ	9	O
kidney	kidney	NOUN	NN	9	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
vascular	vascular	ADJ	JJ	5	O
endothelial	endothelial	ADJ	JJ	3	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
mild	mild	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
,	,	PUNCT	,	9	O
reflecting	reflect	VERB	VBG	5	O
distinct	distinct	ADJ	JJ	9	O
behaviors	behavior	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
genes	gene	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypoxia	hypoxia	NOUN	NN	3	B-Disease
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
with	with	ADP	IN	5	O
microscopic	microscopic	ADJ	JJ	9	O
tubulointerstitial	tubulointerstitial	ADJ	JJ	3	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
identified	identify	VERB	VBD	9	O
the	the	DET	DT	5	O
localization	localization	NOUN	NN	3	O
of	of	ADP	IN	5	O
proliferating	proliferate	VERB	VBG	3	O
cell	cell	NOUN	NN	3	O
nuclear	nuclear	ADJ	JJ	3	O
antigen	antigen	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
ED	ED	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
terminal	terminal	ADJ	JJ	9	O
dUTP	dUTP	PROPN	NNP	0	O
nick	nick	ADJ	JJ	0	O
-	-	PUNCT	HYPH	7	O
end	end	NOUN	NN	9	O
labeled	label	VERB	VBN	3	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hypoxic	hypoxic	ADJ	JJ	3	B-Disease
cortical	cortical	ADJ	JJ	5	O
area	area	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
remnant	remnant	ADJ	JJ	9	O
kidney	kidney	NOUN	NN	9	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
propose	propose	VERB	VBP	9	O
here	here	ADV	RB	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
pathological	pathological	ADJ	JJ	5	O
tie	tie	NOUN	NN	5	O
between	between	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
tubulointerstitial	tubulointerstitial	ADJ	JJ	3	O
hypoxia	hypoxia	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
progressive	progressive	ADJ	JJ	5	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Adequate	adequate	ADJ	JJ	5	O
timing	timing	NOUN	NN	5	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	ADJ	JJ	9	B-Chemical
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
during	during	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
of	of	ADP	IN	5	O
interferon	interferon	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
C	C	PROPN	NNP	9	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
of	of	ADP	IN	5	O
interferon	interferon	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
dose	dose	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
retrospective	retrospective	ADJ	JJ	5	O
cohort	cohort	NOUN	NN	9	O
study	study	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
have	have	VERB	VBP	5	O
examined	examine	VERB	VBN	9	O
the	the	DET	DT	5	O
suitable	suitable	ADJ	JJ	5	O
timing	timing	NOUN	NN	5	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	ADJ	JJ	9	B-Chemical
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
during	during	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	METHODS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
seven	seven	NUM	CD	9	O
of	of	ADP	IN	5	O
160	160	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
HCV	HCV	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
genotype	genotype	PROPN	NNP	9	O
1b	1b	NUM	CD	9	O
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
virus	virus	NOUN	NN	9	O
load	load	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
received	receive	VERB	VBD	9	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
anemia	anemia	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
level	level	NOUN	NN	9	O
<	<	X	XX	0	O
10	10	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
or	or	CCONJ	CC	5	O
anemia	anemia	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
signs	sign	NOUN	NNS	5	O
during	during	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
that	that	DET	DT	5	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
37	37	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
one	one	NUM	CD	5	O
tablet	tablet	NOUN	NN	0	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
27	27	NUM	CD	7	O
of	of	ADP	IN	5	O
37	37	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
could	could	VERB	MD	9	O
continue	continue	VERB	VB	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
24	24	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
A	A	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
of	of	ADP	IN	5	O
37	37	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
could	could	VERB	MD	9	O
not	not	ADV	RB	5	O
continue	continue	VERB	VB	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
because	because	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
<	<	X	XX	0	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
hemoglobin	hemoglobin	NOUN	NN	0	O
values	value	NOUN	NNS	5	O
decreased	decrease	VERB	VBD	9	O
to	to	ADP	IN	5	O
or	or	CCONJ	CC	5	O
anemia	anemia	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
severe	severe	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
B	B	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
assessed	assess	VERB	VBD	9	O
the	the	DET	DT	5	O
final	final	ADJ	JJ	9	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
after	after	ADP	IN	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
in	in	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
A	a	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
B	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
sustained	sustained	ADJ	JJ	5	O
virological	virological	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
SVR	SVR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
29	29	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
/	/	SYM	SYM	9	O
27	27	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
A	A	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
B	B	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
34	34	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
/	/	SYM	SYM	9	O
27	27	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
SVR	SVR	PROPN	NNP	9	O
+	+	CCONJ	CC	9	O
biological	biological	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
A	A	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
B	B	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
051	051	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
slight	slight	ADJ	JJ	9	O
significance	significance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
level	level	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	ADJ	JJ	9	B-Chemical
reduction	reduction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
continuation	continuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
hemoglobin	hemoglobin	NOUN	NN	0	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
<	<	X	XX	0	O
10	10	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
036	036	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
at	at	ADP	IN	9	O
hemoglobin	hemoglobin	NOUN	NN	0	O
level	level	NOUN	NN	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
is	be	VERB	VBZ	5	O
suitable	suitable	ADJ	JJ	5	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Aging	age	VERB	VBG	2	O
process	process	NOUN	NN	5	O
of	of	ADP	IN	5	O
epithelial	epithelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
prostate	prostate	NOUN	NN	3	O
lateral	lateral	ADJ	JJ	5	O
lobe	lobe	NOUN	NN	5	O
in	in	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
HAL	HAL	PROPN	NNP	2	B-Chemical
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
age	age	NOUN	NN	5	O
related	related	ADJ	JJ	9	O
morphology	morphology	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
function	function	NOUN	NN	9	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
epithelial	epithelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
prostate	prostate	NOUN	NN	3	O
lateral	lateral	ADJ	JJ	5	O
lobe	lobe	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
sexually	sexually	ADV	RB	5	O
mature	mature	ADJ	JJ	3	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
prolactin	prolactin	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
PRL	PRL	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
T	t	NOUN	NN	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Tissue	tissue	NOUN	NN	9	O
sections	section	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
with	with	ADP	IN	5	O
light	light	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
electron	electron	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Immunohistochemical	immunohistochemical	ADJ	JJ	3	O
reactions	reaction	NOUN	NNS	9	O
for	for	ADP	IN	5	O
Anti	Anti	PROPN	NNP	3	O
-	-	ADJ	JJ	7	O
Proliferating	proliferate	VERB	VBG	3	O
Cell	Cell	PROPN	NNP	3	O
Nuclear	Nuclear	PROPN	NNP	9	O
Antigen	Antigen	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
PCNA	PCNA	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
rats	rat	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
:	:	PUNCT	:	9	O
PRL	PRL	PROPN	NNP	3	B-Chemical
was	be	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
twice	twice	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
T	T	PROPN	NNP	3	B-Chemical
concentration	concentration	NOUN	NN	0	O
was	be	VERB	VBD	9	O
almost	almost	ADV	RB	9	O
twice	twice	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Light	light	ADJ	JJ	9	O
microscopy	microscopy	NOUN	NN	9	O
visualized	visualize	VERB	VBD	9	O
the	the	DET	DT	5	O
following	following	NOUN	NN	9	O
:	:	PUNCT	:	9	O
hypertrophy	hypertrophy	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
epithelium	epithelium	NOUN	NN	3	O
hyperplasia	hyperplasia	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glandular	glandular	ADJ	JJ	9	O
ducts	duct	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
PCNA	pcna	NOUN	NN	3	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Electron	Electron	PROPN	NNP	0	O
microscopy	microscopy	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
columnar	columnar	ADJ	JJ	5	O
epithelial	epithelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
concerning	concern	VERB	VBG	5	O
organelles	organelle	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
engaged	engage	VERB	VBN	5	O
in	in	ADP	IN	5	O
protein	protein	NOUN	NN	1	O
synthesis	synthesis	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
secretion	secretion	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Relation	relation	NOUN	NN	9	O
of	of	ADP	IN	5	O
perfusion	perfusion	NOUN	NN	5	O
defects	defect	NOUN	NNS	9	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
contrast	contrast	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
correlation	correlation	NOUN	NN	9	O
with	with	ADP	IN	5	O
thallium	thallium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
201	201	NUM	CD	7	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
photon	photon	NOUN	NN	5	O
emission	emission	NOUN	NN	0	O
tomography	tomography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
contrast	contrast	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
valuable	valuable	ADJ	JJ	5	O
technique	technique	NOUN	NN	5	O
for	for	ADP	IN	5	O
delineating	delineate	VERB	VBG	5	O
regions	region	NOUN	NNS	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
underperfusion	underperfusion	NOUN	NN	5	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
to	to	ADP	IN	5	O
critical	critical	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
stenoses	stenosis	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
hyperemic	hyperemic	ADJ	JJ	5	B-Disease
stimulation	stimulation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
myocardial	myocardial	ADJ	JJ	9	O
contrast	contrast	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
performed	perform	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
stable	stable	ADJ	JJ	9	O
solution	solution	NOUN	NN	0	O
of	of	ADP	IN	5	O
sonicated	sonicated	ADJ	JJ	0	O
albumin	albumin	NOUN	NN	0	O
could	could	VERB	MD	9	O
detect	detect	VERB	VB	9	O
regions	region	NOUN	NNS	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
underperfusion	underperfusion	NOUN	NN	5	O
resulting	result	VERB	VBG	9	O
from	from	ADP	IN	9	O
various	various	ADJ	JJ	9	O
degrees	degree	NOUN	NNS	5	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
perfusion	perfusion	NOUN	NN	5	O
defect	defect	NOUN	NN	9	O
produced	produce	VERB	VBN	9	O
in	in	ADP	IN	5	O
16	16	NUM	CD	9	O
open	open	ADJ	JJ	5	O
chest	chest	NOUN	NN	5	O
dogs	dog	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
anatomic	anatomic	ADJ	JJ	5	O
area	area	NOUN	NN	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
postmortem	postmortem	ADJ	JJ	9	O
dual	dual	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
perfusion	perfusion	NOUN	NN	5	O
technique	technique	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
thallium	thallium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
201	201	NUM	CD	7	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
photon	photon	NOUN	NN	5	O
emission	emission	NOUN	NN	0	O
tomography	tomography	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
SPECT	SPECT	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
a	a	DET	DT	5	O
transient	transient	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
s	s	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
perfusion	perfusion	NOUN	NN	5	O
defect	defect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
in	in	ADP	IN	5	O
14	14	NUM	CD	7	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
15	15	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
occlusion	occlusion	NOUN	NN	5	O
was	be	VERB	VBD	9	O
produced	produce	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
perfusion	perfusion	NOUN	NN	5	O
defect	defect	NOUN	NN	9	O
correlated	correlate	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
anatomic	anatomic	ADJ	JJ	5	O
area	area	NOUN	NN	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
74	74	NUM	CD	7	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
dipyridamole	dipyridamole	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperemia	hyperemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
16	16	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
visible	visible	ADJ	JJ	9	O
area	area	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypoperfusion	hypoperfusion	NOUN	NN	5	O
by	by	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
four	four	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
without	without	ADP	IN	9	O
a	a	DET	DT	5	O
perfusion	perfusion	NOUN	NN	5	O
defect	defect	NOUN	NN	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
stenosis	stenosis	NOUN	NN	5	O
that	that	DET	WDT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
mild	mild	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperemia	hyperemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
size	size	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
perfusion	perfusion	NOUN	NN	5	O
defect	defect	NOUN	NN	9	O
during	during	ADP	IN	5	O
stenosis	stenosis	NOUN	NN	5	O
correlated	correlate	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
anatomic	anatomic	ADJ	JJ	5	O
area	area	NOUN	NN	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
61	61	NUM	CD	7	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Thallium	Thallium	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
201	201	NUM	CD	7	O
SPECT	SPECT	PROPN	NNP	5	O
demonstrated	demonstrate	VERB	VBD	9	O
a	a	DET	DT	5	O
perfusion	perfusion	NOUN	NN	5	O
defect	defect	NOUN	NN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
14	14	NUM	CD	7	O
dogs	dog	NOUN	NNS	5	O
analyzed	analyze	VERB	VBN	9	O
during	during	ADP	IN	5	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperemia	hyperemia	NOUN	NN	5	B-Disease
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
size	size	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
perfusion	perfusion	NOUN	NN	5	O
defect	defect	NOUN	NN	9	O
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
anatomic	anatomic	ADJ	JJ	5	O
area	area	NOUN	NN	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
58	58	NUM	CD	7	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
perfusion	perfusion	NOUN	NN	5	O
defect	defect	NOUN	NN	9	O
by	by	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
58	58	NUM	CD	7	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
myocardial	myocardial	ADJ	JJ	9	O
contrast	contrast	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
visualize	visualize	VERB	VB	9	O
and	and	CCONJ	CC	5	O
quantitate	quantitate	VERB	VB	9	O
the	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
jeopardized	jeopardized	ADJ	JJ	5	O
myocardium	myocardium	NOUN	NN	9	O
during	during	ADP	IN	5	O
moderate	moderate	ADJ	JJ	9	O
to	to	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
degrees	degree	NOUN	NNS	5	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
obtained	obtain	VERB	VBD	9	O
show	show	VERB	VBP	9	O
a	a	DET	DT	5	O
correlation	correlation	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
anatomic	anatomic	ADJ	JJ	5	O
area	area	NOUN	NN	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
obtained	obtain	VERB	VBN	9	O
with	with	ADP	IN	5	O
thallium	thallium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
201	201	NUM	CD	7	O
SPECT	spect	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
receptors	receptor	NOUN	NNS	3	O
may	may	VERB	MD	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
degeneration	degeneration	NOUN	NN	9	O
of	of	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
neurons	neuron	NOUN	NNS	3	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
neuraxial	neuraxial	ADJ	JJ	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
noninjurious	noninjurious	ADJ	JJ	5	O
interval	interval	NOUN	NN	5	O
of	of	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	B-Disease
cord	cord	NOUN	NN	9	I-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
degeneration	degeneration	NOUN	NN	9	O
of	of	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
neurons	neuron	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
d	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
(	(	PUNCT	-LRB-	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
receptors	receptor	NOUN	NNS	3	O
after	after	ADP	IN	9	O
neuraxial	neuraxial	ADJ	JJ	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
noninjurious	noninjurious	ADJ	JJ	5	O
interval	interval	NOUN	NN	5	O
of	of	ADP	IN	5	O
aortic	aortic	ADJ	JJ	9	B-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Spinal	spinal	ADJ	JJ	9	B-Disease
cord	cord	NOUN	NN	9	I-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
aortic	aortic	ADJ	JJ	9	B-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
min	min	NOUN	NN	0	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
balloon	balloon	NOUN	NN	5	O
catheter	catheter	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
microdialysis	microdialysis	NOUN	NN	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
muL	mul	NOUN	NN	2	O
of	of	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
C	C	PROPN	NNP	9	O
;	;	PUNCT	:	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
30	30	NUM	CD	9	O
mug	mug	NOUN	NN	5	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
M	M	PROPN	NNP	9	O
;	;	PUNCT	:	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
intrathecally	intrathecally	ADV	RB	3	O
(	(	PUNCT	-LRB-	9	O
IT	it	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
reflow	reflow	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
mug	mug	NOUN	NN	5	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
SM	SM	PROPN	NNP	9	O
;	;	PUNCT	:	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
10	10	NUM	CD	9	O
muL	mul	NOUN	NN	2	O
of	of	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
SC	SC	PROPN	NNP	9	O
;	;	PUNCT	:	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
IT	IT	PROPN	NNP	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
sham	sham	ADJ	JJ	9	O
operation	operation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Microdialysis	microdialysis	NOUN	NN	0	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
preischemia	preischemia	ADJ	JJ	0	O
,	,	PUNCT	,	9	O
before	before	ADP	IN	9	O
IT	it	NOUN	NN	9	O
injection	injection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
24	24	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
of	of	ADP	IN	5	O
reperfusion	reperfusion	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
after	after	ADP	IN	9	O
IT	it	NOUN	NN	9	O
injection	injection	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Second	second	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
IT	IT	PROPN	NNP	9	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
mug	mug	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
histopathologic	histopathologic	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
spinal	spinal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
after	after	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
spastic	spastic	ADJ	JJ	5	B-Disease
paraparesis	paraparesis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
IT	IT	PROPN	NNP	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
cerebrospinal	cerebrospinal	ADJ	JJ	9	O
fluid	fluid	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CSF	CSF	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
M	M	PROPN	NNP	9	O
relative	relative	ADJ	JJ	9	O
to	to	ADP	IN	5	O
both	both	DET	DT	9	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
group	group	NOUN	NN	9	O
C	C	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
increase	increase	NOUN	NN	9	O
persisted	persist	VERB	VBD	9	O
for	for	ADP	IN	5	O
8	8	NUM	CD	9	O
hrs	hrs	NOUN	NN	9	O
.	.	PUNCT	.	9	O

IT	IT	PROPN	NNP	9	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
dark	dark	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
stained	stain	VERB	VBN	3	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
motoneurons	motoneuron	NOUN	NNS	3	O
after	after	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
spastic	spastic	ADJ	JJ	5	B-Disease
paraparesis	paraparesis	NOUN	NN	5	I-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
saline	saline	NOUN	NN	0	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
IT	it	NOUN	NN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
induces	induce	VERB	VBZ	3	O
spastic	spastic	ADJ	JJ	5	B-Disease
paraparesis	paraparesis	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
concomitant	concomitant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
CSF	csf	NOUN	NN	9	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
opioids	opioid	NOUN	NNS	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
setting	setting	NOUN	NN	5	O
of	of	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	B-Disease
cord	cord	NOUN	NN	9	I-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
via	via	ADP	IN	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Acute	Acute	PROPN	NNP	5	O
low	low	ADJ	JJ	9	B-Disease
back	back	ADJ	JJ	5	I-Disease
pain	pain	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Amiodarone	Amiodarone	PROPN	NNP	7	B-Chemical
represents	represent	VERB	VBZ	9	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
for	for	ADP	IN	5	O
cardioversion	cardioversion	NOUN	NN	5	O
of	of	ADP	IN	5	O
recent	recent	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
onset	onset	NOUN	NN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AF	AF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
maintenance	maintenance	NOUN	NN	9	O
of	of	ADP	IN	5	O
sinus	sinus	NOUN	NN	5	O
rhythm	rhythm	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
briefly	briefly	ADV	RB	9	O
describe	describe	VERB	VBP	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
recent	recent	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
onset	onset	NOUN	NN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
experienced	experience	VERB	VBD	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
devastating	devastating	ADJ	JJ	5	O
low	low	ADJ	JJ	9	B-Disease
back	back	ADJ	JJ	5	I-Disease
pain	pain	NOUN	NN	5	I-Disease
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
amiodarone	amiodarone	ADJ	JJ	0	B-Chemical
loading	loading	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Notably	notably	ADV	RB	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
ever	ever	ADV	RB	5	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Clinicians	clinician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
reaction	reaction	NOUN	NN	9	O
since	since	ADP	IN	9	O
prompt	prompt	ADJ	JJ	5	O
termination	termination	NOUN	NN	9	O
of	of	ADP	IN	5	O
parenteral	parenteral	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
leads	lead	VERB	VBZ	9	O
to	to	PART	TO	5	O
complete	complete	ADJ	JJ	9	O
resolution	resolution	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Quantitative	quantitative	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
stimulant	stimulant	ADJ	JJ	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
relationship	relationship	NOUN	NN	5	O
to	to	ADP	IN	5	O
symptom	symptom	NOUN	NN	5	O
severity	severity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
catecholamines	catecholamine	NOUN	NNS	9	B-Chemical
and	and	CCONJ	CC	5	O
hyperkinesia	hyperkinesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
quantitative	quantitative	ADJ	JJ	9	O
stimulant	stimulant	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
catecholamines	catecholamine	NOUN	NNS	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
psychotic	psychotic	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
nineteen	nineteen	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
emergency	emergency	NOUN	NN	5	O
service	service	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
interviewed	interview	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
for	for	ADP	IN	5	O
quantitative	quantitative	ADJ	JJ	9	O
assays	assay	NOUN	NNS	3	O
of	of	ADP	IN	5	O
stimulant	stimulant	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
catecholamine	catecholamine	NOUN	NN	9	B-Chemical
metabolite	metabolite	ADJ	JJ	0	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Methamphetamine	Methamphetamine	PROPN	NNP	7	B-Chemical
or	or	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
several	several	ADJ	JJ	9	O
psychopathology	psychopathology	NOUN	NN	5	O
scores	score	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
global	global	ADJ	JJ	5	O
hyperkinesia	hyperkinesia	ADJ	JJ	5	B-Disease
rating	rating	NOUN	NN	5	O
.	.	PUNCT	.	9	O

HVA	hva	NOUN	NN	0	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
global	global	ADJ	JJ	5	O
hyperkinesia	hyperkinesia	NOUN	NN	5	B-Disease
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
to	to	ADP	IN	5	O
psychopathology	psychopathology	NOUN	NN	5	O
ratings	rating	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
many	many	ADJ	JJ	5	O
other	other	ADJ	JJ	5	O
factors	factor	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
sensitization	sensitization	NOUN	NN	9	O
may	may	VERB	MD	5	O
play	play	VERB	VB	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
,	,	PUNCT	,	9	O
intensity	intensity	NOUN	NN	5	O
of	of	ADP	IN	5	O
stimulant	stimulant	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
psychotic	psychotic	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
stereotypies	stereotypie	NOUN	NNS	5	B-Disease
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
in	in	ADP	IN	5	O
part	part	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Pheochromocytoma	pheochromocytoma	NOUN	NN	2	B-Disease
unmasked	unmasked	ADJ	JJ	5	O
by	by	ADP	IN	9	O
amisulpride	amisulpride	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
tiapride	tiapride	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
describe	describe	VERB	VB	5	O
the	the	DET	DT	5	O
unmasking	unmasking	NOUN	NN	9	O
of	of	ADP	IN	5	O
pheochromocytoma	pheochromocytoma	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
amisulpride	amisulpride	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
tiapride	tiapride	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
42	42	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
white	white	ADJ	JJ	9	O
man	man	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
headache	headache	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
vomiting	vomit	VERB	VBG	5	B-Disease
2	2	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
amisulpride	amisulpride	NOUN	NN	5	B-Chemical
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
tiapride	tiapride	NOUN	NN	0	B-Chemical
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
immediately	immediately	ADV	RB	9	O
discontinued	discontinue	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
recovered	recover	VERB	VBN	9	O
after	after	ADP	IN	9	O
subsequent	subsequent	ADJ	JJ	9	O
nicardipine	nicardipine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
verapamil	verapamil	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Abdominal	abdominal	ADJ	JJ	7	O
ultrasound	ultrasound	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
an	an	DET	DT	5	O
adrenal	adrenal	ADJ	JJ	9	O
mass	mass	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
postoperative	postoperative	ADJ	JJ	5	O
histologic	histologic	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
confirmed	confirm	VERB	VBD	9	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
pheochromocytoma	pheochromocytoma	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
pheochromocytoma	pheochromocytoma	NOUN	NN	3	B-Disease
are	be	VERB	VBP	5	O
often	often	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
substituted	substitute	VERB	VBN	0	O
benzamide	benzamide	ADJ	JJ	0	B-Chemical
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
mechanism	mechanism	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
case	case	NOUN	NN	5	O
,	,	PUNCT	,	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Naranjo	Naranjo	PROPN	NNP	6	O
probability	probability	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
indicated	indicate	VERB	VBD	9	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
crisis	crisis	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
amisulpride	amisulpride	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
tiapride	tiapride	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
As	as	ADP	IN	9	O
of	of	ADP	IN	5	O
March	March	PROPN	NNP	2	O
24	24	NUM	CD	9	O
,	,	PUNCT	,	9	O
2005	2005	NUM	CD	2	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
reported	report	VERB	VBN	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
amisulpride	amisulpride	NOUN	NN	5	B-Chemical
-	-	PUNCT	,	7	O
and	and	CCONJ	CC	5	O
tiapride	tiapride	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
crisis	crisis	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
pheochromocytoma	pheochromocytoma	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Physicians	physician	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
healthcare	healthcare	NOUN	NN	5	O
professionals	professional	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
tiapride	tiapride	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
amisulpride	amisulpride	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Minor	minor	ADJ	JJ	9	O
neurological	neurological	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
cognitive	cognitive	ADJ	JJ	5	O
development	development	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
somatic	somatic	ADJ	JJ	9	O
development	development	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
to	to	PART	TO	5	O
7	7	NUM	CD	9	O
years	year	NOUN	NNS	5	O
after	after	ADP	IN	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
very	very	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
low	low	ADJ	JJ	9	O
birth	birth	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
weight	weight	NOUN	NN	9	O
infants	infant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
minor	minor	ADJ	JJ	9	O
neurological	neurological	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
cognitive	cognitive	ADJ	JJ	5	O
development	development	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
somatic	somatic	ADJ	JJ	9	O
development	development	NOUN	NN	9	O
after	after	ADP	IN	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
very	very	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
birthweight	birthweight	ADJ	JJ	5	O
infants	infant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
children	child	NOUN	NNS	5	O
after	after	ADP	IN	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
were	be	VERB	VBD	9	O
matched	match	VERB	VBN	9	O
to	to	ADP	IN	5	O
33	33	NUM	CD	7	O
children	child	NOUN	NNS	5	O
without	without	ADP	IN	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Dexamethasone	Dexamethasone	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
started	start	VERB	VBN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
7th	7th	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
28th	28th	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
over	over	ADP	IN	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Exclusion	exclusion	NOUN	NN	5	O
criteria	criterion	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
asphyxia	asphyxia	ADV	RB	5	B-Disease
,	,	PUNCT	,	9	O
malformations	malformation	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
major	major	ADJ	JJ	9	O
surgical	surgical	ADJ	JJ	5	O
interventions	intervention	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
small	small	ADJ	JJ	9	O
for	for	ADP	IN	5	O
gestational	gestational	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
intraventricular	intraventricular	ADJ	JJ	5	O
haemorrhage	haemorrhage	NOUN	NN	5	B-Disease
grades	grade	VERB	VBZ	5	O
III	III	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
IV	IV	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
periventricular	periventricular	ADJ	JJ	5	B-Disease
leukomalacia	leukomalacia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
psychomotor	psychomotor	NOUN	NN	5	B-Disease
retardation	retardation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Each	each	DET	DT	5	O
child	child	NOUN	NN	5	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
neuropediatrician	neuropediatrician	NOUN	NN	5	O
for	for	ADP	IN	5	O
minor	minor	ADJ	JJ	9	O
neurological	neurological	ADJ	JJ	5	B-Disease
dysfunctions	dysfunction	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
tested	test	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
psychologist	psychologist	NOUN	NN	5	O
for	for	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	O
development	development	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
Kaufman	Kaufman	PROPN	NNP	6	O
Assessment	Assessment	PROPN	NNP	5	O
Battery	Battery	PROPN	NNP	5	O
for	for	ADP	IN	5	O
Children	Children	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
Draw	draw	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
a	a	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
Man	man	NOUN	NN	2	O
Test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
demographic	demographic	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
growth	growth	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
socio	socio	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
economic	economic	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Fine	fine	ADJ	JJ	9	O
motor	motor	NOUN	NN	5	O
skills	skill	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
gross	gross	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
function	function	NOUN	NN	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
better	well	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
Draw	Draw	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
a	a	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
Man	man	NOUN	NN	2	O
Test	Test	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
better	well	ADJ	JJR	5	O
results	result	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
speech	speech	NOUN	NN	5	O
,	,	PUNCT	,	9	O
social	social	ADJ	JJ	5	O
development	development	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Kaufman	Kaufman	PROPN	NNP	6	O
Assessment	Assessment	PROPN	NNP	5	O
Battery	Battery	PROPN	NNP	5	O
for	for	ADP	IN	5	O
Children	Children	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
dexamethasone	dexamethasone	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
children	child	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
minor	minor	ADJ	JJ	9	O
neurological	neurological	ADJ	JJ	5	B-Disease
dysfunctions	dysfunction	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Neurological	neurological	ADJ	JJ	5	O
development	development	NOUN	NN	9	O
was	be	VERB	VBD	9	O
affected	affect	VERB	VBN	9	O
even	even	ADV	RB	5	O
without	without	ADP	IN	9	O
neurological	neurological	ADJ	JJ	5	O
diagnosis	diagnosis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
studies	study	NOUN	NNS	9	O
will	will	VERB	MD	5	O
be	be	VERB	VB	5	O
necessary	necessary	ADJ	JJ	5	O
to	to	PART	TO	5	O
fully	fully	ADV	RB	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
impact	impact	NOUN	NN	5	O
of	of	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
neurological	neurological	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
cognitive	cognitive	ADJ	JJ	5	O
development	development	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Valproic	Valproic	PROPN	NNP	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
I	-PRON-	PRON	PRP	9	O
:	:	PUNCT	:	9	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
biomarkers	biomarker	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
liver	liver	NOUN	NN	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
valproic	valproic	VERB	VB	0	B-Chemical
acid	acid	ADJ	JJ	0	I-Chemical
metabolite	metabolite	NOUN	NN	0	O
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
valproic	valproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
VPA	VPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
recently	recently	ADV	RB	9	O
demonstrated	demonstrate	VERB	VBN	9	O
by	by	ADP	IN	9	O
elevated	elevated	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
F	f	NOUN	NN	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2t	2t	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
isoprostane	isoprostane	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
F	f	NOUN	NN	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2t	2t	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
IsoP	IsoP	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
temporal	temporal	ADJ	JJ	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
adult	adult	NOUN	NN	9	O
male	male	NOUN	NN	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
ip	ip	PRON	PRP	0	O
with	with	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
vehicle	vehicle	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
once	once	ADV	RB	5	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
determining	determine	VERB	VBG	9	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
F	f	NOUN	NN	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2t	2t	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
IsoP	IsoP	PROPN	NNP	0	I-Chemical
,	,	PUNCT	,	9	O
lipid	lipid	NOUN	NN	0	B-Chemical
hydroperoxides	hydroperoxide	NOUN	NNS	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
LPO	LPO	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
thiobarbituric	thiobarbituric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
reactive	reactive	ADJ	JJ	9	I-Chemical
substances	substance	NOUN	NNS	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
TBARs	TBARs	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Plasma	Plasma	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
15	15	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
F	f	NOUN	NN	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2t	2t	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
IsoP	isop	CCONJ	CC	0	I-Chemical
were	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
reached	reach	VERB	VBN	9	O
a	a	DET	DT	5	O
plateau	plateau	NOUN	NN	9	O
after	after	ADP	IN	9	O
day	day	NOUN	NN	9	O
2	2	NUM	CD	9	O
of	of	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
.	.	PUNCT	.	9	O

Liver	Liver	PROPN	NNP	9	O
LPO	LPO	PROPN	NNP	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
elevated	elevate	VERB	VBN	9	O
until	until	ADP	IN	5	O
day	day	NOUN	NN	9	O
7	7	NUM	CD	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
-	-	ADV	RB	7	O
fold	fold	VERB	VB	9	O
versus	versus	ADP	IN	9	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
plasma	plasma	NOUN	NN	9	O
TBARs	tbar	NOUN	NNS	0	B-Chemical
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
increased	increase	VERB	VBN	9	O
until	until	ADP	IN	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
fold	fold	VERB	VB	9	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glutathione	glutathione	VERB	VBN	0	B-Chemical
S	s	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
transferase	transferase	PROPN	NNP	1	O
(	(	PUNCT	-LRB-	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
GST	GST	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
histology	histology	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
GST	gst	ADJ	JJ	1	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
elevated	elevate	VERB	VBN	9	O
by	by	ADP	IN	9	O
day	day	NOUN	NN	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
corresponded	correspond	VERB	VBD	9	O
to	to	PART	TO	5	O
hepatotoxicity	hepatotoxicity	VERB	VB	9	B-Disease
as	as	ADP	IN	5	O
shown	show	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
increasing	increase	VERB	VBG	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
inflammation	inflammation	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
capsule	capsule	NOUN	NN	9	O
,	,	PUNCT	,	9	O
necrosis	necrosis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
steatosis	steatosis	NOUN	NN	9	B-Disease
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
oxidation	oxidation	NOUN	NN	0	O
metabolites	metabolite	NOUN	NNS	0	O
of	of	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
were	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
by	by	ADP	IN	9	O
day	day	NOUN	NN	9	O
14	14	NUM	CD	7	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ene	ene	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
VPA	VPA	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
E	E	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
diene	diene	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
VPA	VPA	PROPN	NNP	9	I-Chemical
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
elevated	elevate	VERB	VBN	9	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Overall	overall	ADV	RB	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
F	f	NOUN	NN	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2t	2t	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
IsoP	IsoP	PROPN	NNP	0	I-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
precedes	precede	VERB	VBZ	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
steatosis	steatosis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
elevated	elevated	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
GST	gst	ADJ	JJ	1	O
.	.	PUNCT	.	9	O

Assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
perinatal	perinatal	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
and	and	CCONJ	CC	5	O
rubella	rubella	NOUN	NN	5	B-Disease
prevention	prevention	NOUN	NN	5	O
in	in	ADP	IN	5	O
New	New	PROPN	NNP	2	O
Hampshire	Hampshire	PROPN	NNP	2	O
delivery	delivery	NOUN	NN	5	O
hospitals	hospital	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
current	current	ADJ	JJ	5	O
performance	performance	NOUN	NN	5	O
on	on	ADP	IN	5	O
recommended	recommend	VERB	VBN	5	O
perinatal	perinatal	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
and	and	CCONJ	CC	5	O
rubella	rubella	NOUN	NN	5	B-Disease
prevention	prevention	NOUN	NN	5	O
practices	practice	NOUN	NNS	5	O
in	in	ADP	IN	5	O
New	New	PROPN	NNP	2	O
Hampshire	Hampshire	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Data	datum	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
extracted	extract	VERB	VBN	9	O
from	from	ADP	IN	9	O
2021	2021	NUM	CD	7	O
paired	pair	VERB	VBN	9	O
mother	mother	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
infant	infant	NOUN	NN	5	O
records	record	NOUN	NNS	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
year	year	NOUN	NN	5	O
2000	2000	NUM	CD	9	O
birth	birth	NOUN	NN	5	O
cohort	cohort	NOUN	NN	9	O
in	in	ADP	IN	5	O
New	New	PROPN	NNP	2	O
Hampshire	Hampshire	PROPN	NNP	2	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
25	25	NUM	CD	9	O
delivery	delivery	NOUN	NN	5	O
hospitals	hospital	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Assessment	Assessment	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
:	:	PUNCT	:	9	O
prenatal	prenatal	ADJ	JJ	5	O
screening	screening	NOUN	NN	5	O
for	for	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
and	and	CCONJ	CC	5	O
rubella	rubella	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
vaccine	vaccine	NOUN	NN	5	O
birth	birth	NOUN	NN	5	O
dose	dose	NOUN	NN	9	O
to	to	ADP	IN	5	O
all	all	DET	DT	5	O
infants	infant	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
immune	immune	ADJ	JJ	3	O
globulin	globulin	NOUN	NN	9	O
to	to	ADP	IN	5	O
infants	infant	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
born	bear	VERB	VBN	5	O
to	to	PART	TO	5	O
hepatitis	hepatitis	VERB	VB	9	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
surface	surface	NOUN	NN	9	I-Chemical
antigen	antigen	NOUN	NN	3	I-Chemical
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
mothers	mother	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
rubella	rubella	NOUN	NN	5	B-Disease
immunity	immunity	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
in	in	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
hospital	hospital	NOUN	NN	5	O
postpartum	postpartum	NOUN	NN	5	O
rubella	rubella	NOUN	NN	5	B-Disease
vaccine	vaccine	NOUN	NN	5	O
to	to	ADP	IN	5	O
rubella	rubella	NOUN	NN	5	B-Disease
nonimmune	nonimmune	ADJ	JJ	3	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Prenatal	prenatal	ADJ	JJ	5	O
screening	screening	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
for	for	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
(	(	PUNCT	-LRB-	9	O
98	98	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
rubella	rubella	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
99	99	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Hepatitis	Hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
vaccine	vaccine	NOUN	NN	5	O
birth	birth	NOUN	NN	5	O
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
76	76	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
infants	infant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
infants	infant	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
born	bear	VERB	VBN	5	O
to	to	PART	TO	5	O
hepatitis	hepatitis	VERB	VB	9	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
surface	surface	NOUN	NN	9	I-Chemical
antigen	antigen	NOUN	NN	3	I-Chemical
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
mothers	mother	NOUN	NNS	5	O
also	also	ADV	RB	9	O
received	receive	VERB	VBD	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
immune	immune	ADJ	JJ	3	O
globulin	globulin	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Multivariate	multivariate	ADJ	JJ	5	O
logistic	logistic	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
month	month	NOUN	NN	5	O
of	of	ADP	IN	5	O
delivery	delivery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
infant	infant	ADJ	JJ	5	O
birth	birth	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
were	be	VERB	VBD	9	O
independent	independent	ADJ	JJ	9	O
predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
vaccination	vaccination	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
proportion	proportion	NOUN	NN	9	O
of	of	ADP	IN	5	O
infants	infant	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
vaccinated	vaccinate	VERB	VBN	9	O
in	in	ADP	IN	5	O
January	January	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
February	February	PROPN	NNP	2	O
2000	2000	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
48	48	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
67	67	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
any	any	DET	DT	5	O
other	other	ADJ	JJ	5	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
proportion	proportion	NOUN	NN	9	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
vaccinated	vaccinate	VERB	VBN	9	O
in	in	ADP	IN	5	O
December	December	PROPN	NNP	2	O
2000	2000	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
88	88	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
.	.	PUNCT	.	9	O

Women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
born	bear	VERB	VBN	5	O
between	between	ADP	IN	5	O
1971	1971	NUM	CD	2	O
and	and	CCONJ	CC	5	O
1975	1975	NUM	CD	2	O
had	have	VERB	VBD	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
rubella	rubella	NOUN	NN	5	B-Disease
nonimmunity	nonimmunity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
hospital	hospital	NOUN	NN	5	O
postpartum	postpartum	NOUN	NN	5	O
rubella	rubella	NOUN	NN	5	B-Disease
vaccine	vaccine	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
was	be	VERB	VBD	9	O
documented	document	VERB	VBN	9	O
for	for	ADP	IN	5	O
75	75	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
nonimmune	nonimmune	NOUN	NN	3	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
documents	document	VERB	VBZ	5	O
good	good	ADJ	JJ	5	O
compliance	compliance	NOUN	NN	5	O
in	in	ADP	IN	5	O
New	New	PROPN	NNP	2	O
Hampshire	Hampshire	PROPN	NNP	2	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
birthing	birth	VERB	VBG	5	O
hospitals	hospital	NOUN	NNS	5	O
with	with	ADP	IN	5	O
national	national	ADJ	JJ	5	O
guidelines	guideline	NOUN	NNS	5	O
for	for	ADP	IN	5	O
perinatal	perinatal	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
and	and	CCONJ	CC	5	O
rubella	rubella	NOUN	NN	5	B-Disease
prevention	prevention	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
highlights	highlight	VERB	VBZ	5	O
potential	potential	ADJ	JJ	9	O
areas	area	NOUN	NNS	5	O
for	for	ADP	IN	5	O
improvement	improvement	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Succinylcholine	Succinylcholine	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
masseter	masseter	NOUN	NN	5	B-Disease
muscle	muscle	NOUN	NN	9	I-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
bronchoscopic	bronchoscopic	ADJ	JJ	5	O
removal	removal	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
tracheal	tracheal	ADJ	JJ	9	O
foreign	foreign	ADJ	JJ	5	O
body	body	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Masseter	Masseter	PROPN	NNP	7	B-Disease
muscle	muscle	NOUN	NN	9	I-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
general	general	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
considered	consider	VERB	VBN	5	O
an	an	DET	DT	5	O
early	early	ADJ	JJ	9	O
warning	warning	NOUN	NN	5	O
sign	sign	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
episode	episode	NOUN	NN	5	O
of	of	ADP	IN	5	O
malignant	malignant	ADJ	JJ	3	B-Disease
hyperthermia	hyperthermia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
decision	decision	NOUN	NN	5	O
whether	whether	ADP	IN	9	O
to	to	PART	TO	5	O
continue	continue	VERB	VB	5	O
or	or	CCONJ	CC	5	O
discontinue	discontinue	VERB	VB	5	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
depends	depend	VERB	VBZ	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
urgency	urgency	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
masseter	masseter	NOUN	NN	5	B-Disease
muscle	muscle	NOUN	NN	9	I-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
masseter	masseter	NOUN	NN	5	B-Disease
muscle	muscle	NOUN	NN	9	I-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
jaw	jaw	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
steel	steel	NOUN	NN	0	I-Disease
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
Sch	Sch	PROPN	NNP	2	B-Chemical
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
during	during	ADP	IN	5	O
general	general	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
management	management	NOUN	NN	5	O
for	for	ADP	IN	5	O
rigid	rigid	ADJ	JJ	5	O
bronchoscopic	bronchoscopic	ADJ	JJ	5	O
removal	removal	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
tracheal	tracheal	ADJ	JJ	9	O
foreign	foreign	ADJ	JJ	5	O
body	body	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Anesthesia	Anesthesia	PROPN	NNP	2	O
was	be	VERB	VBD	9	O
continued	continue	VERB	VBN	9	O
uneventfully	uneventfully	ADV	RB	5	O
with	with	ADP	IN	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
while	while	ADP	IN	9	O
all	all	DET	DT	5	O
facilities	facility	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
available	available	ADJ	JJ	5	O
to	to	PART	TO	5	O
detect	detect	VERB	VB	9	O
and	and	CCONJ	CC	5	O
treat	treat	VERB	VB	5	O
malignant	malignant	ADJ	JJ	3	B-Disease
hyperthermia	hyperthermia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Dexrazoxane	dexrazoxane	NOUN	NN	0	B-Chemical
protects	protect	VERB	VBZ	3	O
against	against	ADP	IN	9	O
myelosuppression	myelosuppression	NOUN	NN	5	B-Disease
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
DNA	dna	NOUN	NN	9	O
cleavage	cleavage	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
enhancing	enhance	VERB	VBG	9	O
drugs	drug	NOUN	NNS	5	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
daunorubicin	daunorubicin	VERB	VBD	0	B-Chemical
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
anthracyclines	anthracycline	NOUN	NNS	0	B-Chemical
daunorubicin	daunorubicin	VERB	VBP	0	B-Chemical
and	and	CCONJ	CC	5	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
epipodophyllotoxin	epipodophyllotoxin	NOUN	NN	0	B-Chemical
etoposide	etoposide	NOUN	NN	3	B-Chemical
are	be	VERB	VBP	5	O
potent	potent	ADJ	JJ	3	O
DNA	dna	NOUN	NN	9	O
cleavage	cleavage	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
enhancing	enhance	VERB	VBG	9	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
oncology	oncology	NOUN	NN	5	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
myelosuppression	myelosuppression	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
limit	limit	VERB	VBP	5	O
their	-PRON-	DET	PRP$	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Dexrazoxane	Dexrazoxane	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ICRF	ICRF	PROPN	NNP	2	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
187	187	NUM	CD	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
for	for	ADP	IN	5	O
protection	protection	NOUN	NN	9	O
against	against	ADP	IN	9	O
anthracycline	anthracycline	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

EXPERIMENTAL	EXPERIMENTAL	PROPN	NNP	2	O
DESIGN	DESIGN	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Because	because	ADP	IN	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
widespread	widespread	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
hematologic	hematologic	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
following	follow	VERB	VBG	9	O
coadministration	coadministration	NOUN	NN	0	O
of	of	ADP	IN	5	O
dexrazoxane	dexrazoxane	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
these	these	DET	DT	5	O
three	three	NUM	CD	9	O
structurally	structurally	ADV	RB	9	O
different	different	ADJ	JJ	9	O
DNA	dna	NOUN	NN	9	O
cleavage	cleavage	NOUN	NN	1	O
enhancers	enhancer	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
:	:	PUNCT	:	9	O
Sensitivity	sensitivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
human	human	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
murine	murine	ADJ	JJ	3	O
blood	blood	NOUN	NN	9	O
progenitor	progenitor	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
to	to	PART	TO	5	O
etoposide	etoposide	VERB	VB	3	B-Chemical
,	,	PUNCT	,	9	O
daunorubicin	daunorubicin	VERB	VB	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
dexrazoxane	dexrazoxane	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
granulocyte	granulocyte	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
macrophage	macrophage	NOUN	NN	3	O
colony	colony	NOUN	NN	9	O
forming	form	VERB	VBG	9	O
assays	assay	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Likewise	likewise	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
B6D2F1	B6D2F1	ADJ	JJR	3	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
daunorubicin	daunorubicin	VERB	VB	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
dexrazoxane	dexrazoxane	NOUN	NN	0	B-Chemical
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
wide	wide	ADJ	JJ	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
:	:	PUNCT	:	9	O
posttreatment	posttreatment	VERB	VB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
full	full	ADJ	JJ	5	O
hematologic	hematologic	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
was	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Nontoxic	Nontoxic	PROPN	NNP	0	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
dexrazoxane	dexrazoxane	NOUN	NN	0	B-Chemical
reduced	reduce	VERB	VBN	9	O
myelosuppression	myelosuppression	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
weight	weight	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
from	from	ADP	IN	9	O
daunorubicin	daunorubicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
antagonized	antagonize	VERB	VBD	3	O
their	-PRON-	DET	PRP$	5	O
antiproliferative	antiproliferative	ADJ	JJ	3	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
colony	colony	NOUN	NN	9	O
assay	assay	NOUN	NN	3	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
dexrazoxane	dexrazoxane	VERB	VB	0	B-Chemical
neither	neither	CCONJ	CC	9	O
reduced	reduce	VERB	VBN	9	O
myelosuppression	myelosuppression	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
weight	weight	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
nor	nor	CCONJ	CC	9	O
the	the	DET	DT	5	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
cytotoxicity	cytotoxicity	NOUN	NN	3	B-Disease
from	from	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Although	although	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
findings	finding	NOUN	NNS	9	O
support	support	VERB	VBP	5	O
the	the	DET	DT	5	O
observation	observation	NOUN	NN	9	O
that	that	ADP	IN	5	O
dexrazoxane	dexrazoxane	NOUN	NN	0	B-Chemical
reduces	reduce	VERB	VBZ	9	O
neither	neither	CCONJ	CC	9	O
hematologic	hematologic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
nor	nor	CCONJ	CC	9	O
antitumor	antitumor	ADJ	JJ	3	O
activity	activity	NOUN	NN	9	O
from	from	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
clinically	clinically	ADV	RB	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
antagonism	antagonism	NOUN	NN	9	O
of	of	ADP	IN	5	O
daunorubicin	daunorubicin	ADJ	JJ	0	B-Chemical
activity	activity	NOUN	NN	9	O
raises	raise	VERB	VBZ	9	O
concern	concern	NOUN	NN	5	O
;	;	PUNCT	:	9	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
interference	interference	NOUN	NN	9	O
with	with	ADP	IN	5	O
anticancer	anticancer	NOUN	NN	0	O
efficacy	efficacy	NOUN	NN	9	O
certainly	certainly	ADV	RB	5	O
would	would	VERB	MD	5	O
call	call	VERB	VB	5	O
for	for	ADP	IN	5	O
renewed	renew	VERB	VBN	5	O
attention	attention	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
data	datum	NOUN	NNS	5	O
also	also	ADV	RB	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
dose	dose	NOUN	NN	9	O
escalation	escalation	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
perhaps	perhaps	ADV	RB	5	O
possible	possible	ADJ	JJ	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
dexrazoxane	dexrazoxane	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
metastases	metastasis	NOUN	NNS	5	B-Disease
combining	combine	VERB	VBG	5	O
dexrazoxane	dexrazoxane	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
is	be	VERB	VBZ	5	O
ongoing	ongoing	ADJ	JJ	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
improving	improve	VERB	VBG	5	O
efficacy	efficacy	NOUN	NN	9	O
without	without	ADP	IN	9	O
aggravating	aggravate	VERB	VBG	5	O
hematologic	hematologic	NOUN	NN	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

If	if	ADP	IN	5	O
successful	successful	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
represents	represent	VERB	VBZ	9	O
an	an	DET	DT	5	O
exciting	exciting	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
for	for	ADP	IN	5	O
pharmacologic	pharmacologic	ADJ	JJ	9	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
from	from	ADP	IN	9	O
cytotoxic	cytotoxic	NOUN	NN	3	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
persistence	persistence	NOUN	NN	9	O
of	of	ADP	IN	5	O
amnesia	amnesia	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
procedural	procedural	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
with	with	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
repeat	repeat	VERB	VB	9	O
and	and	CCONJ	CC	5	O
recall	recall	NOUN	NN	5	O
words	word	NOUN	NNS	5	O
presented	present	VERB	VBN	5	O
to	to	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
while	while	ADP	IN	9	O
undergoing	undergo	VERB	VBG	9	O
procedural	procedural	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
with	with	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
correlate	correlate	VERB	VB	9	O
their	-PRON-	DET	PRP$	5	O
recall	recall	NOUN	NN	5	O
with	with	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
awareness	awareness	NOUN	NN	5	O
as	as	ADP	IN	5	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
bispectral	bispectral	ADJ	JJ	5	O
index	index	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BIS	BIS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
monitoring	monitoring	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
intervention	intervention	NOUN	NN	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
consenting	consent	VERB	VBG	5	O
adult	adult	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
procedural	procedural	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
with	with	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
between	between	ADP	IN	5	O
December	December	PROPN	NNP	2	O
28	28	NUM	CD	7	O
,	,	PUNCT	,	9	O
2002	2002	NUM	CD	2	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
October	October	PROPN	NNP	2	O
31	31	NUM	CD	7	O
,	,	PUNCT	,	9	O
2003	2003	NUM	CD	2	O
.	.	PUNCT	.	9	O

BIS	BIS	PROPN	NNP	5	O
monitoring	monitoring	NOUN	NN	5	O
was	be	VERB	VBD	9	O
initiated	initiate	VERB	VBN	9	O
starting	start	VERB	VBG	9	O
3	3	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
continuing	continue	VERB	VBG	5	O
until	until	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
regained	regain	VERB	VBN	5	O
baseline	baseline	ADJ	JJ	5	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
intervals	interval	NOUN	NNS	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
procedural	procedural	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
until	until	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
regained	regain	VERB	VBD	5	O
baseline	baseline	ADJ	JJ	5	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
word	word	NOUN	NN	5	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
standardized	standardized	ADJ	JJ	5	O
list	list	NOUN	NN	5	O
was	be	VERB	VBD	9	O
read	read	VERB	VBN	5	O
aloud	aloud	ADV	RB	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
asked	ask	VERB	VBN	5	O
to	to	PART	TO	5	O
immediately	immediately	ADV	RB	9	O
repeat	repeat	VERB	VB	9	O
the	the	DET	DT	5	O
word	word	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
investigator	investigator	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
BIS	BIS	PROPN	NNP	5	O
score	score	NOUN	NN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
the	the	DET	DT	5	O
word	word	NOUN	NN	5	O
was	be	VERB	VBD	9	O
read	read	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
repeat	repeat	VERB	VB	9	O
the	the	DET	DT	5	O
word	word	NOUN	NN	5	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
asked	ask	VERB	VBN	5	O
to	to	PART	TO	5	O
state	state	VERB	VB	5	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
words	word	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
list	list	NOUN	NN	5	O
that	that	ADP	IN	5	O
he	-PRON-	PRON	PRP	5	O
or	or	CCONJ	CC	5	O
she	-PRON-	PRON	PRP	5	O
could	could	VERB	MD	9	O
recall	recall	VERB	VB	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
word	word	NOUN	NN	5	O
recalled	recall	VERB	VBD	5	O
from	from	ADP	IN	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
word	word	NOUN	NN	5	O
recalled	recall	VERB	VBD	5	O
from	from	ADP	IN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
completed	complete	VERB	VBN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Seventy	seventy	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
consenting	consent	VERB	VBG	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
;	;	PUNCT	:	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
excluded	exclude	VERB	VBN	9	O
from	from	ADP	IN	9	O
data	datum	NOUN	NNS	5	O
analysis	analysis	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
protocol	protocol	NOUN	NN	9	O
violation	violation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
procedural	procedural	ADJ	JJ	5	O
sedations	sedation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
standard	standard	ADJ	JJ	5	O
deviation	deviation	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
data	datum	NOUN	NNS	5	O
collection	collection	NOUN	NN	5	O
was	be	VERB	VBD	9	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
;	;	PUNCT	:	9	O
range	range	VERB	VB	9	O
5	5	NUM	CD	9	O
to	to	PART	TO	5	O
34	34	NUM	CD	7	O
minutes	minute	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
initial	initial	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
preprocedure	preprocedure	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
BIS	BIS	PROPN	NNP	5	O
score	score	NOUN	NN	5	O
was	be	VERB	VBD	9	O
97	97	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
;	;	PUNCT	:	9	O
range	range	VERB	VBP	9	O
92	92	NUM	CD	7	O
to	to	ADP	IN	5	O
99	99	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
lowest	low	ADJ	JJS	9	O
BIS	BIS	PROPN	NNP	5	O
score	score	NOUN	NN	5	O
occurring	occur	VERB	VBG	9	O
during	during	ADP	IN	5	O
these	these	DET	DT	5	O
procedural	procedural	ADJ	JJ	5	O
sedations	sedation	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
66	66	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
;	;	PUNCT	:	9	O
range	range	VERB	VBP	9	O
33	33	NUM	CD	7	O
to	to	PART	TO	5	O
91	91	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
lowest	low	ADJ	JJS	9	O
BIS	BIS	PROPN	NNP	5	O
score	score	NOUN	NN	5	O
corresponding	correspond	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
to	to	PART	TO	5	O
immediately	immediately	ADV	RB	9	O
repeat	repeat	VERB	VB	9	O
words	word	NOUN	NNS	5	O
read	read	VERB	VBP	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
list	list	NOUN	NN	5	O
was	be	VERB	VBD	9	O
77	77	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
74	74	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
to	to	PART	TO	5	O
80	80	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
highest	high	ADJ	JJS	9	O
BIS	BIS	PROPN	NNP	5	O
score	score	NOUN	NN	5	O
corresponding	correspond	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
inability	inability	NOUN	NN	9	B-Disease
to	to	PART	TO	5	I-Disease
repeat	repeat	VERB	VB	9	I-Disease
words	word	NOUN	NNS	5	I-Disease
was	be	VERB	VBD	9	O
81	81	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	PROPN	NNP	7	O
78	78	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
84	84	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
BIS	BIS	PROPN	NNP	5	O
score	score	NOUN	NN	5	O
corresponding	correspond	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
word	word	NOUN	NN	5	O
recalled	recall	VERB	VBD	5	O
from	from	ADP	IN	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sedation	sedation	NOUN	NN	5	O
was	be	VERB	VBD	9	O
96	96	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
;	;	PUNCT	:	9	O
range	range	VERB	VBP	9	O
84	84	NUM	CD	7	O
to	to	PART	TO	5	O
98	98	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
BIS	BIS	PROPN	NNP	5	O
score	score	NOUN	NN	5	O
corresponding	correspond	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
word	word	NOUN	NN	5	O
recalled	recall	VERB	VBD	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
completed	complete	VERB	VBN	5	O
was	be	VERB	VBD	9	O
91	91	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
=	=	NOUN	NNS	7	O
88	88	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
94	94	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
recalled	recall	VERB	VBD	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
one	one	NUM	CD	5	O
word	word	NOUN	NN	5	O
that	that	DET	WDT	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
read	read	VERB	VBN	5	O
to	to	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
protocol	protocol	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
lowest	low	ADJ	JJS	9	O
BIS	BIS	PROPN	NNP	5	O
score	score	NOUN	NN	5	O
for	for	ADP	IN	5	O
any	any	DET	DT	5	O
recalled	recalled	ADJ	JJ	5	O
word	word	NOUN	NN	5	O
was	be	VERB	VBD	9	O
91	91	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
;	;	PUNCT	:	9	O
range	range	VERB	VB	9	O
79	79	NUM	CD	7	O
to	to	PART	TO	5	O
98	98	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
words	word	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
recalled	recall	VERB	VBN	5	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
corresponding	correspond	VERB	VBG	9	O
BIS	BIS	PROPN	NNP	5	O
score	score	NOUN	NN	5	O
was	be	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
90	90	NUM	CD	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
BIS	BIS	PROPN	NNP	5	O
scores	score	NOUN	NNS	5	O
during	during	ADP	IN	5	O
which	which	DET	WDT	5	O
sedated	sedate	VERB	VBN	5	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
repeat	repeat	VERB	VB	9	O
words	word	NOUN	NNS	5	O
read	read	VERB	VBN	5	O
to	to	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
but	but	CCONJ	CC	9	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
subsequently	subsequently	ADV	RB	9	O
recall	recall	VERB	VB	5	O
these	these	DET	DT	5	O
words	word	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
recall	recall	NOUN	NN	5	O
of	of	ADP	IN	5	O
words	word	NOUN	NNS	5	O
repeated	repeat	VERB	VBN	5	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
procedural	procedural	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
in	in	ADP	IN	5	O
BIS	BIS	PROPN	NNP	5	O
ranges	range	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
recall	recall	NOUN	NN	5	O
after	after	ADP	IN	9	O
procedural	procedural	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
suggestive	suggestive	NOUN	NN	9	O
of	of	ADP	IN	5	O
retrograde	retrograde	NOUN	NN	5	B-Disease
amnesia	amnesia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Amiodarone	amiodarone	ADJ	JJ	7	B-Chemical
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Amiodarone	Amiodarone	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
whose	whose	DET	WP$	9	O
utility	utility	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
limited	limit	VERB	VBN	5	O
by	by	ADP	IN	9	O
many	many	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
problematic	problematic	ADJ	JJ	5	O
being	be	VERB	VBG	5	O
pneumonitis	pneumonitis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
thought	think	VERB	VBN	5	O
to	to	PART	TO	5	O
result	result	VERB	VB	9	O
from	from	ADP	IN	9	O
direct	direct	ADJ	JJ	9	O
injury	injury	NOUN	NN	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
intracellular	intracellular	ADJ	JJ	3	O
accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
phospholipid	phospholipid	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
T	T	PROPN	NNP	3	O
cell	cell	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
pneumonitis	pneumonitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
radiographic	radiographic	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
are	be	VERB	VBP	5	O
characteristic	characteristic	ADJ	JJ	9	O
but	but	CCONJ	CC	9	O
nonspecific	nonspecific	ADJ	JJ	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
depends	depend	VERB	VBZ	5	O
on	on	ADP	IN	5	O
exclusion	exclusion	NOUN	NN	5	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
entities	entity	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
infection	infection	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
malignancy	malignancy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
leads	lead	NOUN	NNS	9	O
to	to	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
majority	majority	NOUN	NN	9	O
of	of	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
always	always	ADV	RB	5	O
possible	possible	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
advisable	advisable	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Dose	dose	NOUN	NN	0	O
reduction	reduction	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
concomitant	concomitant	ADJ	JJ	9	O
steroid	steroid	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
selected	select	VERB	VBN	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
prodrugs	prodrug	NOUN	NNS	0	O
of	of	ADP	IN	5	O
potent	potent	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
selective	selective	ADJ	JJ	9	O
GluR5	GluR5	PROPN	NNP	3	O
kainate	kainate	NOUN	NN	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	VERB	VBZ	3	O
actives	active	VERB	VBZ	5	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
animal	animal	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Amino	amino	ADJ	JJ	0	O
acids	acid	NOUN	NNS	0	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
potent	potent	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
selective	selective	ADJ	JJ	9	O
competitive	competitive	ADJ	JJ	9	O
GluR5	GluR5	PROPN	NNP	3	O
KA	KA	PROPN	NNP	9	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
exhibited	exhibit	VERB	VBN	9	O
high	high	ADJ	JJ	9	O
GluR5	GluR5	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
affinity	affinity	NOUN	NN	0	O
over	over	ADP	IN	5	O
other	other	ADJ	JJ	5	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Their	-PRON-	DET	PRP$	5	O
ester	ester	NOUN	NN	0	O
prodrugs	prodrug	VERB	VBZ	0	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
were	be	VERB	VBD	9	O
orally	orally	ADV	RB	0	O
active	active	ADJ	JJ	9	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
formalin	formalin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
paw	paw	PRON	PRP	5	O
licking	lick	VERB	VBG	5	O
,	,	PUNCT	,	9	O
carrageenan	carrageenan	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
thermal	thermal	ADJ	JJ	9	B-Disease
hyperalgesia	hyperalgesia	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
mechanical	mechanical	ADJ	JJ	5	B-Disease
hyperalgesia	hyperalgesia	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
azithromycin	azithromycin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
hiccups	hiccup	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
hiccups	hiccup	NOUN	NNS	5	B-Disease
associated	associate	VERB	VBN	9	O
by	by	ADP	IN	9	O
azithromycin	azithromycin	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
76	76	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
hiccups	hiccup	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
beginning	begin	VERB	VBG	5	O
azithromycin	azithromycin	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
pharyngitis	pharyngitis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Hiccups	hiccup	NOUN	NNS	7	B-Disease
were	be	VERB	VBD	9	O
persistent	persistent	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
exhausting	exhausting	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
azithromycin	azithromycin	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
baclofen	baclofen	NOUN	NNS	0	B-Chemical
finally	finally	ADV	RB	9	O
resolved	resolve	VERB	VBN	9	O
hiccups	hiccup	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
organic	organic	ADJ	JJ	0	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
hiccups	hiccup	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
despite	despite	ADP	IN	9	O
extensive	extensive	ADJ	JJ	5	O
investigation	investigation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Pharmacotherapeutic	pharmacotherapeutic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
uncommonly	uncommonly	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
hiccups	hiccup	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Corticosteroids	corticosteroid	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
dexamethasone	dexamethasone	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
methylprednisolone	methylprednisolone	ADJ	JJ	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
benzodiazepines	benzodiazepine	NOUN	NNS	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
general	general	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
the	the	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
mentioned	mention	VERB	VBD	5	O
most	most	ADV	RBS	9	O
frequently	frequently	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
as	as	ADP	IN	5	O
being	be	VERB	VBG	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
hiccups	hiccup	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Few	few	ADJ	JJ	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hiccups	hiccup	NOUN	NNS	5	B-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
related	related	ADJ	JJ	9	O
to	to	ADP	IN	5	O
macrolide	macrolide	NOUN	NN	9	B-Chemical
antimicrobials	antimicrobial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
Naranjo	Naranjo	PROPN	NNP	6	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
reaction	reaction	NOUN	NN	9	O
probability	probability	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
this	this	DET	DT	5	O
event	event	NOUN	NN	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
classified	classify	VERB	VBN	5	O
as	as	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
score	score	NOUN	NN	5	O
5	5	NUM	CD	9	O
points	point	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
mostly	mostly	ADV	RB	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
close	close	ADJ	JJ	5	O
temporal	temporal	ADJ	JJ	5	O
sequence	sequence	NOUN	NN	1	O
,	,	PUNCT	,	9	O
previous	previous	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
on	on	ADP	IN	5	O
this	this	DET	DT	5	O
reaction	reaction	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
macrolides	macrolide	NOUN	NNS	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
alternative	alternative	ADJ	JJ	5	O
explanation	explanation	NOUN	NN	5	O
for	for	ADP	IN	5	O
hiccups	hiccup	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
hypothesis	hypothesis	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
vagal	vagal	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
azithromycin	azithromycin	NOUN	NN	9	B-Chemical
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
hiccups	hiccup	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Diagnosis	diagnosis	NOUN	NN	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hiccups	hiccup	NOUN	NNS	5	B-Disease
is	be	VERB	VBZ	5	O
difficult	difficult	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
often	often	ADV	RB	5	O
achieved	achieve	VERB	VBN	5	O
only	only	ADV	RB	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
process	process	NOUN	NN	5	O
of	of	ADP	IN	5	O
elimination	elimination	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
macrolide	macrolide	NOUN	NN	9	B-Chemical
antimicrobials	antimicrobial	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
hiccups	hiccup	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
vagal	vagal	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
could	could	VERB	MD	9	O
explain	explain	VERB	VB	9	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Calcium	calcium	NOUN	NN	0	B-Chemical
carbonate	carbonate	NOUN	NN	0	I-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
updated	update	VERB	VBN	5	O
milk	milk	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
alkali	alkali	ADJ	JJ	0	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
;	;	PUNCT	:	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
describe	describe	VERB	VB	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
carbonate	carbonate	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
gain	gain	VERB	VB	5	O
insights	insight	NOUN	NNS	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
milk	milk	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
alkali	alkali	ADJ	JJ	0	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
data	datum	NOUN	NNS	5	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
presented	present	VERB	VBD	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
corrected	correct	VERB	VBN	5	O
serum	serum	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
14	14	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
review	review	VERB	VB	5	O
the	the	DET	DT	5	O
pertinent	pertinent	ADJ	JJ	5	O
literature	literature	NOUN	NN	5	O
on	on	ADP	IN	5	O
milk	milk	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
alkali	alkali	ADJ	JJ	0	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
relative	relative	ADJ	JJ	9	O
metabolic	metabolic	ADJ	JJ	9	B-Disease
alkalosis	alkalosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
parathyroid	parathyroid	ADJ	JJ	9	O
hormone	hormone	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PTH	PTH	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
PTH	PTH	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
peptide	peptide	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
25	25	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroxyvitamin	dihydroxyvitamin	NOUN	NN	0	I-Chemical
D	d	NOUN	NN	9	I-Chemical
concentrations	concentration	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
malignant	malignant	ADJ	JJ	3	O
lesion	lesion	NOUN	NN	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
included	include	VERB	VBD	5	O
aggressive	aggressive	ADJ	JJ	5	O
hydration	hydration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
varied	varied	ADJ	JJ	9	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
furosemide	furosemide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
higher	high	ADJ	JJR	9	O
serum	serum	NOUN	NN	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
received	receive	VERB	VBN	9	O
pamidronate	pamidronate	ADJ	JJ	0	B-Chemical
intravenously	intravenously	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
caused	cause	VERB	VBD	9	O
severe	severe	ADJ	JJ	5	O
hypocalcemia	hypocalcemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
were	be	VERB	VBD	9	O
ingesting	ingest	VERB	VBG	5	O
acceptable	acceptable	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
elemental	elemental	ADJ	JJ	0	O
calcium	calcium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
g	g	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
carbonate	carbonate	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
highlighted	highlight	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
review	review	VERB	VBP	5	O
the	the	DET	DT	5	O
history	history	NOUN	NN	5	O
,	,	PUNCT	,	9	O
classification	classification	NOUN	NN	5	O
,	,	PUNCT	,	9	O
pathophysiologic	pathophysiologic	NOUN	NN	5	O
features	feature	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
milk	milk	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
alkali	alkali	ADJ	JJ	0	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
summarize	summarize	VERB	VBP	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
reported	report	VERB	VBN	9	O
from	from	ADP	IN	9	O
early	early	ADJ	JJ	9	O
1995	1995	NUM	CD	2	O
to	to	ADP	IN	5	O
November	November	PROPN	NNP	2	O
2003	2003	NUM	CD	2	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Milk	milk	NOUN	NN	7	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
alkali	alkali	ADJ	JJ	0	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
unexplained	unexplained	ADJ	JJ	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
precipitated	precipitate	VERB	VBN	0	O
by	by	ADP	IN	9	O
small	small	ADJ	JJ	9	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
orally	orally	ADV	RB	0	O
ingested	ingest	VERB	VBN	0	O
calcium	calcium	NOUN	NN	0	B-Chemical
carbonate	carbonate	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
susceptible	susceptible	ADJ	JJ	9	O
persons	person	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
hydration	hydration	NOUN	NN	0	O
,	,	PUNCT	,	9	O
furosemide	furosemide	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	NOUN	NN	9	I-Chemical
source	source	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
adequate	adequate	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Pamidronate	pamidronate	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
considerable	considerable	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
hypocalcemia	hypocalcemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
in	in	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
initially	initially	ADV	RB	9	O
severe	severe	ADJ	JJ	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
leukocytoclastic	leukocytoclastic	ADJ	JJ	5	B-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Skin	skin	NOUN	NN	9	O
reactions	reaction	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
coumarin	coumarin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
derived	derive	VERB	VBN	9	O
anticoagulants	anticoagulant	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
an	an	DET	DT	5	O
uncommon	uncommon	ADJ	JJ	5	O
occurrence	occurrence	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Leukocytoclastic	leukocytoclastic	ADJ	JJ	5	B-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
LV	LV	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
primarily	primarily	ADV	RB	9	O
a	a	DET	DT	5	O
cutaneous	cutaneous	ADJ	JJ	5	B-Disease
small	small	ADJ	JJ	9	I-Disease
vessel	vessel	NOUN	NN	5	I-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
though	though	ADP	IN	9	O
systemic	systemic	ADJ	JJ	9	O
involvement	involvement	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
encountered	encounter	VERB	VBN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
late	late	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
onset	onset	NOUN	NN	5	O
LV	LV	PROPN	NNP	9	B-Disease
probably	probably	ADV	RB	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
skin	skin	NOUN	NN	5	B-Disease
eruptions	eruption	NOUN	NNS	5	I-Disease
that	that	DET	WDT	5	O
developed	develop	VERB	VBD	5	O
after	after	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
several	several	ADJ	JJ	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
skin	skin	NOUN	NN	5	B-Disease
lesion	lesion	NOUN	NN	5	I-Disease
biopsies	biopsy	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
available	available	ADJ	JJ	5	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
confirming	confirm	VERB	VBG	9	O
LV	LV	PROPN	NNP	9	B-Disease
Cutaneous	Cutaneous	PROPN	NNP	5	I-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
resolved	resolve	VERB	VBD	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
after	after	ADP	IN	9	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
2	2	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
rechallenge	rechallenge	NOUN	NN	3	O
with	with	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lesions	lesion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

LV	LV	PROPN	NNP	9	B-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
late	late	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
onset	onset	NOUN	NN	5	O
adverse	adverse	ADJ	JJ	5	O
reaction	reaction	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
brainstem	brainstem	NOUN	NN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
behavior	behavior	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
abnormal	abnormal	ADJ	JJ	9	O
sensory	sensory	ADJ	JJ	5	O
/	/	SYM	SYM	9	O
motor	motor	NOUN	NN	5	O
behaviors	behavior	NOUN	NNS	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
electrical	electrical	ADJ	JJ	5	O
discharges	discharge	NOUN	NNS	5	O
recorded	record	VERB	VBN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
bilateral	bilateral	ADJ	JJ	5	O
brainstem	brainstem	NOUN	NN	5	O
were	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
WKY	wky	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
by	by	ADP	IN	9	O
mechanical	mechanical	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
electrode	electrode	NOUN	NN	5	O
implants	implant	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
DC	DC	PROPN	NNP	3	O
electrical	electrical	ADJ	JJ	5	O
current	current	ADJ	JJ	5	O
stimulations	stimulation	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
acute	acute	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
electrode	electrode	NOUN	NN	5	O
implant	implant	NOUN	NN	5	O
implicated	implicate	VERB	VBD	9	O
one	one	NUM	CD	5	O
side	side	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
reticular	reticular	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
brainstem	brainstem	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
incapacitated	incapacitate	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
stimulations	stimulation	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Cocaine	Cocaine	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
subcutaneously	subcutaneously	ADV	RB	3	O
for	for	ADP	IN	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
experiment	experiment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
doses	dose	VERB	VBZ	0	O
twice	twice	ADV	RB	9	O
daily	daily	ADJ	JJ	5	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cocaine	cocaine	NOUN	NN	5	B-Chemical
generated	generate	VERB	VBD	9	O
more	more	ADV	RBR	5	O
abnormal	abnormal	ADJ	JJ	9	O
behaviors	behavior	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brainstem	brainstem	NOUN	NN	5	O
perturbation	perturbation	NOUN	NN	5	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
the	the	DET	DT	5	O
electrically	electrically	ADV	RB	5	O
perturbated	perturbate	VERB	VBN	5	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
abnormal	abnormal	ADJ	JJ	9	O
behaviors	behavior	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
yawning	yawn	VERB	VBG	5	O
,	,	PUNCT	,	9	O
retrocollis	retrocollis	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
"	"	PUNCT	''	5	O
beating	beat	VERB	VBG	5	O
drum	drum	NOUN	NN	5	O
"	"	PUNCT	''	5	O
behavior	behavior	NOUN	NN	5	O
,	,	PUNCT	,	9	O
squealing	squealing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
head	head	NOUN	NN	5	O
bobbing	bob	VERB	VBG	5	O
,	,	PUNCT	,	9	O
circling	circle	VERB	VBG	5	O
,	,	PUNCT	,	9	O
sniffing	sniffing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
abnormal	abnormal	ADJ	JJ	9	O
posturing	posturing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
facial	facial	ADJ	JJ	5	O
twitching	twitching	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Shifts	shift	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
power	power	NOUN	NN	5	O
frequency	frequency	NOUN	NN	5	O
spectra	spectra	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
discharge	discharge	NOUN	NN	5	O
patterns	pattern	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
between	between	ADP	IN	5	O
quiet	quiet	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
pacing	pace	VERB	VBG	5	O
behavioral	behavioral	ADJ	JJ	5	O
states	state	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
to	to	ADP	IN	5	O
various	various	ADJ	JJ	9	O
auditory	auditory	NOUN	NN	5	O
,	,	PUNCT	,	9	O
tactile	tactile	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
visual	visual	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
shifts	shift	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brainstem	brainstem	NOUN	NN	5	O
ambient	ambient	ADJ	JJ	5	O
power	power	NOUN	NN	5	O
spectral	spectral	ADJ	JJ	5	O
frequency	frequency	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	PART	TO	5	O
tactile	tactile	VERB	VB	5	O
stimulation	stimulation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
brainstem	brainstem	NOUN	NN	5	O
generates	generate	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
propagates	propagate	VERB	VBZ	5	O
pathological	pathological	ADJ	JJ	5	O
discharges	discharge	NOUN	NNS	5	O
that	that	DET	WDT	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
elicited	elicit	VERB	VBN	9	O
by	by	ADP	IN	9	O
mechanical	mechanical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
DC	DC	PROPN	NNP	3	O
electrical	electrical	ADJ	JJ	5	O
perturbation	perturbation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cocaine	Cocaine	PROPN	NNP	5	B-Chemical
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
activate	activate	VERB	VB	3	O
the	the	DET	DT	5	O
discharge	discharge	NOUN	NN	5	O
system	system	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
thus	thus	ADV	RB	9	O
induce	induce	VERB	VB	3	O
abnormal	abnormal	ADJ	JJ	9	O
behaviors	behavior	NOUN	NNS	5	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
generated	generate	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
discharge	discharge	ADJ	JJ	5	O
site	site	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
distant	distant	ADJ	JJ	5	O
sites	site	NOUN	NNS	9	O
to	to	PART	TO	5	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
discharge	discharge	ADJ	JJ	5	O
propagates	propagate	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cognitive	cognitive	ADJ	JJ	5	O
functions	function	NOUN	NNS	9	O
may	may	VERB	MD	5	O
also	also	ADV	RB	9	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
since	since	ADP	IN	9	O
dopaminergic	dopaminergic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
serotonergic	serotonergic	ADJ	JJ	5	O
cellular	cellular	ADJ	JJ	3	O
elements	element	NOUN	NNS	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
brainstem	brainstem	NOUN	NN	5	O
level	level	NOUN	NN	9	O
are	be	VERB	VBP	5	O
also	also	ADV	RB	9	O
implicated	implicate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

rTMS	rtms	NOUN	NN	5	O
of	of	ADP	IN	5	O
supplementary	supplementary	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
area	area	NOUN	NN	5	O
modulates	modulate	NOUN	NNS	9	O
therapy	therapy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
neural	neural	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
circuitry	circuitry	NOUN	NN	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
repetitive	repetitive	ADJ	JJ	5	O
transcranial	transcranial	ADJ	JJ	5	O
magnetic	magnetic	ADJ	JJ	0	O
stimulation	stimulation	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
rTMS	rTMS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
supplementary	supplementary	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
area	area	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
SMA	SMA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
investigated	investigate	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
SMA	SMA	PROPN	NNP	9	O
excitability	excitability	NOUN	NN	5	O
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
modification	modification	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
dyskinetic	dyskinetic	ADJ	JJ	5	B-Disease
state	state	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
continuous	continuous	ADJ	JJ	5	O
apomorphine	apomorphine	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

rTMS	rtms	NOUN	NN	5	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
Hz	Hz	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
to	to	PART	TO	5	O
markedly	markedly	ADV	RB	9	O
reduce	reduce	VERB	VB	5	O
drug	drug	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
induced	induce	VERB	VBN	3	I-Disease
dyskinesias	dyskinesia	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	:	7	O
Hz	Hz	PROPN	NNP	5	O
rTMS	rtms	NOUN	NN	5	O
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
slight	slight	ADJ	JJ	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Intracavitary	intracavitary	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
liquid	liquid	ADJ	JJ	0	O
crystalline	crystalline	ADJ	JJ	0	O
cubic	cubic	ADJ	JJ	5	O
phases	phase	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
glioblastoma	glioblastoma	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
clinical	clinical	ADJ	JJ	5	O
observations	observation	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Human	human	ADJ	JJ	9	O
malignant	malignant	ADJ	JJ	3	O
brain	brain	NOUN	NN	5	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
poor	poor	ADJ	JJ	5	O
prognosis	prognosis	NOUN	NN	5	O
in	in	ADP	IN	5	O
spite	spite	NOUN	NN	9	O
of	of	ADP	IN	5	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
radiation	radiation	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cubic	cubic	ADJ	JJ	0	O
phases	phase	NOUN	NNS	5	O
consist	consist	VERB	VBP	5	O
of	of	ADP	IN	5	O
curved	curve	VERB	VBN	5	O
biocontinuous	biocontinuous	ADJ	JJ	_	O
lipid	lipid	NOUN	NN	0	O
bilayers	bilayer	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
separating	separate	VERB	VBG	9	O
two	two	NUM	CD	5	O
congruent	congruent	ADJ	JJ	5	O
networks	network	NOUN	NNS	5	O
of	of	ADP	IN	5	O
water	water	NOUN	NN	0	O
channels	channel	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Used	use	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
host	host	NOUN	NN	9	O
for	for	ADP	IN	5	O
cytotoxic	cytotoxic	NOUN	NN	3	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
gel	gel	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
matrix	matrix	NOUN	NN	5	O
can	can	VERB	MD	5	O
easily	easily	ADV	RB	5	O
be	be	VERB	VB	5	O
applied	apply	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
walls	wall	NOUN	NNS	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
surgical	surgical	ADJ	JJ	5	O
resection	resection	NOUN	NN	5	O
cavity	cavity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
human	human	ADJ	JJ	3	O
glioblastoma	glioblastoma	NOUN	NN	3	B-Disease
recurrences	recurrence	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
feasibility	feasibility	NOUN	NN	5	O
,	,	PUNCT	,	9	O
safety	safety	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
surgical	surgical	ADJ	JJ	5	O
intracavitary	intracavitary	ADJ	JJ	5	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
encapsulated	encapsulate	VERB	VBN	0	O
by	by	ADP	IN	9	O
liquid	liquid	ADJ	JJ	0	O
crystalline	crystalline	ADJ	JJ	0	O
cubic	cubic	ADJ	JJ	5	O
phases	phase	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
pilot	pilot	NOUN	NN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
glioblastoma	glioblastoma	NOUN	NN	3	B-Disease
multiforme	multiforme	NOUN	NN	9	O
underwent	underwent	NOUN	NN	5	O
re	re	NOUN	NN	5	O
-	-	NOUN	NN	7	O
resection	resection	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
received	receive	VERB	VBD	9	O
an	an	DET	DT	5	O
intracavitary	intracavitary	ADJ	JJ	5	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
carboplatin	carboplatin	ADJ	JJ	0	B-Chemical
cubic	cubic	ADJ	JJ	5	O
phases	phase	NOUN	NNS	5	O
in	in	ADP	IN	5	O
different	different	ADJ	JJ	9	O
dosages	dosage	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
suffered	suffer	VERB	VBD	5	O
from	from	ADP	IN	9	O
moderate	moderate	ADJ	JJ	9	O
to	to	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
brain	brain	NOUN	NN	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
only	only	ADV	RB	9	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
brain	brain	NOUN	NN	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
dealt	deal	VERB	VBD	5	O
medically	medically	ADV	RB	5	O
.	.	PUNCT	.	9	O

Intracavitary	intracavitary	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
glioblastoma	glioblastoma	NOUN	NN	3	B-Disease
using	use	VERB	VBG	9	O
cubic	cubic	ADJ	JJ	5	O
phases	phase	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
feasible	feasible	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
safe	safe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
yet	yet	CCONJ	CC	9	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
benefit	benefit	NOUN	NN	5	O
remains	remain	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lamotrigine	Lamotrigine	PROPN	NNP	0	B-Chemical
associated	associate	VERB	VBD	9	O
with	with	ADP	IN	5	O
exacerbation	exacerbation	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
de	de	X	FW	2	O
novo	novo	NOUN	NN	9	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
generalized	generalize	VERB	VBN	5	I-Disease
epilepsies	epilepsy	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
generalized	generalize	VERB	VBN	5	I-Disease
epilepsies	epilepsy	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
IGE	IGE	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
lamotrigine	lamotrigine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
LTG	LTG	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
experienced	experience	VERB	VBN	5	O
exacerbation	exacerbation	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
de	de	X	FW	2	O
novo	novo	NOUN	NN	9	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
myoclonic	myoclonic	ADJ	JJ	5	B-Disease
jerks	jerk	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MJ	MJ	PROPN	NNP	2	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
LTG	LTG	PROPN	NNP	0	B-Chemical
exacerbated	exacerbate	VERB	VBD	9	O
MJ	MJ	PROPN	NNP	2	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
with	with	ADP	IN	5	O
early	early	ADJ	JJ	9	O
aggravation	aggravation	NOUN	NN	5	O
during	during	ADP	IN	5	O
titration	titration	NOUN	NN	0	O
.	.	PUNCT	.	9	O

MJ	MJ	PROPN	NNP	2	B-Disease
disappeared	disappear	VERB	VBD	9	O
when	when	ADV	WRB	5	O
LTG	LTG	PROPN	NNP	0	B-Chemical
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
by	by	ADP	IN	9	O
25	25	NUM	CD	9	O
to	to	PART	TO	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
LTG	LTG	PROPN	NNP	0	B-Chemical
exacerbated	exacerbate	VERB	VBD	9	O
MJ	MJ	PROPN	NNP	2	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
delayed	delay	VERB	VBN	9	O
but	but	CCONJ	CC	9	O
more	more	ADV	RBR	5	O
severe	severe	ADJ	JJ	5	O
manner	manner	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
myoclonic	myoclonic	ADJ	JJ	5	B-Disease
status	status	NOUN	NN	9	I-Disease
that	that	DET	WDT	5	O
only	only	ADV	RB	9	O
ceased	cease	VERB	VBD	5	O
after	after	ADP	IN	9	O
LTG	LTG	PROPN	NNP	0	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Absence	absence	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
cerebral	cerebral	ADJ	JJ	5	O
vasoconstriction	vasoconstriction	NOUN	NN	9	O
after	after	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
subarachnoid	subarachnoid	NOUN	NN	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

INTRODUCTION	INTRODUCTION	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
Cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
neurovascular	neurovascular	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
arterial	arterial	ADJ	JJ	5	O
vasoconstriction	vasoconstriction	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
few	few	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
angiographic	angiographic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
human	human	ADJ	JJ	3	O
cerebral	cerebral	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Information	information	NOUN	NN	5	O
on	on	ADP	IN	5	O
these	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
obtained	obtain	VERB	VBN	9	O
from	from	ADP	IN	9	O
angiograms	angiogram	NOUN	NNS	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
subarachnoid	subarachnoid	NOUN	NN	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SAH	SAH	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
angiography	angiography	NOUN	NN	5	O
shortly	shortly	ADV	RB	9	O
after	after	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
screened	screen	VERB	VBD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
SAH	SAH	PROPN	NNP	9	B-Disease
retrospectively	retrospectively	ADV	RB	5	O
and	and	CCONJ	CC	5	O
identified	identify	VERB	VBD	9	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
positive	positive	ADJ	JJ	9	O
urine	urine	NOUN	NN	9	O
toxicology	toxicology	NOUN	NN	5	O
for	for	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
metabolites	metabolite	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Quantitative	quantitative	ADJ	JJ	9	O
arterial	arterial	ADJ	JJ	5	O
diameter	diameter	NOUN	NN	9	O
measurements	measurement	NOUN	NNS	5	O
from	from	ADP	IN	9	O
angiograms	angiogram	NOUN	NNS	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
measurements	measurement	NOUN	NNS	5	O
from	from	ADP	IN	9	O
control	control	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
SAH	SAH	PROPN	NNP	9	B-Disease
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
matched	match	VERB	VBN	9	O
for	for	ADP	IN	5	O
factors	factor	NOUN	NNS	9	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
influence	influence	VERB	VB	5	O
arterial	arterial	ADJ	JJ	5	O
diameter	diameter	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Qualitative	qualitative	ADJ	JJ	5	O
comparisons	comparison	NOUN	NNS	5	O
of	of	ADP	IN	5	O
small	small	ADJ	JJ	9	O
artery	artery	NOUN	NN	5	O
changes	change	NOUN	NNS	9	O
also	also	ADV	RB	9	O
were	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Thirteen	thirteen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
positive	positive	ADJ	JJ	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
toxicology	toxicology	NOUN	NN	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
26	26	NUM	CD	7	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
diameters	diameter	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
intradural	intradural	ADJ	JJ	5	O
internal	internal	ADJ	JJ	5	O
carotid	carotid	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sphenoidal	sphenoidal	NOUN	NN	5	O
segment	segment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
middle	middle	ADJ	JJ	9	O
cerebral	cerebral	NOUN	NN	5	O
,	,	PUNCT	,	9	O
precommunicating	precommunicate	VERB	VBG	9	O
segment	segment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anterior	anterior	ADJ	JJ	5	O
cerebral	cerebral	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
basilar	basilar	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
for	for	ADP	IN	5	O
all	all	DET	DT	5	O
comparisons	comparison	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
unpaired	unpaired	ADJ	JJ	9	O
t	t	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
tests	test	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
also	also	ADV	RB	9	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
when	when	ADV	WRB	5	O
expressing	express	VERB	VBG	3	O
diameters	diameter	NOUN	NNS	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
sum	sum	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
precommunicating	precommunicate	VERB	VBG	9	O
segment	segment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anterior	anterior	ADJ	JJ	5	O
cerebral	cerebral	NOUN	NN	5	O
+	+	CCONJ	CC	9	O
sphenoidal	sphenoidal	NOUN	NN	5	O
segment	segment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
middle	middle	ADJ	JJ	9	O
cerebral	cerebral	NOUN	NN	5	O
+	+	CCONJ	CC	9	O
supraclinoid	supraclinoid	ADJ	JJ	5	O
internal	internal	ADJ	JJ	5	O
carotid	carotid	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
+	+	CCONJ	CC	9	O
basilar	basilar	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
divided	divide	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
diameter	diameter	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
petrous	petrous	ADJ	JJ	5	O
internal	internal	ADJ	JJ	5	O
carotid	carotid	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
,	,	PUNCT	,	9	O
unpaired	unpaired	ADJ	JJ	9	O
t	t	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
tests	test	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Qualitative	qualitative	ADJ	JJ	5	O
assessments	assessment	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
two	two	NUM	CD	5	O
arterial	arterial	ADJ	JJ	5	O
irregularities	irregularity	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
distal	distal	ADJ	JJ	9	O
vasculature	vasculature	NOUN	NN	5	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
No	no	DET	DT	9	O
quantitative	quantitative	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
narrowing	narrow	VERB	VBG	5	O
of	of	ADP	IN	5	O
large	large	ADJ	JJ	5	O
cerebral	cerebral	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
qualitative	qualitative	ADJ	JJ	5	O
angiographic	angiographic	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
distal	distal	ADJ	JJ	9	O
narrowing	narrowing	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
angiography	angiography	ADV	RB	5	O
after	after	ADP	IN	9	O
aneurysmal	aneurysmal	ADJ	JJ	5	B-Disease
SAH	SAH	PROPN	NNP	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Methamphetamine	Methamphetamine	PROPN	NNP	7	B-Chemical
causes	cause	VERB	VBZ	9	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
MAP	MAP	PROPN	NNP	9	O
kinase	kinase	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
pathways	pathway	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brains	brain	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
that	that	DET	WDT	5	O
display	display	VERB	VBP	9	O
increased	increase	VERB	VBN	9	O
aggressiveness	aggressiveness	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Aggressive	aggressive	ADJ	JJ	5	B-Disease
behaviors	behavior	NOUN	NNS	5	I-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
suffer	suffer	VERB	VBP	5	O
from	from	ADP	IN	9	O
some	some	DET	DT	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
are	be	VERB	VBP	5	O
common	common	ADJ	JJ	5	O
in	in	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
METH	METH	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
abusers	abuser	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Herein	Herein	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
report	report	VERB	VBP	5	O
that	that	ADP	IN	5	O
multiple	multiple	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
single	single	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
aggressiveness	aggressiveness	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
CD	cd	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
aggressiveness	aggressiveness	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
using	use	VERB	VBG	9	O
antibody	antibody	NOUN	NN	3	O
microarrays	microarray	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
Western	western	ADJ	JJ	3	O
blotting	blotting	NOUN	NN	3	O
revealed	reveal	VERB	VBD	9	O
differential	differential	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
MAP	MAP	PROPN	NNP	9	O
kinase	kinase	NUM	CD	3	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
pathways	pathway	NOUN	NNS	9	O
after	after	ADP	IN	9	O
multiple	multiple	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
single	single	ADJ	JJ	9	O
METH	METH	PROPN	NNP	9	B-Chemical
injections	injection	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
decreases	decrease	VERB	VBZ	9	O
in	in	ADP	IN	5	O
MEK1	MEK1	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
Erk2p	Erk2p	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
GSK3alpha	GSK3alpha	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
3e	3e	NUM	CD	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
MEK7	MEK7	PROPN	NNP	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striata	striata	NOUN	NN	4	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
after	after	ADP	IN	9	O
multiple	multiple	ADJ	JJ	5	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

MEK1	MEK1	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
also	also	ADV	RB	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
much	much	ADV	RB	5	O
lesser	less	ADJ	JJR	9	O
degree	degree	NOUN	NN	5	O
than	than	ADP	IN	5	O
after	after	ADP	IN	9	O
multiple	multiple	ADJ	JJ	5	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
frontal	frontal	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
GSK3alpha	GSK3alpha	PROPN	NNP	_	O
after	after	ADP	IN	9	O
multiple	multiple	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
single	single	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
MAP	MAP	PROPN	NNP	9	O
kinase	kinase	NUM	CD	3	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
pathways	pathway	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prefronto	prefronto	NOUN	NN	_	O
-	-	PUNCT	HYPH	7	O
striatal	striatal	ADJ	JJ	3	O
circuitries	circuitry	NOUN	NNS	5	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
manifestation	manifestation	NOUN	NN	5	O
of	of	ADP	IN	5	O
aggressive	aggressive	ADJ	JJ	5	B-Disease
behaviors	behavior	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Amisulpride	amisulpride	ADP	IN	0	B-Chemical
related	related	ADJ	JJ	9	O
tic	tic	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
adolescent	adolescent	NOUN	NN	5	O
schizophrenic	schizophrenic	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Tic	tic	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
effectively	effectively	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
atypical	atypical	ADJ	JJ	5	O
antipsychotics	antipsychotic	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
ziprasidone	ziprasidone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
two	two	NUM	CD	5	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
that	that	DET	WDT	5	O
show	show	VERB	VBP	9	O
tic	tic	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
motor	motor	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
phonic	phonic	ADJ	JJ	5	O
variants	variant	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
occurring	occur	VERB	VBG	9	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
girl	girl	NOUN	NN	5	O
schizophrenic	schizophrenic	NOUN	NN	5	B-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
frequent	frequent	ADJ	JJ	5	O
involuntary	involuntary	ADJ	JJ	5	B-Disease
eye	eye	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
blinking	blink	VERB	VBG	5	I-Disease
movements	movement	NOUN	NNS	5	I-Disease
after	after	ADP	IN	9	O
5	5	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
amisulpride	amisulpride	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1000	1000	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
tic	tic	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
resolved	resolve	VERB	VBN	9	O
completely	completely	ADV	RB	9	O
after	after	ADP	IN	9	O
we	-PRON-	PRON	PRP	5	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
amisulpride	amisulpride	NOUN	NN	5	B-Chemical
down	down	ADP	IN	9	O
to	to	ADP	IN	5	O
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
her	-PRON-	DET	PRP$	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
recurred	recur	VERB	VBD	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
then	then	ADV	RB	9	O
placed	place	VERB	VBD	5	O
her	-PRON-	PRON	PRP	5	O
on	on	ADP	IN	5	O
an	an	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
in	in	ADP	IN	5	O
complete	complete	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
combined	combine	VERB	VBN	9	O
medications	medication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
maintains	maintain	VERB	VBZ	9	O
a	a	DET	DT	5	O
fair	fair	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
more	more	ADV	RBR	5	O
tic	tic	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
tic	tic	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
might	may	VERB	MD	9	O
occur	occur	VERB	VB	5	O
in	in	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
vulnerable	vulnerable	ADJ	JJ	5	O
individuals	individual	NOUN	NNS	5	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
atypical	atypical	ADJ	JJ	5	O
antipsychotics	antipsychotic	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
amisulpride	amisulpride	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Chloroquine	Chloroquine	PROPN	NNP	0	B-Chemical
related	relate	VERB	VBD	9	O
complete	complete	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
block	block	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
blindness	blindness	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
27	27	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
African	african	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
regular	regular	ADJ	JJ	5	O
chloroquine	chloroquine	NOUN	NN	0	B-Chemical
ingestion	ingestion	NOUN	NN	9	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	O
deterioration	deterioration	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
vision	vision	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
easy	easy	ADJ	JJ	5	O
fatiguability	fatiguability	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
dyspnoea	dyspnoea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
dizziness	dizziness	NOUN	NN	5	B-Disease
progressing	progressing	NOUN	NN	5	O
to	to	ADP	IN	5	O
syncopal	syncopal	ADJ	JJ	5	B-Disease
attacks	attack	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Ophthalmological	ophthalmological	ADJ	JJ	2	O
assessment	assessment	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
chloroquine	chloroquine	NOUN	NN	0	B-Chemical
retinopathy	retinopathy	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
block	block	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
right	right	ADJ	JJ	5	B-Disease
bundle	bundle	NOUN	NN	5	I-Disease
branch	branch	NOUN	NN	5	I-Disease
block	block	NOUN	NN	9	I-Disease
pattern	pattern	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
heart	heart	NOUN	NN	5	B-Disease
block	block	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
pacemaker	pacemaker	NOUN	NN	5	O
insertion	insertion	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
resolved	resolve	VERB	VBD	9	O
spontaneously	spontaneously	ADV	RB	5	O
following	follow	VERB	VBG	9	O
chloroquine	chloroquine	NOUN	NN	0	B-Chemical
discontinuation	discontinuation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
however	however	ADV	RB	9	O
remains	remain	VERB	VBZ	9	O
blind	blind	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
suprofen	suprofen	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
isolated	isolate	VERB	VBN	9	O
perfused	perfused	ADJ	JJ	0	O
rat	rat	NOUN	NN	3	O
kidney	kidney	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
suprofen	suprofen	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
100	100	NUM	CD	0	O
subjects	subject	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
damage	damage	NOUN	NN	9	O
remains	remain	VERB	VBZ	9	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
suprofen	suprofen	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
recirculating	recirculating	NOUN	NN	0	O
isolated	isolate	VERB	VBN	9	O
rat	rat	NOUN	NN	3	O
kidney	kidney	NOUN	NN	9	O
perfused	perfuse	VERB	VBN	0	O
with	with	ADP	IN	5	O
cell	cell	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
buffer	buffer	NOUN	NN	0	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
the	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	NOUN	NNS	7	O
of	of	ADP	IN	5	O
uric	uric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
excretion	excretion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
urinary	urinary	ADJ	JJ	9	O
flow	flow	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
in	in	ADP	IN	5	O
kidneys	kidney	NOUN	NNS	9	O
perfused	perfuse	VERB	VBN	0	O
with	with	ADP	IN	5	O
suprofen	suprofen	NOUN	NN	0	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decline	decline	NOUN	NN	9	O
in	in	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
introduction	introduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
suprofen	suprofen	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
perfused	perfuse	VERB	VBN	0	O
with	with	ADP	IN	5	O
uric	uric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
;	;	PUNCT	:	9	O
no	no	DET	DT	9	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
with	with	ADP	IN	5	O
suprofen	suprofen	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
uric	uric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
baseline	baseline	ADJ	JJ	5	O
excretion	excretion	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
uric	uric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
suprofen	suprofen	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
fractional	fractional	ADJ	JJ	5	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
uric	uric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
groups	group	NOUN	NNS	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
summary	summary	NOUN	NN	9	O
,	,	PUNCT	,	9	O
suprofen	suprofen	ADJ	JJ	0	B-Chemical
causes	cause	VERB	VBZ	9	O
acute	acute	ADJ	JJ	9	B-Disease
declines	decline	NOUN	NNS	9	I-Disease
in	in	ADP	IN	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
most	most	ADV	RBS	9	O
likely	likely	ADJ	JJ	5	O
by	by	ADP	IN	9	O
directly	directly	ADV	RB	9	O
altering	alter	VERB	VBG	9	O
the	the	DET	DT	5	O
intrarenal	intrarenal	ADJ	JJ	5	O
distribution	distribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
uric	uric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Microinjection	microinjection	NOUN	NN	3	O
of	of	ADP	IN	5	O
ritanserin	ritanserin	NOUN	NN	0	B-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
CA1	CA1	PROPN	NNPS	3	O
region	region	NOUN	NN	9	O
of	of	ADP	IN	5	O
hippocampus	hippocampus	NOUN	NN	9	O
improves	improve	VERB	VBZ	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
ritanserin	ritanserin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HT2	ht2	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
muscarinic	muscarinic	ADJ	JJ	3	O
cholinergic	cholinergic	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
Morris	Morris	PROPN	NNP	6	O
water	water	NOUN	NN	0	O
maze	maze	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MWM	MWM	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
eight	eight	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
bilaterally	bilaterally	ADV	RB	5	O
cannulated	cannulate	VERB	VBN	5	O
into	into	ADP	IN	9	O
CA1	CA1	PROPN	NNPS	3	O
region	region	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
received	receive	VERB	VBD	9	O
repeatedly	repeatedly	ADV	RB	5	O
vehicles	vehicle	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
DMSO	DMSO	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
saline	saline	NOUN	NN	0	O
+	+	CCONJ	CC	9	O
DMSO	DMSO	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
saline	saline	NOUN	NN	0	O
/	/	SYM	SYM	9	O
side	side	NOUN	NN	5	O
;	;	PUNCT	:	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
training	training	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
ritanserin	ritanserin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
DMSO	DMSO	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
side	side	NOUN	NN	5	O
;	;	PUNCT	:	9	O
20	20	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
training	training	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
;	;	PUNCT	:	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
ritanserin	ritanserin	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
+	+	CCONJ	CC	9	O
ritanserin	ritanserin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
DMSO	DMSO	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
through	through	ADP	IN	9	O
cannulae	cannulae	NOUN	NN	5	O
each	each	DET	DT	5	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
for	for	ADP	IN	5	O
four	four	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
trial	trial	NOUN	NN	5	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
MWM	MWM	PROPN	NNP	5	O
during	during	ADP	IN	5	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
position	position	NOUN	NN	9	O
of	of	ADP	IN	5	O
hidden	hidden	ADJ	JJ	5	O
platform	platform	NOUN	NN	5	O
was	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
fifth	fifth	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
platform	platform	NOUN	NN	5	O
was	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
above	above	ADP	IN	9	O
the	the	DET	DT	5	O
water	water	NOUN	NN	0	O
surface	surface	NOUN	NN	9	O
in	in	ADP	IN	5	O
another	another	DET	DT	9	O
position	position	NOUN	NN	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
,	,	PUNCT	,	9	O
motivational	motivational	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
visual	visual	ADJ	JJ	5	O
systems	system	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
escape	escape	NOUN	NN	5	O
latencies	latency	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
traveled	travel	VERB	VBD	5	O
distances	distance	NOUN	NNS	5	O
to	to	PART	TO	5	O
find	find	VERB	VB	5	O
platform	platform	NOUN	NN	5	O
in	in	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
saline	saline	VERB	VB	0	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Ritanserin	ritanserin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
/	/	SYM	SYM	9	O
side	side	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mentioned	mention	VERB	VBN	5	O
parameters	parameter	NOUN	NNS	5	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
DMSO	DMSO	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
scopolamine	scopolamine	VERB	VB	0	B-Chemical
and	and	CCONJ	CC	5	O
ritanserin	ritanserin	NOUN	NN	0	B-Chemical
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
escape	escape	NOUN	NN	5	O
latencies	latency	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
traveled	travel	VERB	VBD	5	O
distances	distance	NOUN	NNS	5	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
findings	finding	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
microinjection	microinjection	NOUN	NN	3	O
of	of	ADP	IN	5	O
ritanserin	ritanserin	NOUN	NN	0	B-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
CA1	CA1	PROPN	NNPS	3	O
region	region	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
improves	improve	VERB	VBZ	5	O
the	the	DET	DT	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

PTU	ptu	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
girl	girl	NOUN	NN	5	O
with	with	ADP	IN	5	O
Turner	Turner	PROPN	NNP	6	B-Disease
Syndrome	Syndrome	PROPN	NNP	5	I-Disease
and	and	CCONJ	CC	5	O
Graves	Graves	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Palpable	palpable	ADJ	JJ	7	O
purpura	purpura	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
concerning	concern	VERB	VBG	5	O
clinical	clinical	ADJ	JJ	5	O
finding	finding	NOUN	NN	9	O
in	in	ADP	IN	5	O
pediatric	pediatric	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
can	can	VERB	MD	5	O
have	have	VERB	VB	5	O
many	many	ADJ	JJ	5	O
causes	cause	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
infectious	infectious	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
autoimmune	autoimmune	ADJ	JJ	3	O
processes	process	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
rare	rare	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
,	,	PUNCT	,	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
antineutrophil	antineutrophil	NOUN	NN	3	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
antibodies	antibody	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
ANCAs	ANCAs	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
girl	girl	NOUN	NN	5	O
with	with	ADP	IN	5	O
Turner	Turner	PROPN	NNP	6	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
Graves	Graves	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
presented	present	VERB	VBD	5	O
with	with	ADP	IN	5	O
palpable	palpable	ADJ	JJ	5	O
purpuric	purpuric	NOUN	NN	5	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PTU	PTU	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
by	by	ADP	IN	9	O
observation	observation	NOUN	NN	9	O
of	of	ADP	IN	5	O
consistent	consistent	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
elevated	elevated	ADJ	JJ	9	O
ANA	ANA	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
ANCA	ANCA	PROPN	NNP	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
observed	observed	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
following	follow	VERB	VBG	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
PTU	PTU	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Subsequent	subsequent	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
hyperthyroidism	hyperthyroidism	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
radioablation	radioablation	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
exacerbation	exacerbation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
complication	complication	NOUN	NN	5	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Daidzein	daidzein	NOUN	NN	0	B-Chemical
activates	activate	VERB	VBZ	3	O
choline	choline	NOUN	NN	0	B-Chemical
acetyltransferase	acetyltransferase	NOUN	NN	1	O
from	from	ADP	IN	9	O
MC	MC	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
IXC	IXC	PROPN	NNP	_	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
improves	improve	VERB	VBZ	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
choline	choline	NOUN	NN	0	B-Chemical
acetyltransferase	acetyltransferase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
ChAT	ChAT	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
activator	activator	NOUN	NN	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
enhances	enhance	VERB	VBZ	3	O
cholinergic	cholinergic	NOUN	NN	3	O
transmission	transmission	NOUN	NN	5	O
via	via	ADP	IN	9	O
an	an	DET	DT	5	O
augmentation	augmentation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
enzymatic	enzymatic	ADJ	JJ	0	O
production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ACh	ACh	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AD	ad	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Methanolic	methanolic	NOUN	NN	4	O
extracts	extract	NOUN	NNS	0	O
from	from	ADP	IN	9	O
Pueraria	Pueraria	PROPN	NNP	4	O
thunbergiana	thunbergiana	NOUN	NNS	0	O
exhibited	exhibit	VERB	VBD	9	O
an	an	DET	DT	5	O
activation	activation	NOUN	NN	3	O
effect	effect	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
46	46	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
ChAT	ChAT	PROPN	NNP	3	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Via	via	ADP	IN	2	O
the	the	DET	DT	5	O
sequential	sequential	ADJ	JJ	5	O
isolation	isolation	NOUN	NN	9	O
of	of	ADP	IN	5	O
Pueraria	Pueraria	PROPN	NNP	4	O
thunbergiana	thunbergiana	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
active	active	ADJ	JJ	9	O
component	component	NOUN	NN	9	O
was	be	VERB	VBD	9	O
ultimately	ultimately	ADV	RB	5	O
identified	identify	VERB	VBN	9	O
as	as	ADP	IN	5	O
daidzein	daidzein	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	B-Chemical
'	'	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
7	7	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroxy	dihydroxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
isoflavone	isoflavone	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
daidzein	daidzein	NOUN	NN	0	B-Chemical
from	from	ADP	IN	9	O
Pueraria	Pueraria	PROPN	NNP	4	O
thunbergiana	thunbergiana	NOUN	NNS	0	O
on	on	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
impairments	impairment	NOUN	NNS	5	B-Disease
of	of	ADP	IN	5	I-Disease
learning	learning	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
daidzein	daidzein	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
shown	show	VERB	VBN	9	O
significantly	significantly	ADV	RB	9	O
to	to	PART	TO	5	O
reverse	reverse	VERB	VB	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
Y	Y	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
maze	maze	NOUN	NN	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
into	into	ADP	IN	9	O
mice	mouse	NOUN	NNS	3	O
resulted	result	VERB	VBN	9	O
in	in	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	O
performance	performance	NOUN	NN	5	O
on	on	ADP	IN	5	O
Y	Y	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
maze	maze	PROPN	NNP	5	O
tests	test	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
a	a	DET	DT	5	O
37	37	NUM	CD	9	O
%	%	NOUN	NN	9	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
alternation	alternation	NOUN	NN	5	O
behavior	behavior	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
way	way	NOUN	NN	5	O
of	of	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mice	mouse	NOUN	NNS	3	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
daidzein	daidzein	NOUN	NN	0	B-Chemical
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
injections	injection	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
noticeably	noticeably	ADV	RB	9	O
protected	protect	VERB	VBN	9	O
from	from	ADP	IN	9	O
this	this	DET	DT	5	O
performance	performance	NOUN	NN	5	O
impairment	impairment	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
an	an	DET	DT	5	O
approximately	approximately	ADV	RB	9	O
12	12	NUM	CD	9	O
%	%	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
alternation	alternation	NOUN	NN	5	O
behavior	behavior	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
daidzein	daidzein	NOUN	NN	0	B-Chemical
might	may	VERB	MD	9	O
play	play	VERB	VB	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
biosynthesis	biosynthesis	NOUN	NN	0	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
ChAT	ChAT	PROPN	NNP	3	O
activator	activator	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
ameliorates	ameliorate	VERB	VBZ	3	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Urinary	urinary	NOUN	NN	9	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
Thai	thai	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
overactive	overactive	ADJ	JJ	5	B-Disease
bladder	bladder	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
tolterodine	tolterodine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
urinary	urinary	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
Thai	thai	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
overactive	overactive	ADJ	JJ	5	B-Disease
bladder	bladder	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
OAB	OAB	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
tolterodine	tolterodine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

MATERIAL	MATERIAL	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Thirty	thirty	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
aged	age	VERB	VBN	9	O
30	30	NUM	CD	9	O
-	-	SYM	SYM	7	O
77	77	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
diagnosed	diagnose	VERB	VBN	5	O
as	as	ADP	IN	5	O
having	have	VERB	VBG	5	O
OAB	OAB	PROPN	NNP	5	B-Disease
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
Gynecology	Gynecology	PROPN	NNP	2	O
Clinic	Clinic	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
King	King	PROPN	NNP	6	O
Chulalongkorn	Chulalongkorn	PROPN	NNP	2	O
Memorial	Memorial	PROPN	NNP	6	O
Hospital	Hospital	PROPN	NNP	2	O
from	from	ADP	IN	9	O
January	January	PROPN	NNP	2	O
to	to	ADP	IN	5	O
April	April	PROPN	NNP	2	O
2004	2004	NUM	CD	2	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Tolterodine	Tolterodine	PROPN	NNP	0	B-Chemical
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
twice	twice	ADV	RB	9	O
daily	daily	ADV	RB	5	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
micturition	micturition	NOUN	NN	5	O
diary	diary	NOUN	NN	5	O
variables	variable	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Short	short	ADJ	JJ	5	O
form	form	NOUN	NN	9	O
36	36	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
SF36	SF36	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
questionaires	questionaire	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
Thai	thai	ADJ	JJ	5	O
version	version	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
At	at	ADP	IN	9	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
micturition	micturition	NOUN	NN	5	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
from	from	ADP	IN	9	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O

7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O

3	3	NUM	CD	9	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O

7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
times	time	NOUN	NNS	5	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
nocturia	nocturia	NOUN	NN	5	B-Disease
episodes	episode	NOUN	NNS	5	O
decreased	decrease	VERB	VBD	9	O
from	from	ADP	IN	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
times	time	NOUN	NNS	5	O
per	per	ADP	IN	9	O
night	night	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
dry	dry	ADJ	JJ	0	B-Disease
month	month	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
2	2	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
reporting	report	VERB	VBG	5	O
a	a	DET	DT	5	O
moderate	moderate	ADJ	JJ	9	O
degree	degree	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
case	case	NOUN	NN	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
degree	degree	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
withdrew	withdraw	VERB	VBD	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
dry	dry	ADJ	JJ	0	B-Disease
mouth	mouth	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
SF	SF	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
36	36	NUM	CD	9	O
scores	score	NOUN	NNS	5	O
changed	change	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
domains	domain	NOUN	NNS	1	O
of	of	ADP	IN	5	O
physical	physical	ADJ	JJ	5	O
functioning	functioning	NOUN	NN	5	O
,	,	PUNCT	,	9	O
role	role	NOUN	NN	9	O
function	function	NOUN	NN	9	O
emotional	emotional	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
social	social	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
mental	mental	ADJ	JJ	5	O
heath	heath	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Tolterodine	Tolterodine	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
effects	effect	NOUN	NNS	9	O
improved	improve	VERB	VBD	5	O
the	the	DET	DT	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
in	in	ADP	IN	5	O
Thai	Thai	PROPN	NNP	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
OAB	OAB	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Remifentanil	remifentanil	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
reduces	reduce	VERB	VBZ	9	O
myoclonus	myoclonus	ADV	RB	5	B-Disease
after	after	ADP	IN	9	O
etomidate	etomidate	VERB	VBP	5	B-Chemical
.	.	PUNCT	.	9	O

STUDY	study	NOUN	NN	2	O
OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
1	1	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
gender	gender	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
anesthesia	anesthesia	ADJ	JJ	5	O
induction	induction	NOUN	NN	3	O
with	with	ADP	IN	5	O
etomidate	etomidate	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

SETTING	setting	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
university	university	NOUN	NN	5	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Sixty	sixty	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
pretreated	pretreate	VERB	VBN	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blinded	blinded	ADJ	JJ	5	O
fashion	fashion	NOUN	NN	5	O
with	with	ADP	IN	5	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
1	1	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
injection	injection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
etomidate	etomidate	VERB	VB	5	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	PROPN	NNP	0	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
.	.	PUNCT	.	9	O

MEASUREMENTS	measurement	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Myoclonus	myoclonus	NOUN	NN	7	B-Disease
was	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
scale	scale	NOUN	NN	5	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
grade	grade	NOUN	NN	9	O
of	of	ADP	IN	5	O
sedation	sedation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
none	none	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mild	mild	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
moderate	moderate	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
severe	severe	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
pruritus	pruritus	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
apnea	apnea	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

MAIN	main	ADJ	JJ	2	O
RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
70	70	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
sedation	sedation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
apnea	apnea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
pruritus	pruritus	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
male	male	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
etomidate	etomidate	VERB	VBP	5	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Pretreatment	pretreatment	NOUN	NN	3	O
with	with	ADP	IN	5	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
1	1	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	ADP	IN	0	O
reduced	reduce	VERB	VBN	9	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
etomidate	etomidate	VERB	VBP	5	B-Chemical
induction	induction	NOUN	NN	3	O
without	without	ADP	IN	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
sedation	sedation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
apnea	apnea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
pruritus	pruritus	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Men	men	NOUN	NN	7	O
experience	experience	NOUN	NN	5	O
increased	increase	VERB	VBN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
than	than	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
after	after	ADP	IN	9	O
etomidate	etomidate	VERB	VBP	5	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Memory	memory	NOUN	NN	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
transporter	transporter	NOUN	NN	1	O
promoter	promoter	NOUN	NN	1	O
gene	gene	NOUN	NN	1	O
polymorphism	polymorphism	NOUN	NN	9	O
in	in	ADP	IN	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
3	3	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylenedioxymethamphetamine	methylenedioxymethamphetamine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
or	or	CCONJ	CC	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
damage	damage	NOUN	NN	9	O
brain	brain	NOUN	NN	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
possibly	possibly	ADV	RB	9	O
humans	human	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
little	little	ADJ	JJ	9	O
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
consequences	consequence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	ht	NOUN	NN	9	I-Chemical
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
on	on	ADP	IN	5	O
functions	function	NOUN	NNS	9	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
transporters	transporter	NOUN	NNS	1	O
play	play	VERB	VBP	9	O
a	a	DET	DT	5	O
key	key	ADJ	JJ	9	O
element	element	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
synaptic	synaptic	ADJ	JJ	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
transmission	transmission	NOUN	NN	5	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
important	important	ADJ	JJ	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
covariance	covariance	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
polymorphism	polymorphism	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
transporter	transporter	NOUN	NN	1	O
promoter	promoter	NOUN	NN	1	O
gene	gene	NOUN	NN	1	O
region	region	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HTTLPR	HTTLPR	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
when	when	ADV	WRB	5	O
studying	study	VERB	VBG	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	O
functioning	functioning	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
moderate	moderate	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
heavy	heavy	ADJ	JJ	9	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
use	use	NOUN	NN	5	O
on	on	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
abstention	abstention	NOUN	NN	5	O
from	from	ADP	IN	9	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
genotyped	genotype	VERB	VBN	9	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HTTLPR	httlpr	NOUN	NN	1	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
second	second	ADJ	JJ	9	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
these	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
differ	differ	VERB	VBP	9	O
for	for	ADP	IN	5	O
females	female	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
males	male	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Fifteen	fifteen	NUM	CD	9	O
moderate	moderate	ADJ	JJ	9	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
users	user	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
55	55	NUM	CD	7	O
lifetime	lifetime	NOUN	NN	5	O
tablets	tablet	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
22	22	NUM	CD	7	O
heavy	heavy	ADJ	JJ	9	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
+	+	CCONJ	CC	9	O
users	user	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
55	55	NUM	CD	7	O
lifetime	lifetime	NOUN	NN	5	O
tablets	tablet	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
16	16	NUM	CD	9	O
ex	ex	NOUN	NN	9	O
-	-	ADJ	JJ	7	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
+	+	CCONJ	CC	9	O
users	user	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
last	last	ADJ	JJ	5	O
tablet	tablet	NOUN	NN	0	O
>	>	X	XX	0	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
ago	ago	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
13	13	NUM	CD	7	O
controls	control	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
battery	battery	NOUN	NN	5	O
of	of	ADP	IN	5	O
neuropsychological	neuropsychological	ADJ	JJ	5	O
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

DNA	dna	NOUN	NN	9	O
from	from	ADP	IN	9	O
peripheral	peripheral	ADJ	JJ	9	O
nuclear	nuclear	ADJ	JJ	3	O
blood	blood	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
genotyped	genotype	VERB	VBN	9	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HTTLPR	httlpr	NOUN	NN	1	O
using	use	VERB	VBG	9	O
standard	standard	ADJ	JJ	5	O
polymerase	polymerase	NOUN	NN	1	O
chain	chain	NOUN	NN	9	O
reaction	reaction	NOUN	NN	9	O
methods	method	NOUN	NNS	5	O
.	.	PUNCT	.	9	O
A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
only	only	ADV	RB	9	O
on	on	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
function	function	NOUN	NN	9	O
tasks	task	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
on	on	ADP	IN	5	O
reaction	reaction	NOUN	NN	9	O
times	time	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
61	61	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
attention	attention	NOUN	NN	5	O
/	/	SYM	SYM	9	O
executive	executive	NOUN	NN	5	O
functioning	functioning	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
59	59	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Heavy	heavy	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
ex	ex	PROPN	NNP	9	O
-	-	ADJ	JJ	7	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
+	+	CCONJ	CC	9	O
users	user	NOUN	NNS	5	O
performed	perform	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
poorer	poorer	ADV	RBR	5	O
on	on	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
tasks	task	NOUN	NNS	5	O
than	than	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
memory	memory	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
moderate	moderate	ADJ	JJ	9	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HTTLPR	HTTLPR	PROPN	NNP	1	O
or	or	CCONJ	CC	5	O
gender	gender	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
in	in	ADP	IN	5	O
quantities	quantity	NOUN	NNS	9	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
"	"	PUNCT	``	5	O
moderate	moderate	ADJ	JJ	9	O
"	"	PUNCT	''	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
memory	memory	NOUN	NN	5	I-Disease
functioning	functioning	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
heavy	heavy	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
use	use	NOUN	NN	5	O
may	may	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
long	long	ADJ	JJ	5	O
lasting	last	VERB	VBG	5	O
memory	memory	NOUN	NN	5	B-Disease
impairments	impairment	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HTTLPR	HTTLPR	PROPN	NNP	1	O
or	or	CCONJ	CC	5	O
gender	gender	NOUN	NN	5	O
on	on	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
function	function	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
use	use	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
mangiferin	mangiferin	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
biochemical	biochemical	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
antioxidant	antioxidant	ADJ	JJ	0	O
status	status	NOUN	NN	9	O
in	in	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
dealt	deal	VERB	VBD	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
mangiferin	mangiferin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
polyphenol	polyphenol	NOUN	NN	0	B-Chemical
from	from	ADP	IN	9	O
Mangifera	Mangifera	PROPN	NNP	4	O
indica	indica	NOUN	NN	4	O
Linn	Linn	PROPN	NNP	4	O
.	.	PUNCT	.	9	O

(	(	PUNCT	-LRB-	9	O
Anacardiaceae	Anacardiaceae	PROPN	NNP	4	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ISPH	ISPH	PROPN	NNP	7	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MI	MI	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
through	through	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
antioxidative	antioxidative	ADJ	JJ	0	O
mechanism	mechanism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Subcutaneous	subcutaneous	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
ISPH	ISPH	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
saline	saline	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
caused	cause	VERB	VBD	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
heart	heart	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
lactate	lactate	NOUN	NN	0	B-Chemical
dehydrogenase	dehydrogenase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
LDH	LDH	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
creatine	creatine	NOUN	NN	0	B-Chemical
phosphokinase	phosphokinase	NOUN	NN	0	O
isoenzymes	isoenzyme	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
CK	CK	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MB	MB	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBN	9	O
uric	uric	ADJ	JJ	0	B-Chemical
acid	acid	ADJ	JJ	0	I-Chemical
level	level	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
reduced	reduced	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
iron	iron	NOUN	NN	0	B-Chemical
binding	bind	VERB	VBG	1	O
capacity	capacity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
mangiferin	mangiferin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
by	by	ADP	IN	9	O
triphenyl	triphenyl	NOUN	NN	0	B-Chemical
tetrazolium	tetrazolium	NOUN	NN	0	I-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
TTC	TTC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
test	test	NOUN	NN	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
macroscopic	macroscopic	ADJ	JJ	5	O
enzyme	enzyme	ADJ	JJ	0	O
mapping	mapping	NOUN	NN	5	O
assay	assay	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
myocardium	myocardium	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
tissue	tissue	NOUN	NN	9	O
antioxidant	antioxidant	NOUN	NN	0	O
enzymes	enzyme	VERB	VBZ	1	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
dismutase	dismutase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
catalase	catalase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
glutathione	glutathione	ADJ	JJ	0	B-Chemical
peroxidase	peroxidase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
glutathione	glutathione	ADJ	JJ	0	B-Chemical
transferase	transferase	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
glutathione	glutathione	NOUN	NN	0	B-Chemical
reductase	reductase	NOUN	NN	0	O
activities	activity	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
enzymic	enzymic	ADJ	JJ	0	O
antioxidants	antioxidant	NOUN	NNS	0	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
cerruloplasmin	cerruloplasmin	NOUN	NN	9	O
,	,	PUNCT	,	9	O
Vitamin	Vitamin	PROPN	NNP	0	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
Vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
glutathione	glutathione	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
altered	alter	VERB	VBN	9	O
in	in	ADP	IN	5	O
MI	MI	PROPN	NNP	9	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Upon	upon	ADP	IN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
mangiferin	mangiferin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
suspended	suspend	VERB	VBD	0	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
ml	ml	NOUN	NNS	0	O
of	of	ADP	IN	5	O
dimethyl	dimethyl	ADJ	JJ	0	B-Chemical
sulphoxide	sulphoxide	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
given	give	VERB	VBN	5	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
for	for	ADP	IN	5	O
28	28	NUM	CD	7	O
days	day	NOUN	NNS	9	O
to	to	ADP	IN	5	O
MI	MI	PROPN	NNP	9	B-Disease
rats	rat	NOUN	NNS	9	O
protected	protect	VERB	VBD	9	O
the	the	DET	DT	5	O
above	above	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
mentioned	mention	VERB	VBN	5	O
parameters	parameter	NOUN	NNS	5	O
to	to	PART	TO	5	O
fall	fall	VERB	VB	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
tissue	tissue	NOUN	NN	9	O
enzymic	enzymic	ADJ	JJ	0	O
antioxidants	antioxidant	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
serum	serum	ADJ	JJ	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
enzymic	enzymic	ADJ	JJ	0	O
antioxidants	antioxidant	NOUN	NNS	0	O
levels	level	NOUN	NNS	3	O
rose	rise	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
upon	upon	ADP	IN	9	O
mangiferin	mangiferin	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
ISPH	ISPH	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
MI	MI	PROPN	NNP	9	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
mangiferin	mangiferin	NOUN	NN	0	B-Chemical
exerts	exert	VERB	VBZ	9	O
a	a	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
against	against	ADP	IN	9	O
ISPH	ISPH	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
MI	MI	PROPN	NNP	9	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
antioxidant	antioxidant	ADJ	JJ	0	O
potential	potential	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
regulated	regulate	VERB	VBD	3	O
the	the	DET	DT	5	O
tissues	tissue	NOUN	NNS	9	O
defense	defense	NOUN	NN	5	O
system	system	NOUN	NN	5	O
against	against	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Cardiovascular	cardiovascular	ADJ	JJ	2	O
risk	risk	NOUN	NN	5	O
with	with	ADP	IN	5	O
cyclooxygenase	cyclooxygenase	NOUN	NN	0	B-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
:	:	PUNCT	:	9	O
general	general	ADJ	JJ	5	O
problem	problem	NOUN	NN	5	O
with	with	ADP	IN	5	O
substance	substance	NOUN	NN	5	O
specific	specific	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
?	?	PUNCT	.	5	O

Randomised	randomise	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
observational	observational	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
stroke	stroke	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
cyclooxygenase	cyclooxygenase	NOUN	NN	0	B-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
mainly	mainly	ADV	RB	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
exclusively	exclusively	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
concomitant	concomitant	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Cyclooxygenase	cyclooxygenase	NOUN	NN	0	B-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
cause	cause	VERB	VBP	5	O
complex	complex	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
vascular	vascular	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
prostanoid	prostanoid	NOUN	NN	0	O
profiles	profile	NOUN	NNS	9	O
thereby	thereby	ADV	RB	9	O
increasing	increase	VERB	VBG	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
fluid	fluid	ADJ	JJ	5	O
retention	retention	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
tends	tend	VERB	VBZ	5	O
to	to	PART	TO	5	O
increase	increase	VERB	VB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
total	total	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
time	time	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
individual	individual	ADJ	JJ	5	O
selective	selective	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
unselective	unselective	ADJ	JJ	0	O
cyclooxygenase	cyclooxygenase	NOUN	NN	0	B-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
suggests	suggest	VERB	VBZ	9	O
substance	substance	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
depend	depend	VERB	VB	5	O
on	on	ADP	IN	5	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
potency	potency	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
contributed	contribute	VERB	VBN	9	O
by	by	ADP	IN	9	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
independent	independent	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Diagnostic	diagnostic	ADJ	JJ	5	O
markers	marker	NOUN	NNS	3	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
terminal	terminal	NOUN	NN	9	I-Chemical
pro	pro	ADJ	JJ	9	I-Chemical
brain	brain	NOUN	NN	5	I-Chemical
natriuretic	natriuretic	ADJ	JJ	9	I-Chemical
peptide	peptide	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
NT	NT	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
proBNP	proBNP	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
C	c	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
reactive	reactive	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
might	may	VERB	MD	9	O
help	help	VERB	VB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
identification	identification	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
,	,	PUNCT	,	9	O
thus	thus	ADV	RB	9	O
avoiding	avoid	VERB	VBG	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
seizures	seizure	NOUN	NNS	5	B-Disease
cause	cause	VERB	VBP	5	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
impairment	impairment	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	I-Disease
auditory	auditory	NOUN	NN	5	I-Disease
location	location	NOUN	NN	5	I-Disease
discrimination	discrimination	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Children	child	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
have	have	VERB	VBP	5	O
continuous	continuous	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
rapidly	rapidly	ADV	RB	9	O
repeating	repeat	VERB	VBG	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
long	long	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
behavior	behavior	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
to	to	PART	TO	5	O
which	which	DET	WDT	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
causes	cause	VERB	VBZ	9	O
deficits	deficit	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	I-Disease
auditory	auditory	NOUN	NN	5	I-Disease
discrimination	discrimination	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
naturalistic	naturalistic	ADJ	JJ	5	O
auditory	auditory	NOUN	NN	5	O
location	location	NOUN	NN	5	O
discrimination	discrimination	NOUN	NN	5	O
method	method	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
this	this	DET	DT	5	O
question	question	NOUN	NN	5	O
using	use	VERB	VBG	9	O
an	an	DET	DT	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
on	on	ADP	IN	5	O
postnatal	postnatal	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
20	20	NUM	CD	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
convulsant	convulsant	ADJ	JJ	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
P20	P20	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
P45	P45	PROPN	NNP	1	O
.	.	PUNCT	.	9	O

Pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
either	either	DET	DT	9	O
day	day	NOUN	NN	9	O
induced	induce	VERB	VBD	3	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
;	;	PUNCT	:	9	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
at	at	ADP	IN	9	O
P45	P45	PROPN	NNP	1	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
CA3	CA3	PROPN	NNP	3	O
cell	cell	NOUN	NN	3	O
loss	loss	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
P20	P20	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
cell	cell	NOUN	NN	3	O
loss	loss	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Mature	mature	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
trained	train	VERB	VBN	5	O
with	with	ADP	IN	5	O
sound	sound	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
source	source	NOUN	NN	5	O
location	location	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
sound	sound	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
silence	silence	NOUN	NN	9	O
discriminations	discrimination	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Control	Control	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
saline	saline	VERB	VB	0	O
P20	P20	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
acquired	acquire	VERB	VBD	5	O
both	both	DET	DT	9	O
discriminations	discrimination	NOUN	NNS	5	O
immediately	immediately	ADV	RB	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
P20	P20	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
acquisition	acquisition	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sound	sound	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
source	source	NOUN	NN	5	O
location	location	NOUN	NN	5	O
discrimination	discrimination	NOUN	NN	5	O
was	be	VERB	VBD	9	O
moderately	moderately	ADV	RB	9	O
impaired	impair	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Status	Status	PROPN	NNP	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
P45	P45	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
acquire	acquire	VERB	VB	5	O
either	either	DET	DT	9	O
sound	sound	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
source	source	NOUN	NN	5	O
location	location	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
sound	sound	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
silence	silence	NOUN	NN	9	O
discriminations	discrimination	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
causes	cause	VERB	VBZ	9	O
an	an	DET	DT	5	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
impairment	impairment	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	I-Disease
auditory	auditory	NOUN	NN	5	I-Disease
discrimination	discrimination	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
impairment	impairment	NOUN	NN	5	O
may	may	VERB	MD	5	O
explain	explain	VERB	VB	9	O
one	one	NUM	CD	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
auditory	auditory	NOUN	NN	5	I-Disease
location	location	NOUN	NN	5	I-Disease
discrimination	discrimination	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Nerve	nerve	NOUN	NN	5	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
prostaglandins	prostaglandin	NOUN	NNS	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
urine	urine	NOUN	NN	9	O
of	of	ADP	IN	5	O
female	female	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
overactive	overactive	ADJ	JJ	5	B-Disease
bladder	bladder	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
NGF	NGF	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
PGs	pg	NOUN	NNS	9	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
pathological	pathological	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
these	these	DET	DT	5	O
changes	change	NOUN	NNS	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
urine	urine	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
NGF	NGF	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
PGs	pg	NOUN	NNS	9	B-Chemical
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
OAB	OAB	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
65	65	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
OAB	OAB	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
without	without	ADP	IN	9	O
bladder	bladder	NOUN	NN	9	O
symptoms	symptom	NOUN	NNS	5	O
who	who	PRON	WP	5	O
served	serve	VERB	VBD	9	O
as	as	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Evaluation	evaluation	NOUN	NN	5	O
included	include	VERB	VBD	5	O
patient	patient	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
,	,	PUNCT	,	9	O
urinalysis	urinalysis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
voiding	void	VERB	VBG	5	O
diary	diary	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
urodynamic	urodynamic	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Urine	Urine	PROPN	NNP	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

NGF	NGF	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
PGF2alpha	PGF2alpha	PROPN	NNP	3	B-Chemical
and	and	CCONJ	CC	5	O
PGI2	PGI2	PROPN	NNP	0	B-Chemical
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
using	use	VERB	VBG	9	O
enzyme	enzyme	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
linked	link	VERB	VBN	9	O
immunosorbent	immunosorbent	NOUN	NN	3	O
assay	assay	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
correlations	correlation	NOUN	NNS	5	O
between	between	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
NGF	NGF	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
PG	PG	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
urodynamic	urodynamic	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
OAB	OAB	PROPN	NNP	5	B-Disease
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Urinary	Urinary	PROPN	NNP	9	O
NGF	NGF	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
and	and	CCONJ	CC	5	O
PGF2alpha	PGF2alpha	PROPN	NNP	3	B-Chemical
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
OAB	OAB	PROPN	NNP	5	B-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
urinary	urinary	NOUN	NN	9	O
PGI2	PGI2	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
different	different	ADJ	JJ	9	O
between	between	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
OAB	OAB	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
OAB	OAB	PROPN	NNP	5	B-Disease
urinary	urinary	NOUN	NN	9	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
positively	positively	ADV	RB	9	O
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
volume	volume	NOUN	NN	9	O
at	at	ADP	IN	9	O
first	first	ADJ	JJ	9	O
desire	desire	NOUN	NN	5	O
to	to	PART	TO	5	O
void	void	VERB	VB	5	O
and	and	CCONJ	CC	5	O
maximum	maximum	ADJ	JJ	5	O
cystometric	cystometric	ADJ	JJ	5	O
capacity	capacity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Urinary	Urinary	PROPN	NNP	9	O
NGF	NGF	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
PGF2alpha	PGF2alpha	PROPN	NNP	3	B-Chemical
and	and	CCONJ	CC	5	O
PGI2	PGI2	PROPN	NNP	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
correlate	correlate	VERB	VB	9	O
with	with	ADP	IN	5	O
urodynamic	urodynamic	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
OAB	OAB	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
NGF	NGF	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
PGs	pg	NOUN	NNS	9	B-Chemical
have	have	VERB	VBP	5	O
important	important	ADJ	JJ	9	O
roles	role	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
OAB	OAB	PROPN	NNP	5	B-Disease
symptoms	symptom	NOUN	NNS	5	O
in	in	ADP	IN	5	O
female	female	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Urinary	urinary	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
factors	factor	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
markers	marker	NOUN	NNS	3	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
OAB	OAB	PROPN	NNP	5	B-Disease
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Definition	definition	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
anemia	anemia	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
infected	infect	VERB	VBN	3	B-Disease
with	with	ADP	IN	5	I-Disease
hepatitis	hepatitis	PROPN	NNP	9	I-Disease
C	C	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	B-Disease
infection	infection	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	I-Disease
hepatitis	hepatitis	PROPN	NNP	9	I-Disease
C	C	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
HCV	HCV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
can	can	VERB	MD	5	O
progress	progress	VERB	VB	5	O
to	to	ADP	IN	5	O
cirrhosis	cirrhosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hepatocellular	hepatocellular	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
liver	liver	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
best	good	ADJ	JJS	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
HCV	HCV	PROPN	NNP	9	B-Disease
infection	infection	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
pegylated	pegylated	ADJ	JJ	0	O
interferon	interferon	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
this	this	DET	DT	5	O
regimen	regimen	NOUN	NN	5	O
produces	produce	VERB	VBZ	9	O
sustained	sustain	VERB	VBD	5	O
virologic	virologic	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
SVRs	svr	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Hemoglobin	hemoglobin	NOUN	NN	7	O
concentrations	concentration	NOUN	NNS	0	O
decrease	decrease	NOUN	NN	9	O
mainly	mainly	ADV	RB	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
this	this	DET	DT	5	O
anemia	anemia	NOUN	NN	9	B-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
problematic	problematic	ADJ	JJ	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
HCV	HCV	PROPN	NNP	9	B-Disease
infection	infection	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
those	those	DET	DT	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
comorbid	comorbid	NOUN	NN	5	O
renal	renal	ADJ	JJ	9	B-Disease
or	or	CCONJ	CC	5	I-Disease
cardiovascular	cardiovascular	ADJ	JJ	5	I-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
general	general	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
anemia	anemia	NOUN	NN	9	B-Disease
can	can	VERB	MD	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
morbidity	morbidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
negative	negative	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
anemia	anemia	NOUN	NN	9	B-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
reversed	reverse	VERB	VBN	9	O
by	by	ADP	IN	9	O
dose	dose	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
discontinuation	discontinuation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
approach	approach	NOUN	NN	5	O
compromises	compromise	VERB	VBZ	9	O
outcomes	outcome	NOUN	NNS	5	O
by	by	ADP	IN	9	O
significantly	significantly	ADV	RB	9	O
decreasing	decrease	VERB	VBG	9	O
SVR	SVR	PROPN	NNP	9	O
rates	rate	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Recombinant	recombinant	ADJ	JJ	3	O
human	human	ADJ	JJ	3	O
erythropoietin	erythropoietin	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
manage	manage	VERB	VB	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
anemia	anemia	NOUN	NN	9	B-Disease
but	but	CCONJ	CC	9	O
has	have	VERB	VBZ	9	O
other	other	ADJ	JJ	5	O
potential	potential	ADJ	JJ	9	O
disadvantages	disadvantage	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Viramidine	Viramidine	PROPN	NNP	_	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
liver	liver	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
targeting	target	VERB	VBG	3	O
prodrug	prodrug	NOUN	NN	0	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
the	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
to	to	PART	TO	5	O
maintain	maintain	VERB	VB	5	O
the	the	DET	DT	5	O
virologic	virologic	ADJ	JJ	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
while	while	ADP	IN	9	O
decreasing	decrease	VERB	VBG	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
C	C	PROPN	NNP	9	I-Disease
.	.	PUNCT	.	9	O

Impact	impact	NOUN	NN	5	O
of	of	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
exposure	exposure	NOUN	NN	9	O
after	after	ADP	IN	9	O
pregnancy	pregnancy	NOUN	NN	5	O
recognition	recognition	NOUN	NN	5	O
on	on	ADP	IN	5	O
ultrasonographic	ultrasonographic	ADJ	JJ	5	O
fetal	fetal	ADJ	JJ	9	O
growth	growth	NOUN	NN	3	O
measures	measure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
More	More	ADJ	JJR	5	O
than	than	ADP	IN	5	O
3	3	NUM	CD	9	O
decades	decade	NOUN	NNS	5	O
after	after	ADP	IN	9	O
Jones	Jones	PROPN	NNP	6	O
and	and	CCONJ	CC	5	O
Smith	Smith	PROPN	NNP	6	O
(	(	PUNCT	-LRB-	9	O
1973	1973	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
reported	report	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
devastation	devastation	NOUN	NN	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
exposure	exposure	NOUN	NN	9	O
on	on	ADP	IN	5	O
fetal	fetal	ADJ	JJ	9	O
development	development	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
heavy	heavy	ADJ	JJ	9	O
drinking	drinking	NOUN	NN	5	O
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
remain	remain	VERB	VBP	9	O
relatively	relatively	ADV	RB	5	O
unchanged	unchanged	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Early	early	ADJ	JJ	9	O
identification	identification	NOUN	NN	9	O
of	of	ADP	IN	5	O
fetal	fetal	ADJ	JJ	9	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
exposure	exposure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
maternal	maternal	ADJ	JJ	9	O
abstinence	abstinence	NOUN	NN	5	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
better	well	ADJ	JJR	5	O
infant	infant	NOUN	NN	5	O
outcomes	outcome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
utility	utility	NOUN	NN	5	O
of	of	ADP	IN	5	O
biometry	biometry	NOUN	NN	5	O
for	for	ADP	IN	5	O
detecting	detect	VERB	VBG	9	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
fetal	fetal	ADJ	JJ	9	O
growth	growth	NOUN	NN	3	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
obtained	obtain	VERB	VBD	9	O
fetal	fetal	ADJ	JJ	9	O
ultrasound	ultrasound	ADJ	JJ	5	O
measures	measure	NOUN	NNS	5	O
from	from	ADP	IN	9	O
routine	routine	ADJ	JJ	5	O
ultrasound	ultrasound	ADJ	JJ	5	O
examinations	examination	NOUN	NNS	5	O
for	for	ADP	IN	5	O
167	167	NUM	CD	7	O
pregnant	pregnant	ADJ	JJ	5	O
hazardous	hazardous	ADJ	JJ	5	O
drinkers	drinker	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
brief	brief	ADJ	JJ	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
intervention	intervention	NOUN	NN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
fetal	fetal	ADJ	JJ	9	O
measures	measure	NOUN	NNS	5	O
for	for	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
quit	quit	VERB	VBP	5	O
after	after	ADP	IN	9	O
learning	learn	VERB	VBG	5	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
pregnancies	pregnancy	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
measures	measure	NOUN	NNS	5	O
for	for	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
continued	continue	VERB	VBD	9	O
some	some	DET	DT	5	O
drinking	drinking	NOUN	NN	5	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
pregnancies	pregnancy	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
intensity	intensity	NOUN	NN	5	O
of	of	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
consumption	consumption	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
poorer	poor	ADJ	JJR	5	O
fetal	fetal	ADJ	JJ	9	O
outcomes	outcome	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
separate	separate	ADJ	JJ	9	O
analyses	analysis	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
heavy	heavy	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
average	average	ADJ	JJ	5	O
of	of	ADP	IN	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
5	5	NUM	CD	9	O
drinks	drink	NOUN	NNS	5	O
per	per	ADP	IN	9	O
drinking	drinking	NOUN	NN	5	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
consumers	consumer	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Fetal	fetal	ADJ	JJ	9	O
measures	measure	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
heavy	heavy	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
fetuses	fetus	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
measures	measure	NOUN	NNS	5	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
nondrinking	nondrinking	NOUN	NN	5	O
group	group	NOUN	NN	9	O
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
representative	representative	NOUN	NN	9	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
uncomplicated	uncomplicated	ADJ	JJ	5	O
pregnancies	pregnancy	NOUN	NNS	5	O
from	from	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
clinics	clinic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Analyses	analysis	NOUN	NNS	9	O
of	of	ADP	IN	5	O
covariance	covariance	NOUN	NN	5	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
after	after	ADP	IN	9	O
controlling	control	VERB	VBG	9	O
for	for	ADP	IN	5	O
influences	influence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
gestational	gestational	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
drug	drug	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Nearly	nearly	ADV	RB	9	O
half	half	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pregnant	pregnant	ADJ	JJ	5	O
drinkers	drinker	NOUN	NNS	5	O
abstained	abstain	VERB	VBD	5	O
after	after	ADP	IN	9	O
learning	learn	VERB	VBG	5	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
pregnancies	pregnancy	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
women	woman	NOUN	NNS	5	O
reportedly	reportedly	ADV	RB	9	O
quit	quit	VERB	VBP	5	O
drinking	drink	VERB	VBG	5	O
early	early	ADV	RB	9	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
pregnancies	pregnancy	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
fetal	fetal	ADJ	JJ	9	O
growth	growth	NOUN	NN	3	O
measures	measure	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
regardless	regardless	ADV	RB	9	O
of	of	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
drinking	drinking	NOUN	NN	5	O
patterns	pattern	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Any	any	DET	DT	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
consumption	consumption	NOUN	NN	5	O
postpregnancy	postpregnancy	NOUN	NN	5	O
recognition	recognition	NOUN	NN	5	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
heavy	heavy	ADJ	JJ	9	O
drinkers	drinker	NOUN	NNS	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
reduced	reduce	VERB	VBN	9	B-Disease
cerebellar	cerebellar	ADJ	JJ	5	I-Disease
growth	growth	NOUN	NN	3	I-Disease
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	B-Disease
cranial	cranial	NOUN	NN	5	I-Disease
to	to	ADP	IN	5	I-Disease
body	body	NOUN	NN	5	I-Disease
growth	growth	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
either	either	CCONJ	CC	9	O
quit	quit	VERB	VBD	5	O
drinking	drinking	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
nondrinkers	nondrinker	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Amphetamine	Amphetamine	PROPN	NNP	7	B-Chemical
abuse	abuse	NOUN	NN	5	O
was	be	VERB	VBD	9	O
predictive	predictive	ADJ	JJ	5	O
of	of	ADP	IN	5	O
larger	large	ADJ	JJR	5	O
cranial	cranial	NOUN	NN	5	O
to	to	ADP	IN	5	O
body	body	NOUN	NN	5	O
growth	growth	NOUN	NN	3	O
ratios	ratio	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
fetal	fetal	ADJ	JJ	9	O
biometric	biometric	ADJ	JJ	5	O
measurements	measurement	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
heavy	heavy	ADJ	JJ	9	O
drinkers	drinker	NOUN	NNS	5	O
only	only	ADV	RB	9	O
when	when	ADV	WRB	5	O
they	-PRON-	PRON	PRP	5	O
continued	continue	VERB	VBD	9	O
drinking	drink	VERB	VBG	5	O
after	after	ADP	IN	9	O
becoming	become	VERB	VBG	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
pregnancies	pregnancy	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
reliance	reliance	NOUN	NN	5	O
on	on	ADP	IN	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
reported	report	VERB	VBN	9	O
drinking	drinking	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
limitation	limitation	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
support	support	VERB	VBP	5	O
the	the	DET	DT	5	O
benefits	benefit	NOUN	NNS	5	O
of	of	ADP	IN	5	O
early	early	ADJ	JJ	9	O
abstinence	abstinence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
for	for	ADP	IN	5	O
ultrasound	ultrasound	ADJ	JJ	5	O
examinations	examination	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
fetal	fetal	ADJ	JJ	9	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Ethambutol	Ethambutol	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

INTRODUCTION	INTRODUCTION	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
Ethambutol	Ethambutol	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
tuberculosis	tuberculosis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
prevalent	prevalent	ADJ	JJ	9	O
in	in	ADP	IN	5	O
Southeast	Southeast	PROPN	NNP	4	O
Asia	Asia	PROPN	NNP	4	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
permanent	permanent	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
3	3	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
which	which	DET	WDT	5	O
presented	present	VERB	VBD	5	O
with	with	ADP	IN	5	O
bitemporal	bitemporal	ADJ	JJ	5	B-Disease
hemianopia	hemianopia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

CLINICAL	CLINICAL	PROPN	NNP	2	O
PICTURE	PICTURE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
toxic	toxic	ADJ	JJ	0	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
are	be	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
central	central	ADJ	JJ	5	I-Disease
visual	visual	ADJ	JJ	5	I-Disease
acuity	acuity	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	I-Disease
colour	colour	NOUN	NN	5	I-Disease
vision	vision	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
Ishihara	Ishihara	PROPN	NNP	6	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
visual	visual	ADJ	JJ	5	I-Disease
field	field	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
loss	loss	NOUN	NN	9	I-Disease
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
bitemporal	bitemporal	ADJ	JJ	5	O
flavour	flavour	NOUN	NN	5	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
optic	optic	ADJ	JJ	5	O
chiasm	chiasm	NOUN	NN	5	O
.	.	PUNCT	.	9	O

TREATMENT	treatment	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Despite	despite	ADP	IN	5	O
stopping	stop	VERB	VBG	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
diagnosis	diagnosis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
visual	visual	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
continued	continue	VERB	VBD	9	O
to	to	PART	TO	5	O
deteriorate	deteriorate	VERB	VB	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Subsequent	subsequent	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
was	be	VERB	VBD	9	O
mild	mild	ADJ	JJ	9	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
,	,	PUNCT	,	9	O
visual	visual	ADJ	JJ	5	O
acuity	acuity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
colour	colour	NOUN	NN	5	O
vision	vision	NOUN	NN	5	O
normalised	normalise	VERB	VBN	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
optic	optic	ADJ	JJ	5	O
discs	discs	NOUN	NN	9	O
were	be	VERB	VBD	9	O
pale	pale	ADJ	JJ	4	O
.	.	PUNCT	.	9	O

OUTCOME	outcome	NOUN	NN	2	O
:	:	PUNCT	:	9	O
All	all	DET	DT	9	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
some	some	DET	DT	5	O
permanent	permanent	ADJ	JJ	5	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
visual	visual	ADJ	JJ	5	I-Disease
function	function	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Ethambutol	Ethambutol	PROPN	NNP	0	B-Chemical
usage	usage	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
permanent	permanent	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
avoided	avoid	VERB	VBN	5	O
if	if	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
used	use	VERB	VBN	5	O
with	with	ADP	IN	5	O
caution	caution	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
proper	proper	ADJ	JJ	5	O
ophthalmological	ophthalmological	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
author	author	NOUN	NN	5	O
postulates	postulate	VERB	VBZ	5	O
that	that	DET	WDT	5	O
in	in	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
associated	associate	VERB	VBN	9	O
chiasmopathy	chiasmopathy	NOUN	NN	_	O
,	,	PUNCT	,	9	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
initially	initially	ADV	RB	9	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
optic	optic	ADJ	JJ	5	O
nerves	nerve	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
subsequently	subsequently	ADV	RB	9	O
progress	progress	VERB	VBP	5	O
to	to	PART	TO	5	O
involve	involve	VERB	VB	5	O
the	the	DET	DT	5	O
optic	optic	ADJ	JJ	5	O
chiasm	chiasm	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
concomitant	concomitant	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
paroxetine	paroxetine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
alprazolam	alprazolam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
74	74	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
depressive	depressive	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
hospital	hospital	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
insomnia	insomnia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
appetite	appetite	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
exhaustion	exhaustion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
agitation	agitation	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Medical	medical	ADJ	JJ	2	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
initiated	initiate	VERB	VBN	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
paroxetine	paroxetine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
alprazolam	alprazolam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
10th	10th	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
paroxetine	paroxetine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
alprazolam	alprazolam	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
exhibited	exhibit	VERB	VBD	9	O
marked	mark	VERB	VBN	9	O
psychomotor	psychomotor	NOUN	NN	5	B-Disease
retardation	retardation	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
disorientation	disorientation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
tremors	tremor	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
fever	fever	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
38	38	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
degrees	degree	NOUN	NNS	5	O
C	C	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
fluctuating	fluctuate	VERB	VBG	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
between	between	ADP	IN	5	O
165	165	NUM	CD	7	O
/	/	SYM	SYM	9	O
90	90	NUM	CD	9	O
and	and	CCONJ	CC	5	O
130	130	NUM	CD	9	O
/	/	SYM	SYM	9	O
70	70	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Laboratory	laboratory	NOUN	NN	2	O
tests	test	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
an	an	DET	DT	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
creatine	creatine	NOUN	NN	0	B-Chemical
phosphokinase	phosphokinase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
2218	2218	NUM	CD	7	O
IU	IU	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
aspartate	aspartate	VERB	VB	1	B-Chemical
aminotransferase	aminotransferase	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
134	134	NUM	CD	7	O
IU	IU	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
alanine	alanine	NOUN	NN	1	B-Chemical
aminotransferase	aminotransferase	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
78	78	NUM	CD	7	O
IU	IU	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
BUN	BUN	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
27	27	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
received	receive	VERB	VBD	9	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
his	-PRON-	DET	PRP$	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RBR	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
fever	fever	NOUN	NN	5	B-Disease
disappeared	disappear	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
serum	serum	ADJ	JJ	9	O
CPK	CPK	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
normalized	normalize	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
175	175	NUM	CD	7	O
IU	IU	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
presented	present	VERB	VBD	5	O
with	with	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
NMS	NMS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
thus	thus	ADV	RB	9	O
demonstrating	demonstrate	VERB	VBG	9	O
that	that	ADP	IN	5	O
NMS	nms	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
can	can	VERB	MD	5	O
occur	occur	VERB	VB	5	O
after	after	ADP	IN	9	O
combined	combined	ADJ	JJ	9	O
paroxetine	paroxetine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
alprazolam	alprazolam	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
reaction	reaction	NOUN	NN	9	O
score	score	NOUN	NN	5	O
obtained	obtain	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
Naranjo	Naranjo	PROPN	NNP	6	O
algorithm	algorithm	NOUN	NN	5	O
was	be	VERB	VBD	9	O
6	6	NUM	CD	9	O
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
case	case	NOUN	NN	5	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
a	a	DET	DT	5	O
probable	probable	ADJ	JJ	9	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
NMS	nms	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
combined	combined	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
physiologic	physiologic	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
environmental	environmental	ADJ	JJ	5	O
aspects	aspect	NOUN	NNS	5	O
specific	specific	ADJ	JJ	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
suspected	suspect	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Several	several	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
NMS	NMS	PROPN	NNP	9	B-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
depressive	depressive	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
whose	whose	DET	WP$	9	O
symptoms	symptom	NOUN	NNS	5	O
often	often	ADV	RB	5	O
include	include	VERB	VBP	5	O
dehydration	dehydration	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
agitation	agitation	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
malnutrition	malnutrition	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
exhaustion	exhaustion	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Careful	careful	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
intervention	intervention	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
necessary	necessary	ADJ	JJ	5	O
in	in	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
involving	involve	VERB	VBG	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
suffer	suffer	VERB	VBP	5	O
from	from	ADP	IN	9	O
depression	depression	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Down	down	ADP	IN	7	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
transporter	transporter	NOUN	NN	1	O
function	function	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
linking	linking	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
alteration	alteration	NOUN	NN	9	O
of	of	ADP	IN	5	O
sensitivity	sensitivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
local	local	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
anesthetics	anesthetic	NOUN	NNS	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
counteraction	counteraction	NOUN	NN	3	O
by	by	ADP	IN	9	O
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
with	with	ADP	IN	5	O
local	local	ADJ	JJ	5	O
anesthetics	anesthetic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Alterations	alteration	NOUN	NNS	9	O
of	of	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
transporter	transporter	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
NET	net	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
function	function	NOUN	NN	9	O
by	by	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
NET	net	NOUN	NN	9	O
in	in	ADP	IN	5	O
relation	relation	NOUN	NN	5	O
to	to	PART	TO	5	O
sensitization	sensitization	NOUN	NN	9	O
to	to	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
induce	induce	VERB	VB	3	O
by	by	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
local	local	ADJ	JJ	5	O
anesthetics	anesthetic	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Daily	daily	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
NET	net	NOUN	NN	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
decreased	decrease	VERB	VBD	9	O
[	[	PUNCT	-LRB-	9	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
H	h	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
uptake	uptake	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
P2	P2	PROPN	NNP	9	O
fractions	fraction	NOUN	NNS	0	O
of	of	ADP	IN	5	O
hippocampus	hippocampus	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
striatum	striatum	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
amygdalae	amygdalae	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Co	co	NOUN	NN	0	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
tricaine	tricaine	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
reversed	reverse	VERB	VBD	9	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Daily	daily	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
increased	increase	VERB	VBD	9	O
[	[	PUNCT	-LRB-	9	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
H	h	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
uptake	uptake	NOUN	NN	0	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Daily	daily	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Co	co	NOUN	NN	0	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
reversed	reverse	VERB	VBD	9	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
repeated	repeat	VERB	VBN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
down	down	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
NET	net	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
relevant	relevant	ADJ	JJ	5	O
to	to	PART	TO	5	O
desipramine	desipramine	VERB	VB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
sensitization	sensitization	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
channels	channel	NOUN	NNS	9	O
by	by	ADP	IN	9	O
local	local	ADJ	JJ	5	O
anesthetics	anesthetic	NOUN	NNS	5	O
may	may	VERB	MD	5	O
regulate	regulate	VERB	VB	3	O
desipramine	desipramine	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
down	down	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
NET	net	NOUN	NN	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Repeated	repeat	VERB	VBN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
induces	induce	VERB	VBZ	3	O
up	up	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
NET	net	NOUN	NN	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Desipramine	desipramine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
sensitization	sensitization	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
seizures	seizure	NOUN	NNS	5	B-Disease
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
distinct	distinct	NOUN	NN	9	O
from	from	ADP	IN	9	O
kindling	kindle	VERB	VBG	5	O
resulting	result	VERB	VBG	9	O
from	from	ADP	IN	9	O
repeated	repeat	VERB	VBN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Atorvastatin	Atorvastatin	PROPN	NNP	0	B-Chemical
prevented	prevent	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
reversed	reverse	VERB	VBD	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
antioxidant	antioxidant	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
atorvastatin	atorvastatin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
atorva	atorva	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
dex	dex	NOUN	NN	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
male	male	NOUN	NN	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
atorva	atorva	NOUN	NN	9	B-Chemical
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
tap	tap	NOUN	NN	5	O
water	water	NOUN	NN	0	O
for	for	ADP	IN	5	O
15	15	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Dex	dex	VERB	VB	3	B-Chemical
increased	increase	VERB	VBD	9	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
SBP	SBP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
109	109	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
to	to	ADP	IN	5	O
135	135	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mmHg	mmHg	NOUN	NNS	7	O
and	and	CCONJ	CC	5	O
plasma	plasma	VERB	VB	9	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5711	5711	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
284	284	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
7931	7931	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
392	392	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
dex	dex	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
SBP	SBP	PROPN	NNP	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
atorva	atorva	NOUN	NN	9	B-Chemical
+	+	PUNCT	-LRB-	9	O
dex	dex	NOUN	NN	3	B-Chemical
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
from	from	ADP	IN	9	O
115	115	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
to	to	ADP	IN	5	O
124	124	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mmHg	mmhg	SYM	SYM	7	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
this	this	DET	DT	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dex	dex	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
only	only	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
'	'	PUNCT	''	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Atorva	Atorva	PROPN	NNP	7	B-Chemical
reversed	reverse	VERB	VBN	9	O
dex	dex	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
129	129	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mmHg	mmhg	SYM	SYM	7	O
,	,	PUNCT	,	9	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
135	135	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mmHg	mmhg	SYM	SYM	7	O
P	p	NOUN	NN	9	O
'	'	PUNCT	''	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
plasma	plasma	NOUN	NN	9	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
7931	7931	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
392	392	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
dex	dex	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
1187	1187	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
441	441	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
atorva	atorva	NOUN	NN	9	B-Chemical
+	+	CCONJ	CC	9	O
dex	dex	VERB	VB	3	B-Chemical
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Plasma	Plasma	PROPN	NNP	0	O
nitrate	nitrate	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
nitrite	nitrite	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
NOx	NOx	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
dex	dex	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
08	08	NUM	CD	7	O
microm	microm	NOUN	NN	0	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
17	17	NUM	CD	7	O
microm	microm	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Atorva	Atorva	PROPN	NNP	7	B-Chemical
affected	affect	VERB	VBD	9	O
neither	neither	CCONJ	CC	9	O
plasma	plasma	NOUN	NN	9	O
NOx	NOx	NOUN	NNS	0	O
nor	nor	CCONJ	CC	9	O
thymus	thymus	ADJ	JJ	3	O
weight	weight	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
atorvastatin	atorvastatin	ADV	RB	0	B-Chemical
prevented	prevent	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
reversed	reverse	VERB	VBD	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
cytosine	cytosine	NOUN	NN	1	B-Chemical
arabinoside	arabinoside	NOUN	NN	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
myeloid	myeloid	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
cytosine	cytosine	NOUN	NN	1	B-Chemical
arabinoside	arabinoside	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
well	well	ADV	RB	9	O
recognized	recognize	VERB	VBN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
cytosine	cytosine	ADJ	JJ	1	B-Chemical
arabinoside	arabinoside	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
infrequently	infrequently	ADV	RB	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
49	49	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Japanese	japanese	ADJ	JJ	9	O
man	man	NOUN	NN	5	O
was	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
myeloid	myeloid	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
he	-PRON-	PRON	PRP	5	O
achieved	achieve	VERB	VBD	5	O
complete	complete	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
received	receive	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
cytosine	cytosine	NOUN	NN	1	B-Chemical
arabinoside	arabinoside	NOUN	NN	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
twice	twice	ADV	RB	9	O
a	a	DET	DT	5	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
total	total	NOUN	NN	9	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
consolidation	consolidation	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
cytosine	cytosine	NOUN	NN	1	B-Chemical
arabinoside	arabinoside	NOUN	NN	0	I-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
no	no	DET	DT	9	O
unusual	unusual	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
21	21	NUM	CD	7	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
numbness	numbness	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
right	right	ADJ	JJ	5	O
foot	foot	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Electromyogram	Electromyogram	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
nerve	nerve	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
conduction	conduction	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
peroneal	peroneal	NOUN	NN	5	O
nerves	nerve	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
gradually	gradually	ADV	RB	9	O
resolving	resolve	VERB	VBG	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
received	receive	VERB	VBD	9	O
allogeneic	allogeneic	ADJ	JJ	3	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
worsened	worsen	VERB	VBD	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
graft	graft	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
versus	versus	ADP	IN	9	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
host	host	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
subsequently	subsequently	ADV	RB	9	O
responded	respond	VERB	VBD	9	O
to	to	ADP	IN	5	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
are	be	VERB	VBP	5	O
still	still	ADV	RB	5	O
unclear	unclear	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
cytosine	cytosine	NOUN	NN	1	B-Chemical
arabinoside	arabinoside	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
therapy	therapy	NOUN	NN	5	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
potentially	potentially	ADV	RB	5	O
toxic	toxic	ADJ	JJ	0	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
auto	auto	NOUN	NN	5	O
/	/	SYM	SYM	9	O
alloimmunity	alloimmunity	NOUN	NN	3	O
may	may	VERB	MD	5	O
play	play	VERB	VB	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tocopherol	tocopherol	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
deferoxamine	deferoxamine	VERB	VB	0	B-Chemical
on	on	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Methamphetamine	Methamphetamine	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
MA	MA	PROPN	NNP	2	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
believed	believe	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
free	free	ADJ	JJ	9	O
radicals	radical	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tocopherol	tocopherol	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
TC	TC	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
scavenger	scavenger	NOUN	NN	0	O
of	of	ADP	IN	5	O
reactive	reactive	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
species	specie	NOUN	NNS	4	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
deferoxamine	deferoxamine	VERB	VB	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DFO	DFO	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
iron	iron	NOUN	NN	0	B-Chemical
chelator	chelator	NOUN	NN	0	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
MA	MA	PROPN	NNP	2	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Male	male	ADJ	JJ	7	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
MA	MA	PROPN	NNP	2	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
every	every	DET	DT	5	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
for	for	ADP	IN	5	O
four	four	NUM	CD	9	O
injections	injection	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
received	receive	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
TC	tc	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
MA	MA	PROPN	NNP	2	B-Chemical
administration	administration	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
DFO	DFO	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
subcutaneously	subcutaneously	ADV	RB	3	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
MA	MA	PROPN	NNP	2	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
DA	DA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
metabolites	metabolite	NOUN	NNS	0	O
decreased	decrease	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
after	after	ADP	IN	9	O
MA	MA	PROPN	NNP	2	B-Chemical
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
inhibited	inhibit	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
TC	tc	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
DFO	DFO	PROPN	NNP	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
.	.	PUNCT	.	9	O

alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	:	7	I-Chemical
TC	tc	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
DFO	DFO	PROPN	NNP	0	B-Chemical
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
MA	MA	PROPN	NNP	2	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperthermia	hyperthermia	NOUN	NN	5	B-Disease
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
reduced	reduced	ADJ	JJ	9	O
glutathione	glutathione	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
was	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
MA	ma	NOUN	NN	2	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBN	3	O
by	by	ADP	IN	9	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
TC	tc	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
DFO	DFO	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
TC	tc	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
DFO	DFO	PROPN	NNP	0	B-Chemical
ameliorate	ameliorate	VERB	VBP	9	O
the	the	DET	DT	5	O
MA	ma	NOUN	NN	2	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
damage	damage	NOUN	NN	9	I-Disease
by	by	ADP	IN	9	O
decreasing	decrease	VERB	VBG	9	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Blockade	Blockade	PROPN	NNP	3	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
D	D	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
D	D	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptors	receptor	NOUN	NNS	3	O
may	may	VERB	MD	5	O
induce	induce	VERB	VB	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

1	1	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
antagonists	antagonist	NOUN	NNS	3	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
tested	test	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
subtypes	subtype	NOUN	NNS	9	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

2	2	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Dopamine	dopamine	NOUN	NN	0	B-Chemical
antagonist	antagonist	NOUN	NN	3	O
fluphenazine	fluphenazine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
D	D	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
antagonist	antagonist	NOUN	NN	3	O
SCH	SCH	PROPN	NNP	9	B-Chemical
23390	23390	NUM	CD	0	I-Chemical
or	or	CCONJ	CC	5	O
D	D	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
antagonist	antagonist	NOUN	NN	3	O
sulpiride	sulpiride	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
fluphenazine	fluphenazine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
sulpiride	sulpiride	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
SCH	SCH	PROPN	NNP	9	B-Chemical
23390	23390	NUM	CD	0	I-Chemical
with	with	ADP	IN	5	O
sulpiride	sulpiride	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
induce	induce	VERB	VB	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
potentiation	potentiation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

3	3	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

D	D	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
agonist	agonist	NOUN	NN	3	O
SKF	SKF	PROPN	NNP	3	B-Chemical
38393	38393	NUM	CD	3	I-Chemical
or	or	CCONJ	CC	5	O
D	D	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
agonist	agonist	NOUN	NN	3	O
quinpirole	quinpirole	NOUN	NN	3	B-Chemical
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
fluphenazine	fluphenazine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
SCH	SCH	PROPN	NNP	9	B-Chemical
23390	23390	NUM	CD	0	I-Chemical
or	or	CCONJ	CC	5	O
sulpiride	sulpiride	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

4	4	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
SKF	SKF	PROPN	NNP	3	B-Chemical
38393	38393	NUM	CD	3	I-Chemical
with	with	ADP	IN	5	O
quinpirole	quinpirole	NOUN	NN	3	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
cause	cause	VERB	VB	5	O
potentiated	potentiate	VERB	VBN	3	O
inhibitory	inhibitory	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
antagonists	antagonist	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

5	5	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
may	may	VERB	MD	5	O
indicate	indicate	VERB	VB	9	O
that	that	ADP	IN	5	O
although	although	ADP	IN	9	O
D	D	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
receptor	receptor	NOUN	NN	3	O
blockade	blockade	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
D	D	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
receptor	receptor	NOUN	NN	3	O
may	may	VERB	MD	5	O
plan	plan	VERB	VB	5	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Sustained	sustained	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
improvement	improvement	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
decompensated	decompensated	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
cirrhosis	cirrhosis	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
lamivudine	lamivudine	ADJ	JJ	5	B-Chemical
monotherapy	monotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hepatitis	Hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	PROPN	NNP	9	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
HBV	HBV	PROPN	NNP	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
infection	infection	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
causes	cause	VERB	VBZ	9	O
liver	liver	NOUN	NN	9	B-Disease
cirrhosis	cirrhosis	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
hepatocellular	hepatocellular	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
remains	remain	VERB	VBZ	9	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
health	health	NOUN	NN	5	O
problem	problem	NOUN	NN	5	O
in	in	ADP	IN	5	O
Asian	asian	ADJ	JJ	4	O
countries	country	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Recent	recent	ADJ	JJ	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
vaccine	vaccine	NOUN	NN	5	O
for	for	ADP	IN	5	O
prevention	prevention	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
successful	successful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
reducing	reduce	VERB	VBG	9	O
the	the	DET	DT	5	O
size	size	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronically	chronically	ADV	RB	9	O
infected	infect	VERB	VBN	3	O
carriers	carrier	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
therapies	therapy	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
established	establish	VERB	VBN	9	O
up	up	PART	RP	5	O
to	to	ADP	IN	5	O
now	now	ADV	RB	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
report	report	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
encountered	encounter	VERB	VBD	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
decompensated	decompensated	ADJ	JJ	5	O
HBV	HBV	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
cirrhosis	cirrhosis	NOUN	NN	5	B-Disease
who	who	PRON	WP	5	O
exhibited	exhibit	VERB	VBD	9	O
the	the	DET	DT	5	O
dramatic	dramatic	ADJ	JJ	9	O
improvements	improvement	NOUN	NNS	5	O
after	after	ADP	IN	9	O
antiviral	antiviral	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
50	50	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
conventional	conventional	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
treatments	treatment	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
thus	thus	ADV	RB	9	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
referred	refer	VERB	VBN	5	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
reverse	reverse	ADJ	JJ	9	O
transcriptase	transcriptase	NOUN	NN	9	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
23	23	NUM	CD	7	O
months	month	NOUN	NNS	5	O
dramatically	dramatically	ADV	RB	9	O
improved	improve	VERB	VBD	5	O
her	-PRON-	DET	PRP$	5	O
liver	liver	NOUN	NN	9	O
severity	severity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
this	this	DET	DT	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
drug	drug	NOUN	NN	5	O
resistant	resistant	ADJ	JJ	9	O
mutant	mutant	ADJ	JJ	1	O
HBV	HBV	PROPN	NNP	9	O
emerged	emerge	VERB	VBD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
HBV	HBV	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
DNA	DNA	PROPN	NNP	9	O
level	level	NOUN	NN	9	O
was	be	VERB	VBD	9	O
continuously	continuously	ADV	RB	5	O
suppressed	suppress	VERB	VBN	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
virological	virological	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
maintained	maintain	VERB	VBN	9	O
even	even	ADV	RB	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
antiviral	antiviral	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
hepatitis	hepatitis	PROPN	NNP	9	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
surface	surface	NOUN	NN	9	I-Chemical
antigen	antigen	NOUN	NN	3	I-Chemical
and	and	CCONJ	CC	5	I-Chemical
e	e	NOUN	NN	9	I-Chemical
antigen	antigen	NOUN	NN	3	I-Chemical
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
disappeared	disappear	VERB	VBN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
cirrhosis	cirrhosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
like	like	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
present	present	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
,	,	PUNCT	,	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
medical	medical	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
option	option	NOUN	NN	5	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
countries	country	NOUN	NNS	5	O
where	where	ADV	WRB	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
reliably	reliably	ADV	RB	5	O
available	available	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Antiarrhythmic	antiarrhythmic	ADJ	JJ	7	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
optical	optical	ADJ	JJ	5	O
isomers	isomer	NOUN	NNS	0	O
of	of	ADP	IN	5	O
cibenzoline	cibenzoline	NOUN	NN	9	B-Chemical
on	on	ADP	IN	5	O
canine	canine	NOUN	NN	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Antiarrhythmic	antiarrhythmic	ADJ	JJ	7	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
cibenzoline	cibenzoline	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
cibenzoline	cibenzoline	NOUN	NN	9	B-Chemical
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
using	use	VERB	VBG	9	O
two	two	NUM	CD	5	O
canine	canine	NOUN	NN	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmia	arrhythmia	NOUN	NN	5	I-Disease
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Digitalis	digitalis	NOUN	NN	4	B-Chemical
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
suppressed	suppress	VERB	VBN	3	O
by	by	ADP	IN	9	O
Na	Na	PROPN	NNP	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
intermittent	intermittent	ADJ	JJ	5	O
intravenous	intravenous	ADJ	JJ	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
pentobarbital	pentobarbital	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
anesthetized	anesthetized	ADJ	JJ	0	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Adrenaline	adrenaline	NOUN	NN	0	B-Disease
arrhythmia	arrhythmia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
suppressed	suppress	VERB	VBN	3	O
by	by	ADP	IN	9	O
Ca	Ca	VERB	VBG	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
in	in	ADP	IN	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
anesthetized	anesthetized	ADJ	JJ	0	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ten	ten	NUM	CD	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
cibenzoline	cibenzoline	NOUN	NN	9	B-Chemical
suppressed	suppress	VERB	VBD	3	O
digitalis	digitalis	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
minimum	minimum	ADJ	JJ	5	O
effective	effective	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
cibenzoline	cibenzoline	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
digitalis	digitalis	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	SD	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
lower	low	ADJ	JJR	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
cibenzoline	cibenzoline	NOUN	NN	9	B-Chemical
suppressed	suppress	VERB	VBD	3	O
the	the	DET	DT	5	O
digitalis	digitalis	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
was	be	VERB	VBD	9	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
suppress	suppress	VERB	VB	3	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
minimum	minimum	ADJ	JJ	5	O
effective	effective	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
cibenzoline	cibenzoline	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
digitalis	digitalis	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
06	06	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	SD	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
stronger	strong	ADJ	JJR	9	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
cibenzoline	cibenzoline	NOUN	NN	9	B-Chemical
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
isomer	isomer	NOUN	NN	0	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
an	an	DET	DT	5	O
effect	effect	NOUN	NN	9	O
nearly	nearly	ADV	RB	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
times	time	NOUN	NNS	5	O
stronger	strong	ADJ	JJR	9	O
in	in	ADP	IN	5	O
suppressing	suppress	VERB	VBG	3	O
Na	Na	PROPN	NNP	0	B-Chemical
channels	channel	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
on	on	ADP	IN	5	O
Ca	ca	NOUN	NN	0	B-Chemical
channels	channel	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
almost	almost	ADV	RB	9	O
equipotent	equipotent	ADJ	JJ	0	O
.	.	PUNCT	.	9	O

Passage	passage	NOUN	NN	9	O
of	of	ADP	IN	5	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
around	around	ADP	IN	5	O
gliomas	glioma	NOUN	NNS	3	B-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
rebound	rebound	NOUN	NN	5	O
phenomenon	phenomenon	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
study	study	NOUN	NN	9	O
on	on	ADP	IN	5	O
21	21	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Widespread	widespread	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
brain	brain	NOUN	NN	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
lower	low	ADJ	JJR	9	O
elevated	elevated	ADJ	JJ	9	B-Disease
ICP	icp	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	B-Disease
tumor	tumor	NOUN	NN	3	I-Disease
patients	patient	NOUN	NNS	5	O
continues	continue	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
afflicted	afflict	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
so	so	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
called	call	VERB	VBN	5	O
rebound	rebound	NOUN	NN	5	O
phenomenon	phenomenon	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Leakage	leakage	NOUN	NN	0	O
of	of	ADP	IN	5	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
parenchyma	parenchyma	NOUN	NN	9	O
through	through	ADP	IN	9	O
an	an	DET	DT	5	O
altered	alter	VERB	VBN	9	O
BBB	BBB	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
secondary	secondary	ADJ	JJ	9	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
osmotic	osmotic	ADJ	JJ	0	O
gradient	gradient	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
considered	consider	VERB	VBN	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
rebound	rebound	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
has	have	VERB	VBZ	9	O
only	only	ADV	RB	9	O
been	be	VERB	VBN	9	O
demonstrated	demonstrate	VERB	VBN	9	O
experimentally	experimentally	ADV	RB	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
a	a	DET	DT	5	O
contribution	contribution	NOUN	NN	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
issue	issue	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
decided	decide	VERB	VBD	5	O
to	to	PART	TO	5	O
research	research	VERB	VB	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
passage	passage	NOUN	NN	9	O
of	of	ADP	IN	5	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
to	to	ADP	IN	5	O
21	21	NUM	CD	7	O
brain	brain	NOUN	NN	5	B-Disease
tumor	tumor	NOUN	NN	3	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Mannitol	Mannitol	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
18	18	NUM	CD	7	O
%	%	NOUN	NN	9	O
solution	solution	NOUN	NN	0	O
;	;	PUNCT	:	9	O
1	1	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
bolus	bolus	NOUN	NN	0	O
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
ten	ten	NUM	CD	9	O
had	have	VERB	VBD	9	O
malignant	malignant	ADJ	JJ	3	B-Disease
glioma	glioma	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
seven	seven	NUM	CD	9	O
brain	brain	NOUN	NN	5	O
metastases	metastasis	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
four	four	NUM	CD	9	O
meningioma	meningioma	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
about	about	ADP	IN	5	O
30	30	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
before	before	ADP	IN	9	O
craniotomy	craniotomy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
resection	resection	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
sample	sample	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
surrounding	surround	VERB	VBG	9	O
edematous	edematous	ADJ	JJ	5	B-Disease
white	white	ADJ	JJ	9	O
matter	matter	NOUN	NN	5	O
was	be	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
10	10	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
venous	venous	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
sample	sample	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Mannitol	Mannitol	PROPN	NNP	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
white	white	ADJ	JJ	9	O
matter	matter	NOUN	NN	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
modified	modify	VERB	VBN	9	O
version	version	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
enzyme	enzyme	ADJ	JJ	0	O
assay	assay	NOUN	NN	3	O
of	of	ADP	IN	5	O
Blonquist	Blonquist	PROPN	NNP	_	O
et	et	X	FW	6	O
al	al	PROPN	NNP	6	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
most	most	ADJ	JJS	9	O
glioma	glioma	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
white	white	ADJ	JJ	9	O
matter	matter	NOUN	NN	5	O
were	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	O
times	time	NOUN	NNS	5	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
times	time	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
meningioma	meningioma	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
metastases	metastase	VERB	VBZ	5	B-Disease
patients	patient	NOUN	NNS	5	O
plasma	plasma	VERB	VBP	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
white	white	ADJ	JJ	9	O
matter	matter	NOUN	NN	5	O
concentrations	concentration	NOUN	NNS	0	O
except	except	ADP	IN	9	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
with	with	ADP	IN	5	O
infiltration	infiltration	NOUN	NN	3	O
by	by	ADP	IN	9	O
neoplastic	neoplastic	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
study	study	NOUN	NN	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
even	even	ADV	RB	5	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
bolus	bolus	NOUN	NN	0	O
,	,	PUNCT	,	9	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
leak	leak	VERB	VB	5	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
altered	altered	ADJ	JJ	9	O
BBB	BBB	PROPN	NNP	9	O
near	near	ADP	IN	9	O
gliomas	glioma	NOUN	NNS	3	B-Disease
,	,	PUNCT	,	9	O
reversing	reverse	VERB	VBG	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
blood	blood	NOUN	NN	9	O
osmotic	osmotic	ADJ	JJ	0	O
gradient	gradient	NOUN	NN	9	O
,	,	PUNCT	,	9	O
aggravating	aggravate	VERB	VBG	5	O
peritumoral	peritumoral	ADJ	JJ	3	O
edema	edema	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
promoting	promote	VERB	VBG	9	O
rebound	rebound	NOUN	NN	5	O
of	of	ADP	IN	5	O
ICP	ICP	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Placebo	placebo	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
level	level	NOUN	NN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
EPS	EPS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
controlled	control	VERB	VBN	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
mania	mania	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
EPS	EPS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
akathisia	akathisia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
mania	mania	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Data	datum	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
from	from	ADP	IN	9	O
four	four	NUM	CD	9	O
similarly	similarly	ADV	RB	9	O
designed	design	VERB	VBN	9	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
studies	study	NOUN	NNS	9	O
evaluated	evaluate	VERB	VBD	9	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
monotherapy	monotherapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
up	up	ADP	IN	5	O
to	to	ADP	IN	5	O
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
209	209	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
198	198	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
monotherapy	monotherapy	NOUN	NN	5	O
as	as	ADP	IN	5	O
respective	respective	ADJ	JJ	9	O
active	active	ADJ	JJ	9	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
studies	study	NOUN	NNS	9	O
evaluated	evaluate	VERB	VBD	9	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
up	up	ADP	IN	5	O
to	to	ADP	IN	5	O
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
mood	mood	NOUN	NN	5	O
stabilizer	stabilizer	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
divalproex	divalproex	VERB	VBN	5	B-Chemical
,	,	PUNCT	,	9	O
QTP	QTP	PROPN	NNP	4	B-Chemical
+	+	CCONJ	CC	9	O
Li	Li	PROPN	NNP	6	B-Chemical
/	/	SYM	SYM	9	O
DVP	DVP	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
196	196	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
mood	mood	NOUN	NN	5	O
stabilizer	stabilizer	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
PBO	PBO	PROPN	NNP	0	O
+	+	CCONJ	CC	9	O
Li	Li	PROPN	NNP	6	B-Chemical
/	/	SYM	SYM	9	O
DVP	DVP	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
203	203	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
Simpson	Simpson	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Angus	Angus	PROPN	NNP	6	O
Scale	Scale	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
SAS	SAS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
Barnes	Barnes	PROPN	NNP	6	O
Akathisia	Akathisia	PROPN	NNP	5	O
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
BARS	BARS	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
adverse	adverse	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
anticholinergic	anticholinergic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
usage	usage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
EPS	EPS	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
akathisia	akathisia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
no	no	ADV	RB	9	O
different	different	ADJ	JJ	9	O
with	with	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
monotherapy	monotherapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
EPS	EPS	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
with	with	ADP	IN	5	O
QTP	QTP	PROPN	NNP	4	B-Chemical
+	+	CCONJ	CC	9	O
Li	Li	PROPN	NNP	6	B-Chemical
/	/	SYM	SYM	9	O
DVP	DVP	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
21	21	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
no	no	ADV	RB	9	O
different	different	ADJ	JJ	9	O
than	than	ADP	IN	5	O
with	with	ADP	IN	5	O
PBO	PBO	PROPN	NNP	0	O
+	+	CCONJ	CC	9	O
Li	Li	PROPN	NNP	6	B-Chemical
/	/	SYM	SYM	9	O
DVP	DVP	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
EPS	EPS	PROPN	NNP	9	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
59	59	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
99	99	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
monotherapy	monotherapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
26	26	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
98	98	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
monotherapy	monotherapy	NOUN	NN	5	O
experienced	experience	VERB	VBD	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
EPS	EPS	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
akathisia	akathisia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
low	low	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
similar	similar	ADJ	JJ	9	O
with	with	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
monotherapy	monotherapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
QTP	QTP	PROPN	NNP	4	B-Chemical
+	+	CCONJ	CC	9	O
Li	Li	PROPN	NNP	6	B-Chemical
/	/	SYM	SYM	9	O
DVP	DVP	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
PBO	PBO	PROPN	NNP	0	O
+	+	CCONJ	CC	9	O
Li	Li	PROPN	NNP	6	B-Chemical
/	/	SYM	SYM	9	O
DVP	DVP	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Lithium	Lithium	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
tremor	tremor	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
18	18	NUM	CD	7	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
cerebellar	cerebellar	ADJ	JJ	5	O
tremor	tremor	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
known	know	VERB	VBN	9	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
contributed	contribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
elevated	elevated	ADJ	JJ	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
tremor	tremor	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Haloperidol	Haloperidol	PROPN	NNP	7	B-Chemical
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
akathisia	akathisia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
tremor	tremor	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
35	35	NUM	CD	9	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
on	on	ADP	IN	5	O
SAS	SAS	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
BARS	BARS	PROPN	NNP	3	O
scores	score	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Anticholinergic	Anticholinergic	PROPN	NNP	5	O
use	use	NOUN	NN	5	O
was	be	VERB	VBD	9	O
low	low	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
similar	similar	ADJ	JJ	9	O
with	with	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
mania	mania	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
EPS	EPS	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
akathisia	akathisia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
quetiapine	quetiapine	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Is	be	VERB	VBZ	9	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
safe	safe	ADJ	JJ	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
hypothermic	hypothermic	ADJ	JJ	5	B-Disease
child	child	NOUN	NN	5	O
?	?	PUNCT	.	5	O

A	a	DET	DT	9	O
male	male	ADJ	JJ	9	O
neonate	neonate	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
Chiari	Chiari	PROPN	NNP	5	B-Disease
malformation	malformation	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
leaking	leak	VERB	VBG	5	O
myelomeningocoele	myelomeningocoele	NOUN	NN	5	O
underwent	underwent	NOUN	NN	5	O
ventriculoperitoneal	ventriculoperitoneal	NOUN	NN	5	O
shunt	shunt	NOUN	NN	5	O
insertion	insertion	NOUN	NN	1	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
repair	repair	NOUN	NN	9	O
of	of	ADP	IN	5	O
myelomeningocoele	myelomeningocoele	NOUN	NN	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
inadvertently	inadvertently	ADV	RB	5	O
became	become	VERB	VBD	9	O
moderately	moderately	ADV	RB	9	O
hypothermic	hypothermic	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
later	later	ADJ	JJ	9	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
surgery	surgery	NOUN	NN	5	O
for	for	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
prophylaxis	prophylaxis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBN	5	O
acute	acute	ADJ	JJ	9	O
severe	severe	ADJ	JJ	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
refractory	refractory	NOUN	NN	9	O
to	to	ADP	IN	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
depressant	depressant	NOUN	NN	5	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
hypothermia	hypothermia	NOUN	NN	5	B-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
additive	additive	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypothermia	hypothermia	NOUN	NN	5	B-Disease
may	may	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
clinicians	clinician	NOUN	NNS	5	O
need	need	VERB	VBP	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Valproate	valproate	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
chorea	chorea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
in	in	ADP	IN	5	O
atypical	atypical	ADJ	JJ	5	O
nonketotic	nonketotic	ADJ	JJ	5	B-Disease
hyperglycinemia	hyperglycinemia	NOUN	NN	0	I-Disease
.	.	PUNCT	.	9	O

Nonketotic	nonketotic	ADJ	JJ	7	B-Disease
hyperglycinemia	hyperglycinemia	NOUN	NN	0	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
disorder	disorder	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
amino	amino	ADJ	JJ	1	I-Disease
acid	acid	NOUN	NN	0	I-Disease
metabolism	metabolism	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
a	a	DET	DT	5	O
defect	defect	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
glycine	glycine	NOUN	NN	0	B-Chemical
cleavage	cleavage	NOUN	NN	1	O
system	system	NOUN	NN	5	O
leads	lead	VERB	VBZ	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
glycine	glycine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
body	body	NOUN	NN	5	O
compartments	compartment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
classical	classical	ADJ	JJ	9	O
form	form	NOUN	NN	9	O
it	-PRON-	PRON	PRP	5	O
presents	present	VERB	VBZ	5	O
as	as	ADP	IN	5	O
neonatal	neonatal	ADJ	JJ	9	O
apnea	apnea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
intractable	intractable	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hypotonia	hypotonia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
significant	significant	ADJ	JJ	9	O
psychomotor	psychomotor	NOUN	NN	5	B-Disease
retardation	retardation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
subset	subset	NOUN	NN	9	O
of	of	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
nonketotic	nonketotic	ADJ	JJ	5	B-Disease
hyperglycinemia	hyperglycinemia	NOUN	NN	0	I-Disease
are	be	VERB	VBP	5	O
atypical	atypical	ADJ	JJ	5	O
variants	variant	NOUN	NNS	1	O
who	who	PRON	WP	5	O
present	present	VERB	VBP	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
heterogeneous	heterogeneous	ADJ	JJ	5	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
describes	describe	VERB	VBZ	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
language	language	NOUN	NN	5	B-Disease
delay	delay	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
mental	mental	ADJ	JJ	5	B-Disease
retardation	retardation	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
nonketotic	nonketotic	ADJ	JJ	5	B-Disease
hyperglycinemia	hyperglycinemia	NOUN	NN	0	I-Disease
following	follow	VERB	VBG	9	O
her	-PRON-	DET	PRP$	5	O
presentation	presentation	NOUN	NN	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
chorea	chorea	NOUN	NN	5	B-Disease
shortly	shortly	ADV	RB	9	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Delayed	delay	VERB	VBN	5	O
institution	institution	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
focal	focal	ADJ	JJ	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
:	:	PUNCT	:	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
brain	brain	NOUN	NN	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
induced	induced	ADJ	JJ	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
instituted	institute	VERB	VBN	5	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
h	h	NOUN	NN	0	O
delay	delay	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
middle	middle	ADJ	JJ	9	B-Disease
cerebral	cerebral	ADJ	JJ	5	I-Disease
artery	artery	NOUN	NN	5	I-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MCAO	MCAO	PROPN	NNP	3	B-Disease
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
brain	brain	NOUN	NN	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
formation	formation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
histochemical	histochemical	NOUN	NN	9	O
injury	injury	NOUN	NN	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Under	under	ADP	IN	9	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
anesthesia	anesthesia	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
MCA	MCA	PROPN	NNP	9	O
of	of	ADP	IN	5	O
14	14	NUM	CD	7	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
occluded	occlude	VERB	VBN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MAP	MAP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
manipulated	manipulate	VERB	VBN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
MAP	MAP	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
by	by	ADP	IN	9	O
25	25	NUM	CD	9	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
beginning	begin	VERB	VBG	5	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
MCAO	MCAO	PROPN	NNP	3	B-Disease
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
MCAO	MCAO	PROPN	NNP	3	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
killed	kill	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
brains	brain	NOUN	NNS	9	O
harvested	harvest	VERB	VBD	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
brains	brain	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
sectioned	section	VERB	VBN	9	O
along	along	ADP	IN	9	O
coronal	coronal	ADJ	JJ	5	O
planes	plane	NOUN	NNS	5	O
spanning	span	VERB	VBG	9	O
the	the	DET	DT	5	O
distribution	distribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
ischemia	ischemia	NOUN	NN	9	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
MCAO	MCAO	PROPN	NNP	3	B-Disease
.	.	PUNCT	.	9	O

Specific	specific	ADJ	JJ	9	O
gravity	gravity	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
SG	SG	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
subcortex	subcortex	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
sites	site	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cortex	cortex	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
core	core	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
periphery	periphery	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
territory	territory	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
injury	injury	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
2	2	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
triphenyltetrazolium	triphenyltetrazolium	NOUN	NN	0	I-Chemical
staining	staining	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
core	core	NOUN	NN	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
SG	SG	PROPN	NNP	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
subcortex	subcortex	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cortex	cortex	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
periphery	periphery	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
territory	territory	NOUN	NN	5	O
,	,	PUNCT	,	9	O
SG	SG	PROPN	NNP	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cortex	cortex	NOUN	NN	5	O
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
(	(	PUNCT	-LRB-	9	O
less	less	ADJ	JJR	5	O
edema	edema	NOUN	NN	5	B-Disease
accumulation	accumulation	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
041	041	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
vs	vs	ADP	IN	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
039	039	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
area	area	NOUN	NN	5	O
of	of	ADP	IN	5	O
histochemical	histochemical	ADJ	JJ	9	O
injury	injury	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
sectional	sectional	ADJ	JJ	5	O
area	area	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hemisphere	hemisphere	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
21	21	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
instituted	institute	VERB	VBD	5	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
MCAO	MCAO	PROPN	NNP	3	B-Disease
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
aggravate	aggravate	VERB	VB	9	O
edema	edema	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
core	core	NOUN	NN	9	O
,	,	PUNCT	,	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
improves	improve	VERB	VBZ	5	O
edema	edema	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
periphery	periphery	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
territory	territory	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
area	area	NOUN	NN	5	O
of	of	ADP	IN	5	O
histochemical	histochemical	ADJ	JJ	9	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
pubertal	pubertal	ADJ	JJ	5	O
anabolic	anabolic	ADJ	JJ	9	O
androgenic	androgenic	NOUN	NN	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
exposure	exposure	NOUN	NN	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
goal	goal	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
interactive	interactive	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
anabolic	anabolic	ADJ	JJ	9	O
androgenic	androgenic	NOUN	NN	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
AAS	AAS	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
exposure	exposure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxytryptamine	hydroxytryptamine	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
-	-	SYM	SYM	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
depletion	depletion	NOUN	NN	3	O
on	on	ADP	IN	5	O
behavior	behavior	NOUN	NN	5	O
of	of	ADP	IN	5	O
pubertal	pubertal	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Serotonin	Serotonin	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
depleted	deplete	VERB	VBN	3	O
beginning	beginning	NOUN	NN	5	O
on	on	ADP	IN	5	O
postnatal	postnatal	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
26	26	NUM	CD	7	O
with	with	ADP	IN	5	O
parachlorophenylalanine	parachlorophenylalanine	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
PCPA	PCPA	PROPN	NNP	3	B-Chemical
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
every	every	DET	DT	5	O
other	other	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
controls	control	NOUN	NNS	9	O
received	receive	VERB	VBN	9	O
saline	saline	NOUN	NN	0	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
puberty	puberty	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P40	P40	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
half	half	DET	PDT	5	O
the	the	DET	DT	5	O
PCPA	pcpa	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
half	half	DET	PDT	5	O
the	the	DET	DT	5	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
began	begin	VERB	VBD	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
T	t	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
/	/	SYM	SYM	9	O
week	week	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Behavioral	behavioral	ADJ	JJ	5	O
measures	measure	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
locomotion	locomotion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
irritability	irritability	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
copulation	copulation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
partner	partner	NOUN	NN	5	O
preference	preference	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
aggression	aggression	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
for	for	ADP	IN	5	O
aggression	aggression	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
home	home	NOUN	NN	5	O
cage	cage	NOUN	NN	5	O
,	,	PUNCT	,	9	O
both	both	CCONJ	CC	9	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
physical	physical	ADJ	JJ	5	O
provocation	provocation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
mild	mild	ADJ	JJ	9	O
tail	tail	NOUN	NN	9	O
pinch	pinch	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Brain	brain	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
metabolite	metabolite	NOUN	NN	0	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxyindoleacetic	hydroxyindoleacetic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HIAA	HIAA	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
using	use	VERB	VBG	9	O
HPLC	HPLC	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

PCPA	PCPA	NOUN	NNS	3	B-Chemical
significantly	significantly	ADV	RB	9	O
and	and	CCONJ	CC	5	O
substantially	substantially	ADV	RB	9	O
depleted	deplete	VERB	VBD	3	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HIAA	HIAA	PROPN	NNP	0	I-Chemical
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
brain	brain	NOUN	NN	5	O
regions	region	NOUN	NNS	9	O
examined	examine	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Chronic	Chronic	PROPN	NNP	9	O
T	T	PROPN	NNP	3	B-Chemical
treatment	treatment	NOUN	NN	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
5	5	NUM	CD	9	B-Chemical
-	-	SYM	SYM	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HIAA	HIAA	PROPN	NNP	0	I-Chemical
in	in	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
brain	brain	NOUN	NN	5	O
areas	area	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
much	much	ADV	RB	5	O
lesser	less	ADJ	JJR	9	O
extent	extent	NOUN	NN	9	O
than	than	ADP	IN	5	O
PCPA	PCPA	PROPN	NNP	3	B-Chemical
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
PCPA	PCPA	PROPN	NNP	3	B-Chemical
alone	alone	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
irritability	irritability	NOUN	NN	5	B-Disease
but	but	CCONJ	CC	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
behavior	behavior	NOUN	NN	5	O
,	,	PUNCT	,	9	O
partner	partner	NOUN	NN	5	O
preference	preference	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
aggression	aggression	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

T	t	NOUN	NN	3	B-Chemical
alone	alone	ADV	RB	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
locomotion	locomotion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
irritability	irritability	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
sexual	sexual	ADJ	JJ	5	O
behavior	behavior	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
increased	increase	VERB	VBD	9	O
partner	partner	NOUN	NN	5	O
preference	preference	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
aggression	aggression	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
striking	striking	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
combining	combine	VERB	VBG	5	O
T	t	NOUN	NN	3	B-Chemical
+	+	CCONJ	CC	9	O
PCPA	PCPA	PROPN	NNP	3	B-Chemical
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
attack	attack	NOUN	NN	5	O
frequency	frequency	NOUN	NN	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
latency	latency	NOUN	NN	5	O
to	to	PART	TO	5	O
attack	attack	VERB	VB	5	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
following	follow	VERB	VBG	9	O
physical	physical	ADJ	JJ	5	O
provocation	provocation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
these	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
speculated	speculate	VERB	VBN	9	O
that	that	ADP	IN	5	O
pubertal	pubertal	ADJ	JJ	5	O
AAS	AAS	PROPN	NNP	0	O
users	user	NOUN	NNS	5	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
central	central	ADJ	JJ	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
especially	especially	ADV	RB	5	O
prone	prone	ADJ	JJ	5	O
to	to	PART	TO	5	O
exhibit	exhibit	VERB	VB	9	O
aggressive	aggressive	ADJ	JJ	5	B-Disease
behavior	behavior	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
UMB24	UMB24	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
SM	sm	NOUN	NN	9	B-Chemical
21	21	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
putative	putative	ADJ	JJ	1	O
sigma2	sigma2	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
preferring	prefer	VERB	VBG	5	O
antagonists	antagonist	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
behavioral	behavioral	ADJ	JJ	5	O
toxic	toxic	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
stimulant	stimulant	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Earlier	early	ADJ	JJR	9	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
demonstrated	demonstrate	VERB	VBN	9	O
that	that	ADP	IN	5	O
antagonism	antagonism	NOUN	NN	9	O
of	of	ADP	IN	5	O
sigma1	sigma1	NOUN	NN	3	O
receptors	receptor	NOUN	NNS	3	O
attenuates	attenuate	VERB	VBZ	3	O
the	the	DET	DT	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
lethal	lethal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
locomotor	locomotor	NOUN	NN	5	O
stimulatory	stimulatory	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
rewarding	rewarding	ADJ	JJ	5	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
contribution	contribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
sigma2	sigma2	ADJ	JJ	9	O
receptors	receptor	NOUN	NNS	3	O
is	be	VERB	VBZ	5	O
unclear	unclear	ADJ	JJ	9	O
because	because	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
tools	tool	NOUN	NNS	5	O
to	to	PART	TO	5	O
selectively	selectively	ADV	RB	3	O
target	target	VERB	VB	9	O
this	this	DET	DT	5	O
subtype	subtype	NOUN	NN	9	O
are	be	VERB	VBP	5	O
unavailable	unavailable	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
begin	begin	VERB	VB	5	O
addressing	address	VERB	VBG	5	O
this	this	DET	DT	5	O
need	need	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
characterized	characterize	VERB	VBD	9	O
UMB24	UMB24	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phenethyl	phenethyl	ADV	RB	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pyridyl	pyridyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
piperazine	piperazine	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
SM	sm	NOUN	NN	9	B-Chemical
21	21	NUM	CD	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
3alpha	3alpha	NUM	CD	1	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tropanyl	tropanyl	NOUN	NN	_	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chorophenoxy	chorophenoxy	PROPN	NNP	_	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
butyrate	butyrate	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
receptor	receptor	NOUN	NN	3	O
binding	binding	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
behavioral	behavioral	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Receptor	receptor	NOUN	NN	3	O
binding	bind	VERB	VBG	1	O
studies	study	NOUN	NNS	9	O
confirmed	confirm	VERB	VBD	9	O
that	that	ADP	IN	5	O
UMB24	UMB24	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
SM	sm	NOUN	NN	9	B-Chemical
21	21	NUM	CD	7	I-Chemical
display	display	NOUN	NN	9	O
preferential	preferential	ADJ	JJ	9	O
affinity	affinity	NOUN	NN	0	O
for	for	ADP	IN	5	O
sigma2	sigma2	NOUN	NN	9	O
over	over	ADP	IN	5	O
sigma1	sigma1	NOUN	NN	3	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
behavioral	behavioral	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
pretreatment	pretreatment	NOUN	NN	0	O
of	of	ADP	IN	5	O
Swiss	Swiss	PROPN	NNP	2	O
Webster	Webster	PROPN	NNP	6	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
UMB24	UMB24	PROPN	NNP	_	B-Chemical
or	or	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
SM	sm	NOUN	NN	9	B-Chemical
21	21	NUM	CD	7	I-Chemical
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBN	3	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
lethality	lethality	NOUN	NN	3	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
administered	administer	VERB	VBN	9	O
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
SM	sm	NOUN	NN	9	B-Chemical
21	21	NUM	CD	7	I-Chemical
produced	produce	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
UMB24	UMB24	PROPN	NNP	_	B-Chemical
had	have	VERB	VBD	9	O
locomotor	locomotor	NOUN	NN	5	O
depressant	depressant	NOUN	NN	5	O
actions	action	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Together	together	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	DET	DT	5	O
sigma2	sigma2	ADJ	JJ	9	O
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
have	have	VERB	VBP	5	O
the	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
to	to	PART	TO	5	O
attenuate	attenuate	VERB	VB	9	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
further	further	ADJ	JJ	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
more	more	ADV	RBR	5	O
selective	selective	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
affinity	affinity	NOUN	NN	0	O
ligands	ligand	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
warranted	warrant	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
child	child	NOUN	NN	5	O
with	with	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
palsy	palsy	ADJ	JJ	5	I-Disease
undergoing	undergo	VERB	VBG	9	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anesthesia	anesthesia	NOUN	NN	5	O
after	after	ADP	IN	9	O
preoperative	preoperative	ADJ	JJ	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Clonidine	Clonidine	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
frequently	frequently	ADV	RB	5	O
administered	administer	VERB	VBN	9	O
alpha2	alpha2	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
agonist	agonist	NOUN	NN	3	O
which	which	DET	WDT	5	O
can	can	VERB	MD	5	O
decrease	decrease	VERB	VB	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
child	child	NOUN	NN	5	O
with	with	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
palsy	palsy	ADJ	JJ	5	I-Disease
and	and	CCONJ	CC	5	O
seizure	seizure	VERB	VB	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
receiving	receive	VERB	VBG	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
restlessness	restlessness	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
presented	present	VERB	VBD	5	O
for	for	ADP	IN	5	O
placement	placement	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
baclofen	baclofen	NOUN	NN	0	B-Chemical
pump	pump	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Without	without	ADP	IN	9	O
the	the	DET	DT	5	O
knowledge	knowledge	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
personnel	personnel	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
mother	mother	NOUN	NN	5	O
administered	administer	VERB	VBD	9	O
three	three	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
evening	evening	NOUN	NN	5	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
morning	morning	NOUN	NN	5	O
of	of	ADP	IN	5	O
surgery	surgery	NOUN	NN	5	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anesthesia	anesthesia	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
requiring	require	VERB	VBG	5	O
cardiac	cardiac	ADJ	JJ	5	O
resuscitation	resuscitation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
no	no	DET	DT	9	O
previous	previous	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
child	child	NOUN	NN	5	O
undergoing	undergo	VERB	VBG	9	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anesthesia	anesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Angiotensin	angiotensin	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
ACE	ACE	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
inhibitor	inhibitor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
angioedema	angioedema	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
stomach	stomach	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
small	small	ADJ	JJ	9	O
intestine	intestine	NOUN	NN	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
45	45	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
African	african	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
American	american	ADJ	JJ	9	O
female	female	NOUN	NN	9	O
with	with	ADP	IN	5	O
newly	newly	ADV	RB	9	O
diagnosed	diagnose	VERB	VBN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
started	start	VERB	VBN	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
pill	pill	NOUN	NN	5	O
of	of	ADP	IN	5	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
benazapril	benazapril	ADJ	JJ	5	B-Chemical
10	10	NUM	CD	9	O
/	/	SYM	SYM	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
very	very	ADV	RB	5	O
next	next	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
presented	present	VERB	VBD	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
room	room	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ER	ER	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
abdominal	abdominal	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Physical	physical	ADJ	JJ	5	O
exam	exam	NOUN	NN	5	O
,	,	PUNCT	,	9	O
complete	complete	ADJ	JJ	9	O
metabolic	metabolic	ADJ	JJ	9	O
panel	panel	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hemogram	hemogram	NOUN	NN	5	O
were	be	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
range	range	NOUN	NN	9	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
discharged	discharge	VERB	VBN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
ER	ER	PROPN	NNP	3	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
hours	hour	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
fluid	fluid	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
analgesics	analgesic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
ER	ER	PROPN	NNP	3	O
the	the	DET	DT	5	O
next	next	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
complaints	complaint	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
time	time	NOUN	NN	5	O
the	the	DET	DT	5	O
physical	physical	ADJ	JJ	5	O
exam	exam	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
distended	distended	ADJ	JJ	5	O
abdomen	abdoman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
dullness	dullness	NOUN	NN	5	O
to	to	ADP	IN	5	O
percussion	percussion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CT	CT	PROPN	NNP	9	O
scan	scan	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
abdomen	abdoman	NOUN	NNS	5	O
revealed	reveal	VERB	VBN	9	O
markedly	markedly	ADV	RB	9	O
thickened	thicken	VERB	VBN	5	O
antrum	antrum	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
stomach	stomach	NOUN	NN	9	O
,	,	PUNCT	,	9	O
duodenum	duodenum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
jejunum	jejunum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
along	along	ADP	IN	9	O
with	with	ADP	IN	5	O
fluid	fluid	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
abdominal	abdominal	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
pelvic	pelvic	ADJ	JJ	5	O
cavity	cavity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Angiotensin	angiotensin	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitor	inhibitor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
ACEI	ACEI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
angioedema	angioedema	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
suspected	suspect	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
medications	medication	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
symptoms	symptom	NOUN	NNS	5	O
improved	improve	VERB	VBD	5	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
next	next	ADJ	JJ	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
repeat	repeat	VERB	VB	9	O
CT	CT	PROPN	NNP	9	O
after	after	ADP	IN	9	O
72	72	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
marked	marked	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
stomach	stomach	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
small	small	ADJ	JJ	9	O
bowel	bowel	NOUN	NN	5	O
thickening	thickening	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
ascites	ascite	NOUN	NNS	3	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
recognition	recognition	NOUN	NN	5	O
of	of	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
ACE	ACE	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
receptor	receptor	NOUN	NN	3	O
blocker	blocker	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
ARB	ARB	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
intestinal	intestinal	ADJ	JJ	9	B-Disease
angioedema	angioedema	NOUN	NN	5	I-Disease
constitutes	constitute	VERB	VBZ	9	O
a	a	DET	DT	5	O
challenge	challenge	NOUN	NN	9	O
to	to	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
care	care	NOUN	NN	5	O
physicians	physician	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
internists	internist	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
emergency	emergency	NOUN	NN	5	O
room	room	NOUN	NN	9	O
personal	personal	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
surgeons	surgeon	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Characterization	characterization	NOUN	NN	9	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
distinct	distinct	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
syndromes	syndrome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
sinus	sinus	NOUN	NN	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
atrioventricular	atrioventricular	ADJ	JJ	5	B-Disease
block	block	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
prompted	prompt	VERB	VBD	9	O
an	an	DET	DT	5	O
extensive	extensive	ADJ	JJ	5	O
literature	literature	NOUN	NN	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
the	the	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
distinct	distinct	ADJ	JJ	9	O
forms	form	NOUN	NNS	9	O
of	of	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
emerged	emerge	VERB	VBD	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
group	group	NOUN	NN	9	O
developed	develop	VERB	VBD	5	O
sinus	sinus	NOUN	NN	5	B-Disease
tachycardias	tachycardias	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
setting	setting	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
massive	massive	ADJ	JJ	9	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
consisted	consist	VERB	VBD	5	O
almost	almost	ADV	RB	9	O
exclusively	exclusively	ADV	RB	9	O
of	of	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
potentially	potentially	ADV	RB	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
bradyarrhythmias	bradyarrhythmia	NOUN	NNS	5	B-Disease
or	or	CCONJ	CC	5	O
atrioventricular	atrioventricular	ADJ	JJ	5	B-Disease
conduction	conduction	NOUN	NN	5	I-Disease
delay	delay	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
either	either	CCONJ	CC	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
modestly	modestly	ADV	RB	9	O
elevated	elevate	VERB	VBN	9	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
serum	serum	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
many	many	ADJ	JJ	5	O
neurologic	neurologic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
conditions	condition	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
recognition	recognition	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
syndrome	syndrome	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
important	important	ADJ	JJ	9	O
implications	implication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
abnormal	abnormal	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
adrenergic	adrenergic	ADP	IN	9	O
neuron	neuron	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
iodine	iodine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
125	125	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
metaiodobenzylguanidine	metaiodobenzylguanidine	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Radiolabeled	radiolabeled	ADJ	JJ	0	B-Chemical
metaiodobenzylguanidine	metaiodobenzylguanidine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
MIBG	MIBG	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
analog	analog	NOUN	NN	0	O
of	of	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
NE	NE	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
serves	serve	VERB	VBZ	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
index	index	NOUN	NN	5	O
of	of	ADP	IN	5	O
adrenergic	adrenergic	NOUN	NN	9	O
neuron	neuron	NOUN	NN	5	O
integrity	integrity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
tested	test	VERB	VBD	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	WDT	5	O
abnormal	abnormal	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
adrenergic	adrenergic	ADP	IN	9	O
neuron	neuron	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
may	may	VERB	MD	5	O
appear	appear	VERB	VB	9	O
and	and	CCONJ	CC	5	O
be	be	VERB	VB	5	O
exacerbated	exacerbate	VERB	VBN	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	:	7	O
dependently	dependently	ADV	RB	3	O
in	in	ADP	IN	5	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
vacuolar	vacuolar	ADJ	JJ	1	B-Disease
degeneration	degeneration	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	I-Disease
myocardial	myocardial	ADJ	JJ	9	I-Disease
cells	cell	NOUN	NNS	3	I-Disease
was	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
in	in	ADP	IN	5	O
relation	relation	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
once	once	ADV	RB	5	O
a	a	DET	DT	5	O
week	week	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
abnormalities	abnormality	NOUN	NNS	9	O
or	or	CCONJ	CC	5	O
only	only	ADV	RB	9	O
isolated	isolate	VERB	VBN	9	O
degeneration	degeneration	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
wk	wk	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
isolated	isolate	VERB	VBN	9	O
or	or	CCONJ	CC	5	O
scattered	scatter	VERB	VBN	5	O
degeneration	degeneration	NOUN	NN	9	O
in	in	ADP	IN	5	O
half	half	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
wk	wk	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
frequent	frequent	ADJ	JJ	5	O
scattered	scatter	VERB	VBN	5	O
degeneration	degeneration	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
wk	wk	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
scattered	scatter	VERB	VBN	5	O
or	or	CCONJ	CC	5	O
focal	focal	ADJ	JJ	5	O
degeneration	degeneration	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
wk	wk	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
extensive	extensive	ADJ	JJ	5	O
degeneration	degeneration	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
wk	wk	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Myocardial	myocardial	ADJ	JJ	9	O
accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	O
125I	125i	NUM	CD	0	O
]	]	PUNCT	-RRB-	9	O
MIBG	MIBG	PROPN	NNP	0	B-Chemical
4	4	NUM	CD	9	O
hr	hr	INTJ	UH	0	O
after	after	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
injection	injection	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
controls	control	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
groups	group	NOUN	NNS	9	O
treated	treat	VERB	VBD	3	O
3	3	NUM	CD	9	O
wk	wk	ADP	IN	9	O
or	or	CCONJ	CC	5	O
less	less	ADJ	JJR	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
wk	wk	NOUN	NN	9	O
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
slightly	slightly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
accumulation	accumulation	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
82	82	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
accumulation	accumulation	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
about	about	ADV	RB	5	O
66	66	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
:	:	PUNCT	:	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
wk	wk	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
MIBG	MIBG	PROPN	NNP	0	B-Chemical
accumulation	accumulation	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
was	be	VERB	VBD	9	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
27	27	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
that	that	DET	DT	5	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
wk	wk	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
MIBG	MIBG	PROPN	NNP	0	B-Chemical
accumulation	accumulation	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
was	be	VERB	VBD	9	O
18	18	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
14	14	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
that	that	DET	DT	5	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
MIBG	MIBG	PROPN	NNP	0	B-Chemical
accumulation	accumulation	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
myocardium	myocardium	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
adrenergic	adrenergic	ADP	IN	9	O
neuron	neuron	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
slight	slight	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
scattered	scatter	VERB	VBN	5	O
or	or	CCONJ	CC	5	O
focal	focal	ADJ	JJ	5	O
vacuolar	vacuolar	ADJ	JJ	1	B-Disease
degeneration	degeneration	NOUN	NN	9	I-Disease
)	)	PUNCT	-RRB-	9	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
MIBG	MIBG	PROPN	NNP	0	B-Chemical
scintigraphy	scintigraphy	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
for	for	ADP	IN	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Syncope	Syncope	PROPN	NNP	7	B-Disease
and	and	CCONJ	CC	5	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
among	among	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
heroin	heroin	NOUN	NN	5	B-Chemical
dependence	dependence	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
city	city	NOUN	NN	5	O
of	of	ADP	IN	5	O
Copenhagen	Copenhagen	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Methadone	Methadone	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
prescribed	prescribe	VERB	VBN	5	O
to	to	PART	TO	5	O
heroin	heroin	VERB	VB	5	B-Chemical
addicts	addict	NOUN	NNS	5	O
to	to	PART	TO	5	O
decrease	decrease	VERB	VB	9	O
illicit	illicit	ADJ	JJ	5	O
opioid	opioid	NOUN	NN	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Prolongation	prolongation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ECG	ECG	PROPN	NNP	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TdP	tdp	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
heroin	heroin	NOUN	NN	5	B-Chemical
addicts	addict	NOUN	NNS	5	O
sometimes	sometimes	ADV	RB	5	O
faint	faint	ADJ	JJ	9	O
while	while	ADP	IN	9	O
using	use	VERB	VBG	9	O
illicit	illicit	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
doctors	doctor	NOUN	NNS	5	O
might	may	VERB	MD	9	O
attribute	attribute	VERB	VB	5	O
too	too	ADV	RB	5	O
many	many	ADJ	JJ	5	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
syncope	syncope	NOUN	NN	5	B-Disease
to	to	PART	TO	5	O
illicit	illicit	VERB	VB	5	O
drug	drug	NOUN	NN	5	O
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
thereby	thereby	ADV	RB	9	O
underestimate	underestimate	VERB	VB	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
TdP	tdp	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
special	special	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
mortality	mortality	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
population	population	NOUN	NN	5	O
may	may	VERB	MD	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
part	part	NOUN	NN	9	O
,	,	PUNCT	,	9	O
be	be	VERB	VB	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
proarrhythmic	proarrhythmic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
this	this	DET	DT	5	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
sectional	sectional	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
interview	interview	NOUN	NN	5	O
,	,	PUNCT	,	9	O
ECGs	ecg	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
population	population	NOUN	NN	5	O
of	of	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
heroin	heroin	NOUN	NN	5	B-Chemical
addicts	addict	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
buprenorphine	buprenorphine	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
daily	daily	ADJ	JJ	5	O
basis	basis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
Drug	Drug	PROPN	NNP	5	O
Addiction	Addiction	PROPN	NNP	5	O
Service	Service	PROPN	NNP	2	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
municipal	municipal	NOUN	NN	5	O
of	of	ADP	IN	5	O
Copenhagen	Copenhagen	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
450	450	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
approximately	approximately	ADV	RB	9	O
52	52	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
was	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
from	from	ADP	IN	9	O
12	12	NUM	CD	9	O
lead	lead	NOUN	NN	5	O
ECGs	ecg	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
participants	participant	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
interviewed	interview	VERB	VBN	5	O
about	about	ADP	IN	5	O
any	any	DET	DT	5	O
experience	experience	NOUN	NN	5	O
of	of	ADP	IN	5	O
syncope	syncope	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
opioid	opioid	NOUN	NN	5	O
dose	dose	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
QT	QT	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
dose	dose	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
reporting	reporting	NOUN	NN	5	O
of	of	ADP	IN	5	O
syncope	syncope	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
using	use	VERB	VBG	9	O
multivariate	multivariate	ADJ	JJ	5	O
linear	linear	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
logistic	logistic	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Methadone	Methadone	PROPN	NNP	7	B-Chemical
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
longer	long	ADJ	JJR	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
140	140	NUM	CD	9	O
ms	ms	NOUN	NN	5	O
/	/	SYM	SYM	9	O
mg	mg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
buprenorphine	buprenorphine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
QTc	QTc	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
the	the	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
28	28	NUM	CD	7	O
%	%	NOUN	NN	9	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
32	32	NUM	CD	7	O
%	%	NOUN	NN	9	O
women	woman	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
prolonged	prolong	VERB	VBN	9	B-Disease
QTc	qtc	ADJ	JJ	5	I-Disease
interval	interval	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
buprenorphine	buprenorphine	NOUN	NN	5	B-Chemical
had	have	VERB	VBD	9	O
QTc	qtc	ADJ	JJ	5	O
interval	interval	NOUN	NN	5	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
440	440	NUM	CD	9	O
s	s	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
higher	high	ADJ	JJR	9	O
methadone	methadone	NOUN	NN	5	B-Chemical
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
times	time	NOUN	NNS	5	O
higher	high	ADJ	JJR	9	O
odds	odd	NOUN	NNS	5	O
for	for	ADP	IN	5	O
syncope	syncope	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Methadone	Methadone	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
QT	QT	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
reporting	reporting	NOUN	NN	5	O
of	of	ADP	IN	5	O
syncope	syncope	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
population	population	NOUN	NN	5	O
of	of	ADP	IN	5	O
heroin	heroin	NOUN	NN	5	B-Chemical
addicts	addict	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Neuroleptic	neuroleptic	ADJ	JJ	2	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
ziprasidone	ziprasidone	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Neuroleptic	neuroleptic	ADJ	JJ	2	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
NMS	nms	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
rarest	rare	ADJ	JJS	5	O
and	and	CCONJ	CC	5	O
most	most	ADV	RBS	9	O
serious	serious	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
movement	movement	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
NMS	NMS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
ziprasidone	ziprasidone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
conventional	conventional	ADJ	JJ	5	O
neuroleptics	neuroleptic	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
more	more	ADV	RBR	5	O
frequently	frequently	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
NMS	NMS	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
atypical	atypical	ADJ	JJ	5	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
like	like	ADP	IN	9	O
ziprasidone	ziprasidone	NOUN	NN	5	B-Chemical
may	may	VERB	MD	5	O
also	also	ADV	RB	9	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
cause	cause	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
NMS	NMS	PROPN	NNP	9	B-Disease
after	after	ADP	IN	9	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
80	80	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
orally	orally	ADV	RB	0	O
administrated	administrate	VERB	VBN	0	O
ziprasidone	ziprasidone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
earliest	early	ADJ	JJS	9	O
(	(	PUNCT	-LRB-	9	O
second	second	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
NMS	nms	NOUN	NN	9	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
ziprasidone	ziprasidone	NOUN	NN	5	B-Chemical
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Peripheral	peripheral	ADJ	JJ	9	O
iron	iron	NOUN	NN	0	B-Chemical
dextran	dextran	NOUN	NN	0	I-Chemical
induced	induced	ADJ	JJ	3	O
degeneration	degeneration	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
dopaminergic	dopaminergic	ADJ	JJ	5	I-Disease
neurons	neuron	NOUN	NNS	3	I-Disease
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
substantia	substantia	NOUN	NN	9	O
nigra	nigra	NOUN	NN	4	O
.	.	PUNCT	.	9	O

Iron	iron	NOUN	NN	0	B-Chemical
accumulation	accumulation	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
considered	consider	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
demonstrate	demonstrate	VERB	VB	9	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	O
iron	iron	NOUN	NN	0	B-Chemical
overload	overload	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neuron	neuron	NOUN	NN	5	O
loss	loss	NOUN	NN	9	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
substantia	substantia	NOUN	NN	9	O
nigra	nigra	NOUN	NN	4	O
(	(	PUNCT	-LRB-	9	O
SN	SN	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
used	use	VERB	VBD	5	O
fast	fast	ADJ	JJ	5	O
cyclic	cyclic	NOUN	NN	0	O
voltammetry	voltammetry	NOUN	NN	0	O
,	,	PUNCT	,	9	O
tyrosine	tyrosine	NOUN	NN	3	B-Chemical
hydroxylase	hydroxylase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
TH	th	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
,	,	PUNCT	,	9	O
Perls	Perls	PROPN	NNP	0	O
'	'	PART	POS	9	O
iron	iron	NOUN	NN	0	B-Chemical
staining	staining	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
performance	performance	NOUN	NN	5	O
liquid	liquid	NOUN	NN	0	O
chromatography	chromatography	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
electrochemical	electrochemical	ADJ	JJ	0	O
detection	detection	NOUN	NN	9	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
degeneration	degeneration	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
dopaminergic	dopaminergic	ADJ	JJ	5	I-Disease
neurons	neuron	NOUN	NNS	3	I-Disease
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
iron	iron	NOUN	NN	0	B-Chemical
content	content	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
SN	sn	NOUN	NN	9	O
of	of	ADP	IN	5	O
iron	iron	NOUN	NN	0	B-Chemical
dextran	dextran	NOUN	NN	0	I-Chemical
overloaded	overload	VERB	VBN	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	O
iron	iron	NOUN	NN	0	B-Chemical
dextran	dextran	NOUN	NN	0	I-Chemical
overload	overload	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
iron	iron	NOUN	NN	0	B-Chemical
staining	stain	VERB	VBG	3	O
positive	positive	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
TH	th	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
immunoreactive	immunoreactive	ADJ	JJ	3	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
SN	sn	NOUN	NN	9	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
,	,	PUNCT	,	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
release	release	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
content	content	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
metabolites	metabolite	NOUN	NNS	0	O
contents	content	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
caudate	caudate	ADJ	JJ	5	O
putamen	putaman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Even	even	ADV	RB	5	O
more	more	ADV	RBR	5	O
dramatic	dramatic	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
overload	overload	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	O
iron	iron	NOUN	NN	0	B-Chemical
dextran	dextran	NOUN	NN	0	I-Chemical
can	can	VERB	MD	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
iron	iron	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
SN	sn	NOUN	NN	9	O
,	,	PUNCT	,	9	O
where	where	ADV	WRB	5	O
excessive	excessive	ADJ	JJ	5	O
iron	iron	NOUN	NN	0	B-Chemical
causes	cause	VERB	VBZ	9	O
the	the	DET	DT	5	O
degeneration	degeneration	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
dopaminergic	dopaminergic	ADJ	JJ	5	I-Disease
neurons	neuron	NOUN	NNS	3	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	O
iron	iron	NOUN	NN	0	B-Chemical
overload	overload	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
more	more	ADV	RBR	5	O
destructive	destructive	ADJ	JJ	5	O
to	to	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
iron	iron	NOUN	NN	0	B-Chemical
overload	overload	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Attenuated	attenuate	VERB	VBN	9	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
prepulse	prepulse	NOUN	NN	5	O
inhibition	inhibition	NOUN	NN	3	O
by	by	ADP	IN	9	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
after	after	ADP	IN	9	O
maternal	maternal	ADJ	JJ	9	O
deprivation	deprivation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
adolescent	adolescent	NOUN	NN	5	O
corticosterone	corticosterone	ADJ	JJ	3	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
may	may	VERB	MD	5	O
include	include	VERB	VB	5	O
an	an	DET	DT	5	O
early	early	ADJ	JJ	9	O
neurodevelopmental	neurodevelopmental	ADJ	JJ	5	O
stress	stress	NOUN	NN	9	O
component	component	NOUN	NN	9	O
which	which	DET	WDT	5	O
increases	increase	VERB	VBZ	9	O
vulnerability	vulnerability	NOUN	NN	5	O
to	to	PART	TO	5	O
later	later	ADV	RB	9	O
stressful	stressful	ADJ	JJ	5	O
life	life	NOUN	NN	5	O
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
overt	overt	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
early	early	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
maternal	maternal	ADJ	JJ	9	O
deprivation	deprivation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
later	later	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
,	,	PUNCT	,	9	O
simulated	simulate	VERB	VBN	5	O
by	by	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
periadolescent	periadolescent	ADJ	JJ	5	O
corticosterone	corticosterone	NOUN	NN	3	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
behaviour	behaviour	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
caused	cause	VERB	VBN	9	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
prepulse	prepulse	NOUN	NN	5	O
inhibition	inhibition	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
PPI	PPI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
that	that	DET	WDT	5	O
had	have	VERB	VBD	9	O
undergone	undergo	VERB	VBN	5	O
either	either	CCONJ	CC	9	O
maternal	maternal	ADJ	JJ	9	O
deprivation	deprivation	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
corticosterone	corticosterone	NOUN	NN	3	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
surprisingly	surprisingly	ADV	RB	9	O
absent	absent	ADJ	JJ	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
that	that	DET	WDT	5	O
had	have	VERB	VBD	9	O
undergone	undergo	VERB	VBN	5	O
the	the	DET	DT	5	O
combined	combine	VERB	VBN	9	O
early	early	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
late	late	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Amphetamine	amphetamine	ADJ	JJ	7	B-Chemical
treatment	treatment	NOUN	NN	9	O
significantly	significantly	ADV	RB	9	O
disrupted	disrupt	VERB	VBD	9	O
PPI	PPI	PROPN	NNP	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
deprived	deprived	ADJ	JJ	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
absent	absent	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
maternally	maternally	ADV	RB	9	O
deprived	deprive	VERB	VBN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
1A	1a	ADJ	JJ	9	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
OH	oh	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DPAT	DPAT	PROPN	NNP	0	I-Chemical
,	,	PUNCT	,	9	O
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
PPI	PPI	PROPN	NNP	5	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Amphetamine	amphetamine	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	B-Disease
hyperactivity	hyperactivity	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
an	an	DET	DT	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
interaction	interaction	NOUN	NN	9	O
of	of	ADP	IN	5	O
early	early	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
,	,	PUNCT	,	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
maternal	maternal	ADJ	JJ	9	O
deprivation	deprivation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
'	'	PUNCT	``	9	O
adolescent	adolescent	NOUN	NN	5	O
'	'	PUNCT	''	9	O
stress	stress	NOUN	NN	9	O
,	,	PUNCT	,	9	O
simulated	simulate	VERB	VBN	5	O
by	by	ADP	IN	9	O
corticosterone	corticosterone	NOUN	NN	3	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
PPI	PPI	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
altered	altered	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
could	could	VERB	MD	9	O
indicate	indicate	VERB	VB	9	O
differential	differential	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptor	receptor	NOUN	NN	3	O
signalling	signal	VERB	VBG	3	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
functional	functional	ADJ	JJ	9	O
desensitisation	desensitisation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
altered	altered	ADJ	JJ	9	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
sensory	sensory	ADJ	JJ	5	O
gating	gating	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
nucleus	nucleus	NOUN	NN	9	O
accumbens	accumben	NOUN	NNS	5	O
by	by	ADP	IN	9	O
limbic	limbic	ADJ	JJ	5	O
structures	structure	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
extremely	extremely	ADV	RB	5	O
rare	rare	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
delusional	delusional	ADJ	JJ	5	B-Disease
parasitosis	parasitosis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
C	C	PROPN	NNP	9	I-Disease
patient	patient	NOUN	NN	5	O
during	during	ADP	IN	5	O
pegylated	pegylate	VERB	VBN	0	B-Chemical
interferon	interferon	ADJ	JJ	3	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2b	2b	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
C	C	PROPN	NNP	9	I-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
interferon	interferon	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
lot	lot	NOUN	NN	5	O
of	of	ADP	IN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
to	to	ADP	IN	5	O
44	44	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
develop	develop	VERB	VBP	5	O
depression	depression	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
minority	minority	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
evolve	evolve	VERB	VBP	5	O
to	to	ADP	IN	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
the	the	DET	DT	5	O
best	good	ADJ	JJS	5	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
psychogenic	psychogenic	ADJ	JJ	5	B-Disease
parasitosis	parasitosis	NOUN	NN	5	I-Disease
occurring	occur	VERB	VBG	9	O
during	during	ADP	IN	5	O
interferon	interferon	NOUN	NN	3	O
therapy	therapy	NOUN	NN	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
49	49	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
delusional	delusional	ADJ	JJ	5	B-Disease
parasitosis	parasitosis	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
pegylated	pegylated	ADJ	JJ	0	B-Chemical
interferon	interferon	ADJ	JJ	3	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2b	2b	NUM	CD	9	I-Chemical
weekly	weekly	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
seeing	see	VERB	VBG	5	O
parasites	parasite	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
larvae	larvae	NOUN	NN	4	O
of	of	ADP	IN	5	O
fleas	flea	NOUN	NNS	4	O
in	in	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
stools	stool	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
could	could	VERB	MD	9	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
any	any	DET	DT	5	O
technical	technical	ADJ	JJ	6	O
examination	examination	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	PDT	9	O
the	the	DET	DT	5	O
complaints	complaint	NOUN	NNS	5	O
disappeared	disappear	VERB	VBD	9	O
after	after	ADP	IN	9	O
stopping	stop	VERB	VBG	5	O
pegylated	pegylate	VERB	VBN	0	B-Chemical
interferon	interferon	ADJ	JJ	3	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2b	2b	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
reappeared	reappear	VERB	VBN	9	O
after	after	ADP	IN	9	O
restarting	restart	VERB	VBG	5	O
it	-PRON-	PRON	PRP	5	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
sustained	sustain	VERB	VBN	5	O
viral	viral	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Hepatonecrosis	Hepatonecrosis	PROPN	NNP	_	B-Disease
and	and	CCONJ	CC	5	O
cholangitis	cholangitis	NOUN	NN	5	B-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
autopsy	autopsy	ADJ	JJ	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Phenobarbital	Phenobarbital	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PB	PB	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
reputation	reputation	NOUN	NN	5	O
for	for	ADP	IN	5	O
safety	safety	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
commonly	commonly	ADV	RB	5	O
believed	believe	VERB	VBN	5	O
that	that	ADP	IN	5	O
PB	pb	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
aminotransferase	aminotransferase	NOUN	NN	7	O
levels	level	NOUN	NNS	3	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
indicate	indicate	VERB	VB	9	O
or	or	CCONJ	CC	5	O
predict	predict	VERB	VB	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
chronic	chronic	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
report	report	VERB	VBP	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
adult	adult	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
long	long	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
PB	PB	PROPN	NNP	9	B-Chemical
who	who	PRON	WP	5	O
died	die	VERB	VBD	9	O
suddenly	suddenly	ADV	RB	5	O
:	:	PUNCT	:	9	O
one	one	NUM	CD	5	O
as	as	ADP	IN	5	O
consequence	consequence	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
bronchopneumonia	bronchopneumonia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
autopsy	autopsy	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
parenchyma	parenchyma	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
rich	rich	ADJ	JJ	9	O
portal	portal	ADJ	JJ	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
infiltrate	infiltrate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
mixed	mixed	ADJ	JJ	9	O
eosinophil	eosinophil	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
monocyte	monocyte	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
several	several	ADJ	JJ	9	O
foci	foci	NOUN	NN	9	O
of	of	ADP	IN	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
surrounded	surround	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
hard	hard	ADJ	JJ	5	O
ring	ring	NOUN	NN	0	O
of	of	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
specific	specific	ADJ	JJ	9	O
granulomatous	granulomatous	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Inflammatory	inflammatory	ADJ	JJ	9	O
reactions	reaction	NOUN	NNS	9	O
of	of	ADP	IN	5	O
internal	internal	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
external	external	ADJ	JJ	5	O
hepatic	hepatic	ADJ	JJ	9	O
biliary	biliary	ADJ	JJ	5	O
ducts	duct	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
seen	see	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
findings	finding	NOUN	NNS	9	O
illustrate	illustrate	VERB	VBP	5	O
that	that	ADP	IN	5	O
PB	PB	PROPN	NNP	9	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
more	more	ADV	RBR	5	O
serious	serious	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
deleterious	deleterious	ADJ	JJ	9	O
consequences	consequence	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
this	this	DET	DT	5	O
reason	reason	NOUN	NN	5	O
,	,	PUNCT	,	9	O
each	each	DET	DT	5	O
clinician	clinician	NOUN	NN	5	O
should	should	VERB	MD	5	O
recognize	recognize	VERB	VB	9	O
this	this	DET	DT	5	O
entity	entity	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
PB	PB	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
enzyme	enzyme	ADJ	JJ	0	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Delayed	delay	VERB	VBN	5	O
leukoencephalopathy	leukoencephalopathy	ADJ	JJ	5	B-Disease
with	with	ADP	IN	5	O
stroke	stroke	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
presentation	presentation	NOUN	NN	5	O
in	in	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
recipients	recipient	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
transient	transient	ADJ	JJ	9	O
leukoencephalopathy	leukoencephalopathy	ADJ	JJ	5	B-Disease
mimicking	mimicking	NOUN	NN	9	O
cerebrovascular	cerebrovascular	ADJ	JJ	5	B-Disease
accident	accident	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
most	most	ADV	RBS	9	O
commonly	commonly	ADV	RB	5	O
in	in	ADP	IN	5	O
recipients	recipient	NOUN	NNS	9	O
of	of	ADP	IN	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
childhood	childhood	NOUN	NN	5	O
leukaemia	leukaemia	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
published	publish	VERB	VBN	9	O
neuroimaging	neuroimage	VERB	VBG	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
agents	agent	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
modes	mode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
reviewed	review	VERB	VBD	9	O
the	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
literature	literature	NOUN	NN	5	O
for	for	ADP	IN	5	O
single	single	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
case	case	NOUN	NN	5	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
presenting	present	VERB	VBG	5	O
with	with	ADP	IN	5	O
stroke	stroke	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
episodes	episode	NOUN	NNS	5	O
while	while	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
systemic	systemic	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
only	only	ADV	RB	9	O
included	include	VERB	VBD	5	O
studies	study	NOUN	NNS	9	O
providing	provide	VERB	VBG	9	O
detailed	detailed	ADJ	JJ	5	O
neuroimaging	neuroimaging	NOUN	NN	5	O
data	datum	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cerebrovascular	cerebrovascular	ADJ	JJ	5	B-Disease
accidents	accident	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
excluded	exclude	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
identified	identify	VERB	VBD	9	O
27	27	NUM	CD	7	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	O
leukoencephalopathy	leukoencephalopathy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
intrathecal	intrathecal	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
systemic	systemic	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
derivative	derivative	ADJ	JJ	0	O
carmofur	carmofur	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
capecitabine	capecitabine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Diffusion	diffusion	NOUN	NN	5	O
weighted	weight	VERB	VBD	5	O
imaging	image	VERB	VBG	5	O
(	(	PUNCT	-LRB-	9	O
DWI	DWI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
well	well	ADV	RB	9	O
demarcated	demarcated	ADJ	JJ	5	O
hyperintense	hyperintense	NOUN	NN	5	O
lesions	lesion	NOUN	NNS	5	B-Disease
within	within	ADP	IN	9	I-Disease
the	the	DET	DT	5	I-Disease
subcortical	subcortical	ADJ	JJ	5	I-Disease
white	white	ADJ	JJ	9	I-Disease
matter	matter	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cerebral	cerebral	ADJ	JJ	5	O
hemispheres	hemisphere	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
corpus	corpus	NOUN	NN	5	O
callosum	callosum	NOUN	NN	5	O
,	,	PUNCT	,	9	O
corresponding	correspond	VERB	VBG	9	O
to	to	ADP	IN	5	O
areas	area	NOUN	NNS	5	O
of	of	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	O
proton	proton	NOUN	NN	0	O
diffusion	diffusion	NOUN	NN	5	O
on	on	ADP	IN	5	O
apparent	apparent	ADJ	JJ	9	O
diffusion	diffusion	NOUN	NN	5	O
coefficient	coefficient	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ADC	adc	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
maps	map	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
available	available	ADJ	JJ	5	O
in	in	ADP	IN	5	O
21	21	NUM	CD	7	O
/	/	SYM	SYM	9	O
27	27	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Lesions	lesion	NOUN	NNS	5	O
exceeded	exceed	VERB	VBD	9	O
the	the	DET	DT	5	O
confines	confine	NOUN	NNS	5	O
of	of	ADP	IN	5	O
adjacent	adjacent	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
territories	territory	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Complete	complete	ADJ	JJ	9	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
within	within	ADP	IN	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
normalisation	normalisation	NOUN	NN	5	O
of	of	ADP	IN	5	O
ADC	adc	NOUN	NN	5	O
abnormalities	abnormality	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
fluid	fluid	ADJ	JJ	5	O
attenuated	attenuate	VERB	VBN	3	O
inversion	inversion	NOUN	NN	5	O
recovery	recovery	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
FLAIR	FLAIR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
sequences	sequence	VERB	VBZ	1	O
frequently	frequently	ADV	RB	5	O
revealed	reveal	VERB	VBD	9	O
persistent	persistent	ADJ	JJ	5	O
white	white	ADJ	JJ	9	B-Disease
matter	matter	NOUN	NN	5	I-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Several	several	ADJ	JJ	9	O
pathophysiological	pathophysiological	ADJ	JJ	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
delayed	delay	VERB	VBN	9	O
leukoencephalopathy	leukoencephalopathy	ADJ	JJ	5	B-Disease
after	after	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
or	or	CCONJ	CC	5	O
systemic	systemic	ADJ	JJ	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
proposed	propose	VERB	VBN	5	O
.	.	PUNCT	.	9	O

DWI	DWI	PROPN	NNP	5	O
findings	finding	NOUN	NNS	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
cohort	cohort	NOUN	NN	9	O
are	be	VERB	VBP	5	O
indicative	indicative	ADJ	JJ	9	O
of	of	ADP	IN	5	O
cytotoxic	cytotoxic	ADJ	JJ	3	B-Disease
oedema	oedema	NOUN	NN	5	I-Disease
within	within	ADP	IN	9	I-Disease
cerebral	cerebral	ADJ	JJ	5	I-Disease
white	white	ADJ	JJ	9	I-Disease
matter	matter	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
lend	lend	VERB	VB	5	O
support	support	NOUN	NN	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
partially	partially	ADV	RB	9	O
reversible	reversible	ADJ	JJ	9	O
metabolic	metabolic	NOUN	NN	9	O
derangement	derangement	NOUN	NN	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Prenatal	prenatal	ADJ	JJ	5	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
induces	induce	NOUN	NNS	3	O
fetal	fetal	ADJ	JJ	9	B-Disease
pulmonary	pulmonary	ADJ	JJ	5	I-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

RATIONALE	RATIONALE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Fluoxetine	Fluoxetine	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
antidepressant	antidepressant	NOUN	NN	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
by	by	ADP	IN	9	O
pregnant	pregnant	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Epidemiological	epidemiological	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
prenatally	prenatally	ADV	RB	5	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
newborn	newborn	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
unclear	unclear	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
paradoxical	paradoxical	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
considering	consider	VERB	VBG	5	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
protective	protective	ADJ	JJ	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
rodents	rodent	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
fetal	fetal	ADJ	JJ	9	O
rat	rat	NOUN	NN	3	O
pulmonary	pulmonary	ADJ	JJ	5	O
vascular	vascular	NOUN	NN	5	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
mechanical	mechanical	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
cell	cell	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Pregnant	pregnant	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
Day	day	NOUN	NN	9	O
11	11	NUM	CD	7	O
through	through	ADP	IN	9	O
Day	day	NOUN	NN	9	O
21	21	NUM	CD	7	O
of	of	ADP	IN	5	O
gestation	gestation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

MEASUREMENTS	measurement	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
MAIN	main	ADJ	JJ	2	O
RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Fetuses	fetus	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
delivered	deliver	VERB	VBN	5	O
by	by	ADP	IN	9	O
cesarean	cesarean	ADJ	JJ	5	O
section	section	NOUN	NN	5	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
fetal	fetal	ADJ	JJ	9	B-Disease
pulmonary	pulmonary	ADJ	JJ	5	I-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
as	as	ADP	IN	5	O
evidenced	evidence	VERB	VBN	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
weight	weight	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
ventricle	ventricle	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
ventricle	ventricle	NOUN	NN	5	O
plus	plus	CCONJ	CC	9	O
septum	septum	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
medial	medial	ADJ	JJ	5	O
thickness	thickness	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Postnatal	postnatal	NOUN	NN	9	O
mortality	mortality	NOUN	NN	5	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
among	among	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
arterial	arterial	ADJ	JJ	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
saturation	saturation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
96	96	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
pups	pup	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
79	79	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vitro	vitro	NOUN	NN	3	O
,	,	PUNCT	,	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBN	3	O
pulmonary	pulmonary	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
contraction	contraction	NOUN	NN	9	O
in	in	ADP	IN	5	O
fetal	fetal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
adult	adult	NOUN	NN	9	O
,	,	PUNCT	,	9	O
animals	animal	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBN	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
contraction	contraction	NOUN	NN	9	O
at	at	ADP	IN	9	O
both	both	DET	DT	9	O
ages	age	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
in	in	ADP	IN	5	O
utero	utero	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
the	the	DET	DT	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
arterial	arterial	NOUN	NN	5	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
cell	cell	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
fetal	fetal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
adult	adult	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cells	cell	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
adult	adult	NOUN	NN	9	O
,	,	PUNCT	,	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
in	in	ADP	IN	5	O
utero	utero	ADJ	JJ	9	O
induces	induce	NOUN	NNS	3	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
fetal	fetal	ADJ	JJ	9	O
rat	rat	NOUN	NN	3	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
developmentally	developmentally	ADV	RB	3	O
regulated	regulated	ADJ	JJ	3	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
vascular	vascular	NOUN	NN	5	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
proliferation	proliferation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Disulfiram	Disulfiram	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
transient	transient	ADJ	JJ	9	O
optic	optic	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
peripheral	peripheral	ADJ	JJ	9	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
optic	optic	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
peripheral	peripheral	ADJ	JJ	9	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
disulfiram	disulfiram	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Disease
dependence	dependence	NOUN	NN	5	I-Disease
management	management	NOUN	NN	5	O
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
57	57	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	NOUN	NN	9	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
gradual	gradual	ADJ	JJ	9	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
vision	vision	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
eyes	eye	NOUN	NNS	5	O
with	with	ADP	IN	5	O
intermittent	intermittent	ADJ	JJ	5	O
headaches	headache	NOUN	NNS	5	B-Disease
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
paraesthesia	paraesthesia	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
numbness	numbness	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
feet	foot	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

His	-PRON-	DET	PRP$	9	O
vision	vision	NOUN	NN	5	O
was	be	VERB	VBD	9	O
6	6	NUM	CD	9	O
/	/	SYM	SYM	9	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
60	60	NUM	CD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
left	left	ADJ	JJ	5	O
eyes	eye	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Fundoscopy	Fundoscopy	PROPN	NNP	5	O
revealed	reveal	VERB	VBD	9	O
bilaterally	bilaterally	ADV	RB	5	O
swollen	swollen	ADJ	JJ	9	O
optic	optic	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
heads	head	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Visual	visual	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
testing	testing	NOUN	NN	5	O
confirmed	confirm	VERB	VBD	9	O
bilateral	bilateral	ADJ	JJ	5	O
central	central	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
caecal	caecal	ADJ	JJ	5	O
scotomata	scotomata	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
taking	take	VERB	VBG	5	O
disulfiram	disulfiram	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Disease
dependence	dependence	NOUN	NN	5	I-Disease
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
preceding	precede	VERB	VBG	5	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Disulfiram	Disulfiram	PROPN	NNP	0	B-Chemical
discontinuation	discontinuation	NOUN	NN	5	O
lead	lead	VERB	VBP	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
immediate	immediate	ADJ	JJ	5	O
symptomatic	symptomatic	ADJ	JJ	5	O
improvement	improvement	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Physicians	physician	NOUN	NNS	5	O
initiating	initiate	VERB	VBG	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
disulfiram	disulfiram	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
should	should	VERB	MD	5	O
recommend	recommend	VERB	VB	5	O
annual	annual	ADJ	JJ	5	O
ophthalmic	ophthalmic	ADJ	JJ	5	O
reviews	review	NOUN	NNS	5	O
with	with	ADP	IN	5	O
visual	visual	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
testing	testing	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
reassured	reassure	VERB	VBN	5	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
reversibility	reversibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Intraocular	intraocular	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
uveitis	uveitis	ADJ	JJ	5	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
fluocinolone	fluocinolone	NOUN	NN	0	B-Chemical
acetonide	acetonide	NOUN	NN	0	I-Chemical
implants	implant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
elevated	elevated	ADJ	JJ	9	B-Disease
intraocular	intraocular	ADJ	JJ	5	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
IOP	IOP	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
uveitis	uveitis	ADJ	JJ	5	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
fluocinolone	fluocinolone	NOUN	NN	0	B-Chemical
acetonide	acetonide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
FA	FA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
intravitreal	intravitreal	ADJ	JJ	0	O
implant	implant	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Pooled	pool	VERB	VBN	9	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
3	3	NUM	CD	9	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
masked	masked	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
phase	phase	NOUN	NN	5	O
2b	2b	NUM	CD	9	O
/	/	SYM	SYM	9	O
3	3	NUM	CD	9	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
evaluating	evaluate	VERB	VBG	5	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
59	59	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
mg	mg	NOUN	NN	0	O
FA	FA	PROPN	NNP	9	B-Chemical
intravitreal	intravitreal	ADJ	JJ	0	O
implant	implant	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
standard	standard	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
During	during	ADP	IN	5	O
the	the	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
,	,	PUNCT	,	9	O
71	71	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
implanted	implanted	ADJ	JJ	9	O
eyes	eye	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
an	an	DET	DT	5	O
IOP	IOP	PROPN	NNP	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
55	55	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
eyes	eye	NOUN	NNS	5	O
reached	reach	VERB	VBD	9	O
an	an	DET	DT	5	O
IOP	IOP	PROPN	NNP	5	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Topical	topical	ADJ	JJ	0	O
IOP	IOP	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
lowering	lower	VERB	VBG	9	O
medication	medication	NOUN	NN	5	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
74	74	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
implanted	implanted	ADJ	JJ	9	O
eyes	eye	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
IOP	IOP	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
lowering	lower	VERB	VBG	9	O
surgeries	surgery	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
most	most	ADJ	JJS	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
trabeculectomies	trabeculectomie	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
76	76	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
36	36	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
implanted	implanted	ADJ	JJ	9	O
eyes	eye	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Intraocular	intraocular	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
lowering	lower	VERB	VBG	9	O
surgeries	surgery	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
a	a	DET	DT	5	O
success	success	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
postoperative	postoperative	ADJ	JJ	5	O
IOP	IOP	PROPN	NNP	5	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
21	21	NUM	CD	7	O
mm	mm	NOUN	NNS	9	O
Hg	Hg	PROPN	NNP	0	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
additional	additional	ADJ	JJ	9	O
IOP	IOP	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
lowering	lower	VERB	VBG	9	O
medication	medication	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
85	85	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
eyes	eye	NOUN	NNS	5	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypotony	hypotony	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
IOP	IOP	PROPN	NNP	5	O
<	<	X	XX	0	O
/	/	SYM	SYM	9	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
following	follow	VERB	VBG	9	O
IOP	IOP	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
lowering	lower	VERB	VBG	9	O
surgery	surgery	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
42	42	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
implanted	implant	VERB	VBN	9	O
eyes	eye	NOUN	NNS	5	O
not	not	ADV	RB	5	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
surgery	surgery	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
35	35	NUM	CD	9	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
09	09	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Elevated	elevated	ADJ	JJ	9	O
IOP	IOP	PROPN	NNP	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
complication	complication	NOUN	NN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
FA	FA	PROPN	NNP	9	O
intravitreal	intravitreal	ADJ	JJ	0	O
implant	implant	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
controlled	control	VERB	VBN	5	O
with	with	ADP	IN	5	O
medication	medication	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Myocardial	Myocardial	PROPN	NNP	9	O
Fas	Fas	PROPN	NNP	3	O
ligand	ligand	NOUN	NN	3	O
expression	expression	NOUN	NN	3	O
increases	increase	VERB	VBZ	9	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Dilated	dilate	VERB	VBN	5	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
DCM	DCM	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
myocarditis	myocarditis	NOUN	NN	9	B-Disease
occur	occur	VERB	VBP	5	O
in	in	ADP	IN	5	O
many	many	ADJ	JJ	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
infected	infect	VERB	VBN	3	I-Disease
individuals	individual	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
symptomatic	symptomatic	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Highly	highly	ADV	RB	9	O
active	active	ADJ	JJ	9	O
antiretroviral	antiretroviral	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
HAART	HAART	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
morbidity	morbidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
of	of	ADP	IN	5	O
acquired	acquire	VERB	VBN	5	B-Disease
immunodeficiency	immunodeficiency	NOUN	NN	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
has	have	VERB	VBZ	9	O
resulted	result	VERB	VBN	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
skeletal	skeletal	ADJ	JJ	9	I-Disease
myopathies	myopathy	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
HAART	HAART	PROPN	NNP	5	O
component	component	NOUN	NN	9	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	B-Chemical
'	'	PART	POS	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
azido	azido	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
'	'	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
'	'	PART	POS	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
deoxythymidine	deoxythymidine	NOUN	NN	0	I-Chemical
;	;	PUNCT	:	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
triggers	trigger	VERB	VBZ	9	O
the	the	DET	DT	5	O
Fas	Fas	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
death	death	NOUN	NN	9	O
pathway	pathway	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
cause	cause	VERB	VB	5	O
cytoskeletal	cytoskeletal	ADJ	JJ	3	O
disruption	disruption	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
murine	murine	ADJ	JJ	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
DCM	DCM	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
transgenic	transgenic	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
expressing	express	VERB	VBG	3	O
Fas	Fas	PROPN	NNP	3	O
ligand	ligand	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
myocardium	myocardium	NOUN	NN	9	O
:	:	PUNCT	:	9	O
FasL	FasL	PROPN	NNP	3	O
Tg	Tg	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
transgenic	transgenic	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
NTg	NTg	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
received	receive	VERB	VBD	9	O
water	water	NOUN	NN	0	O
ad	ad	NOUN	NN	9	O
libitum	libitum	NOUN	NN	9	O
containing	contain	VERB	VBG	0	O
different	different	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
07	07	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
morphology	morphology	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
histopathologic	histopathologic	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
immunohistochemical	immunohistochemical	ADJ	JJ	3	O
methods	method	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

NTg	NTg	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
untreated	untreated	ADJ	JJ	3	O
FasL	FasL	PROPN	NNP	3	O
Tg	Tg	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
showed	show	VERB	VBD	9	O
little	little	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
structure	structure	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
FasL	FasL	PROPN	NNP	3	O
Tg	Tg	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
developed	develop	VERB	VBD	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dilation	dilation	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
depressed	depressed	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
concomitant	concomitant	ADJ	JJ	9	O
inflammatory	inflammatory	ADJ	JJ	3	O
infiltration	infiltration	NOUN	NN	3	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
ventricles	ventricle	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
sarcolemmal	sarcolemmal	ADJ	JJ	3	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
Fas	Fas	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
FasL	FasL	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
caspase	caspase	NOUN	NN	3	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
translocation	translocation	NOUN	NN	3	O
of	of	ADP	IN	5	O
calpain	calpain	NOUN	NN	3	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
sarcolemma	sarcolemma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
sarcomere	sarcomere	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
numbers	number	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cells	cell	NOUN	NNS	3	O
undergoing	undergo	VERB	VBG	9	O
apoptosis	apoptosis	NOUN	NN	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
dystrophin	dystrophin	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
troponin	troponin	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
localization	localization	VERB	VBP	3	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
sarcolemmal	sarcolemmal	ADJ	JJ	3	O
integrity	integrity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
Fas	Fas	PROPN	NNP	3	O
ligand	ligand	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
myocardium	myocardium	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
identified	identify	VERB	VBN	9	O
in	in	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
might	may	VERB	MD	9	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
HAART	HAART	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
apoptotic	apoptotic	ADJ	JJ	3	O
pathways	pathway	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dilation	dilation	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Gastrointestinal	gastrointestinal	ADJ	JJ	9	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
etoricoxib	etoricoxib	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
patients	patient	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
etoricoxib	etoricoxib	NOUN	NN	0	B-Chemical
vs	vs	ADP	IN	7	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
gastrointestinal	gastrointestinal	ADJ	JJ	9	O
tolerability	tolerability	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
effectiveness	effectiveness	NOUN	NN	5	O
trial	trial	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
EDGE	EDGE	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
II	II	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
randomised	randomise	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
GI	GI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
tolerability	tolerability	NOUN	NN	5	O
,	,	PUNCT	,	9	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
etoricoxib	etoricoxib	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
RA	RA	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
4086	4086	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
age	age	NOUN	NN	5	O
60	60	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
diagnosed	diagnose	VERB	VBN	5	O
with	with	ADP	IN	5	O
RA	RA	PROPN	NNP	9	B-Disease
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
received	receive	VERB	VBN	9	O
etoricoxib	etoricoxib	NOUN	NN	0	B-Chemical
90	90	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
2032	2032	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
twice	twice	ADV	RB	9	O
daily	daily	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
2054	2054	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
gastroprotective	gastroprotective	ADJ	JJ	0	O
agents	agent	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
was	be	VERB	VBD	9	O
allowed	allow	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
prespecified	prespecifie	VERB	VBN	5	O
primary	primary	ADJ	JJ	9	O
end	end	NOUN	NN	9	O
point	point	NOUN	NN	5	O
consisted	consist	VERB	VBN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
patient	patient	ADJ	JJ	5	O
discontinuations	discontinuation	NOUN	NNS	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
GI	GI	PROPN	NNP	9	O
adverse	adverse	ADJ	JJ	5	O
experiences	experience	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
AEs	ae	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

General	general	ADJ	JJ	2	O
safety	safety	NOUN	NN	5	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
assessed	assess	VERB	VBN	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
adjudicated	adjudicate	VERB	VBN	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
cardiovascular	cardiovascular	ADJ	JJ	5	I-Disease
event	event	NOUN	NN	5	O
data	datum	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Efficacy	Efficacy	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
Patient	Patient	PROPN	NNP	5	O
Global	Global	PROPN	NNP	5	O
Assessment	Assessment	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Disease	Disease	PROPN	NNP	2	O
Status	Status	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
PGADS	PGADS	PROPN	NNP	5	O
;	;	PUNCT	:	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
point	point	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Mean	Mean	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
SD	sd	NOUN	NN	7	O
;	;	PUNCT	:	9	O
maximum	maximum	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
;	;	PUNCT	:	9	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
;	;	SYM	SYM	9	O
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
months	month	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
etoricoxib	etoricoxib	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
discontinuation	discontinuation	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
GI	GI	PROPN	NNP	9	B-Disease
AEs	ae	NOUN	NNS	5	I-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
with	with	ADP	IN	5	O
etoricoxib	etoricoxib	NOUN	NN	0	B-Chemical
than	than	ADP	IN	5	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	NOUN	NN	9	O
2	2	NUM	CD	9	O
vs	vs	ADP	IN	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
events	event	NOUN	NNS	5	O
per	per	ADP	IN	9	O
100	100	NUM	CD	0	O
patient	patient	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
;	;	PUNCT	:	9	O
hazard	hazard	NOUN	NN	5	O
ratio	ratio	NOUN	NN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
62	62	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
:	:	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
47	47	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
81	81	NUM	CD	7	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
discontinuations	discontinuation	NOUN	NNS	5	O
for	for	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
oedema	oedema	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
AEs	ae	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
with	with	ADP	IN	5	O
etoricoxib	etoricoxib	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
respectively	respectively	ADV	RB	9	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
for	for	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
for	for	ADP	IN	5	O
oedema	oedema	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Etoricoxib	etoricoxib	NOUN	NN	7	B-Chemical
and	and	CCONJ	CC	5	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
similar	similar	ADJ	JJ	9	O
efficacy	efficacy	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PGADS	PGADS	PROPN	NNP	5	O
mean	mean	VERB	VB	5	O
changes	change	NOUN	NNS	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
62	62	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
58	58	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Etoricoxib	Etoricoxib	PROPN	NNP	7	B-Chemical
90	90	NUM	CD	9	O
mg	mg	NOUN	NNS	0	O
demonstrated	demonstrate	VERB	VBD	9	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
discontinuing	discontinue	VERB	VBG	5	O
treatment	treatment	NOUN	NN	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
GI	GI	PROPN	NNP	9	B-Disease
AEs	ae	NOUN	NNS	5	I-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Discontinuations	discontinuation	NOUN	NNS	7	O
from	from	ADP	IN	9	O
renovascular	renovascular	ADJ	JJ	5	O
AEs	ae	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
less	less	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
than	than	ADP	IN	5	O
discontinuations	discontinuation	NOUN	NNS	5	O
from	from	ADP	IN	9	O
GI	GI	PROPN	NNP	9	B-Disease
AEs	ae	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
with	with	ADP	IN	5	O
etoricoxib	etoricoxib	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Anxiogenic	anxiogenic	ADJ	JJ	0	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
ciprofloxacin	ciprofloxacin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
norfloxacin	norfloxacin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

INTRODUCTION	introduction	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
anxiogenic	anxiogenic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
fluoroquinolones	fluoroquinolone	NOUN	NNS	5	B-Chemical
,	,	PUNCT	,	9	O
namely	namely	ADV	RB	9	O
ciprofloxacin	ciprofloxacin	VERB	VBD	0	B-Chemical
and	and	CCONJ	CC	5	O
norfloxacin	norfloxacin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
Charles	Charles	PROPN	NNP	6	O
Foster	Foster	PROPN	NNP	6	O
albino	albino	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
weighing	weigh	VERB	VBG	5	O
150	150	NUM	CD	0	O
-	-	SYM	SYM	7	O
200	200	NUM	CD	0	O
g	g	NOUN	NN	0	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
orally	orally	ADV	RB	0	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	VERB	VB	0	O
for	for	ADP	IN	5	O
five	five	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
experiments	experiment	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
fifth	fifth	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
tests	test	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
field	field	NOUN	NN	5	O
exploratory	exploratory	ADJ	JJ	5	O
behaviour	behaviour	NOUN	NN	5	O
,	,	PUNCT	,	9	O
elevated	elevated	ADJ	JJ	9	O
plus	plus	CCONJ	CC	9	O
maze	maze	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
elevated	elevate	VERB	VBD	9	O
zero	zero	NUM	CD	5	O
maze	maze	NOUN	NN	5	O
,	,	PUNCT	,	9	O
social	social	ADJ	JJ	5	O
interaction	interaction	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
novelty	novelty	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
suppressed	suppress	VERB	VBN	3	O
feeding	feed	VERB	VBG	5	O
latency	latency	NOUN	NN	5	O
behaviour	behaviour	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
ciprofloxacin	ciprofloxacin	NOUN	NN	0	B-Chemical
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
norfloxacin	norfloxacin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
anxious	anxious	ADJ	JJ	5	B-Disease
behaviour	behaviour	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
parameters	parameter	NOUN	NNS	5	O
studied	study	VERB	VBD	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
ciprofloxacin	ciprofloxacin	NOUN	NN	0	B-Chemical
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
norfloxacin	norfloxacin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
from	from	ADP	IN	9	O
each	each	DET	DT	5	O
other	other	ADJ	JJ	5	O
in	in	ADP	IN	5	O
various	various	ADJ	JJ	9	O
behavioural	behavioural	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
substantiate	substantiate	VERB	VBP	9	O
the	the	DET	DT	5	O
clinically	clinically	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
anxiogenic	anxiogenic	ADJ	JJ	5	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
ciprofloxacin	ciprofloxacin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
norfloxacin	norfloxacin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
with	with	ADP	IN	5	O
target	target	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Pain	pain	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
unpleasant	unpleasant	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
hypothesized	hypothesize	VERB	VBD	9	O
that	that	ADP	IN	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
pain	pain	NOUN	NN	5	B-Disease
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
infusing	infuse	VERB	VBG	0	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
before	before	ADP	IN	9	O
starting	start	VERB	VBG	9	O
the	the	DET	DT	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
setting	setting	NOUN	NN	5	O
where	where	ADV	WRB	5	O
target	target	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
infusions	infusion	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
TCI	TCI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
site	site	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
Ce	Ce	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
the	the	DET	DT	5	O
pain	pain	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	O
producing	produce	VERB	VBG	9	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
128	128	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
general	general	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
allocated	allocate	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
control	control	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
target	target	NOUN	NN	9	O
Ce	Ce	PROPN	NNP	0	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
ng	ng	ADP	IN	0	O
ml	ml	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
R2	R2	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
ng	ng	ADP	IN	0	O
ml	ml	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
R4	R4	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
6	6	NUM	CD	9	O
ng	ng	NOUN	NNS	0	O
ml	ml	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
R6	R6	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
administered	administer	VERB	VBD	9	O
via	via	ADP	IN	9	O
TCI	TCI	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
target	target	NOUN	NN	9	O
Ce	Ce	PROPN	NNP	0	O
was	be	VERB	VBD	9	O
achieved	achieve	VERB	VBN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
was	be	VERB	VBD	9	O
started	start	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Remifentanil	remifentanil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
complications	complication	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
infusion	infusion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
propofol	propofol	ADJ	JJ	0	B-Chemical
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
four	four	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
point	point	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
Groups	Groups	PROPN	NNP	9	O
R4	R4	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
R6	r6	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
R2	R2	PROPN	NNP	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
/	/	SYM	SYM	9	O
32	32	NUM	CD	7	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
/	/	SYM	SYM	9	O
31	31	NUM	CD	7	O
vs	vs	ADP	IN	7	O
26	26	NUM	CD	7	O
/	/	SYM	SYM	9	O
31	31	NUM	CD	7	O
and	and	CCONJ	CC	5	O
25	25	NUM	CD	9	O
/	/	SYM	SYM	9	O
32	32	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Pain	Pain	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
severe	severe	ADJ	JJ	5	O
in	in	ADP	IN	5	O
Groups	Groups	PROPN	NNP	9	O
R4	R4	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
R6	r6	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
R2	R2	PROPN	NNP	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
both	both	CCONJ	CC	9	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
different	different	ADJ	JJ	9	O
between	between	ADP	IN	5	O
Groups	Groups	PROPN	NNPS	9	O
R4	R4	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
R6	r6	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
complications	complication	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
During	during	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
with	with	ADP	IN	5	O
TCI	TCI	PROPN	NNP	5	O
of	of	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
pain	pain	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
achieved	achieve	VERB	VBN	5	O
without	without	ADP	IN	9	O
significant	significant	ADJ	JJ	9	O
complications	complication	NOUN	NNS	5	O
by	by	ADP	IN	9	O
prior	prior	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
remifentanil	remifentanil	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
target	target	NOUN	NN	9	O
Ce	Ce	PROPN	NNP	0	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
ng	ng	ADP	IN	0	O
ml	ml	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Dexmedetomidine	dexmedetomidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
protection	protection	NOUN	NN	9	O
for	for	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
cardiac	cardiac	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
meta	meta	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
randomised	randomise	VERB	VBN	5	O
controlled	control	VERB	VBN	5	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
systematic	systematic	ADJ	JJ	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
following	follow	VERB	VBG	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
cardiac	cardiac	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
included	include	VERB	VBD	5	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomised	randomise	VERB	VBN	5	O
peri	peri	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
operative	operative	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
that	that	DET	WDT	5	O
reported	report	VERB	VBD	9	O
mortality	mortality	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	O
morbidity	morbidity	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
PubMed	PubMed	PROPN	NNP	5	O
Central	Central	PROPN	NNP	4	O
and	and	CCONJ	CC	5	O
EMBASE	EMBASE	PROPN	NNP	2	O
search	search	NOUN	NN	5	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
up	up	PART	RP	5	O
to	to	ADP	IN	5	O
July	July	PROPN	NNP	2	O
2007	2007	NUM	CD	2	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
reference	reference	NOUN	NN	9	O
lists	list	NOUN	NNS	5	O
of	of	ADP	IN	5	O
identified	identify	VERB	VBN	9	O
papers	paper	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
for	for	ADP	IN	5	O
further	further	ADJ	JJ	9	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
425	425	NUM	CD	7	O
studies	study	NOUN	NNS	9	O
identified	identify	VERB	VBN	9	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
meta	meta	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
analysis	analysis	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
840	840	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Dexmedetomidine	Dexmedetomidine	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
trend	trend	NOUN	NN	9	O
towards	towards	ADP	IN	5	O
improved	improve	VERB	VBD	5	O
cardiac	cardiac	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
all	all	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
cause	cause	NOUN	NN	5	O
mortality	mortality	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
27	27	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
13	13	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
44	44	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
fatal	fatal	ADJ	JJ	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
26	26	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
60	60	NUM	CD	9	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
14	14	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischaemia	ischaemia	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
65	65	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
26	26	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
63	63	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
36	36	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Peri	peri	NOUN	NN	6	O
-	-	PUNCT	HYPH	7	O
operative	operative	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
OR	or	CCONJ	CC	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
80	80	NUM	CD	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
91	91	NUM	CD	7	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
54	54	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
OR	or	CCONJ	CC	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
45	45	NUM	CD	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
98	98	NUM	CD	7	O
-	-	SYM	SYM	7	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
95	95	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
00001	00001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
anticholinergic	anticholinergic	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
reduce	reduce	VERB	VB	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
43	43	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
randomised	randomise	VERB	VBN	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
warranted	warrant	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
clomiphene	clomiphene	NOUN	NN	5	B-Chemical
citrate	citrate	NOUN	NN	0	I-Chemical
for	for	ADP	IN	5	O
ovulation	ovulation	NOUN	NN	5	O
induction	induction	NOUN	NN	3	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Clomiphene	Clomiphene	PROPN	NNP	0	B-Chemical
citrate	citrate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CC	CC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
commonly	commonly	ADV	RB	5	O
prescribed	prescribe	VERB	VBN	5	O
for	for	ADP	IN	5	O
ovulation	ovulation	NOUN	NN	5	O
induction	induction	NOUN	NN	3	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
considered	consider	VERB	VBN	5	O
safe	safe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
minimal	minimal	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Thromboembolism	thromboembolism	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
complication	complication	NOUN	NN	5	O
that	that	DET	WDT	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
after	after	ADP	IN	9	O
ovulation	ovulation	NOUN	NN	5	O
induction	induction	NOUN	NN	3	O
with	with	ADP	IN	5	O
CC	CC	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Spontaneous	spontaneous	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
thromboembolism	thromboembolism	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
clot	clot	NOUN	NN	5	O
lysis	lysis	NOUN	NN	3	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
suggested	suggest	VERB	VBN	9	O
as	as	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MI	MI	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
subsequently	subsequently	ADV	RB	9	O
normal	normal	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	O
angiogram	angiogram	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
33	33	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
gestation	gestation	NOUN	NN	9	O
had	have	VERB	VBD	9	O
recently	recently	ADV	RB	9	O
received	receive	VERB	VBN	9	O
CC	cc	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
ovulation	ovulation	NOUN	NN	5	O
induction	induction	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
lateral	lateral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
anterior	anterior	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
myocardial	myocardial	NOUN	NN	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	O
enzymes	enzyme	NOUN	NNS	1	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
peak	peak	NOUN	NN	9	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
troponin	troponin	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
to	to	ADP	IN	5	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
10	10	NUM	CD	9	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
exercise	exercise	NOUN	NN	5	O
stress	stress	NOUN	NN	9	O
test	test	NOUN	NN	5	O
was	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
admission	admission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
at	at	ADP	IN	9	O
high	high	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
radiation	radiation	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
fetus	fetus	NOUN	NN	5	O
,	,	PUNCT	,	9	O
so	so	ADV	RB	5	O
a	a	DET	DT	5	O
coronary	coronary	ADJ	JJ	5	O
angiogram	angiogram	NOUN	NN	5	O
was	be	VERB	VBD	9	O
postponed	postpone	VERB	VBN	5	O
until	until	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
trimester	trimester	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
showed	show	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	O
vessels	vessel	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
reported	report	VERB	VBN	9	O
case	case	NOUN	NN	5	O
documenting	document	VERB	VBG	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
CC	cc	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Thrombosis	thrombosis	NOUN	NN	2	B-Disease
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
hazardous	hazardous	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
CC	CC	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
this	this	DET	DT	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
complication	complication	NOUN	NN	5	O
,	,	PUNCT	,	9	O
appropriate	appropriate	ADJ	JJ	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
measures	measure	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
woman	woman	NOUN	NN	5	O
undergoing	undergo	VERB	VBG	9	O
ovarian	ovarian	ADJ	JJ	9	O
stimulation	stimulation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Reverse	Reverse	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
inverted	invert	VERB	VBD	9	O
left	leave	VERB	VBN	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
apical	apical	ADJ	JJ	9	I-Disease
ballooning	ballooning	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
reverse	reverse	ADJ	JJ	9	O
Takotsubo	Takotsubo	PROPN	NNP	5	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
young	young	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
setting	setting	NOUN	NN	5	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Transient	Transient	PROPN	NNP	9	O
left	leave	VERB	VBD	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
apical	apical	ADJ	JJ	9	I-Disease
ballooning	ballooning	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
first	first	ADV	RB	9	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
Japan	Japan	PROPN	NNP	2	O
as	as	ADP	IN	5	O
"	"	PUNCT	``	5	O
Takotsubo	takotsubo	NOUN	NN	5	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O
"	"	PUNCT	''	5	O
This	this	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
identified	identify	VERB	VBN	9	O
in	in	ADP	IN	5	O
many	many	ADJ	JJ	5	O
other	other	ADJ	JJ	5	O
countries	country	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Many	many	ADJ	JJ	5	O
variations	variation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
recently	recently	ADV	RB	9	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rarest	rare	ADJ	JJS	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
reverse	reverse	ADJ	JJ	9	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
hyperdynamic	hyperdynamic	ADJ	JJ	5	O
apex	apex	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
complete	complete	ADJ	JJ	9	O
akinesia	akinesia	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
base	base	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
as	as	ADP	IN	5	O
opposed	oppose	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
classic	classic	ADJ	JJ	5	O
apical	apical	ADJ	JJ	9	B-Disease
ballooning	ballooning	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
article	article	NOUN	NN	6	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
report	report	VERB	VBP	5	O
an	an	DET	DT	5	O
interesting	interesting	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
young	young	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
who	who	PRON	WP	5	O
presented	present	VERB	VBD	5	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
reverse	reverse	ADJ	JJ	9	O
apical	apical	ADJ	JJ	9	B-Disease
ballooning	ballooning	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
occurring	occur	VERB	VBG	9	O
after	after	ADP	IN	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
comparative	comparative	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
phase	phase	NOUN	NN	5	O
III	iii	NUM	CD	9	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
,	,	PUNCT	,	9	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
fixed	fix	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
telmisartan	telmisartan	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
amlodipine	amlodipine	VERB	VBP	0	B-Chemical
versus	versus	ADP	IN	9	O
amlodipine	amlodipine	ADJ	JJ	0	B-Chemical
monotherapy	monotherapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
Indian	indian	ADJ	JJ	4	O
adults	adult	NOUN	NNS	5	O
with	with	ADP	IN	5	O
stage	stage	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
fixed	fix	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
combination	combination	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
FDC	FDC	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
telmisartan	telmisartan	ADV	RB	0	B-Chemical
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
+	+	CCONJ	CC	9	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
T	t	NOUN	NN	3	O
+	+	CCONJ	CC	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
amlodipine	amlodipine	ADJ	JJ	0	B-Chemical
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
monotherapy	monotherapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
Indian	indian	ADJ	JJ	4	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
stage	stage	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
comparative	comparative	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
Phase	Phase	PROPN	NNP	9	O
III	III	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
,	,	PUNCT	,	9	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
in	in	ADP	IN	5	O
Indian	indian	ADJ	JJ	4	O
patients	patient	NOUN	NNS	5	O
aged	age	VERB	VBN	9	O
18	18	NUM	CD	7	O
to	to	PART	TO	5	O
65	65	NUM	CD	7	O
years	year	NOUN	NNS	5	O
with	with	ADP	IN	5	O
established	establish	VERB	VBN	9	O
stage	stage	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
FDC	FDC	PROPN	NNP	3	O
of	of	ADP	IN	5	O
T	T	PROPN	NNP	3	O
+	+	CCONJ	CC	9	O
A	a	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
A	a	DET	DT	9	O
QD	QD	PROPN	NNP	0	O
before	before	ADP	IN	9	O
breakfast	breakfast	NOUN	NN	5	O
for	for	ADP	IN	5	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BP	BP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
sitting	sit	VERB	VBG	5	O
position	position	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Primary	primary	ADJ	JJ	9	O
efficacy	efficacy	NOUN	NN	9	O
end	end	NOUN	NN	9	O
points	point	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
systolic	systolic	NOUN	NN	5	O
BP	BP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
SBP	SBP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
diastolic	diastolic	ADJ	JJ	5	O
BP	BP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
DBP	DBP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
end	end	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
responders	responder	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
ie	ie	X	FW	5	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
achieved	achieve	VERB	VBD	5	O
target	target	NOUN	NN	9	O
SBP	SBP	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
DBP	DBP	PROPN	NNP	9	O
<	<	X	XX	0	O
130	130	NUM	CD	9	O
/	/	SYM	SYM	9	O
<	<	X	XX	0	O
80	80	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Tolerability	tolerability	NOUN	NN	5	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
emergent	emergent	NOUN	NN	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
identified	identify	VERB	VBD	9	O
using	use	VERB	VBG	9	O
physical	physical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
,	,	PUNCT	,	9	O
laboratory	laboratory	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
electrocardiography	electrocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
210	210	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
;	;	PUNCT	:	9	O
203	203	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
143	143	NUM	CD	7	O
men	man	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
completed	complete	VERB	VBD	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
while	while	ADP	IN	9	O
7	7	NUM	CD	9	O
were	be	VERB	VBD	9	O
lost	lose	VERB	VBN	9	O
to	to	PART	TO	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
T	t	NOUN	NN	3	O
+	+	CCONJ	CC	9	O
A	a	DET	DT	9	O
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
A	a	DET	DT	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
considered	consider	VERB	VBN	5	O
with	with	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
drawn	draw	VERB	VBN	5	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
study	study	NOUN	NN	9	O
end	end	NOUN	NN	9	O
,	,	PUNCT	,	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
percentage	percentage	NOUN	NN	9	O
reductions	reduction	NOUN	NNS	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
within	within	ADP	IN	9	O
groups	group	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
SBP	SBP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
T	t	NOUN	NN	3	O
+	+	CCONJ	CC	9	O
A	a	DET	DT	9	O
[	[	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
27	27	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
A	a	DET	DT	9	O
[	[	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
DBP	DBP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
T	t	NOUN	NN	3	O
+	+	CCONJ	CC	9	O
A	a	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
A	a	DET	DT	9	O
[	[	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
all	all	DET	DT	5	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Response	response	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
87	87	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
89	89	NUM	CD	7	O
/	/	SYM	SYM	9	O
102	102	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
T	t	NOUN	NN	3	O
+	+	CCONJ	CC	9	O
A	a	DET	DT	9	O
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
69	69	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
70	70	NUM	CD	9	O
/	/	SYM	SYM	9	O
101	101	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
A	a	DET	DT	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
prevalences	prevalence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
T	t	NOUN	NN	3	O
+	+	CCONJ	CC	9	O
A	a	NOUN	NN	9	O
,	,	PUNCT	,	9	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
/	/	SYM	SYM	9	O
106	106	NUM	CD	9	O
]	]	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
A	a	DET	DT	9	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
16	16	NUM	CD	9	O
/	/	SYM	SYM	9	O
104	104	NUM	CD	9	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Peripheral	peripheral	ADJ	JJ	9	O
edema	edema	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
/	/	SYM	SYM	9	O
106	106	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
T	t	NOUN	NN	3	O
+	+	CCONJ	CC	9	O
A	a	DET	DT	9	O
group	group	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
/	/	SYM	SYM	9	O
104	104	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
A	a	DET	DT	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cough	cough	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
/	/	SYM	SYM	9	O
106	106	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
T	t	NOUN	NN	3	O
+	+	CCONJ	CC	9	O
A	a	DET	DT	9	O
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
104	104	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
A	a	DET	DT	9	O
group	group	NOUN	NN	9	O
;	;	PUNCT	:	9	O
these	these	DET	DT	5	O
differences	difference	NOUN	NNS	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
reach	reach	VERB	VB	5	O
statistical	statistical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidences	incidence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
headache	headache	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
dizziness	dizziness	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
diarrhea	diarrhea	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Among	among	ADP	IN	9	O
these	these	DET	DT	5	O
Indian	indian	ADJ	JJ	4	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
stage	stage	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
FDC	FDC	PROPN	NNP	3	O
of	of	ADP	IN	5	O
T	T	PROPN	NNP	3	O
+	+	CCONJ	CC	9	O
A	a	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
effective	effective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
regard	regard	NOUN	NN	5	O
to	to	ADP	IN	5	O
BP	BP	PROPN	NNP	9	O
reductions	reduction	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
than	than	ADP	IN	5	O
A	A	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
both	both	DET	DT	9	O
treatments	treatment	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
mental	mental	ADJ	JJ	5	B-Disease
slowing	slowing	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
APOE	apoe	NOUN	NN	9	O
epsilon4	epsilon4	NOUN	NN	1	O
allele	allele	NOUN	NN	1	O
after	after	ADP	IN	9	O
trihexyphenidyl	trihexyphenidyl	NOUN	NN	0	B-Chemical
oral	oral	ADJ	JJ	9	O
anticholinergic	anticholinergic	ADJ	JJ	5	O
challenge	challenge	NOUN	NN	9	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
elderly	elderly	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
objectives	objective	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
were	be	VERB	VBD	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
APOE	apoe	NOUN	NN	9	O
epsilon4	epsilon4	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
subjective	subjective	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
trihexyphenidyl	trihexyphenidyl	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
measures	measure	NOUN	NNS	5	O
reflecting	reflect	VERB	VBG	5	O
sedation	sedation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
confusion	confusion	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
trihexyphenidyl	trihexyphenidyl	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
subjective	subjective	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
objective	objective	ADJ	JJ	5	O
memory	memory	NOUN	NN	5	O
performance	performance	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
comprised	comprise	VERB	VBD	9	O
24	24	NUM	CD	9	O
cognitively	cognitively	ADV	RB	5	O
intact	intact	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
health	health	NOUN	NN	5	O
elderly	elderly	ADJ	JJ	5	O
adults	adult	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
APOE	apoe	NOUN	NN	9	O
epsilon4	epsilon4	NOUN	NN	1	O
carriers	carrier	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
outpatient	outpatient	NOUN	NN	5	O
geriatric	geriatric	ADJ	JJ	5	O
psychiatry	psychiatry	NOUN	NN	5	O
research	research	NOUN	NN	5	O
clinic	clinic	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
way	way	NOUN	NN	5	O
,	,	PUNCT	,	9	O
crossover	crossover	NOUN	NN	5	O
experimental	experimental	ADJ	JJ	5	O
design	design	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
participants	participant	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
trihexyphenidyl	trihexyphenidyl	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
counterbalanced	counterbalanced	ADJ	JJ	5	O
sequences	sequence	NOUN	NNS	1	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Bond	bond	NOUN	NN	6	O
and	and	CCONJ	CC	5	O
Lader	Lader	PROPN	NNP	6	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
visual	visual	ADJ	JJ	5	O
analog	analog	NOUN	NN	0	O
scales	scale	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
alternate	alternate	ADJ	JJ	9	O
versions	version	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Buschke	Buschke	PROPN	NNP	6	O
Selective	Selective	PROPN	NNP	9	O
Reminding	Reminding	PROPN	NNP	5	O
Test	Test	PROPN	NNP	5	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
repeated	repeat	VERB	VBN	5	O
measures	measure	NOUN	NNS	5	O
design	design	NOUN	NN	5	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
postdrug	postdrug	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
oral	oral	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
trihexyphenidyl	trihexyphenidyl	NOUN	NN	0	B-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
subjective	subjective	ADJ	JJ	5	O
ratings	rating	NOUN	NNS	5	O
of	of	ADP	IN	5	O
mental	mental	ADJ	JJ	5	B-Disease
slowness	slowness	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
carriers	carrier	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
APOE	apoe	NOUN	NN	9	O
epsilon4	epsilon4	NOUN	NN	1	O
allele	allele	NOUN	NN	1	O
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
as	as	ADP	IN	5	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
difference	difference	NOUN	NN	9	O
scores	score	NOUN	NNS	5	O
between	between	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
trihexyphenidyl	trihexyphenidyl	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
on	on	ADP	IN	5	O
ratings	rating	NOUN	NNS	5	O
of	of	ADP	IN	5	O
mental	mental	ADJ	JJ	5	B-Disease
slowness	slowness	NOUN	NN	5	I-Disease
significantly	significantly	ADV	RB	9	O
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
total	total	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
delayed	delay	VERB	VBN	9	O
recall	recall	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
Buschke	Buschke	PROPN	NNP	6	O
Selective	Selective	PROPN	NNP	9	O
Reminding	Reminding	PROPN	NNP	5	O
Test	test	NOUN	NN	5	O
in	in	ADP	IN	5	O
carriers	carrier	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
APOE	apoe	NOUN	NN	9	O
epsilon4	epsilon4	NOUN	NN	1	O
allele	allele	NOUN	NN	1	O
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	O
analog	analog	NOUN	NN	0	O
scales	scale	NOUN	NNS	5	O
reflecting	reflect	VERB	VBG	5	O
subjective	subjective	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
clear	clear	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
headedness	headedness	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
epsilon4	epsilon4	NOUN	NN	1	O
allele	allele	NOUN	NN	1	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
elderly	elderly	ADJ	JJ	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
subjective	subjective	ADJ	JJ	5	O
mental	mental	ADJ	JJ	5	B-Disease
slowing	slowing	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
trihexyphenidyl	trihexyphenidyl	NOUN	NN	0	B-Chemical
anticholinergic	anticholinergic	NOUN	NN	5	O
challenge	challenge	NOUN	NN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
amikacin	amikacin	ADJ	JJ	0	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hematology	hematology	NOUN	NN	5	O
/	/	SYM	SYM	9	O
oncology	oncology	NOUN	NN	5	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Amikacin	Amikacin	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
aminoglycoside	aminoglycoside	NOUN	NN	9	B-Chemical
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
provide	provide	VERB	VB	5	O
empirical	empirical	ADJ	JJ	5	O
double	double	ADJ	JJ	9	O
gram	gram	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
negative	negative	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
febrile	febrile	ADJ	JJ	5	B-Disease
neutropenia	neutropenia	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
suspected	suspect	VERB	VBN	5	O
infections	infection	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Strategies	strategy	NOUN	NNS	5	O
of	of	ADP	IN	5	O
extended	extended	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
interval	interval	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
conventional	conventional	ADJ	JJ	5	O
dosing	dosing	NOUN	NN	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
utilized	utilize	VERB	VBN	9	O
extensively	extensively	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
general	general	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
data	datum	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
lacking	lack	VERB	VBG	1	O
to	to	PART	TO	5	O
support	support	VERB	VB	5	O
a	a	DET	DT	5	O
dosing	dosing	ADJ	JJ	9	O
strategy	strategy	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hematology	hematology	NOUN	NN	5	O
/	/	SYM	SYM	9	O
oncology	oncology	NOUN	NN	5	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
amikacin	amikacin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
adult	adult	NOUN	NN	9	O
hematology	hematology	NOUN	NN	5	O
/	/	SYM	SYM	9	O
oncology	oncology	NOUN	NN	5	O
population	population	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
trial	trial	NOUN	NN	5	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
university	university	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
affiliated	affiliate	VERB	VBN	2	O
medical	medical	ADJ	JJ	5	O
center	center	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
hematologic	hematologic	NOUN	NN	5	B-Disease
/	/	SYM	SYM	9	I-Disease
oncologic	oncologic	ADJ	JJ	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
required	require	VERB	VBD	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
aminoglycoside	aminoglycoside	NOUN	NN	9	B-Chemical
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	ADP	IN	5	O
either	either	CCONJ	CC	9	O
conventional	conventional	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
extended	extended	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
interval	interval	ADJ	JJ	5	O
amikacin	amikacin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
by	by	ADP	IN	9	O
means	mean	NOUN	NNS	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
efficacy	efficacy	NOUN	NN	9	O
via	via	ADP	IN	9	O
amikacin	amikacin	VERB	VBG	0	B-Chemical
serum	serum	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
with	with	ADP	IN	5	O
respective	respective	ADJ	JJ	9	O
pathogens	pathogen	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
conventional	conventional	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
extended	extended	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
interval	interval	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
00	00	PUNCT	NFP	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
conventional	conventional	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
culture	culture	NOUN	NN	9	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
none	none	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
extended	extended	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
interval	interval	NOUN	NN	5	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
dosing	dose	VERB	VBG	9	O
regimens	regimen	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
distribution	distribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
variable	variable	ADJ	JJ	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Efficacy	efficacy	NOUN	NN	5	O
could	could	VERB	MD	9	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
assessed	assess	VERB	VBN	9	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
sole	sole	ADJ	JJ	9	O
sedative	sedative	NOUN	NN	5	O
for	for	ADP	IN	5	O
pediatric	pediatric	ADJ	JJ	5	O
MRI	mri	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
large	large	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
scale	scale	NOUN	NN	5	O
retrospective	retrospective	ADJ	JJ	5	O
review	review	NOUN	NN	5	O
evaluates	evaluate	VERB	VBZ	5	O
the	the	DET	DT	5	O
sedation	sedation	NOUN	NN	5	O
profile	profile	NOUN	NN	9	O
of	of	ADP	IN	5	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
sole	sole	ADJ	JJ	9	O
sedative	sedative	NOUN	NN	5	O
for	for	ADP	IN	5	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MRI	MRI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Dexmedetomidine	Dexmedetomidine	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
at	at	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
institution	institution	NOUN	NN	5	O
since	since	ADP	IN	9	O
2005	2005	NUM	CD	2	O
to	to	PART	TO	5	O
provide	provide	VERB	VB	5	O
sedation	sedation	NOUN	NN	5	O
for	for	ADP	IN	5	O
pediatric	pediatric	ADJ	JJ	5	O
radiological	radiological	ADJ	JJ	5	O
imaging	imaging	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Over	over	ADP	IN	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
protocol	protocol	NOUN	NN	9	O
utilizing	utilize	VERB	VBG	9	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
sole	sole	ADJ	JJ	9	O
sedative	sedative	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
evolved	evolve	VERB	VBN	5	O
.	.	PUNCT	.	9	O

METHODS	METHODS	PROPN	NNP	2	O
/	/	SYM	SYM	9	O
MATERIALS	material	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
As	as	ADP	IN	9	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ongoing	ongoing	ADJ	JJ	5	O
Quality	Quality	PROPN	NNP	5	O
Assurance	Assurance	PROPN	NNP	2	O
process	process	NOUN	NN	5	O
,	,	PUNCT	,	9	O
data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
all	all	DET	DT	5	O
sedations	sedation	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
reviewed	review	VERB	VBN	9	O
monthly	monthly	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
protocols	protocol	NOUN	NNS	5	O
modified	modify	VERB	VBN	9	O
as	as	ADP	IN	5	O
needed	need	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
from	from	ADP	IN	9	O
all	all	DET	DT	5	O
747	747	NUM	CD	7	O
consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
MRI	MRI	PROPN	NNP	5	O
sedation	sedation	NOUN	NN	5	O
from	from	ADP	IN	9	O
April	April	PROPN	NNP	2	O
2005	2005	NUM	CD	2	O
to	to	ADP	IN	5	O
April	April	PROPN	NNP	2	O
2007	2007	NUM	CD	2	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Since	since	ADP	IN	9	O
2005	2005	NUM	CD	2	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
min	min	NOUN	NN	0	O
loading	loading	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
protocol	protocol	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
to	to	PART	TO	5	O
2	2	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
h	h	DET	DT	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
protocol	protocol	NOUN	NN	9	O
progressively	progressively	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
successful	successful	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
complete	complete	VERB	VB	9	O
the	the	DET	DT	5	O
imaging	image	VERB	VBG	5	O
study	study	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
when	when	ADV	WRB	5	O
using	use	VERB	VBG	9	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
alone	alone	ADV	RB	9	O
from	from	ADP	IN	9	O
91	91	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
97	97	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
009	009	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
reducing	reduce	VERB	VBG	9	O
the	the	DET	DT	5	O
requirement	requirement	NOUN	NN	9	O
for	for	ADP	IN	5	O
adjuvant	adjuvant	ADJ	JJ	9	O
pentobarbital	pentobarbital	ADJ	JJ	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
event	event	NOUN	NN	5	O
of	of	ADP	IN	5	O
sedation	sedation	NOUN	NN	5	O
failure	failure	NOUN	NN	5	O
with	with	ADP	IN	5	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
alone	alone	ADV	RB	9	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
time	time	NOUN	NN	5	O
by	by	ADP	IN	9	O
10	10	NUM	CD	9	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
sedation	sedation	NOUN	NN	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
16	16	NUM	CD	9	O
%	%	NOUN	NN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
concomitant	concomitant	ADJ	JJ	9	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressures	pressure	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
within	within	ADP	IN	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
adjusted	adjust	VERB	VBN	9	O
normal	normal	ADJ	JJ	9	O
range	range	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
saturations	saturation	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Dexmedetomidine	dexmedetomidine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
provides	provide	VERB	VBZ	5	O
adequate	adequate	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
for	for	ADP	IN	5	O
pediatric	pediatric	ADJ	JJ	5	O
MRI	MRI	PROPN	NNP	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
outside	outside	ADP	IN	5	O
the	the	DET	DT	5	O
established	establish	VERB	VBN	9	O
'	'	PUNCT	``	9	O
awake	awake	ADJ	JJ	5	O
'	'	PUNCT	''	9	O
norms	norm	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
deviation	deviation	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
generally	generally	ADV	RB	5	O
within	within	ADP	IN	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
norms	norm	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
sequelae	sequelae	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Dexmedetomidine	Dexmedetomidine	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
useful	useful	ADJ	JJ	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
sole	sole	ADJ	JJ	9	O
sedative	sedative	NOUN	NN	5	O
for	for	ADP	IN	5	O
pediatric	pediatric	ADJ	JJ	5	O
MRI	mri	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hepatotoxicity	hepatotoxicity	NOUN	NN	0	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
sulfasalazine	sulfasalazine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
arthritis	arthritis	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
series	series	NOUN	NN	5	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
local	local	ADJ	JJ	5	O
surveillance	surveillance	NOUN	NN	5	O
of	of	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Spontaneous	spontaneous	ADJ	JJ	9	O
reporting	reporting	NOUN	NN	5	O
systems	system	NOUN	NNS	5	O
for	for	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
reactions	reaction	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
ADRs	adr	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
handicapped	handicap	VERB	VBN	5	O
by	by	ADP	IN	9	O
under	under	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
reporting	report	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
limited	limited	ADJ	JJ	5	O
detail	detail	NOUN	NN	5	O
on	on	ADP	IN	5	O
individual	individual	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
an	an	DET	DT	5	O
investigation	investigation	NOUN	NN	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
local	local	ADJ	JJ	5	O
surveillance	surveillance	NOUN	NN	5	O
for	for	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
reactions	reaction	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
disease	disease	NOUN	NN	5	O
modifying	modify	VERB	VBG	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
rheumatic	rheumatic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
triggered	trigger	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Serious	serious	ADJ	JJ	5	O
ADR	ADR	PROPN	NNP	9	O
reports	report	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
solicited	solicit	VERB	VBN	5	O
from	from	ADP	IN	9	O
local	local	ADJ	JJ	5	O
clinicians	clinician	NOUN	NNS	5	O
by	by	ADP	IN	9	O
regular	regular	ADJ	JJ	5	O
postcards	postcard	NOUN	NNS	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
past	past	ADJ	JJ	5	O
seven	seven	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
on	on	ADP	IN	5	O
sulfasalazine	sulfasalazine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
met	meet	VERB	VBD	5	O
a	a	DET	DT	5	O
definition	definition	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
serious	serious	ADJ	JJ	5	O
ADR	ADR	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
clinicians	clinician	NOUN	NNS	5	O
reviewed	review	VERB	VBD	9	O
structured	structured	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
assessed	assessed	ADJ	JJ	9	O
causality	causality	NOUN	NN	5	O
by	by	ADP	IN	9	O
consensus	consensus	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
causality	causality	NOUN	NN	5	O
assessment	assessment	NOUN	NN	5	O
instrument	instrument	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
likely	likely	ADJ	JJ	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
sulfasalazine	sulfasalazine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
by	by	ADP	IN	9	O
making	make	VERB	VBG	5	O
a	a	DET	DT	5	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
conservative	conservative	ADJ	JJ	5	O
assumptions	assumption	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Ten	ten	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
:	:	PUNCT	:	9	O
eight	eight	NUM	CD	9	O
occurred	occur	VERB	VBD	9	O
during	during	ADP	IN	5	O
surveillance	surveillance	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
hospitalised	hospitalise	VERB	VBN	5	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
in	in	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	O
one	one	NOUN	NN	5	O
died	die	VERB	VBD	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
liver	liver	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
but	but	ADP	IN	9	O
one	one	NUM	CD	5	O
event	event	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
within	within	ADP	IN	9	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Seven	seven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
skin	skin	NOUN	NN	5	B-Disease
rash	rash	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
eosinophilia	eosinophilia	NOUN	NNS	3	B-Disease
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
of	of	ADP	IN	5	O
Black	Black	PROPN	NNP	9	O
British	British	PROPN	NNP	2	O
of	of	ADP	IN	5	O
African	african	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
Caribbean	caribbean	ADJ	JJ	4	O
descent	descent	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	O
enzymes	enzyme	NOUN	NNS	1	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
hepatocellular	hepatocellular	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
mixed	mixed	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
judged	judge	VERB	VBN	5	O
probable	probable	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
highly	highly	ADV	RB	9	O
probable	probable	ADJ	JJ	9	O
in	in	ADP	IN	5	O
8	8	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
likely	likely	ADJ	JJ	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
sulfasalazine	sulfasalazine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
at	at	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Serious	serious	ADJ	JJ	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
sulfasalazine	sulfasalazine	NOUN	NN	0	B-Chemical
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
under	under	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
appreciated	appreciate	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
intensive	intensive	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
vigilance	vigilance	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
especially	especially	ADV	RB	5	O
important	important	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Complete	complete	VERB	VB	9	O
atrioventricular	atrioventricular	ADJ	JJ	5	B-Disease
block	block	NOUN	NN	9	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sinus	sinus	NOUN	NN	5	B-Disease
node	node	NOUN	NN	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
most	most	ADV	RBS	9	O
frequently	frequently	ADV	RB	5	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
,	,	PUNCT	,	9	O
complete	complete	ADJ	JJ	9	O
atrioventricular	atrioventricular	ADJ	JJ	5	B-Disease
(	(	PUNCT	-LRB-	9	I-Disease
AV	av	NOUN	NN	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
block	block	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
syncopal	syncopal	ADJ	JJ	5	B-Disease
attacks	attack	NOUN	NNS	5	I-Disease
developed	develop	VERB	VBD	5	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
necessitating	necessitate	VERB	VBG	5	O
permanent	permanent	ADJ	JJ	5	O
pacemaker	pacemaker	NOUN	NN	5	O
implantation	implantation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
remained	remain	VERB	VBD	9	O
under	under	ADP	IN	9	O
or	or	CCONJ	CC	5	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
range	range	NOUN	NN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
syncopal	syncopal	ADJ	JJ	5	B-Disease
attacks	attack	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Lithium	Lithium	PROPN	NNP	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
with	with	ADP	IN	5	O
extreme	extreme	ADJ	JJ	5	O
caution	caution	NOUN	NN	5	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
disturbance	disturbance	NOUN	NN	5	O
of	of	ADP	IN	5	O
AV	av	NOUN	NN	9	O
conduction	conduction	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Exaggerated	exaggerated	ADJ	JJ	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
mediators	mediator	NOUN	NNS	9	O
in	in	ADP	IN	5	O
vasoactive	vasoactive	ADJ	JJ	5	O
intestinal	intestinal	ADJ	JJ	9	O
polypeptide	polypeptide	NOUN	NN	1	O
knockout	knockout	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
VIP	VIP	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CYP	CYP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Vasoactive	vasoactive	ADJ	JJ	7	O
intestinal	intestinal	ADJ	JJ	9	O
polypeptide	polypeptide	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
VIP	VIP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
immunomodulatory	immunomodulatory	ADJ	JJ	9	O
neuropeptide	neuropeptide	NOUN	NN	9	O
distributed	distribute	VERB	VBN	5	O
in	in	ADP	IN	5	O
micturition	micturition	NOUN	NN	5	O
pathways	pathway	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

VIP	VIP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
exhibit	exhibit	NOUN	NN	9	O
altered	alter	VERB	VBN	9	O
bladder	bladder	NOUN	NN	9	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
neurochemical	neurochemical	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
in	in	ADP	IN	5	O
micturition	micturition	NOUN	NN	5	O
pathways	pathway	NOUN	NNS	9	O
after	after	ADP	IN	9	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CYP	CYP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
VIP	vip	NOUN	NN	9	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
role	role	NOUN	NN	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
mediator	mediator	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
hypothesized	hypothesize	VERB	VBD	9	O
that	that	ADP	IN	5	O
VIP	VIP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
would	would	VERB	MD	5	O
exhibit	exhibit	VERB	VB	9	O
enhanced	enhance	VERB	VBN	3	O
inflammatory	inflammatory	ADJ	JJ	3	O
mediator	mediator	NOUN	NN	9	O
expression	expression	NOUN	NN	3	O
after	after	ADP	IN	9	O
cystitis	cystitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
mouse	mouse	NOUN	NN	3	O
inflammatory	inflammatory	ADJ	JJ	3	O
cytokine	cytokine	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
receptor	receptor	NOUN	NN	3	O
RT2	rt2	NOUN	NN	3	O
profiler	profiler	NOUN	NN	5	O
array	array	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
regulated	regulated	ADJ	JJ	3	O
transcripts	transcript	NOUN	NNS	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
urinary	urinary	ADJ	JJ	9	O
bladder	bladder	NOUN	NN	9	O
of	of	ADP	IN	5	O
wild	wild	ADJ	JJ	1	O
type	type	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
WT	WT	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
VIP	VIP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
CYP	CYP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
;	;	PUNCT	:	9	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
binary	binary	ADJ	JJ	5	O
comparisons	comparison	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
:	:	PUNCT	:	9	O
WT	wt	NOUN	NN	3	O
control	control	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
CYP	CYP	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
VIP	VIP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
control	control	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
CYP	CYP	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
WT	wt	NOUN	NN	3	O
control	control	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
VIP	VIP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
WT	WT	PROPN	NNP	3	O
with	with	ADP	IN	5	O
CYP	CYP	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
VIP	VIP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
CYP	CYP	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
genes	gene	NOUN	NNS	1	O
presented	present	VERB	VBD	5	O
represent	represent	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	:	7	O
fold	fold	VERB	VB	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
either	either	DET	DT	9	O
direction	direction	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
p	p	NOUN	NN	7	O
value	value	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
comparison	comparison	NOUN	NN	9	O
being	be	VERB	VBG	5	O
made	make	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Several	several	ADJ	JJ	9	O
regulated	regulate	VERB	VBN	3	O
genes	gene	NOUN	NNS	1	O
were	be	VERB	VBD	9	O
validated	validate	VERB	VBN	5	O
using	use	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
-	-	PUNCT	HYPH	7	O
linked	link	VERB	VBN	9	O
immunoassays	immunoassay	NOUN	NNS	9	O
including	include	VERB	VBG	9	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
1beta	1beta	PROPN	NNP	7	O
and	and	CCONJ	CC	5	O
CXCL1	CXCL1	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

CYP	CYP	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
significantly	significantly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBN	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
CXCL1	CXCL1	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
1beta	1beta	PROPN	NNP	7	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
urinary	urinary	ADJ	JJ	9	O
bladder	bladder	NOUN	NN	9	O
of	of	ADP	IN	5	O
WT	WT	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
VIP	VIP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
VIP	VIP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
CYP	CYP	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
greater	great	ADJ	JJR	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	:	7	O
to	to	ADP	IN	5	O
13	13	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
fold	fold	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
WT	WT	PROPN	NNP	3	O
urinary	urinary	NOUN	NN	9	O
bladder	bladder	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
fold	fold	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
in	in	ADP	IN	5	O
VIP	VIP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
inflammation	inflammation	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
inflammatory	inflammatory	ADJ	JJ	3	O
mediators	mediator	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
increased	increase	VERB	VBN	9	O
above	above	ADP	IN	9	O
that	that	DET	DT	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
WT	WT	PROPN	NNP	3	O
with	with	ADP	IN	5	O
CYP	CYP	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
shift	shift	NOUN	NN	9	O
in	in	ADP	IN	5	O
balance	balance	NOUN	NN	5	O
may	may	VERB	MD	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
bladder	bladder	NOUN	NN	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
VIP	VIP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
inflammation	inflammation	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
altered	alter	VERB	VBN	9	O
neurochemical	neurochemical	ADJ	JJ	5	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
micturition	micturition	NOUN	NN	5	O
pathways	pathway	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Debrisoquine	debrisoquine	NOUN	NN	2	B-Chemical
phenotype	phenotype	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
pharmacokinetics	pharmacokinetic	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
receptor	receptor	NOUN	NN	3	O
pharmacodynamics	pharmacodynamic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
enantiomers	enantiomer	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
metabolism	metabolism	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cardioselective	cardioselective	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocker	blocker	NOUN	NN	0	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
under	under	ADP	IN	9	O
genetic	genetic	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
debrisoquine	debrisoquine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
sparteine	sparteine	NOUN	NN	0	B-Chemical
type	type	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
two	two	NUM	CD	5	O
metabolic	metabolic	ADJ	JJ	9	O
phenotypes	phenotype	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
extensive	extensive	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
EM	EM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
poor	poor	ADJ	JJ	5	O
metabolizers	metabolizer	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
PM	PM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
show	show	VERB	VBP	9	O
different	different	ADJ	JJ	9	O
stereoselective	stereoselective	ADJ	JJ	0	O
metabolism	metabolism	NOUN	NN	9	O
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
apparently	apparently	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
antagonistic	antagonistic	ADJ	JJ	9	O
potency	potency	NOUN	NN	9	O
of	of	ADP	IN	5	O
racemic	racemic	ADJ	JJ	0	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
EMs	em	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
if	if	ADP	IN	5	O
the	the	DET	DT	5	O
latter	latter	NOUN	NN	9	O
also	also	ADV	RB	9	O
applies	apply	VERB	VBZ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
antagonism	antagonism	NOUN	NN	9	O
by	by	ADP	IN	9	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
studied	study	VERB	VBD	9	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
antagonism	antagonism	NOUN	NN	9	O
by	by	ADP	IN	9	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
using	use	VERB	VBG	9	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
pharmacodynamic	pharmacodynamic	NOUN	NN	5	O
modeling	model	VERB	VBG	5	O
the	the	DET	DT	5	O
pharmacodynamics	pharmacodynamic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
racemic	racemic	NOUN	NN	0	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
active	active	ADJ	JJ	9	O
S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
isomer	isomer	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
quantitated	quantitate	VERB	VBN	9	O
in	in	ADP	IN	5	O
EMs	em	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
PMs	pm	NOUN	NNS	5	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
IC50	ic50	ADJ	JJ	0	O
values	value	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
representing	represent	VERB	VBG	9	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
half	half	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
maximum	maximum	ADJ	JJ	5	O
receptor	receptor	NOUN	NN	3	O
occupancy	occupancy	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
EMs	em	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
s	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
on	on	ADP	IN	5	O
two	two	NUM	CD	5	O
different	different	ADJ	JJ	9	O
occasions	occasion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
hr	hr	NOUN	NN	0	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
hr	hr	NOUN	NN	0	O
after	after	ADP	IN	9	O
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
PMs	pm	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
protocol	protocol	NOUN	NN	9	O
,	,	PUNCT	,	9	O
except	except	ADP	IN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
racemic	racemic	NOUN	NN	0	O
,	,	PUNCT	,	9	O
R	r	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
S	S	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
isomer	isomer	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxymetoprolol	hydroxymetoprolol	NOUN	NN	_	I-Chemical
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
at	at	ADP	IN	9	O
regular	regular	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
intervals	interval	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
8	8	NUM	CD	9	O
hr	hr	NOUN	NNS	0	O
after	after	ADP	IN	9	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
PMs	pm	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
area	area	NOUN	NN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
time	time	NOUN	NN	5	O
curve	curve	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
67	67	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Higher	high	ADJ	JJR	9	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxymetoprolol	hydroxymetoprolol	NOUN	NN	_	I-Chemical
ratios	ratio	NOUN	NNS	9	O
in	in	ADP	IN	5	O
PMs	pm	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
predictive	predictive	ADJ	JJ	5	O
for	for	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
R	r	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
S	s	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
isomer	isomer	NOUN	NN	0	O
ratios	ratio	NOUN	NNS	9	O
of	of	ADP	IN	5	O
unchanged	unchanged	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
potency	potency	NOUN	NN	9	O
with	with	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
racemic	racemic	NOUN	NN	0	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
IC50	ic50	DET	PRP$	0	O
values	value	NOUN	NNS	5	O
in	in	ADP	IN	5	O
PMs	pm	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
72	72	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
ng	ng	NOUN	NN	0	O
.	.	PUNCT	.	9	O
ml	ml	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
EMs	em	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
42	42	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
ng	ng	NOUN	NN	0	O
.	.	PUNCT	.	9	O
ml	ml	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

The	the	DET	DT	5	O
hemodynamics	hemodynamic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
oxytocin	oxytocin	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
vasoactive	vasoactive	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
during	during	ADP	IN	5	O
neuraxial	neuraxial	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
for	for	ADP	IN	5	O
cesarean	cesarean	ADJ	JJ	5	O
delivery	delivery	NOUN	NN	5	O
:	:	PUNCT	:	9	O
findings	finding	NOUN	NNS	9	O
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Oxytocin	Oxytocin	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
uterotonic	uterotonic	ADJ	JJ	5	O
that	that	DET	WDT	5	O
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
significant	significant	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
even	even	ADV	RB	5	O
fatal	fatal	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
bolus	bolus	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
resulting	result	VERB	VBG	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
through	through	ADP	IN	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
venous	venous	ADJ	JJ	5	O
return	return	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Parturients	parturient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
volume	volume	NOUN	NN	9	O
status	status	NOUN	NN	9	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	O
valves	valve	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
vasculature	vasculature	NOUN	NN	5	O
most	most	ADV	RBS	9	O
often	often	ADV	RB	5	O
respond	respond	VERB	VBP	5	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
compensatory	compensatory	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
stroke	stroke	NOUN	NN	5	B-Disease
volume	volume	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Oxytocin	Oxytocin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
cesarean	cesarean	ADJ	JJ	5	O
delivery	delivery	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
incorrectly	incorrectly	ADV	RB	5	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
blood	blood	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Pulse	pulse	VERB	VB	5	O
power	power	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
also	also	ADV	RB	9	O
called	call	VERB	VBN	5	O
"	"	PUNCT	``	5	O
pulse	pulse	NOUN	NN	5	O
contour	contour	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
"	"	PUNCT	''	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
wave	wave	NOUN	NN	5	O
form	form	NOUN	NN	9	O
allows	allow	VERB	VBZ	5	O
continuous	continuous	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
in	in	ADP	IN	5	O
real	real	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
thereby	thereby	ADV	RB	9	O
elucidating	elucidate	VERB	VBG	9	O
the	the	DET	DT	5	O
causative	causative	ADJ	JJ	9	O
factors	factor	NOUN	NNS	9	O
behind	behind	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pulse	pulse	NOUN	NN	5	O
power	power	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cesarean	cesarean	ADJ	JJ	5	O
delivery	delivery	NOUN	NN	5	O
performed	perform	VERB	VBN	9	O
under	under	ADP	IN	9	O
neuraxial	neuraxial	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hypotension	hypotension	NOUN	NN	7	B-Disease
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
oxytocin	oxytocin	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
compensatory	compensatory	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
stroke	stroke	NOUN	NN	5	B-Disease
volume	volume	NOUN	NN	9	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pulse	pulse	NOUN	NN	5	O
power	power	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
helpful	helpful	ADJ	JJ	6	O
in	in	ADP	IN	5	O
determining	determine	VERB	VBG	9	O
the	the	DET	DT	5	O
etiology	etiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
and	and	CCONJ	CC	5	O
treating	treat	VERB	VBG	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
cesarean	cesarean	ADJ	JJ	5	O
delivery	delivery	NOUN	NN	5	O
under	under	ADP	IN	9	O
neuraxial	neuraxial	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Protective	protective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
antithrombin	antithrombin	NOUN	NN	9	O
on	on	ADP	IN	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
nephrosis	nephrosis	NOUN	NN	0	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
antithrombin	antithrombin	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
coagulation	coagulation	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrosis	nephrosis	NOUN	NN	0	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Antithrombin	Antithrombin	PROPN	NNP	7	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
or	or	CCONJ	CC	5	O
500	500	NUM	CD	0	O
IU	iu	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	PART	TO	5	O
rats	rat	NOUN	NNS	9	O
once	once	ADV	RB	5	O
a	a	DET	DT	5	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
antithrombin	antithrombin	NOUN	NN	9	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hematological	hematological	ADJ	JJ	9	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

Puromycin	Puromycin	PROPN	NNP	0	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
hyperlipidemia	hyperlipidemia	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
suppressed	suppress	VERB	VBN	3	O
.	.	PUNCT	.	9	O

Histopathological	histopathological	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
severe	severe	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
proteinaceous	proteinaceous	ADJ	JJ	0	O
casts	cast	NOUN	NNS	5	O
in	in	ADP	IN	5	O
tubuli	tubuli	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
tubular	tubular	ADJ	JJ	9	O
expansion	expansion	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
of	of	ADP	IN	5	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
an	an	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
damage	damage	NOUN	NN	9	O
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
antithrombin	antithrombin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
antithrombin	antithrombin	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
markedly	markedly	ADV	RB	9	O
suppressed	suppress	VERB	VBD	3	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
apoptosis	apoptosis	NOUN	NN	3	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	O
epithelial	epithelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
cytokine	cytokine	NOUN	NN	3	O
content	content	NOUN	NN	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
thrombin	thrombin	NOUN	NN	0	O
plays	play	VERB	VBZ	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
antithrombin	antithrombin	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
clinically	clinically	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Heparin	Heparin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Unfractionated	unfractionated	ADJ	JJ	0	B-Chemical
heparin	heparin	ADJ	JJ	0	I-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
UFH	UFH	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
low	low	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
molecular	molecular	ADJ	JJ	9	I-Chemical
weight	weight	NOUN	NN	9	I-Chemical
heparin	heparin	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
LMWH	LMWH	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
anticoagulant	anticoagulant	ADJ	JJ	9	O
protocols	protocol	NOUN	NNS	5	O
at	at	ADP	IN	9	O
several	several	ADJ	JJ	9	O
institutions	institution	NOUN	NNS	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Heparin	Heparin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
HIT	HIT	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
immune	immune	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
reaction	reaction	NOUN	NN	9	O
to	to	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
platelet	platelet	NOUN	NN	9	O
count	count	NOUN	NN	9	O
decreases	decrease	NOUN	NNS	9	O
of	of	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
frequencies	frequency	NOUN	NNS	9	O
of	of	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
platelet	platelet	NOUN	NN	9	O
factor	factor	NOUN	NN	9	O
4	4	NUM	CD	9	O
/	/	SYM	SYM	9	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
reactive	reactive	ADJ	JJ	9	O
antibody	antibody	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
HIT	HIT	PROPN	NNP	5	B-Disease
antibody	antibody	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
positivity	positivity	NOUN	NN	9	O
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
32	32	NUM	CD	7	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
underwent	undergo	VERB	VBD	5	O
living	live	VERB	VBG	5	O
donor	donor	NOUN	NN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
started	start	VERB	VBD	5	O
LMWH	LMWH	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
IU	iu	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
POD	POD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
switching	switch	VERB	VBG	5	O
to	to	ADP	IN	5	O
UFH	UFH	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
5000	5000	NUM	CD	0	O
U	U	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
POD	POD	PROPN	NNP	9	O
2	2	NUM	CD	9	O
or	or	CCONJ	CC	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
UFH	UFH	PROPN	NNP	5	B-Chemical
was	be	VERB	VBD	9	O
changed	change	VERB	VBN	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
activated	activate	VERB	VBN	3	O
clotting	clot	VERB	VBG	5	O
time	time	NOUN	NN	5	O
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

HIT	HIT	PROPN	NNP	5	B-Disease
antibody	antibody	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
the	the	DET	DT	5	O
day	day	NOUN	NN	9	O
before	before	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
POD	POD	PROPN	NNP	9	O
7	7	NUM	CD	9	O
and	and	CCONJ	CC	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O

Platelet	Platelet	PROPN	NNP	9	O
count	count	NOUN	NN	9	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
platelet	platelet	NOUN	NN	9	O
counts	count	NOUN	NNS	9	O
preoperatively	preoperatively	ADV	RB	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
POD	POD	PROPN	NNP	9	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
21	21	NUM	CD	7	O
were	be	VERB	VBD	9	O
65	65	NUM	CD	7	O
,	,	PUNCT	,	9	O
88	88	NUM	CD	7	O
,	,	PUNCT	,	9	O
149	149	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
169	169	NUM	CD	7	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
hepatic	hepatic	ADJ	JJ	9	O
artery	artery	NOUN	NN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
POD	POD	PROPN	NNP	9	O
11	11	NUM	CD	7	O
and	and	CCONJ	CC	5	O
19	19	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
HIT	HIT	VERB	VBN	5	B-Disease
antibody	antibody	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
negative	negative	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
platelet	platelet	NOUN	NN	9	O
counts	count	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
stable	stable	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
2	2	NUM	CD	9	O
other	other	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
platelet	platelet	NOUN	NN	9	O
count	count	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
suddenly	suddenly	ADV	RB	5	O
from	from	ADP	IN	9	O
107	107	NUM	CD	9	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
on	on	ADP	IN	5	O
POD	POD	PROPN	NNP	9	O
4	4	NUM	CD	9	O
to	to	ADP	IN	5	O
65	65	NUM	CD	7	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
on	on	ADP	IN	5	O
POD	POD	PROPN	NNP	9	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
from	from	ADP	IN	9	O
76	76	NUM	CD	7	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
on	on	ADP	IN	5	O
POD	POD	PROPN	NNP	9	O
7	7	NUM	CD	9	O
to	to	PART	TO	5	O
33	33	NUM	CD	7	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
on	on	ADP	IN	5	O
POD	POD	PROPN	NNP	9	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
platelet	platelet	NOUN	NN	9	B-Disease
aggregation	aggregation	NOUN	NN	9	I-Disease
test	test	NOUN	NN	5	O
was	be	VERB	VBD	9	O
negative	negative	ADJ	JJ	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
antibody	antibody	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
preoperatively	preoperatively	ADV	RB	5	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
on	on	ADP	IN	5	O
POD	POD	PROPN	NNP	9	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
on	on	ADP	IN	5	O
POD	POD	PROPN	NNP	9	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
UFH	UFH	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
HIT	HIT	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
series	series	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
uncommon	uncommon	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Doxorubicin	Doxorubicin	PROPN	NNP	0	B-Chemical
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
inflammation	inflammation	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
apoptosis	apoptosis	NOUN	NN	3	O
are	be	VERB	VBP	5	O
attenuated	attenuate	VERB	VBN	3	O
by	by	ADP	IN	9	O
gene	gene	NOUN	NN	1	O
deletion	deletion	NOUN	NN	1	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
kinin	kinin	NOUN	NN	0	O
B1	b1	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anthracycline	anthracycline	ADJ	JJ	9	B-Chemical
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
limited	limit	VERB	VBN	5	O
by	by	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
cardiotoxic	cardiotoxic	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
are	be	VERB	VBP	5	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
apoptosis	apoptosis	NOUN	NN	3	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
elucidate	elucidate	VERB	VB	9	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
kinin	kinin	NOUN	NN	0	O
B1	b1	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
B1R	B1R	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
studied	study	VERB	VBD	9	O
B1R	B1R	PROPN	NNP	3	O
knockout	knockout	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
B1R	B1R	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
by	by	ADP	IN	9	O
investigating	investigate	VERB	VBG	5	O
cardiac	cardiac	ADJ	JJ	5	O
inflammation	inflammation	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
apoptosis	apoptosis	NOUN	NN	3	O
after	after	ADP	IN	9	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

DOX	dox	NOUN	NN	0	B-Chemical
control	control	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
showed	show	VERB	VBD	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
pressure	pressure	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
volume	volume	NOUN	NN	9	O
loops	loop	NOUN	NNS	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
reduced	reduced	ADJ	JJ	9	O
activation	activation	NOUN	NN	3	O
state	state	NOUN	NN	5	O
of	of	ADP	IN	5	O
AKT	AKT	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
bax	bax	NOUN	NN	3	O
/	/	SYM	SYM	9	O
bcl2	bcl2	NOUN	NN	3	O
ratio	ratio	NOUN	NN	9	O
in	in	ADP	IN	5	O
Western	western	ADJ	JJ	3	O
blots	blot	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
apoptosis	apoptosis	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
proinflammatory	proinflammatory	NOUN	NN	3	O
cytokine	cytokine	NOUN	NN	3	O
interleukin	interleukin	NOUN	NN	3	O
6	6	NUM	CD	9	O
were	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
B1R	B1R	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
improved	improve	VERB	VBN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
control	control	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
normalization	normalization	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
bax	bax	NOUN	NN	3	O
/	/	SYM	SYM	9	O
bcl	bcl	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
ratio	ratio	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
interleukin	interleukin	NOUN	NN	3	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
AKT	AKT	PROPN	NNP	3	O
activation	activation	NOUN	NN	3	O
state	state	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
B1R	B1R	PROPN	NNP	3	O
is	be	VERB	VBZ	5	O
detrimental	detrimental	ADJ	JJ	9	O
in	in	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
mediates	mediate	VERB	VBZ	3	O
the	the	DET	DT	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
apoptosis	apoptosis	NOUN	NN	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
insights	insight	NOUN	NNS	5	O
might	may	VERB	MD	9	O
have	have	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
implications	implication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
future	future	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
utilizing	utilize	VERB	VBG	9	O
B1R	B1R	PROPN	NNP	3	O
antagonists	antagonist	NOUN	NNS	3	O
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
DOX	DOX	PROPN	NNP	0	B-Chemical
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Detailed	detailed	ADJ	JJ	5	O
spectral	spectral	ADJ	JJ	5	O
profile	profile	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
epileptiform	epileptiform	NOUN	NN	5	B-Disease
activity	activity	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
anesthetized	anesthetized	ADJ	JJ	0	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Penicillin	Penicillin	PROPN	NNP	0	B-Chemical
model	model	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
research	research	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
aimed	aim	VERB	VBD	5	O
to	to	PART	TO	5	O
portray	portray	VERB	VB	5	O
a	a	DET	DT	5	O
detailed	detailed	ADJ	JJ	5	O
spectral	spectral	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
epileptiform	epileptiform	NOUN	NN	5	B-Disease
activity	activity	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
basal	basal	NOUN	NN	3	O
brain	brain	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
anesthetized	anesthetized	ADJ	JJ	0	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
anesthetized	anesthetize	VERB	VBN	0	O
with	with	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
urethane	urethane	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
connected	connect	VERB	VBD	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
electrocorticogram	electrocorticogram	ADJ	JJ	5	O
setup	setup	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
a	a	DET	DT	5	O
short	short	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
basal	basal	NOUN	NN	3	O
activity	activity	NOUN	NN	9	O
recording	recording	NOUN	NN	5	O
,	,	PUNCT	,	9	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
focus	focus	NOUN	NN	5	O
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
injecting	inject	VERB	VBG	9	O
400IU	400IU	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
G	g	NOUN	NN	9	I-Chemical
potassium	potassium	NOUN	NN	0	I-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
lateral	lateral	ADJ	JJ	5	O
ventricle	ventricle	NOUN	NN	5	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
cortical	cortical	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
continuously	continuously	ADV	RB	5	O
recorded	record	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Basal	basal	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
latent	latent	NOUN	NN	5	O
period	period	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
epileptiform	epileptiform	NOUN	NN	5	B-Disease
activity	activity	NOUN	NN	9	I-Disease
periods	period	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
analyzed	analyze	VERB	VBN	9	O
using	use	VERB	VBG	9	O
both	both	DET	DT	9	O
conventional	conventional	ADJ	JJ	5	O
methods	method	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
spectral	spectral	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Spectral	spectral	ADJ	JJ	5	O
analyses	analysis	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
by	by	ADP	IN	9	O
dividing	divide	VERB	VBG	9	O
the	the	DET	DT	5	O
whole	whole	ADJ	JJ	9	O
spectrum	spectrum	NOUN	NN	9	O
into	into	ADP	IN	9	O
different	different	ADJ	JJ	9	O
frequency	frequency	NOUN	NN	5	O
bands	band	NOUN	NNS	9	O
including	include	VERB	VBG	9	O
delta	delta	NOUN	NN	9	O
,	,	PUNCT	,	9	O
theta	theta	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
slow	slow	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
fast	fast	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
sigma	sigma	NOUN	NN	9	O
,	,	PUNCT	,	9	O
beta	beta	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
gamma	gamma	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
bands	band	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
affected	affected	ADJ	JJ	9	O
frequency	frequency	NOUN	NN	5	O
bands	band	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
delta	delta	NOUN	NN	9	O
,	,	PUNCT	,	9	O
theta	theta	NOUN	NN	5	O
,	,	PUNCT	,	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
gamma	gamma	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
bands	band	NOUN	NNS	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
epileptiform	epileptiform	NOUN	NN	5	B-Disease
activity	activity	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
marked	mark	VERB	VBN	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
spectral	spectral	ADJ	JJ	5	O
densities	density	NOUN	NNS	9	O
between	between	ADP	IN	5	O
three	three	NUM	CD	9	O
investigated	investigate	VERB	VBN	9	O
episodes	episode	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
basal	basal	NOUN	NN	3	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
latent	latent	NOUN	NN	5	O
period	period	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
epileptiform	epileptiform	NOUN	NN	5	B-Disease
activity	activity	NOUN	NN	9	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
may	may	VERB	MD	5	O
help	help	VERB	VB	5	O
to	to	PART	TO	5	O
analyze	analyze	VERB	VB	9	O
novel	novel	ADJ	JJ	9	O
data	datum	NOUN	NNS	5	O
obtained	obtain	VERB	VBN	9	O
using	use	VERB	VBG	9	O
similar	similar	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
models	model	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
simple	simple	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
method	method	NOUN	NN	5	O
described	describe	VERB	VBN	9	O
here	here	ADV	RB	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
similar	similar	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
basic	basic	ADJ	JJ	5	O
neuronal	neuronal	ADJ	JJ	3	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
epilepsies	epilepsy	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
fat	fat	ADJ	JJ	9	B-Chemical
diet	diet	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
fed	feed	VERB	VBN	9	O
obese	obese	ADJ	JJ	9	B-Disease
rats	rat	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
highly	highly	ADV	RB	9	O
sensitive	sensitive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Often	often	ADV	RB	5	O
,	,	PUNCT	,	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
by	by	ADP	IN	9	O
doxorubicin	doxorubicin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Adriamycin	Adriamycin	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
limited	limit	VERB	VBN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
life	life	NOUN	NN	5	O
threatening	threaten	VERB	VBG	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
during	during	ADP	IN	5	O
and	and	CCONJ	CC	5	O
posttherapy	posttherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
that	that	DET	DT	5	O
moderate	moderate	ADJ	JJ	9	O
diet	diet	NOUN	NN	9	O
restriction	restriction	NOUN	NN	9	O
remarkably	remarkably	ADV	RB	9	O
protects	protect	VERB	VBZ	3	O
against	against	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
cardioprotection	cardioprotection	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
decreased	decrease	VERB	VBN	9	O
cardiac	cardiac	ADJ	JJ	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
triglycerides	triglyceride	NOUN	NNS	9	B-Chemical
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
cardiac	cardiac	ADJ	JJ	5	O
fatty	fatty	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
acid	acid	NOUN	NN	0	O
oxidation	oxidation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
ATP	ATP	PROPN	NNP	0	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
upregulated	upregulate	VERB	VBD	3	O
JAK	JAK	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
STAT3	STAT3	PROPN	NNP	3	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
a	a	DET	DT	5	O
physiological	physiological	ADJ	JJ	9	O
intervention	intervention	NOUN	NN	5	O
by	by	ADP	IN	9	O
feeding	feed	VERB	VBG	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
high	high	ADJ	JJ	9	O
fat	fat	ADJ	JJ	9	B-Chemical
diet	diet	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HFD	HFD	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
induces	induce	VERB	VBZ	3	O
obesity	obesity	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
250	250	NUM	CD	0	O
-	-	SYM	SYM	7	O
275	275	NUM	CD	9	O
g	g	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
sensitizes	sensitize	VERB	VBZ	3	O
to	to	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
LD	LD	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
ip	ip	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
administered	administer	VERB	VBD	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
43	43	NUM	CD	7	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
HFD	HFD	PROPN	NNP	3	O
feeding	feeding	NOUN	NN	5	O
regimen	regimen	NOUN	NN	5	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
80	80	NUM	CD	9	O
%	%	NOUN	NN	9	O
mortality	mortality	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
obese	obese	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
OB	OB	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	B-Disease
or	or	CCONJ	CC	5	I-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
toxicokinetics	toxicokinetic	NOUN	NNS	0	O
studies	study	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
doxorubicinol	doxorubicinol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
toxic	toxic	ADJ	JJ	0	O
metabolite	metabolite	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
diet	diet	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
fed	fed	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
ND	ND	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
OB	OB	PROPN	NNP	9	B-Disease
hearts	heart	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Mechanistic	mechanistic	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
OB	OB	PROPN	NNP	9	B-Disease
rats	rat	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
sensitized	sensitize	VERB	VBN	3	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
:	:	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
higher	high	ADJ	JJR	9	O
oxyradical	oxyradical	ADJ	JJ	0	O
stress	stress	NOUN	NN	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
upregulation	upregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
uncoupling	uncoupling	ADJ	JJ	9	O
proteins	protein	NOUN	NNS	1	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
downregulation	downregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
peroxisome	peroxisome	NOUN	NN	3	O
proliferators	proliferator	NOUN	NNS	3	O
activated	activate	VERB	VBD	3	O
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
alpha	alpha	NOUN	NN	9	O
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
decreased	decrease	VERB	VBN	9	O
plasma	plasma	NOUN	NN	9	O
adiponectin	adiponectin	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
decreased	decrease	VERB	VBD	9	O
cardiac	cardiac	ADJ	JJ	5	O
fatty	fatty	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
acid	acid	NOUN	NN	0	O
oxidation	oxidation	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
666	666	NUM	CD	7	O
.	.	NOUN	NN	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
nmol	nmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
/	/	SYM	SYM	9	O
g	g	NOUN	NN	0	O
heart	heart	NOUN	NN	5	O
in	in	ADP	IN	5	O
ND	ND	PROPN	NNP	7	O
versus	versus	ADP	IN	9	O
400	400	NUM	CD	0	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
nmol	nmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
/	/	SYM	SYM	9	O
g	g	NOUN	NN	0	O
heart	heart	NOUN	NN	5	O
in	in	ADP	IN	5	O
OB	OB	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
5	5	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
decreased	decrease	VERB	VBD	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
AMP	AMP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
alpha2	alpha2	NOUN	NN	9	O
protein	protein	NOUN	NN	1	O
kinase	kinase	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
86	86	NUM	CD	7	O
%	%	NOUN	NN	9	O
drop	drop	NOUN	NN	9	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
ATP	ATP	PROPN	NNP	0	B-Chemical
levels	level	NOUN	NNS	3	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
decreased	decrease	VERB	VBN	9	O
ATP	ATP	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
ADP	ADP	PROPN	NNP	0	B-Chemical
ratio	ratio	NOUN	NN	9	O
after	after	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Decreased	decrease	VERB	VBN	9	O
cardiac	cardiac	ADJ	JJ	5	O
erythropoietin	erythropoietin	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
SOCS3	SOCS3	PROPN	NNP	3	O
further	further	ADV	RB	9	O
downregulated	downregulate	VERB	VBD	3	O
the	the	DET	DT	5	O
cardioprotective	cardioprotective	ADJ	JJ	9	O
JAK	JAK	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
STAT3	STAT3	PROPN	NNP	3	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
HFD	HFD	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
obese	obese	ADJ	JJ	9	B-Disease
rats	rat	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
highly	highly	ADV	RB	9	O
sensitized	sensitize	VERB	VBN	3	O
to	to	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
by	by	ADP	IN	9	O
substantially	substantially	ADV	RB	9	O
downregulating	downregulate	VERB	VBG	3	O
cardiac	cardiac	ADJ	JJ	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
ATP	ATP	PROPN	NNP	0	B-Chemical
generation	generation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
increasing	increase	VERB	VBG	9	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
downregulating	downregulate	VERB	VBG	3	O
the	the	DET	DT	5	O
JAK	JAK	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
STAT3	STAT3	PROPN	NNP	3	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
induces	induce	VERB	VBZ	3	O
primary	primary	ADJ	JJ	9	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
dystrophin	dystrophin	NOUN	NN	3	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
hearts	heart	NOUN	NNS	3	O
:	:	PUNCT	:	9	O
correlation	correlation	NOUN	NN	9	O
with	with	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
unknown	unknown	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
a	a	DET	DT	5	O
mismatch	mismatch	NOUN	NN	5	O
of	of	ADP	IN	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
supply	supply	NOUN	NN	5	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
demand	demand	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
coronary	coronary	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
hyperactivity	hyperactivity	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
best	good	ADJ	JJS	5	O
explanation	explanation	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
complex	complex	ADJ	JJ	9	O
morphological	morphological	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
observed	observe	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
structural	structural	ADJ	JJ	9	O
integrity	integrity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sarcolemma	sarcolemma	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiomyocytes	cardiomyocyte	NOUN	NNS	3	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
demonstrated	demonstrate	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Taking	take	VERB	VBG	5	O
into	into	ADP	IN	9	O
account	account	NOUN	NN	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
sarcolemmal	sarcolemmal	ADJ	JJ	3	O
integrity	integrity	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
stabilized	stabilize	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
dystrophin	dystrophin	ADV	RB	3	O
-	-	PUNCT	HYPH	7	O
glycoprotein	glycoprotein	NOUN	NN	3	O
complex	complex	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
DGC	DGC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
that	that	DET	WDT	5	O
connects	connect	VERB	VBZ	5	O
actin	actin	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
laminin	laminin	ADJ	JJ	3	O
in	in	ADP	IN	5	O
contractile	contractile	NOUN	NN	9	O
machinery	machinery	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
extracellular	extracellular	ADJ	JJ	9	O
matrix	matrix	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
integrins	integrin	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
tests	test	VERB	VBZ	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	WDT	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
affects	affect	VERB	VBZ	9	O
sarcolemmal	sarcolemmal	ADJ	JJ	3	O
stability	stability	NOUN	NN	9	O
through	through	ADP	IN	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
DGC	DGC	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
integrins	integrin	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
different	different	ADJ	JJ	9	O
sensitivity	sensitivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
DGC	DGC	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
integrin	integrin	NOUN	NN	3	O
to	to	PART	TO	5	O
isoproterenol	isoproterenol	VERB	VB	0	B-Chemical
subcutaneous	subcutaneous	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Immunofluorescent	immunofluorescent	ADJ	JJ	3	O
staining	staining	NOUN	NN	3	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
dystrophin	dystrophin	ADV	RB	3	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
sensitive	sensitive	ADJ	JJ	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
structures	structure	NOUN	NNS	9	O
connecting	connect	VERB	VBG	5	O
the	the	DET	DT	5	O
actin	actin	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
cytoskeleton	cytoskeleton	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
extracellular	extracellular	ADJ	JJ	9	O
matrix	matrix	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
sarcomeric	sarcomeric	ADJ	JJ	3	O
actin	actin	NOUN	NN	3	O
dissolution	dissolution	NOUN	NN	0	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
dystrophin	dystrophin	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Subsequently	subsequently	ADV	RB	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
lysis	lysis	NOUN	NN	3	O
of	of	ADP	IN	5	O
myofilaments	myofilament	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
gamma	gamma	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
sarcoglycan	sarcoglycan	ADJ	JJ	1	O
,	,	PUNCT	,	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dystroglycan	dystroglycan	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
beta1	beta1	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
integrin	integrin	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
laminin	laminin	ADJ	JJ	3	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
expressions	expression	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
their	-PRON-	DET	PRP$	5	O
breakdown	breakdown	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
epiphenomena	epiphenomenon	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
myocytolytic	myocytolytic	ADJ	JJ	9	O
process	process	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
rats	rats	VERB	VB	9	O
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
dystrophin	dystrophin	NOUN	NN	3	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
sensitive	sensitive	ADJ	JJ	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
structural	structural	ADJ	JJ	9	O
proteins	protein	NOUN	NNS	1	O
that	that	DET	WDT	5	O
form	form	VERB	VBP	9	O
the	the	DET	DT	5	O
DGC	DGC	PROPN	NNP	9	O
that	that	DET	WDT	5	O
connects	connect	VERB	VBZ	5	O
the	the	DET	DT	5	O
extracellular	extracellular	ADJ	JJ	9	O
matrix	matrix	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
cytoskeleton	cytoskeleton	NOUN	NN	3	O
in	in	ADP	IN	5	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
changes	change	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
ischaemic	ischaemic	ADJ	JJ	5	B-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
explain	explain	VERB	VB	9	O
the	the	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
structural	structural	ADJ	JJ	9	O
integrity	integrity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sarcolemma	sarcolemma	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiomyocytes	cardiomyocyte	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
hence	hence	ADV	RB	5	O
severe	severe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
irreversible	irreversible	ADJ	JJ	9	O
injury	injury	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Etiologic	etiologic	ADJ	JJ	2	O
factors	factor	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

Within	within	ADP	IN	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
several	several	ADJ	JJ	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
previously	previously	ADV	RB	9	O
rare	rare	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
using	use	VERB	VBG	9	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptive	contraceptive	ADJ	JJ	5	I-Chemical
steroids	steroid	NOUN	NNS	9	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Registry	Registry	PROPN	NNP	2	O
for	for	ADP	IN	5	O
Liver	Liver	PROPN	NNP	9	B-Disease
Tumors	Tumors	PROPN	NNP	9	I-Disease
Associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
Oral	Oral	PROPN	NNP	9	B-Chemical
Contraceptives	Contraceptives	PROPN	NNP	7	I-Chemical
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
University	University	PROPN	NNP	2	O
of	of	ADP	IN	5	O
California	California	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Irvine	Irvine	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
clearly	clearly	ADV	RB	9	O
identified	identify	VERB	VBN	9	O
27	27	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
recent	recent	ADJ	JJ	5	O
literature	literature	NOUN	NN	5	O
contains	contain	VERB	VBZ	9	O
44	44	NUM	CD	7	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Common	common	ADJ	JJ	9	O
to	to	ADP	IN	5	O
these	these	DET	DT	5	O
71	71	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
a	a	DET	DT	5	O
histopathologic	histopathologic	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
focal	focal	ADJ	JJ	5	B-Disease
nodular	nodular	ADJ	JJ	5	I-Disease
hyperplasia	hyperplasia	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
adenoma	adenoma	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
hamartoma	hamartoma	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hepatoma	hepatoma	ADJ	JJ	3	B-Disease
.	.	PUNCT	.	9	O

Significant	significant	ADJ	JJ	9	O
statistical	statistical	ADJ	JJ	5	O
etiologic	etiologic	ADJ	JJ	9	O
factors	factor	NOUN	NNS	9	O
include	include	VERB	VBP	5	O
prolonged	prolong	VERB	VBN	9	O
uninterrupted	uninterrupted	ADJ	JJ	5	O
usage	usage	NOUN	NN	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptive	contraceptive	ADJ	JJ	5	I-Chemical
steroids	steroid	NOUN	NNS	9	B-Chemical
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
deaths	death	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
rupture	rupture	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
18	18	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
attest	attest	VERB	VBP	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
seriousness	seriousness	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
new	new	ADJ	JJ	5	O
potentially	potentially	ADV	RB	5	O
lethal	lethal	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
phenomenon	phenomenon	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ifosfamide	ifosfamide	ADJ	JJ	0	B-Chemical
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
without	without	ADP	IN	9	O
mesna	mesna	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
phase	phase	NOUN	NN	5	O
I	-PRON-	PRON	PRP	9	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
14	14	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
cycle	cycle	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
27	27	NUM	CD	7	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
administered	administer	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
for	for	ADP	IN	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
without	without	ADP	IN	9	O
Mesna	Mesna	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
goal	goal	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
deliver	deliver	VERB	VB	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
total	total	ADJ	JJ	9	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
that	that	DET	WDT	5	O
would	would	VERB	MD	5	O
be	be	VERB	VB	5	O
comparable	comparable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
bolus	bolus	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
infusions	infusion	NOUN	NNS	9	O
administered	administer	VERB	VBN	9	O
with	with	ADP	IN	5	O
Mesna	Mesna	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Dose	dose	NOUN	NN	0	O
escalations	escalation	NOUN	NNS	5	O
proceeded	proceed	VERB	VBD	9	O
from	from	ADP	IN	9	O
200	200	NUM	CD	0	O
to	to	ADP	IN	5	O
300	300	NUM	CD	0	O
,	,	PUNCT	,	9	O
400	400	NUM	CD	0	O
,	,	PUNCT	,	9	O
450	450	NUM	CD	9	O
,	,	PUNCT	,	9	O
500	500	NUM	CD	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
550	550	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
transient	transient	ADJ	JJ	9	O
microscopic	microscopic	ADJ	JJ	9	O
hematuria	hematuria	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
400	400	NUM	CD	0	O
,	,	PUNCT	,	9	O
450	450	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
instances	instance	NOUN	NNS	5	O
of	of	ADP	IN	5	O
macroscopic	macroscopic	ADJ	JJ	5	O
hematuria	hematuria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
550	550	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
nonurologic	nonurologic	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
;	;	PUNCT	:	9	O
confusion	confusion	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Grade	Grade	PROPN	NNP	9	O
2	2	NUM	CD	9	O
leukopenia	leukopenia	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
recommended	recommend	VERB	VBN	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
d	d	PROPN	NNP	9	O
delivers	deliver	VERB	VBZ	5	O
a	a	DET	DT	5	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
7	7	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
per	per	ADP	IN	9	O
cycle	cycle	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
comparable	comparable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
delivered	deliver	VERB	VBN	5	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
for	for	ADP	IN	5	O
bolus	bolus	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
few	few	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
multiple	multiple	ADJ	JJ	5	O
courses	course	NOUN	NNS	5	O
over	over	ADP	IN	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
indeterminate	indeterminate	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
predictability	predictability	NOUN	NN	5	O
of	of	ADP	IN	5	O
hematuria	hematuria	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
precise	precise	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
daily	daily	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
by	by	ADP	IN	9	O
urine	urine	NOUN	NN	9	O
Hematest	Hematest	PROPN	NNP	_	O
is	be	VERB	VBZ	5	O
essential	essential	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
adding	add	VERB	VBG	0	O
Mesna	Mesna	PROPN	NNP	0	B-Chemical
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
infusate	infusate	NOUN	NN	0	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
hematuria	hematuria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
protracted	protracted	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
schedule	schedule	NOUN	NN	5	O
for	for	ADP	IN	5	O
ifosfamide	ifosfamide	ADJ	JJ	0	B-Chemical
permits	permit	NOUN	NNS	5	O
convenient	convenient	ADJ	JJ	5	O
outpatient	outpatient	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
without	without	ADP	IN	9	O
Mesna	Mesna	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
cost	cost	NOUN	NN	5	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
usage	usage	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
agent	agent	NOUN	NN	9	O
by	by	ADP	IN	9	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
890	890	NUM	CD	7	O
per	per	ADP	IN	9	O
cycle	cycle	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
demonstrated	demonstrate	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
a	a	DET	DT	5	O
comparative	comparative	ADJ	JJ	9	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
bolus	bolus	NOUN	NN	0	O
schedules	schedule	NOUN	NNS	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
protracted	protract	VERB	VBN	5	O
infusion	infusion	NOUN	NN	0	O
schedule	schedule	NOUN	NN	5	O
will	will	VERB	MD	5	O
be	be	VERB	VB	5	O
necessary	necessary	ADJ	JJ	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
effectiveness	effectiveness	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
maintained	maintain	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Suboptimal	suboptimal	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
duration	duration	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
commonly	commonly	ADV	RB	5	O
encountered	encounter	VERB	VBN	5	O
in	in	ADP	IN	5	O
electroconvulsive	electroconvulsive	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
practice	practice	NOUN	NN	5	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
seizure	seizure	NOUN	NN	5	B-Disease
thresholds	threshold	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
seizure	seizure	NOUN	NN	5	B-Disease
duration	duration	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
quality	quality	NOUN	NN	5	O
in	in	ADP	IN	5	O
such	such	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
generally	generally	ADV	RB	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
aside	aside	ADV	RB	5	O
from	from	ADP	IN	9	O
occasional	occasional	ADJ	JJ	5	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
relatively	relatively	ADV	RB	5	O
benign	benign	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
ectopy	ectopy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
previous	previous	ADJ	JJ	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
sustained	sustain	VERB	VBN	5	O
bigeminy	bigeminy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
brief	brief	ADJ	JJ	5	O
runs	run	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
generally	generally	ADV	RB	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
clinician	clinician	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
for	for	ADP	IN	5	O
unpredictable	unpredictable	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
serious	serious	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Fatal	fatal	ADJ	JJ	5	O
haemopericardium	haemopericardium	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
haemorrhage	haemorrhage	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
interaction	interaction	NOUN	NN	9	O
of	of	ADP	IN	5	O
cranberry	cranberry	ADJ	JJ	4	O
juice	juice	NOUN	NN	0	O
with	with	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
internal	internal	ADJ	JJ	5	O
haemorrhage	haemorrhage	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
who	who	PRON	WP	5	O
consumed	consume	VERB	VBD	5	O
only	only	ADV	RB	9	O
cranberry	cranberry	ADJ	JJ	4	O
juice	juice	NOUN	NN	0	O
for	for	ADP	IN	5	O
two	two	NUM	CD	5	O
weeks	week	NOUN	NNS	9	O
while	while	ADP	IN	9	O
maintaining	maintain	VERB	VBG	9	O
his	-PRON-	DET	PRP$	5	O
usual	usual	ADJ	JJ	5	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
propose	propose	VERB	VBP	9	O
that	that	ADP	IN	5	O
naturally	naturally	ADV	RB	9	O
occurring	occur	VERB	VBG	9	O
compounds	compound	NOUN	NNS	0	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
flavonoids	flavonoid	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
are	be	VERB	VBP	5	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
fruit	fruit	NOUN	NN	4	O
juices	juice	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
potency	potency	NOUN	NN	9	O
of	of	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
by	by	ADP	IN	9	O
competing	compete	VERB	VBG	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
enzymes	enzyme	NOUN	NNS	1	O
that	that	DET	WDT	5	O
normally	normally	ADV	RB	9	O
inactivate	inactivate	VERB	VBP	9	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
traditionally	traditionally	ADV	RB	5	O
regarded	regard	VERB	VBN	5	O
as	as	ADP	IN	5	O
foodstuffs	foodstuff	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
consumption	consumption	NOUN	NN	5	O
of	of	ADP	IN	5	O
fruit	fruit	NOUN	NN	4	O
juices	juice	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
when	when	ADV	WRB	5	O
patients	patient	NOUN	NNS	5	O
develop	develop	VERB	VB	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
reactions	reaction	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
intraperitoneal	intraperitoneal	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
rates	rate	NOUN	NNS	5	O
on	on	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
known	know	VERB	VBN	9	O
if	if	ADP	IN	5	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
input	input	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
important	important	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
since	since	ADP	IN	9	O
different	different	ADJ	JJ	9	O
controlled	control	VERB	VBN	5	O
release	release	NOUN	NN	9	O
formulations	formulation	NOUN	NNS	0	O
of	of	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
release	release	VERB	VBP	9	O
the	the	DET	DT	5	O
active	active	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
at	at	ADP	IN	9	O
different	different	ADJ	JJ	9	O
rates	rate	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
varying	vary	VERB	VBG	5	O
the	the	DET	DT	5	O
intraperitoneal	intraperitoneal	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
HCl	HCl	PROPN	NNPS	0	I-Chemical
120	120	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
known	know	VERB	VBN	9	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
dose	dose	NOUN	NN	9	O
50	50	NUM	CD	0	O
(	(	PUNCT	-LRB-	9	O
CD50	CD50	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Swiss	swiss	ADJ	JJ	2	O
albino	albino	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
69	69	NUM	CD	7	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
approximately	approximately	ADV	RB	9	O
7	7	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
weighing	weigh	VERB	VBG	5	O
21	21	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
29	29	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
g	g	NOUN	NN	0	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
HCl	HCl	NOUN	NNS	0	I-Chemical
120	120	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
treatment	treatment	NOUN	NN	9	O
by	by	ADP	IN	9	O
intraperitoneal	intraperitoneal	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
IP	IP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
to	to	PART	TO	5	O
10	10	NUM	CD	9	O
animals	animal	NOUN	NNS	9	O
per	per	ADP	IN	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Bupropion	bupropion	NOUN	NN	0	B-Chemical
HCl	HCl	NOUN	NNS	0	I-Chemical
was	be	VERB	VBD	9	O
infused	infuse	VERB	VBN	9	O
through	through	ADP	IN	9	O
a	a	DET	DT	5	O
surgically	surgically	ADV	RB	5	O
implanted	implant	VERB	VBN	9	O
IP	IP	PROPN	NNP	9	O
dosing	dose	VERB	VBG	9	O
catheter	catheter	NOUN	NN	5	O
with	with	ADP	IN	5	O
infusions	infusion	NOUN	NNS	9	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
90	90	NUM	CD	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
120	120	NUM	CD	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
240	240	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
,	,	PUNCT	,	9	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
onset	onset	NOUN	NN	5	O
,	,	PUNCT	,	9	O
duration	duration	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
intensity	intensity	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
or	or	CCONJ	CC	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
IP	IP	PROPN	NNP	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
HCl	HCl	PROPN	NNPS	0	I-Chemical
120	120	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	VERB	VB	0	O
by	by	ADP	IN	9	O
bolus	bolus	NOUN	NN	0	O
injection	injection	NOUN	NN	9	O
induced	induce	VERB	VBD	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
convulsing	convulsing	NOUN	NN	5	O
mice	mouse	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O

Logistic	logistic	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
infusion	infusion	NOUN	NN	0	O
time	time	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0004	0004	NUM	CD	7	O
;	;	PUNCT	:	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
=	=	PUNCT	NFP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
974	974	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
increasing	increase	VERB	VBG	9	O
the	the	DET	DT	5	O
IP	IP	PROPN	NNP	9	O
infusion	infusion	NOUN	NN	0	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
HCl	HCl	PROPN	NNPS	0	I-Chemical
120	120	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	PROPN	NNP	0	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
91	91	NUM	CD	7	O
%	%	NOUN	NN	9	O
reduced	reduce	VERB	VBN	9	O
odds	odd	NOUN	NNS	5	O
of	of	ADP	IN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
at	at	ADP	IN	9	O
infusion	infusion	NOUN	NN	0	O
times	time	NOUN	NNS	5	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
to	to	PART	TO	5	O
90	90	NUM	CD	9	O
min	min	NOUN	NN	0	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
bolus	bolus	NOUN	NN	0	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Further	further	ADV	RB	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
infusion	infusion	NOUN	NN	0	O
time	time	NOUN	NN	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
further	further	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
odds	odd	NOUN	NNS	5	O
of	of	ADP	IN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
to	to	ADP	IN	5	O
99	99	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
at	at	ADP	IN	9	O
240	240	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
demonstration	demonstration	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
inverse	inverse	NOUN	NN	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
infusion	infusion	NOUN	NN	0	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
fixed	fix	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
novel	novel	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Graft	graft	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
versus	versus	ADP	IN	9	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
host	host	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
prophylaxis	prophylaxis	NOUN	NN	5	O
with	with	ADP	IN	5	O
everolimus	everolimus	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
sinusoidal	sinusoidal	ADJ	JJ	5	B-Disease
obstruction	obstruction	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
microangiopathy	microangiopathy	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
EVTAC	EVTAC	PROPN	NNP	_	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
calcineurin	calcineurin	NOUN	NN	3	O
inhibitor	inhibitor	NOUN	NN	3	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
prophylaxis	prophylaxis	NOUN	NN	5	O
for	for	ADP	IN	5	O
graft	graft	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
versus	versus	ADP	IN	9	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
host	host	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
GVHD	GVHD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
allogeneic	allogeneic	ADJ	JJ	3	O
hematopoietic	hematopoietic	ADJ	JJ	3	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HSCT	HSCT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Everolimus	Everolimus	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
derivative	derivative	NOUN	NN	0	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
mediate	mediate	VERB	VB	3	O
antileukemia	antileukemia	ADJ	JJ	3	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
everolimus	everolimus	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
tacrolimus	tacrolimus	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
24	24	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
median	median	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
62	62	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
either	either	CCONJ	CC	9	O
myelodysplastic	myelodysplastic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MDS	MDS	PROPN	NNP	9	B-Disease
;	;	PUNCT	:	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
17	17	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
myeloid	myeloid	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
AML	aml	NOUN	NN	3	B-Disease
;	;	PUNCT	:	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
undergoing	undergo	VERB	VBG	9	O
intensive	intensive	ADJ	JJ	5	O
conditioning	conditioning	NOUN	NN	5	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
HSCT	HSCT	PROPN	NNP	9	O
from	from	ADP	IN	9	O
related	related	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
unrelated	unrelated	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
20	20	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
donors	donor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
engrafted	engraft	VERB	VBD	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
only	only	ADV	RB	9	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
experienced	experienced	ADJ	JJ	5	O
grade	grade	NOUN	NN	9	O
IV	IV	PROPN	NNP	9	O
mucositis	mucositis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Nine	nine	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
37	37	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBN	5	O
acute	acute	ADJ	JJ	9	O
grade	grade	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
IV	IV	PROPN	NNP	9	O
GVHD	GVHD	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	O
of	of	ADP	IN	5	O
17	17	NUM	CD	7	O
evaluable	evaluable	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
64	64	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBD	5	O
chronic	chronic	ADJ	JJ	5	O
extensive	extensive	ADJ	JJ	5	O
GVHD	GVHD	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Transplantation	transplantation	NOUN	NN	2	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
associated	associate	VERB	VBN	9	I-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TMA	tma	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
29	29	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
2	2	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
terminated	terminate	VERB	VBN	9	O
prematurely	prematurely	ADV	RB	5	O
because	because	ADP	IN	5	O
an	an	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
6	6	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBD	5	O
sinusoidal	sinusoidal	ADJ	JJ	5	B-Disease
obstruction	obstruction	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SOS	SOS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
fatal	fatal	ADJ	JJ	5	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
a	a	DET	DT	5	O
median	median	ADJ	JJ	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
26	26	NUM	CD	7	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
overall	overall	ADJ	JJ	5	O
survival	survival	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
47	47	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
this	this	DET	DT	5	O
new	new	ADJ	JJ	5	O
combination	combination	NOUN	NN	9	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
effective	effective	ADJ	JJ	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
regimen	regimen	NOUN	NN	5	O
for	for	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
GVHD	GVHD	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
TMA	tma	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
SOS	sos	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
considerably	considerably	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
seen	see	VERB	VBN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
regimens	regimen	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Longitudinal	longitudinal	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
air	air	NOUN	NN	5	O
conduction	conduction	NOUN	NN	5	O
audiograms	audiogram	NOUN	NNS	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
phase	phase	NOUN	NN	5	O
III	iii	NUM	CD	9	O
clinical	clinical	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
difluoromethylornithine	difluoromethylornithine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
sporadic	sporadic	ADJ	JJ	9	O
colorectal	colorectal	ADJ	JJ	9	B-Disease
adenomas	adenoma	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
phase	phase	NOUN	NN	5	O
III	iii	NUM	CD	9	O
clinical	clinical	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
assessed	assess	VERB	VBD	9	O
the	the	DET	DT	5	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
adenomatous	adenomatous	ADJ	JJ	9	B-Disease
polyps	polyp	NOUN	NNS	5	I-Disease
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
36	36	NUM	CD	9	O
months	month	NOUN	NNS	5	O
with	with	ADP	IN	5	O
difluoromethylornithine	difluoromethylornithine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DFMO	DFMO	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
plus	plus	CCONJ	CC	9	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
matched	match	VERB	VBN	9	O
placebos	placebo	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Temporary	temporary	ADJ	JJ	5	O
hearing	hearing	NOUN	NN	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
known	known	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
DFMO	DFMO	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
thus	thus	ADV	RB	9	O
a	a	DET	DT	5	O
comprehensive	comprehensive	ADJ	JJ	5	O
approach	approach	NOUN	NN	5	O
was	be	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
to	to	PART	TO	5	O
analyze	analyze	VERB	VB	9	O
serial	serial	ADJ	JJ	9	O
air	air	NOUN	NN	5	O
conduction	conduction	NOUN	NN	5	O
audiograms	audiogram	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
generalized	generalized	ADJ	JJ	5	O
estimating	estimate	VERB	VBG	5	O
equation	equation	NOUN	NN	5	O
method	method	NOUN	NN	5	O
estimated	estimate	VERB	VBD	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
arms	arm	NOUN	NNS	5	O
with	with	ADP	IN	5	O
regard	regard	NOUN	NN	5	O
to	to	PART	TO	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
air	air	NOUN	NN	5	O
conduction	conduction	NOUN	NN	5	O
pure	pure	ADJ	JJ	9	O
tone	tone	NOUN	NN	5	O
thresholds	threshold	VERB	VBZ	5	O
while	while	ADP	IN	9	O
accounting	account	VERB	VBG	5	O
for	for	ADP	IN	5	O
within	within	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
subject	subject	NOUN	NN	5	O
correlation	correlation	NOUN	NN	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
repeated	repeat	VERB	VBN	5	O
measurements	measurement	NOUN	NNS	5	O
at	at	ADP	IN	9	O
frequencies	frequency	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
290	290	NUM	CD	7	O
subjects	subject	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
an	an	DET	DT	5	O
average	average	ADJ	JJ	5	O
difference	difference	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
50	50	NUM	CD	0	O
dB	db	NOUN	NN	5	O
between	between	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
DFMO	DFMO	PROPN	NNP	3	B-Chemical
plus	plus	CCONJ	CC	9	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
64	64	NUM	CD	7	O
to	to	PART	TO	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
63	63	NUM	CD	7	O
dB	db	NOUN	NN	5	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
39	39	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
adjusted	adjust	VERB	VBN	9	O
for	for	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
values	value	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
frequencies	frequency	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
speech	speech	NOUN	NN	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
500	500	NUM	CD	0	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
Hz	Hz	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
estimated	estimate	VERB	VBN	5	O
difference	difference	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
99	99	NUM	CD	7	O
dB	dB	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
17	17	NUM	CD	7	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
14	14	NUM	CD	7	O
dB	db	NOUN	NN	5	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
09	09	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Dose	dose	NOUN	NN	0	O
intensity	intensity	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
add	add	VERB	VB	5	O
information	information	NOUN	NN	5	O
to	to	ADP	IN	5	O
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
14	14	NUM	CD	7	O
of	of	ADP	IN	5	O
151	151	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
DFMO	DFMO	PROPN	NNP	3	B-Chemical
plus	plus	CCONJ	CC	9	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
of	of	ADP	IN	5	O
139	139	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
who	who	PRON	WP	5	O
experienced	experience	VERB	VBD	5	O
at	at	ADV	RB	9	O
least	least	ADJ	JJS	9	O
15	15	NUM	CD	9	O
dB	db	NOUN	NN	5	O
hearing	hearing	NOUN	NN	5	O
reduction	reduction	NOUN	NN	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
consecutive	consecutive	ADJ	JJ	5	O
frequencies	frequency	NOUN	NNS	9	O
across	across	ADP	IN	5	O
the	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
range	range	NOUN	NN	9	O
tested	test	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
air	air	NOUN	NN	5	O
conduction	conduction	NOUN	NN	5	O
done	do	VERB	VBN	9	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
an	an	DET	DT	5	O
adjusted	adjust	VERB	VBN	9	O
mean	mean	ADJ	JJ	5	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
hearing	hear	VERB	VBG	5	O
thresholds	threshold	NOUN	NNS	5	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
08	08	NUM	CD	7	O
dB	dB	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
81	81	NUM	CD	7	O
to	to	PART	TO	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
96	96	NUM	CD	9	O
dB	db	NUM	CD	5	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
26	26	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
between	between	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
arms	arm	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
proportion	proportion	NOUN	NN	9	O
of	of	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
DFMO	DFMO	PROPN	NNP	3	B-Chemical
plus	plus	CCONJ	CC	9	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
who	who	PRON	WP	5	O
experienced	experience	VERB	VBD	5	O
clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
hearing	hearing	NOUN	NN	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
estimated	estimate	VERB	VBN	5	O
attributable	attributable	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
from	from	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
8	8	NUM	CD	9	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
<	<	X	XX	0	O
2	2	NUM	CD	9	O
dB	db	NUM	CD	5	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
threshold	threshold	NOUN	NN	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
DFMO	DFMO	PROPN	NNP	3	B-Chemical
plus	plus	CCONJ	CC	9	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Proteinase	proteinase	NOUN	NN	0	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
antineutrophil	antineutrophil	NOUN	NN	3	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
antibody	antibody	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
(	(	PUNCT	-LRB-	9	O
PR3	PR3	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
positive	positive	ADJ	JJ	9	O
necrotizing	necrotize	VERB	VBG	5	O
glomerulonephritis	glomerulonephritis	ADJ	JJ	3	B-Disease
after	after	ADP	IN	9	O
restarting	restart	VERB	VBG	5	O
sulphasalazine	sulphasalazine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
59	59	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
ulcerative	ulcerative	ADJ	JJ	5	B-Disease
colitis	colitis	NOUN	NN	3	I-Disease
developed	develop	VERB	VBD	5	O
red	red	ADJ	JJ	9	B-Disease
eyes	eye	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
pleural	pleural	ADJ	JJ	5	B-Disease
effusion	effusion	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
eosinophilia	eosinophilia	NOUN	NNS	3	B-Disease
and	and	CCONJ	CC	5	O
urinary	urinary	NOUN	NN	9	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
after	after	ADP	IN	9	O
restarting	restart	VERB	VBG	5	O
of	of	ADP	IN	5	O
sulphasalazine	sulphasalazine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Light	light	ADJ	JJ	9	O
microscopy	microscopy	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
segmental	segmental	ADJ	JJ	5	B-Disease
necrotizing	necrotize	VERB	VBG	5	I-Disease
glomerulonephritis	glomerulonephritis	ADJ	JJ	3	I-Disease
without	without	ADP	IN	9	O
deposition	deposition	NOUN	NN	9	O
of	of	ADP	IN	5	O
immunoglobulin	immunoglobulin	NOUN	NN	3	O
or	or	CCONJ	CC	5	O
complement	complement	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Proteinase	proteinase	NOUN	NN	0	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
antineutrophil	antineutrophil	NOUN	NN	3	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
antibody	antibody	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
PR3	PR3	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
titer	titer	NOUN	NN	9	O
was	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
at	at	ADP	IN	9	O
183	183	NUM	CD	7	O
ELISA	ELISA	PROPN	NNP	3	O
units	unit	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
EU	EU	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
sera	sera	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
normal	normal	ADJ	JJ	9	O
range	range	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
10	10	NUM	CD	9	O
EU	EU	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
myeloperoxidase	myeloperoxidase	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
negative	negative	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

PR3	PR3	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
titer	titer	NOUN	NN	9	O
was	be	VERB	VBD	9	O
250	250	NUM	CD	0	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
070	070	NUM	CD	7	O
EU	EU	PROPN	NNP	9	O
in	in	ADP	IN	5	O
pleural	pleural	ADJ	JJ	5	B-Disease
effusions	effusion	NOUN	NNS	5	I-Disease
on	on	ADP	IN	5	O
right	right	ADV	RB	5	O
and	and	CCONJ	CC	5	O
left	leave	VERB	VBD	5	O
side	side	NOUN	NN	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
sulphasalazine	sulphasalazine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
improvements	improvement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
fever	fever	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
red	red	ADJ	JJ	9	B-Disease
eyes	eye	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
titer	titer	NOUN	NN	9	O
of	of	ADP	IN	5	O
C	c	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
reactive	reactive	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
volume	volume	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pleural	pleural	ADJ	JJ	5	B-Disease
effusions	effusion	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
initiated	initiate	VERB	VBD	9	O
steroid	steroid	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
PR3	PR3	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
titer	titer	NOUN	NN	9	O
rose	rise	VERB	VBD	9	O
to	to	ADP	IN	5	O
320	320	NUM	CD	9	O
EU	EU	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
eosinophil	eosinophil	NOUN	NN	3	O
count	count	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
microl	microl	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
pleural	pleural	ADJ	JJ	5	B-Disease
effusion	effusion	NOUN	NN	5	I-Disease
remained	remain	VERB	VBD	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
month	month	NOUN	NN	5	O
after	after	ADP	IN	9	O
steroid	steroid	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
pleural	pleural	ADJ	JJ	5	B-Disease
effusion	effusion	NOUN	NN	5	I-Disease
disappeared	disappear	VERB	VBD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
PR3	PR3	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
titer	titer	NOUN	NN	9	O
normalized	normalize	VERB	VBN	9	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
sulphasalazine	sulphasalazine	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
induce	induce	VERB	VB	3	O
PR3	PR3	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ANCA	ANCA	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
necrotizing	necrotizing	NOUN	NN	5	O
glomerulonephritis	glomerulonephritis	ADJ	JJ	3	B-Disease
.	.	PUNCT	.	9	O

Comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
unilateral	unilateral	ADJ	JJ	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
subthalamotomy	subthalamotomy	NOUN	NN	5	O
findings	finding	NOUN	NNS	9	O
in	in	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
Parkinson	Parkinson	PROPN	NNP	5	I-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
pilot	pilot	NOUN	NN	5	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
stereotactic	stereotactic	ADJ	JJ	5	O
unilateral	unilateral	ADJ	JJ	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
subthalamotomy	subthalamotomy	NOUN	NN	5	O
in	in	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
Parkinson	Parkinson	PROPN	NNP	5	I-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	PD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
refractory	refractory	NOUN	NN	9	O
to	to	ADP	IN	5	O
medical	medical	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Ten	ten	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
58	58	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
years	year	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
7	7	NUM	CD	9	O
men	man	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
similar	similar	ADJ	JJ	9	O
characteristics	characteristic	NOUN	NNS	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
disease	disease	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
disabling	disable	VERB	VBG	5	O
motor	motor	NOUN	NN	5	O
fluctuations	fluctuation	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
Hoehn	Hoehn	PROPN	NNP	5	O
_	_	PROPN	NNP	7	O
Yahr	Yahr	PROPN	NNP	5	O
stage	stage	NOUN	NN	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
in	in	ADP	IN	5	O
off	off	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
phases	phase	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
selected	select	VERB	VBN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
bilateral	bilateral	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
equivalent	equivalent	NOUN	NN	9	O
dosing	dosing	NOUN	NN	9	O
were	be	VERB	VBD	9	O
analysed	analyse	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
operated	operate	VERB	VBN	5	O
on	on	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
globus	globus	NOUN	NN	5	O
pallidus	pallidus	NOUN	NN	4	O
interna	interna	NOUN	NN	2	O
(	(	PUNCT	-LRB-	9	O
GPi	GPi	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
four	four	NUM	CD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
subthalamic	subthalamic	ADJ	JJ	5	O
nucleus	nucleus	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
STN	STN	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
included	include	VERB	VBD	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Unified	Unified	PROPN	NNP	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
Disease	Disease	PROPN	NNP	2	I-Disease
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
UPDRS	UPDRS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
Hoehn	Hoehn	PROPN	NNP	5	O
_	_	PROPN	NNP	7	O
Yahr	Yahr	PROPN	NNP	5	O
score	score	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
Schwab	Schwab	PROPN	NNP	6	O
England	England	PROPN	NNP	2	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
living	living	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ADL	ADL	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
score	score	VERB	VB	5	O
in	in	ADP	IN	5	O
'	'	PUNCT	``	9	O
on	on	ADP	IN	5	O
'	'	PUNCT	''	9	O
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
'	'	PUNCT	``	9	O
off	off	PART	RP	5	O
'	'	PUNCT	``	9	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
conditions	condition	NOUN	NNS	9	O
before	before	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
contralateral	contralateral	ADJ	JJ	5	O
major	major	ADJ	JJ	9	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
motor	motor	NOUN	NN	5	O
signs	sign	NOUN	NNS	5	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
followed	follow	VERB	VBD	9	O
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Levodopa	levodopa	ADJ	JJ	0	B-Chemical
equivalent	equivalent	ADJ	JJ	9	O
daily	daily	ADV	RB	5	O
intake	intake	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
STN	STN	PROPN	NNP	5	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
UPDRS	UPDRS	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
Hoehn	Hoehn	PROPN	NNP	5	O
_	_	PROPN	NNP	7	O
Yahr	Yahr	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Schwab	Schwab	PROPN	NNP	6	O
England	England	PROPN	NNP	2	O
ADL	ADL	PROPN	NNP	5	O
scores	score	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Cognitive	cognitive	ADJ	JJ	5	O
functions	function	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Complications	complication	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
one	one	PRON	PRP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
left	left	ADJ	JJ	5	O
homonymous	homonymous	ADJ	JJ	5	B-Disease
hemianopsia	hemianopsia	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
pallidotomy	pallidotomy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
another	another	DET	DT	9	O
one	one	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
left	leave	VERB	VBN	5	O
hemiballistic	hemiballistic	ADJ	JJ	_	O
movements	movement	NOUN	NNS	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
subthalamotomy	subthalamotomy	NOUN	NN	5	O
which	which	DET	WDT	5	O
partly	partly	ADV	RB	9	O
improved	improve	VERB	VBD	5	O
within	within	ADP	IN	9	O
1	1	NUM	CD	9	O
month	month	NOUN	NN	5	O
with	with	ADP	IN	5	O
Valproate	Valproate	PROPN	NNP	0	B-Chemical
1000	1000	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
lesions	lesion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
unilateral	unilateral	ADJ	JJ	5	O
STN	STN	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
GPi	GPi	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
equally	equally	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
PD	pd	NOUN	NN	9	B-Disease
refractory	refractory	NOUN	NN	9	O
to	to	ADP	IN	5	O
medical	medical	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

DSMM	DSMM	PROPN	NNP	5	O
XI	XI	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
:	:	PUNCT	:	9	O
dose	dose	NOUN	NN	9	O
definition	definition	NOUN	NN	5	O
for	for	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
bortezomib	bortezomib	NOUN	NN	3	B-Chemical
/	/	SYM	SYM	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
remission	remission	NOUN	NN	5	O
induction	induction	NOUN	NN	3	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
newly	newly	ADV	RB	9	O
diagnosed	diagnose	VERB	VBN	5	O
myeloma	myeloma	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
clinical	clinical	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
was	be	VERB	VBD	9	O
initiated	initiate	VERB	VBN	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
recommended	recommend	VERB	VBN	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
bortezomib	bortezomib	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
before	before	ADP	IN	9	O
stem	stem	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
for	for	ADP	IN	5	O
younger	young	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
newly	newly	ADV	RB	9	O
diagnosed	diagnose	VERB	VBN	5	O
multiple	multiple	ADJ	JJ	5	B-Disease
myeloma	myeloma	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
MM	MM	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
three	three	NUM	CD	9	O
21	21	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
cycles	cycle	NOUN	NNS	9	O
of	of	ADP	IN	5	O
bortezomib	bortezomib	NOUN	NN	3	B-Chemical
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	O
plus	plus	CCONJ	CC	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
bortezomib	bortezomib	NOUN	NN	3	B-Chemical
injection	injection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
plus	plus	CCONJ	CC	9	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
900	900	NUM	CD	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
200	200	NUM	CD	0	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
tolerated	tolerate	VERB	VBN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
900	900	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
this	this	DET	DT	5	O
dose	dose	NOUN	NN	9	O
level	level	NOUN	NN	9	O
,	,	PUNCT	,	9	O
92	92	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
achieved	achieve	VERB	VBN	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
a	a	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
complete	complete	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
CR	CR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
plus	plus	CCONJ	CC	9	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PR	PR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
]	]	PUNCT	-RRB-	9	O
across	across	ADP	IN	5	O
all	all	DET	DT	5	O
dose	dose	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
77	77	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
CR	cr	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
patient	patient	NOUN	NN	5	O
experienced	experience	VERB	VBD	5	O
progressive	progressive	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
frequent	frequent	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
hematological	hematological	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
gastrointestinal	gastrointestinal	ADJ	JJ	9	I-Disease
toxicities	toxicity	NOUN	NNS	5	I-Disease
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
bortezomib	bortezomib	NOUN	NN	3	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
900	900	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
induction	induction	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
newly	newly	ADV	RB	9	O
diagnosed	diagnose	VERB	VBN	5	O
MM	mm	NOUN	NN	9	B-Disease
that	that	DET	WDT	5	O
warrants	warrant	VERB	VBZ	9	O
further	further	ADJ	JJ	9	O
investigation	investigation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Naloxone	naloxone	NOUN	NN	0	B-Chemical
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
captopril	captopril	ADJ	JJ	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
converting	convert	VERB	VBG	9	I-Chemical
enzyme	enzyme	ADJ	JJ	0	I-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
endogenous	endogenous	ADJ	JJ	3	O
opioid	opioid	NOUN	NN	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
opioid	opioid	NOUN	NN	5	O
antagonist	antagonist	NOUN	NN	3	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
block	block	VERB	VB	9	O
or	or	CCONJ	CC	5	O
reverse	reverse	VERB	VB	9	O
the	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
intentional	intentional	ADJ	JJ	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
,	,	PUNCT	,	9	O
manifested	manifest	VERB	VBN	9	O
by	by	ADP	IN	9	O
marked	mark	VERB	VBN	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
that	that	DET	WDT	5	O
resolved	resolve	VERB	VBD	9	O
promptly	promptly	ADV	RB	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
reported	report	VERB	VBN	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
experience	experience	NOUN	NN	5	O
demonstrates	demonstrate	VERB	VBZ	9	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
resulting	result	VERB	VBG	9	O
from	from	ADP	IN	9	O
captopril	captopril	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Identification	identification	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
simple	simple	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
sensitive	sensitive	ADJ	JJ	9	O
microplate	microplate	ADJ	JJ	0	O
method	method	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
oversulfated	oversulfate	VERB	VBN	0	O
chondroitin	chondroitin	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
products	product	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Heparin	Heparin	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
commonly	commonly	ADV	RB	5	O
implemented	implement	VERB	VBN	5	O
anticoagulant	anticoagulant	NOUN	NN	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
critically	critically	ADV	RB	9	O
ill	ill	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
commercial	commercial	ADJ	JJ	5	O
lots	lot	NOUN	NNS	5	O
of	of	ADP	IN	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
products	product	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
contaminated	contaminate	VERB	VBN	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
oversulfated	oversulfate	VERB	VBN	0	O
chondroitin	chondroitin	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
OSCS	OSCS	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
derivative	derivative	ADJ	JJ	0	O
that	that	DET	WDT	5	O
could	could	VERB	MD	9	O
elicit	elicit	VERB	VB	9	O
a	a	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
response	response	NOUN	NN	9	O
in	in	ADP	IN	5	O
pigs	pig	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
both	both	DET	DT	9	O
contaminated	contaminate	VERB	VBN	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
products	product	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
synthetically	synthetically	ADV	RB	1	O
produced	produce	VERB	VBN	9	O
derivative	derivative	ADJ	JJ	0	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
OSCS	OSCS	PROPN	NNP	0	O
produces	produce	VERB	VBZ	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
pigs	pig	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
no	no	DET	DT	9	O
observed	observed	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
level	level	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
NOEL	noel	NOUN	NN	2	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
contaminant	contaminant	NOUN	NN	9	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
approximately	approximately	ADV	RB	9	O
1mg	1mg	ADJ	JJ	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
corresponding	correspond	VERB	VBG	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
contamination	contamination	NOUN	NN	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
also	also	ADV	RB	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
OSCS	OSCS	PROPN	NNP	0	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
identified	identify	VERB	VBN	9	O
in	in	ADP	IN	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
products	product	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
simple	simple	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
inexpensive	inexpensive	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
commercially	commercially	ADV	RB	0	O
available	available	ADJ	JJ	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
enzyme	enzyme	ADJ	JJ	0	O
immunoassay	immunoassay	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
EIA	EIA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
kit	kit	NOUN	NN	0	O
that	that	DET	WDT	5	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
limit	limit	NOUN	NN	5	O
of	of	ADP	IN	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
well	well	ADV	RB	9	O
below	below	ADP	IN	9	O
the	the	DET	DT	5	O
NOEL	NOEL	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
kit	kit	NOUN	NN	0	O
may	may	VERB	MD	5	O
provide	provide	VERB	VB	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
to	to	PART	TO	5	O
test	test	VERB	VB	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
products	product	NOUN	NNS	9	O
for	for	ADP	IN	5	O
contamination	contamination	NOUN	NN	9	O
with	with	ADP	IN	5	O
oversulfated	oversulfate	VERB	VBN	0	O
GAG	GAG	PROPN	NNP	9	O
derivatives	derivative	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

5	5	NUM	CD	9	B-Chemical
flourouracil	flourouracil	ADJ	JJ	9	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
apical	apical	ADJ	JJ	9	B-Disease
ballooning	ballooning	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
apical	apical	ADJ	JJ	9	B-Disease
ballooning	ballooning	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ABS	abs	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
recently	recently	ADV	RB	9	O
described	describe	VERB	VBN	9	O
stress	stress	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
cardiac	cardiac	ADJ	JJ	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
transient	transient	ADJ	JJ	9	O
wall	wall	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
motion	motion	NOUN	NN	5	O
abnormalities	abnormality	NOUN	NNS	9	O
involving	involve	VERB	VBG	5	O
the	the	DET	DT	5	O
apex	apex	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
midventricle	midventricle	NOUN	NN	5	O
with	with	ADP	IN	5	O
hyperkinesis	hyperkinesis	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
basal	basal	NOUN	NN	3	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
LV	LV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
segments	segment	NOUN	NNS	9	O
without	without	ADP	IN	9	O
obstructive	obstructive	ADJ	JJ	5	O
epicardial	epicardial	ADJ	JJ	5	B-Disease
coronary	coronary	ADJ	JJ	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
an	an	DET	DT	5	O
uncommon	uncommon	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
no	no	DET	DT	9	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ABS	abs	NOUN	NN	9	B-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
woman	woman	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
the	the	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
after	after	ADP	IN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
cancer	cancer	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
79	79	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
typical	typical	ADJ	JJ	9	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
elevated	elevate	VERB	VBD	9	O
cardiac	cardiac	ADJ	JJ	5	O
enzymes	enzyme	NOUN	NNS	1	O
with	with	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
ST	ST	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
segment	segment	NOUN	NN	9	O
abnormalities	abnormality	NOUN	NNS	9	O
on	on	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
underwent	undergo	VERB	VBD	5	O
recent	recent	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
fluorouracil	fluorouracil	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
colorectal	colorectal	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Echocardiography	Echocardiography	PROPN	NNP	5	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
wall	wall	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
motion	motion	NOUN	NN	5	O
abnormality	abnormality	NOUN	NN	9	O
involving	involve	VERB	VBG	5	O
the	the	DET	DT	5	O
apical	apical	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
periapical	periapical	ADJ	JJ	5	O
segments	segment	NOUN	NNS	9	O
which	which	DET	WDT	5	O
appeared	appear	VERB	VBD	9	O
akinetic	akinetic	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

Coronary	coronary	ADJ	JJ	5	O
angiography	angiography	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
no	no	DET	DT	9	O
obstructive	obstructive	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
lesions	lesion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
stabilized	stabilize	VERB	VBN	9	O
with	with	ADP	IN	5	O
medical	medical	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
later	later	ADV	RB	9	O
she	-PRON-	PRON	PRP	5	O
remained	remain	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Echocardiogram	Echocardiogram	PROPN	NNP	5	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
apical	apical	ADJ	JJ	9	O
akinesis	akinesis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Pathogenetic	pathogenetic	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
include	include	VERB	VBP	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
vasospasm	vasospasm	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
endothelial	endothelial	ADJ	JJ	3	O
damage	damage	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
consequent	consequent	ADJ	JJ	9	O
thrombus	thrombus	NOUN	NN	5	B-Disease
formation	formation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
supraphysiologic	supraphysiologic	ADJ	JJ	3	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
catecholamines	catecholamine	NOUN	NNS	9	B-Chemical
and	and	CCONJ	CC	5	O
stress	stress	NOUN	NN	9	O
related	related	ADJ	JJ	9	O
neuropeptides	neuropeptide	NOUN	NNS	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
cancer	cancer	NOUN	NN	3	B-Disease
diagnosis	diagnosis	NOUN	NN	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
contributed	contribute	VERB	VBN	9	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
ABS	abs	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Rapid	rapid	ADJ	JJ	9	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
reduces	reduce	VERB	VBZ	9	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
volume	volume	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
mouse	mouse	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
W	W	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ICH	ICH	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
stroke	stroke	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
consensus	consensus	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
optimal	optimal	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
W	W	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ICH	ICH	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
mouse	mouse	NOUN	NN	3	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
tested	test	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
using	use	VERB	VBG	9	O
human	human	ADJ	JJ	3	O
prothrombin	prothrombin	NOUN	NN	9	B-Chemical
complex	complex	ADJ	JJ	9	I-Chemical
concentrate	concentrate	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
PCC	PCC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
can	can	VERB	MD	5	O
reduce	reduce	VERB	VB	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Male	male	ADJ	JJ	7	O
CD	CD	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
over	over	ADP	IN	5	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
s	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
International	International	PROPN	NNP	2	O
Normalized	Normalized	PROPN	NNP	9	O
Ratio	Ratio	PROPN	NNP	9	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O

First	first	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
an	an	DET	DT	5	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
PCC	PCC	PROPN	NNP	9	B-Chemical
rapidly	rapidly	ADV	RB	9	O
reversed	reverse	VERB	VBD	9	O
anticoagulation	anticoagulation	NOUN	NN	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Second	second	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
stereotactic	stereotactic	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
collagenase	collagenase	NOUN	NN	0	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
striatum	striatum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
later	later	ADV	RBR	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
PCC	PCC	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
saline	saline	VERB	VB	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
12	12	NUM	CD	9	O
per	per	ADP	IN	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
induction	induction	NOUN	NN	3	O
,	,	PUNCT	,	9	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
was	be	VERB	VBD	9	O
quantified	quantify	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
photometric	photometric	ADJ	JJ	0	O
hemoglobin	hemoglobin	NOUN	NN	0	O
assay	assay	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
PCC	PCC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
microL	microL	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
microL	microL	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
015	015	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
saline	saline	NOUN	NN	0	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
45	45	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mice	mouse	NOUN	NNS	3	O
developed	develop	VERB	VBD	5	O
large	large	ADJ	JJ	5	O
hematomas	hematomas	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
>	>	X	XX	0	O
15	15	NUM	CD	9	O
microL	microL	PROPN	NNPS	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
extensive	extensive	ADJ	JJ	5	O
lesions	lesion	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
never	never	ADV	RB	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PCC	PCC	PROPN	NNP	9	B-Chemical
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
provide	provide	VERB	VBP	5	O
experimental	experimental	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
suggesting	suggest	VERB	VBG	9	O
PCC	PCC	PROPN	NNP	9	B-Chemical
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
acute	acute	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
W	W	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ICH	ICH	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
reducing	reduce	VERB	VBG	9	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Future	future	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
potential	potential	NOUN	NN	9	O
emerging	emerge	VERB	VBG	5	O
from	from	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
finding	finding	NOUN	NN	9	O
for	for	ADP	IN	5	O
human	human	ADJ	JJ	3	O
W	W	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ICH	ICH	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
term	term	NOUN	NN	5	O
hormone	hormone	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
perimenopausal	perimenopausal	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
postmenopausal	postmenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Hormone	hormone	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
HT	HT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
controlling	control	VERB	VBG	9	O
menopausal	menopausal	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
has	have	VERB	VBZ	9	O
also	also	ADV	RB	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
osteoporosis	osteoporosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
dementia	dementia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
updated	update	VERB	VBN	5	O
version	version	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
original	original	ADJ	JJ	5	O
Cochrane	Cochrane	PROPN	NNP	5	O
review	review	NOUN	NN	5	O
first	first	ADV	RB	9	O
published	publish	VERB	VBN	9	O
in	in	ADP	IN	5	O
2005	2005	NUM	CD	2	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
HT	HT	PROPN	NNP	9	O
on	on	ADP	IN	5	O
mortality	mortality	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
cancer	cancer	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
gallbladder	gallbladder	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
cognition	cognition	NOUN	NN	5	O
,	,	PUNCT	,	9	O
fractures	fracture	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
.	.	PUNCT	.	9	O

SEARCH	SEARCH	PROPN	NNP	2	O
STRATEGY	strategy	NOUN	NN	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
searched	search	VERB	VBD	9	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
databases	database	NOUN	NNS	5	O
to	to	ADP	IN	5	O
November	November	PROPN	NNP	2	O
2007	2007	NUM	CD	2	O
:	:	PUNCT	:	9	O
Trials	Trials	PROPN	NNPS	5	O
Register	Register	PROPN	NNP	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Cochrane	Cochrane	PROPN	NNP	5	O
Menstrual	Menstrual	PROPN	NNP	5	B-Disease
Disorders	Disorders	PROPN	NNPS	2	I-Disease
and	and	CCONJ	CC	5	O
Subfertility	Subfertility	PROPN	NNP	5	O
Group	Group	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
Cochrane	Cochrane	PROPN	NNP	5	O
Central	Central	PROPN	NNP	4	O
Register	Register	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Controlled	Controlled	PROPN	NNP	5	O
Trials	Trials	PROPN	NNPS	5	O
,	,	PUNCT	,	9	O
MEDLINE	MEDLINE	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
EMBASE	EMBASE	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Biological	Biological	PROPN	NNP	2	O
Abstracts	Abstracts	PROPN	NNPS	2	O
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
relevant	relevant	ADJ	JJ	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
indexed	indexed	ADJ	JJ	5	O
journals	journal	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
conference	conference	NOUN	NN	5	O
abstracts	abstract	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

SELECTION	selection	NOUN	NN	2	O
CRITERIA	criterion	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Randomised	randomise	VERB	VBN	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
of	of	ADP	IN	5	O
HT	HT	PROPN	NNP	9	O
versus	versus	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
taken	take	VERB	VBN	5	O
for	for	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
by	by	ADP	IN	9	O
perimenopausal	perimenopausal	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
postmenopausal	postmenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

HT	HT	PROPN	NNP	9	O
included	include	VERB	VBD	5	O
oestrogens	oestrogen	NOUN	NNS	5	B-Chemical
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
progestogens	progestogen	NOUN	NNS	5	B-Chemical
,	,	PUNCT	,	9	O
via	via	ADP	IN	9	O
oral	oral	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
transdermal	transdermal	ADJ	JJ	0	O
,	,	PUNCT	,	9	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
transnasal	transnasal	ADJ	JJ	5	O
routes	route	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

DATA	data	ADJ	JJ	2	O
COLLECTION	collection	NOUN	NN	2	O
AND	and	CCONJ	CC	2	O
ANALYSIS	analysis	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
authors	author	NOUN	NNS	5	O
independently	independently	ADV	RB	9	O
assessed	assess	VERB	VBD	9	O
trial	trial	NOUN	NN	5	O
quality	quality	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
extracted	extract	VERB	VBN	9	O
data	datum	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

MAIN	main	ADJ	JJ	2	O
RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Nineteen	nineteen	NUM	CD	9	O
trials	trial	NOUN	NNS	5	O
involving	involve	VERB	VBG	5	O
41	41	NUM	CD	7	O
,	,	PUNCT	,	9	O
904	904	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
relatively	relatively	ADV	RB	5	O
healthy	healthy	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
combined	combine	VERB	VBN	9	O
continuous	continuous	ADJ	JJ	5	O
HT	HT	PROPN	NNP	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thrombo	thrombo	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
embolism	embolism	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
coronary	coronary	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
after	after	ADP	IN	9	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
use	use	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
stroke	stroke	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
after	after	ADP	IN	9	O
three	three	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
gallbladder	gallbladder	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
oestrogen	oestrogen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
only	only	ADV	RB	9	O
HT	HT	PROPN	NNP	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thrombo	thrombo	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
embolism	embolism	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
stroke	stroke	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
gallbladder	gallbladder	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
after	after	ADP	IN	9	O
one	one	NUM	CD	5	O
to	to	PART	TO	5	O
two	two	NUM	CD	5	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
years	year	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
seven	seven	NUM	CD	9	O
years	year	NOUN	NNS	5	O
'	'	PART	POS	9	O
use	use	NOUN	NN	5	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
benefits	benefit	NOUN	NNS	5	O
of	of	ADP	IN	5	O
HT	HT	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
a	a	DET	DT	5	O
decreased	decrease	VERB	VBN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
fractures	fracture	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
for	for	ADP	IN	5	O
combined	combine	VERB	VBN	9	O
HT	HT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
colon	colon	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
women	woman	NOUN	NNS	5	O
aged	age	VERB	VBN	9	O
over	over	ADP	IN	5	O
65	65	NUM	CD	7	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
relatively	relatively	ADV	RB	5	O
healthy	healthy	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
generally	generally	ADV	RB	5	O
fit	fit	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
overt	overt	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
taking	take	VERB	VBG	5	O
continuous	continuous	ADJ	JJ	5	O
combined	combine	VERB	VBN	9	O
HT	HT	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
dementia	dementia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
combined	combined	ADJ	JJ	9	O
continuous	continuous	ADJ	JJ	5	O
HT	HT	PROPN	NNP	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thrombo	thrombo	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
embolism	embolism	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O
One	one	NUM	CD	5	O
trial	trial	NOUN	NN	5	O
analysed	analyse	VERB	VBD	9	O
subgroups	subgroup	NOUN	NNS	9	O
of	of	ADP	IN	5	O
2839	2839	NUM	CD	7	O
relatively	relatively	ADV	RB	5	O
healthy	healthy	ADJ	JJ	5	O
50	50	NUM	CD	0	O
to	to	PART	TO	5	O
59	59	NUM	CD	7	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
combined	combine	VERB	VBN	9	O
continuous	continuous	ADJ	JJ	5	O
HT	HT	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
1637	1637	NUM	CD	7	O
taking	take	VERB	VBG	5	O
oestrogen	oestrogen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
only	only	ADV	RB	9	O
HT	HT	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
versus	versus	ADP	IN	9	O
similar	similar	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
sized	sized	ADJ	JJ	5	O
placebo	placebo	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
reported	report	VERB	VBN	9	O
was	be	VERB	VBD	9	O
for	for	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thrombo	thrombo	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
embolism	embolism	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
combined	combine	VERB	VBN	9	O
continuous	continuous	ADJ	JJ	5	O
HT	HT	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
their	-PRON-	DET	PRP$	5	O
absolute	absolute	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
remained	remain	VERB	VBD	9	O
low	low	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
500	500	NUM	CD	0	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
powered	power	VERB	VBN	5	O
to	to	PART	TO	5	O
detect	detect	VERB	VB	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
younger	young	ADJ	JJR	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

AUTHORS	authors	NOUN	NN	2	O
'	'	PUNCT	''	9	O
CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
HT	HT	PROPN	NNP	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
indicated	indicate	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
routine	routine	ADJ	JJ	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
need	need	VERB	VBP	5	O
more	more	ADJ	JJR	5	O
evidence	evidence	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
HT	HT	PROPN	NNP	9	O
for	for	ADP	IN	5	O
menopausal	menopausal	ADJ	JJ	5	O
symptom	symptom	NOUN	NN	5	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
though	though	ADP	IN	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
relatively	relatively	ADV	RB	5	O
safe	safe	ADJ	JJ	5	O
for	for	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
younger	young	ADJ	JJR	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
on	on	ADP	IN	5	O
tenofovir	tenofovir	ADJ	JJ	0	B-Chemical
while	while	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
prolonged	prolong	VERB	VBN	9	O
vancomycin	vancomycin	NOUN	NN	9	B-Chemical
course	course	NOUN	NN	5	O
for	for	ADP	IN	5	O
osteomyelitis	osteomyelitis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
developed	develop	VERB	VBD	5	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
prolonged	prolong	VERB	VBN	9	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
vancomycin	vancomycin	PROPN	NNP	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
tenofovir	tenofovir	ADJ	JJ	0	B-Chemical
disoproxil	disoproxil	NOUN	NN	0	I-Chemical
fumarate	fumarate	NOUN	NN	0	I-Chemical
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
antiretroviral	antiretroviral	ADJ	JJ	5	O
regimen	regimen	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Tenofovir	tenofovir	DET	DT	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
Fanconi	Fanconi	PROPN	NNP	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
proximal	proximal	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
tubule	tubule	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Vancomycin	Vancomycin	PROPN	NNP	0	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
infrequent	infrequent	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
from	from	ADP	IN	9	O
coadministration	coadministration	NOUN	NN	0	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Clinicians	clinician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
that	that	ADP	IN	5	O
tenofovir	tenofovir	DET	DT	0	B-Chemical
may	may	VERB	MD	5	O
raise	raise	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
vancomycin	vancomycin	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Recurrent	Recurrent	PROPN	NNP	5	O
dysosmia	dysosmia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
pyrazinamide	pyrazinamide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Pyrazinamide	pyrazinamide	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
have	have	VERB	VB	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
hyperuricemia	hyperuricemia	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
digestive	digestive	ADJ	JJ	9	O
disorders	disorder	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
rare	rare	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
taste	taste	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
smell	smell	NOUN	NN	5	O
function	function	NOUN	NN	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
for	for	ADP	IN	5	O
pyrazinamide	pyrazinamide	NOUN	NN	0	B-Chemical
when	when	ADV	WRB	5	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
reversible	reversible	ADJ	JJ	9	O
olfactory	olfactory	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
related	relate	VERB	VBN	9	O
to	to	PART	TO	5	O
pyrazinamide	pyrazinamide	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
woman	woman	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
rechallenge	rechallenge	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
presented	present	VERB	VBD	5	O
every	every	DET	DT	5	O
day	day	NOUN	NN	9	O
a	a	DET	DT	5	O
sensation	sensation	NOUN	NN	5	O
of	of	ADP	IN	5	O
smelling	smell	VERB	VBG	5	O
something	something	NOUN	NN	5	O
burning	burn	VERB	VBG	5	O
15	15	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
intake	intake	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Dysosmia	Dysosmia	PROPN	NNP	9	B-Disease
disappeared	disappear	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
after	after	ADP	IN	9	O
pyrazinamide	pyrazinamide	NOUN	NN	0	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
recurred	recur	VERB	VBD	5	O
after	after	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
rechallenge	rechallenge	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
case	case	NOUN	NN	5	O
was	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Tunisian	Tunisian	PROPN	NNP	4	O
Centre	Centre	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Pharmacovigilance	Pharmacovigilance	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Mice	mouse	NOUN	NNS	3	O
lacking	lack	VERB	VBG	1	O
mPGES	mPGES	PROPN	NNP	3	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
are	be	VERB	VBP	5	O
resistant	resistant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
polyuria	polyuria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Cyclooxygenase	Cyclooxygenase	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
activity	activity	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
required	require	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
polyuria	polyuria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
terminal	terminal	ADJ	JJ	9	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PG	PG	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
isomerase	isomerase	NOUN	NN	1	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
polyuria	polyuria	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
deficient	deficient	ADJ	JJ	3	O
in	in	ADP	IN	5	O
microsomal	microsomal	ADJ	JJ	0	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
synthase	synthase	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
mPGES	mpges	NUM	CD	3	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
wk	wk	NOUN	NN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
LiCl	LiCl	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
mmol	mmol	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	X	FW	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
ip	ip	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
mPGES	mPGES	PROPN	NNP	3	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
+	+	NOUN	NN	9	O
/	/	SYM	SYM	9	O
+	+	SYM	SYM	9	O
mice	mouse	NOUN	NNS	3	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
marked	mark	VERB	VBN	9	O
polyuria	polyuria	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
hyposmotic	hyposmotic	ADJ	JJ	0	O
urine	urine	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
elevated	elevated	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
mPGES	mPGES	PROPN	NNP	3	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
urine	urine	NOUN	NN	9	O
PGE	PGE	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	PUNCT	LS	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
excretion	excretion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mPGES	mpges	NUM	CD	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
largely	largely	ADV	RB	9	O
resistant	resistant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
polyuria	polyuria	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
urine	urine	NOUN	NN	9	O
concentrating	concentrating	NOUN	NN	5	O
defect	defect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
nearly	nearly	ADV	RB	9	O
complete	complete	ADJ	JJ	9	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
urine	urine	NOUN	NN	9	O
PGE	PGE	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
and	and	CCONJ	CC	5	O
cAMP	cAMP	PROPN	NNP	3	O
output	output	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Immunoblotting	immunoblotting	NOUN	NN	3	O
,	,	PUNCT	,	9	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
quantitative	quantitative	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
q	q	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
RT	RT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
PCR	PCR	PROPN	NNP	9	O
consistently	consistently	ADV	RB	9	O
detected	detect	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
aquaporin	aquaporin	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
AQP2	AQP2	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
cortex	cortex	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
medulla	medulla	NOUN	NN	9	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
+	+	SYM	SYM	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

qRT	qRT	PUNCT	LS	3	O
-	-	PUNCT	HYPH	7	O
PCR	PCR	PROPN	NNP	9	O
detected	detect	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
patterns	pattern	NOUN	NNS	5	O
of	of	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
AQP2	AQP2	PROPN	NNP	3	O
mRNA	mRNA	PROPN	NNPS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
medulla	medulla	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
abundance	abundance	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Na	Na	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
K	K	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
2Cl	2cl	NUM	CD	0	B-Chemical
cotransporter	cotransporter	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
NKCC2	NKCC2	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
medulla	medulla	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cortex	cortex	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
+	+	NOUN	NN	9	O
/	/	SYM	SYM	9	O
+	+	CCONJ	CC	9	O
mice	mouse	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
dowregulation	dowregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
medullary	medullary	NOUN	NN	5	O
NKCC2	nkcc2	DET	DT	3	O
expression	expression	NOUN	NN	3	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
mPGES	mpges	NUM	CD	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
derived	derive	VERB	VBN	9	O
PGE	PGE	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	PUNCT	LS	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
mediates	mediate	VERB	VBZ	3	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
polyuria	polyuria	NOUN	NN	5	B-Disease
likely	likely	ADJ	JJ	5	O
via	via	ADP	IN	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
AQP2	AQP2	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
NKCC2	NKCC2	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Preservation	preservation	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
during	during	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
with	with	ADP	IN	5	O
fenoldopam	fenoldopam	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
introduction	introduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
could	could	VERB	MD	9	O
induce	induce	VERB	VB	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
different	different	ADJ	JJ	9	O
pharmacological	pharmacological	ADJ	JJ	9	O
actions	action	NOUN	NNS	5	O
would	would	VERB	MD	5	O
be	be	VERB	VB	5	O
advantageous	advantageous	ADJ	JJ	5	O
because	because	ADP	IN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
unique	unique	ADJ	JJ	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
minimized	minimize	VERB	VBN	5	O
by	by	ADP	IN	9	O
selecting	select	VERB	VBG	5	O
appropriate	appropriate	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Specific	specific	ADJ	JJ	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
DA1	da1	NOUN	NN	1	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
DA2	DA2	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
agonists	agonist	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
now	now	ADV	RB	5	O
under	under	ADP	IN	9	O
clinical	clinical	ADJ	JJ	5	O
investigation	investigation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Fenoldopam	fenoldopam	NOUN	NN	0	B-Chemical
mesylate	mesylate	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
DA1	da1	ADJ	JJ	1	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
that	that	DET	WDT	5	O
lowers	lower	VERB	VBZ	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
by	by	ADP	IN	9	O
vasodilatation	vasodilatation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	DT	5	O
fenoldopam	fenoldopam	NOUN	NN	0	B-Chemical
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
preserve	preserve	VERB	VB	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
was	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Systemic	systemic	ADJ	JJ	9	O
aortic	aortic	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
continuously	continuously	ADV	RB	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
carotid	carotid	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
catheter	catheter	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
electromagnetic	electromagnetic	ADJ	JJ	5	O
flow	flow	NOUN	NN	5	O
probe	probe	NOUN	NN	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
fenoldopam	fenoldopam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
nitroprusside	nitroprusside	ADV	RB	0	B-Chemical
in	in	ADP	IN	5	O
ten	ten	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
under	under	ADP	IN	9	O
halothane	halothane	NOUN	NN	0	B-Chemical
general	general	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
30	30	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
per	per	NOUN	NN	9	O
cent	cent	NOUN	NN	5	O
from	from	ADP	IN	9	O
control	control	NOUN	NN	9	O
with	with	ADP	IN	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
fenoldopam	fenoldopam	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
micrograms	micrograms	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
34	34	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
with	with	ADP	IN	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
nitroprusside	nitroprusside	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
micrograms	microgram	NOUN	NNS	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
NS	NS	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
RBF	RBF	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBD	9	O
during	during	ADP	IN	5	O
fenoldopam	fenoldopam	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
11	11	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
per	per	NOUN	NN	9	O
cent	cent	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
21	21	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
per	per	NOUN	NN	9	O
cent	cent	NOUN	NN	5	O
during	during	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
nitroprusside	nitroprusside	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Sodium	sodium	NOUN	NN	0	O
nitroprusside	nitroprusside	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
selective	selective	ADJ	JJ	9	O
arteriolar	arteriolar	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
venous	venous	ADJ	JJ	5	O
vasodilator	vasodilator	NOUN	NN	0	O
that	that	DET	WDT	5	O
can	can	VERB	MD	5	O
produce	produce	VERB	VB	9	O
redistribution	redistribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
flow	flow	VERB	VB	5	O
away	away	ADV	RB	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
during	during	ADP	IN	5	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Fenoldopam	Fenoldopam	PROPN	NNP	0	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
DA1	da1	NOUN	NN	1	O
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
that	that	DET	WDT	5	O
causes	cause	VERB	VBZ	9	O
vasodilatation	vasodilatation	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
organs	organ	NOUN	NNS	9	O
with	with	ADP	IN	5	O
DA1	da1	ADJ	JJ	1	O
receptors	receptor	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
preserves	preserve	VERB	VBZ	9	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
during	during	ADP	IN	5	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Seizures	seizure	NOUN	NNS	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
levofloxacin	levofloxacin	ADJ	JJ	0	B-Chemical
:	:	PUNCT	:	9	O
case	case	NOUN	NN	5	O
presentation	presentation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
literature	literature	NOUN	NN	5	O
review	review	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
shortly	shortly	ADV	RB	9	O
after	after	ADP	IN	9	O
initiating	initiate	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
levofloxacin	levofloxacin	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
discuss	discuss	VERB	VB	5	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
interactions	interaction	NOUN	NNS	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
cytochrome	cytochrome	ADJ	JJ	0	O
P450	P450	PROPN	NNP	1	O
(	(	PUNCT	-LRB-	9	O
CYP	CYP	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
1A2	1a2	NUM	CD	0	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
other	other	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
of	of	ADP	IN	5	O
levofloxacin	levofloxacin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Several	several	ADJ	JJ	9	O
biomedical	biomedical	ADJ	JJ	5	O
databases	database	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
searched	search	VERB	VBN	9	O
including	include	VERB	VBG	9	O
MEDLINE	MEDLINE	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
Cochrane	Cochrane	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Ovid	Ovid	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
search	search	NOUN	NN	5	O
terms	term	NOUN	NNS	5	O
utilized	utilize	VERB	VBN	9	O
were	be	VERB	VBD	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
levofloxacin	levofloxacin	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
search	search	NOUN	NN	5	O
was	be	VERB	VBD	9	O
limited	limit	VERB	VBN	5	O
to	to	ADP	IN	5	O
studies	study	NOUN	NNS	9	O
published	publish	VERB	VBN	9	O
in	in	ADP	IN	5	O
English	English	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Six	six	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
levofloxacin	levofloxacin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
interactions	interaction	NOUN	NNS	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
CYP1A2	cyp1a2	NOUN	NN	9	O
by	by	ADP	IN	9	O
levofloxacin	levofloxacin	ADJ	JJ	0	B-Chemical
are	be	VERB	VBP	5	O
likely	likely	ADV	RB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Clinicians	clinician	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
exhorted	exhort	VERB	VBN	5	O
to	to	PART	TO	5	O
pay	pay	VERB	VB	5	O
close	close	ADJ	JJ	5	O
attention	attention	NOUN	NN	5	O
when	when	ADV	WRB	5	O
initiating	initiate	VERB	VBG	9	O
levofloxacin	levofloxacin	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
medications	medication	NOUN	NNS	5	O
with	with	ADP	IN	5	O
epileptogenic	epileptogenic	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
CYP1A2	cyp1a2	NOUN	NN	9	O
substrates	substrate	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Dextran	dextran	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
etodolac	etodolac	NOUN	NN	0	B-Chemical
conjugates	conjugate	NOUN	NNS	0	O
:	:	PUNCT	:	9	O
synthesis	synthesis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
evaluation	evaluation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Etodolac	Etodolac	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
E	E	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
narcotic	narcotic	ADJ	JJ	5	O
analgesic	analgesic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
antiinflammatory	antiinflammatory	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
biodegradable	biodegradable	ADJ	JJ	0	O
polymer	polymer	NOUN	NN	0	O
dextran	dextran	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
utilized	utilize	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
carrier	carrier	NOUN	NN	9	O
for	for	ADP	IN	5	O
synthesis	synthesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
etodolac	etodolac	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
dextran	dextran	NOUN	NN	0	B-Chemical
conjugates	conjugate	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
ED	ED	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
its	-PRON-	DET	PRP$	9	O
aqueous	aqueous	ADJ	JJ	0	O
solubility	solubility	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
reduce	reduce	VERB	VB	5	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
activated	activate	VERB	VBN	3	O
moiety	moiety	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
acylimidazole	acylimidazole	NOUN	NN	_	I-Chemical
derivative	derivative	NOUN	NN	0	O
of	of	ADP	IN	5	O
etodolac	etodolac	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
EAI	EAI	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
condensed	condense	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
polysaccharide	polysaccharide	NOUN	NN	0	O
polymer	polymer	NOUN	NN	0	O
dextran	dextran	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	O
different	different	ADJ	JJ	9	O
molecular	molecular	ADJ	JJ	9	O
weights	weight	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
40000	40000	NUM	CD	0	O
,	,	PUNCT	,	9	O
60000	60000	NUM	CD	0	O
,	,	PUNCT	,	9	O
110000	110000	NUM	CD	7	O
and	and	CCONJ	CC	5	O
200000	200000	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

IR	IR	PROPN	NNP	9	O
spectral	spectral	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
confirmed	confirm	VERB	VBD	9	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
ester	ester	NOUN	NN	0	O
bonding	bonding	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
conjugates	conjugate	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Etodolac	Etodolac	PROPN	NNP	0	B-Chemical
contents	content	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
UV	uv	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
spectrophotometric	spectrophotometric	NOUN	NN	0	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
weights	weight	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
measuring	measure	VERB	VBG	9	O
viscosity	viscosity	NOUN	NN	0	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
Mark	Mark	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Howink	Howink	PROPN	NNP	_	O
-	-	PUNCT	HYPH	7	O
Sakurada	Sakurada	PROPN	NNP	6	O
equation	equation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vitro	vitro	X	FW	3	O
hydrolysis	hydrolysis	NOUN	NN	0	O
of	of	ADP	IN	5	O
ED	ED	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
in	in	ADP	IN	5	O
aqueous	aqueous	ADJ	JJ	0	O
buffers	buffer	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
pH	pH	NOUN	NNS	0	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
80	80	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
v	v	NOUN	NN	0	O
/	/	SYM	SYM	9	O
v	v	PUNCT	LS	0	O
)	)	PUNCT	-RRB-	9	O
human	human	ADJ	JJ	3	O
plasma	plasma	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
pH	ph	X	XX	0	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
pH	pH	PROPN	NNP	0	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
etodolac	etodolac	NOUN	NN	0	B-Chemical
release	release	NOUN	NN	9	O
from	from	ADP	IN	9	O
ED	ED	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
aqueous	aqueous	ADJ	JJ	0	O
buffer	buffer	NOUN	NN	0	O
of	of	ADP	IN	5	O
pH	pH	NOUN	NNS	0	O
7	7	NUM	CD	9	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
80	80	NUM	CD	9	O
%	%	NOUN	NN	9	O
human	human	ADJ	JJ	3	O
plasma	plasma	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
pH	ph	X	XX	0	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
following	follow	VERB	VBG	9	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
order	order	NOUN	NN	5	O
kinetics	kinetic	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vivo	vivo	NOUN	NNS	3	O
investigations	investigation	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
analgesic	analgesic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
antiinflammatory	antiinflammatory	NOUN	NN	9	O
activities	activity	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
ascertained	ascertain	VERB	VBN	9	O
using	use	VERB	VBG	9	O
acetic	acetic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
induced	induce	VERB	VBN	3	O
writhing	writhing	NOUN	NN	0	B-Disease
model	model	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
mice	mouse	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
carrageenan	carrageenan	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
rat	rat	NOUN	NN	3	O
paw	paw	DET	PRP$	5	O
edema	edema	NOUN	NN	5	B-Disease
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
comparison	comparison	NOUN	NN	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
,	,	PUNCT	,	9	O
E	e	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
ED1	ED1	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
ED4	ED4	PROPN	NNP	3	O
showed	show	VERB	VBD	9	O
highly	highly	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
analgesic	analgesic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
antiinflammatory	antiinflammatory	NOUN	NN	9	O
activities	activity	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Biological	biological	ADJ	JJ	2	O
evaluation	evaluation	NOUN	NN	5	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
conjugates	conjugate	VERB	VBZ	0	O
(	(	PUNCT	-LRB-	9	O
ED1	ED1	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
ED4	ED4	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
retained	retain	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
analgesic	analgesic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
antiinflammatory	antiinflammatory	NOUN	NN	9	O
activities	activity	NOUN	NNS	9	O
with	with	ADP	IN	5	O
remarkably	remarkably	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
ulcerogenicity	ulcerogenicity	NOUN	NN	5	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
parent	parent	NOUN	NN	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
etodolac	etodolac	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
possible	possible	ADJ	JJ	5	O
ionic	ionic	ADJ	JJ	0	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
animal	animal	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
explore	explore	VERB	VB	5	O
the	the	DET	DT	5	O
underlying	underlying	ADJ	JJ	5	O
ionic	ionic	ADJ	JJ	0	O
mechanism	mechanism	NOUN	NN	9	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
both	both	CCONJ	CC	9	O
aconitine	aconitine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rat	rat	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
ouabain	ouabain	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
guinea	guinea	NOUN	NN	9	O
pig	pig	NOUN	NN	9	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Confocal	confocal	ADJ	JJ	3	O
microscopy	microscopy	NOUN	NN	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
measure	measure	VERB	VB	5	O
intracellular	intracellular	ADJ	JJ	3	O
free	free	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
calcium	calcium	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
[	[	PUNCT	-LRB-	9	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
]	]	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
isolated	isolated	ADJ	JJ	9	O
myocytes	myocyte	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
significantly	significantly	ADV	RB	9	O
delayed	delay	VERB	VBD	9	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
reduced	reduce	VERB	VBN	9	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
score	score	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
survival	survival	NOUN	NN	9	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
arrhythmic	arrhythmic	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
guinea	guinea	NOUN	NN	9	O
pigs	pig	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

[	[	PUNCT	-LRB-	9	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
]	]	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
overload	overload	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
aconitine	aconitine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
isolated	isolated	ADJ	JJ	9	O
myocytes	myocyte	NOUN	NNS	3	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
M	M	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
muscarinic	muscarinic	ADJ	JJ	3	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
mAChR	machr	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
antagonist	antagonist	VERB	VBP	3	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	:	7	I-Chemical
DAMP	damp	NOUN	NN	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
diphenylacetoxy	diphenylacetoxy	ADJ	JJ	_	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
N	n	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylpiperidine	methylpiperidine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methiodide	methiodide	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
partially	partially	ADV	RB	9	O
abolished	abolish	VERB	VBD	3	O
the	the	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
produced	produce	VERB	VBD	9	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
actions	action	NOUN	NNS	5	O
on	on	ADP	IN	5	O
arrhythmic	arrhythmic	ADJ	JJ	5	B-Disease
rat	rat	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
guinea	guinea	NOUN	NN	9	O
pig	pig	NOUN	NN	9	O
models	model	NOUN	NNS	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
aconitine	aconitine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
via	via	ADP	IN	9	O
stimulating	stimulate	VERB	VBG	9	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
M	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
mAChR	machr	NUM	CD	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
of	of	ADP	IN	5	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
handling	handling	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
Hibiscus	Hibiscus	PROPN	NNP	4	B-Chemical
rosa	rosa	NOUN	NN	4	I-Chemical
sinensis	sinensis	NOUN	NN	4	I-Chemical
on	on	ADP	IN	5	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neurobehavioral	neurobehavioral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
biochemical	biochemical	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
methanolic	methanolic	ADJ	JJ	0	O
extract	extract	NOUN	NN	0	O
of	of	ADP	IN	5	O
Hibiscus	Hibiscus	PROPN	NNP	4	B-Chemical
rosa	rosa	NOUN	NN	4	I-Chemical
sinensis	sinensis	NOUN	NN	4	I-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
-	-	SYM	SYM	7	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
on	on	ADP	IN	5	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
orofacial	orofacial	ADJ	JJ	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
neurochemical	neurochemical	ADJ	JJ	5	O
alterations	alteration	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
intraperitoneal	intraperitoneal	ADJ	JJ	0	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
ip	ip	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
every	every	DET	DT	5	O
other	other	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
vacuous	vacuous	ADJ	JJ	5	O
chewing	chewing	NOUN	NN	5	O
movements	movement	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
tongue	tongue	NOUN	NN	5	O
protrusions	protrusion	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
counted	count	VERB	VBN	9	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Reserpine	reserpine	NOUN	NN	0	B-Chemical
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
significantly	significantly	ADV	RB	9	O
developed	develop	VERB	VBD	5	O
vacuous	vacuous	ADJ	JJ	5	O
chewing	chewing	NOUN	NN	5	O
movements	movement	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
tongue	tongue	NOUN	NN	5	O
protrusions	protrusion	NOUN	NNS	3	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
coadministration	coadministration	NOUN	NN	0	O
of	of	ADP	IN	5	O
Hibiscus	Hibiscus	PROPN	NNP	4	B-Chemical
rosa	rosa	NOUN	NN	4	I-Chemical
sinensis	sinensis	NOUN	NN	4	I-Chemical
roots	root	NOUN	NNS	4	O
extract	extract	VERB	VBP	0	O
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
200	200	NUM	CD	0	O
and	and	CCONJ	CC	5	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
per	per	ADP	IN	9	O
orally	orally	ADV	RB	0	O
)	)	PUNCT	-RRB-	9	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Biochemical	biochemical	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
dismutase	dismutase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
SOD	SOD	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
catalase	catalase	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
CAT	CAT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
glutathione	glutathione	NOUN	NN	0	B-Chemical
reductase	reductase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
GSH	GSH	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
index	index	NOUN	NN	5	O
of	of	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
process	process	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Coadministration	coadministration	NOUN	NN	0	O
of	of	ADP	IN	5	O
extract	extract	NOUN	NN	0	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
reversed	reverse	VERB	VBD	9	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
SOD	SOD	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
CAT	CAT	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
GSH	GSH	PROPN	NNP	0	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
Hibiscus	Hibiscus	PROPN	NNP	4	B-Chemical
rosa	rosa	NOUN	NN	4	I-Chemical
sinensis	sinensis	NOUN	NN	4	I-Chemical
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
against	against	ADP	IN	9	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
orofacial	orofacial	ADJ	JJ	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Dynamic	dynamic	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
vessel	vessel	NOUN	NN	5	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
postulated	postulate	VERB	VBD	9	O
that	that	ADP	IN	5	O
during	during	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
the	the	DET	DT	5	O
transient	transient	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
dynamic	dynamic	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
vessels	vessel	NOUN	NNS	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
affected	affect	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
antioxidants	antioxidant	NOUN	NNS	0	O
can	can	VERB	MD	5	O
prevent	prevent	VERB	VB	5	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
dynamic	dynamic	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
vessels	vessel	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
new	new	ADJ	JJ	5	O
approach	approach	NOUN	NN	5	O
to	to	ADP	IN	5	O
ex	ex	NOUN	NN	9	O
vivo	vivo	NOUN	NNS	3	O
blood	blood	NOUN	NN	9	O
vessel	vessel	NOUN	NN	5	O
experiments	experiment	NOUN	NNS	9	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
not	not	ADV	RB	5	O
only	only	ADV	RB	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
points	point	NOUN	NNS	5	O
of	of	ADP	IN	5	O
vessels	vessel	NOUN	NNS	5	O
response	response	NOUN	NN	9	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
considered	consider	VERB	VBN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
also	also	ADV	RB	9	O
dynamics	dynamic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
paper	paper	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
confirm	confirm	VERB	VBP	9	O
the	the	DET	DT	5	O
alteration	alteration	NOUN	NN	9	O
in	in	ADP	IN	5	O
dynamic	dynamic	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
vessels	vessel	NOUN	NNS	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
change	change	NOUN	NN	9	O
of	of	ADP	IN	5	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
C	c	NOUN	NN	9	I-Chemical
administration	administration	NOUN	NN	9	O
to	to	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
also	also	ADV	RB	9	O
confirmed	confirm	VERB	VBN	9	O
through	through	ADP	IN	9	O
:	:	PUNCT	:	9	O
lower	low	ADJ	JJR	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
urea	urea	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pressure	pressure	NOUN	NN	5	O
dynamic	dynamic	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
of	of	ADP	IN	5	O
isolated	isolated	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
vessels	vessel	NOUN	NNS	5	O
show	show	VERB	VBP	9	O
a	a	DET	DT	5	O
faster	fast	ADJ	JJR	5	O
pressure	pressure	NOUN	NN	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
07	07	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
s	s	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
64	64	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
18	18	NUM	CD	7	O
s	s	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Vitamin	vitamin	NOUN	NN	0	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
administration	administration	NOUN	NN	9	O
induced	induce	VERB	VBD	3	O
slowdown	slowdown	NOUN	NN	5	O
of	of	ADP	IN	5	O
pressure	pressure	NOUN	NN	5	O
change	change	VERB	VBP	9	O
back	back	ADV	RB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
values	value	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pressure	pressure	NOUN	NN	5	O
dynamic	dynamic	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
quantitatively	quantitatively	ADV	RB	9	O
defined	define	VERB	VBN	5	O
by	by	ADP	IN	9	O
comparative	comparative	ADJ	JJ	9	O
pressure	pressure	NOUN	NN	5	O
dynamic	dynamic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
total	total	ADJ	JJ	9	O
pressure	pressure	NOUN	NN	5	O
dynamic	dynamic	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
confirm	confirm	VERB	VB	9	O
the	the	DET	DT	5	O
alteration	alteration	NOUN	NN	9	O
in	in	ADP	IN	5	O
dynamic	dynamic	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
vessels	vessel	NOUN	NNS	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
change	change	NOUN	NN	9	O
of	of	ADP	IN	5	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
beneficial	beneficial	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
C	c	NOUN	NN	9	I-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Reversible	reversible	ADJ	JJ	0	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
pediatric	pediatric	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
transplant	transplant	NOUN	NN	9	O
recipient	recipient	NOUN	NN	9	O
:	:	PUNCT	:	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Tacrolimus	Tacrolimus	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
immunosuppressant	immunosuppressant	NOUN	NN	9	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
frequently	frequently	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
organ	organ	NOUN	NN	5	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
include	include	VERB	VBP	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Herein	Herein	PROPN	NNP	9	O
we	-PRON-	PRON	PRP	5	O
describe	describe	VERB	VBP	5	O
transient	transient	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
after	after	ADP	IN	9	O
heart	heart	NOUN	NN	5	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hypertrophy	hypertrophy	NOUN	NN	9	B-Disease
caused	cause	VERB	VBD	9	O
no	no	DET	DT	9	O
clinical	clinical	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
brain	brain	NOUN	NN	5	O
natriuretic	natriuretic	ADJ	JJ	9	O
peptide	peptide	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
confirmed	confirm	VERB	VBD	9	O
at	at	ADP	IN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Initially	initially	ADV	RB	9	O
,	,	PUNCT	,	9	O
allograft	allograft	NOUN	NN	5	O
rejection	rejection	NOUN	NN	5	O
was	be	VERB	VBD	9	O
feared	fear	VERB	VBN	5	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
myocardial	myocardial	ADJ	JJ	9	O
biopsy	biopsy	NOUN	NN	5	O
samples	sample	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
only	only	ADV	RB	9	O
interstitial	interstitial	ADJ	JJ	9	O
edema	edema	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
mild	mild	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
;	;	PUNCT	:	9	O
neither	neither	CCONJ	CC	9	O
cellular	cellular	ADJ	JJ	3	O
nor	nor	CCONJ	CC	9	O
humoral	humoral	ADJ	JJ	3	O
rejection	rejection	NOUN	NN	5	O
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
usual	usual	ADJ	JJ	5	O
at	at	ADP	IN	9	O
that	that	DET	DT	5	O
time	time	NOUN	NN	5	O
;	;	PUNCT	:	9	O
thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
tacrolimus	tacrolimus	ADJ	JJ	0	B-Chemical
dosage	dosage	NOUN	NN	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Myocardial	myocardial	ADJ	JJ	9	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
completely	completely	ADV	RB	9	O
resolved	resolve	VERB	VBD	9	O
upon	upon	ADP	IN	9	O
reducing	reduce	VERB	VBG	9	O
the	the	DET	DT	5	O
target	target	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
recur	recur	VERB	VB	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
confirmed	confirm	VERB	VBN	9	O
at	at	ADP	IN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
myocardial	myocardial	ADJ	JJ	9	O
biopsy	biopsy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
induces	induce	NOUN	NNS	3	O
reversible	reversible	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
blood	blood	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
carefully	carefully	ADV	RB	5	O
controlled	control	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
extreme	extreme	ADJ	JJ	5	O
attention	attention	NOUN	NN	5	O
paid	pay	VERB	VBN	5	O
to	to	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
involvement	involvement	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Nimodipine	nimodipine	NOUN	NN	0	B-Chemical
prevents	prevent	VERB	VBZ	9	O
memory	memory	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
nitroglycerin	nitroglycerin	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Hypotension	hypotension	NOUN	NN	7	B-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
resultant	resultant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
tested	test	VERB	VBD	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
nimodipine	nimodipine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
NIMO	NIMO	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
administered	administer	VERB	VBD	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
NTG	NTG	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
would	would	VERB	MD	5	O
preserve	preserve	VERB	VB	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
associative	associative	ADJ	JJ	5	O
memory	memory	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PA	PA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
paradigm	paradigm	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
memory	memory	NOUN	NN	5	O
retention	retention	NOUN	NN	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
PA	PA	PROPN	NNP	9	O
training	training	NOUN	NN	5	O
,	,	PUNCT	,	9	O
latencies	latency	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
seconds	second	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
for	for	ADP	IN	5	O
entry	entry	NOUN	NN	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
suspended	suspend	VERB	VBN	0	O
platform	platform	NOUN	NN	5	O
into	into	ADP	IN	9	O
a	a	DET	DT	5	O
Plexiglas	Plexiglas	PROPN	NNP	5	O
tube	tube	NOUN	NN	9	O
where	where	ADV	WRB	5	O
a	a	DET	DT	5	O
shock	shock	NOUN	NN	9	O
was	be	VERB	VBD	9	O
automatically	automatically	ADV	RB	5	O
delivered	deliver	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Latencies	latency	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
later	later	ADV	RB	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
testing	testing	NOUN	NN	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ninety	ninety	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
Swiss	Swiss	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Webster	Webster	PROPN	NNP	6	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
-	-	SYM	SYM	7	O
35	35	NUM	CD	9	O
g	g	NOUN	NN	0	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
wk	wk	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
into	into	ADP	IN	9	O
6	6	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
control	control	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
NTG	NTG	PROPN	NNP	9	B-Chemical
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
learning	learn	VERB	VBG	5	O
,	,	PUNCT	,	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
NTG	NTG	PROPN	NNP	9	B-Chemical
3	3	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
learning	learn	VERB	VBG	5	O
,	,	PUNCT	,	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
NTG	NTG	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
NIMO	NIMO	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
vehicle	vehicle	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
6	6	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
NIMO	nimo	ADV	RB	9	B-Chemical
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
tissue	tissue	NOUN	NN	9	O
oxygenation	oxygenation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PbtO	PbtO	PROPN	NNP	_	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
separate	separate	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
All	all	DET	DT	9	O
groups	group	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
training	training	NOUN	NN	5	O
latencies	latency	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
s	s	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Mice	mouse	NOUN	NNS	3	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
episodes	episode	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
latency	latency	NOUN	NN	5	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
178	178	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
156	156	NUM	CD	7	O
s	s	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
NTG	NTG	PROPN	NNP	9	B-Chemical
+	+	CCONJ	CC	9	O
NIMO	nimo	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
delayed	delay	VERB	VBN	9	O
NTG	NTG	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
580	580	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
81	81	NUM	CD	7	O
s	s	NOUN	NN	9	O
,	,	PUNCT	,	9	O
557	557	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
67	67	NUM	CD	7	O
s	s	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
493	493	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
146	146	NUM	CD	7	O
s	s	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
Kruskal	Kruskal	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
Wallis	Wallis	PROPN	NNP	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
way	way	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
variance	variance	NOUN	NN	5	O
indicated	indicate	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
4	4	NUM	CD	9	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
H	h	NOUN	NN	9	O
=	=	SYM	SYM	7	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
34	34	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
separate	separate	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
not	not	ADV	RB	5	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
behavioral	behavioral	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
NTG	NTG	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
NTG	NTG	PROPN	NNP	9	B-Chemical
+	+	CCONJ	CC	9	O
NIMO	NIMO	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
caused	cause	VERB	VBD	9	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
to	to	PART	TO	5	O
decrease	decrease	VERB	VB	9	O
from	from	ADP	IN	9	O
85	85	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
sem	sem	ADJ	JJ	9	O
to	to	ADP	IN	5	O
31	31	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
sem	sem	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
from	from	ADP	IN	9	O
86	86	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
sem	sem	NOUN	NN	9	O
to	to	ADP	IN	5	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
sem	sem	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
NIMO	NIMO	PROPN	NNP	9	B-Chemical
alone	alone	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
from	from	ADP	IN	9	O
88	88	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
to	to	ADP	IN	5	O
80	80	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
intergroup	intergroup	NOUN	NN	5	O
difference	difference	NOUN	NN	9	O
was	be	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

PbtO	PbtO	PROPN	NNP	_	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
decreased	decrease	VERB	VBD	9	O
from	from	ADP	IN	9	O
51	51	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
sem	sem	ADJ	JJ	9	O
to	to	ADP	IN	5	O
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
sem	sem	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
NTG	NTG	PROPN	NNP	9	B-Chemical
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
from	from	ADP	IN	9	O
38	38	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
sem	sem	ADJ	JJ	9	O
to	to	ADP	IN	5	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
sem	sem	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
NTG	NTG	PROPN	NNP	9	B-Chemical
+	+	CCONJ	CC	9	O
NIMO	nimo	ADJ	JJ	9	B-Chemical
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
among	among	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
a	a	DET	DT	5	O
PA	PA	PROPN	NNP	9	O
retention	retention	NOUN	NN	9	O
paradigm	paradigm	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
NTG	NTG	PROPN	NNP	9	B-Chemical
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
learning	learn	VERB	VBG	5	O
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
impairment	impairment	NOUN	NN	5	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
associative	associative	ADJ	JJ	5	O
memory	memory	NOUN	NN	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
delayed	delay	VERB	VBN	9	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

NIMO	NIMO	PROPN	NNP	9	B-Chemical
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
disruption	disruption	NOUN	NN	9	O
in	in	ADP	IN	5	O
consolidation	consolidation	NOUN	NN	5	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
memory	memory	NOUN	NN	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
NTG	NTG	PROPN	NNP	9	B-Chemical
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
improve	improve	VERB	VB	5	O
latency	latency	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
observed	observed	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
NIMO	NIMO	PROPN	NNP	9	B-Chemical
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
attributable	attributable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
preservation	preservation	NOUN	NN	9	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
homeostasis	homeostasis	NOUN	NN	9	O
during	during	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PbtO	PbtO	PROPN	NNP	_	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
indices	index	NOUN	NNS	5	O
among	among	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Metabotropic	Metabotropic	PROPN	NNP	7	O
glutamate	glutamate	VERB	VBP	0	B-Chemical
7	7	NUM	CD	9	O
receptor	receptor	NOUN	NN	3	O
subtype	subtype	NOUN	NN	9	O
modulates	modulate	NOUN	NNS	9	O
motor	motor	NOUN	NN	5	O
symptoms	symptom	NOUN	NNS	5	O
in	in	ADP	IN	5	O
rodent	rodent	ADJ	JJ	9	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Metabotropic	Metabotropic	PROPN	NNP	7	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
mGlu	mGlu	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
receptors	receptor	NOUN	NNS	3	O
modulate	modulate	VERB	VBP	9	O
synaptic	synaptic	ADJ	JJ	5	O
transmission	transmission	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
represent	represent	VERB	VB	9	O
promising	promising	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
targets	target	NOUN	NNS	9	O
for	for	ADP	IN	5	O
symptomatic	symptomatic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	PD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
the	the	DET	DT	5	O
eight	eight	NUM	CD	9	O
mGlu	mGlu	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
subtypes	subtype	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
mGlu7	mglu7	DET	DT	3	O
receptor	receptor	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
prominently	prominently	ADV	RB	9	O
expressed	express	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
basal	basal	NOUN	NN	3	O
ganglia	ganglion	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
its	-PRON-	DET	PRP$	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
restoring	restore	VERB	VBG	9	O
motor	motor	NOUN	NN	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
animal	animal	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
PD	PD	PROPN	NNP	9	B-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
known	know	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
N	N	PROPN	NNP	9	I-Chemical
'	'	PART	POS	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dibenzhydrylethane	dibenzhydrylethane	NOUN	NN	_	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
diamine	diamine	NOUN	NN	0	I-Chemical
dihydrochloride	dihydrochloride	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
AMN082	AMN082	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
selective	selective	ADJ	JJ	9	O
allosteric	allosteric	ADJ	JJ	9	O
activator	activator	NOUN	NN	3	O
of	of	ADP	IN	5	O
mGlu7	mglu7	NUM	CD	3	O
receptors	receptor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
thus	thus	ADV	RB	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
different	different	ADJ	JJ	9	O
rodent	rodent	ADJ	JJ	9	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
PD	PD	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
intrastriatal	intrastriatal	ADJ	JJ	3	O
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
nmol	nmol	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
AMN082	AMN082	PROPN	NNP	0	B-Chemical
reverses	reverse	VERB	VBZ	3	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

AMN082	AMN082	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
reduces	reduce	VERB	VBZ	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rotations	rotation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
unilateral	unilateral	ADJ	JJ	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxydopamine	hydroxydopamine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
OHDA	ohda	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
lesioned	lesione	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
complex	complex	ADJ	JJ	9	O
task	task	NOUN	NN	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
major	major	ADJ	JJ	9	O
akinetic	akinetic	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
PD	pd	NOUN	NN	9	B-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
AMN082	AMN082	PROPN	NNP	0	B-Chemical
reverses	reverse	VERB	VBZ	3	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
reaction	reaction	NOUN	NN	9	O
time	time	NOUN	NN	5	O
to	to	PART	TO	5	O
respond	respond	VERB	VB	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
cue	cue	NOUN	NN	5	O
of	of	ADP	IN	5	O
bilateral	bilateral	ADJ	JJ	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
OHDA	ohda	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
lesioned	lesione	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
AMN082	AMN082	PROPN	NNP	0	B-Chemical
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
mGlu7	mglu7	NUM	CD	3	O
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
in	in	ADP	IN	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
mGlu7	mglu7	DET	DT	3	O
receptor	receptor	NOUN	NN	3	O
knockout	knockout	NOUN	NN	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Higher	high	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
AMN082	AMN082	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
PD	PD	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Overall	overall	ADV	RB	9	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
mGlu7	mglu7	NUM	CD	3	O
receptor	receptor	NOUN	NN	3	O
activation	activation	NOUN	NN	3	O
can	can	VERB	MD	5	O
reverse	reverse	VERB	VB	9	O
motor	motor	NOUN	NN	5	O
dysfunction	dysfunction	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
reduced	reduced	ADJ	JJ	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Selective	selective	ADJ	JJ	9	O
ligands	ligand	NOUN	NNS	3	O
of	of	ADP	IN	5	O
mGlu7	mglu7	NUM	CD	3	O
receptor	receptor	NOUN	NN	3	O
subtypes	subtype	NOUN	NNS	9	O
may	may	VERB	MD	5	O
thus	thus	ADV	RB	9	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
as	as	ADP	IN	5	O
promising	promising	ADJ	JJ	5	O
compounds	compound	NOUN	NNS	0	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
antiparkinsonian	antiparkinsonian	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
strategies	strategy	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Sorafenib	Sorafenib	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
spasm	spasm	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
65	65	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
cell	cell	NOUN	NN	3	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
continuing	continue	VERB	VBG	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
at	at	ADP	IN	9	O
rest	rest	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
before	before	ADP	IN	9	O
his	-PRON-	DET	PRP$	5	O
admission	admission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sorafenib	sorafenib	NOUN	NN	3	B-Chemical
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
started	start	VERB	VBN	5	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
with	with	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
ST	st	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
elevation	elevation	NOUN	NN	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
laboratory	laboratory	NOUN	NN	9	O
data	datum	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Enhanced	enhanced	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
also	also	ADV	RB	9	O
showed	show	VERB	VBD	9	O
subendocardial	subendocardial	ADJ	JJ	5	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
stenosis	stenosis	NOUN	NN	5	O
in	in	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
on	on	ADP	IN	5	O
angiography	angiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
spasm	spasm	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
provocative	provocative	ADJ	JJ	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
sorafenib	sorafenib	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
Ca	ca	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
channel	channel	NOUN	NN	9	O
blocker	blocker	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
nitrates	nitrate	NOUN	NNS	0	B-Chemical
ameliorated	ameliorate	VERB	VBD	9	O
his	-PRON-	DET	PRP$	5	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
relapse	relapse	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
resumption	resumption	NOUN	NN	9	O
of	of	ADP	IN	5	O
sorafenib	sorafenib	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

Addition	addition	NOUN	NN	0	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
nicorandil	nicorandil	NOUN	NNS	0	B-Chemical
reduced	reduce	VERB	VBD	9	O
his	-PRON-	DET	PRP$	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
maintained	maintain	VERB	VBD	9	O
stable	stable	ADJ	JJ	9	B-Disease
angina	angina	NOUN	NN	5	I-Disease
status	status	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
sorafenib	sorafenib	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
spasm	spasm	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Sorafenib	Sorafenib	PROPN	NNP	3	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
multikinase	multikinase	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
that	that	DET	WDT	5	O
targets	target	VERB	VBZ	9	O
signaling	signal	VERB	VBG	3	O
pathways	pathway	NOUN	NNS	9	O
necessary	necessary	ADJ	JJ	5	O
for	for	ADP	IN	5	O
cellular	cellular	ADJ	JJ	3	O
proliferation	proliferation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
survival	survival	NOUN	NN	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
Rho	Rho	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
ROCK	ROCK	PROPN	NNP	3	O
pathway	pathway	NOUN	NN	3	O
has	have	VERB	VBZ	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
spasm	spasm	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
report	report	NOUN	NN	5	O
may	may	VERB	MD	5	O
show	show	VERB	VB	9	O
an	an	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
Rho	Rho	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
ROCK	ROCK	PROPN	NNP	3	O
pathway	pathway	NOUN	NN	3	O
by	by	ADP	IN	9	O
sorafenib	sorafenib	ADJ	JJ	3	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
novel	novel	ADJ	JJ	9	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
delivery	delivery	NOUN	NN	5	O
system	system	NOUN	NN	5	O
to	to	PART	TO	5	O
promote	promote	VERB	VB	3	O
the	the	DET	DT	5	O
passage	passage	NOUN	NN	9	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
BBB	BBB	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
investigation	investigation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
explore	explore	VERB	VB	5	O
the	the	DET	DT	5	O
potentiality	potentiality	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
delivery	delivery	NOUN	NN	5	O
system	system	NOUN	NN	5	O
to	to	PART	TO	5	O
promote	promote	VERB	VB	3	O
the	the	DET	DT	5	O
passage	passage	NOUN	NN	9	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BBB	BBB	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
localization	localization	NOUN	NN	3	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
bioactive	bioactive	ADJ	JJ	0	O
compound	compound	NOUN	NN	0	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
Tween	Tween	PROPN	NNP	0	O
80	80	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
coated	coat	VERB	VBN	0	O
poly	poly	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
L	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lactid	lactid	NOUN	NN	_	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
nanoparticles	nanoparticle	NOUN	NNS	0	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
colloidal	colloidal	ADJ	JJ	0	O
drug	drug	NOUN	NN	5	O
delivery	delivery	NOUN	NN	5	O
system	system	NOUN	NN	5	O
,	,	PUNCT	,	9	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
trespass	trespass	VERB	VB	5	O
the	the	DET	DT	5	O
BBB	BBB	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Tacrine	Tacrine	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
LiCl	LiCl	PROPN	NNP	0	B-Chemical
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treated	treated	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
induces	induce	VERB	VBZ	3	O
electrocorticographic	electrocorticographic	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
delayed	delay	VERB	VBD	9	O
hippocampal	hippocampal	ADJ	JJ	3	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
tacrine	tacrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
loaded	load	VERB	VBN	0	O
poly	poly	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
L	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lactid	lactid	NOUN	NN	_	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
nanoparticles	nanoparticle	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
5mg	5mg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
saline	saline	NOUN	NN	0	O
solution	solution	NOUN	NN	0	O
of	of	ADP	IN	5	O
tacrine	tacrine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5mg	5mg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
empty	empty	ADJ	JJ	3	O
colloidal	colloidal	ADJ	JJ	0	O
nanoparticle	nanoparticle	NOUN	NN	0	O
suspension	suspension	NOUN	NN	0	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
following	follow	VERB	VBG	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
LiCl	LiCl	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
pre	pre	PROPN	NNP	9	O
-	-	ADJ	JJ	7	O
treated	treated	ADJ	JJ	3	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

All	all	DET	PDT	9	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
tacrine	tacrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
loaded	load	VERB	VBN	0	O
nanoparticles	nanoparticle	NOUN	NNS	0	O
showed	show	VERB	VBD	9	O
an	an	DET	DT	5	O
earlier	early	ADJ	JJR	9	O
outcome	outcome	NOUN	NN	5	O
of	of	ADP	IN	5	O
CNS	CNS	PROPN	NNP	9	O
adverse	adverse	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
onset	onset	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
free	free	ADJ	JJ	9	O
compound	compound	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
min	min	NOUN	NN	0	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
22	22	NUM	CD	7	O
min	min	NOUN	NN	0	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
tacrine	tacrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
loaded	load	VERB	VBN	0	O
nanoparticles	nanoparticle	NOUN	NNS	0	O
administration	administration	NOUN	NN	9	O
induced	induce	VERB	VBD	3	O
damage	damage	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
neuronal	neuronal	ADJ	JJ	3	I-Disease
cells	cell	NOUN	NNS	3	I-Disease
in	in	ADP	IN	5	O
CA1	CA1	NOUN	NNS	3	O
field	field	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
saline	saline	NOUN	NN	0	O
solution	solution	NOUN	NN	0	O
of	of	ADP	IN	5	O
tacrine	tacrine	NOUN	NN	0	B-Chemical
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Empty	empty	ADJ	JJ	9	O
nanoparticles	nanoparticle	NOUN	NNS	0	O
provided	provide	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
(	(	PUNCT	-LRB-	9	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
)	)	PUNCT	-RRB-	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
neurodegenerative	neurodegenerative	ADJ	JJ	9	O
processes	process	NOUN	NNS	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
tacrine	tacrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
lithium	lithium	NOUN	NN	0	B-Chemical
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
,	,	PUNCT	,	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
preliminarily	preliminarily	ADV	RB	9	O
the	the	DET	DT	5	O
capability	capability	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
delivery	delivery	NOUN	NN	5	O
system	system	NOUN	NN	5	O
to	to	ADP	IN	5	O
trespass	trespass	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
or	or	CCONJ	CC	5	O
not	not	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
BBB	BBB	PROPN	NNP	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
tranexamic	tranexamic	NOUN	NN	0	B-Chemical
Acid	Acid	PROPN	NNP	0	I-Chemical
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
nonischemic	nonischemic	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
surgical	surgical	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
2	2	NUM	CD	9	O
separate	separate	ADJ	JJ	9	O
centers	center	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
observed	observe	VERB	VBD	9	O
a	a	DET	DT	5	O
notable	notable	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
seizures	seizure	NOUN	NNS	5	B-Disease
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
having	have	VERB	VBG	5	O
undergone	undergo	VERB	VBN	5	O
major	major	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
surgical	surgical	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
temporally	temporally	ADV	RB	5	O
coincident	coincident	ADJ	JJ	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
tranexamic	tranexamic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
TXA	TXA	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
therapy	therapy	NOUN	NN	5	O
after	after	ADP	IN	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
aprotinin	aprotinin	NOUN	NN	0	O
from	from	ADP	IN	9	O
general	general	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
usage	usage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
review	review	NOUN	NN	5	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
perform	perform	VERB	VB	5	O
a	a	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
relation	relation	NOUN	NN	5	O
between	between	ADP	IN	5	O
TXA	txa	NOUN	NN	5	B-Chemical
usage	usage	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
An	an	DET	DT	5	O
in	in	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
depth	depth	NOUN	NN	5	O
chart	chart	NOUN	NN	5	O
review	review	NOUN	NN	5	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
24	24	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
perioperative	perioperative	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Electroencephalographic	electroencephalographic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
formal	formal	ADJ	JJ	5	O
neurological	neurological	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
24	24	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
new	new	ADJ	JJ	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
ischemic	ischemic	ADJ	JJ	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
likely	likely	ADV	RB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
brain	brain	NOUN	NN	5	I-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
permanent	permanent	ADJ	JJ	5	O
neurological	neurological	ADJ	JJ	5	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
24	24	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
received	receive	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
TXA	TXA	PROPN	NNP	5	B-Chemical
intraoperatively	intraoperatively	ADV	RB	5	O
ranging	range	VERB	VBG	9	O
from	from	ADP	IN	9	O
61	61	NUM	CD	7	O
to	to	ADP	IN	5	O
259	259	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
69	69	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
21	21	NUM	CD	7	O
of	of	ADP	IN	5	O
24	24	NUM	CD	9	O
had	have	VERB	VBD	9	O
undergone	undergo	VERB	VBN	5	O
open	open	ADJ	JJ	5	O
chamber	chamber	NOUN	NN	9	O
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	O
bypass	bypass	NOUN	NN	5	O
procedures	procedure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
but	but	ADP	IN	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
were	be	VERB	VBD	9	O
managed	manage	VERB	VBN	5	O
using	use	VERB	VBG	9	O
cardiopulmonary	cardiopulmonary	ADJ	JJ	5	O
bypass	bypass	NOUN	NN	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
brain	brain	NOUN	NN	5	B-Disease
ischemic	ischemic	ADJ	JJ	9	I-Disease
,	,	PUNCT	,	9	O
metabolic	metabolic	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
hyperthermia	hyperthermia	ADV	RB	5	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
causes	cause	NOUN	NNS	9	O
for	for	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
apparent	apparent	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
TXA	txa	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
conjunction	conjunction	NOUN	NN	9	O
with	with	ADP	IN	5	O
cardiopulmonary	cardiopulmonary	ADJ	JJ	5	O
bypass	bypass	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
chamber	chamber	NOUN	NN	9	O
cardiac	cardiac	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
susceptible	susceptible	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Electrocardiographic	electrocardiographic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
psychotropic	psychotropic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
cardiac	cardiac	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
in	in	ADP	IN	5	O
five	five	NUM	CD	9	O
while	while	ADP	IN	9	O
taking	take	VERB	VBG	5	O
psychotropic	psychotropic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
either	either	CCONJ	CC	9	O
phenothiazines	phenothiazine	NOUN	NNS	0	B-Chemical
or	or	CCONJ	CC	5	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressants	antidepressant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
most	most	ADJ	JJS	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
several	several	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
Mellaril	Mellaril	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
thioridazine	thioridazine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
five	five	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
fatal	fatal	ADJ	JJ	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
35	35	NUM	CD	9	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Supraventricular	supraventricular	ADJ	JJ	7	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
developed	develop	VERB	VBD	5	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
receiving	receive	VERB	VBG	9	O
Thorazine	Thorazine	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
chlorpromazine	chlorpromazine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Aventyl	Aventyl	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
nortriptyline	nortriptyline	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Elavil	Elavil	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
amitriptyline	amitriptyline	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
each	each	DET	DT	5	O
produced	produce	VERB	VBD	9	O
left	leave	VERB	VBD	5	B-Disease
bundle	bundle	NOUN	NN	5	I-Disease
branch	branch	NOUN	NN	5	I-Disease
block	block	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
73	73	NUM	CD	7	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Electrocardiographic	Electrocardiographic	PROPN	NNP	5	O
T	T	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
U	u	NOUN	NN	9	O
wave	wave	NOUN	NN	5	O
abnormalities	abnormality	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
responded	respond	VERB	VBD	9	O
to	to	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
direct	direct	VERB	VB	9	O
current	current	ADJ	JJ	5	O
electric	electric	ADJ	JJ	5	O
shock	shock	NOUN	NN	9	O
;	;	PUNCT	:	9	O
ventricular	ventricular	ADJ	JJ	5	O
pacing	pacing	NOUN	NN	5	O
was	be	VERB	VBD	9	O
required	require	VERB	VBN	9	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
instances	instance	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	O
pacing	pacing	NOUN	NN	5	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
tachyarrhythmias	tachyarrhythmia	NOUN	NNS	5	B-Disease
generally	generally	ADV	RB	5	O
subsided	subside	VERB	VBD	5	O
within	within	ADP	IN	9	O
48	48	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
50	50	NUM	CD	0	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
younger	young	ADJ	JJR	5	O
;	;	PUNCT	:	9	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
clearly	clearly	ADV	RB	9	O
had	have	VERB	VBD	9	O
antecedent	antecedent	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Major	major	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
are	be	VERB	VBP	5	O
a	a	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
hazard	hazard	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
heart	heart	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
receiving	receive	VERB	VBG	9	O
customary	customary	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
psychotropic	psychotropic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
prospective	prospective	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
to	to	PART	TO	5	O
quantify	quantify	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
phenothiazines	phenothiazine	NOUN	NNS	0	B-Chemical
or	or	CCONJ	CC	5	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressant	antidepressant	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Sensitivity	sensitivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
erythroid	erythroid	ADJ	JJ	3	O
progenitor	progenitor	NOUN	NN	3	O
colonies	colony	NOUN	NNS	9	O
to	to	ADP	IN	5	O
erythropoietin	erythropoietin	NOUN	NN	9	O
in	in	ADP	IN	5	O
azidothymidine	azidothymidine	ADJ	JJ	0	B-Chemical
treated	treated	ADJ	JJ	3	O
immunodeficient	immunodeficient	NOUN	NN	3	B-Disease
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
anaemia	anaemia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
3	3	NUM	CD	9	B-Chemical
'	'	PART	POS	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
azido	azido	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
'	'	PART	POS	9	I-Chemical
dideoxythymidine	dideoxythymidine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
poorly	poorly	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
used	use	VERB	VBN	5	O
a	a	DET	DT	5	O
murine	murine	ADJ	JJ	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
infection	infection	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
female	female	ADJ	JJ	9	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
LP	LP	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
BM5	bm5	NOUN	NN	3	O
murine	murine	NOUN	NN	3	O
leukaemia	leukaemia	NOUN	NN	3	B-Disease
(	(	PUNCT	-LRB-	9	O
MuLV	MuLV	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
virus	virus	NOUN	NN	9	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anaemia	anaemia	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
due	due	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
part	part	NOUN	NN	9	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
decreased	decrease	VERB	VBN	9	O
responsiveness	responsiveness	NOUN	NN	9	O
of	of	ADP	IN	5	O
erythropoietic	erythropoietic	ADJ	JJ	3	O
precursors	precursor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
BFU	BFU	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
e	e	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
erythropoietin	erythropoietin	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
EPO	EPO	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Mice	mouse	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
of	of	ADP	IN	5	O
LP	LP	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
BM5	BM5	PROPN	NNP	3	O
MuLV	MuLV	PROPN	NNP	3	O
disease	disease	NOUN	NN	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
drinking	drinking	NOUN	NN	5	O
water	water	NOUN	NN	0	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

AZT	AZT	PROPN	NNP	0	B-Chemical
produced	produce	VERB	VBD	9	O
anaemia	anaemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
fashion	fashion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
the	the	DET	DT	5	O
anaemia	anaemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
splenic	splenic	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
BFU	BFU	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
e	e	PROPN	NNP	9	O
in	in	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
treated	treat	VERB	VBD	3	O
mice	mouse	NOUN	NNS	3	O
increased	increase	VERB	VBD	9	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
five	five	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
fold	fold	VERB	VB	9	O
over	over	ADP	IN	5	O
levels	level	NOUN	NNS	3	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
infected	infected	ADJ	JJ	3	O
untreated	untreated	ADJ	JJ	3	O
animals	animal	NOUN	NNS	9	O
after	after	ADP	IN	9	O
15	15	NUM	CD	9	O
d	d	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Colony	colony	NOUN	NN	9	O
formation	formation	NOUN	NN	9	O
by	by	ADP	IN	9	O
splenic	splenic	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
BFUe	BFUe	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
stimulated	stimulate	VERB	VBN	3	O
at	at	ADP	IN	9	O
lower	low	ADJ	JJR	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
EPO	EPO	PROPN	NNP	3	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
receiving	receive	VERB	VBG	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
for	for	ADP	IN	5	O
15	15	NUM	CD	9	O
d	d	NOUN	NN	9	O
than	than	ADP	IN	5	O
for	for	ADP	IN	5	O
infected	infect	VERB	VBN	3	O
,	,	PUNCT	,	9	O
untreated	untreated	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
day	day	NOUN	NN	9	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
sensitivity	sensitivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
splenic	splenic	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
BFU	BFU	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
e	e	PROPN	NNP	9	O
of	of	ADP	IN	5	O
treated	treated	ADJ	JJ	3	O
animals	animal	NOUN	NNS	9	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
observed	observe	VERB	VBD	9	O
from	from	ADP	IN	9	O
cells	cell	NOUN	NNS	3	O
of	of	ADP	IN	5	O
infected	infected	ADJ	JJ	3	O
untreated	untreated	ADJ	JJ	3	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
EPO	EPO	PROPN	NNP	3	O
observed	observe	VERB	VBD	9	O
in	in	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
treated	treat	VERB	VBD	3	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
appropriate	appropriate	ADJ	JJ	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
anaemia	anaemia	NOUN	NN	5	B-Disease
observed	observe	VERB	VBN	9	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
phenylhydrazine	phenylhydrazine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PHZ	PHZ	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
treated	treat	VERB	VBN	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
numbers	number	NOUN	NNS	9	O
of	of	ADP	IN	5	O
BFU	BFU	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
e	e	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
erythroblasts	erythroblast	NOUN	NNS	3	O
observed	observe	VERB	VBN	9	O
were	be	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
in	in	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
PHZ	PHZ	PROPN	NNP	3	B-Chemical
treated	treat	VERB	VBD	3	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
similar	similar	ADJ	JJ	9	O
degrees	degree	NOUN	NNS	5	O
of	of	ADP	IN	5	O
anaemia	anaemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
reticulocytosis	reticulocytosis	NOUN	NN	3	B-Disease
was	be	VERB	VBD	9	O
inappropriate	inappropriate	ADJ	JJ	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
anaemia	anaemia	NOUN	NN	5	B-Disease
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
treated	treat	VERB	VBD	3	O
infected	infected	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

AZT	AZT	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
peripheral	peripheral	ADJ	JJ	9	O
anaemia	anaemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
face	face	NOUN	NN	5	O
of	of	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
numbers	number	NOUN	NNS	9	O
of	of	ADP	IN	5	O
BFU	BFU	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
e	e	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
EPO	EPO	PROPN	NNP	3	O
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
lesion	lesion	NOUN	NN	5	O
in	in	ADP	IN	5	O
terminal	terminal	ADJ	JJ	9	O
differentiation	differentiation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Sedation	sedation	NOUN	NN	5	O
depth	depth	NOUN	NN	5	O
during	during	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
delirium	delirium	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
hip	hip	NOUN	NN	5	B-Disease
fracture	fracture	NOUN	NN	5	I-Disease
repair	repair	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
limiting	limit	VERB	VBG	9	O
intraoperative	intraoperative	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
depth	depth	NOUN	NN	5	O
during	during	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
for	for	ADP	IN	5	O
hip	hip	NOUN	NN	5	B-Disease
fracture	fracture	NOUN	NN	5	I-Disease
repair	repair	NOUN	NN	9	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
can	can	VERB	MD	5	O
decrease	decrease	VERB	VB	9	O
the	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
delirium	delirium	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
performed	perform	VERB	VBD	9	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBD	5	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
academic	academic	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
center	center	NOUN	NN	5	O
of	of	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
65	65	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
without	without	ADP	IN	9	O
preoperative	preoperative	ADJ	JJ	5	O
delirium	delirium	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
dementia	dementia	NOUN	NN	5	B-Disease
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
hip	hip	NOUN	NN	5	B-Disease
fracture	fracture	NOUN	NN	5	I-Disease
repair	repair	NOUN	NN	9	O
under	under	ADP	IN	9	O
spinal	spinal	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
with	with	ADP	IN	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
sedation	sedation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sedation	sedation	NOUN	NN	5	O
depth	depth	NOUN	NN	5	O
was	be	VERB	VBD	9	O
titrated	titrate	VERB	VBN	0	O
using	use	VERB	VBG	9	O
processed	process	VERB	VBN	9	O
electroencephalography	electroencephalography	NOUN	NN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
bispectral	bispectral	ADJ	JJ	5	O
index	index	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BIS	BIS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
either	either	CCONJ	CC	9	O
deep	deep	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
BIS	BIS	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
approximately	approximately	ADV	RB	9	O
50	50	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
light	light	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
BIS	BIS	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
80	80	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
sedation	sedation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Postoperative	postoperative	ADJ	JJ	5	B-Disease
delirium	delirium	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
as	as	ADP	IN	5	O
defined	define	VERB	VBN	5	O
by	by	ADP	IN	9	O
Diagnostic	Diagnostic	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Statistical	Statistical	PROPN	NNP	5	O
Manual	Manual	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Mental	Mental	PROPN	NNP	5	B-Disease
Disorders	Disorders	PROPN	NNP	2	I-Disease
(	(	PUNCT	-LRB-	9	O
Third	Third	PROPN	NNP	9	O
Edition	Edition	PROPN	NNP	2	O
Revised	Revised	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
criteria	criterion	NOUN	NNS	5	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
Confusion	Confusion	PROPN	NNP	5	O
Assessment	Assessment	PROPN	NNP	5	O
Method	Method	PROPN	NNP	5	O
beginning	begin	VERB	VBG	5	O
at	at	ADP	IN	9	O
any	any	DET	DT	5	O
time	time	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
From	from	ADP	IN	5	O
April	April	PROPN	NNP	2	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
2005	2005	NUM	CD	2	O
,	,	PUNCT	,	9	O
through	through	ADP	IN	9	O
October	October	PROPN	NNP	2	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
2008	2008	NUM	CD	2	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
114	114	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
delirium	delirium	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
light	light	ADJ	JJ	9	O
sedation	sedation	NOUN	NN	5	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
/	/	SYM	SYM	9	O
57	57	NUM	CD	7	O
[	[	PUNCT	-LRB-	9	O
19	19	NUM	CD	7	O
%	%	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
vs	vs	ADP	IN	7	O
23	23	NUM	CD	7	O
/	/	SYM	SYM	9	O
57	57	NUM	CD	7	O
[	[	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
deep	deep	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
group	group	NOUN	NN	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
1	1	NUM	CD	9	O
incident	incident	NOUN	NN	5	O
of	of	ADP	IN	5	O
delirium	delirium	NOUN	NN	5	B-Disease
will	will	VERB	MD	5	O
be	be	VERB	VB	5	O
prevented	prevent	VERB	VBN	9	O
for	for	ADP	IN	5	O
every	every	DET	DT	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
light	light	ADJ	JJ	9	O
sedation	sedation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
delirium	delirium	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
hospitalization	hospitalization	NOUN	NN	5	O
was	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
light	light	ADJ	JJ	9	O
sedation	sedation	NOUN	NN	5	O
group	group	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
deep	deep	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
vs	vs	ADP	IN	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
days	day	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	NOUN	NNS	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
light	light	ADJ	JJ	9	O
propofol	propofol	ADJ	JJ	0	B-Chemical
sedation	sedation	NOUN	NN	5	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
delirium	delirium	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
deep	deep	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Limiting	limit	VERB	VBG	5	O
depth	depth	NOUN	NN	5	O
of	of	ADP	IN	5	O
sedation	sedation	NOUN	NN	5	O
during	during	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
simple	simple	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
safe	safe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cost	cost	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effective	effective	ADJ	JJ	5	O
intervention	intervention	NOUN	NN	5	O
for	for	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
delirium	delirium	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
that	that	DET	WDT	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
widely	widely	ADV	RB	5	O
and	and	CCONJ	CC	5	O
readily	readily	ADV	RB	9	O
adopted	adopt	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
Nrf2	Nrf2	PROPN	NNP	3	O
in	in	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
reactive	reactive	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
species	specie	NOUN	NNS	4	O
(	(	PUNCT	-LRB-	9	O
ROS	ROS	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Nrf2	Nrf2	PROPN	NNP	3	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
transcription	transcription	NOUN	NN	1	O
factor	factor	NOUN	NN	9	O
that	that	DET	WDT	5	O
controls	control	VERB	VBZ	9	O
the	the	DET	DT	5	O
antioxidant	antioxidant	ADJ	JJ	0	O
response	response	NOUN	NN	9	O
essential	essential	ADJ	JJ	9	O
for	for	ADP	IN	5	O
maintaining	maintain	VERB	VBG	9	O
cellular	cellular	ADJ	JJ	3	O
redox	redox	NOUN	NN	0	O
homeostasis	homeostasis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
report	report	VERB	VBP	5	O
our	-PRON-	DET	PRP$	5	O
findings	finding	NOUN	NNS	9	O
demonstrating	demonstrate	VERB	VBG	9	O
a	a	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
Nrf2	Nrf2	PROPN	NNP	3	O
against	against	ADP	IN	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

RESEARCH	research	NOUN	NN	2	O
DESIGN	DESIGN	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
explore	explore	VERB	VBP	5	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
Nrf2	Nrf2	PROPN	NNP	3	O
against	against	ADP	IN	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
using	use	VERB	VBG	9	O
human	human	ADJ	JJ	3	O
kidney	kidney	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
tissues	tissue	NOUN	NNS	9	O
from	from	ADP	IN	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
streptozotocin	streptozotocin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	ADJ	JJ	9	I-Disease
model	model	NOUN	NN	5	O
in	in	ADP	IN	5	O
Nrf2	Nrf2	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cultured	culture	VERB	VBN	3	O
human	human	ADJ	JJ	3	O
mesangial	mesangial	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
glomeruli	glomeruli	NOUN	NN	9	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
under	under	ADP	IN	9	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
Nrf2	Nrf2	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
animal	animal	NOUN	NN	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
Nrf2	Nrf2	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
demonstrated	demonstrate	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
crucial	crucial	ADJ	JJ	9	O
in	in	ADP	IN	5	O
ameliorating	ameliorate	VERB	VBG	9	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
evident	evident	ADJ	JJ	9	O
by	by	ADP	IN	9	O
Nrf2	Nrf2	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
having	have	VERB	VBG	5	O
higher	high	ADJ	JJR	9	O
ROS	ROS	PROPN	NNP	3	O
production	production	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
greater	great	ADJ	JJR	5	O
oxidative	oxidative	ADJ	JJ	9	O
DNA	dna	NOUN	NN	9	O
damage	damage	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
Nrf2	Nrf2	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
+	+	X	XX	9	O
/	/	SYM	SYM	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Mechanistic	mechanistic	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
systems	system	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
Nrf2	nrf2	ADV	RB	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
protection	protection	NOUN	NN	9	O
against	against	ADP	IN	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
,	,	PUNCT	,	9	O
partially	partially	ADV	RB	9	O
through	through	ADP	IN	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
transforming	transform	VERB	VBG	9	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
beta1	beta1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
TGF	TGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
beta1	beta1	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
extracellular	extracellular	ADJ	JJ	9	O
matrix	matrix	NOUN	NN	5	O
production	production	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
human	human	ADJ	JJ	3	O
renal	renal	ADJ	JJ	9	O
mesangial	mesangial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBD	3	O
ROS	ROS	PROPN	NNP	3	O
production	production	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
activated	activate	VERB	VBN	3	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
Nrf2	Nrf2	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
downstream	downstream	ADJ	JJ	1	O
genes	gene	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
activation	activation	NOUN	NN	3	O
or	or	CCONJ	CC	5	O
overexpression	overexpression	NOUN	NN	3	O
of	of	ADP	IN	5	O
Nrf2	Nrf2	PROPN	NNP	3	O
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
promoter	promoter	NOUN	NN	1	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
TGF	TGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
beta1	beta1	PROPN	NNP	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
knockdown	knockdown	NOUN	NN	3	O
of	of	ADP	IN	5	O
Nrf2	Nrf2	PROPN	NNP	3	O
by	by	ADP	IN	9	O
siRNA	siRNA	PROPN	NNP	3	O
enhanced	enhance	VERB	VBD	3	O
TGF	TGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
beta1	beta1	NOUN	NN	3	O
transcription	transcription	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
fibronectin	fibronectin	NOUN	NN	3	O
production	production	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
work	work	NOUN	NN	5	O
clearly	clearly	ADV	RB	9	O
indicates	indicate	VERB	VBZ	9	O
a	a	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
Nrf2	Nrf2	PROPN	NNP	3	O
in	in	ADP	IN	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
dietary	dietary	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
Nrf2	Nrf2	PROPN	NNP	3	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
strategy	strategy	NOUN	NN	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
or	or	CCONJ	CC	5	O
slow	slow	VERB	VB	5	O
down	down	PART	RP	9	O
the	the	DET	DT	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Metformin	metformin	NOUN	NN	0	B-Chemical
prevents	prevent	VERB	VBZ	9	O
experimental	experimental	ADJ	JJ	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
mitochondria	mitochondria	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
antidiabetic	antidiabetic	ADJ	JJ	0	O
drug	drug	NOUN	NN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
can	can	VERB	MD	5	O
diminish	diminish	VERB	VB	9	O
apoptosis	apoptosis	NOUN	NN	3	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
in	in	ADP	IN	5	O
endothelial	endothelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
prevent	prevent	VERB	VB	5	O
vascular	vascular	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
even	even	ADV	RB	5	O
in	in	ADP	IN	5	O
nondiabetic	nondiabetic	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
tested	test	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Mitochondrial	mitochondrial	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respiration	respiration	NOUN	NN	9	O
intensity	intensity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
reactive	reactive	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
species	specie	NOUN	NNS	4	O
,	,	PUNCT	,	9	O
permeability	permeability	NOUN	NN	0	O
transition	transition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cytochrome	cytochrome	ADJ	JJ	0	O
c	c	DET	DT	9	O
release	release	NOUN	NN	9	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Metformin	metformin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
fully	fully	ADV	RB	9	O
blocked	block	VERB	VBD	3	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
acetyl	acetyl	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
D	d	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glucosaminidase	glucosaminidase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
antioxidant	antioxidant	ADJ	JJ	0	O
systems	system	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Metformin	Metformin	PROPN	NNP	0	B-Chemical
also	also	ADV	RB	9	O
protected	protect	VERB	VBD	9	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
from	from	ADP	IN	9	O
histological	histological	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
6	6	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
markers	marker	NOUN	NNS	3	O
of	of	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
correction	correction	NOUN	NN	5	O
by	by	ADP	IN	9	O
metformin	metformin	NOUN	NN	3	B-Chemical
were	be	VERB	VBD	9	O
complemented	complement	VERB	VBN	1	O
by	by	ADP	IN	9	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
depleted	deplete	VERB	VBD	3	O
respiratory	respiratory	ADJ	JJ	5	O
components	component	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
cytochrome	cytochrome	ADJ	JJ	0	O
c	c	NOUN	NN	9	O
,	,	PUNCT	,	9	O
NADH	NADH	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
probably	probably	ADV	RB	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
opening	opening	NOUN	NN	5	O
of	of	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
transition	transition	NOUN	NN	9	O
pores	pore	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
injuries	injury	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
partly	partly	ADV	RB	9	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
reactive	reactive	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
species	specie	NOUN	NNS	4	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
electron	electron	NOUN	NN	0	O
transfer	transfer	NOUN	NN	9	O
chain	chain	NOUN	NN	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
by	by	ADP	IN	9	O
metformin	metformin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
our	-PRON-	DET	PRP$	5	O
study	study	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
pleiotropic	pleiotropic	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
metformin	metformin	NOUN	NN	3	B-Chemical
can	can	VERB	MD	5	O
lessen	lessen	VERB	VB	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
improve	improve	VERB	VB	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
homeostasis	homeostasis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
consumption	consumption	NOUN	NN	5	O
of	of	ADP	IN	5	O
nonionic	nonionic	ADJ	JJ	0	O
contrast	contrast	NOUN	NN	9	B-Chemical
media	medium	NOUN	NNS	9	I-Chemical
by	by	ADP	IN	9	O
children	child	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
cardiac	cardiac	ADJ	JJ	5	O
angiography	angiography	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
reports	report	NOUN	NNS	9	O
on	on	ADP	IN	5	O
nonionic	nonionic	ADJ	JJ	0	O
contrast	contrast	NOUN	NN	9	B-Chemical
media	medium	NOUN	NNS	9	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
CIN	CIN	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
hospitalized	hospitalize	VERB	VBN	5	O
adult	adult	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
during	during	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
studies	study	NOUN	NNS	9	O
in	in	ADP	IN	5	O
pediatrics	pediatric	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
limited	limit	VERB	VBN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
even	even	ADV	RB	5	O
less	less	ADJ	JJR	5	O
focus	focus	NOUN	NN	5	O
on	on	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
predisposing	predispose	VERB	VBG	5	O
factors	factor	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
preventive	preventive	ADJ	JJ	5	O
measures	measure	NOUN	NNS	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
cardiac	cardiac	ADJ	JJ	5	O
angiography	angiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
determined	determine	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
CIN	CIN	PROPN	NNP	9	B-Disease
for	for	ADP	IN	5	O
two	two	NUM	CD	5	O
nonionic	nonionic	ADJ	JJ	0	O
contrast	contrast	NOUN	NN	9	B-Chemical
media	medium	NOUN	NNS	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
CM	CM	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
iopromide	iopromide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
among	among	ADP	IN	5	O
80	80	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
younger	young	ADJ	JJR	5	O
than	than	ADP	IN	5	O
18	18	NUM	CD	7	O
years	year	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBD	9	O
the	the	DET	DT	5	O
rates	rate	NOUN	NNS	5	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
in	in	ADP	IN	5	O
relation	relation	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
type	type	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
CM	CM	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyanosis	cyanosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
80	80	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
consecutively	consecutively	ADV	RB	5	O
received	receive	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
iopromide	iopromide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
A	A	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
40	40	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
B	B	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
40	40	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Na	Na	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
K	K	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
creatinine	creatinine	VERB	VB	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Cr	Cr	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NNS	0	O
before	before	ADV	RB	9	O
angiography	angiography	NOUN	NN	5	O
as	as	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
values	value	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
then	then	ADV	RB	9	O
measured	measure	VERB	VBN	9	O
again	again	ADV	RB	9	O
at	at	ADP	IN	9	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
48	48	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
h	h	NOUN	NN	0	O
intervals	interval	NOUN	NNS	5	O
after	after	ADP	IN	9	O
CM	CM	PROPN	NNP	9	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Urine	urine	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
for	for	ADP	IN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
Cr	Cr	PROPN	NNP	0	B-Chemical
also	also	ADV	RB	9	O
were	be	VERB	VBD	9	O
checked	check	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
intervals	interval	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
Injury	Injury	PROPN	NNP	5	B-Disease
to	to	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
kidney	kidney	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
Failure	failure	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
kidney	kidney	NOUN	NN	9	I-Disease
function	function	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
Loss	Loss	PROPN	NNP	9	B-Disease
of	of	ADP	IN	5	I-Disease
kidney	kidney	NOUN	NN	9	I-Disease
function	function	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
End	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
stage	stage	NOUN	NN	9	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
RIFLE	rifle	NOUN	NN	5	O
criteria	criterion	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
define	define	VERB	VB	5	O
CIN	CIN	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
incidence	incidence	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Accordingly	accordingly	ADV	RB	9	O
,	,	PUNCT	,	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
15	15	NUM	CD	9	O
CIN	CIN	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
A	A	PROPN	NNP	9	O
had	have	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
had	have	VERB	VBD	9	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
group	group	NOUN	NN	9	O
B	B	PROPN	NNP	9	O
had	have	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
had	have	VERB	VBD	9	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Whereas	whereas	ADP	IN	9	O
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
CIN	CIN	PROPN	NNP	9	B-Disease
were	be	VERB	VBD	9	O
among	among	ADP	IN	5	O
those	those	DET	DT	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
the	the	DET	DT	5	O
proper	proper	ADJ	JJ	5	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
CM	CM	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
to	to	ADP	IN	5	O
66	66	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
among	among	ADP	IN	5	O
those	those	DET	DT	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
larger	large	ADJ	JJR	5	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
CIN	CIN	PROPN	NNP	9	B-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
different	different	ADJ	JJ	9	O
dosages	dosage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CM	CM	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
014	014	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
the	the	DET	DT	5	O
15	15	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
CIN	CIN	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
had	have	VERB	VBD	9	O
cyanotic	cyanotic	ADJ	JJ	5	O
congenital	congenital	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
diseases	disease	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
from	from	ADP	IN	9	O
that	that	DET	DT	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
noncyanotic	noncyanotic	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
243	243	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
clinically	clinically	ADV	RB	5	O
silent	silent	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
CIN	CIN	PROPN	NNP	9	B-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
rare	rare	ADJ	JJ	5	O
in	in	ADP	IN	5	O
pediatrics	pediatric	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
depends	depend	VERB	VBZ	5	O
on	on	ADP	IN	5	O
dosage	dosage	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
consumed	consume	VERB	VBN	5	O
nonionic	nonionic	ADJ	JJ	0	O
CM	CM	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
nor	nor	CCONJ	CC	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyanosis	cyanosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
although	although	ADP	IN	9	O
CIN	CIN	PROPN	NNP	9	B-Disease
usually	usually	ADV	RB	5	O
is	be	VERB	VBZ	5	O
reversible	reversible	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
more	more	ADJ	JJR	5	O
concern	concern	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
needed	need	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
such	such	DET	PDT	5	O
a	a	DET	DT	5	O
complication	complication	NOUN	NN	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
hemodynamics	hemodynamic	NOUN	NNS	5	O
during	during	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
20	20	NUM	CD	9	O
human	human	ADJ	JJ	3	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Glomerular	glomerular	ADJ	JJ	9	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
GFR	GFR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
effective	effective	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ERPF	ERPF	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
inulin	inulin	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
para	para	NOUN	NN	2	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminohippurate	aminohippurate	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
PAH	PAH	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
clearance	clearance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Anesthesia	Anesthesia	PROPN	NNP	2	O
was	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
with	with	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
nitrous	nitrous	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Hypotension	hypotension	NOUN	NN	7	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
for	for	ADP	IN	5	O
236	236	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
min	min	NOUN	NN	0	O
by	by	ADP	IN	9	O
increasing	increase	VERB	VBG	9	O
the	the	DET	DT	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
inspired	inspire	VERB	VBN	5	O
concentration	concentration	NOUN	NN	0	O
to	to	PART	TO	5	O
maintain	maintain	VERB	VB	5	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
of	of	ADP	IN	5	O
59	59	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
mmHg	mmhg	SYM	SYM	7	O
.	.	PUNCT	.	9	O

GFR	GFR	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
ERPF	ERPF	PROPN	NNP	0	O
decreased	decrease	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anesthesia	anesthesia	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
during	during	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Postoperatively	postoperatively	ADV	RB	5	O
,	,	PUNCT	,	9	O
ERPF	ERPF	PROPN	NNP	0	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
preoperative	preoperative	ADJ	JJ	5	O
values	value	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
GFR	GFR	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
preoperative	preoperative	ADJ	JJ	5	O
values	value	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
during	during	ADP	IN	5	O
anesthesia	anesthesia	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
decreased	decrease	VERB	VBD	9	O
when	when	ADV	WRB	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
,	,	PUNCT	,	9	O
allowing	allow	VERB	VBG	5	O
the	the	DET	DT	5	O
maintenance	maintenance	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
compensatory	compensatory	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
preserved	preserve	VERB	VBN	9	O
during	during	ADP	IN	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
hemodynamics	hemodynamic	NOUN	NNS	5	O
quickly	quickly	ADV	RB	5	O
return	return	VERB	VB	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
when	when	ADV	WRB	5	O
normotension	normotension	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
resumed	resume	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Brainstem	Brainstem	PROPN	NNP	5	B-Disease
dysgenesis	dysgenesis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
infant	infant	NOUN	NN	5	O
prenatally	prenatally	ADV	RB	5	O
exposed	expose	VERB	VBN	9	O
to	to	PART	TO	5	O
cocaine	cocaine	VERB	VB	5	B-Chemical
.	.	PUNCT	.	9	O

Many	many	ADJ	JJ	5	O
authors	author	NOUN	NNS	5	O
described	describe	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
fetus	fetus	NOUN	NN	5	O
of	of	ADP	IN	5	O
maternal	maternal	ADJ	JJ	9	O
cocaine	cocaine	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Vasoconstriction	vasoconstriction	NOUN	NN	5	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
common	common	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
wide	wide	ADJ	JJ	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
fetal	fetal	ADJ	JJ	9	B-Disease
anomalies	anomaly	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
on	on	ADP	IN	5	O
an	an	DET	DT	5	O
infant	infant	NOUN	NN	5	O
with	with	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	B-Disease
cranial	cranial	ADJ	JJ	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
nerve	nerve	NOUN	NN	5	I-Disease
involvement	involvement	NOUN	NN	9	I-Disease
attributable	attributable	ADJ	JJ	9	O
to	to	PART	TO	5	O
brainstem	brainstem	VERB	VB	5	B-Disease
dysgenesis	dysgenesis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
born	bear	VERB	VBN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
cocaine	cocaine	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
addicted	addict	VERB	VBN	5	I-Disease
mother	mother	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
sectional	sectional	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
selective	selective	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
on	on	ADP	IN	5	O
bone	bone	NOUN	NN	5	O
mineral	mineral	NOUN	NN	0	O
density	density	NOUN	NN	9	O
in	in	ADP	IN	5	O
boys	boy	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
trabecular	trabecular	ADJ	JJ	5	O
bone	bone	NOUN	NN	5	O
mineral	mineral	NOUN	NN	0	O
density	density	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
BMD	BMD	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
adolescents	adolescent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Medically	medically	ADV	RB	5	O
healthy	healthy	ADJ	JJ	5	O
7	7	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
17	17	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
males	male	NOUN	NNS	9	O
chronically	chronically	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
naturalistic	naturalistic	ADJ	JJ	5	O
setting	setting	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
recruited	recruit	VERB	VBN	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
sectional	sectional	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
through	through	ADP	IN	9	O
child	child	NOUN	NN	5	O
psychiatry	psychiatry	NOUN	NN	5	O
outpatient	outpatient	NOUN	NN	5	O
clinics	clinic	NOUN	NNS	5	O
between	between	ADP	IN	5	O
November	November	PROPN	NNP	2	O
2005	2005	NUM	CD	2	O
and	and	CCONJ	CC	5	O
June	June	PROPN	NNP	2	O
2007	2007	NUM	CD	2	O
.	.	PUNCT	.	9	O

Anthropometric	anthropometric	ADJ	JJ	5	O
measurements	measurement	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
testing	testing	NOUN	NN	5	O
were	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
diagnoses	diagnosis	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
chart	chart	NOUN	NN	5	O
review	review	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
developmental	developmental	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
history	history	NOUN	NN	5	O
was	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
record	record	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Volumetric	Volumetric	PROPN	NNP	5	O
BMD	BMD	PROPN	NNP	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ultradistal	ultradistal	ADJ	JJ	5	O
radius	radius	NOUN	NN	5	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
using	use	VERB	VBG	9	O
peripheral	peripheral	ADJ	JJ	9	O
quantitative	quantitative	ADJ	JJ	9	O
computed	computed	ADJ	JJ	5	O
tomography	tomography	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
areal	areal	ADJ	JJ	5	O
BMD	BMD	PROPN	NNP	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lumbar	lumbar	ADJ	JJ	5	O
spine	spine	NOUN	NN	5	O
was	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
using	use	VERB	VBG	9	O
dual	dual	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
energy	energy	NOUN	NN	5	O
x	x	NOUN	NNS	9	O
-	-	PUNCT	HYPH	7	O
ray	ray	NOUN	NN	5	O
absorptiometry	absorptiometry	NOUN	NN	0	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Hyperprolactinemia	Hyperprolactinemia	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
49	49	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
83	83	NUM	CD	7	O
boys	boy	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
41	41	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
mean	mean	NOUN	NN	5	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
concentration	concentration	NOUN	NN	0	O
increased	increase	VERB	VBD	9	O
with	with	ADP	IN	5	O
pubertal	pubertal	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
expected	expect	VERB	VBN	9	O
,	,	PUNCT	,	9	O
bone	bone	NOUN	NN	5	O
mineral	mineral	NOUN	NN	0	O
content	content	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
BMD	BMD	PROPN	NNP	5	O
increased	increase	VERB	VBD	9	O
with	with	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
maturity	maturity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
adjusting	adjust	VERB	VBG	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
stage	stage	NOUN	NN	9	O
of	of	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
development	development	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
height	height	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
BMI	BMI	PROPN	NNP	5	O
z	z	PROPN	NNP	9	O
scores	score	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
serum	serum	NOUN	NN	9	O
prolactin	prolactin	NOUN	NN	3	O
was	be	VERB	VBD	9	O
negatively	negatively	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
trabecular	trabecular	ADJ	JJ	5	O
volumetric	volumetric	ADJ	JJ	5	O
BMD	BMD	PROPN	NNP	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
ultradistal	ultradistal	ADJ	JJ	5	O
radius	radius	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Controlling	control	VERB	VBG	5	O
for	for	ADP	IN	5	O
relevant	relevant	ADJ	JJ	5	O
covariates	covariate	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
found	find	VERB	VBD	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
SSRIs	ssri	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
lower	low	ADJ	JJR	9	O
trabecular	trabecular	ADJ	JJ	5	O
BMD	BMD	PROPN	NNP	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
radius	radius	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
BMD	BMD	PROPN	NNP	5	O
z	z	X	XX	9	O
score	score	NOUN	NN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
lumbar	lumbar	ADJ	JJ	5	O
spine	spine	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
became	become	VERB	VBD	9	O
more	more	ADV	RBR	5	O
marked	marked	ADJ	JJ	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
restricted	restrict	VERB	VBN	9	O
to	to	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
Hispanic	hispanic	ADJ	JJ	7	O
white	white	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
13	13	NUM	CD	7	O
documented	document	VERB	VBN	9	O
fractures	fracture	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
SSRIs	SSRIs	PROPN	NNPS	5	O
were	be	VERB	VBD	9	O
started	start	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
none	none	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
link	link	VERB	VB	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
SSRI	SSRI	PROPN	NNP	5	O
treatment	treatment	NOUN	NN	9	O
to	to	PART	TO	5	O
lower	lower	VERB	VB	9	O
BMD	BMD	PROPN	NNP	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
adolescents	adolescent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Future	future	ADJ	JJ	5	O
research	research	NOUN	NN	5	O
should	should	VERB	MD	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
longitudinal	longitudinal	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
its	-PRON-	DET	PRP$	9	O
temporal	temporal	ADJ	JJ	5	O
stability	stability	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
whether	whether	ADP	IN	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
fracture	fracture	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
ensues	ensue	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Fear	fear	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
potentiated	potentiate	VERB	VBN	3	O
startle	startle	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
light	light	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
enhanced	enhance	VERB	VBN	3	O
startle	startle	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
enhanced	enhance	VERB	VBN	3	O
by	by	ADP	IN	9	O
anxiogenic	anxiogenic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RATIONALE	RATIONALE	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
light	light	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
enhanced	enhance	VERB	VBN	3	O
startle	startle	ADJ	JJ	5	B-Disease
paradigm	paradigm	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
LES	LES	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
to	to	PART	TO	5	O
model	model	VERB	VB	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
specific	specific	ADJ	JJ	9	O
cue	cue	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
fear	fear	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
potentiated	potentiate	VERB	VBN	3	O
startle	startle	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
FPS	FPS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
to	to	PART	TO	5	O
model	model	VERB	VB	5	O
conditioned	condition	VERB	VBN	9	O
fear	fear	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
profiles	profile	NOUN	NNS	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
paradigms	paradigms	NOUN	NN	5	O
are	be	VERB	VBP	5	O
very	very	ADV	RB	5	O
similar	similar	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
putative	putative	ADJ	JJ	1	O
anxiogenic	anxiogenic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
on	on	ADP	IN	5	O
LES	LES	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
FPS	FPS	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
aimed	aim	VERB	VBN	5	O
at	at	ADP	IN	9	O
determining	determine	VERB	VBG	9	O
the	the	DET	DT	5	O
sensitivity	sensitivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
LES	LES	PROPN	NNP	9	O
for	for	ADP	IN	5	O
anxiogenic	anxiogenic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
potentially	potentially	ADV	RB	5	O
showing	show	VERB	VBG	9	O
a	a	DET	DT	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
differentiation	differentiation	NOUN	NN	3	O
between	between	ADP	IN	5	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
paradigms	paradigms	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Male	Male	PROPN	NNP	7	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
each	each	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
antagonist	antagonist	NOUN	NN	3	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0mg	0mg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
2C	2C	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
m	m	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chlorophenylpiperazine	chlorophenylpiperazine	NOUN	NN	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
mCPP	mCPP	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0mg	0mg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	A	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
inverse	inverse	ADJ	JJ	5	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
pentylenetetrazole	pentylenetetrazole	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PTZ	PTZ	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
30mg	30mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
subsequently	subsequently	ADV	RB	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
either	either	DET	DT	9	O
LES	LES	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
FPS	FPS	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
enhanced	enhance	VERB	VBN	3	O
LES	LES	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
mCPP	mCPP	PROPN	NNP	0	B-Chemical
increased	increase	VERB	VBD	9	O
percentage	percentage	NOUN	NN	9	O
FPS	FPS	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
increased	increase	VERB	VBD	9	O
absolute	absolute	ADJ	JJ	5	O
FPS	FPS	PROPN	NNP	5	O
values	value	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
increased	increase	VERB	VBD	9	O
baseline	baseline	ADJ	JJ	5	O
startle	startle	NOUN	NN	5	B-Disease
amplitude	amplitude	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
LES	LES	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
mCPP	mCPP	PROPN	NNP	0	B-Chemical
suppressed	suppress	VERB	VBD	3	O
baseline	baseline	NOUN	NN	5	O
startle	startle	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
LES	LES	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
FPS	FPS	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
PTZ	PTZ	PROPN	NNP	0	B-Chemical
suppressed	suppress	VERB	VBD	3	O
baseline	baseline	NOUN	NN	5	O
startle	startle	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
FPS	FPS	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
findings	finding	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
FPS	FPS	PROPN	NNP	5	O
paradigm	paradigm	NOUN	NN	5	O
,	,	PUNCT	,	9	O
none	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
exacerbate	exacerbate	VERB	VB	9	O
the	the	DET	DT	5	O
LES	LES	PROPN	NNP	9	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
clear	clear	ADJ	JJ	9	O
pharmacological	pharmacological	ADJ	JJ	9	O
differentiation	differentiation	NOUN	NN	3	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
between	between	ADP	IN	5	O
LES	LES	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
FPS	FPS	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Rosaceiform	rosaceiform	NOUN	NN	_	O
dermatitis	dermatitis	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
topical	topical	ADJ	JJ	0	O
tacrolimus	tacrolimus	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
herein	herein	NOUN	NN	9	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
rosacea	rosacea	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
dermatitis	dermatitis	ADJ	JJ	5	B-Disease
eruptions	eruption	NOUN	NNS	5	B-Disease
while	while	ADP	IN	9	O
using	use	VERB	VBG	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
%	%	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
ointment	ointment	NOUN	NN	0	O
for	for	ADP	IN	5	O
facial	facial	ADJ	JJ	5	B-Disease
dermatitis	dermatitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Skin	skin	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
specimens	specimen	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
telangiectasia	telangiectasia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
noncaseating	noncaseate	VERB	VBG	5	O
epithelioid	epithelioid	VERB	VB	3	O
granulomatous	granulomatous	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
formation	formation	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
papillary	papillary	NOUN	NN	5	O
to	to	ADP	IN	5	O
mid	mid	ADJ	JJ	9	O
dermis	dermis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Continuous	continuous	ADJ	JJ	5	O
topical	topical	ADJ	JJ	0	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
immunomodulators	immunomodulator	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
pimecrolimus	pimecrolimus	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
regarded	regard	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
rosaceiform	rosaceiform	NOUN	NN	_	O
dermatitis	dermatitis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
many	many	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Coenzyme	Coenzyme	PROPN	NNP	0	B-Chemical
Q10	Q10	PROPN	NNP	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
ameliorates	ameliorate	NOUN	NNS	3	O
acute	acute	ADJ	JJ	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
nephroprotective	nephroprotective	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
coenzyme	coenzyme	NOUN	NN	0	B-Chemical
Q10	Q10	PROPN	NNP	0	I-Chemical
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Coenzyme	Coenzyme	PROPN	NNP	0	B-Chemical
Q10	Q10	PROPN	NNP	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
applied	apply	VERB	VBN	5	O
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
starting	start	VERB	VBG	9	O
1	1	NUM	CD	9	O
day	day	NOUN	NN	9	O
before	before	ADP	IN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Coenzyme	Coenzyme	PROPN	NNP	0	B-Chemical
Q10	Q10	PROPN	NNP	0	I-Chemical
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
blood	blood	NOUN	NN	9	B-Chemical
urea	urea	ADJ	JJ	0	I-Chemical
nitrogen	nitrogen	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

Coenzyme	Coenzyme	PROPN	NNP	0	B-Chemical
Q10	Q10	PROPN	NNP	0	I-Chemical
significantly	significantly	ADV	RB	9	O
compensated	compensate	VERB	VBD	5	O
deficits	deficit	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
antioxidant	antioxidant	ADJ	JJ	0	O
defense	defense	NOUN	NN	5	O
mechanisms	mechanism	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
reduced	reduce	VERB	VBN	9	B-Chemical
glutathione	glutathione	ADJ	JJ	0	I-Chemical
level	level	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
dismutase	dismutase	NOUN	NN	0	O
activity	activity	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
suppressed	suppress	VERB	VBN	3	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
elevations	elevation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
necrosis	necrosis	NOUN	NN	9	B-Disease
factor	factor	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
alpha	alpha	NOUN	NN	9	O
,	,	PUNCT	,	9	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
platinum	platinum	NOUN	NN	0	B-Chemical
ion	ion	NOUN	NN	0	O
concentration	concentration	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
reductions	reduction	NOUN	NNS	9	O
of	of	ADP	IN	5	O
selenium	selenium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
zinc	zinc	NOUN	NN	9	B-Chemical
ions	ion	NOUN	NNS	0	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
from	from	ADP	IN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
,	,	PUNCT	,	9	O
histopathological	histopathological	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	B-Disease
tissue	tissue	NOUN	NN	9	I-Disease
damage	damage	NOUN	NN	9	I-Disease
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
was	be	VERB	VBD	9	O
ameliorated	ameliorate	VERB	VBN	9	O
by	by	ADP	IN	9	O
coenzyme	coenzyme	NOUN	NN	0	B-Chemical
Q10	Q10	PROPN	NNP	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Immunohistochemical	immunohistochemical	ADJ	JJ	3	O
analysis	analysis	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
coenzyme	coenzyme	NOUN	NN	0	B-Chemical
Q10	Q10	PROPN	NNP	0	I-Chemical
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
overexpression	overexpression	NOUN	NN	3	O
of	of	ADP	IN	5	O
inducible	inducible	ADJ	JJ	3	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
synthase	synthase	NOUN	NN	1	O
,	,	PUNCT	,	9	O
nuclear	nuclear	ADJ	JJ	3	O
factor	factor	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
kappaB	kappaB	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
caspase	caspase	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
p53	p53	NOUN	NN	3	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
coenzyme	coenzyme	NOUN	NN	0	B-Chemical
Q10	Q10	PROPN	NNP	0	I-Chemical
represents	represent	VERB	VBZ	9	O
a	a	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
option	option	NOUN	NN	5	O
to	to	PART	TO	5	O
protect	protect	VERB	VB	9	O
against	against	ADP	IN	9	O
acute	acute	ADJ	JJ	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
commonly	commonly	ADV	RB	5	O
encountered	encounter	VERB	VBN	5	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Reversible	reversible	ADJ	JJ	0	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
bile	bile	ADJ	JJ	0	B-Disease
duct	duct	NOUN	NN	5	I-Disease
injury	injury	NOUN	NN	9	I-Disease
following	follow	VERB	VBG	9	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
67	67	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
polymyositis	polymyositis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
previous	previous	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
developed	develop	VERB	VBD	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
biochemical	biochemical	ADJ	JJ	9	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
both	both	CCONJ	CC	9	O
cytological	cytological	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
architectural	architectural	ADJ	JJ	5	O
alterations	alteration	NOUN	NNS	9	O
of	of	ADP	IN	5	O
interlobular	interlobular	ADJ	JJ	5	O
bile	bile	NOUN	NN	0	O
ducts	duct	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Azathioprine	Azathioprine	PROPN	NNP	0	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
resulted	result	VERB	VBD	9	O
after	after	ADP	IN	9	O
7	7	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
biochemical	biochemical	ADJ	JJ	9	O
abnormalities	abnormality	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
believed	believe	VERB	VBN	5	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
reported	report	VERB	VBN	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
reversible	reversible	ADJ	JJ	9	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
histological	histological	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
bile	bile	ADJ	JJ	0	B-Disease
duct	duct	NOUN	NN	5	I-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Dopamine	dopamine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
essential	essential	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
widely	widely	ADV	RB	5	O
believed	believe	VERB	VBN	5	O
that	that	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
DA	DA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
mediates	mediate	VERB	VBZ	3	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
METH	METH	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
toxicity	toxicity	NOUN	NN	9	B-Disease
to	to	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
interfere	interfere	VERB	VBP	9	O
with	with	ADP	IN	5	O
DA	DA	PROPN	NNP	9	B-Chemical
neurotransmission	neurotransmission	NOUN	NN	5	O
decrease	decrease	NOUN	NN	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
increase	increase	VERB	VBP	9	O
DA	DA	PROPN	NNP	9	B-Chemical
neurotransmission	neurotransmission	NOUN	NN	5	O
enhance	enhance	VERB	VB	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
temperature	temperature	NOUN	NN	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
manipulate	manipulate	VERB	VB	5	O
brain	brain	NOUN	NN	5	O
DA	DA	PROPN	NNP	9	B-Chemical
neurotransmission	neurotransmission	NOUN	NN	5	O
confound	confound	NOUN	NN	5	O
interpretation	interpretation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
recently	recently	ADV	RB	9	O
reported	report	VERB	VBN	9	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroxyphenylalanine	dihydroxyphenylalanine	NOUN	NN	0	I-Chemical
to	to	PART	TO	5	O
reverse	reverse	VERB	VB	9	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
para	para	NOUN	NN	2	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tyrosine	tyrosine	NOUN	NN	3	I-Chemical
on	on	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
DA	DA	PROPN	NNP	9	B-Chemical
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
also	also	ADV	RB	9	O
confounded	confound	VERB	VBN	5	O
by	by	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
body	body	NOUN	NN	5	O
temperature	temperature	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Further	further	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
genetically	genetically	ADV	RB	9	O
engineered	engineer	VERB	VBN	3	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
deficient	deficient	ADJ	JJ	3	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
DA	DA	PROPN	NNP	9	B-Chemical
develop	develop	VERB	VB	5	O
METH	METH	PROPN	NNP	9	B-Chemical
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
long	long	ADV	RB	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
thermic	thermic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
are	be	VERB	VBP	5	O
preserved	preserve	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
genetically	genetically	ADV	RB	9	O
engineered	engineer	VERB	VBN	3	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
unilateral	unilateral	ADJ	JJ	5	O
brain	brain	NOUN	NN	5	O
DA	DA	PROPN	NNP	9	B-Chemical
deficits	deficit	NOUN	NNS	5	O
develop	develop	VERB	VBP	5	O
METH	METH	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dopaminergic	dopaminergic	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
of	of	ADP	IN	5	O
comparable	comparable	ADJ	JJ	9	O
magnitude	magnitude	NOUN	NN	5	O
on	on	ADP	IN	5	O
both	both	DET	DT	9	O
sides	side	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Taken	take	VERB	VBN	9	O
together	together	ADV	RB	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
DA	DA	PROPN	NNP	9	B-Chemical
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
essential	essential	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
mechanisms	mechanism	NOUN	NNS	9	O
independent	independent	ADJ	JJ	9	O
of	of	ADP	IN	5	O
DA	DA	PROPN	NNP	9	B-Chemical
warrant	warrant	VERB	VBP	9	O
more	more	ADV	RBR	5	O
intense	intense	ADJ	JJ	9	O
investigation	investigation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Swallowing	swallow	VERB	VBG	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
atrial	atrial	ADJ	JJ	5	B-Disease
tachyarrhythmia	tachyarrhythmia	NOUN	NN	5	I-Disease
triggered	trigger	VERB	VBN	9	O
by	by	ADP	IN	9	O
salbutamol	salbutamol	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
49	49	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
experienced	experience	VERB	VBD	5	O
chest	chest	NOUN	NN	5	O
discomfort	discomfort	NOUN	NN	5	O
while	while	ADP	IN	9	O
swallowing	swallow	VERB	VBG	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
,	,	PUNCT	,	9	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
tachyarrhythmia	tachyarrhythmia	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
swallowing	swallow	VERB	VBG	5	O
;	;	PUNCT	:	9	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
Holter	holter	NOUN	NN	5	O
monitoring	monitoring	NOUN	NN	5	O
recorded	record	VERB	VBD	5	O
several	several	ADJ	JJ	9	O
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
resolved	resolve	VERB	VBD	9	O
after	after	ADP	IN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
atenolol	atenolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
recurred	recur	VERB	VBD	5	O
a	a	DET	DT	5	O
year	year	NOUN	NN	5	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
noticed	notice	VERB	VBD	9	O
that	that	ADP	IN	5	O
before	before	ADP	IN	9	O
these	these	DET	DT	5	O
episodes	episode	NOUN	NNS	5	O
he	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
using	use	VERB	VBG	9	O
an	an	DET	DT	5	O
inhalator	inhalator	NOUN	NN	0	O
of	of	ADP	IN	5	O
salbutamol	salbutamol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
stopping	stop	VERB	VBG	5	O
the	the	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
agonist	agonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
week	week	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
atenolol	atenolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
disappeared	disappear	VERB	VBD	9	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Swallowing	swallow	VERB	VBG	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
atrial	atrial	ADJ	JJ	5	B-Disease
tachyarrhythmia	tachyarrhythmia	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SIAT	SIAT	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
phenomenon	phenomenon	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Fewer	few	ADJ	JJR	5	O
than	than	ADP	IN	5	O
50	50	NUM	CD	0	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
SIAT	SIAT	PROPN	NNP	9	B-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
article	article	NOUN	NN	6	O
summarizes	summarize	VERB	VBZ	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
published	publish	VERB	VBN	9	O
,	,	PUNCT	,	9	O
creating	create	VERB	VBG	5	O
a	a	DET	DT	5	O
comprehensive	comprehensive	ADJ	JJ	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
knowledge	knowledge	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
approach	approach	VERB	VB	5	O
to	to	ADP	IN	5	O
SIAT	SIAT	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
discusses	discuss	VERB	VBZ	5	O
demographics	demographic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
clinical	clinical	ADJ	JJ	5	O
characteristics	characteristic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
postulated	postulated	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
SIAT	SIAT	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
different	different	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
possibilities	possibility	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
medications	medication	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
radiofrequency	radiofrequency	NOUN	NN	5	O
catheter	catheter	NOUN	NN	5	O
ablation	ablation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
RFCA	RFCA	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Salbutamol	Salbutamol	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
here	here	ADV	RB	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
trigger	trigger	NOUN	NN	9	O
for	for	ADP	IN	5	O
SIAT	SIAT	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
difficult	difficult	ADJ	JJ	5	O
to	to	PART	TO	5	O
define	define	VERB	VB	5	O
causality	causality	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
logical	logical	ADJ	JJ	5	O
to	to	PART	TO	5	O
think	think	VERB	VB	5	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
agonist	agonist	NOUN	NN	3	O
like	like	ADP	IN	9	O
salbutamol	salbutamol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
trigger	trigger	NOUN	NN	9	O
of	of	ADP	IN	5	O
adrenergic	adrenergic	NOUN	NN	9	O
reflexes	reflex	NOUN	NNS	5	O
originating	originate	VERB	VBG	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
esophagus	esophagus	NOUN	NN	5	O
while	while	ADP	IN	9	O
swallowing	swallow	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocker	blocker	NOUN	NN	0	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
atenolol	atenolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
that	that	DET	WDT	5	O
blocks	block	VERB	VBZ	9	O
the	the	DET	DT	5	O
adrenergic	adrenergic	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
may	may	VERB	MD	5	O
relieve	relieve	VERB	VB	5	O
it	-PRON-	PRON	PRP	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
insulin	insulin	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
to	to	PART	TO	5	O
reverse	reverse	VERB	VB	9	O
or	or	CCONJ	CC	5	O
prevent	prevent	VERB	VB	5	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
bladder	bladder	NOUN	NN	9	O
function	function	NOUN	NN	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetes	diabetes	NOUN	NN	5	B-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

1	1	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
insulin	insulin	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
urinary	urinary	ADJ	JJ	9	O
bladder	bladder	NOUN	NN	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

2	2	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Diabetes	diabete	NOUN	NNS	7	B-Disease
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
months	month	NOUN	NNS	5	O
duration	duration	NOUN	NN	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
fluid	fluid	ADJ	JJ	5	O
consumption	consumption	NOUN	NN	5	O
,	,	PUNCT	,	9	O
urine	urine	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
,	,	PUNCT	,	9	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
micturition	micturition	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
average	average	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
per	per	ADP	IN	9	O
micturition	micturition	NOUN	NN	5	O
;	;	PUNCT	:	9	O
effects	effect	NOUN	NNS	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
insulin	insulin	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

3	3	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Insulin	Insulin	PROPN	NNP	9	O
treatment	treatment	NOUN	NN	9	O
also	also	ADV	RB	9	O
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
contractile	contractile	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
body	body	NOUN	NN	5	O
strips	strip	NOUN	NNS	0	O
from	from	ADP	IN	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
rats	rat	NOUN	NNS	9	O
to	to	PART	TO	5	O
nerve	nerve	VERB	VB	5	O
stimulation	stimulation	NOUN	NN	3	O
,	,	PUNCT	,	9	O
ATP	ATP	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
bethanechol	bethanechol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

4	4	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Diabetes	diabete	NOUN	NNS	7	B-Disease
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
duration	duration	NOUN	NN	5	O
also	also	ADV	RB	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
fluid	fluid	ADJ	JJ	5	O
consumption	consumption	NOUN	NN	5	O
,	,	PUNCT	,	9	O
urine	urine	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
,	,	PUNCT	,	9	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
micturition	micturition	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
average	average	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
per	per	ADP	IN	9	O
micturition	micturition	NOUN	NN	5	O
,	,	PUNCT	,	9	O
effects	effect	NOUN	NNS	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
reversed	reverse	VERB	VBN	9	O
by	by	ADP	IN	9	O
insulin	insulin	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
final	final	ADJ	JJ	9	O
2	2	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

5	5	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Insulin	Insulin	PROPN	NNP	9	O
treatment	treatment	NOUN	NN	9	O
reversed	reverse	VERB	VBD	9	O
the	the	DET	DT	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
contractile	contractile	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
body	body	NOUN	NN	5	O
strips	strip	NOUN	NNS	0	O
from	from	ADP	IN	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
rats	rat	NOUN	NNS	9	O
to	to	PART	TO	5	O
nerve	nerve	VERB	VB	5	O
stimulation	stimulation	NOUN	NN	3	O
,	,	PUNCT	,	9	O
ATP	ATP	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
bethanechol	bethanechol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

6	6	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetes	diabete	NOUN	NNS	5	B-Disease
on	on	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
bladder	bladder	NOUN	NN	9	O
function	function	NOUN	NN	9	O
are	be	VERB	VBP	5	O
both	both	DET	DT	9	O
prevented	prevent	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
reversed	reverse	VERB	VBN	9	O
by	by	ADP	IN	9	O
insulin	insulin	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Glutamatergic	glutamatergic	ADJ	JJ	5	O
neurotransmission	neurotransmission	NOUN	NN	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
inferior	inferior	ADJ	JJ	5	O
colliculus	colliculus	NOUN	NN	5	O
can	can	VERB	MD	5	O
modulate	modulate	VERB	VB	9	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
inferior	inferior	ADJ	JJ	5	O
colliculus	colliculus	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
IC	IC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
primarily	primarily	ADV	RB	9	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
processing	processing	NOUN	NN	5	O
of	of	ADP	IN	5	O
auditory	auditory	NOUN	NN	5	O
information	information	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
distinguished	distinguish	VERB	VBN	9	O
from	from	ADP	IN	9	O
other	other	ADJ	JJ	5	O
auditory	auditory	NOUN	NN	5	O
nuclei	nucleus	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brainstem	brainstem	NOUN	NN	5	O
by	by	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
connections	connection	NOUN	NNS	5	O
with	with	ADP	IN	5	O
structures	structure	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
motor	motor	NOUN	NN	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Functional	functional	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
relating	relate	VERB	VBG	5	O
the	the	DET	DT	5	O
IC	IC	PROPN	NNP	9	O
to	to	PART	TO	5	O
motor	motor	NOUN	NN	5	O
behavior	behavior	NOUN	NN	5	O
derives	derive	NOUN	NNS	5	O
from	from	ADP	IN	9	O
experiments	experiment	NOUN	NNS	9	O
showing	show	VERB	VBG	9	O
that	that	DET	DT	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
IC	IC	PROPN	NNP	9	O
by	by	ADP	IN	9	O
electrical	electrical	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
or	or	CCONJ	CC	5	O
excitatory	excitatory	ADJ	JJ	5	O
amino	amino	ADJ	JJ	1	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
microinjection	microinjection	NOUN	NN	3	O
causes	cause	VERB	VBZ	9	O
freezing	freezing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
escape	escape	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
behavior	behavior	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
immobility	immobility	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
nature	nature	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
immobility	immobility	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
excitatory	excitatory	ADJ	JJ	5	O
amino	amino	ADJ	JJ	1	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
mechanisms	mechanism	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
IC	IC	PROPN	NNP	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptor	receptor	NOUN	NN	3	O
blocker	blocker	NOUN	NN	0	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
administered	administer	VERB	VBN	9	O
systemically	systemically	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
or	or	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Haloperidol	haloperidol	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
challenged	challenge	VERB	VBN	3	O
with	with	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
intracollicular	intracollicular	ADJ	JJ	0	O
microinjections	microinjection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
NMDA	nmda	ADJ	JJ	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
or	or	CCONJ	CC	5	O
30	30	NUM	CD	9	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
AP7	AP7	PROPN	NNP	1	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
or	or	CCONJ	CC	5	O
20	20	NUM	CD	9	O
nmol	nmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
d	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
(	(	PUNCT	-LRB-	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
or	or	CCONJ	CC	5	O
30	30	NUM	CD	9	O
nmol	nmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
intracollicular	intracollicular	ADJ	JJ	0	O
microinjection	microinjection	NOUN	NN	3	O
of	of	ADP	IN	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
and	and	CCONJ	CC	5	O
AP7	ap7	VERB	VB	1	B-Chemical
previous	previous	ADJ	JJ	9	O
to	to	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
indicated	indicate	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
reduced	reduce	VERB	VBN	9	O
latency	latency	NOUN	NN	5	O
to	to	PART	TO	5	O
step	step	VERB	VB	9	O
down	down	PART	RP	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
horizontal	horizontal	ADJ	JJ	5	O
bar	bar	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Accordingly	accordingly	ADV	RB	9	O
,	,	PUNCT	,	9	O
intracollicular	intracollicular	ADJ	JJ	0	O
microinjection	microinjection	NOUN	NN	3	O
of	of	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
latency	latency	NOUN	NN	5	O
to	to	PART	TO	5	O
step	step	VERB	VB	9	O
down	down	PART	RP	9	O
the	the	DET	DT	5	O
bar	bar	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
glutamate	glutamate	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
mechanisms	mechanism	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
neural	neural	ADJ	JJ	5	O
circuits	circuit	NOUN	NNS	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
IC	IC	PROPN	NNP	9	O
level	level	NOUN	NN	9	O
influence	influence	NOUN	NN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
participate	participate	VERB	VB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
patient	patient	NOUN	NN	5	O
on	on	ADP	IN	5	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
presenting	present	VERB	VBG	5	O
with	with	ADP	IN	5	O
myxedemic	myxedemic	ADJ	JJ	_	B-Disease
coma	coma	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
myxedema	myxedema	NOUN	NN	5	B-Disease
coma	coma	NOUN	NN	5	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypothyroidism	hypothyroidism	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
CHF	CHF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
reviewing	review	VERB	VBG	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
myxedema	myxedema	NOUN	NN	5	B-Disease
coma	coma	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
long	long	ADJ	JJ	5	O
term	term	NOUN	NN	5	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Myxedema	Myxedema	PROPN	NNP	2	B-Disease
coma	coma	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
life	life	NOUN	NN	5	O
threatening	threaten	VERB	VBG	5	O
condition	condition	NOUN	NN	5	O
that	that	DET	WDT	5	O
carries	carry	VERB	VBZ	9	O
a	a	DET	DT	5	O
mortality	mortality	NOUN	NN	5	O
reaching	reach	VERB	VBG	5	O
as	as	ADV	RB	5	O
high	high	ADJ	JJ	9	O
as	as	ADP	IN	5	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
with	with	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
condition	condition	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
thyroxine	thyroxine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
T4	T4	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
intravenous	intravenous	ADJ	JJ	0	O
tri	tri	NOUN	NNS	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
iodo	iodo	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
thyronine	thyronine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
T3	T3	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
CHF	CHF	PROPN	NNP	9	B-Disease
on	on	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
suffer	suffer	VERB	VB	5	O
serious	serious	ADJ	JJ	5	O
morbidity	morbidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
from	from	ADP	IN	9	O
hypothyroidism	hypothyroidism	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
thus	thus	ADV	RB	9	O
may	may	VERB	MD	5	O
deserve	deserve	VERB	VB	5	O
closer	close	ADJ	JJR	5	O
follow	follow	VERB	VB	5	O
up	up	PART	RP	5	O
for	for	ADP	IN	5	O
thyroid	thyroid	NOUN	NN	9	O
stimulating	stimulate	VERB	VBG	9	O
hormone	hormone	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
TSH	TSH	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
carries	carry	VERB	VBZ	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
application	application	NOUN	NN	5	O
given	give	VERB	VBN	5	O
the	the	DET	DT	5	O
frequent	frequent	ADJ	JJ	5	O
usage	usage	NOUN	NN	9	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
among	among	ADP	IN	5	O
CHF	CHF	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
myriad	myriad	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
presentation	presentation	NOUN	NN	5	O
of	of	ADP	IN	5	O
myxedema	myxedema	NOUN	NN	5	B-Disease
coma	coma	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
serious	serious	ADJ	JJ	5	O
morbidity	morbidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
stresses	stress	VERB	VBZ	9	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
to	to	PART	TO	5	O
suspect	suspect	VERB	VB	5	O
this	this	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
syndrome	syndrome	NOUN	NN	5	O
among	among	ADP	IN	5	O
CHF	CHF	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
presenting	present	VERB	VBG	5	O
with	with	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
weakness	weakness	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
unexplained	unexplained	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
active	active	ADJ	JJ	9	O
constituents	constituent	NOUN	NNS	0	O
of	of	ADP	IN	5	O
Crocus	Crocus	PROPN	NNP	4	O
sativus	sativus	NOUN	NN	4	O
L	L	PROPN	NNP	0	O
.	.	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
crocin	crocin	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
streptozocin	streptozocin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
sporadic	sporadic	ADJ	JJ	9	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
water	water	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
soluble	soluble	ADJ	JJ	0	O
carotenoids	carotenoid	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
crocins	crocin	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
active	active	ADJ	JJ	9	O
components	component	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Crocus	Crocus	PROPN	NNP	4	O
sativus	sativus	NOUN	NN	4	O
L	L	PROPN	NNP	0	O
.	.	PUNCT	.	9	O
extract	extract	NOUN	NN	0	O
in	in	ADP	IN	5	O
learning	learning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
memory	memory	NOUN	NN	5	O
processes	process	NOUN	NNS	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
proposed	propose	VERB	VBN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
crocins	crocin	NOUN	NNS	0	B-Chemical
on	on	ADP	IN	5	O
sporadic	sporadic	ADJ	JJ	9	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
intracerebroventricular	intracerebroventricular	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
icv	icv	ADJ	JJ	0	O
)	)	PUNCT	-RRB-	9	O
streptozocin	streptozocin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Male	male	ADJ	JJ	7	O
adult	adult	NOUN	NN	9	O
Wistar	wistar	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
90	90	NUM	CD	9	O
and	and	CCONJ	CC	5	O
260	260	NUM	CD	9	O
-	-	SYM	SYM	7	O
290	290	NUM	CD	7	O
g	g	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
control	control	NOUN	NN	9	O
;	;	PUNCT	:	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
crocins	crocin	NOUN	NNS	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
;	;	PUNCT	:	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
+	+	SYM	SYM	9	O
crocins	crocin	NOUN	NNS	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
icv	icv	VERB	VBN	0	O
bilaterally	bilaterally	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
first	first	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
icv	icv	VERB	VBN	0	O
application	application	NOUN	NN	5	O
was	be	VERB	VBD	9	O
repeated	repeat	VERB	VBN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
+	+	SYM	SYM	9	O
crocin	crocin	ADJ	JJ	0	B-Chemical
animal	animal	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
crocin	crocin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
applied	apply	VERB	VBN	5	O
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
day	day	NOUN	NN	9	O
pre	pre	ADJ	JJ	9	O
-	-	NOUN	NN	7	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
continued	continue	VERB	VBD	9	O
for	for	ADP	IN	5	O
three	three	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Prescription	prescription	NOUN	NN	5	O
of	of	ADP	IN	5	O
crocin	crocin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
repeated	repeat	VERB	VBN	5	O
once	once	ADV	RB	5	O
for	for	ADP	IN	5	O
two	two	NUM	CD	5	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
learning	learning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
memory	memory	NOUN	NN	5	O
performance	performance	NOUN	NN	5	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
using	use	VERB	VBG	9	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
paradigm	paradigm	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
spatial	spatial	ADJ	JJ	5	O
cognition	cognition	NOUN	NN	5	O
evaluation	evaluation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
Y	Y	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
maze	maze	NOUN	NN	5	O
task	task	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
out	out	PART	RP	9	O
that	that	ADP	IN	5	O
crocin	crocin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
injected	inject	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
higher	high	ADJ	JJR	9	O
correct	correct	ADJ	JJ	5	O
choices	choice	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
lower	low	ADJ	JJR	9	O
errors	error	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Y	Y	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
maze	maze	PROPN	NNP	5	O
than	than	ADP	IN	5	O
vehicle	vehicle	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
injected	inject	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
crocin	crocin	ADJ	JJ	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mentioned	mention	VERB	VBN	5	O
dose	dose	NOUN	NN	9	O
could	could	VERB	MD	9	O
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBN	3	O
learning	learning	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
impairment	impairment	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
treated	treated	ADJ	JJ	3	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
injected	inject	VERB	VBN	3	O
group	group	NOUN	NN	9	O
in	in	ADP	IN	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
the	the	DET	DT	5	O
effectiveness	effectiveness	NOUN	NN	5	O
of	of	ADP	IN	5	O
crocin	crocin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
antagonizing	antagonize	VERB	VBG	3	O
the	the	DET	DT	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
STZ	STZ	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
icv	icv	VERB	VBN	0	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
potential	potential	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
neurodegenerative	neurodegenerative	ADJ	JJ	9	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Serotonin	serotonin	ADP	IN	0	B-Chemical
6	6	NUM	CD	9	O
receptor	receptor	NOUN	NN	3	O
gene	gene	NOUN	NN	1	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
Japanese	japanese	ADJ	JJ	9	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Altered	alter	VERB	VBN	9	O
serotonergic	serotonergic	ADJ	JJ	5	O
neural	neural	ADJ	JJ	5	O
transmission	transmission	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
hypothesized	hypothesize	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
susceptibility	susceptibility	NOUN	NN	9	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
psychotic	psychotic	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
6	6	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT6	ht6	NOUN	NN	1	I-Chemical
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
therapeutically	therapeutically	ADV	RB	9	O
targeted	target	VERB	VBN	9	O
by	by	ADP	IN	9	O
several	several	ADJ	JJ	9	O
second	second	ADJ	JJ	9	O
generation	generation	NOUN	NN	9	O
antipsychotics	antipsychotic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
d	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
amphetamine	amphetamine	NOUN	NN	5	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
corrected	correct	VERB	VBN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT6	HT6	PROPN	NNP	1	I-Chemical
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
disrupted	disrupt	VERB	VBN	9	O
prepulse	prepulse	NOUN	NN	5	O
inhibition	inhibition	NOUN	NN	3	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
d	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
amphetamine	amphetamine	NOUN	NN	5	I-Chemical
or	or	CCONJ	CC	5	O
phencyclidine	phencyclidine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
restored	restore	VERB	VBN	3	O
by	by	ADP	IN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT6	ht6	PART	RP	1	I-Chemical
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
animal	animal	NOUN	NN	5	O
study	study	NOUN	NN	9	O
using	use	VERB	VBG	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
animal	animal	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
to	to	PART	TO	5	O
reflect	reflect	VERB	VB	5	O
the	the	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
above	above	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
altered	alter	VERB	VBN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT6	HT6	PROPN	NNP	1	I-Chemical
receptors	receptor	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
psychotic	psychotic	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
METH	METH	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
paranoid	paranoid	ADJ	JJ	5	B-Disease
type	type	NOUN	NN	9	I-Disease
schizophrenia	schizophrenia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
conducted	conduct	VERB	VBD	9	O
an	an	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT6	HT6	PROPN	NNP	1	I-Chemical
gene	gene	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
HTR6	HTR6	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Using	use	VERB	VBG	9	O
five	five	NUM	CD	9	O
tagging	tagging	NOUN	NN	5	O
SNPs	snp	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
rs6693503	rs6693503	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
rs1805054	rs1805054	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
rs4912138	rs4912138	INTJ	UH	_	O
,	,	PUNCT	,	9	O
rs3790757	rs3790757	PROPN	NNPS	_	O
and	and	CCONJ	CC	5	O
rs9659997	rs9659997	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
genetic	genetic	ADJ	JJ	5	O
association	association	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
197	197	NUM	CD	7	O
METH	METH	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
337	337	NUM	CD	7	O
controls	control	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Japanese	japanese	ADJ	JJ	9	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
sex	sex	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
from	from	ADP	IN	9	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
dependence	dependence	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
rs6693503	rs6693503	PROPN	NNP	_	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
allele	allele	NOUN	NN	1	O
/	/	SYM	SYM	9	O
genotype	genotype	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
wise	wise	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
association	association	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
after	after	ADP	IN	9	O
Bonferroni	Bonferroni	PROPN	NNP	5	O
correction	correction	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
haplotype	haplotype	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
wise	wise	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
detected	detect	VERB	VBD	9	O
an	an	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
two	two	NUM	CD	5	O
markers	marker	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
rs6693503	rs6693503	PROPN	NNP	_	O
and	and	CCONJ	CC	5	O
rs1805054	rs1805054	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
three	three	NUM	CD	9	O
markers	marker	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
rs6693503	rs6693503	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
rs1805054	rs1805054	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
rs4912138	rs4912138	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
HTR6	HTR6	PROPN	NNP	1	O
and	and	CCONJ	CC	5	O
METH	METH	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
HTR6	HTR6	PROPN	NNP	1	O
may	may	VERB	MD	5	O
play	play	VERB	VB	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Japanese	japanese	ADJ	JJ	9	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neural	neural	ADJ	JJ	5	O
correlates	correlate	NOUN	NNS	9	O
of	of	ADP	IN	5	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ketamine	ketamine	PROPN	NNP	0	I-Chemical
induced	induced	ADJ	JJ	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
overt	overt	ADJ	JJ	5	O
continuous	continuous	ADJ	JJ	5	O
verbal	verbal	ADJ	JJ	5	O
fluency	fluency	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
glutamatergic	glutamatergic	ADJ	JJ	3	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
(	(	PUNCT	-LRB-	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Administered	administer	VERB	VBN	2	O
to	to	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
subanesthetic	subanesthetic	ADJ	JJ	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
competitive	competitive	ADJ	JJ	9	O
NMDA	nmda	ADJ	JJ	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
leads	lead	VERB	VBZ	9	O
to	to	ADP	IN	5	O
psychopathological	psychopathological	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
exacerbates	exacerbate	VERB	VBZ	9	O
the	the	DET	DT	5	O
core	core	NOUN	NN	9	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
illness	illness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
supporting	support	VERB	VBG	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
glutamatergic	glutamatergic	ADJ	JJ	3	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
counterbalanced	counterbalanced	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
design	design	NOUN	NN	5	O
,	,	PUNCT	,	9	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
a	a	DET	DT	5	O
continuous	continuous	ADJ	JJ	5	O
subanesthetic	subanesthetic	ADJ	JJ	0	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ketamine	ketamine	NOUN	NN	0	I-Chemical
infusion	infusion	NOUN	NN	0	O
while	while	ADP	IN	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
BOLD	BOLD	PROPN	NNP	5	O
responses	response	NOUN	NNS	5	O
measured	measure	VERB	VBN	9	O
with	with	ADP	IN	5	O
fMRI	fMRI	PROPN	NNP	5	O
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
scanning	scanning	NOUN	NN	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
subjects	subject	NOUN	NNS	5	O
performed	perform	VERB	VBD	9	O
continuous	continuous	ADJ	JJ	5	O
overt	overt	ADJ	JJ	5	O
verbal	verbal	ADJ	JJ	5	O
fluency	fluency	NOUN	NN	5	O
tasks	task	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
phonological	phonological	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
lexical	lexical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
semantic	semantic	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Ketamine	ketamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
psychopathological	psychopathological	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
Positive	Positive	PROPN	NNP	7	O
and	and	CCONJ	CC	5	O
Negative	Negative	PROPN	NNP	7	O
Syndrome	Syndrome	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
PANSS	PANSS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Ketamine	Ketamine	PROPN	NNP	0	B-Chemical
elicited	elicit	VERB	VBD	9	O
psychosis	psychosis	NOUN	NN	5	B-Disease
like	like	ADP	IN	9	O
psychopathology	psychopathology	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Post	Post	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
hoc	hoc	X	FW	5	O
t	t	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
tests	test	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
words	word	NOUN	NNS	5	O
generated	generate	VERB	VBN	9	O
during	during	ADP	IN	5	O
lexical	lexical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
semantic	semantic	ADJ	JJ	5	O
verbal	verbal	ADJ	JJ	5	O
fluency	fluency	NOUN	NN	5	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
phonological	phonological	ADJ	JJ	5	O
domain	domain	NOUN	NN	1	O
remained	remain	VERB	VBD	9	O
unaffected	unaffected	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Ketamine	Ketamine	PROPN	NNP	0	B-Chemical
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
enhanced	enhance	VERB	VBN	3	O
cortical	cortical	ADJ	JJ	5	O
activations	activation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
supramarginal	supramarginal	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
frontal	frontal	ADJ	JJ	5	O
brain	brain	NOUN	NN	5	O
regions	region	NOUN	NNS	9	O
for	for	ADP	IN	5	O
phonological	phonological	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
lexical	lexical	ADJ	JJ	5	O
verbal	verbal	ADJ	JJ	5	O
fluency	fluency	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
for	for	ADP	IN	5	O
semantic	semantic	ADJ	JJ	5	O
verbal	verbal	ADJ	JJ	5	O
fluency	fluency	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ketamine	ketamine	NOUN	NN	0	B-Chemical
induces	induce	VERB	VBZ	3	O
activation	activation	NOUN	NN	3	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
in	in	ADP	IN	5	O
frontal	frontal	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
temporal	temporal	ADJ	JJ	5	O
brain	brain	NOUN	NN	5	O
regions	region	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
provide	provide	VERB	VBP	5	O
further	further	ADJ	JJ	9	O
support	support	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
NMDA	nmda	ADJ	JJ	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
dysfunction	dysfunction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
prognosis	prognosis	NOUN	NN	5	O
for	for	ADP	IN	5	O
transplant	transplant	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
survivors	survivor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
prognosis	prognosis	NOUN	NN	5	O
for	for	ADP	IN	5	O
transplant	transplant	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
survivors	survivor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
remains	remain	VERB	VBZ	9	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
examine	examine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
increases	increase	VERB	VBZ	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
mortality	mortality	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
followed	follow	VERB	VBD	9	O
up	up	PART	RP	5	O
all	all	DET	DT	5	O
transplant	transplant	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
survivors	survivor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
hospitalized	hospitalize	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
Danish	danish	ADJ	JJ	5	O
national	national	ADJ	JJ	5	O
referral	referral	ADJ	JJ	5	O
centre	centre	NOUN	NN	5	O
during	during	ADP	IN	5	O
1984	1984	NUM	CD	2	O
-	-	SYM	SYM	7	O
2004	2004	NUM	CD	2	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
compared	compare	VERB	VBD	9	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
mortality	mortality	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
discharge	discharge	NOUN	NN	5	O
through	through	ADP	IN	9	O
2008	2008	NUM	CD	2	O
between	between	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
it	-PRON-	PRON	PRP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
included	include	VERB	VBD	5	O
641	641	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
average	average	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
mortality	mortality	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
slightly	slightly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
101	101	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
whose	whose	DET	WP$	9	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
liver	liver	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
had	have	VERB	VBD	9	O
caused	cause	VERB	VBN	9	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
adjusted	adjust	VERB	VBN	9	O
mortality	mortality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
=	=	VERB	VBZ	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
70	70	NUM	CD	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
85	85	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
was	be	VERB	VBD	9	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
survivors	survivor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
died	die	VERB	VBD	9	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
suicides	suicide	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
frequent	frequent	ADJ	JJ	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
observations	observation	NOUN	NNS	9	O
speak	speak	VERB	VBP	5	O
against	against	ADP	IN	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

More	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
elevated	elevated	ADJ	JJ	9	O
mortality	mortality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
from	from	ADP	IN	9	O
incomplete	incomplete	ADJ	JJ	9	O
adjustment	adjustment	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
greater	great	ADJ	JJR	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
substance	substance	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
among	among	ADP	IN	5	O
survivors	survivor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Paracetamol	paracetamol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
mortality	mortality	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
justified	justify	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
itself	-PRON-	PRON	PRP	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vivo	vivo	NOUN	NNS	3	O
characterization	characterization	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
dual	dual	ADJ	JJ	9	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
A2A	A2A	PROPN	NNP	3	I-Chemical
/	/	SYM	SYM	9	I-Chemical
A1	A1	PROPN	NNP	9	I-Chemical
receptor	receptor	NOUN	NN	3	I-Chemical
antagonist	antagonist	NOUN	NN	3	I-Chemical
in	in	ADP	IN	5	O
animal	animal	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
characterization	characterization	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
dual	dual	ADJ	JJ	9	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
A	a	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2A	2a	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
/	/	SYM	SYM	9	I-Chemical
A	a	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
receptor	receptor	NOUN	NN	3	I-Chemical
antagonist	antagonist	NOUN	NN	3	I-Chemical
in	in	ADP	IN	5	O
several	several	ADJ	JJ	9	O
animal	animal	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Discovery	discovery	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
scale	scale	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
syntheses	synthesis	NOUN	NNS	9	O
of	of	ADP	IN	5	O
compound	compound	NOUN	NN	0	O
1	1	NUM	CD	9	O
are	be	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
detail	detail	NOUN	NN	5	O
,	,	PUNCT	,	9	O
highlighting	highlight	VERB	VBG	9	O
optimization	optimization	NOUN	NN	5	O
steps	step	NOUN	NNS	5	O
that	that	DET	WDT	5	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
yield	yield	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
from	from	ADP	IN	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
30	30	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Compound	Compound	PROPN	NNP	0	O
1	1	NUM	CD	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
A	a	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2A	2a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
A	a	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2A	2a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
K	K	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
=	=	VERB	VBZ	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
nM	nm	NOUN	NN	0	O
;	;	PUNCT	:	9	O
A	a	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
K	K	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
=	=	SYM	SYM	7	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
nM	nm	X	XX	0	O
)	)	PUNCT	-RRB-	9	O
that	that	DET	WDT	5	O
has	have	VERB	VBZ	9	O
excellent	excellent	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
across	across	ADP	IN	5	O
a	a	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
animal	animal	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
including	include	VERB	VBG	9	O
mouse	mouse	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
rat	rat	NOUN	NN	3	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
mouse	mouse	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
akinesia	akinesia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
rat	rat	NOUN	NN	3	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxydopamine	hydroxydopamine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
OHDA	ohda	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
lesion	lesion	NOUN	NN	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rotation	rotation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
MPTP	MPTP	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
human	human	ADJ	JJ	3	O
primate	primate	ADJ	JJ	9	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
deep	deep	ADJ	JJ	5	O
brain	brain	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
on	on	ADP	IN	5	O
cortical	cortical	ADJ	JJ	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
discharges	discharge	NOUN	NNS	5	O
in	in	ADP	IN	5	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
model	model	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Experimental	experimental	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
revealed	reveal	VERB	VBN	9	O
that	that	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
DBS	DBS	PROPN	NNP	5	O
can	can	VERB	MD	5	O
control	control	VERB	VB	9	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
obscure	obscure	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
optimal	optimal	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
parameters	parameter	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
clearly	clearly	ADV	RB	9	O
defined	define	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
frequency	frequency	NOUN	NN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
stimulation	stimulation	NOUN	NN	3	O
on	on	ADP	IN	5	O
cortical	cortical	ADJ	JJ	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

MATERIAL	MATERIAL	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
implanted	implant	VERB	VBN	9	O
DBS	DBS	PROPN	NNP	5	O
electrodes	electrode	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
group	group	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
hippocampal	hippocampal	ADJ	JJ	3	O
DBS	DBS	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
off	off	ADV	RB	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
hippocampal	hippocampal	ADJ	JJ	3	O
DBS	DBS	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
on	on	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
185	185	NUM	CD	7	O
Hz	Hz	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5V	5v	NOUN	NN	0	O
,	,	PUNCT	,	9	O
1V	1V	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
2V	2V	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
5V	5V	PROPN	NNP	0	O
for	for	ADP	IN	5	O
60	60	NUM	CD	9	O
sec	sec	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
following	follow	VERB	VBG	9	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
G	g	NOUN	NN	9	I-Chemical
injection	injection	NOUN	NN	9	O
intracortically	intracortically	ADV	RB	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
hippocampal	hippocampal	ADJ	JJ	3	O
DBS	DBS	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
on	on	ADP	IN	5	O
following	follow	VERB	VBG	9	O
8	8	NUM	CD	9	O
l	l	NOUN	NN	0	O
saline	saline	NOUN	NN	0	O
injection	injection	NOUN	NN	9	O
intracortically	intracortically	ADV	RB	5	O
.	.	PUNCT	.	9	O

EEG	EEG	PROPN	NNP	5	O
recordings	recording	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
following	follow	VERB	VBG	9	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
G	g	NOUN	NN	9	I-Chemical
injection	injection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
10th	10th	ADJ	JJ	9	O
minutes	minute	NOUN	NNS	0	O
following	follow	VERB	VBG	9	O
each	each	DET	DT	5	O
stimulus	stimulus	NOUN	NN	5	O
for	for	ADP	IN	5	O
analysis	analysis	NOUN	NN	9	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
frequency	frequency	NOUN	NN	5	O
,	,	PUNCT	,	9	O
amplitude	amplitude	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
power	power	NOUN	NN	5	O
spectrum	spectrum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
High	high	ADJ	JJ	9	O
frequency	frequency	NOUN	NN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
DBS	DBS	PROPN	NNP	5	O
suppressed	suppress	VERB	VBD	3	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cortical	cortical	ADJ	JJ	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
activity	activity	NOUN	NN	9	O
independent	independent	ADJ	JJ	9	O
from	from	ADP	IN	9	O
stimulus	stimulus	NOUN	NN	5	O
intensity	intensity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
hippocampal	hippocampal	ADJ	JJ	3	O
stimulation	stimulation	NOUN	NN	3	O
alone	alone	ADV	RB	9	O
lead	lead	VERB	VB	5	O
only	only	ADV	RB	9	O
to	to	PART	TO	5	O
diffuse	diffuse	VERB	VB	5	O
slowing	slowing	NOUN	NN	5	O
of	of	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	O
bioelectrical	bioelectrical	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
at	at	ADP	IN	9	O
5V	5V	PROPN	NNP	0	O
stimulation	stimulation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
high	high	ADJ	JJ	9	O
frequency	frequency	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
suppressed	suppress	VERB	VBD	3	O
acute	acute	ADJ	JJ	9	O
cortical	cortical	ADJ	JJ	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
activity	activity	NOUN	NN	9	O
effectively	effectively	ADV	RB	5	O
without	without	ADP	IN	9	O
causing	cause	VERB	VBG	9	O
secondary	secondary	ADJ	JJ	9	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
discharges	discharge	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
important	important	ADJ	JJ	9	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
defining	define	VERB	VBG	5	O
the	the	DET	DT	5	O
optimal	optimal	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
DBS	DBS	PROPN	NNP	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CCNU	CCNU	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
lomustine	lomustine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2002	2002	NUM	CD	2	O
-	-	SYM	SYM	7	O
07	07	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
describe	describe	VERB	VB	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
haematological	haematological	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
,	,	PUNCT	,	9	I-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
gastrointestinal	gastrointestinal	ADJ	JJ	9	I-Disease
toxicities	toxicity	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
tumour	tumour	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
bearing	bear	VERB	VBG	3	O
dogs	dog	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
1	1	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chloroethyl	chloroethyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
cyclohexyl	cyclohexyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitrosourea	nitrosourea	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CCNU	CCNU	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
records	record	NOUN	NNS	5	O
of	of	ADP	IN	5	O
206	206	NUM	CD	7	O
dogs	dog	NOUN	NNS	5	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
CCNU	CCNU	PROPN	NNP	0	B-Chemical
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
Melbourne	Melbourne	PROPN	NNP	2	O
Veterinary	Veterinary	PROPN	NNP	2	O
Specialist	Specialist	PROPN	NNP	2	O
Centre	Centre	PROPN	NNP	2	O
between	between	ADP	IN	5	O
February	February	PROPN	NNP	2	O
2002	2002	NUM	CD	2	O
and	and	CCONJ	CC	5	O
December	December	PROPN	NNP	2	O
2007	2007	NUM	CD	2	O
were	be	VERB	VBD	9	O
retrospectively	retrospectively	ADV	RB	5	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
206	206	NUM	CD	7	O
dogs	dog	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
CCNU	CCNU	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
185	185	NUM	CD	7	O
met	meet	VERB	VBD	5	O
the	the	DET	DT	5	O
inclusion	inclusion	NOUN	NN	5	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
one	one	NUM	CD	5	O
class	class	NOUN	NN	9	O
of	of	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

CCNU	CCNU	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
most	most	ADV	RBS	9	O
commonly	commonly	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
lymphoma	lymphoma	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
mast	mast	ADJ	JJ	3	B-Disease
cell	cell	NOUN	NN	3	I-Disease
tumour	tumour	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
brain	brain	NOUN	NN	5	B-Disease
tumour	tumour	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
histiocytic	histiocytic	ADJ	JJ	3	B-Disease
tumours	tumour	NOUN	NNS	3	I-Disease
and	and	CCONJ	CC	5	O
epitheliotropic	epitheliotropic	VERB	VB	5	B-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Throughout	throughout	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
56	56	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
34	34	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
experienced	experienced	ADJ	JJ	5	O
anaemia	anaemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
experienced	experienced	ADJ	JJ	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
toxicosis	toxicosis	NOUN	NN	0	I-Disease
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
37	37	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
sign	sign	NOUN	NN	5	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
vomiting	vomit	VERB	VBG	5	B-Disease
(	(	PUNCT	-LRB-	9	O
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Potential	potential	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
elevated	elevated	ADJ	JJ	9	O
alanine	alanine	NOUN	NN	1	B-Chemical
transaminase	transaminase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
ALT	ALT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
concentration	concentration	NOUN	NN	0	O
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
48	48	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
CCNU	ccnu	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
common	common	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
is	be	VERB	VBZ	5	O
usually	usually	ADV	RB	5	O
not	not	ADV	RB	5	O
life	life	NOUN	NN	5	O
threatening	threaten	VERB	VBG	5	O
.	.	PUNCT	.	9	O

Central	central	ADJ	JJ	4	O
vein	vein	NOUN	NN	5	B-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
topical	topical	ADJ	JJ	0	O
dipivalyl	dipivalyl	NOUN	NN	_	B-Chemical
epinephrine	epinephrine	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
report	report	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
given	give	VERB	VBN	5	O
on	on	ADP	IN	5	O
an	an	DET	DT	5	O
83	83	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
female	female	NOUN	NN	9	O
who	who	PRON	WP	5	O
acquired	acquire	VERB	VBD	5	O
central	central	ADJ	JJ	5	O
vein	vein	NOUN	NN	5	B-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
seeing	see	VERB	VBG	5	O
eye	eye	NOUN	NN	5	O
one	one	NUM	CD	5	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
having	have	VERB	VBG	5	O
started	start	VERB	VBN	5	O
topical	topical	ADJ	JJ	0	O
medication	medication	NOUN	NN	5	O
with	with	ADP	IN	5	O
dipivalyl	dipivalyl	NOUN	NN	_	B-Chemical
epinephrine	epinephrine	NOUN	NN	0	I-Chemical
for	for	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
discovered	discover	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
eye	eye	NOUN	NN	5	O
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
present	present	ADJ	JJ	9	O
knowledge	knowledge	NOUN	NN	5	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
adrenergic	adrenergic	NOUN	NN	9	O
eye	eye	NOUN	NN	5	O
drops	drop	VERB	VBZ	0	O
on	on	ADP	IN	5	O
ocular	ocular	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
circulation	circulation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
difficult	difficult	ADJ	JJ	5	O
to	to	PART	TO	5	O
suggest	suggest	VERB	VB	9	O
an	an	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
coincidental	coincidental	ADJ	JJ	5	O
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

Benzylacyclouridine	benzylacyclouridine	NOUN	NN	_	B-Chemical
reverses	reverse	VERB	VBZ	3	O
azidothymidine	azidothymidine	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
marrow	marrow	NOUN	NN	3	B-Disease
suppression	suppression	NOUN	NN	9	I-Disease
without	without	ADP	IN	9	O
impairment	impairment	NOUN	NN	5	O
of	of	ADP	IN	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
human	human	ADJ	JJ	3	O
immunodeficiency	immunodeficiency	NOUN	NN	9	B-Disease
virus	virus	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
extracellular	extracellular	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
uridine	uridine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Urd	Urd	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
,	,	PUNCT	,	9	O
azidothymidine	azidothymidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
granulocyte	granulocyte	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
macrophage	macrophage	NOUN	NN	3	O
progenitor	progenitor	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
without	without	ADP	IN	9	O
impairment	impairment	NOUN	NN	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
antihuman	antihuman	ADJ	JJ	3	O
immunodeficiency	immunodeficiency	NOUN	NN	9	B-Disease
virus	virus	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HIV	HIV	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
Urd	Urd	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
benzylacyclouridine	benzylacyclouridine	NOUN	NN	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
BAU	BAU	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anemia	anemia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
leukopenia	leukopenia	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
agent	agent	NOUN	NN	9	O
inhibits	inhibit	VERB	VBZ	3	O
Urd	Urd	PROPN	NNP	0	B-Chemical
catabolism	catabolism	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
Urd	Urd	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
Urd	Urd	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
mice	mouse	NOUN	NNS	3	O
rendered	render	VERB	VBD	9	O
anemic	anemic	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	O
leukopenic	leukopenic	ADJ	JJ	5	B-Disease
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
for	for	ADP	IN	5	O
28	28	NUM	CD	7	O
days	day	NOUN	NNS	9	O
in	in	ADP	IN	5	O
drinking	drinking	NOUN	NN	5	O
water	water	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mL	mL	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
continued	continued	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
plus	plus	CCONJ	CC	9	O
daily	daily	ADJ	JJ	5	O
BAU	BAU	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
orally	orally	ADV	RB	0	O
)	)	PUNCT	-RRB-	9	O
partially	partially	ADV	RB	9	O
reversed	reverse	VERB	VBD	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anemia	anemia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
leukopenia	leukopenia	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBN	9	O
peripheral	peripheral	ADJ	JJ	9	O
reticulocytes	reticulocyte	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
to	to	ADP	IN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBN	9	O
cellularity	cellularity	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
marrow	marrow	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
improved	improved	ADJ	JJ	5	O
megaloblastosis	megaloblastosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
coadministered	coadministere	VERB	VBN	0	O
with	with	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
BAU	BAU	PROPN	NNP	5	B-Chemical
reduced	reduce	VERB	VBD	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
marrow	marrow	NOUN	NN	3	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vitro	vitro	NOUN	NN	3	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
100	100	NUM	CD	0	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
BAU	BAU	PROPN	NNP	5	B-Chemical
possesses	possess	VERB	VBZ	9	O
minimal	minimal	ADJ	JJ	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
HIV	hiv	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
has	have	VERB	VBZ	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
to	to	PART	TO	5	O
reverse	reverse	VERB	VB	9	O
the	the	DET	DT	5	O
HIV	HIV	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cytopathic	cytopathic	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
MT4	MT4	PROPN	NNP	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
biochemical	biochemical	ADJ	JJ	9	O
implications	implication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Lethal	lethal	ADJ	JJ	9	O
anuria	anuria	NOUN	NN	5	B-Disease
complicating	complicate	VERB	VBG	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
ifosfamide	ifosfamide	ADJ	JJ	0	B-Chemical
chemotherapy	chemotherapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
sixty	sixty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
previously	previously	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
developed	develop	VERB	VBD	5	O
an	an	DET	DT	5	O
irreversible	irreversible	ADJ	JJ	9	O
lethal	lethal	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
anuria	anuria	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
5	5	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
bolus	bolus	NOUN	NN	0	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Postrenal	postrenal	ADJ	JJ	7	B-Disease
failure	failure	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
excluded	exclude	VERB	VBN	9	O
by	by	ADP	IN	9	O
echography	echography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
prerenal	prerenal	ADJ	JJ	5	O
component	component	NOUN	NN	9	O
could	could	VERB	MD	9	O
have	have	VERB	VB	5	O
contributed	contribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
transient	transient	ADJ	JJ	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
increasing	increase	VERB	VBG	9	O
ascitis	ascitis	NOUN	NN	3	O
,	,	PUNCT	,	9	O
occurring	occur	VERB	VBG	9	O
just	just	ADV	RB	5	O
before	before	ADP	IN	9	O
anuria	anuria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
correction	correction	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
improve	improve	VERB	VB	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Ifosfamide	Ifosfamide	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
known	know	VERB	VBN	9	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
drug	drug	NOUN	NN	5	O
with	with	ADP	IN	5	O
demonstrated	demonstrate	VERB	VBN	9	O
tubulopathies	tubulopathie	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
strongly	strongly	ADV	RB	9	O
suspect	suspect	VERB	VBP	5	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
lethal	lethal	ADJ	JJ	9	O
anuria	anuria	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
mainly	mainly	ADV	RB	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
occurring	occur	VERB	VBG	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
having	have	VERB	VBG	5	O
received	receive	VERB	VBN	9	O
previous	previous	ADJ	JJ	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
chemotherapy	chemotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
poor	poor	ADJ	JJ	5	O
kidney	kidney	NOUN	NN	9	O
perfusion	perfusion	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
recommend	recommend	VERB	VBP	5	O
careful	careful	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
chemotherapy	chemotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
inadequate	inadequate	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
perfusion	perfusion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Nociceptive	nociceptive	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
intrathecal	intrathecal	ADJ	JJ	3	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
D2	d2	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
E2	E2	PROPN	NNP	3	I-Chemical
,	,	PUNCT	,	9	I-Chemical
or	or	CCONJ	CC	5	I-Chemical
F2	F2	PROPN	NNP	9	I-Chemical
alpha	alpha	VERB	VBP	9	I-Chemical
to	to	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
prostaglandins	prostaglandin	NOUN	NNS	0	B-Chemical
on	on	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
responses	response	NOUN	NNS	5	O
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
using	use	VERB	VBG	9	O
hot	hot	ADJ	JJ	5	O
plate	plate	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
acetic	acetic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
writhing	writhing	NOUN	NN	0	O
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Prostaglandin	Prostaglandin	PROPN	NNP	0	B-Chemical
D2	D2	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
ng	ng	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mouse	mouse	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
hyperalgesic	hyperalgesic	ADJ	JJ	3	B-Disease
action	action	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
hot	hot	ADJ	JJ	5	O
plate	plate	NOUN	NN	0	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
period	period	NOUN	NN	5	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Prostaglandin	Prostaglandin	PROPN	NNP	0	B-Chemical
E2	E2	PROPN	NNP	3	I-Chemical
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
hyperalgesic	hyperalgesic	ADJ	JJ	3	B-Disease
effect	effect	NOUN	NN	9	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
pg	pg	NOUN	NN	7	B-Chemical
to	to	ADP	IN	5	O
10	10	NUM	CD	9	O
ng	ng	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
mouse	mouse	NOUN	NN	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
lasted	last	VERB	VBD	5	O
shorter	shorter	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
D2	d2	NOUN	NN	9	I-Chemical
.	.	PUNCT	.	9	O

Similar	similar	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
by	by	ADP	IN	9	O
acetic	acetic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
writhing	writhing	NOUN	NN	0	O
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hyperalgesic	hyperalgesic	ADJ	JJ	3	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
D2	d2	NOUN	NN	9	I-Chemical
was	be	VERB	VBD	9	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
simultaneous	simultaneous	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
substance	substance	NOUN	NN	5	O
P	p	NOUN	NN	9	O
antagonist	antagonist	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
100	100	NUM	CD	0	O
ng	ng	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
by	by	ADP	IN	9	O
AH6809	AH6809	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
prostanoid	prostanoid	NOUN	NN	0	O
EP1	EP1	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Conversely	conversely	ADV	RB	9	O
,	,	PUNCT	,	9	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
E2	e2	NOUN	NN	3	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
was	be	VERB	VBD	9	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
AH6809	AH6809	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
500	500	NUM	CD	0	O
ng	ng	ADP	IN	0	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
substance	substance	NOUN	NN	5	O
P	p	NOUN	NN	9	O
antagonist	antagonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
F2	F2	PROPN	NNP	9	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
had	have	VERB	VBD	9	O
little	little	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
responses	response	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
both	both	DET	DT	9	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
D2	d2	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
E2	e2	NOUN	NN	3	I-Chemical
exert	exert	VERB	VBP	9	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
spinal	spinal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
in	in	ADP	IN	5	O
different	different	ADJ	JJ	9	O
ways	way	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

D	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
localized	localize	VERB	VBN	9	B-Disease
scleroderma	scleroderma	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

Localized	localize	VERB	VBN	9	B-Disease
scleroderma	scleroderma	NOUN	NN	9	I-Disease
has	have	VERB	VBZ	9	O
no	no	DET	DT	9	O
recognized	recognize	VERB	VBN	9	O
internal	internal	ADJ	JJ	5	O
organ	organ	NOUN	NN	5	O
involvement	involvement	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
disfiguring	disfigure	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
disabling	disable	VERB	VBG	5	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
cutaneous	cutaneous	ADJ	JJ	5	O
lesions	lesion	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
extensive	extensive	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
affect	affect	VERB	VB	9	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
accepted	accepted	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
proven	prove	VERB	VBN	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
localized	localize	VERB	VBN	9	B-Disease
scleroderma	scleroderma	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

Case	case	NOUN	NN	5	O
reports	report	VERB	VBZ	9	O
of	of	ADP	IN	5	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
extensive	extensive	ADJ	JJ	5	O
localized	localize	VERB	VBN	9	B-Disease
scleroderma	scleroderma	NOUN	NNS	9	I-Disease
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
are	be	VERB	VBP	5	O
summarized	summarize	VERB	VBN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
article	article	NOUN	NN	6	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
judged	judge	VERB	VBN	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
favorable	favorable	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
disease	disease	NOUN	NN	5	O
course	course	NOUN	NN	5	O
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
64	64	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Improvement	improvement	NOUN	NN	5	O
began	begin	VERB	VBD	5	O
within	within	ADP	IN	9	O
3	3	NUM	CD	9	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
consisted	consist	VERB	VBN	5	O
of	of	ADP	IN	5	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
active	active	ADJ	JJ	9	O
cutaneous	cutaneous	ADJ	JJ	5	O
lesions	lesion	NOUN	NNS	5	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
7	7	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
skin	skin	NOUN	NN	5	O
softening	softening	NOUN	NN	5	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
normal	normal	ADJ	JJ	9	O
growth	growth	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
affected	affect	VERB	VBN	9	O
limb	limb	NOUN	NN	5	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Joint	joint	ADJ	JJ	5	O
stiffness	stiffness	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
contractures	contracture	NOUN	NNS	5	B-Disease
also	also	ADV	RB	9	O
improved	improve	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
favorable	favorable	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
as	as	ADV	RB	5	O
low	low	ADJ	JJ	9	O
as	as	ADP	IN	5	O
2	2	NUM	CD	9	O
to	to	PART	TO	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
given	give	VERB	VBN	5	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
ranging	range	VERB	VBG	9	O
from	from	ADP	IN	9	O
15	15	NUM	CD	9	O
to	to	PART	TO	5	O
53	53	NUM	CD	7	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Penicillamine	Penicillamine	PROPN	NNP	0	I-Chemical
caused	cause	VERB	VBD	9	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
milder	milder	VERB	VB	9	O
reversible	reversible	ADJ	JJ	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
other	other	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
none	none	NOUN	NN	9	O
developed	develop	VERB	VBD	5	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
localized	localize	VERB	VBN	9	B-Disease
scleroderma	scleroderma	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

Cerebral	cerebral	ADJ	JJ	5	B-Disease
sinus	sinus	NOUN	NN	5	I-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
hazard	hazard	NOUN	NN	5	O
of	of	ADP	IN	5	O
antifibrinolytic	antifibrinolytic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
menorrhagia	menorrhagia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
42	42	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
superior	superior	ADJ	JJ	5	O
sagittal	sagittal	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
left	leave	VERB	VBD	5	I-Disease
transverse	transverse	NOUN	NN	5	I-Disease
sinus	sinus	NOUN	NN	5	I-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
epsilon	epsilon	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminocaproic	aminocaproic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
menorrhagia	menorrhagia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
antifibrinolytic	antifibrinolytic	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
menorrhagia	menorrhagia	NOUN	NN	5	B-Disease
to	to	PART	TO	5	O
promote	promote	VERB	VB	3	O
clotting	clotting	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
reduce	reduce	VERB	VB	5	O
blood	blood	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
thromboembolic	thromboembolic	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
epsilon	epsilon	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminocaproic	aminocaproic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
sinus	sinus	NOUN	NN	5	I-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Careful	careful	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
epsilon	epsilon	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminocaproic	aminocaproic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Seizure	seizure	VERB	VB	5	B-Disease
activity	activity	NOUN	NN	9	O
with	with	ADP	IN	5	O
imipenem	imipenem	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
vascular	vascular	ADJ	JJ	5	I-Disease
accident	accident	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
CVA	CVA	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
head	head	VERB	VB	5	B-Disease
trauma	trauma	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
developed	develop	VERB	VBD	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
while	while	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
maximum	maximum	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
imipenem	imipenem	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	I-Chemical
cilastatin	cilastatin	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Neither	neither	DET	DT	9	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
previous	previous	ADJ	JJ	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
or	or	CCONJ	CC	5	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
nor	nor	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
controlled	control	VERB	VBN	5	O
with	with	ADP	IN	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
maximum	maximum	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lactam	lactam	NOUN	NN	0	I-Chemical
antibiotics	antibiotic	NOUN	NNS	5	O
without	without	ADP	IN	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Midline	Midline	PROPN	NNP	5	O
B3	B3	PROPN	NNP	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
nerves	nerve	NOUN	NNS	5	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
medulla	medulla	NOUN	NN	9	O
are	be	VERB	VBP	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
methyldopa	methyldopa	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
experiments	experiment	NOUN	NNS	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
laboratory	laboratory	NOUN	NN	9	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
that	that	DET	DT	5	O
microinjection	microinjection	NOUN	NN	3	O
of	of	ADP	IN	5	O
methyldopa	methyldopa	NOUN	NN	0	B-Chemical
onto	onto	ADP	IN	0	O
the	the	DET	DT	5	O
ventrolateral	ventrolateral	ADJ	JJ	5	O
cells	cell	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
B3	B3	PROPN	NNP	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
medulla	medulla	NOUN	NN	9	O
elicits	elicit	VERB	VBZ	9	O
a	a	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
response	response	NOUN	NN	9	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
projection	projection	NOUN	NN	5	O
descending	descend	VERB	VBG	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
spinal	spinal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
experiments	experiment	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
midline	midline	NOUN	NN	5	O
cells	cell	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
B3	B3	PROPN	NNP	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
medulla	medulla	NOUN	NN	9	O
,	,	PUNCT	,	9	O
coinciding	coincide	VERB	VBG	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
raphe	raphe	NOUN	NN	5	O
magnus	magnus	NOUN	NN	4	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
stroke	stroke	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
prone	prone	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
microinjection	microinjection	NOUN	NN	3	O
of	of	ADP	IN	5	O
methyldopa	methyldopa	NOUN	NN	0	B-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
area	area	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
midline	midline	NOUN	NN	5	O
B3	B3	PROPN	NNP	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
cell	cell	NOUN	NN	3	O
group	group	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ventral	ventral	ADJ	JJ	5	O
medulla	medulla	NOUN	NN	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
-	-	SYM	SYM	7	O
40	40	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
maximal	maximal	ADJ	JJ	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
abolished	abolish	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
neurotoxin	neurotoxin	NOUN	NN	0	O
5	5	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
7	7	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroxytryptamine	dihydroxytryptamine	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
7	7	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DHT	DHT	PROPN	NNP	3	I-Chemical
)	)	PUNCT	-RRB-	9	O
injected	inject	VERB	VBD	3	O
intracerebroventricularly	intracerebroventricularly	ADV	RB	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
intraspinal	intraspinal	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
7	7	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DHT	DHT	PROPN	NNP	3	I-Chemical
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
selective	selective	ADJ	JJ	9	O
lesion	lesion	NOUN	NN	5	O
of	of	ADP	IN	5	O
only	only	ADV	RB	9	O
descending	descend	VERB	VBG	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
projections	projection	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
spinal	spinal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
this	this	DET	DT	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Further	further	ADV	RB	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
7	7	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DHT	DHT	PROPN	NNP	3	I-Chemical
lesion	lesion	NOUN	NN	5	O
of	of	ADP	IN	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
nerves	nerve	NOUN	NNS	5	O
travelling	travel	VERB	VBG	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
forebrain	forebrain	NOUN	NN	3	O
bundle	bundle	NOUN	NN	5	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
ascending	ascending	NOUN	NN	5	O
pathways	pathway	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
B3	B3	PROPN	NNP	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
midline	midline	NOUN	NN	5	O
B3	B3	PROPN	NNP	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
methyldopa	methyldopa	ADJ	JJ	0	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
therefore	therefore	ADV	RB	5	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
unlike	unlike	ADP	IN	9	O
the	the	DET	DT	5	O
ventrolateral	ventrolateral	ADJ	JJ	5	O
B3	B3	PROPN	NNP	9	O
cells	cell	NOUN	NNS	3	O
which	which	DET	WDT	5	O
mediate	mediate	VERB	VBP	3	O
a	a	DET	DT	5	O
methyldopa	methyldopa	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
via	via	ADP	IN	9	O
descending	descend	VERB	VBG	5	O
projections	projection	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
midline	midline	NOUN	NN	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
B3	B3	PROPN	NNP	9	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
medulla	medulla	NOUN	NN	9	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
methyldopa	methyldopa	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
either	either	CCONJ	CC	9	O
by	by	ADP	IN	9	O
way	way	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
ascending	ascend	VERB	VBG	5	O
projection	projection	NOUN	NN	5	O
which	which	DET	WDT	5	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
pass	pass	VERB	VB	5	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
forebrain	forebrain	NOUN	NN	3	O
bundle	bundle	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
through	through	ADP	IN	9	O
a	a	DET	DT	5	O
projection	projection	NOUN	NN	5	O
restricted	restrict	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
caudal	caudal	ADJ	JJ	5	O
brainstem	brainstem	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Antiarrhythmic	antiarrhythmic	ADJ	JJ	7	O
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
cibenzoline	cibenzoline	NOUN	NN	9	B-Chemical
on	on	ADP	IN	5	O
canine	canine	NOUN	NN	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
two	two	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
stage	stage	NOUN	NN	9	O
coronary	coronary	ADJ	JJ	5	O
ligation	ligation	NOUN	NN	9	O
-	-	PUNCT	:	7	O
,	,	PUNCT	,	9	O
digitalis	digitalis	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
canine	canine	NOUN	NN	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cibenzoline	cibenzoline	NOUN	NN	9	B-Chemical
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
minimum	minimum	ADJ	JJ	5	O
effective	effective	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
for	for	ADP	IN	5	O
each	each	DET	DT	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
model	model	NOUN	NN	5	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Cibenzoline	cibenzoline	NOUN	NN	_	B-Chemical
suppressed	suppress	VERB	VBD	3	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
minimum	minimum	ADJ	JJ	5	O
effective	effective	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
for	for	ADP	IN	5	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
h	h	DET	DT	0	O
coronary	coronary	ADJ	JJ	5	O
ligation	ligation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
48	48	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
h	h	NOUN	NN	0	O
coronary	coronary	ADJ	JJ	5	O
ligation	ligation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
digitalis	digitalis	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
by	by	ADP	IN	9	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
by	by	ADP	IN	9	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	PUNCT	LS	9	O
(	(	PUNCT	-LRB-	9	O
by	by	ADP	IN	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
by	by	ADP	IN	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SDM	SDM	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
for	for	ADP	IN	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
profile	profile	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
mexiletine	mexiletine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
tocainide	tocainide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
three	three	NUM	CD	9	O
drugs	drug	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CNS	CNS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
stimulant	stimulant	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
cibenzoline	cibenzoline	NOUN	NN	9	B-Chemical
had	have	VERB	VBD	9	O
only	only	ADV	RB	9	O
weak	weak	ADJ	JJ	9	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
sinus	sinus	NOUN	NN	5	O
node	node	NOUN	NN	5	O
depressive	depressive	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
orally	orally	ADV	RB	0	O
active	active	ADJ	JJ	9	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	O
ligation	ligation	NOUN	NN	9	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
dogs	dog	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
its	-PRON-	DET	PRP$	9	O
clinical	clinical	ADJ	JJ	5	O
usefulness	usefulness	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
expected	expect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Continuous	continuous	ADJ	JJ	5	O
ambulatory	ambulatory	NOUN	NN	5	O
ECG	ECG	PROPN	NNP	5	O
monitoring	monitoring	NOUN	NN	5	O
during	during	ADP	IN	5	O
fluorouracil	fluorouracil	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
there	there	ADV	EX	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
anecdotal	anecdotal	ADJ	JJ	5	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
fluorouracil	fluorouracil	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
phenomenon	phenomenon	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
systematic	systematic	ADJ	JJ	5	O
fashion	fashion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
prospectively	prospectively	ADV	RB	5	O
performed	perform	VERB	VBD	9	O
continuous	continuous	ADJ	JJ	5	O
ambulatory	ambulatory	NOUN	NN	5	O
ECG	ECG	PROPN	NNP	5	O
monitoring	monitor	VERB	VBG	5	O
on	on	ADP	IN	5	O
25	25	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
infusion	infusion	NOUN	NN	0	O
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
solid	solid	ADJ	JJ	9	O
tumors	tumor	NOUN	NNS	3	B-Disease
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
ST	ST	PROPN	NNP	9	O
changes	change	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
for	for	ADP	IN	5	O
23	23	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
before	before	ADP	IN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
infusion	infusion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
98	98	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
hours	hour	NOUN	NNS	9	O
during	during	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Anginal	anginal	ADJ	JJ	7	B-Disease
episodes	episode	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
rare	rare	ADJ	JJ	5	O
:	:	PUNCT	:	9	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
angina	angina	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
during	during	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
infusion	infusion	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
ST	ST	PROPN	NNP	9	O
changes	change	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
ST	ST	PROPN	NNP	9	O
deviation	deviation	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
common	common	ADJ	JJ	5	O
:	:	PUNCT	:	9	O
six	six	NUM	CD	9	O
of	of	ADP	IN	5	O
25	25	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
ST	ST	PROPN	NNP	9	O
changes	change	NOUN	NNS	9	O
before	before	ADP	IN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
infusion	infusion	NOUN	NN	0	O
v	v	ADP	IN	0	O
17	17	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
68	68	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
infusion	infusion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
episodes	episode	NOUN	NNS	5	O
per	per	ADP	IN	9	O
patient	patient	NOUN	NN	5	O
per	per	ADP	IN	9	O
hour	hour	NOUN	NN	0	O
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
infusion	infusion	NOUN	NN	0	O
v	v	NOUN	NN	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
13	13	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
during	during	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
infusion	infusion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
ECG	ECG	PROPN	NNP	5	O
changes	change	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
per	per	ADP	IN	9	O
patient	patient	NOUN	NN	5	O
per	per	ADP	IN	9	O
hour	hour	NOUN	NN	0	O
before	before	ADP	IN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
v	v	NOUN	NN	0	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
per	per	ADP	IN	9	O
patient	patient	NOUN	NN	5	O
per	per	ADP	IN	9	O
hour	hour	NOUN	NN	0	O
during	during	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

ECG	ECG	PROPN	NNP	5	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
among	among	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
known	know	VERB	VBN	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
sudden	sudden	ADJ	JJ	5	B-Disease
death	death	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
occurred	occur	VERB	VBD	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
course	course	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
infusion	infusion	NOUN	NN	0	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
silent	silent	ADJ	JJ	9	O
ST	ST	PROPN	NNP	9	O
segment	segment	NOUN	NN	9	O
deviation	deviation	NOUN	NN	5	O
suggestive	suggestive	NOUN	NN	9	O
of	of	ADP	IN	5	O
ischemia	ischemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
among	among	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
ECG	ECG	PROPN	NNP	5	O
changes	change	NOUN	NNS	9	O
remain	remain	VERB	VBP	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Nature	nature	NOUN	NN	2	O
,	,	PUNCT	,	9	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
dose	dose	NOUN	NN	9	O
dependence	dependence	NOUN	NN	5	O
of	of	ADP	IN	5	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
results	result	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
Multicenter	Multicenter	PROPN	NNP	2	O
Canadian	Canadian	PROPN	NNP	5	O
Azidothymidine	Azidothymidine	PROPN	NNP	0	B-Chemical
Trial	Trial	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
characterize	characterize	VERB	VB	9	O
the	the	DET	DT	5	O
nature	nature	NOUN	NN	5	O
,	,	PUNCT	,	9	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
dose	dose	NOUN	NN	9	O
dependency	dependency	NOUN	NN	5	O
of	of	ADP	IN	5	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
undertook	undertake	VERB	VBD	9	O
a	a	DET	DT	5	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
range	range	NOUN	NN	9	O
finding	find	VERB	VBG	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
study	study	NOUN	NN	9	O
group	group	NOUN	NN	9	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
74	74	NUM	CD	7	O
HIV	HIV	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
homosexual	homosexual	ADJ	JJ	5	O
men	man	NOUN	NNS	5	O
belonging	belong	VERB	VBG	4	O
to	to	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
II	II	PROPN	NNP	9	O
B	b	NOUN	NN	9	O
,	,	PUNCT	,	9	O
III	III	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
IV	IV	PROPN	NNP	9	O
C2	C2	PROPN	NNP	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
Centers	Centers	PROPN	NNPS	2	O
for	for	ADP	IN	5	O
Disease	Disease	PROPN	NNP	2	O
Control	Control	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
CDC	CDC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
classification	classification	NOUN	NN	5	O
of	of	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
observation	observation	NOUN	NN	9	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
volunteers	volunteer	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
zidovudine	zidovudine	PROPN	NNP	5	B-Chemical
600	600	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
18	18	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
900	900	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
9	9	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
1200	1200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
9	9	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
washout	washout	NOUN	NN	0	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
which	which	DET	WDT	5	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
re	re	VERB	VBN	5	O
-	-	VERB	VBN	7	O
started	start	VERB	VBN	5	O
on	on	ADP	IN	5	O
1200	1200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
highest	highest	ADV	RBS	9	O
tolerated	tolerated	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
at	at	ADP	IN	9	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hourly	hourly	ADJ	JJ	5	O
intervals	interval	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hourly	hourly	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hourly	hourly	ADJ	JJ	5	O
regimens	regimen	NOUN	NNS	5	O
within	within	ADP	IN	9	O
CDC	CDC	PROPN	NNP	9	O
groups	group	NOUN	NNS	9	O
while	while	ADP	IN	9	O
taking	take	VERB	VBG	5	O
600	600	NUM	CD	0	O
and	and	CCONJ	CC	5	O
1200	1200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
evaluations	evaluation	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
at	at	ADP	IN	9	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
intervals	interval	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Symptomatic	symptomatic	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
96	96	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
most	most	ADV	RBS	9	O
commonly	commonly	ADV	RB	5	O
nausea	nausea	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
64	64	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
fatigue	fatigue	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
55	55	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
headache	headache	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
49	49	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
were	be	VERB	VBD	9	O
generally	generally	ADV	RB	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
limited	limit	VERB	VBN	5	O
,	,	PUNCT	,	9	O
reappearing	reappear	VERB	VBG	5	O
briefly	briefly	NOUN	NN	9	O
at	at	ADP	IN	9	O
each	each	DET	DT	5	O
dose	dose	NOUN	NN	9	O
increment	increment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
occurred	occur	VERB	VBD	9	O
shortly	shortly	ADV	RB	9	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
dose	dose	NOUN	NN	9	O
dependent	dependent	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
reversed	reverse	VERB	VBD	9	O
rapidly	rapidly	ADV	RB	9	O
upon	upon	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
red	red	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cell	cell	NOUN	NN	3	O
count	count	NOUN	NN	9	O
decrease	decrease	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
cell	cell	NOUN	NN	3	O
volume	volume	NOUN	NN	9	O
increase	increase	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
granulocyte	granulocyte	NOUN	NN	3	O
count	count	NOUN	NN	9	O
decrease	decrease	NOUN	NN	9	O
developed	develop	VERB	VBD	5	O
early	early	ADV	RB	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
independent	independent	ADJ	JJ	9	O
fashion	fashion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
reverting	revert	VERB	VBG	9	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
partially	partially	ADV	RB	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
washout	washout	NOUN	NN	0	O
phase	phase	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
reticulocyte	reticulocyte	NOUN	NN	3	O
count	count	NOUN	NN	9	O
was	be	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
related	relate	VERB	VBN	9	O
between	between	ADP	IN	5	O
600	600	NUM	CD	0	O
and	and	CCONJ	CC	5	O
900	900	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
further	further	ADJ	JJ	9	O
change	change	NOUN	NN	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
escalated	escalate	VERB	VBN	5	O
to	to	ADP	IN	5	O
1200	1200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Bone	bone	NOUN	NN	9	O
marrow	marrow	NOUN	NN	3	O
changes	change	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
rapidly	rapidly	ADV	RB	9	O
as	as	ADP	IN	5	O
demonstrated	demonstrate	VERB	VBN	9	O
by	by	ADP	IN	9	O
megaloblastosis	megaloblastosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
65	65	NUM	CD	7	O
specimens	specimen	NOUN	NNS	9	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

National	national	ADJ	JJ	2	O
project	project	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
mother	mother	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
infant	infant	NOUN	NN	5	O
infection	infection	NOUN	NN	9	B-Disease
by	by	ADP	IN	9	I-Disease
hepatitis	hepatitis	PROPN	NNP	9	I-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
Japan	Japan	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
Japan	Japan	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
nationwide	nationwide	ADJ	JJ	5	O
prevention	prevention	NOUN	NN	5	O
program	program	NOUN	NN	5	O
against	against	ADP	IN	9	O
mother	mother	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
infant	infant	NOUN	NN	5	O
infection	infection	NOUN	NN	9	B-Disease
by	by	ADP	IN	9	I-Disease
hepatitis	hepatitis	PROPN	NNP	9	I-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	PROPN	NNP	9	I-Disease
(	(	PUNCT	-LRB-	9	O
HBV	HBV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
started	start	VERB	VBD	5	O
in	in	ADP	IN	5	O
1985	1985	NUM	CD	2	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
program	program	NOUN	NN	5	O
consists	consist	VERB	VBZ	5	O
of	of	ADP	IN	5	O
double	double	ADJ	JJ	9	O
screenings	screening	NOUN	NNS	5	O
of	of	ADP	IN	5	O
pregnant	pregnant	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
infants	infant	NOUN	NNS	5	O
born	bear	VERB	VBN	5	O
to	to	ADP	IN	5	O
both	both	DET	DT	9	O
hepatitis	hepatitis	PROPN	NNP	9	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
surface	surface	NOUN	NN	9	I-Chemical
antigen	antigen	NOUN	NN	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
e	e	PROPN	NNP	9	I-Chemical
antigen	antigen	NOUN	NN	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
HBeAg	HBeAg	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
positive	positive	ADJ	JJ	9	O
mothers	mother	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
infants	infant	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
two	two	NUM	CD	5	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
immune	immune	ADJ	JJ	3	O
globulin	globulin	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HBIG	HBIG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
three	three	NUM	CD	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
derived	derive	VERB	VBD	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
vaccine	vaccine	NOUN	NN	5	I-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
sent	send	VERB	VBD	5	O
questionnaires	questionnaire	NOUN	NNS	5	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
numbers	number	NOUN	NNS	9	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
examination	examination	NOUN	NN	5	O
during	during	ADP	IN	5	O
nine	nine	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
investigation	investigation	NOUN	NN	9	O
period	period	NOUN	NN	5	O
to	to	ADP	IN	5	O
each	each	DET	DT	5	O
local	local	ADJ	JJ	5	O
government	government	NOUN	NN	5	O
in	in	ADP	IN	5	O
1986	1986	NUM	CD	2	O
and	and	CCONJ	CC	5	O
1987	1987	NUM	CD	2	O
.	.	PUNCT	.	9	O

93	93	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
pregnant	pregnant	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
the	the	DET	DT	5	O
chance	chance	NOUN	NN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
examined	examine	VERB	VBN	9	O
for	for	ADP	IN	5	O
HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
HBeAg	HBeAg	PROPN	NNP	9	B-Chemical
positive	positive	ADJ	JJ	9	O
rate	rate	NOUN	NN	9	O
in	in	ADP	IN	5	O
HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
positive	positive	ADJ	JJ	9	O
was	be	VERB	VBD	9	O
23	23	NUM	CD	7	O
to	to	PART	TO	5	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
positive	positive	ADJ	JJ	9	O
rate	rate	NOUN	NN	9	O
in	in	ADP	IN	5	O
neonates	neonate	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
infants	infant	NOUN	NNS	5	O
before	before	ADP	IN	9	O
two	two	NUM	CD	5	O
months	month	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Some	some	DET	DT	5	O
problems	problem	NOUN	NNS	5	O
may	may	VERB	MD	5	O
arise	arise	VERB	VB	5	O
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
27	27	NUM	CD	7	O
to	to	PART	TO	5	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
infants	infant	NOUN	NNS	5	O
need	need	VERB	VBP	5	O
the	the	DET	DT	5	O
fourth	fourth	ADJ	JJ	9	O
vaccination	vaccination	NOUN	NN	5	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
restricted	restrict	VERB	VBN	9	O
areas	area	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mu	mu	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
opiate	opiate	ADJ	JJ	5	O
receptor	receptor	NOUN	NN	3	O
in	in	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	O
analgesia	analgesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
intradermal	intradermal	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
mu	mu	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
Tyr	Tyr	PROPN	NNP	1	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	D	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Ala	Ala	PROPN	NNP	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Gly	Gly	PROPN	NNP	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NMe	NMe	PROPN	NNP	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Phe	Phe	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Gly	Gly	PROPN	NNP	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ol	ol	PROPN	NNP	3	I-Chemical
and	and	CCONJ	CC	5	O
morphiceptin	morphiceptin	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
kappa	kappa	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
trans	trans	PROPN	NNP	9	B-Chemical
-	-	PROPN	NNP	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dichloro	dichloro	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
N	n	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
N	N	PROPN	NNP	9	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pyrrolidinyl	pyrrolidinyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
cyclohexyl	cyclohexyl	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
benzeneactemide	benzeneactemide	NOUN	NN	_	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
delta	delta	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
[	[	PUNCT	-LRB-	9	B-Chemical
D	D	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Pen2	Pen2	PROPN	NNP	1	I-Chemical
.	.	PUNCT	.	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
enkephalin	enkephalin	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
[	[	PUNCT	-LRB-	9	B-Chemical
D	D	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Ser2	ser2	NOUN	NN	1	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
Leu	Leu	PROPN	NNP	1	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
enkephalin	enkephalin	PROPN	NNP	0	I-Chemical
-	-	PUNCT	:	7	I-Chemical
Thr	Thr	PROPN	NNP	1	I-Chemical
)	)	PUNCT	-RRB-	9	O
selective	selective	ADJ	JJ	9	O
opioid	opioid	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
agonists	agonist	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
themselves	-PRON-	PRON	PRP	5	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
mechanical	mechanical	ADJ	JJ	5	O
nociceptive	nociceptive	ADJ	JJ	5	O
threshold	threshold	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hindpaw	hindpaw	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Intradermal	intradermal	ADJ	JJ	3	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
mu	mu	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
delta	delta	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
kappa	kappa	NOUN	NNS	9	O
opioid	opioid	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
agonists	agonist	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
produced	produce	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
E2	e2	NOUN	NN	3	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
analgesic	analgesic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mu	mu	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
agonist	agonist	ADJ	JJ	3	O
morphine	morphine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	:	7	O
dependently	dependently	ADV	RB	3	O
antagonized	antagonize	VERB	VBN	3	O
by	by	ADP	IN	9	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
pertussis	pertussis	NOUN	NN	9	O
toxin	toxin	NOUN	NN	1	O
.	.	PUNCT	.	9	O

Morphine	Morphine	PROPN	NNP	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
alter	alter	VERB	VB	9	O
the	the	DET	DT	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
8	8	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
bromo	bromo	NOUN	NNS	0	I-Chemical
cyclic	cyclic	ADJ	JJ	0	I-Chemical
adenosine	adenosine	NOUN	NN	0	I-Chemical
monophosphate	monophosphate	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
analgesic	analgesic	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
opioids	opioid	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
terminals	terminal	NOUN	NNS	9	O
of	of	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
afferents	afferent	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
via	via	ADP	IN	9	O
a	a	DET	DT	5	O
binding	bind	VERB	VBG	1	O
site	site	NOUN	NN	9	O
with	with	ADP	IN	5	O
characteristics	characteristic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mu	mu	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
opioid	opioid	ADJ	JJ	5	O
receptor	receptor	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
action	action	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cyclic	cyclic	ADJ	JJ	0	B-Chemical
adenosine	adenosine	NOUN	NN	0	I-Chemical
monophosphate	monophosphate	VERB	VBP	0	I-Chemical
second	second	ADJ	JJ	9	O
messenger	messenger	NOUN	NN	9	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
locus	locus	NOUN	NN	1	O
coeruleus	coeruleus	NOUN	NN	4	O
and	and	CCONJ	CC	5	O
noradrenergic	noradrenergic	ADJ	JJ	5	O
neurotransmission	neurotransmission	NOUN	NN	5	O
in	in	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
muscular	muscular	ADJ	JJ	5	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Whereas	whereas	ADP	IN	9	O
muscular	muscular	ADJ	JJ	5	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
known	know	VERB	VBN	9	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
anesthesia	anesthesia	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
paucity	paucity	NOUN	NN	9	O
of	of	ADP	IN	5	O
information	information	NOUN	NN	5	O
exists	exist	VERB	VBZ	9	O
with	with	ADP	IN	5	O
regard	regard	NOUN	NN	5	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
underlying	underlying	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
s	s	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
engagement	engagement	NOUN	NN	5	O
of	of	ADP	IN	5	O
locus	locus	NOUN	NN	1	O
coeruleus	coeruleus	NOUN	NN	4	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pons	pon	NOUN	NNS	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
phenomenon	phenomenon	NOUN	NN	5	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
male	male	NOUN	NN	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
anesthetized	anesthetize	VERB	VBD	0	O
with	with	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Under	under	ADP	IN	9	O
proper	proper	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
respiration	respiration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
body	body	NOUN	NN	5	O
temperature	temperature	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
tidal	tidal	ADJ	JJ	5	O
CO2	CO2	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
or	or	CCONJ	CC	5	O
100	100	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
consistently	consistently	ADV	RB	9	O
promoted	promote	VERB	VBD	3	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
electromyographic	electromyographic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
recorded	record	VERB	VBN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
gastrocnemius	gastrocnemius	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
abdominal	abdominal	ADJ	JJ	5	O
rectus	rectus	NOUN	NN	5	O
muscles	muscle	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Such	such	DET	PDT	5	O
an	an	DET	DT	5	O
induced	induced	ADJ	JJ	3	O
muscular	muscular	ADJ	JJ	5	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
narcotic	narcotic	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
antagonized	antagonize	VERB	VBN	3	O
or	or	CCONJ	CC	5	O
even	even	ADV	RB	5	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
prior	prior	ADJ	JJ	9	O
electrolytic	electrolytic	ADJ	JJ	0	O
lesions	lesion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
locus	locus	NOUN	NN	1	O
coeruleus	coeruleus	NOUN	NN	4	O
or	or	CCONJ	CC	5	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
blocker	blocker	NOUN	NN	0	O
,	,	PUNCT	,	9	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Microinjection	microinjection	NOUN	NN	3	O
of	of	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
50	50	NUM	CD	0	O
nl	nl	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
directly	directly	ADV	RB	9	O
into	into	ADP	IN	9	O
this	this	DET	DT	5	O
pontine	pontine	NOUN	NN	5	O
nucleus	nucleus	NOUN	NN	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
elicited	elicit	VERB	VBD	9	O
discernible	discernible	ADJ	JJ	9	O
electromyographic	electromyographic	ADJ	JJ	5	O
excitation	excitation	NOUN	NN	0	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
speculated	speculate	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
muscular	muscular	ADJ	JJ	5	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
involve	involve	VERB	VB	5	O
the	the	DET	DT	5	O
coerulospinal	coerulospinal	ADJ	JJ	9	O
noradrenergic	noradrenergic	ADJ	JJ	5	O
fibers	fiber	NOUN	NNS	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
spinal	spinal	ADJ	JJ	5	O
motoneurons	motoneuron	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Dexmedetomidine	Dexmedetomidine	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
acting	act	VERB	VBG	9	O
through	through	ADP	IN	9	O
central	central	ADJ	JJ	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
adrenoceptors	adrenoceptor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
prevents	prevent	NOUN	NNS	9	O
opiate	opiate	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
highly	highly	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
selective	selective	ADJ	JJ	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
adrenergic	adrenergic	NOUN	NN	9	O
agonist	agonist	NOUN	NN	3	O
dexmedetomidine	dexmedetomidine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
MED	MED	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
capable	capable	ADJ	JJ	9	O
of	of	ADP	IN	5	O
inducing	induce	VERB	VBG	3	O
muscle	muscle	NOUN	NN	9	B-Disease
flaccidity	flaccidity	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
anesthesia	anesthesia	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Intense	intense	ADJ	JJ	9	O
generalized	generalized	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
undesirable	undesirable	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
potent	potent	ADJ	JJ	3	O
opiate	opiate	NOUN	NN	5	O
agonists	agonist	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
neurochemistry	neurochemistry	NOUN	NN	5	O
of	of	ADP	IN	5	O
opiate	opiate	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
rigidity	rigidity	NOUN	NN	5	B-Disease
has	have	VERB	VBZ	9	O
yet	yet	ADV	RB	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
fully	fully	ADV	RB	9	O
elucidated	elucidate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
recent	recent	ADJ	JJ	5	O
work	work	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
central	central	ADJ	JJ	5	O
adrenergic	adrenergic	NOUN	NN	9	O
mechanism	mechanism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
determined	determine	VERB	VBD	9	O
if	if	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
MED	MED	PROPN	NNP	9	I-Chemical
prevents	prevent	VERB	VBZ	9	O
the	the	DET	DT	5	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
anesthesia	anesthesia	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
42	42	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
with	with	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
six	six	NUM	CD	9	O
regimens	regimen	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
L	L	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
MED	MED	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
the	the	DET	DT	5	O
inactive	inactive	ADJ	JJ	9	O
L	l	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
isomer	isomer	NOUN	NN	0	O
of	of	ADP	IN	5	O
medetomidine	medetomidine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
MED	MED	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
MED	MED	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
MED	MED	PROPN	NNP	9	I-Chemical
[	[	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
idazoxan	idazoxan	ADJ	JJ	0	B-Chemical
[	[	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
5	5	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
MED	MED	PROPN	NNP	9	I-Chemical
[	[	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
peripheral	peripheral	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
antagonist	antagonist	NOUN	NN	3	O
DG	DG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5128	5128	NUM	CD	7	I-Chemical
[	[	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
;	;	PUNCT	:	9	O
6	6	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
saline	saline	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Baseline	baseline	ADJ	JJ	9	O
electromyographic	electromyographic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
gastrocnemius	gastrocnemius	NOUN	NN	9	O
muscle	muscle	NOUN	NN	9	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Each	each	DET	DT	5	O
rat	rat	NOUN	NN	3	O
was	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
alfentanil	alfentanil	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ALF	ALF	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
sc	sc	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

ALF	alf	NOUN	NN	9	B-Chemical
injection	injection	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
hindlimb	hindlimb	ADJ	JJ	9	O
EMG	EMG	PROPN	NNP	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
L	L	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
MED	MED	PROPN	NNP	9	O
treatment	treatment	NOUN	NN	9	O
group	group	NOUN	NN	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
indistinguishable	indistinguishable	ADJ	JJ	9	O
from	from	ADP	IN	9	O
that	that	DET	DT	5	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
MED	MED	PROPN	NNP	9	I-Chemical
prevented	prevent	VERB	VBD	9	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
fashion	fashion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
small	small	ADJ	JJ	9	O
EMG	EMG	PROPN	NNP	5	O
values	value	NOUN	NNS	5	O
obtained	obtain	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
MED	MED	PROPN	NNP	9	I-Chemical
group	group	NOUN	NN	9	O
were	be	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
recorded	record	VERB	VBN	5	O
in	in	ADP	IN	5	O
earlier	early	ADJ	JJR	9	O
studies	study	NOUN	NNS	9	O
from	from	ADP	IN	9	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
not	not	ADV	RB	5	O
given	give	VERB	VBN	5	O
any	any	DET	DT	5	O
opiate	opiate	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
MED	MED	PROPN	NNP	9	I-Chemical
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
flaccid	flaccid	NOUN	NN	5	O
,	,	PUNCT	,	9	O
akinetic	akinetic	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
lacked	lack	VERB	VBD	9	O
a	a	DET	DT	5	O
startle	startle	ADJ	JJ	5	B-Disease
response	response	NOUN	NN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Some	some	DET	DT	5	O
central	central	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
repeated	repeat	VERB	VBN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
fluvoxamine	fluvoxamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
repeated	repeat	VERB	VBN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
fluvoxamine	fluvoxamine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
uptake	uptake	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dopaminomimetics	dopaminomimetic	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
methoxamine	methoxamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
animal	animal	NOUN	NN	5	O
behavior	behavior	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
"	"	PUNCT	``	5	O
behavioral	behavioral	ADJ	JJ	5	O
despair	despair	NOUN	NN	5	O
"	"	PUNCT	''	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
repeated	repeat	VERB	VBN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
fluvoxamine	fluvoxamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
twice	twice	ADV	RB	9	O
daily	daily	ADJ	JJ	5	O
for	for	ADP	IN	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
potentiated	potentiate	VERB	VBN	3	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
weaker	weak	ADJ	JJR	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
nomifensine	nomifensine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
remained	remain	VERB	VBD	9	O
unaffected	unaffected	ADJ	JJ	9	O
by	by	ADP	IN	9	O
fluvoxamine	fluvoxamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
by	by	ADP	IN	9	O
intracerebroventricularly	intracerebroventricularly	ADV	RB	3	O
administered	administer	VERB	VBN	9	O
methoxamine	methoxamine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
repeated	repeat	VERB	VBN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
fluvoxamine	fluvoxamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
fluvoxamine	fluvoxamine	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
immobilization	immobilization	NOUN	NN	0	O
time	time	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
"	"	PUNCT	``	5	O
behavioral	behavioral	ADJ	JJ	5	O
despair	despair	NOUN	NN	5	O
"	"	PUNCT	''	5	O
test	test	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
fluvoxamine	fluvoxamine	NOUN	NN	0	B-Chemical
given	give	VERB	VBN	5	O
repeatedly	repeatedly	ADV	RB	5	O
acts	act	VERB	VBZ	9	O
differently	differently	ADV	RB	9	O
than	than	ADP	IN	5	O
citalopram	citalopram	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
another	another	DET	DT	9	O
selective	selective	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
uptake	uptake	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
differs	differ	NOUN	NNS	9	O
also	also	ADV	RB	9	O
from	from	ADP	IN	9	O
other	other	ADJ	JJ	5	O
antidepressant	antidepressant	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
platelet	platelet	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
activating	activate	VERB	VBG	3	O
factor	factor	NOUN	NN	9	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
BN	BN	PROPN	NNP	9	B-Chemical
52021	52021	NUM	CD	0	I-Chemical
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
impairments	impairment	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
local	local	ADJ	JJ	5	O
anaesthetic	anaesthetic	ADJ	JJ	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
elicited	elicit	VERB	VBD	9	O
a	a	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
mean	mean	ADJ	JJ	5	I-Disease
arterial	arterial	ADJ	JJ	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
MBP	MBP	PROPN	NNP	3	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
heart	heart	NOUN	NN	5	I-Disease
rate	rate	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
HR	hr	NOUN	NN	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
death	death	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
in	in	ADP	IN	5	O
67	67	NUM	CD	7	O
%	%	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
platelet	platelet	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
activating	activate	VERB	VBG	3	O
factor	factor	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PAF	PAF	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
antagonist	antagonist	NOUN	NN	3	O
BN	BN	PROPN	NNP	9	B-Chemical
52021	52021	NUM	CD	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
bupivacaine	bupivacaine	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
suppressed	suppress	VERB	VBD	3	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
MBP	MBP	PROPN	NNP	3	I-Disease
and	and	CCONJ	CC	5	I-Disease
HR	hr	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
BN	BN	PROPN	NNP	9	B-Chemical
52021	52021	NUM	CD	0	I-Chemical
given	give	VERB	VBN	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADV	RB	9	O
or	or	CCONJ	CC	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
administered	administer	VERB	VBN	9	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
ineffective	ineffective	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
BN	BN	PROPN	NNP	9	B-Chemical
52021	52021	NUM	CD	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
reversion	reversion	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
MBP	MBP	PROPN	NNP	3	I-Disease
and	and	CCONJ	CC	5	I-Disease
HR	hr	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
was	be	VERB	VBD	9	O
ineffective	ineffective	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
partial	partial	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ECG	ECG	PROPN	NNP	5	O
alterations	alteration	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
after	after	ADP	IN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
BN	BN	PROPN	NNP	9	B-Chemical
52021	52021	NUM	CD	0	I-Chemical
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
BN	BN	PROPN	NNP	9	B-Chemical
52021	52021	NUM	CD	0	I-Chemical
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
all	all	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
studied	study	VERB	VBN	9	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
alter	alter	VERB	VB	9	O
MBP	MBP	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
HR	hr	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
used	use	VERB	VBN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
bulk	bulk	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
clearly	clearly	ADV	RB	9	O
demonstrate	demonstrate	VERB	VBP	9	O
a	a	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
BN	BN	PROPN	NNP	9	B-Chemical
52021	52021	NUM	CD	0	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
antagonist	antagonist	NOUN	NN	3	O
of	of	ADP	IN	5	O
PAF	PAF	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
against	against	ADP	IN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
direct	direct	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
,	,	PUNCT	,	9	O
PAF	PAF	PROPN	NNP	9	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
alterations	alteration	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
epidemiology	epidemiology	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
flank	flank	NOUN	NN	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	O
from	from	ADP	IN	9	O
suprofen	suprofen	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Suprofen	Suprofen	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
marketed	market	VERB	VBN	5	O
in	in	ADP	IN	5	O
early	early	ADJ	JJ	9	O
1986	1986	NUM	CD	2	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
analgesic	analgesic	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Until	until	ADP	IN	5	O
physicians	physician	NOUN	NNS	5	O
began	begin	VERB	VBD	5	O
reporting	report	VERB	VBG	5	O
an	an	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
acute	acute	ADJ	JJ	9	O
flank	flank	NOUN	NN	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
reporting	reporting	NOUN	NN	5	O
system	system	NOUN	NN	5	O
,	,	PUNCT	,	9	O
700	700	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
persons	person	NOUN	NNS	5	O
used	use	VERB	VBD	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
States	States	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Through	through	ADP	IN	5	O
August	August	PROPN	NNP	2	O
1986	1986	NUM	CD	2	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
163	163	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
elucidate	elucidate	VERB	VB	9	O
the	the	DET	DT	5	O
epidemiology	epidemiology	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
,	,	PUNCT	,	9	O
comparing	compare	VERB	VBG	9	O
62	62	NUM	CD	7	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
reporting	reporting	NOUN	NN	5	O
system	system	NOUN	NN	5	O
to	to	ADP	IN	5	O
185	185	NUM	CD	7	O
suprofen	suprofen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
who	who	PRON	WP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
the	the	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Case	case	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
men	man	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
suffer	suffer	VERB	VBP	5	O
from	from	ADP	IN	9	O
hay	hay	ADJ	JJ	4	B-Disease
fever	fever	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
asthma	asthma	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
to	to	PART	TO	5	O
participate	participate	VERB	VB	5	O
in	in	ADP	IN	5	O
regular	regular	ADJ	JJ	5	O
exercise	exercise	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
Nautilus	nautilus	ADJ	JJ	4	O
equipment	equipment	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	X	XX	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
use	use	VERB	VB	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
young	young	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
concurrent	concurrent	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
analgesic	analgesic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
especially	especially	ADV	RB	5	O
ibuprofen	ibuprofen	ADJ	JJ	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
preexisting	preexist	VERB	VBG	9	O
renal	renal	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	B-Disease
stones	stone	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
gout	gout	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
recent	recent	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
recent	recent	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
sun	sun	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
residence	residence	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Sunbelt	Sunbelt	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
were	be	VERB	VBD	9	O
findings	finding	NOUN	NNS	9	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
suggestive	suggestive	ADJ	JJ	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
reach	reach	VERB	VB	5	O
conventional	conventional	ADJ	JJ	5	O
statistical	statistical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
postulated	postulated	ADJ	JJ	9	O
mechanism	mechanism	NOUN	NN	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
syndrome	syndrome	NOUN	NN	5	O
:	:	PUNCT	:	9	O
acute	acute	ADJ	JJ	9	O
diffuse	diffuse	NOUN	NN	5	O
crystallization	crystallization	NOUN	NN	0	O
of	of	ADP	IN	5	O
uric	uric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
tubules	tubule	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Phlorizin	Phlorizin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
glycosuria	glycosuria	NOUN	NN	5	B-Disease
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
prevent	prevent	VERB	VB	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetes	diabetes	NOUN	NN	5	B-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
DM	DM	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
solute	solute	NOUN	NN	0	O
diuresis	diuresis	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
glycosuria	glycosuria	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
to	to	PART	TO	5	O
12	12	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
have	have	VERB	VBP	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
may	may	VERB	MD	5	O
in	in	ADP	IN	5	O
part	part	NOUN	NN	9	O
be	be	VERB	VB	5	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
resistance	resistance	NOUN	NN	9	O
to	to	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ARF	ARF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
protection	protection	NOUN	NN	9	O
from	from	ADP	IN	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
solute	solute	NOUN	NN	0	O
diuresis	diuresis	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
blockage	blockage	NOUN	NN	9	O
of	of	ADP	IN	5	O
tubular	tubular	ADJ	JJ	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
reabsorption	reabsorption	NOUN	NN	0	O
with	with	ADP	IN	5	O
phlorizin	phlorizin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

DM	dm	VERB	VB	9	B-Disease
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
glycosuria	glycosuria	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
degree	degree	NOUN	NN	5	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
P	p	NOUN	NN	9	B-Chemical
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Unanesthetized	unanesthetize	VERB	VBN	3	O
adult	adult	NOUN	NN	9	O
female	female	NOUN	NN	9	O
,	,	PUNCT	,	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
studied	study	VERB	VBD	9	O
for	for	ADP	IN	5	O
15	15	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Group	group	NOUN	NN	9	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	B-Chemical
alone	alone	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
P	p	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
360	360	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
15	15	NUM	CD	9	O
days	day	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
Group	Group	PROPN	NNP	9	O
II	II	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	B-Chemical
+	+	SYM	SYM	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
Group	Group	PROPN	NNP	9	O
III	III	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Group	Group	PROPN	NNP	9	O
IV	IV	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
mild	mild	ADJ	JJ	9	O
DM	DM	PROPN	NNP	9	B-Disease
+	+	SYM	SYM	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Nephrotoxic	Nephrotoxic	PROPN	NNP	0	B-Disease
doses	dose	VERB	VBZ	0	O
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
wt	wt	NOUN	NN	3	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
nine	nine	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
study	study	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
of	of	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
II	II	PROPN	NNP	9	O
to	to	ADP	IN	5	O
IV	IV	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
Group	Group	PROPN	NNP	9	O
I	I	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	B-Chemical
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
moderate	moderate	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
stable	stable	ADJ	JJ	9	O
glycosuria	glycosuria	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
SE	SE	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
functional	functional	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
morphologic	morphologic	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
baseline	baseline	NOUN	NN	5	O
CCr	CCr	NOUN	NNS	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
undetectable	undetectable	ADJ	JJ	3	O
lysozymuria	lysozymuria	NOUN	NNS	_	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
damage	damage	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
tubular	tubular	ADJ	JJ	9	B-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
score	score	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
maximum	maximum	NOUN	NN	5	O
4	4	NUM	CD	9	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
zero	zero	NUM	CD	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
Group	Group	PROPN	NNP	9	O
II	II	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
prevent	prevent	VERB	VB	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
ARF	ARF	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
maximal	maximal	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
CCr	CCr	NOUN	NNS	9	O
at	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
89	89	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	B-Chemical
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
;	;	PUNCT	:	9	O
peak	peak	NOUN	NN	9	O
lysozymuria	lysozymuria	NOUN	NN	_	O
,	,	PUNCT	,	9	O
1863	1863	NUM	CD	4	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
321	321	NUM	CD	7	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
tubular	tubular	ADJ	JJ	9	B-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
score	score	NOUN	NN	5	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
values	value	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
III	III	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
maximal	maximal	NOUN	NN	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
CCr	CCr	PROPN	NNP	9	O
73	73	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	B-Chemical
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
lysozymuria	lysozymuria	NOUN	NNS	_	O
,	,	PUNCT	,	9	O
2147	2147	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
701	701	NUM	CD	7	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
;	;	PUNCT	:	9	O
tubular	tubular	ADJ	JJ	9	B-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
score	score	NOUN	NN	5	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Catalepsy	catalepsy	NOUN	NN	0	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
combinations	combination	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
potentiation	potentiation	NOUN	NN	3	O
,	,	PUNCT	,	9	O
antagonism	antagonism	NOUN	NN	9	O
,	,	PUNCT	,	9	O
tolerance	tolerance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cross	cross	NOUN	NN	5	O
-	-	NOUN	NN	7	O
tolerance	tolerance	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
both	both	DET	DT	9	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
induced	induced	ADJ	JJ	3	O
analgesia	analgesia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
produced	produce	VERB	VBD	9	O
cross	cross	ADJ	JJ	5	O
-	-	NOUN	NN	7	O
tolerance	tolerance	NOUN	NN	9	O
to	to	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
induce	induce	VERB	VB	3	O
cross	cross	ADJ	JJ	5	O
-	-	NOUN	NN	7	O
tolerance	tolerance	NOUN	NN	9	O
to	to	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
but	but	CCONJ	CC	9	O
rather	rather	ADV	RB	5	O
augmented	augment	VERB	VBD	9	O
the	the	DET	DT	5	O
cataleptic	cataleptic	ADJ	JJ	5	B-Disease
response	response	NOUN	NN	9	O
;	;	PUNCT	:	9	O
this	this	DET	DT	5	O
augmentation	augmentation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
residual	residual	ADJ	JJ	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
explored	explore	VERB	VBD	9	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
righting	right	VERB	VBG	5	O
reflex	reflex	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
effective	effective	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
administered	administer	VERB	VBD	9	O
simultaneously	simultaneously	ADV	RB	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
mutual	mutual	ADJ	JJ	5	O
potentiation	potentiation	NOUN	NN	3	O
between	between	ADP	IN	5	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
effective	effective	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
effective	effective	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
partly	partly	ADV	RB	9	O
antagonized	antagonize	VERB	VBN	3	O
fully	fully	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
effective	effective	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Latency	latency	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
righting	right	VERB	VBG	5	O
reflex	reflex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
rigidity	rigidity	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
behavior	behavior	NOUN	NN	5	O
on	on	ADP	IN	5	O
recovery	recovery	NOUN	NN	9	O
,	,	PUNCT	,	9	O
reflected	reflect	VERB	VBD	5	O
the	the	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
predominance	predominance	NOUN	NN	9	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
combination	combination	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Naloxone	naloxone	NOUN	NN	0	B-Chemical
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
induced	induced	ADJ	JJ	3	O
cataleptic	cataleptic	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
tolerance	tolerance	NOUN	NN	9	O
to	to	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
effective	effective	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
combinations	combination	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
tolerant	tolerant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
dominant	dominant	ADJ	JJ	9	O
combinations	combination	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
tolerant	tolerant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
those	those	DET	DT	5	O
tolerant	tolerant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
dominant	dominant	ADJ	JJ	9	O
combinations	combination	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
tolerant	tolerant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
but	but	CCONJ	CC	9	O
showed	show	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
no	no	DET	DT	9	O
cross	cross	ADJ	JJ	5	O
-	-	NOUN	NN	7	O
tolerance	tolerance	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
an	an	DET	DT	5	O
augmented	augmented	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
the	the	DET	DT	5	O
mutual	mutual	ADJ	JJ	5	O
potentiation	potentiation	NOUN	NN	3	O
,	,	PUNCT	,	9	O
antagonism	antagonism	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tolerance	tolerance	NOUN	NN	9	O
suggest	suggest	VERB	VBP	9	O
common	common	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
latency	latency	NOUN	NN	5	O
,	,	PUNCT	,	9	O
rigidity	rigidity	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
behavior	behavior	NOUN	NN	5	O
,	,	PUNCT	,	9	O
asymmetry	asymmetry	NOUN	NN	5	O
of	of	ADP	IN	5	O
cross	cross	ADJ	JJ	5	O
-	-	NOUN	NN	7	O
tolerance	tolerance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
widely	widely	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
different	different	ADJ	JJ	9	O
ID50	ID50	PROPN	NNP	0	O
for	for	ADP	IN	5	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
would	would	VERB	MD	5	O
argue	argue	VERB	VB	5	O
against	against	ADP	IN	9	O
an	an	DET	DT	5	O
action	action	NOUN	NN	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
opioid	opioid	NOUN	NN	5	O
site	site	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Hydrocortisone	hydrocortisone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
pressor	pressor	NOUN	NN	5	O
responsiveness	responsiveness	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
hydrocortisone	hydrocortisone	NOUN	NN	0	B-Chemical
increases	increase	VERB	VBZ	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
enhances	enhance	VERB	VBZ	3	O
pressor	pressor	NOUN	NN	5	O
responsiveness	responsiveness	NOUN	NN	9	O
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
human	human	ADJ	JJ	3	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
week	week	NOUN	NN	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
hydrocortisone	hydrocortisone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
peripheral	peripheral	ADJ	JJ	9	O
resistance	resistance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
forearm	forearm	NOUN	NN	5	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
norepinephrine	norepinephrine	ADJ	JJ	9	B-Chemical
spillover	spillover	NOUN	NN	5	O
to	to	PART	TO	5	O
plasma	plasma	VERB	VB	9	O
in	in	ADP	IN	5	O
eight	eight	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
volunteers	volunteer	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
diastolic	diastolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
119	119	NUM	CD	7	O
to	to	PART	TO	5	O
135	135	NUM	CD	7	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
SED	SED	PROPN	NNP	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	B-Disease
cardiac	cardiac	ADJ	JJ	5	I-Disease
output	output	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
85	85	NUM	CD	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
73	73	NUM	CD	7	O
l	l	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
SED	SED	PROPN	NNP	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
46	46	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	NOUN	NNS	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Total	total	ADJ	JJ	7	O
peripheral	peripheral	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
fell	fall	VERB	VBD	5	O
from	from	ADP	IN	9	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
l	l	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
SED	sed	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Resting	rest	VERB	VBG	9	O
forearm	forearm	NOUN	NN	5	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
reflex	reflex	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
cold	cold	ADJ	JJ	9	O
pressor	pressor	NOUN	NN	5	O
test	test	NOUN	NN	5	O
was	be	VERB	VBD	9	O
accentuated	accentuate	VERB	VBN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
resistance	resistance	NOUN	NN	9	O
increasing	increase	VERB	VBG	9	O
from	from	ADP	IN	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
R	r	NOUN	NN	9	O
units	unit	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
before	before	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
to	to	ADP	IN	5	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
R	r	NOUN	NN	9	O
units	unit	NOUN	NNS	9	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
SED	SED	PROPN	NNP	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
025	025	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
forearm	forearm	NOUN	NN	5	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
accompanying	accompany	VERB	VBG	5	O
intra	intra	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
arterial	arterial	ADJ	JJ	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
,	,	PUNCT	,	9	O
50	50	NUM	CD	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
100	100	NUM	CD	0	O
ng	ng	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
after	after	ADP	IN	9	O
hydrocortisone	hydrocortisone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
increasing	increase	VERB	VBG	9	O
from	from	ADP	IN	9	O
an	an	DET	DT	5	O
average	average	NOUN	NN	5	O
of	of	ADP	IN	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
R	r	NOUN	NN	9	O
units	unit	NOUN	NNS	9	O
before	before	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
to	to	ADP	IN	5	O
35	35	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
R	r	NOUN	NN	9	O
units	unit	NOUN	NNS	9	O
after	after	ADP	IN	9	O
hydrocortisone	hydrocortisone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
SED	SED	PROPN	NNP	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
,	,	PUNCT	,	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
shift	shift	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
relation	relation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
fall	fall	VERB	VB	5	O
in	in	ADP	IN	5	O
threshold	threshold	NOUN	NN	5	O
suggested	suggest	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
sensitivity	sensitivity	NOUN	NN	9	O
to	to	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Measurement	measurement	NOUN	NN	9	O
of	of	ADP	IN	5	O
resting	rest	VERB	VBG	5	O
norepinephrine	norepinephrine	ADJ	JJ	9	B-Chemical
spillover	spillover	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
to	to	PART	TO	5	O
plasma	plasma	VERB	VB	9	O
and	and	CCONJ	CC	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
uptake	uptake	NOUN	NN	0	O
indicated	indicate	VERB	VBD	9	O
that	that	ADP	IN	5	O
overall	overall	ADV	RB	5	O
resting	rest	VERB	VBG	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
increased	increase	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rise	rise	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
resting	rest	VERB	VBG	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
hydrocortisone	hydrocortisone	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	B-Disease
cardiac	cardiac	ADJ	JJ	5	I-Disease
output	output	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
presumably	presumably	ADV	RB	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
blood	blood	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Neuromuscular	neuromuscular	ADJ	JJ	2	B-Disease
blockade	blockade	NOUN	NN	3	I-Disease
with	with	ADP	IN	5	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
tocolysis	tocolysis	NOUN	NN	5	O
with	with	ADP	IN	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
developed	develop	VERB	VBN	5	O
neuromuscular	neuromuscular	ADJ	JJ	5	B-Disease
blockade	blockade	NOUN	NN	3	I-Disease
after	after	ADP	IN	9	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
reaction	reaction	NOUN	NN	9	O
demonstrates	demonstrate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
seriously	seriously	ADV	RB	5	O
potentiate	potentiate	VERB	VB	3	O
the	the	DET	DT	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Caution	caution	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
exercised	exercise	VERB	VBN	5	O
when	when	ADV	WRB	5	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
tocolytics	tocolytic	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
combined	combine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
inhibits	inhibit	VERB	VBZ	3	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
local	local	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
kindled	kindle	VERB	VBN	5	O
by	by	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
local	local	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
kindled	kindle	VERB	VBN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
lethality	lethality	NOUN	NN	3	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
different	different	ADJ	JJ	9	O
stages	stage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
kindling	kindle	VERB	VBG	5	O
process	process	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
under	under	ADP	IN	9	O
different	different	ADJ	JJ	9	O
methods	method	NOUN	NNS	5	O
of	of	ADP	IN	5	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
oral	oral	ADJ	JJ	9	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
had	have	VERB	VBD	9	O
little	little	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
fully	fully	ADV	RB	9	O
developed	develop	VERB	VBN	5	O
local	local	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
also	also	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
mortality	mortality	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
injected	inject	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
-	-	SYM	SYM	7	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
completed	complete	VERB	VBN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
kindled	kindle	VERB	VBN	5	O
or	or	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Repeated	repeat	VERB	VBN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
also	also	ADV	RB	9	O
was	be	VERB	VBD	9	O
without	without	ADP	IN	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
kindled	kindle	VERB	VBN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
depending	depend	VERB	VBG	5	O
upon	upon	ADP	IN	9	O
stage	stage	NOUN	NN	9	O
of	of	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
development	development	NOUN	NN	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
distinct	distinct	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
underlie	underlie	VERB	VBP	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
maintenance	maintenance	NOUN	NN	9	O
of	of	ADP	IN	5	O
local	local	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
kindled	kindle	VERB	VBN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effectiveness	effectiveness	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
repeated	repeat	VERB	VBN	5	O
,	,	PUNCT	,	9	O
intermittent	intermittent	ADJ	JJ	5	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
different	different	ADJ	JJ	9	O
biochemical	biochemical	ADJ	JJ	9	O
consequences	consequence	NOUN	NNS	5	O
result	result	VERB	VBP	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
different	different	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
regimens	regimen	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
utility	utility	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
CBZ	cbz	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
human	human	ADJ	JJ	3	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
by	by	ADP	IN	9	O
these	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
remains	remain	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
directly	directly	ADV	RB	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Magnetic	magnetic	ADJ	JJ	5	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
of	of	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	O
venous	venous	ADJ	JJ	5	B-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
"	"	PUNCT	``	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
"	"	PUNCT	''	5	O
birth	birth	NOUN	NN	5	O
control	control	NOUN	NN	9	O
pills	pill	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
radiographic	radiographic	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	O
deep	deep	ADJ	JJ	5	B-Disease
venous	venous	ADJ	JJ	5	I-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
21	21	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
white	white	ADJ	JJ	9	O
woman	woman	NOUN	NN	5	O
are	be	VERB	VBP	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
nulliparous	nulliparous	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
relatively	relatively	ADV	RB	5	O
mild	mild	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
progressing	progress	VERB	VBG	5	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
changes	change	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
only	only	ADV	RB	9	O
known	know	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
was	be	VERB	VBD	9	O
"	"	PUNCT	``	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
"	"	PUNCT	``	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptive	contraceptive	ADJ	JJ	5	I-Chemical
pills	pill	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
image	image	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MRI	MRI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
signal	signal	NOUN	NN	9	O
intensity	intensity	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
internal	internal	ADJ	JJ	5	O
cerebral	cerebral	NOUN	NN	5	O
veins	vein	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
vein	vein	NOUN	NN	5	O
of	of	ADP	IN	5	O
Galen	Galen	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
straight	straight	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
was	be	VERB	VBD	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
arterial	arterial	ADJ	JJ	5	O
angiography	angiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
abolishment	abolishment	NOUN	NN	3	O
by	by	ADP	IN	9	O
oxprenolol	oxprenolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
concentration	concentration	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
relationship	relationship	NOUN	NN	5	O
of	of	ADP	IN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
computer	computer	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
aided	aid	VERB	VBN	5	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
dynamic	dynamic	ADJ	JJ	5	O
modeling	modeling	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Subsequently	subsequently	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
oxprenolol	oxprenolol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
antagonizing	antagonize	VERB	VBG	3	O
such	such	ADJ	JJ	5	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
a	a	DET	DT	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
two	two	NUM	CD	5	O
occasions	occasion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
after	after	ADP	IN	9	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
after	after	ADP	IN	9	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
oxprenolol	oxprenolol	NOUN	NN	0	B-Chemical
orally	orally	ADV	RB	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
7	7	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
period	period	NOUN	NN	5	O
after	after	ADP	IN	9	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
plasma	plasma	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
for	for	ADP	IN	5	O
determination	determination	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
drug	drug	NOUN	NN	5	O
concentrations	concentration	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
sigmoid	sigmoid	NOUN	NN	5	O
Emax	Emax	PROPN	NNP	0	O
model	model	NOUN	NN	5	O
offered	offer	VERB	VBD	5	O
a	a	DET	DT	5	O
good	good	ADJ	JJ	5	O
description	description	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
relation	relation	NOUN	NN	5	O
between	between	ADP	IN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Oxprenolol	Oxprenolol	PROPN	NNP	7	B-Chemical
caused	cause	VERB	VBD	9	O
decreases	decrease	NOUN	NNS	9	O
of	of	ADP	IN	5	O
65	65	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
56	56	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
volume	volume	NOUN	NN	9	O
of	of	ADP	IN	5	O
distribution	distribution	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
clearance	clearance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
130	130	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
AUC	AUC	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
spite	spite	NOUN	NN	9	O
of	of	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
after	after	ADP	IN	9	O
oxprenolol	oxprenolol	ADJ	JJ	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
almost	almost	ADV	RB	9	O
completely	completely	ADV	RB	9	O
antagonized	antagonize	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
beta	beta	ADJ	JJ	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
blocking	block	VERB	VBG	3	O
action	action	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
dystonia	dystonia	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
syndrome	syndrome	NOUN	NN	5	O
after	after	ADP	IN	9	O
neuropeptide	neuropeptide	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
MSH	MSH	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
ACTH	ACTH	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
locus	locus	NOUN	NN	1	O
ceruleus	ceruleus	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
movement	movement	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
has	have	VERB	VBZ	9	O
some	some	DET	DT	5	O
features	feature	NOUN	NNS	5	O
in	in	ADP	IN	5	O
common	common	ADJ	JJ	5	O
with	with	ADP	IN	5	O
human	human	ADJ	JJ	3	O
idiopathic	idiopathic	ADJ	JJ	5	O
dystonia	dystonia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
information	information	NOUN	NN	5	O
obtained	obtain	VERB	VBN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
benefit	benefit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
results	result	NOUN	NNS	9	O
indicated	indicate	VERB	VBD	9	O
that	that	ADP	IN	5	O
peptidergic	peptidergic	ADJ	JJ	3	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
LC	LC	PROPN	NNP	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
NE	NE	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
cerebellar	cerebellar	ADJ	JJ	5	O
Purkinje	Purkinje	PROPN	NNP	3	O
cells	cell	NOUN	NNS	3	O
located	locate	VERB	VBN	9	O
at	at	ADP	IN	9	O
terminals	terminal	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ceruleo	ceruleo	ADJ	JJ	_	O
-	-	PUNCT	HYPH	7	O
cerebellar	cerebellar	ADJ	JJ	5	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
certain	certain	ADJ	JJ	5	O
as	as	ADP	IN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
:	:	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
a	a	PUNCT	LS	5	O
)	)	PUNCT	-RRB-	9	O
what	what	PRON	WP	5	O
receptors	receptor	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
stimulated	stimulate	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
ACTH	ACTH	PROPN	NNP	0	B-Chemical
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
terminal	terminal	NOUN	NN	9	O
fragments	fragment	NOUN	NNS	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
LC	LC	PROPN	NNP	9	O
that	that	DET	WDT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
disorder	disorder	NOUN	NN	5	O
;	;	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
b	b	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
whether	whether	ADP	IN	9	O
NE	NE	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
released	release	VERB	VBN	9	O
onto	onto	ADP	IN	0	O
Purkinje	Purkinje	PROPN	NNP	3	O
cell	cell	NOUN	NN	3	O
synapses	synapsis	NOUN	NNS	5	O
located	locate	VERB	VBN	9	O
at	at	ADP	IN	9	O
terminals	terminal	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ceruleo	ceruleo	ADJ	JJ	_	O
-	-	PUNCT	HYPH	7	O
cerebellar	cerebellar	ADJ	JJ	5	O
pathway	pathway	NOUN	NN	3	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
indeed	indeed	ADV	RB	9	O
cause	cause	VERB	VB	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
depression	depression	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
Purkinje	Purkinje	PROPN	NNP	3	O
cell	cell	NOUN	NN	3	O
synapses	synapsis	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
previously	previously	ADV	RB	9	O
described	describe	VERB	VBN	9	O
by	by	ADP	IN	9	O
others	other	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
that	that	DET	WDT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
movement	movement	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
;	;	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
c	c	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
Purkinje	Purkinje	PROPN	NNP	3	O
cells	cell	NOUN	NNS	3	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
disinhibition	disinhibition	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
excitability	excitability	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
unilateral	unilateral	ADJ	JJ	5	O
cerebellar	cerebellar	ADJ	JJ	5	O
fastigial	fastigial	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
interpositus	interpositus	NOUN	NN	5	O
nuclei	nucleus	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
output	output	NOUN	NN	5	O
targets	target	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Purkinje	Purkinje	PROPN	NNP	3	O
cell	cell	NOUN	NN	3	O
axons	axon	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
contributing	contributing	NOUN	NN	9	O
factor	factor	NOUN	NN	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
disorder	disorder	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
questions	question	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
currently	currently	ADV	RB	5	O
being	be	VERB	VBG	5	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Enhanced	enhance	VERB	VBN	9	O
stimulus	stimulus	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neurotransmitter	neurotransmitter	NOUN	NN	9	O
overflow	overflow	NOUN	NN	5	O
in	in	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
prejunctional	prejunctional	ADJ	JJ	0	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
examines	examine	VERB	VBZ	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	VERB	VB	0	O
per	per	ADP	IN	9	O
h	h	DET	DT	0	O
,	,	PUNCT	,	9	O
s	s	X	XX	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
stimulus	stimulus	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
Hz	Hz	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
endogenous	endogenous	ADJ	JJ	3	O
neurotransmitter	neurotransmitter	NOUN	NN	9	O
overflow	overflow	ADV	RB	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
isolated	isolate	VERB	VBN	9	O
perfused	perfuse	VERB	VBN	0	O
kidney	kidney	NOUN	NN	9	O
of	of	ADP	IN	5	O
vehicle	vehicle	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
catecholamine	catecholamine	NOUN	NN	9	B-Chemical
stores	store	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
stimulus	stimulus	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
overflow	overflow	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
vehicle	vehicle	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
incorporation	incorporation	NOUN	NN	0	O
of	of	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
into	into	ADP	IN	9	O
renal	renal	ADJ	JJ	9	O
catecholamine	catecholamine	NOUN	NN	9	B-Chemical
stores	store	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
that	that	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
catecholamine	catecholamine	NOUN	NN	9	B-Chemical
present	present	NOUN	NN	9	O
was	be	VERB	VBD	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
content	content	NOUN	NN	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
degree	degree	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Total	total	ADJ	JJ	7	O
tissue	tissue	NOUN	NN	9	O
catecholamine	catecholamine	NOUN	NN	9	B-Chemical
content	content	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
molar	molar	ADJ	JJ	0	O
basis	basis	NOUN	NN	5	O
was	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Stimulus	stimulus	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
fractional	fractional	ADJ	JJ	5	O
overflow	overflow	NOUN	NN	5	O
of	of	ADP	IN	5	O
neurotransmitter	neurotransmitter	NOUN	NN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
kidneys	kidney	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
approximately	approximately	ADV	RB	9	O
twice	twice	ADV	RB	9	O
normal	normal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
consisted	consisted	ADJ	JJ	5	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
proportions	proportion	NOUN	NNS	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
fractional	fractional	ADJ	JJ	5	O
overflow	overflow	NOUN	NN	5	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
neuronal	neuronal	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
extraneuronal	extraneuronal	ADJ	JJ	0	O
uptake	uptake	ADJ	JJ	0	O
blockade	blockade	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Propranolol	Propranolol	PROPN	NNP	0	B-Chemical
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
stimulus	stimulus	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
overflow	overflow	NOUN	NN	5	O
in	in	ADP	IN	5	O
either	either	DET	DT	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Phentolamine	Phentolamine	PROPN	NNP	0	B-Chemical
increased	increase	VERB	VBD	9	O
stimulus	stimulus	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
overflow	overflow	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
increment	increment	NOUN	NN	9	O
in	in	ADP	IN	5	O
overflow	overflow	NOUN	NN	5	O
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
chronic	chronic	ADJ	JJ	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
enhanced	enhance	VERB	VBN	3	O
fractional	fractional	ADJ	JJ	5	O
neurotransmitter	neurotransmitter	NOUN	NN	9	O
overflow	overflow	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
neither	neither	DET	DT	9	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
prejunctional	prejunctional	ADJ	JJ	0	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
influences	influence	NOUN	NNS	5	O
nor	nor	CCONJ	CC	9	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
neuronal	neuronal	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
extraneuronal	extraneuronal	ADJ	JJ	0	O
uptake	uptake	NOUN	NN	0	O
mechanisms	mechanism	NOUN	NNS	9	O
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
alteration	alteration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
data	datum	NOUN	NNS	5	O
obtained	obtain	VERB	VBN	9	O
with	with	ADP	IN	5	O
phentolamine	phentolamine	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
suggest	suggest	VERB	VB	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
desensitization	desensitization	NOUN	NN	3	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
enhanced	enhance	VERB	VBN	3	O
neurotransmitter	neurotransmitter	NOUN	NN	9	O
overflow	overflow	ADV	RB	5	O
after	after	ADP	IN	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

GABA	GABA	PROPN	NNP	0	B-Chemical
involvement	involvement	NOUN	NN	9	O
in	in	ADP	IN	5	O
naloxone	naloxone	ADV	RB	0	B-Chemical
induced	induced	ADJ	JJ	3	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
paralysis	paralysis	NOUN	NN	5	I-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
thiopental	thiopental	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
agent	agent	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
yet	yet	ADV	RB	9	O
available	available	ADJ	JJ	5	O
to	to	PART	TO	5	O
reverse	reverse	VERB	VB	9	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
paralysis	paralysis	NOUN	NN	5	I-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
CNS	CNS	PROPN	NNP	9	O
depressants	depressant	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
general	general	ADJ	JJ	5	O
anesthetics	anesthetic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
naloxone	naloxone	ADV	RB	0	B-Chemical
reversed	reverse	VERB	VBD	9	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
paralysis	paralysis	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
thiopental	thiopental	ADJ	JJ	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
thiopental	thiopental	ADJ	JJ	0	B-Chemical
produced	produce	VERB	VBN	9	O
anesthesia	anesthesia	NOUN	NN	5	O
without	without	ADP	IN	9	O
altering	alter	VERB	VBG	9	O
respiratory	respiratory	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBD	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
aspartate	aspartate	NOUN	NN	1	B-Chemical
or	or	CCONJ	CC	5	O
glycine	glycine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
cortex	cortex	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
stem	stem	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
thiosemicarbazide	thiosemicarbazide	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
30	30	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
abolished	abolish	VERB	VBD	3	O
the	the	DET	DT	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
respiratory	respiratory	ADJ	JJ	5	O
depressant	depressant	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
thiopental	thiopental	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
thiopental	thiopental	ADJ	JJ	0	B-Chemical
produced	produce	VERB	VBD	9	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
with	with	ADP	IN	5	O
further	further	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
decrease	decrease	VERB	VB	9	O
in	in	ADP	IN	5	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
again	again	ADV	RB	9	O
in	in	ADP	IN	5	O
cortex	cortex	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
stem	stem	NOUN	NN	3	O
without	without	ADP	IN	9	O
affecting	affect	VERB	VBG	9	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
amino	amino	ADJ	JJ	1	B-Chemical
acids	acid	NOUN	NNS	0	I-Chemical
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
regions	region	NOUN	NNS	9	O
of	of	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Naloxone	naloxone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
reversed	reverse	VERB	VBD	9	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
paralysis	paralysis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
levels	level	NOUN	NNS	3	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
values	value	NOUN	NNS	5	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
stem	stem	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
cortex	cortex	NOUN	NN	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
caudate	caudate	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
cerebellum	cerebellum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
naloxone	naloxone	ADV	RB	0	B-Chemical
reverses	reverse	NOUN	NNS	3	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
paralysis	paralysis	NOUN	NN	5	I-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
thiopental	thiopental	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
involves	involve	VERB	VBZ	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
action	action	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Diazepam	diazepam	NOUN	NN	0	B-Chemical
facilitates	facilitate	NOUN	NNS	9	O
reflex	reflex	VERB	VBP	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
,	,	PUNCT	,	9	O
reflex	reflex	ADJ	JJ	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
produced	produce	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
by	by	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
pretreatment	pretreatment	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
causing	cause	VERB	VBG	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
pressor	pressor	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
enhance	enhance	VERB	VB	9	O
the	the	DET	DT	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
reflex	reflex	ADJ	JJ	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
reflex	reflex	ADJ	JJ	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
antagonized	antagonize	VERB	VBN	3	O
by	by	ADP	IN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
intravenous	intravenous	ADJ	JJ	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
an	an	DET	DT	5	O
agent	agent	NOUN	NN	9	O
blocks	block	VERB	VBZ	9	O
chloride	chloride	NOUN	NN	0	B-Chemical
channels	channel	NOUN	NNS	9	O
by	by	ADP	IN	9	O
binding	bind	VERB	VBG	1	O
to	to	ADP	IN	5	O
sites	site	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
benzodiazepine	benzodiazepine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
GABA	gaba	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
chloride	chloride	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
macromolecular	macromolecular	NOUN	NN	0	O
complex	complex	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
acts	act	VERB	VBZ	9	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
benzodiazepine	benzodiazepine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
GABA	gaba	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
chloride	chloride	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
macromolecular	macromolecular	NOUN	NN	0	O
complex	complex	NOUN	NN	9	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
to	to	PART	TO	5	O
facilitate	facilitate	VERB	VB	5	O
reflex	reflex	ADJ	JJ	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
mediated	mediate	VERB	VBN	3	O
through	through	ADP	IN	9	O
baroreceptor	baroreceptor	NOUN	NN	5	O
reflexes	reflex	NOUN	NNS	5	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Initial	initial	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
loss	loss	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
hypokalaemia	hypokalaemia	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
chlorthalidone	chlorthalidone	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
essential	essential	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
dietary	dietary	ADJ	JJ	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
restriction	restriction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
loss	loss	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypokalaemia	hypokalaemia	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
oral	oral	ADJ	JJ	9	O
diuretic	diuretic	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
metabolic	metabolic	ADJ	JJ	9	O
balance	balance	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
ten	ten	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
essential	essential	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
shown	show	VERB	VBN	9	O
hypokalaemia	hypokalaemia	NOUN	NN	5	B-Disease
under	under	ADP	IN	9	O
prior	prior	ADJ	JJ	9	O
oral	oral	ADJ	JJ	9	O
diuretic	diuretic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Chlorthalidone	Chlorthalidone	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
for	for	ADP	IN	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
sodium	sodium	NOUN	NN	0	B-Chemical
diet	diet	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
four	four	NUM	CD	9	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
sodium	sodium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
diet	diet	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
initial	initial	ADJ	JJ	9	O
total	total	ADJ	JJ	9	O
body	body	NOUN	NN	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
40K	40k	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
electrolyte	electrolyte	NOUN	NN	0	O
balances	balance	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
bromide	bromide	ADP	IN	0	O
space	space	NOUN	NN	5	O
,	,	PUNCT	,	9	O
plasma	plasma	NOUN	NN	9	O
renin	renin	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
secretion	secretion	NOUN	NN	3	O
rate	rate	NOUN	NN	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
a	a	DET	DT	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
deficit	deficit	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
proportionally	proportionally	ADV	RB	9	O
larger	large	ADJ	JJR	5	O
losses	loss	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
extracellular	extracellular	NOUN	NN	9	O
than	than	ADP	IN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
intracellular	intracellular	ADJ	JJ	3	O
compartment	compartment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
sodium	sodium	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
mean	mean	ADJ	JJ	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
deficit	deficit	NOUN	NN	5	O
was	be	VERB	VBD	9	O
176	176	NUM	CD	7	O
mmol	mmol	NOUN	NN	0	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
which	which	DET	WDT	5	O
some	some	DET	DT	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
regained	regain	VERB	VBN	5	O
;	;	PUNCT	:	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
sodium	sodium	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
deficit	deficit	NOUN	NN	5	O
was	be	VERB	VBD	9	O
276	276	NUM	CD	7	O
mmol	mmol	NOUN	NN	0	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
sodium	sodium	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
an	an	DET	DT	5	O
immediate	immediate	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
temporary	temporary	ADJ	JJ	5	O
rise	rise	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
renin	renin	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
levels	level	NOUN	NNS	3	O
;	;	PUNCT	:	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
sodium	sodium	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
renin	renin	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
increased	increase	VERB	VBD	9	O
more	more	ADV	RBR	5	O
slowly	slowly	ADV	RB	5	O
but	but	CCONJ	CC	9	O
remained	remain	VERB	VBD	9	O
elevated	elevated	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
dietary	dietary	ADJ	JJ	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
restriction	restriction	NOUN	NN	9	O
increases	increase	VERB	VBZ	9	O
diuretic	diuretic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
potassium	potassium	NOUN	NN	0	B-Chemical
loss	loss	NOUN	NN	9	O
,	,	PUNCT	,	9	O
presumably	presumably	ADV	RB	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
increased	increased	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
renin	renin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
system	system	NOUN	NN	5	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
delivery	delivery	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
distal	distal	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
tubules	tubule	NOUN	NNS	9	O
remains	remain	VERB	VBZ	9	O
sufficiently	sufficiently	ADV	RB	5	O
high	high	ADJ	JJ	9	O
to	to	PART	TO	5	O
allow	allow	VERB	VB	5	O
increased	increase	VERB	VBN	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
secretion	secretion	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
novel	novel	ADJ	JJ	9	O
aryl	aryl	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
piperazine	piperazine	NOUN	NN	0	I-Chemical
anxiolytic	anxiolytic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
anxiolytic	anxiolytic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
buspirone	buspirone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
reverses	reverse	VERB	VBZ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
aryl	aryl	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
piperazine	piperazine	NOUN	NN	0	I-Chemical
analogues	analogue	NOUN	NNS	0	O
of	of	ADP	IN	5	O
buspirone	buspirone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxytryptaminergic	hydroxytryptaminergic	NOUN	NN	_	I-Chemical
agonists	agonist	NOUN	NNS	3	I-Chemical
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
for	for	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
reverse	reverse	VERB	VB	9	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Those	those	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
with	with	ADP	IN	5	O
strong	strong	ADJ	JJ	9	O
affinity	affinity	NOUN	NN	0	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxytryptamine1a	hydroxytryptamine1a	ADJ	JJ	_	I-Chemical
receptors	receptor	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
reverse	reverse	VERB	VB	9	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Drugs	drug	NOUN	NNS	0	O
with	with	ADP	IN	5	O
affinity	affinity	NOUN	NN	0	O
for	for	ADP	IN	5	O
other	other	ADJ	JJ	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
receptors	receptor	NOUN	NNS	3	O
or	or	CCONJ	CC	5	O
weak	weak	ADJ	JJ	9	O
affinity	affinity	NOUN	NN	0	O
were	be	VERB	VBD	9	O
ineffective	ineffective	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
postsynaptic	postsynaptic	ADJ	JJ	3	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
receptors	receptor	NOUN	NNS	3	O
neither	neither	CCONJ	CC	9	O
inhibited	inhibit	VERB	VBD	3	O
nor	nor	CCONJ	CC	9	O
potentiated	potentiate	VERB	VBN	3	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
leaves	leave	NOUN	NNS	4	O
open	open	VERB	VBP	5	O
the	the	DET	DT	5	O
question	question	NOUN	NN	5	O
as	as	ADP	IN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
site	site	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
mechanism	mechanism	NOUN	NN	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Glycopyrronium	glycopyrronium	NOUN	NN	0	B-Chemical
requirements	requirement	NOUN	NNS	5	O
for	for	ADP	IN	5	O
antagonism	antagonism	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
muscarinic	muscarinic	ADJ	JJ	3	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
edrophonium	edrophonium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
compared	compare	VERB	VBN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
60	60	NUM	CD	9	O
adult	adult	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
glycopyrronium	glycopyrronium	NOUN	NN	0	B-Chemical
5	5	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
given	give	VERB	VBN	5	O
either	either	CCONJ	CC	9	O
simultaneously	simultaneously	ADV	RB	5	O
or	or	CCONJ	CC	5	O
1	1	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
edrophonium	edrophonium	NOUN	NN	0	B-Chemical
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O

Significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
four	four	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
receiving	receive	VERB	VBG	9	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
showed	show	VERB	VBD	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
30	30	NUM	CD	9	O
beat	beat	VERB	VBN	5	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
limits	limit	VERB	VBZ	5	O
28	28	NUM	CD	7	O
-	-	SYM	SYM	7	O
32	32	NUM	CD	7	O
beat	beat	VERB	VBN	5	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Use	Use	PROPN	NNP	5	O
of	of	ADP	IN	5	O
glycopyrronium	glycopyrronium	NOUN	NN	0	B-Chemical
5	5	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
provided	provide	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
stability	stability	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
1	1	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
edrophonium	edrophonium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
sufficient	sufficient	ADJ	JJ	9	O
to	to	PART	TO	5	O
minimize	minimize	VERB	VB	5	O
early	early	ADV	RB	9	O
,	,	PUNCT	,	9	O
edrophonium	edrophonium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
bradycardias	bradycardias	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
glycopyrronium	glycopyrronium	NOUN	NN	0	B-Chemical
provided	provide	VERB	VBN	9	O
good	good	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
oropharyngeal	oropharyngeal	ADJ	JJ	5	O
secretions	secretion	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Selective	selective	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
iopentol	iopentol	NOUN	NN	_	B-Chemical
,	,	PUNCT	,	9	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
metrizoate	metrizoate	VERB	VB	0	B-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dog	dog	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
aortic	aortic	ADJ	JJ	9	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
twenty	twenty	NUM	CD	5	O
beagle	beagle	NOUN	NN	0	O
dogs	dog	NOUN	NNS	5	O
selective	selective	ADJ	JJ	9	O
injections	injection	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
with	with	ADP	IN	5	O
iopentol	iopentol	NOUN	NN	_	B-Chemical
,	,	PUNCT	,	9	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
metrizoate	metrizoate	ADJ	JJ	0	B-Chemical
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
ml	ml	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
16	16	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
iopentol	iopentol	NOUN	NN	_	B-Chemical
injections	injection	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
35	35	NUM	CD	9	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
injections	injection	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
37	37	NUM	CD	9	O
metrizoate	metrizoate	ADJ	JJ	0	B-Chemical
injections	injection	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Frequencies	frequency	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
iopentol	iopentol	NOUN	NN	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
after	after	ADP	IN	9	O
metrizoate	metrizoate	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Iopentol	Iopentol	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
iohexol	iohexol	ADJ	JJ	0	B-Chemical
also	also	ADV	RB	9	O
produced	produce	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADJ	JJR	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
aortic	aortic	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
than	than	ADP	IN	5	O
metrizoate	metrizoate	ADJ	JJ	0	B-Chemical
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
different	different	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Thyroid	Thyroid	PROPN	NNP	9	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
concentrating	concentrate	VERB	VBG	5	O
ability	ability	NOUN	NN	9	O
during	during	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
adenylate	adenylate	ADJ	JJ	0	O
cyclase	cyclase	NOUN	NN	0	O
inhibition	inhibition	NOUN	NN	3	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
important	important	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
hypothyroidism	hypothyroidism	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
measured	measure	VERB	VBD	9	O
serum	serum	ADJ	JJ	9	O
thyroxine	thyroxine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
concentrating	concentrate	VERB	VBG	5	O
ability	ability	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Umax	Umax	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
desmopressin	desmopressin	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
DDAVP	DDAVP	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
85	85	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Hypothyroidism	hypothyroidism	NOUN	NN	7	B-Disease
developed	develop	VERB	VBD	5	O
in	in	ADP	IN	5	O
eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
while	while	ADP	IN	9	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
taking	take	VERB	VBG	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Impaired	Impaired	PROPN	NNP	9	O
Umax	Umax	PROPN	NNP	0	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
euthyroid	euthyroid	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
hypothyroid	hypothyroid	ADJ	JJ	9	B-Disease
patients	patient	NOUN	NNS	5	O
while	while	ADP	IN	9	O
some	some	DET	DT	5	O
hypothyroid	hypothyroid	ADJ	JJ	9	B-Disease
patients	patient	NOUN	NNS	5	O
concentrated	concentrate	VERB	VBD	0	O
their	-PRON-	DET	PRP$	5	O
urine	urine	NOUN	NN	9	O
well	well	ADV	RB	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
dominant	dominant	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
exerts	exert	VERB	VBZ	9	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
effects	effect	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
different	different	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Remodelling	remodelling	NOUN	NN	5	O
of	of	ADP	IN	5	O
nerve	nerve	NOUN	NN	5	O
structure	structure	NOUN	NN	9	O
in	in	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
neuropathy	neuropathy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
computer	computer	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
assisted	assist	VERB	VBN	5	O
morphometric	morphometric	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Scatter	Scatter	PROPN	NNP	9	O
diagrams	diagram	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
g	g	NOUN	NN	0	O
ratio	ratio	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
quotient	quotient	ADJ	JJ	5	O
fibre	fibre	NOUN	NN	0	O
diameter	diameter	NOUN	NN	9	O
/	/	SYM	SYM	9	O
axon	axon	VERB	VB	5	O
diameter	diameter	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
define	define	VERB	VB	5	O
regenerating	regenerate	VERB	VBG	9	O
fibres	fibre	NOUN	NNS	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
distinct	distinct	ADJ	JJ	9	O
population	population	NOUN	NN	5	O
,	,	PUNCT	,	9	O
distinguishable	distinguishable	ADJ	JJ	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
surviving	survive	VERB	VBG	9	O
fibres	fibre	NOUN	NNS	9	O
by	by	ADP	IN	9	O
reduced	reduced	ADJ	JJ	9	O
sheath	sheath	NOUN	NN	9	O
thickness	thickness	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
reduced	reduced	ADJ	JJ	9	O
axon	axon	NOUN	NN	5	O
calibre	calibre	ADV	RB	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
subtle	subtle	ADJ	JJ	5	O
direct	direct	ADJ	JJ	9	O
toxic	toxic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
fibre	fibre	NOUN	NN	0	O
population	population	NOUN	NN	5	O
,	,	PUNCT	,	9	O
causing	cause	VERB	VBG	9	O
axon	axon	VERB	VBD	5	O
shrinkage	shrinkage	NOUN	NN	5	O
masked	mask	VERB	VBN	5	O
by	by	ADP	IN	9	O
readjustment	readjustment	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
myelin	myelin	ADJ	JJ	3	O
sheath	sheath	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Multicenter	Multicenter	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
multiple	multiple	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
parallel	parallel	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
groups	group	NOUN	NNS	9	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
azelastine	azelastine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
chlorpheniramine	chlorpheniramine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
spring	spring	NOUN	NN	4	B-Disease
allergic	allergic	ADJ	JJ	9	I-Disease
rhinitis	rhinitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Azelastine	Azelastine	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
antiallergic	antiallergic	NOUN	NN	0	O
medication	medication	NOUN	NN	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
chlorpheniramine	chlorpheniramine	NOUN	NN	0	B-Chemical
maleate	maleate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
for	for	ADP	IN	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
spring	spring	NOUN	NN	4	B-Disease
allergic	allergic	ADJ	JJ	9	I-Disease
rhinitis	rhinitis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
multiple	multiple	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
parallel	parallel	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
groups	group	NOUN	NNS	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
hundred	hundred	NUM	CD	5	O
fifty	fifty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
participated	participate	VERB	VBD	5	O
.	.	PUNCT	.	9	O

Subjects	subject	NOUN	NNS	5	O
ranged	range	VERB	VBD	9	O
in	in	ADP	IN	5	O
age	age	NOUN	NN	5	O
from	from	ADP	IN	9	O
18	18	NUM	CD	7	O
to	to	PART	TO	5	O
60	60	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
spring	spring	NOUN	NN	4	B-Disease
allergic	allergic	ADJ	JJ	9	I-Disease
rhinitis	rhinitis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
positive	positive	ADJ	JJ	9	O
skin	skin	NOUN	NN	5	O
test	test	NOUN	NN	5	O
to	to	PART	TO	5	O
spring	spring	NOUN	NN	4	O
aeroallergens	aeroallergen	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Medications	medication	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
four	four	NUM	CD	9	O
times	time	NOUN	NNS	5	O
daily	daily	ADV	RB	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
azelastine	azelastine	NOUN	NN	0	B-Chemical
groups	group	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
morning	morning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
evening	evening	NOUN	NN	5	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
late	late	ADJ	JJ	9	O
afternoon	afternoon	NOUN	NN	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
chlorpheniramine	chlorpheniramine	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
received	receive	VERB	VBD	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
four	four	NUM	CD	9	O
times	time	NOUN	NNS	5	O
daily	daily	ADV	RB	5	O
.	.	PUNCT	.	9	O

Daily	daily	ADJ	JJ	5	O
subject	subject	ADJ	JJ	5	O
symptom	symptom	NOUN	NN	5	O
cards	card	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
completed	complete	VERB	VBN	5	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
screening	screening	NOUN	NN	5	O
period	period	NOUN	NN	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
pretreatment	pretreatment	ADJ	JJ	0	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
period	period	NOUN	NN	5	O
while	while	ADP	IN	9	O
subjects	subject	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
study	study	NOUN	NN	9	O
medications	medication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Individual	individual	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
major	major	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Elicited	elicit	VERB	VBN	3	O
,	,	PUNCT	,	9	O
volunteered	volunteer	VERB	VBD	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
observed	observe	VERB	VBD	9	O
adverse	adverse	ADJ	JJ	5	O
experiences	experience	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
for	for	ADP	IN	5	O
each	each	DET	DT	5	O
subject	subject	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBN	9	O
among	among	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Vital	vital	ADJ	JJ	2	O
signs	sign	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
body	body	NOUN	NN	5	O
weights	weight	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
serum	serum	ADJ	JJ	9	O
chemistry	chemistry	NOUN	NN	0	O
values	value	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
complete	complete	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cell	cell	NOUN	NN	3	O
counts	count	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
urine	urine	NOUN	NN	9	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
electrocardiograms	electrocardiogram	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
for	for	ADP	IN	5	O
each	each	DET	DT	5	O
subject	subject	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBN	9	O
among	among	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Symptoms	symptom	NOUN	NNS	5	O
relief	relief	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
receiving	receive	VERB	VBG	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
azelastine	azelastine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
twice	twice	ADV	RB	9	O
daily	daily	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
during	during	ADP	IN	5	O
all	all	DET	DT	5	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lower	low	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
azelastine	azelastine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
more	more	ADV	RBR	5	O
effective	effective	ADJ	JJ	5	O
than	than	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
only	only	ADV	RB	9	O
during	during	ADP	IN	5	O
portions	portion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
chlorpheniramine	chlorpheniramine	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
did	do	VERB	VBD	9	O
have	have	VERB	VB	5	O
fewer	few	ADJ	JJR	5	O
symptoms	symptom	NOUN	NNS	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
difference	difference	NOUN	NN	9	O
never	never	ADV	RB	5	O
reached	reach	VERB	VBD	9	O
statistical	statistical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
during	during	ADP	IN	5	O
any	any	DET	DT	5	O
week	week	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
serious	serious	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Drowsiness	drowsiness	NOUN	NN	7	B-Disease
and	and	CCONJ	CC	5	O
altered	altered	ADJ	JJ	9	B-Disease
taste	taste	NOUN	NN	5	I-Disease
perception	perception	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
significantly	significantly	ADV	RB	9	O
over	over	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
azelastine	azelastine	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Azelastine	Azelastine	PROPN	NNP	7	B-Chemical
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
safe	safe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
efficacious	efficacious	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
for	for	ADP	IN	5	O
seasonal	seasonal	ADJ	JJ	5	B-Disease
allergic	allergic	ADJ	JJ	9	I-Disease
rhinitis	rhinitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Toxicity	toxicity	NOUN	NN	9	B-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
remission	remission	NOUN	NN	5	O
inducing	induce	VERB	VBG	3	O
drugs	drug	NOUN	NNS	5	O
in	in	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Association	association	NOUN	NN	2	O
with	with	ADP	IN	5	O
HLA	HLA	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
B35	B35	PROPN	NNP	7	O
and	and	CCONJ	CC	5	O
Cw4	Cw4	PROPN	NNP	7	O
antigens	antigen	VERB	VBZ	3	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
RA	RA	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
while	while	ADP	IN	9	O
taking	take	VERB	VBG	5	O
remission	remission	NOUN	NN	5	O
inducing	induce	VERB	VBG	3	O
drugs	drug	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
without	without	ADP	IN	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
for	for	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
associations	association	NOUN	NNS	5	O
with	with	ADP	IN	5	O
class	class	NOUN	NN	9	O
I	I	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
II	II	PROPN	NNP	9	O
HLA	HLA	PROPN	NNP	9	O
antigens	antigen	VERB	VBZ	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
strong	strong	ADJ	JJ	9	O
association	association	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
found	find	VERB	VBN	9	O
between	between	ADP	IN	5	O
nephritis	nephritis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
dermatitis	dermatitis	NOUN	NN	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
Tiopronin	Tiopronin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
a	a	DET	DT	5	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Penicillamine	penicillamine	NOUN	NN	0	I-Chemical
like	like	ADP	IN	9	O
compound	compound	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
class	class	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
antigens	antigen	VERB	VBZ	3	O
B35	B35	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
Cw4	Cw4	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
between	between	ADP	IN	5	O
dermatitis	dermatitis	NOUN	NN	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
gold	gold	NOUN	NN	0	B-Chemical
thiosulphate	thiosulphate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
B35	B35	PROPN	NNP	7	O
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
controls	control	NOUN	NNS	9	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
DR5	dr5	ADJ	JJ	3	O
frequency	frequency	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
RA	RA	PROPN	NNP	9	B-Disease
except	except	ADP	IN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
Tiopronin	Tiopronin	PROPN	NNP	0	B-Chemical
related	relate	VERB	VBN	9	O
nephritis	nephritis	NOUN	NN	9	B-Disease
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Transient	transient	ADJ	JJ	9	O
contralateral	contralateral	ADJ	JJ	5	B-Disease
rotation	rotation	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
unilateral	unilateral	ADJ	JJ	5	O
substantia	substantia	NOUN	NN	9	B-Disease
nigra	nigra	NOUN	NN	4	I-Disease
lesion	lesion	NOUN	NN	5	I-Disease
reflects	reflect	VERB	VBZ	5	O
susceptibility	susceptibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
nigrostriatal	nigrostriatal	ADJ	JJ	3	O
system	system	NOUN	NN	5	O
to	to	PART	TO	5	O
exhaustion	exhaustion	NOUN	NN	9	O
by	by	ADP	IN	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
unilateral	unilateral	ADJ	JJ	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
OHDA	ohda	NOUN	NN	0	I-Chemical
induced	induce	VERB	VBN	3	O
SN	sn	NOUN	NN	9	B-Disease
lesion	lesion	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
transient	transient	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
contralateral	contralateral	ADJ	JJ	5	B-Disease
rotation	rotation	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
precede	precede	VERB	VB	9	O
the	the	DET	DT	5	O
predominant	predominant	ADJ	JJ	9	O
ipsilateral	ipsilateral	ADJ	JJ	5	B-Disease
circling	circling	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
clarify	clarify	VERB	VB	9	O
the	the	DET	DT	5	O
nature	nature	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
contralateral	contralateral	ADJ	JJ	5	B-Disease
rotation	rotation	NOUN	NN	5	I-Disease
we	-PRON-	PRON	PRP	5	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
recovery	recovery	NOUN	NN	9	O
period	period	NOUN	NN	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
lesion	lesion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rotational	rotational	ADJ	JJ	5	B-Disease
behavior	behavior	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
days	day	NOUN	NNS	9	O
post	post	NOUN	NN	9	O
lesion	lesion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
most	most	ADJ	JJS	9	O
rats	rat	NOUN	NNS	9	O
circled	circle	VERB	VBD	9	O
predominantly	predominantly	ADV	RB	9	O
contralaterally	contralaterally	ADV	RB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
lesion	lesion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
contralateral	contralateral	ADJ	JJ	5	B-Disease
rotation	rotation	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
from	from	ADP	IN	9	O
either	either	DET	DT	9	O
degeneration	degeneration	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
breakdown	breakdown	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
DA	DA	PROPN	NNP	9	O
pool	pool	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
lesion	lesion	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
DA	DA	PROPN	NNP	9	O
turnover	turnover	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
spared	spare	VERB	VBN	5	O
neurons	neuron	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
substantial	substantial	ADJ	JJ	9	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
contralateral	contralateral	ADJ	JJ	5	O
preference	preference	NOUN	NN	5	O
was	be	VERB	VBD	9	O
still	still	ADV	RB	5	O
evident	evident	ADJ	JJ	9	O
when	when	ADV	WRB	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
24	24	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
lesioning	lesione	VERB	VBG	5	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
spared	spare	VERB	VBN	5	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
contralateral	contralateral	ADJ	JJ	5	B-Disease
rotation	rotation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
regardless	regardless	ADV	RB	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
recovery	recovery	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
and	and	CCONJ	CC	5	O
irrespective	irrespective	ADV	RB	9	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
lesion	lesion	NOUN	NN	5	O
volume	volume	NOUN	NN	9	O
,	,	PUNCT	,	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
lesion	lesion	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
exercise	exercise	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rotation	rotation	NOUN	NN	5	B-Disease
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
become	become	VERB	VB	5	O
gradually	gradually	ADV	RB	9	O
more	more	ADV	RBR	5	O
ipsilateral	ipsilateral	ADJ	JJ	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
observation	observation	NOUN	NN	9	O
session	session	NOUN	NN	5	O
progressed	progress	VERB	VBD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
circled	circle	VERB	VBD	9	O
ipsilaterally	ipsilaterally	ADV	RB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
lesion	lesion	NOUN	NN	5	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
further	further	ADJ	JJ	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
injections	injection	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	DET	DT	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
has	have	VERB	VBZ	9	O
an	an	DET	DT	5	O
irreversible	irreversible	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
lesion	lesion	NOUN	NN	5	O
DA	da	NOUN	NN	9	O
pool	pool	NOUN	NN	9	O
contributing	contribute	VERB	VBG	9	O
to	to	ADP	IN	5	O
contralateral	contralateral	ADJ	JJ	5	B-Disease
rotation	rotation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Mitomycin	Mitomycin	PROPN	NNP	0	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
associated	associate	VERB	VBD	9	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
uremic	uremic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Mitomycin	Mitomycin	PROPN	NNP	0	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
associated	associate	VERB	VBD	9	O
Hemolytic	Hemolytic	PROPN	NNP	0	B-Disease
Uremic	Uremic	PROPN	NNP	5	I-Disease
Syndrome	Syndrome	PROPN	NNP	5	I-Disease
(	(	PUNCT	-LRB-	9	O
HUS	HUS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
fatal	fatal	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
uncommon	uncommon	ADJ	JJ	5	O
condition	condition	NOUN	NN	5	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
yet	yet	ADV	RB	9	O
widely	widely	ADV	RB	5	O
recognised	recognise	VERB	VBN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
consists	consist	VERB	VBZ	5	O
of	of	ADP	IN	5	O
microangiopathic	microangiopathic	ADJ	JJ	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
progressive	progressive	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
mitomycin	mitomycin	NOUN	NN	3	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
affects	affect	VERB	VBZ	9	O
about	about	ADP	IN	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
usually	usually	ADV	RB	5	O
develops	develop	VERB	VBZ	5	O
about	about	ADV	RB	5	O
8	8	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
mth	mth	NOUN	NN	5	O
after	after	ADP	IN	9	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
mitomycin	mitomycin	NOUN	NN	3	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mortality	mortality	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
approximately	approximately	ADV	RB	9	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
from	from	ADP	IN	9	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
are	be	VERB	VBP	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
idiopathic	idiopathic	ADJ	JJ	5	O
HUS	HUS	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
include	include	VERB	VBP	5	O
arteriolar	arteriolar	ADJ	JJ	5	O
fibrin	fibrin	NOUN	NN	0	O
thrombi	thrombi	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
expanded	expand	VERB	VBD	9	O
subendothelial	subendothelial	ADJ	JJ	3	O
zones	zone	NOUN	NNS	5	O
in	in	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	O
capillary	capillary	ADJ	JJ	0	O
walls	wall	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
wrinkling	wrinkling	NOUN	NN	5	O
of	of	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	O
basement	basement	NOUN	NN	3	O
membranes	membrane	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
mesangiolysis	mesangiolysis	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
postulated	postulate	VERB	VBN	9	O
as	as	ADP	IN	5	O
mitomycin	mitomycin	NOUN	NN	3	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
endothelial	endothelial	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
pathological	pathological	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
65	65	NUM	CD	7	O
yr	yr	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
gastric	gastric	ADJ	JJ	9	B-Disease
adenocarcinoma	adenocarcinoma	NOUN	NN	3	I-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
while	while	ADP	IN	9	O
on	on	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
mitomycin	mitomycin	NOUN	NN	3	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
died	die	VERB	VBD	9	O
in	in	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Ketanserin	Ketanserin	PROPN	NNP	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
reverses	reverse	VERB	VBZ	3	O
alfentanil	alfentanil	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Systemic	systemic	ADJ	JJ	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
ketanserin	ketanserin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
relatively	relatively	ADV	RB	5	O
specific	specific	ADJ	JJ	9	O
type	type	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
produced	produce	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
short	short	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
opiate	opiate	ADJ	JJ	5	O
agonist	agonist	NOUN	NN	3	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
placement	placement	NOUN	NN	5	O
of	of	ADP	IN	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
electrodes	electrode	NOUN	NNS	5	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
animal	animal	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
left	leave	VERB	VBN	5	O
gastrocnemius	gastrocnemius	NOUN	NN	9	O
muscle	muscle	NOUN	NN	9	O
,	,	PUNCT	,	9	O
rigidity	rigidity	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
analyzing	analyze	VERB	VBG	9	O
root	root	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
mean	mean	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
square	square	ADJ	JJ	5	O
electromyographic	electromyographic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Intraperitoneal	intraperitoneal	NOUN	NN	0	O
ketanserin	ketanserin	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
63	63	NUM	CD	7	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
prevented	prevent	VERB	VBN	9	O
the	the	DET	DT	5	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
electromyographic	electromyographic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Chlordiazepoxide	chlordiazepoxide	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	ADP	IN	0	O
failed	fail	VERB	VBN	9	O
to	to	PART	TO	5	O
significantly	significantly	ADV	RB	9	O
influence	influence	VERB	VB	5	O
the	the	DET	DT	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
ketanserin	ketanserin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
31	31	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
motionless	motionless	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
flaccid	flaccid	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
less	less	ADV	RBR	5	O
responsive	responsive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
external	external	ADJ	JJ	5	O
stimuli	stimulus	NOUN	NNS	5	O
than	than	ADP	IN	5	O
were	be	VERB	VBD	9	O
animals	animal	NOUN	NNS	9	O
receiving	receive	VERB	VBG	9	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
ketanserin	ketanserin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
exhibited	exhibit	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
rearing	rearing	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
exploratory	exploratory	ADJ	JJ	5	O
behavior	behavior	NOUN	NN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
60	60	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
min	min	NOUN	NN	0	O
recording	recording	NOUN	NN	5	O
period	period	NOUN	NN	5	O
than	than	ADP	IN	5	O
did	do	VERB	VBD	9	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
ketanserin	ketanserin	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
previous	previous	ADJ	JJ	9	O
work	work	NOUN	NN	5	O
,	,	PUNCT	,	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
clinically	clinically	ADV	RB	5	O
relevant	relevant	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
parenteral	parenteral	ADJ	JJ	5	O
narcotic	narcotic	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
partly	partly	ADV	RB	9	O
mediated	mediate	VERB	VBN	3	O
via	via	ADP	IN	9	O
serotonergic	serotonergic	NOUN	NN	5	O
pathways	pathway	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
with	with	ADP	IN	5	O
type	type	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
antagonists	antagonist	NOUN	NNS	3	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
clinically	clinically	ADV	RB	5	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
attenuating	attenuate	VERB	VBG	9	O
opiate	opiate	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
rigidity	rigidity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
will	will	VERB	MD	5	O
be	be	VERB	VB	5	O
necessary	necessary	ADJ	JJ	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
of	of	ADP	IN	5	O
possibly	possibly	ADV	RB	9	O
enhanced	enhance	VERB	VBN	3	O
CNS	CNS	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
cardiovascular	cardiovascular	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
respiratory	respiratory	ADJ	JJ	5	I-Disease
depression	depression	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Antagonism	antagonism	NOUN	NN	3	O
of	of	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
sedative	sedative	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
by	by	ADP	IN	9	O
Ro15	Ro15	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1788	1788	NUM	CD	2	I-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
under	under	ADP	IN	9	O
lumbar	lumbar	ADJ	JJ	5	O
epidural	epidural	ADJ	JJ	5	O
block	block	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
investigation	investigation	NOUN	NN	9	O
of	of	ADP	IN	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
Ro15	Ro15	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1788	1788	NUM	CD	2	I-Chemical
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
in	in	ADP	IN	5	O
reversing	reverse	VERB	VBG	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
effects	effect	NOUN	NNS	9	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
under	under	ADP	IN	9	O
epidural	epidural	ADJ	JJ	5	O
block	block	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
local	local	ADJ	JJ	5	O
tolerance	tolerance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
general	general	ADJ	JJ	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
Ro15	Ro15	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1788	1788	NUM	CD	2	I-Chemical
.	.	PUNCT	.	9	O

Fifty	fifty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
seven	seven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
sedated	sedate	VERB	VBN	5	O
with	with	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
surgery	surgery	NOUN	NN	5	O
under	under	ADP	IN	9	O
epidural	epidural	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Antagonism	antagonism	NOUN	NN	3	O
of	of	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
effects	effect	NOUN	NNS	9	O
by	by	ADP	IN	9	O
Ro15	Ro15	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1788	1788	PROPN	NNP	2	I-Chemical
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
postoperatively	postoperatively	ADV	RB	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
subjective	subjective	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
mood	mood	NOUN	NN	5	O
rating	rating	NOUN	NN	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
objective	objective	ADJ	JJ	5	O
test	test	NOUN	NN	5	O
of	of	ADP	IN	5	O
performance	performance	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
test	test	NOUN	NN	5	O
for	for	ADP	IN	5	O
amnesia	amnesia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
vital	vital	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
for	for	ADP	IN	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
300	300	NUM	CD	0	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
trial	trial	NOUN	NN	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
for	for	ADP	IN	5	O
mood	mood	NOUN	NN	5	O
rating	rating	NOUN	NN	5	O
,	,	PUNCT	,	9	O
amnesia	amnesia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
vital	vital	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Ro15	Ro15	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1788	1788	NUM	CD	2	I-Chemical
group	group	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
performance	performance	NOUN	NN	5	O
test	test	NOUN	NN	5	O
up	up	ADP	IN	5	O
to	to	ADP	IN	5	O
120	120	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
reaction	reaction	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
site	site	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Chorea	chorea	NOUN	NN	2	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraception	contraception	NOUN	NN	5	I-Chemical
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
chorea	chorea	NOUN	NN	5	B-Disease
while	while	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
were	be	VERB	VBD	9	O
young	young	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
whose	whose	DET	WP$	9	O
chorea	chorea	NOUN	NN	5	B-Disease
developed	develop	VERB	VBD	5	O
long	long	ADV	RB	5	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
started	start	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
disappeared	disappear	VERB	VBD	9	O
soon	soon	ADV	RB	5	O
after	after	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
discontinued	discontinue	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
acute	acute	ADJ	JJ	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
chorea	chorea	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
oral	oral	ADJ	JJ	9	B-Chemical
contraception	contraception	NOUN	NN	5	I-Chemical
.	.	PUNCT	.	9	O

Prolonged	prolonged	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
female	female	ADJ	JJ	9	O
sex	sex	NOUN	NN	5	O
hormones	hormone	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
chorea	chorea	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
previously	previously	ADV	RB	9	O
had	have	VERB	VBN	9	O
chorea	chorea	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
rheumatic	rheumatic	ADJ	JJ	5	B-Disease
fever	fever	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Co	co	ADJ	JJ	0	O
-	-	ADJ	JJ	7	O
carcinogenic	carcinogenic	ADJ	JJ	0	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
retinyl	retinyl	NOUN	NN	0	B-Chemical
acetate	acetate	ADJ	JJ	0	I-Chemical
on	on	ADP	IN	5	O
forestomach	forestomach	NOUN	NN	3	B-Disease
carcinogenesis	carcinogenesis	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	O
male	male	ADJ	JJ	9	O
F344	f344	NOUN	NN	3	O
rats	rat	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
with	with	ADP	IN	5	O
butylated	butylate	VERB	VBN	0	B-Chemical
hydroxyanisole	hydroxyanisole	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
modifying	modify	VERB	VBG	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
retinyl	retinyl	ADJ	JJ	0	B-Chemical
acetate	acetate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
RA	RA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
butylated	butylate	VERB	VBN	0	B-Chemical
hydroxyanisole	hydroxyanisole	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
BHA	BHA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rat	rat	NOUN	NN	3	O
forestomach	forestomach	NOUN	NN	3	B-Disease
tumorigenesis	tumorigenesis	NOUN	NN	3	I-Disease
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
F344	F344	PROPN	NNP	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
on	on	ADP	IN	5	O
diet	diet	NOUN	NN	9	O
containing	contain	VERB	VBG	0	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
BHA	BHA	PROPN	NNP	0	B-Chemical
by	by	ADP	IN	9	O
weight	weight	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
simultaneously	simultaneously	ADV	RB	5	O
on	on	ADP	IN	5	O
drinking	drinking	NOUN	NN	5	O
water	water	NOUN	NN	0	O
supplemented	supplement	VERB	VBN	0	O
with	with	ADP	IN	5	O
RA	RA	PROPN	NNP	9	B-Chemical
at	at	ADP	IN	9	O
various	various	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
w	w	X	FW	0	O
/	/	SYM	SYM	9	O
v	v	PUNCT	LS	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
52	52	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
groups	group	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
BHA	BHA	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
marked	marked	ADJ	JJ	9	O
hyperplastic	hyperplastic	ADJ	JJ	3	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
forestomach	forestomach	ADJ	JJ	3	O
epithelium	epithelium	NOUN	NN	3	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
RA	RA	PROPN	NNP	9	B-Chemical
significantly	significantly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
forestomach	forestomach	ADJ	JJ	3	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
(	(	PUNCT	-LRB-	9	O
squamous	squamous	ADJ	JJ	5	B-Disease
cell	cell	NOUN	NN	3	I-Disease
papilloma	papilloma	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
/	/	SYM	SYM	9	O
15	15	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
/	/	SYM	SYM	9	O
20	20	NUM	CD	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
rat	rat	NOUN	NN	3	O
with	with	ADP	IN	5	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
given	give	VERB	VBN	5	O
RA	RA	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
water	water	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
rats	rat	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
BHA	BHA	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
RA	RA	PROPN	NNP	9	B-Chemical
co	co	NOUN	NN	9	O
-	-	VERB	VBD	7	O
administered	administer	VERB	VBD	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
or	or	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
enhancing	enhance	VERB	VBG	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
BHA	BHA	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
epithelial	epithelial	ADJ	JJ	3	B-Disease
hyperplasia	hyperplasia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Tumors	tumor	NOUN	NNS	9	B-Disease
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
papillomas	papilloma	NOUN	NNS	3	B-Disease
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
RA	RA	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
rat	rat	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
%	%	NOUN	NN	9	O
RA	RA	PROPN	NNP	9	B-Chemical
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RA	RA	PROPN	NNP	9	B-Chemical
alone	alone	ADV	RB	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
induce	induce	VERB	VB	3	O
hyperplastic	hyperplastic	ADJ	JJ	3	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
forestomach	forestomach	NOUN	NN	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
RA	RA	PROPN	NNP	9	B-Chemical
acted	act	VERB	VBD	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
carcinogen	carcinogen	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
BHA	bha	ADJ	JJ	0	B-Chemical
forestomach	forestomach	NOUN	NN	3	B-Disease
carcinogenesis	carcinogenesis	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
dependency	dependency	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
mitomycin	mitomycin	NOUN	NN	3	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
1975	1975	NUM	CD	2	O
mitomycin	mitomycin	NOUN	NN	3	B-Chemical
C	C	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
MMC	MMC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
suggested	suggest	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
cardiotoxic	cardiotoxic	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
when	when	ADV	WRB	5	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
given	give	VERB	VBN	5	O
following	follow	VERB	VBG	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
dependency	dependency	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
incidence	incidence	NOUN	NN	5	O
concerning	concern	VERB	VBG	5	O
this	this	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
known	know	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
initiated	initiate	VERB	VBN	9	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
obtain	obtain	VERB	VB	5	O
some	some	DET	DT	5	O
more	more	ADJ	JJR	5	O
data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
these	these	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
MMC	MMC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
,	,	PUNCT	,	9	O
37	37	NUM	CD	9	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
by	by	ADP	IN	9	O
repeated	repeat	VERB	VBN	5	O
physical	physical	ADJ	JJ	5	O
examinations	examination	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
chest	chest	NOUN	NN	5	O
X	X	NOUN	NNS	9	O
-	-	NOUN	NNS	7	O
rays	ray	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
electro	electro	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
echocardiography	echocardiography	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
radionuclide	radionuclide	VERB	VB	5	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
EF	EF	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
determinations	determination	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
per	per	ADP	IN	9	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
m	m	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
MMC	mmc	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
only	only	ADV	RB	9	O
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
m	m	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
predicted	predict	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
drop	drop	NOUN	NN	9	O
in	in	ADP	IN	5	O
EF	EF	PROPN	NNP	9	O
determined	determine	VERB	VBD	9	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
cold	cold	ADJ	JJ	9	O
pressor	pressor	NOUN	NN	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
clinical	clinical	ADJ	JJ	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
nor	nor	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
the	the	DET	DT	5	O
studied	study	VERB	VBN	9	O
parameters	parameter	NOUN	NNS	5	O
change	change	VERB	VBP	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
on	on	ADP	IN	5	O
this	this	DET	DT	5	O
subject	subject	NOUN	NN	5	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
combined	combined	ADJ	JJ	9	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
MMC	mmc	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
dose	dose	NOUN	NN	9	O
dependent	dependent	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
occurring	occur	VERB	VBG	9	O
at	at	ADP	IN	9	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
m	m	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
,	,	PUNCT	,	9	O
mainly	mainly	ADV	RB	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
also	also	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
previously	previously	ADV	RB	9	O
or	or	CCONJ	CC	5	O
simultaneously	simultaneously	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
even	even	ADV	RB	5	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
risk	risk	NOUN	NN	5	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Reversible	reversible	ADJ	JJ	0	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
tiazofurin	tiazofurin	NOUN	NN	0	B-Chemical
usage	usage	NOUN	NN	9	O
:	:	PUNCT	:	9	O
MR	MR	PROPN	NNP	9	O
demonstration	demonstration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Tiazofurin	tiazofurin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
agent	agent	NOUN	NN	9	O
currently	currently	ADV	RB	5	O
undergoing	undergo	VERB	VBG	9	O
clinical	clinical	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
our	-PRON-	DET	PRP$	5	O
results	result	NOUN	NNS	9	O
with	with	ADP	IN	5	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MR	MR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
demonstrating	demonstrate	VERB	VBG	9	O
reversible	reversible	ADJ	JJ	9	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
concurrent	concurrent	ADJ	JJ	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
abnormalities	abnormality	NOUN	NNS	9	O
on	on	ADP	IN	5	O
MR	MR	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
findings	finding	NOUN	NNS	9	O
on	on	ADP	IN	5	O
CT	CT	PROPN	NNP	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
with	with	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	O
angiography	angiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
utility	utility	NOUN	NN	5	O
of	of	ADP	IN	5	O
MR	MR	PROPN	NNP	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
this	this	DET	DT	5	O
new	new	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
illustrated	illustrate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Receptor	receptor	NOUN	NN	3	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	B-Disease
hyperactivity	hyperactivity	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
by	by	ADP	IN	9	O
subcutaneously	subcutaneously	ADV	RB	3	O
implanting	implant	VERB	VBG	5	O
each	each	DET	DT	5	O
animal	animal	NOUN	NN	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
Alzet	Alzet	PROPN	NNP	0	O
osmotic	osmotic	ADJ	JJ	0	O
mini	mini	ADJ	JJ	9	O
-	-	PUNCT	:	7	O
pump	pump	NOUN	NN	0	O
which	which	DET	WDT	5	O
continuously	continuously	ADV	RB	5	O
released	release	VERB	VBD	9	O
saline	saline	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
pretreatment	pretreatment	ADJ	JJ	0	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
i	i	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
determining	determine	VERB	VBG	9	O
their	-PRON-	DET	PRP$	5	O
locomotor	locomotor	NOUN	NN	5	O
response	response	NOUN	NN	9	O
to	to	PART	TO	5	O
acutely	acutely	ADV	RB	9	O
injected	inject	VERB	VBN	3	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
s	s	X	XX	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
ii	ii	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
measuring	measure	VERB	VBG	9	O
the	the	DET	DT	5	O
density	density	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
[	[	PUNCT	-LRB-	9	O
3H	3h	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
[	[	PUNCT	-LRB-	9	O
3H	3h	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
spiperone	spiperone	VERB	VBD	0	B-Chemical
binding	bind	VERB	VBG	1	O
sites	site	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
observed	observe	VERB	VBD	9	O
no	no	DET	DT	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	O
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
striatal	striatal	ADJ	JJ	3	O
L	l	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
[	[	PUNCT	-LRB-	9	O
3H	3h	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
[	[	PUNCT	-LRB-	9	O
3H	3h	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
spiperone	spiperone	VERB	VBN	0	B-Chemical
binding	bind	VERB	VBG	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
1	1	NUM	CD	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
rats	rat	NOUN	NNS	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
stimulated	stimulate	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	O
response	response	NOUN	NN	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
[	[	PUNCT	-LRB-	9	O
3H	3h	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
binding	bind	VERB	VBG	1	O
sites	site	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
elevated	elevated	ADJ	JJ	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
DA	DA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
level	level	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
[	[	PUNCT	-LRB-	9	O
3H	3h	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
spiperone	spiperone	VERB	VBD	0	B-Chemical
binding	bind	VERB	VBG	1	O
sites	site	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
animals	animal	NOUN	NNS	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	O
response	response	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
potentiated	potentiate	VERB	VBN	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
elevated	elevated	ADJ	JJ	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
[	[	PUNCT	-LRB-	9	O
3H	3h	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
spiperone	spiperone	VERB	VBD	0	B-Chemical
binding	bind	VERB	VBG	1	O
sites	site	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
L	l	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
[	[	PUNCT	-LRB-	9	O
3H	3h	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
binding	bind	VERB	VBG	1	O
sites	site	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
striatal	striatal	ADJ	JJ	3	O
DA	DA	PROPN	NNP	9	B-Chemical
level	level	NOUN	NN	9	O
were	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
develop	develop	VERB	VBP	5	O
locomotor	locomotor	NOUN	NN	5	B-Disease
hyperactivity	hyperactivity	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
initially	initially	ADV	RB	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
increases	increase	NOUN	NNS	9	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
density	density	NOUN	NN	9	O
of	of	ADP	IN	5	O
nicotinic	nicotinic	ADJ	JJ	0	O
receptors	receptor	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
DA	DA	PROPN	NNP	9	B-Chemical
concentration	concentration	NOUN	NN	0	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
inducing	induce	VERB	VBG	3	O
DA	DA	PROPN	NNP	9	B-Chemical
receptor	receptor	NOUN	NN	3	O
supersensitivity	supersensitivity	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Amelioration	amelioration	NOUN	NN	2	O
of	of	ADP	IN	5	O
bendrofluazide	bendrofluazide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
timolol	timolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
beta	beta	NOUN	NN	9	O
adrenergic	adrenergic	NOUN	NN	9	O
blocking	block	VERB	VBG	3	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
timolol	timolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
correct	correct	VERB	VB	5	O
the	the	DET	DT	5	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
bendrofluazide	bendrofluazide	ADP	IN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
subjects	subject	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
small	small	ADJ	JJ	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Timolol	Timolol	PROPN	NNP	7	B-Chemical
also	also	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
excretion	excretion	NOUN	NN	0	O
following	follow	VERB	VBG	9	O
bendrofluazide	bendrofluazide	ADV	RB	0	B-Chemical
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
urine	urine	NOUN	NN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
ratio	ratio	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
shift	shift	NOUN	NN	9	O
of	of	ADP	IN	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
intracellular	intracellular	NOUN	NN	3	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
extracellular	extracellular	ADJ	JJ	9	O
space	space	NOUN	NN	5	O
.	.	PUNCT	.	9	O

St	st	INTJ	UH	2	B-Disease
.	.	PUNCT	.	9	I-Disease

Anthony	Anthony	PROPN	NNP	6	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
fire	fire	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
then	then	ADV	RB	9	O
and	and	CCONJ	CC	5	O
now	now	ADV	RB	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
historical	historical	ADJ	JJ	5	O
review	review	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
rare	rare	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
morbid	morbid	NOUN	NN	5	O
vasospasm	vasospasm	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
striking	strike	VERB	VBG	9	O
angiographic	angiographic	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
ingestion	ingestion	NOUN	NN	9	O
of	of	ADP	IN	5	O
methysergide	methysergide	NOUN	NN	0	B-Chemical
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
48	48	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
brief	brief	ADJ	JJ	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
on	on	ADP	IN	5	O
similar	similar	ADJ	JJ	9	O
cases	case	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
discussion	discussion	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
ergot	ergot	NOUN	NN	0	B-Chemical
includes	include	VERB	VBZ	5	O
its	-PRON-	DET	PRP$	9	O
original	original	ADJ	JJ	5	O
discovery	discovery	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
epidemics	epidemic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
gangrene	gangrene	NOUN	NN	5	B-Disease
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
caused	cause	VERB	VBN	9	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
ages	age	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
past	past	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
present	present	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
headache	headache	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
the	the	DET	DT	5	O
advent	advent	NOUN	NN	5	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
antagonists	antagonist	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
ergot	ergot	VERB	VBP	0	B-Chemical
preparations	preparation	NOUN	NNS	9	O
continue	continue	VERB	VBP	5	O
to	to	PART	TO	5	O
play	play	VERB	VB	9	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
so	so	ADP	IN	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
danger	danger	NOUN	NN	5	O
of	of	ADP	IN	5	O
St	St	PROPN	NNP	2	B-Disease
.	.	PUNCT	.	9	I-Disease

Anthony	Anthony	PROPN	NNP	6	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
fire	fire	NOUN	NN	5	I-Disease
persists	persist	VERB	VBZ	9	O
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	O
transplantation	transplantation	NOUN	NN	9	O
:	:	PUNCT	:	9	O
improved	improve	VERB	VBN	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
survival	survival	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
modified	modify	VERB	VBN	9	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
protocol	protocol	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
on	on	ADP	IN	5	O
two	two	NUM	CD	5	O
different	different	ADJ	JJ	9	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
protocols	protocol	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
retrospectively	retrospectively	ADV	RB	5	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
subsequent	subsequent	ADJ	JJ	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
group	group	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
,	,	PUNCT	,	9	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
loading	loading	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
continued	continue	VERB	VBD	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
to	to	PART	TO	5	O
keep	keep	VERB	VB	5	O
a	a	DET	DT	5	O
whole	whole	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
level	level	NOUN	NN	9	O
about	about	ADP	IN	5	O
1000	1000	NUM	CD	9	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
group	group	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
started	start	VERB	VBN	5	O
only	only	ADV	RB	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
dosage	dosage	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
complemented	complement	VERB	VBN	1	O
by	by	ADP	IN	9	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
postoperative	postoperative	ADJ	JJ	5	O
week	week	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Group	Group	PROPN	NNP	9	O
II	II	PROPN	NNP	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
better	well	ADJ	JJR	5	O
perioperative	perioperative	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
as	as	ADP	IN	5	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
serum	serum	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
urea	urea	ADJ	JJ	0	B-Chemical
nitrogen	nitrogen	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Group	Group	PROPN	NNP	9	O
II	II	PROPN	NNP	9	O
also	also	ADV	RB	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
this	this	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
late	late	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
group	group	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
still	still	ADV	RB	5	O
shows	show	VERB	VBZ	9	O
a	a	DET	DT	5	O
slow	slow	ADJ	JJ	5	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
think	think	VERB	VBP	5	O
that	that	ADP	IN	5	O
even	even	ADV	RB	5	O
these	these	DET	DT	5	O
lower	low	ADJ	JJR	9	O
dosages	dosage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
chronic	chronic	ADJ	JJ	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
further	further	ADJ	JJ	9	O
modification	modification	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
regimen	regimen	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
required	require	VERB	VBN	9	O
to	to	PART	TO	5	O
completely	completely	ADV	RB	9	O
abolish	abolish	VERB	VB	9	O
this	this	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Ethopropazine	Ethopropazine	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
benztropine	benztropine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
parkinsonism	parkinsonism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
controlled	control	VERB	VBN	5	O
study	study	NOUN	NN	9	O
ethopropazine	ethopropazine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
benztropine	benztropine	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
parkinsonism	parkinsonism	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
fluphenazine	fluphenazine	ADJ	JJ	0	B-Chemical
enanthate	enanthate	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
60	60	NUM	CD	9	O
schizophrenic	schizophrenic	ADJ	JJ	5	B-Disease
outpatients	outpatient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ethopropazine	Ethopropazine	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
benztropine	benztropine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
equally	equally	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
controlling	control	VERB	VBG	9	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
as	as	ADV	RB	5	O
efficacious	efficacious	ADJ	JJ	5	O
as	as	ADP	IN	5	O
procyclidine	procyclidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
their	-PRON-	DET	PRP$	5	O
previous	previous	ADJ	JJ	9	O
antiparkinsonian	antiparkinsonian	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
benztropine	benztropine	NOUN	NN	0	B-Chemical
treated	treat	VERB	VBD	3	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
tardive	tardive	ADJ	JJ	5	B-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
condition	condition	NOUN	NN	5	O
during	during	ADP	IN	5	O
procyclindine	procyclindine	NOUN	NN	_	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
significantly	significantly	ADV	RB	9	O
more	more	ADJ	JJR	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
depression	depression	NOUN	NN	5	B-Disease
than	than	ADP	IN	5	O
ethopropazine	ethopropazine	NOUN	NN	0	B-Chemical
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
benztropine	benztropine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
the	the	DET	DT	5	O
anticholinergic	anticholinergic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
of	of	ADP	IN	5	O
choice	choice	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
more	more	ADV	RBR	5	O
toxic	toxic	ADJ	JJ	0	O
central	central	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	O
atropinic	atropinic	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Quinidine	quinidine	NOUN	NN	0	B-Chemical
phenylethylbarbiturate	phenylethylbarbiturate	NOUN	NN	_	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
fulminant	fulminant	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
pregnant	pregnant	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
19	19	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Laotian	laotian	ADJ	JJ	4	O
patient	patient	NOUN	NN	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
fulminant	fulminant	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
trimester	trimester	NOUN	NN	5	O
of	of	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
pregnancy	pregnancy	NOUN	NN	5	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
quinidine	quinidine	NOUN	NN	0	B-Chemical
phenylethylbarbiturate	phenylethylbarbiturate	NOUN	NN	_	I-Chemical
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
delivery	delivery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
underwent	underwent	NOUN	NN	5	O
orthotopic	orthotopic	ADJ	JJ	3	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
in	in	ADP	IN	5	O
good	good	ADJ	JJ	5	O
condition	condition	NOUN	NN	5	O
16	16	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Quinidine	quinidine	VERB	VB	0	B-Chemical
itself	-PRON-	PRON	PRP	9	O
or	or	CCONJ	CC	5	O
phenylethylbarbiturate	phenylethylbarbiturate	NOUN	NN	_	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
fulminant	fulminant	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
exercise	exercise	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ischemia	ischemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
eliciting	elicit	VERB	VBG	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Objective	objective	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ischemia	ischemia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
factors	factor	NOUN	NNS	9	O
increasing	increase	VERB	VBG	9	O
myocardial	myocardial	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
during	during	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
supine	supine	NOUN	NN	5	O
bicycle	bicycle	NOUN	NN	5	O
exercise	exercise	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
exercise	exercise	NOUN	NN	5	O
produced	produce	VERB	VBD	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
as	as	ADP	IN	5	O
evidenced	evidence	VERB	VBN	9	O
by	by	ADP	IN	9	O
ST	ST	PROPN	NNP	9	O
segment	segment	NOUN	NN	9	O
depression	depression	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
angina	angina	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
exercise	exercise	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Exercise	exercise	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
marked	mark	VERB	VBN	9	O
predominantly	predominantly	ADV	RB	9	O
by	by	ADP	IN	9	O
increased	increase	VERB	VBN	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
rate	rate	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
pressure	pressure	NOUN	NN	5	O
product	product	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
minor	minor	ADJ	JJ	9	O
contribution	contribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ischemia	ischemia	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
contractility	contractility	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
less	less	ADV	RBR	5	O
pronounced	pronounced	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
rate	rate	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
pressure	pressure	NOUN	NN	5	O
product	product	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
ischemia	ischemia	NOUN	NN	9	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
may	may	VERB	MD	5	O
occur	occur	VERB	VB	5	O
during	during	ADP	IN	5	O
states	state	NOUN	NNS	5	O
of	of	ADP	IN	5	O
emotional	emotional	ADJ	JJ	5	O
distress	distress	NOUN	NN	5	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
distinct	distinct	ADJ	JJ	9	O
from	from	ADP	IN	9	O
that	that	DET	DT	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
physical	physical	ADJ	JJ	5	O
exertion	exertion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Recent	recent	ADJ	JJ	9	O
preclinical	preclinical	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
thymidylate	thymidylate	ADJ	JJ	1	O
synthase	synthase	NOUN	NN	1	O
inhibitor	inhibitor	NOUN	NN	3	O
N10	n10	ADJ	JJ	8	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
propargyl	propargyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5	5	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
8	8	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dideazafolic	dideazafolic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CB	CB	PROPN	NNP	9	B-Chemical
3717	3717	NUM	CD	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CB	CB	PROPN	NNP	9	B-Chemical
3717	3717	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
N10	n10	ADJ	JJ	8	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
propargyl	propargyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5	5	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
8	8	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dideazafolic	dideazafolic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
tight	tight	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
binding	bind	VERB	VBG	1	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
thymidylate	thymidylate	NOUN	NN	1	O
synthase	synthase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
TS	TS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
whose	whose	DET	WP$	9	O
cytotoxicity	cytotoxicity	NOUN	NN	3	B-Disease
is	be	VERB	VBZ	5	O
mediated	mediate	VERB	VBN	3	O
solely	solely	ADV	RB	9	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
enzyme	enzyme	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Recent	recent	ADJ	JJ	9	O
preclinical	preclinical	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
focused	focus	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
intracellular	intracellular	ADJ	JJ	3	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
CB	CB	PROPN	NNP	9	B-Chemical
3717	3717	NUM	CD	7	I-Chemical
polyglutamates	polyglutamate	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
exposure	exposure	NOUN	NN	9	O
of	of	ADP	IN	5	O
L1210	L1210	PROPN	NNP	3	O
cells	cell	NOUN	NNS	3	O
to	to	ADP	IN	5	O
50	50	NUM	CD	0	O
microM	microM	PROPN	NNP	0	O
[	[	PUNCT	-LRB-	9	O
3H	3h	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
CB	CB	PROPN	NNP	9	B-Chemical
3717	3717	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
extractable	extractable	ADJ	JJ	0	O
radioactivity	radioactivity	NOUN	NN	0	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
accounted	account	VERB	VBN	5	O
for	for	ADP	IN	5	O
as	as	ADP	IN	5	O
CB	CB	PROPN	NNP	9	B-Chemical
3717	3717	NUM	CD	7	I-Chemical
tetra	tetra	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
pentaglutamate	pentaglutamate	VERB	VB	0	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
pressure	pressure	NOUN	NN	5	O
liquid	liquid	NOUN	NN	0	O
chromatography	chromatography	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
HPLC	HPLC	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
analyses	analyse	VERB	VBZ	9	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
of	of	ADP	IN	5	O
isolated	isolate	VERB	VBN	9	O
L1210	L1210	PROPN	NNP	3	O
TS	TS	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
CB	CB	PROPN	NNP	9	O
3717	3717	NUM	CD	7	O
di	di	NOUN	NN	2	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
tri	tri	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
tetra	tetra	NOUN	NN	0	O
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
pentaglutamate	pentaglutamate	NOUN	NN	0	O
are	be	VERB	VBP	5	O
26	26	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
87	87	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
119	119	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
114	114	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
fold	fold	VERB	VB	9	O
more	more	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
than	than	ADP	IN	5	O
CB	CB	PROPN	NNP	9	B-Chemical
3717	3717	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
formation	formation	NOUN	NN	9	O
may	may	VERB	MD	5	O
,	,	PUNCT	,	9	O
therefore	therefore	ADV	RB	5	O
,	,	PUNCT	,	9	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
determinant	determinant	NOUN	NN	9	O
of	of	ADP	IN	5	O
CB	CB	PROPN	NNP	9	B-Chemical
3717	3717	NUM	CD	7	I-Chemical
cytotoxicity	cytotoxicity	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
early	early	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
with	with	ADP	IN	5	O
CB	CB	PROPN	NNP	9	B-Chemical
3717	3717	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
activity	activity	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
hepatoma	hepatoma	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
mesothelioma	mesothelioma	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Toxicities	toxicity	NOUN	NNS	5	B-Disease
included	include	VERB	VBD	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
malaise	malaise	NOUN	NN	4	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
thought	think	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
precipitation	precipitation	NOUN	NN	0	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
tubule	tubule	NOUN	NN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
poor	poor	ADJ	JJ	5	O
solubility	solubility	NOUN	NN	0	O
of	of	ADP	IN	5	O
CB	CB	PROPN	NNP	9	B-Chemical
3717	3717	NUM	CD	7	I-Chemical
under	under	ADP	IN	9	O
acidic	acidic	ADJ	JJ	0	O
conditions	condition	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
an	an	DET	DT	5	O
attempt	attempt	NOUN	NN	5	O
to	to	PART	TO	5	O
overcome	overcome	VERB	VB	5	O
this	this	DET	DT	5	O
problem	problem	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
CB	CB	PROPN	NNP	9	B-Chemical
3717	3717	NUM	CD	7	I-Chemical
administered	administer	VERB	VBD	9	O
with	with	ADP	IN	5	O
alkaline	alkaline	ADJ	JJ	0	O
diuresis	diuresis	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
under	under	ADP	IN	9	O
way	way	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Preliminary	preliminary	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
at	at	ADP	IN	9	O
400	400	NUM	CD	0	O
and	and	CCONJ	CC	5	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NNS	7	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
achieved	achieve	VERB	VBN	5	O
with	with	ADP	IN	5	O
only	only	ADV	RB	9	O
1	1	NUM	CD	9	O
instance	instance	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Hepatotoxicity	hepatotoxicity	NOUN	NN	0	B-Disease
and	and	CCONJ	CC	5	O
malaise	malaise	NOUN	NN	4	B-Disease
are	be	VERB	VBP	5	O
again	again	ADV	RB	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
frequent	frequent	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
antitumor	antitumor	ADJ	JJ	3	O
activity	activity	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Pharmacokinetic	pharmacokinetic	ADJ	JJ	0	O
investigations	investigation	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
that	that	DET	DT	5	O
alkaline	alkaline	ADJ	JJ	0	O
diuresis	diuresis	NOUN	NN	5	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
alter	alter	VERB	VB	9	O
CB	CB	PROPN	NNP	9	B-Chemical
3717	3717	NUM	CD	7	I-Chemical
plasma	plasma	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
or	or	CCONJ	CC	5	O
urinary	urinary	ADJ	JJ	9	O
excretion	excretion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
satisfactory	satisfactory	ADJ	JJ	5	O
urinary	urinary	ADJ	JJ	9	O
alkalinization	alkalinization	NOUN	NN	0	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
readily	readily	ADV	RB	9	O
achieved	achieve	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Type	type	NOUN	NN	9	B-Disease
B	b	NOUN	NN	9	I-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
needle	needle	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
stick	stick	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
:	:	PUNCT	:	9	O
prevention	prevention	NOUN	NN	5	O
with	with	ADP	IN	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
immune	immune	ADJ	JJ	3	O
globulin	globulin	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Final	final	ADJ	JJ	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Veterans	Veterans	PROPN	NNPS	2	O
Administration	Administration	PROPN	NNP	2	O
Cooperative	Cooperative	PROPN	NNP	2	O
Study	Study	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Hepatitis	Hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
immune	immune	ADJ	JJ	3	O
globulin	globulin	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HBIG	HBIG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
immune	immune	ADJ	JJ	3	O
serum	serum	NOUN	NN	9	O
globulin	globulin	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ISG	ISG	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
their	-PRON-	DET	PRP$	5	O
relative	relative	ADJ	JJ	9	O
efficacies	efficacy	NOUN	NNS	9	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
type	type	NOUN	NN	9	B-Disease
B	b	NOUN	NN	9	I-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
needle	needle	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
stick	stick	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
to	to	PART	TO	5	O
hepatitis	hepatitis	VERB	VB	9	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
surface	surface	NOUN	NN	9	I-Chemical
antigen	antigen	NOUN	NN	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
HBsAG	hbsag	X	ADD	2	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
donors	donor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Clinical	Clinical	PROPN	NNP	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
developed	develop	VERB	VBD	5	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
HBIG	HBIG	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
ISG	ISG	PROPN	NNP	3	O
recipients	recipient	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
016	016	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
seroconversion	seroconversion	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
HBs	HBs	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Mild	mild	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
transient	transient	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
ISG	ISG	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
HBIG	HBIG	PROPN	NNP	5	O
recipients	recipient	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Available	available	ADJ	JJ	9	O
donor	donor	NOUN	NN	9	O
sera	sera	NOUN	NN	3	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
for	for	ADP	IN	5	O
DNA	dna	NOUN	NN	9	O
polymerase	polymerase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
DNAP	DNAP	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
e	e	NOUN	NN	9	O
antigen	antigen	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
antibody	antibody	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
HBeAg	HBeAg	PROPN	NNP	9	B-Chemical
;	;	PUNCT	:	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
HBE	HBE	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
DNAP	DNAP	NOUN	NNS	1	O
and	and	CCONJ	CC	5	O
HBeAg	HBeAg	PROPN	NNP	9	B-Chemical
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
highly	highly	ADV	RB	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
infectivity	infectivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
donors	donor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Hepatitis	Hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
immune	immune	ADJ	JJ	3	O
globulin	globulin	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
superior	superior	ADJ	JJ	5	O
to	to	ADP	IN	5	O
ISG	ISG	PROPN	NNP	3	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
type	type	NOUN	NN	9	B-Disease
B	b	NOUN	NN	9	I-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
even	even	ADV	RB	5	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
confined	confine	VERB	VBN	9	O
to	to	ADP	IN	5	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
subgroups	subgroup	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
ISG	ISG	PROPN	NNP	3	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
type	type	NOUN	NN	9	B-Disease
B	b	NOUN	NN	9	I-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
cannot	cannot	NOUN	NN	5	O
be	be	VERB	VB	5	O
ascertained	ascertain	VERB	VBN	9	O
because	because	ADP	IN	5	O
a	a	DET	DT	5	O
true	true	ADJ	JJ	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
included	include	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
autochthonous	autochthonous	ADJ	JJ	4	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
Lobund	Lobund	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
by	by	ADP	IN	9	O
treatments	treatment	NOUN	NNS	9	O
with	with	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitroso	nitroso	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
N	n	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylurea	methylurea	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

More	More	ADJ	JJR	5	O
than	than	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
Lobund	Lobund	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Wistar	Wistar	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
L	L	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
W	W	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
strain	strain	NOUN	NN	1	O
rats	rat	NOUN	NNS	9	O
developed	develop	VERB	VBD	5	O
large	large	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
palpable	palpable	ADJ	JJ	5	O
prostate	prostate	NOUN	NN	3	B-Disease
adenocarcinomas	adenocarcinoma	NOUN	NNS	3	I-Disease
(	(	PUNCT	-LRB-	9	O
PAs	pa	NOUN	NNS	9	B-Disease
)	)	PUNCT	-RRB-	9	O
following	follow	VERB	VBG	9	O
treatments	treatment	NOUN	NNS	9	O
with	with	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitroso	nitroso	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
N	n	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylurea	methylurea	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CAS	CAS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
684	684	NUM	CD	7	O
-	-	SYM	SYM	7	O
93	93	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
propionate	propionate	NOUN	NN	0	I-Chemical
[	[	PUNCT	-LRB-	9	O
(	(	PUNCT	-LRB-	9	O
TP	TP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
CAS	CAS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
57	57	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
85	85	NUM	CD	9	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
most	most	ADJ	JJS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
tumor	tumor	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	O
bearing	bear	VERB	VBG	3	O
rats	rat	NOUN	NNS	9	O
manifested	manifest	VERB	VBD	9	O
metastatic	metastatic	ADJ	JJ	3	O
lesions	lesion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incubation	incubation	NOUN	NN	0	O
periods	period	NOUN	NNS	5	O
averaged	average	VERB	VBD	5	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Within	within	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
timeframe	timeframe	NOUN	NN	5	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
L	l	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
W	W	PROPN	NNP	9	O
rat	rat	NOUN	NN	3	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
palpable	palpable	ADJ	JJ	5	O
PA	pa	NOUN	NN	9	B-Disease
when	when	ADV	WRB	5	O
treated	treat	VERB	VBN	3	O
only	only	ADV	RB	9	O
with	with	ADP	IN	5	O
TP	TP	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
L	l	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
W	W	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
TP	TP	PROPN	NNP	9	B-Chemical
acted	act	VERB	VBD	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
tumor	tumor	NOUN	NN	3	B-Disease
enhancement	enhancement	NOUN	NN	9	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
emphasis	emphasis	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Relative	relative	ADJ	JJ	9	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
netilmicin	netilmicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
tobramycin	tobramycin	ADJ	JJR	0	B-Chemical
in	in	ADP	IN	5	O
oncology	oncology	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
prospectively	prospectively	ADV	RB	5	O
compared	compare	VERB	VBD	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
netilmicin	netilmicin	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
or	or	CCONJ	CC	5	O
tobramycin	tobramycin	ADJ	JJ	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
conjunction	conjunction	NOUN	NN	9	O
with	with	ADP	IN	5	O
piperacillin	piperacillin	ADJ	JJ	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
118	118	NUM	CD	7	O
immunocompromised	immunocompromise	VERB	VBN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
presumed	presume	VERB	VBN	9	O
severe	severe	ADJ	JJ	5	O
infections	infection	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
two	two	NUM	CD	5	O
treatment	treatment	NOUN	NN	9	O
regimens	regimen	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
equally	equally	ADV	RB	9	O
efficacious	efficacious	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Nephrotoxicity	nephrotoxicity	NOUN	NN	0	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
proportion	proportion	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
netilmicin	netilmicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
tobramycin	tobramycin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
11	11	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Ototoxicity	ototoxicity	NOUN	NN	7	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
42	42	NUM	CD	7	O
netilmicin	netilmicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
piperacillin	piperacillin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
12	12	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
54	54	NUM	CD	7	O
tobramycin	tobramycin	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
piperacillin	piperacillin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
those	those	DET	DT	5	O
evaluated	evaluate	VERB	VBN	9	O
with	with	ADP	IN	5	O
posttherapy	posttherapy	NOUN	NN	5	O
audiograms	audiogram	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
netilmicin	netilmicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
piperacillin	piperacillin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
auditory	auditory	NOUN	NN	5	O
thresholds	threshold	NOUN	NNS	5	O
return	return	VERB	VB	5	O
to	to	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
nine	nine	NUM	CD	9	O
tobramycin	tobramycin	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
piperacillin	piperacillin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
dB	db	NOUN	NN	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
auditory	auditory	NOUN	NN	5	O
threshold	threshold	NOUN	NN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
proportion	proportion	NOUN	NN	9	O
of	of	ADP	IN	5	O
total	total	NOUN	NN	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
dB	db	NOUN	NN	5	O
changes	change	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
increases	increase	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
decreases	decrease	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
netilmicin	netilmicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
piperacillin	piperacillin	NOUN	NN	0	B-Chemical
-	-	PUNCT	:	7	O
vs	vs	ADP	IN	7	O
tobramycin	tobramycin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
piperacillin	piperacillin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
18	18	NUM	CD	7	O
of	of	ADP	IN	5	O
78	78	NUM	CD	7	O
vs	vs	ADP	IN	7	O
67	67	NUM	CD	7	O
of	of	ADP	IN	5	O
115	115	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
aminoglycoside	aminoglycoside	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
severe	severe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
often	often	ADV	RB	5	O
reversible	reversible	ADJ	JJ	9	O
with	with	ADP	IN	5	O
netilmicin	netilmicin	NOUN	NN	0	B-Chemical
than	than	ADP	IN	5	O
with	with	ADP	IN	5	O
tobramycin	tobramycin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Urinary	urinary	NOUN	NN	9	O
enzymes	enzyme	NOUN	NNS	1	O
and	and	CCONJ	CC	5	O
protein	protein	NOUN	NN	1	O
patterns	pattern	NOUN	NNS	5	O
as	as	ADP	IN	5	O
indicators	indicator	NOUN	NNS	5	O
of	of	ADP	IN	5	O
injury	injury	NOUN	NN	9	B-Disease
to	to	ADP	IN	5	I-Disease
different	different	ADJ	JJ	9	I-Disease
regions	region	NOUN	NNS	9	I-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
kidney	kidney	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
experimental	experimental	ADJ	JJ	5	I-Disease
models	model	NOUN	NNS	5	I-Disease
of	of	ADP	IN	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
damage	damage	NOUN	NN	9	I-Disease
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
proximal	proximal	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
glomerular	glomerular	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
papillary	papillary	ADJ	JJ	5	O
regions	region	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
were	be	VERB	VBD	9	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
hexachloro	hexachloro	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
:	:	SYM	SYM	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
butadiene	butadiene	NOUN	NNS	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
HCBD	HCBD	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
puromycin	puromycin	VERB	VBN	3	B-Chemical
aminonucleoside	aminonucleoside	PART	RP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
bromoethylamine	bromoethylamine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
BEA	BEA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Several	several	ADJ	JJ	9	O
routine	routine	ADJ	JJ	5	O
indicators	indicator	NOUN	NNS	5	O
of	of	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
enzymes	enzyme	NOUN	NNS	1	O
alkaline	alkaline	NOUN	NN	0	O
phosphatase	phosphatase	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
acetyl	acetyl	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glucosaminidase	glucosaminidase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
of	of	ADP	IN	5	O
protein	protein	NOUN	NN	1	B-Disease
excretion	excretion	NOUN	NN	0	I-Disease
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
on	on	ADP	IN	5	O
urine	urine	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Tubular	tubular	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
HCBD	HCBD	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
BEA	BEA	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
discriminated	discriminate	VERB	VBN	5	O
both	both	CCONJ	CC	9	O
quantitatively	quantitatively	ADV	RB	9	O
and	and	CCONJ	CC	5	O
qualitatively	qualitatively	ADV	RB	9	O
from	from	ADP	IN	9	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
was	be	VERB	VBD	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
pronounced	pronounced	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
protein	protein	NOUN	NN	1	B-Disease
excretion	excretion	NOUN	NN	0	I-Disease
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
proteins	protein	NOUN	NNS	1	O
with	with	ADP	IN	5	O
molecular	molecular	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
40	40	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
Da	da	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
protein	protein	NOUN	NN	1	B-Disease
excretion	excretion	NOUN	NN	0	I-Disease
in	in	ADP	IN	5	O
tubular	tubular	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
was	be	VERB	VBD	9	O
raised	raise	VERB	VBN	9	O
only	only	ADV	RB	9	O
slightly	slightly	ADV	RB	9	O
and	and	CCONJ	CC	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
excretion	excretion	NOUN	NN	0	B-Disease
of	of	ADP	IN	5	I-Disease
proteins	protein	NOUN	NNS	1	I-Disease
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
wide	wide	ADJ	JJ	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
molecular	molecular	ADJ	JJ	9	O
weights	weight	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Proximal	proximal	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
HCBD	HCBD	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
papillary	papillary	ADJ	JJ	5	O
damage	damage	NOUN	NN	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
BEA	BEA	PROPN	NNP	0	B-Chemical
were	be	VERB	VBD	9	O
distinguished	distinguish	VERB	VBN	9	O
both	both	CCONJ	CC	9	O
by	by	ADP	IN	9	O
conventional	conventional	ADJ	JJ	5	O
urinalysis	urinalysis	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
volume	volume	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
specific	specific	ADJ	JJ	9	O
gravity	gravity	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
measurement	measurement	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
urinary	urinary	ADJ	JJ	9	O
enzymes	enzyme	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

Alkaline	alkaline	ADJ	JJ	0	O
phosphatase	phosphatase	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
glucose	glucose	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
and	and	CCONJ	CC	5	O
transiently	transiently	ADV	RB	3	O
elevated	elevate	VERB	VBN	9	O
in	in	ADP	IN	5	O
proximal	proximal	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
acetyl	acetyl	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glucosaminidase	glucosaminidase	NOUN	NN	0	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
sustained	sustained	ADJ	JJ	5	O
elevation	elevation	NOUN	NN	9	O
in	in	ADP	IN	5	O
papillary	papillary	ADJ	JJ	5	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
both	both	DET	DT	9	O
selective	selective	ADJ	JJ	9	O
urinary	urinary	NOUN	NN	9	O
enzymes	enzyme	NOUN	NNS	1	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
proteins	protein	NOUN	NNS	1	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
provide	provide	VERB	VB	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
information	information	NOUN	NN	5	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
site	site	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
catch	catch	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Reye	Reye	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Reye	Reye	PROPN	NNP	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
from	from	ADP	IN	9	O
The	the	DET	DT	5	O
Children	Children	PROPN	NNPS	5	O
'	'	PART	POS	9	O
s	s	PROPN	NNP	9	O
Hospital	Hospital	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Camperdown	Camperdown	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Australia	Australia	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
occurring	occur	VERB	VBG	9	O
between	between	ADP	IN	5	O
1973	1973	NUM	CD	2	O
and	and	CCONJ	CC	5	O
1982	1982	NUM	CD	2	O
were	be	VERB	VBD	9	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
these	these	DET	DT	5	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
met	meet	VERB	VBD	5	O
the	the	DET	DT	5	O
US	US	PROPN	NNP	5	O
Public	Public	PROPN	NNP	2	O
Health	Health	PROPN	NNP	2	O
Service	Service	PROPN	NNP	2	O
Centers	Centers	PROPN	NNPS	2	O
for	for	ADP	IN	5	O
Disease	Disease	PROPN	NNP	2	O
Control	Control	PROPN	NNP	9	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
Reye	Reye	PROPN	NNP	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Aspirin	Aspirin	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
salicylate	salicylate	ADJ	JJ	0	B-Chemical
ingestion	ingestion	NOUN	NN	9	O
had	have	VERB	VBD	9	O
occurred	occur	VERB	VBN	9	O
in	in	ADP	IN	5	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
20	20	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
only	only	ADV	RB	9	O
six	six	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Pathologic	pathologic	NOUN	NN	9	O
confirmation	confirmation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
Reye	Reye	PROPN	NNP	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
accomplished	accomplish	VERB	VBN	5	O
in	in	ADP	IN	5	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
Reye	Reye	PROPN	NNP	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
New	New	PROPN	NNP	2	O
South	South	PROPN	NNP	4	O
Wales	Wales	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Australia	Australia	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
estimated	estimate	VERB	VBN	5	O
from	from	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
approximately	approximately	ADV	RB	9	O
nine	nine	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
per	per	ADP	IN	9	O
1	1	NUM	CD	9	O
million	million	NUM	CD	5	O
children	child	NOUN	NNS	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
recent	recent	ADJ	JJ	5	O
US	US	PROPN	NNP	5	O
data	datum	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ten	ten	NUM	CD	9	O
to	to	PART	TO	5	O
20	20	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
per	per	ADP	IN	9	O
1	1	NUM	CD	9	O
million	million	NUM	CD	5	O
children	child	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
three	three	NUM	CD	9	O
to	to	PART	TO	5	O
seven	seven	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
per	per	ADP	IN	9	O
1	1	NUM	CD	9	O
million	million	NUM	CD	5	O
children	child	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Great	Great	PROPN	NNP	4	O
Britain	Britain	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mortality	mortality	NOUN	NN	5	O
for	for	ADP	IN	5	O
these	these	DET	DT	5	O
Reye	Reye	PROPN	NNP	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
cases	case	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Australia	Australia	PROPN	NNP	2	O
was	be	VERB	VBD	9	O
45	45	NUM	CD	9	O
%	%	NOUN	NN	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
32	32	NUM	CD	7	O
%	%	NOUN	NN	9	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
fatality	fatality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
States	States	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
Australia	Australia	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
pediatric	pediatric	ADJ	JJ	5	O
usage	usage	NOUN	NN	9	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
extremely	extremely	ADV	RB	5	O
low	low	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
past	past	ADJ	JJ	5	O
25	25	NUM	CD	9	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
total	total	ADJ	JJ	9	O
dosage	dosage	NOUN	NN	9	O
units	unit	NOUN	NNS	9	O
sold	sell	VERB	VBN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
dominating	dominate	VERB	VBG	9	O
the	the	DET	DT	5	O
pediatric	pediatric	ADJ	JJ	5	O
analgesic	analgesic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
antipyretic	antipyretic	ADJ	JJ	0	O
market	market	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Reye	reye	NOUN	NN	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
disappearing	disappear	VERB	VBG	5	O
from	from	ADP	IN	9	O
Australia	Australia	PROPN	NNP	2	O
despite	despite	ADP	IN	9	O
a	a	DET	DT	5	O
total	total	ADJ	JJ	9	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
salicylates	salicylate	NOUN	NNS	0	B-Chemical
or	or	CCONJ	CC	5	O
aspirin	aspirin	ADJ	JJ	9	B-Chemical
ingestion	ingestion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
since	since	ADP	IN	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
cases	case	NOUN	NNS	5	O
found	find	VERB	VBN	9	O
at	at	ADP	IN	9	O
The	the	DET	DT	5	O
Children	Children	PROPN	NNP	5	O
'	'	PART	POS	9	O
s	s	CCONJ	CC	9	O
Hospital	Hospital	PROPN	NNP	2	O
in	in	ADP	IN	5	O
1983	1983	NUM	CD	2	O
,	,	PUNCT	,	9	O
1984	1984	NUM	CD	2	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
1985	1985	NUM	CD	2	O
.	.	PUNCT	.	9	O

Postpartum	Postpartum	PROPN	NNP	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
multigravida	multigravida	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
prior	prior	ADJ	JJ	9	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
history	history	NOUN	NN	5	O
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
with	with	ADP	IN	5	O
postpartum	postpartum	ADJ	JJ	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
having	have	VERB	VBG	5	O
received	receive	VERB	VBN	9	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
inhibition	inhibition	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
lactation	lactation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Bromocriptine	Bromocriptine	PROPN	NNP	0	B-Chemical
given	give	VERB	VBN	5	O
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
for	for	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
cases	case	NOUN	NNS	5	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
even	even	ADV	RB	5	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
in	in	ADP	IN	5	O
low	low	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Hyperglycemic	Hyperglycemic	PROPN	NNP	3	B-Disease
acidotic	acidotic	ADJ	JJ	5	I-Disease
coma	coma	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	O
in	in	ADP	IN	5	O
Kearns	Kearns	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Sayre	Sayre	PROPN	NNP	6	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
paper	paper	NOUN	NN	5	O
presents	present	VERB	VBZ	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
metabolic	metabolic	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
young	young	ADJ	JJ	5	O
boys	boy	NOUN	NNS	5	O
with	with	ADP	IN	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
standing	stand	VERB	VBG	5	O
Kearns	Kearns	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Sayre	Sayre	PROPN	NNP	6	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
short	short	ADJ	JJ	5	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
prednisone	prednisone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
boys	boy	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
lethargy	lethargy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
increasing	increase	VERB	VBG	9	O
somnolence	somnolence	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
polydipsia	polydipsia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
polyphagia	polyphagia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
polyuria	polyuria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
presented	present	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
room	room	NOUN	NN	9	O
with	with	ADP	IN	5	O
profound	profound	ADJ	JJ	9	O
coma	coma	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
severe	severe	ADJ	JJ	5	O
hyperglycemia	hyperglycemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
acidosis	acidosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Nonketotic	nonketotic	ADJ	JJ	7	O
lactic	lactic	ADJ	JJ	0	B-Disease
acidosis	acidosis	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
and	and	CCONJ	CC	5	O
ketosis	ketosis	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	O
a	a	DET	DT	5	O
known	know	VERB	VBN	9	O
serum	serum	ADJ	JJ	9	O
lactate	lactate	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Respiratory	respiratory	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
rapidly	rapidly	ADV	RB	9	O
ensued	ensue	VERB	VBD	5	O
and	and	CCONJ	CC	5	O
both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
expired	expire	VERB	VBD	5	O
in	in	ADP	IN	5	O
spite	spite	NOUN	NN	9	O
of	of	ADP	IN	5	O
efforts	effort	NOUN	NNS	5	O
at	at	ADP	IN	9	O
resuscitation	resuscitation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
believe	believe	VERB	VBP	5	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
represent	represent	VERB	VBP	9	O
a	a	DET	DT	5	O
newly	newly	ADV	RB	9	O
described	describe	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
catastrophic	catastrophic	ADJ	JJ	5	O
metabolic	metabolic	ADJ	JJ	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
endocrine	endocrine	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Kearns	Kearns	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Sayre	Sayre	PROPN	NNP	6	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Experimental	experimental	ADJ	JJ	9	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
concomitant	concomitant	ADJ	JJ	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CSA	CSA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
alone	alone	ADV	RB	9	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
various	various	ADJ	JJ	9	O
chemotherapeutics	chemotherapeutic	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
CSA	CSA	PROPN	NNP	9	B-Chemical
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
caused	cause	VERB	VBD	9	O
renal	renal	ADJ	JJ	9	O
functional	functional	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
structural	structural	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
combined	combined	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
CSA	CSA	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
various	various	ADJ	JJ	9	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
potential	potential	NOUN	NN	9	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
at	at	ADP	IN	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
amphothericin	amphothericin	ADJ	JJ	0	B-Chemical
B	b	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
are	be	VERB	VBP	5	O
frequently	frequently	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
immunosuppressed	immunosuppresse	VERB	VBN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
aggravate	aggravate	VERB	VB	9	O
the	the	DET	DT	5	O
CSA	CSA	PROPN	NNP	9	B-Chemical
induced	induce	VERB	VBD	3	O
toxicity	toxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Gentamicin	gentamicin	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
toxic	toxic	ADJ	JJ	0	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBD	9	O
CSA	CSA	PROPN	NNP	9	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
CSA	CSA	PROPN	NNP	9	B-Chemical
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
different	different	ADJ	JJ	9	O
pathogenetic	pathogenetic	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Diuretics	diuretic	NOUN	NNS	7	O
,	,	PUNCT	,	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
coronary	coronary	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
proposed	propose	VERB	VBN	5	O
that	that	ADP	IN	5	O
modest	modest	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
alter	alter	VERB	VB	9	O
the	the	DET	DT	5	O
tendency	tendency	NOUN	NN	5	O
towards	towards	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

If	if	ADP	IN	5	O
this	this	DET	DT	5	O
were	be	VERB	VBD	9	O
so	so	ADV	RB	5	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
especially	especially	ADV	RB	5	O
susceptible	susceptible	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
myocardial	myocardial	ADJ	JJ	9	O
electrical	electrical	ADJ	JJ	5	O
excitability	excitability	NOUN	NN	5	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
essential	essential	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
known	know	VERB	VBN	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
conserving	conserve	VERB	VBG	5	O
diuretic	diuretic	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
amiloride	amiloride	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
losing	lose	VERB	VBG	5	O
diuretic	diuretic	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
chlorthalidone	chlorthalidone	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
randomised	randomise	VERB	VBN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
potassium	potassium	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
on	on	ADP	IN	5	O
average	average	ADJ	JJ	5	O
1	1	NUM	CD	9	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
lower	low	ADJ	JJR	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
chlorthalidone	chlorthalidone	NOUN	NN	5	B-Chemical
phase	phase	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
amiloride	amiloride	ADP	IN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
volume	volume	NOUN	NN	9	O
states	state	NOUN	NNS	5	O
as	as	ADP	IN	5	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
bodyweight	bodyweight	NOUN	NN	5	O
,	,	PUNCT	,	9	O
plasma	plasma	NOUN	NN	9	O
renin	renin	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
regimens	regimen	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
amiloride	amiloride	VERB	VB	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
chlorthalidone	chlorthalidone	NOUN	NN	5	B-Chemical
phase	phase	NOUN	NN	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
ectopic	ectopic	NOUN	NN	3	I-Disease
beats	beat	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
Holter	holter	NOUN	NN	5	O
monitoring	monitoring	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
Lown	Lown	PROPN	NNP	6	O
grading	grading	NOUN	NN	5	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBN	9	O
upslope	upslope	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
monophasic	monophasic	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
potential	potential	NOUN	NN	9	O
,	,	PUNCT	,	9	O
prolonged	prolong	VERB	VBN	9	O
ventricular	ventricular	ADJ	JJ	5	O
effective	effective	ADJ	JJ	5	O
refractory	refractory	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
electrical	electrical	ADJ	JJ	5	O
instability	instability	NOUN	NN	5	O
during	during	ADP	IN	5	O
programmed	program	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
above	above	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
because	because	ADP	IN	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
losing	lose	VERB	VBG	5	O
diuretic	diuretic	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
can	can	VERB	MD	5	O
increase	increase	VERB	VB	9	O
myocardial	myocardial	ADJ	JJ	9	O
electrical	electrical	ADJ	JJ	5	O
excitability	excitability	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ischaemic	ischaemic	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
minor	minor	ADJ	JJ	9	O
falls	fall	NOUN	NNS	5	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
are	be	VERB	VBP	5	O
probably	probably	ADV	RB	9	O
best	best	ADV	RB	5	O
avoided	avoid	VERB	VBN	5	O
in	in	ADP	IN	5	O
such	such	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Transketolase	transketolase	VERB	VB	7	O
abnormality	abnormality	NOUN	NN	9	O
in	in	ADP	IN	5	O
tolazamide	tolazamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
Wernicke	Wernicke	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PUNCT	LS	9	I-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
a	a	DET	DT	5	O
thiamine	thiamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
enzyme	enzyme	NOUN	NN	0	O
,	,	PUNCT	,	9	O
transketolase	transketolase	NOUN	NN	1	O
,	,	PUNCT	,	9	O
from	from	ADP	IN	9	O
fibroblasts	fibroblast	NOUN	NNS	3	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
Wernicke	Wernicke	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	VERB	VBZ	9	I-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	I-Disease
when	when	ADV	WRB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
tolazamide	tolazamide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
delineate	delineate	VERB	VB	9	O
if	if	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
also	also	ADV	RB	9	O
had	have	VERB	VBD	9	O
transketolase	transketolase	ADJ	JJ	1	O
abnormality	abnormality	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
high	high	ADJ	JJ	9	O
Km	Km	PROPN	NNP	0	O
for	for	ADP	IN	5	O
thiamine	thiamine	NOUN	NN	0	B-Chemical
pyrophosphate	pyrophosphate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
TPP	TPP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
postalcoholic	postalcoholic	ADJ	JJ	_	O
Wernicke	Wernicke	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Korsakoff	Korsakoff	PROPN	NNP	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
studied	study	VERB	VBD	9	O
this	this	DET	DT	5	O
enzyme	enzyme	NOUN	NN	0	O
from	from	ADP	IN	9	O
three	three	NUM	CD	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
kindreds	kindred	NOUN	NNS	5	O
without	without	ADP	IN	9	O
any	any	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
Wernicke	Wernicke	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	VERB	VBZ	9	I-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	I-Disease
and	and	CCONJ	CC	5	O
from	from	ADP	IN	9	O
four	four	NUM	CD	9	O
normal	normal	ADJ	JJ	9	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
above	above	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
mentioned	mention	VERB	VBN	5	O
patient	patient	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
kindreds	kindred	NOUN	NNS	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
Wernicke	Wernicke	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	I-Disease
had	have	VERB	VBD	9	O
abnormal	abnormal	ADJ	JJ	9	O
transketolase	transketolase	NOUN	NN	1	O
as	as	ADP	IN	5	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
Km	Km	PROPN	NNP	0	O
for	for	ADP	IN	5	O
TPP	TPP	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
similarity	similarity	NOUN	NN	5	O
between	between	ADP	IN	5	O
postalcoholic	postalcoholic	ADJ	JJ	_	O
Wernicke	Wernicke	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Korsakoff	Korsakoff	PROPN	NNP	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
tolazamide	tolazamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
Wernicke	Wernicke	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	VERB	VBZ	9	I-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	I-Disease
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
standpoint	standpoint	NOUN	NN	5	O
of	of	ADP	IN	5	O
transketolase	transketolase	ADJ	JJ	1	O
abnormality	abnormality	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Bradycardia	Bradycardia	NOUN	NNS	7	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
trihexyphenidyl	trihexyphenidyl	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
chronic	chronic	ADJ	JJ	5	O
schizophrenic	schizophrenic	ADJ	JJ	5	B-Disease
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
anticholinergic	anticholinergic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
trihexyphenidyl	trihexyphenidyl	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
,	,	PUNCT	,	9	O
paradoxically	paradoxically	ADV	RB	9	O
,	,	PUNCT	,	9	O
sinus	sinus	NOUN	NN	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
reaction	reaction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
specific	specific	ADJ	JJ	9	O
to	to	ADP	IN	5	O
trihexyphenidyl	trihexyphenidyl	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
not	not	ADV	RB	5	O
to	to	ADP	IN	5	O
other	other	ADJ	JJ	5	O
anticholinergic	anticholinergic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
antidyskinetic	antidyskinetic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
practice	practice	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
physicians	physician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
operative	operative	ADJ	JJ	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
thoraco	thoraco	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
abdominal	abdominal	ADJ	JJ	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
operative	operative	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
moderate	moderate	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
successfully	successfully	ADV	RB	5	O
reversed	reverse	VERB	VBN	9	O
by	by	ADP	IN	9	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
possibly	possibly	ADV	RB	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
accident	accident	NOUN	NN	5	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
carcinogenic	carcinogenic	ADJ	JJ	0	B-Disease
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
given	give	VERB	VBN	5	O
simultaneously	simultaneously	ADV	RB	5	O
with	with	ADP	IN	5	O
diethylnitrosamine	diethylnitrosamine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
work	work	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
planned	plan	VERB	VBN	5	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
elucidate	elucidate	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PB	PB	PROPN	NNP	9	B-Chemical
:	:	PUNCT	:	9	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
rat	rat	NOUN	NN	3	O
of	of	ADP	IN	5	O
ingested	ingested	ADJ	JJ	0	O
dose	dose	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
carcinogenesis	carcinogenesis	NOUN	NN	3	B-Disease
when	when	ADV	WRB	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
administered	administer	VERB	VBN	9	O
simultaneously	simultaneously	ADV	RB	5	O
with	with	ADP	IN	5	O
diethylnitrosamine	diethylnitrosamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DEN	DEN	PROPN	NNP	9	B-Chemical
:	:	PUNCT	:	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Wistar	wistar	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
180	180	NUM	CD	9	O
g	g	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
DEN	DEN	PROPN	NNP	9	B-Chemical
alone	alone	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
by	by	ADP	IN	9	O
DEN	DEN	PROPN	NNP	9	B-Chemical
+	+	CCONJ	CC	9	O
PB	pb	NOUN	NN	9	B-Chemical
during	during	ADP	IN	5	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
schedule	schedule	NOUN	NN	5	O
for	for	ADP	IN	5	O
hepatocarcinogenesis	hepatocarcinogenesis	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
size	size	NOUN	NN	9	O
of	of	ADP	IN	5	O
induced	induced	ADJ	JJ	3	O
PAS	PAS	PROPN	NNP	9	O
positive	positive	ADJ	JJ	9	O
preneoplastic	preneoplastic	ADJ	JJ	3	B-Disease
foci	foci	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
when	when	ADV	WRB	5	O
PB	PB	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
simultaneously	simultaneously	ADV	RB	5	O
with	with	ADP	IN	5	O
DEN	DEN	PROPN	NNP	9	B-Chemical
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mitotic	mitotic	ADJ	JJ	3	O
inhibition	inhibition	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
micronuclei	micronuclei	VERB	VBN	3	O
normally	normally	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
after	after	ADP	IN	9	O
partial	partial	ADJ	JJ	9	O
hepatectomy	hepatectomy	NOUN	NN	5	O
in	in	ADP	IN	5	O
DEN	DEN	PROPN	NNP	9	B-Chemical
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
DEN	DEN	PROPN	NNP	9	B-Chemical
+	+	SYM	SYM	9	O
PB	PB	PROPN	NNP	9	B-Chemical
treated	treat	VERB	VBD	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
last	last	ADJ	JJ	5	O
only	only	ADV	RB	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
PB	PB	PROPN	NNP	9	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
DEN	DEN	PROPN	NNP	9	B-Chemical
+	+	CCONJ	CC	9	O
PB	PB	PROPN	NNP	9	B-Chemical
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
survival	survival	NOUN	NN	9	O
was	be	VERB	VBD	9	O
prolonged	prolong	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
tumor	tumor	NOUN	NN	3	B-Disease
incidence	incidence	NOUN	NN	5	O
decreased	decrease	VERB	VBD	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
obtained	obtain	VERB	VBN	9	O
by	by	ADP	IN	9	O
DEN	DEN	PROPN	NNP	9	B-Chemical
alone	alone	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
PB	PB	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
promotes	promote	VERB	VBZ	3	O
carcinogenesis	carcinogenesis	NOUN	NN	3	B-Disease
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
DEN	DEN	PROPN	NNP	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
carcinogen	carcinogen	NOUN	NN	0	O
effect	effect	NOUN	NN	9	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
simultaneously	simultaneously	ADV	RB	5	O
with	with	ADP	IN	5	O
DEN	DEN	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
'	'	PUNCT	``	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
carcinogen	carcinogen	ADJ	JJ	0	O
'	'	PUNCT	''	9	O
effect	effect	NOUN	NN	9	O
acts	act	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
promotion	promotion	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
precancerous	precancerous	ADJ	JJ	5	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Biochemical	biochemical	ADJ	JJ	9	O
investigations	investigation	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
in	in	ADP	IN	5	O
progress	progress	NOUN	NN	5	O
to	to	PART	TO	5	O
obtain	obtain	VERB	VB	5	O
more	more	ADJ	JJR	5	O
information	information	NOUN	NN	5	O
about	about	ADP	IN	5	O
this	this	DET	DT	5	O
'	'	PUNCT	``	9	O
paradoxical	paradoxical	ADJ	JJ	5	O
'	'	PUNCT	``	9	O
PB	PB	PROPN	NNP	9	B-Chemical
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Bilateral	bilateral	ADJ	JJ	5	B-Disease
optic	optic	ADJ	JJ	5	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
combined	combined	ADJ	JJ	9	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
40	40	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
an	an	DET	DT	5	O
unsuccessful	unsuccessful	ADJ	JJ	5	O
cadaver	cadaver	NOUN	NN	5	O
kidney	kidney	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
bilateral	bilateral	ADJ	JJ	5	B-Disease
retrobulbar	retrobulbar	NOUN	NN	5	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
central	central	ADJ	JJ	5	O
bitemporal	bitemporal	ADJ	JJ	5	O
hemianopic	hemianopic	ADJ	JJ	5	O
scotoma	scotoma	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Ethambutol	Ethambutol	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
only	only	ADV	RB	9	O
small	small	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
visual	visual	ADJ	JJ	5	O
acuity	acuity	NOUN	NN	5	O
followed	follow	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Isoniazid	Isoniazid	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
dramatic	dramatic	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
visual	visual	ADJ	JJ	5	O
acuity	acuity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hazards	hazard	NOUN	NNS	5	O
of	of	ADP	IN	5	O
optic	optic	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
known	know	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
emphasize	emphasize	VERB	VBP	5	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
danger	danger	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
ethambutol	ethambutol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
vancomycin	vancomycin	PROPN	NNP	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
prospective	prospective	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
vancomycin	vancomycin	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
in	in	ADP	IN	5	O
54	54	NUM	CD	7	O
consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
16	16	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Vancomycin	Vancomycin	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
curative	curative	ADJ	JJ	5	O
in	in	ADP	IN	5	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
43	43	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
proven	prove	VERB	VBN	5	O
infection	infection	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Drugs	drug	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
ceased	cease	VERB	VBN	5	O
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
vancomycin	vancomycin	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
the	the	DET	DT	5	O
likely	likely	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Reactions	reaction	NOUN	NNS	0	O
included	include	VERB	VBD	5	O
thrombophlebitis	thrombophlebitis	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
of	of	ADP	IN	5	O
54	54	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
rash	rash	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
of	of	ADP	IN	5	O
54	54	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
proteinuria	proteinuria	X	FW	9	B-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
tested	test	VERB	VBN	9	O
by	by	ADP	IN	9	O
audiometry	audiometry	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Thrombophlebitis	Thrombophlebitis	PROPN	NNP	7	B-Disease
occurred	occur	VERB	VBD	9	O
only	only	ADV	RB	9	O
with	with	ADP	IN	5	O
infusion	infusion	NOUN	NN	0	O
through	through	ADP	IN	9	O
peripheral	peripheral	ADJ	JJ	9	O
cannulae	cannulae	NOUN	NN	5	O
;	;	PUNCT	:	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
confined	confine	VERB	VBN	9	O
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
an	an	DET	DT	5	O
aminoglycoside	aminoglycoside	NOUN	NN	9	B-Chemical
plus	plus	CCONJ	CC	9	O
vancomycin	vancomycin	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	DET	DT	5	O
vancomycin	vancomycin	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
administered	administer	VERB	VBD	9	O
appropriately	appropriately	ADV	RB	5	O
,	,	PUNCT	,	9	O
constitutes	constitute	VERB	VBZ	9	O
safe	safe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
effective	effective	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
infections	infection	NOUN	NNS	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
susceptible	susceptible	ADJ	JJ	9	O
bacteria	bacteria	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Factors	factor	NOUN	NNS	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
amikacin	amikacin	ADV	RB	0	B-Chemical
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
60	60	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
amikacin	amikacin	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
for	for	ADP	IN	5	O
factors	factor	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
42	42	NUM	CD	7	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
data	datum	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
for	for	ADP	IN	5	O
factors	factor	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Variables	variable	NOUN	NNS	5	O
evaluated	evaluate	VERB	VBD	9	O
included	include	VERB	VBN	5	O
patient	patient	ADJ	JJ	5	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
serum	serum	ADV	RB	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
,	,	PUNCT	,	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
organism	organism	NOUN	NN	9	O
minimum	minimum	ADJ	JJ	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
concentration	concentration	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
MIC	MIC	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
mean	mean	ADJ	JJ	5	O
peak	peak	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
trough	trough	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
area	area	NOUN	NN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
concentration	concentration	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
curve	curve	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
AUC	AUC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
AUC	AUC	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
AUC	AUC	PROPN	NNP	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
MIC	MIC	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
AUC	AUC	PROPN	NNP	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
MIC	MIC	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
Schumacher	Schumacher	PROPN	NNP	6	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
intensity	intensity	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
IF	IF	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
IF	if	ADP	IN	9	O
,	,	PUNCT	,	9	O
In	in	ADP	IN	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
maximum	maximum	ADJ	JJ	5	O
concentration	concentration	NOUN	NN	0	O
[	[	PUNCT	-LRB-	9	O
Cmax	Cmax	PROPN	NNP	0	O
]	]	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
MIC	MIC	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Model	model	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
calculated	calculate	VERB	VBN	5	O
by	by	ADP	IN	9	O
computer	computer	NOUN	NN	5	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
one	one	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
compartment	compartment	NOUN	NN	9	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
the	the	DET	DT	5	O
parameters	parameter	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
individually	individually	ADV	RB	9	O
,	,	PUNCT	,	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
total	total	ADJ	JJ	9	O
AUC	AUC	PROPN	NNP	9	O
correlated	correlate	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
stepwise	stepwise	ADJ	JJ	5	O
discriminant	discriminant	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
identified	identify	VERB	VBD	9	O
only	only	ADV	RB	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
Bayes	Bayes	PROPN	NNP	5	O
'	'	PART	POS	9	O
theorem	theorem	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
predictive	predictive	ADJ	JJ	5	O
accuracy	accuracy	NOUN	NN	5	O
of	of	ADP	IN	5	O
identifying	identify	VERB	VBG	5	O
"	"	PUNCT	``	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
"	"	PUNCT	''	5	O
patients	patient	NOUN	NNS	5	O
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
17	17	NUM	CD	7	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
39	39	NUM	CD	7	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
examined	examine	VERB	VBN	9	O
individually	individually	ADV	RB	9	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
IF	if	ADP	IN	9	O
,	,	PUNCT	,	9	O
MIC	MIC	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
ln	ln	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
Cmax	Cmax	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
MIC	MIC	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
correlated	correlate	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
cure	cure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
simultaneous	simultaneous	ADJ	JJ	5	O
multivariable	multivariable	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
identified	identify	VERB	VBN	9	O
IF	if	ADP	IN	9	O
,	,	PUNCT	,	9	O
MIC	MIC	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
one	one	NUM	CD	5	O
model	model	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
ln	ln	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
Cmax	Cmax	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
MIC	MIC	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
statistical	statistical	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
parameters	parameter	NOUN	NNS	5	O
selected	select	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
the	the	DET	DT	5	O
greatest	great	ADJ	JJS	9	O
prospective	prospective	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
Bayes	Bayes	PROPN	NNP	5	O
'	'	PART	POS	9	O
theorem	theorem	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
predictive	predictive	ADJ	JJ	5	O
accuracy	accuracy	NOUN	NN	5	O
of	of	ADP	IN	5	O
identifying	identify	VERB	VBG	5	O
patients	patient	NOUN	NNS	5	O
not	not	ADV	RB	5	O
cured	cure	VERB	VBN	5	O
increased	increase	VERB	VBN	9	O
from	from	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
19	19	NUM	CD	7	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
83	83	NUM	CD	7	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
predictive	predictive	ADJ	JJ	5	O
accuracy	accuracy	NOUN	NN	5	O
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
19	19	NUM	CD	7	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
50	50	NUM	CD	0	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Cardiac	cardiac	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Report	Report	PROPN	NNP	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
angina	angina	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
colon	colon	NOUN	NN	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
metastasis	metastasis	NOUN	NN	3	B-Disease
who	who	PRON	WP	5	O
presented	present	VERB	VBD	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
electrocardiographic	electrocardiographic	ADJ	JJ	5	O
evolution	evolution	NOUN	NN	5	O
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
Prinzmetal	Prinzmetal	PROPN	NNP	6	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
angina	angina	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
promptly	promptly	ADV	RB	5	O
resolved	resolve	VERB	VBD	9	O
with	with	ADP	IN	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
antagonists	antagonist	NOUN	NNS	3	O
may	may	VERB	MD	5	O
probably	probably	ADV	RB	9	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Dose	dose	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
beneficial	beneficial	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dietary	dietary	ADJ	JJ	5	O
corticosterone	corticosterone	NOUN	NN	3	B-Chemical
on	on	ADP	IN	5	O
organophosphorus	organophosphorus	ADV	RB	0	B-Chemical
-	-	ADJ	JJ	7	O
induced	induced	ADJ	JJ	3	O
delayed	delay	VERB	VBN	9	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
chickens	chicken	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Tri	Tri	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ortho	ortho	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tolyl	tolyl	NOUN	NN	0	I-Chemical
phosphate	phosphate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
TOTP	TOTP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
360	360	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
po	po	VERB	VB	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	B-Chemical
,	,	PUNCT	,	9	I-Chemical
0	0	NUM	CD	7	I-Chemical
'	'	PUNCT	''	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
diisopropyl	diisopropyl	NOUN	NN	0	I-Chemical
phosphorofluoridate	phosphorofluoridate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
DFP	DFP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
sc	sc	NOUN	NN	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	PART	TO	5	O
adult	adult	VERB	VB	9	O
White	White	PROPN	NNP	9	O
Leghorn	Leghorn	PROPN	NNP	4	O
chickens	chicken	NOUN	NNS	9	O
24	24	NUM	CD	9	O
hr	hr	INTJ	UH	0	O
after	after	ADP	IN	9	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
placed	place	VERB	VBN	5	O
on	on	ADP	IN	5	O
diets	diet	NOUN	NNS	9	O
containing	contain	VERB	VBG	0	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
300	300	NUM	CD	0	O
ppm	ppm	NOUN	NN	0	O
corticosterone	corticosterone	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

Supplemented	supplemented	ADJ	JJ	0	O
diets	diet	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
continued	continue	VERB	VBN	9	O
until	until	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
lesions	lesion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
delayed	delay	VERB	VBN	9	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
appeared	appear	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
low	low	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
50	50	NUM	CD	0	O
ppm	ppm	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
corticosterone	corticosterone	NOUN	NN	3	B-Chemical
had	have	VERB	VBD	9	O
beneficial	beneficial	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
TOTP	TOTP	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
200	200	NUM	CD	0	O
ppm	ppm	NOUN	NN	0	O
exacerbated	exacerbate	VERB	VBN	9	O
clinical	clinical	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
in	in	ADP	IN	5	O
chickens	chicken	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
either	either	CCONJ	CC	9	O
TOTP	TOTP	PROPN	NNP	9	B-Chemical
or	or	CCONJ	CC	5	O
DFP	dfp	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Neurotoxic	neurotoxic	ADJ	JJ	0	B-Disease
esterase	esterase	NOUN	NN	0	O
activities	activity	NOUN	NNS	9	O
24	24	NUM	CD	9	O
hr	hr	INTJ	UH	0	O
after	after	ADP	IN	9	O
TOTP	TOTP	PROPN	NNP	9	B-Chemical
or	or	CCONJ	CC	5	O
DFP	DFP	PROPN	NNP	0	B-Chemical
were	be	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
values	value	NOUN	NNS	5	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
chickens	chicken	NOUN	NNS	9	O
not	not	ADV	RB	5	O
given	give	VERB	VBN	5	O
organophosphorous	organophosphorous	ADJ	JJ	0	B-Chemical
compounds	compound	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Chickens	chicken	NOUN	NNS	9	O
given	give	VERB	VBD	5	O
200	200	NUM	CD	0	O
ppm	ppm	NOUN	NN	0	O
corticosterone	corticosterone	NOUN	NN	3	B-Chemical
without	without	ADP	IN	9	O
TOTP	TOTP	PROPN	NNP	9	B-Chemical
or	or	CCONJ	CC	5	O
DFP	DFP	PROPN	NNP	0	B-Chemical
had	have	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
elevated	elevate	VERB	VBN	9	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
cholinesterase	cholinesterase	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
significantly	significantly	ADV	RB	9	O
inhibited	inhibit	VERB	VBD	3	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
carboxylesterase	carboxylesterase	NOUN	NN	1	O
.	.	PUNCT	.	9	O

Degenerating	degenerate	VERB	VBG	3	B-Disease
myelinated	myelinate	VERB	VBN	5	I-Disease
fibers	fiber	NOUN	NNS	9	I-Disease
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
evident	evident	ADJ	JJ	9	O
in	in	ADP	IN	5	O
distal	distal	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
nerves	nerve	NOUN	NNS	5	O
of	of	ADP	IN	5	O
chickens	chicken	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
TOTP	TOTP	PROPN	NNP	9	B-Chemical
or	or	CCONJ	CC	5	O
DFP	dfp	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Hepatotoxicity	hepatotoxicity	NOUN	NN	0	B-Disease
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Amiodarone	Amiodarone	PROPN	NNP	7	B-Chemical
has	have	VERB	VBZ	9	O
proved	prove	VERB	VBN	9	O
very	very	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
otherwise	otherwise	ADV	RB	9	O
resistant	resistant	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
tachyarrhythmias	tachyarrhythmia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
been	be	VERB	VBN	9	O
limited	limit	VERB	VBN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
serious	serious	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
amiodarone	amiodarone	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
below	below	ADV	RB	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
given	give	VERB	VBN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
solid	solid	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
exists	exist	VERB	VBZ	9	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
amiodarone	amiodarone	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
steatosis	steatosis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
alterations	alteration	NOUN	NNS	9	O
resembling	resemble	VERB	VBG	9	O
alcoholic	alcoholic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
micronodular	micronodular	ADJ	JJ	5	O
cirrhosis	cirrhosis	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
regularly	regularly	ADV	RB	5	O
screened	screen	VERB	VBN	9	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
enzyme	enzyme	ADJ	JJ	0	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Therapy	therapy	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
discontinued	discontinue	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
suspicion	suspicion	NOUN	NN	5	O
of	of	ADP	IN	5	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
injury	injury	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	O
hepatomegaly	hepatomegaly	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Promotional	promotional	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
dietary	dietary	ADJ	JJ	5	O
fat	fat	NOUN	NN	9	O
on	on	ADP	IN	5	O
prostate	prostate	NOUN	NN	3	O
carcinogenesis	carcinogenesis	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
genetically	genetically	ADV	RB	9	O
susceptible	susceptible	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Germfree	Germfree	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
GF	GF	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
Lobund	Lobund	PROPN	NNP	2	O
strain	strain	NOUN	NN	1	O
Wistar	Wistar	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
LW	LW	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
fed	fed	ADJ	JJ	9	O
vegetable	vegetable	NOUN	NN	5	O
diet	diet	NOUN	NN	9	O
L	L	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
485	485	NUM	CD	7	O
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
developed	develop	VERB	VBN	5	O
prostate	prostate	NOUN	NN	3	B-Disease
adenocarcinomas	adenocarcinoma	NOUN	NNS	3	I-Disease
spontaneously	spontaneously	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
incidence	incidence	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
average	average	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
34	34	NUM	CD	7	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Conventional	Conventional	PROPN	NNP	5	O
LW	LW	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
implanted	implant	VERB	VBN	9	O
with	with	ADP	IN	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
at	at	ADP	IN	9	O
age	age	NOUN	NN	5	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
after	after	ADP	IN	9	O
an	an	DET	DT	5	O
average	average	ADJ	JJ	5	O
interval	interval	NOUN	NN	5	O
of	of	ADP	IN	5	O
14	14	NUM	CD	7	O
months	month	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
had	have	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
gross	gross	ADJ	JJ	5	O
tumors	tumor	NOUN	NNS	3	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
when	when	ADV	WRB	5	O
it	-PRON-	PRON	PRP	5	O
included	include	VERB	VBD	5	O
microscopic	microscopic	ADJ	JJ	9	O
tumors	tumor	NOUN	NNS	3	B-Disease
.	.	PUNCT	.	9	O

Preliminary	preliminary	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
LW	LW	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
fed	feed	VERB	VBN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
diet	diet	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
supplemented	supplement	VERB	VBN	0	O
with	with	ADP	IN	5	O
corn	corn	NOUN	NN	4	O
oil	oil	NOUN	NN	0	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
fat	fat	NOUN	NN	9	O
,	,	PUNCT	,	9	O
developed	develop	VERB	VBD	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
after	after	ADP	IN	9	O
intervals	interval	NOUN	NNS	5	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
12	12	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Aged	aged	ADJ	JJ	9	O
GF	GF	PROPN	NNP	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
SD	SD	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
developed	develop	VERB	VBN	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
spontaneously	spontaneously	ADV	RB	5	O
.	.	PUNCT	.	9	O

Conventional	Conventional	PROPN	NNP	5	O
SD	SD	PROPN	NNP	7	O
rats	rat	NOUN	NNS	9	O
fed	feed	VERB	VBD	9	O
diet	diet	NOUN	NN	9	O
L	L	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
485	485	NUM	CD	7	O
and	and	CCONJ	CC	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
developed	develop	VERB	VBN	5	O
only	only	ADJ	JJ	9	O
prostatitis	prostatitis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Experimental	experimental	ADJ	JJ	9	O
designs	design	NOUN	NNS	5	O
should	should	VERB	MD	5	O
consider	consider	VERB	VB	5	O
genetic	genetic	ADJ	JJ	5	O
susceptibility	susceptibility	NOUN	NN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
basic	basic	ADJ	JJ	5	O
prerequisite	prerequisite	NOUN	NN	9	O
for	for	ADP	IN	5	O
studies	study	NOUN	NNS	9	O
on	on	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Time	time	NOUN	NN	9	O
course	course	NOUN	NN	5	O
alterations	alteration	NOUN	NNS	9	O
of	of	ADP	IN	5	O
QTC	QTC	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
hypaque	hypaque	NOUN	NN	0	B-Chemical
76	76	NUM	CD	7	I-Chemical
.	.	PUNCT	.	9	O

Sequential	sequential	ADJ	JJ	5	O
measurement	measurement	NOUN	NN	5	O
of	of	ADP	IN	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
during	during	ADP	IN	5	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
angiography	angiography	NOUN	NN	5	O
was	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
30	30	NUM	CD	9	O
seconds	second	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
,	,	PUNCT	,	9	O
five	five	NUM	CD	9	O
and	and	CCONJ	CC	5	O
ten	ten	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypaque	hypaque	NOUN	NN	0	B-Chemical
76	76	NUM	CD	7	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
ten	ten	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
normal	normal	ADJ	JJ	9	O
left	left	ADJ	JJ	5	O
ventricles	ventricle	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
coronary	coronary	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Significant	significant	ADJ	JJ	9	O
QTC	QTC	PROPN	NNP	5	B-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
30	30	NUM	CD	9	O
seconds	second	NOUN	NNS	5	O
to	to	ADP	IN	5	O
one	one	NUM	CD	5	O
minute	minute	NOUN	NN	5	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
marked	marked	ADJ	JJ	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Rat	Rat	PROPN	NNP	9	O
extraocular	extraocular	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
regeneration	regeneration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Repair	repair	NOUN	NN	5	O
of	of	ADP	IN	5	O
local	local	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Local	local	ADJ	JJ	5	O
anesthetics	anesthetic	NOUN	NNS	5	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
ophthalmic	ophthalmic	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
mepivacaine	mepivacaine	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
plus	plus	CCONJ	CC	9	O
1	1	NUM	CD	9	O
:	:	SYM	SYM	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
retrobulbar	retrobulbar	ADJ	JJ	5	O
area	area	NOUN	NN	5	O
of	of	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
eyes	eye	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Controls	control	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
physiological	physiological	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
three	three	NUM	CD	9	O
anesthetics	anesthetic	NOUN	NNS	5	O
produced	produce	VERB	VBD	9	O
massive	massive	ADJ	JJ	9	O
degeneration	degeneration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
extraocular	extraocular	ADJ	JJ	5	O
muscles	muscle	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Muscle	muscle	NOUN	NN	9	B-Disease
degeneration	degeneration	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
regeneration	regeneration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
damaged	damage	VERB	VBN	9	O
muscle	muscle	NOUN	NN	9	O
fibers	fiber	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
severe	severe	ADJ	JJ	5	O
damage	damage	NOUN	NN	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
harderian	harderian	ADJ	JJ	5	O
glands	gland	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
after	after	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
mepivacaine	mepivacaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
lidocaine	lidocaine	VERB	VB	0	B-Chemical
plus	plus	CCONJ	CC	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
hypothesized	hypothesize	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
temporary	temporary	ADJ	JJ	5	O
diplopia	diplopia	NOUN	NN	5	B-Disease
sometimes	sometimes	ADV	RB	5	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
after	after	ADP	IN	9	O
ophthalmic	ophthalmic	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
damage	damage	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
extraocular	extraocular	ADJ	JJ	5	O
muscles	muscle	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Gentamicin	Gentamicin	PROPN	NNP	0	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
neonate	neonate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
autopsy	autopsy	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
premature	premature	ADJ	JJ	9	O
baby	baby	NOUN	NN	5	O
who	who	PRON	WP	5	O
died	die	VERB	VBD	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
gentamicin	gentamicin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
had	have	VERB	VBD	9	O
reached	reach	VERB	VBN	9	O
toxic	toxic	ADJ	JJ	0	O
levels	level	NOUN	NNS	3	O
when	when	ADV	WRB	5	O
anuria	anuria	NOUN	NN	5	B-Disease
developed	develop	VERB	VBD	5	O
.	.	PUNCT	.	9	O

Numerous	numerous	ADJ	JJ	9	O
periodic	periodic	ADJ	JJ	5	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
Schiff	Schiff	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
PAS	PAS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
positive	positive	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
diastase	diastase	NOUN	NN	0	O
resistant	resistant	ADJ	JJ	9	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
inclusion	inclusion	NOUN	NN	5	O
bodies	body	NOUN	NNS	9	O
which	which	DET	WDT	5	O
appeared	appear	VERB	VBD	9	O
as	as	ADP	IN	5	O
myelin	myelin	ADJ	JJ	3	O
figures	figure	NOUN	NNS	5	O
in	in	ADP	IN	5	O
cytosegresomes	cytosegresome	NOUN	NNS	9	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
electron	electron	NOUN	NN	0	O
microscope	microscope	NOUN	NN	0	O
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
proximal	proximal	ADJ	JJ	9	O
convoluted	convoluted	ADJ	JJ	9	O
tubules	tubule	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pathological	pathological	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
human	human	ADJ	JJ	3	O
neonatal	neonatal	NOUN	NN	9	O
kidneys	kidney	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Induction	induction	NOUN	NN	3	O
by	by	ADP	IN	9	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
tumours	tumour	NOUN	NNS	3	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
hepatocyte	hepatocyte	ADJ	JJ	3	O
fine	fine	ADJ	JJ	5	O
structure	structure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
male	male	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
female	female	ADJ	JJ	9	O
inbred	inbreed	VERB	VBN	9	O
Leeds	Leeds	PROPN	NNP	2	O
strain	strain	NOUN	NN	1	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
fed	feed	VERB	VBN	9	O
diets	diet	NOUN	NNS	9	O
containing	contain	VERB	VBG	0	O
either	either	CCONJ	CC	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
by	by	ADP	IN	9	O
weight	weight	NOUN	NN	9	O
for	for	ADP	IN	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
18	18	NUM	CD	7	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
dosage	dosage	NOUN	NN	9	O
level	level	NOUN	NN	9	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
sexes	sex	NOUN	NNS	9	O
developed	develop	VERB	VBD	5	O
neoplastic	neoplastic	ADJ	JJ	3	O
nodules	nodule	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
also	also	ADV	RB	9	O
showed	show	VERB	VBD	9	O
gross	gross	ADJ	JJ	5	O
enlargement	enlargement	NOUN	NN	5	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
livers	liver	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
foci	foci	NOUN	NN	9	O
of	of	ADP	IN	5	O
cellular	cellular	ADJ	JJ	3	O
alteration	alteration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
also	also	ADV	RB	9	O
being	be	VERB	VBG	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
dosage	dosage	NOUN	NN	9	O
male	male	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Papillomas	papilloma	NOUN	NNS	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
transitional	transitional	ADJ	JJ	9	O
epithelium	epithelium	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
developed	develop	VERB	VBD	5	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
three	three	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
bore	bear	VERB	VBD	5	O
bladder	bladder	NOUN	NN	9	B-Disease
carcinomas	carcinoma	NOUN	NNS	3	I-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
significant	significant	ADJ	JJ	9	O
yields	yield	NOUN	NNS	9	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
tumours	tumour	NOUN	NNS	3	I-Disease
were	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
obtained	obtain	VERB	VBN	9	O
from	from	ADP	IN	9	O
low	low	ADJ	JJ	9	O
dosage	dosage	NOUN	NN	9	O
females	female	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
dosage	dosage	NOUN	NN	9	O
males	male	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
to	to	PART	TO	5	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
developed	develop	VERB	VBD	5	O
hyperplasia	hyperplasia	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
epithelium	epithelium	NOUN	NN	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
coincident	coincident	ADJ	JJ	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
calculi	calculi	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
low	low	ADJ	JJ	9	O
yield	yield	NOUN	NN	9	O
of	of	ADP	IN	5	O
tumours	tumour	NOUN	NNS	3	B-Disease
at	at	ADP	IN	9	O
various	various	ADJ	JJ	9	O
other	other	ADJ	JJ	5	O
sites	site	NOUN	NNS	9	O
also	also	ADV	RB	9	O
arose	arise	VERB	VBD	9	O
following	follow	VERB	VBG	9	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
feeding	feeding	NOUN	NN	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
electron	electron	NOUN	NN	0	O
microscope	microscope	NOUN	NN	0	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
livers	liver	NOUN	NNS	3	O
of	of	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
ultrastructural	ultrastructural	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hepatocytes	hepatocyte	NOUN	NNS	3	O
that	that	DET	WDT	5	O
resemble	resemble	VERB	VBP	9	O
those	those	DET	DT	5	O
that	that	DET	WDT	5	O
result	result	VERB	VBP	9	O
from	from	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
known	known	ADJ	JJ	9	O
hepatocarcinogens	hepatocarcinogen	NOUN	NNS	0	B-Disease
.	.	PUNCT	.	9	O

Transient	transient	ADJ	JJ	9	O
hemiparesis	hemiparesis	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
manifestation	manifestation	NOUN	NN	5	O
of	of	ADP	IN	5	O
diphenylhydantoin	diphenylhydantoin	NOUN	NN	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
the	the	DET	DT	5	O
common	common	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
diphenylhydantoin	diphenylhydantoin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DPH	DPH	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
overdose	overdose	NOUN	NN	0	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
frequently	frequently	ADV	RB	5	O
encountered	encounter	VERB	VBN	5	O
neurological	neurological	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
cerebellar	cerebellar	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Very	very	ADV	RB	5	O
rarely	rarely	ADV	RB	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
neurological	neurological	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
are	be	VERB	VBP	5	O
of	of	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	O
origin	origin	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
presented	present	VERB	VBN	5	O
who	who	PRON	WP	5	O
suffered	suffer	VERB	VBD	5	O
progressive	progressive	ADJ	JJ	5	O
hemiparesis	hemiparesis	NOUN	NN	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
DPH	DPH	PROPN	NNP	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
had	have	VERB	VBD	9	O
brain	brain	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
before	before	ADP	IN	9	O
DPH	DPH	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
assumed	assume	VERB	VBN	5	O
that	that	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
some	some	DET	DT	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
are	be	VERB	VBP	5	O
liable	liable	ADJ	JJ	5	O
to	to	PART	TO	5	O
manifest	manifest	VERB	VB	5	O
DPH	DPH	PROPN	NNP	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
as	as	ADP	IN	5	O
focal	focal	ADJ	JJ	5	O
neurological	neurological	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Tiapride	tiapride	VERB	VB	7	B-Chemical
in	in	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
involuntary	involuntary	ADJ	JJ	5	B-Disease
movements	movement	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Tiapride	Tiapride	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
substituted	substitute	VERB	VBN	0	O
benzamide	benzamide	ADJ	JJ	0	B-Chemical
derivative	derivative	NOUN	NN	0	O
closely	closely	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
metoclopramide	metoclopramide	VERB	VB	0	B-Chemical
,	,	PUNCT	,	9	O
reduced	reduce	VERB	VBD	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
peak	peak	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
involuntary	involuntary	ADJ	JJ	5	B-Disease
movements	movement	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
16	16	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
Parkinson	Parkinson	PROPN	NNP	5	I-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
unacceptable	unacceptable	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
disability	disability	NOUN	NN	5	O
from	from	ADP	IN	9	O
Parkinsonism	Parkinsonism	PROPN	NNP	5	B-Disease
with	with	ADP	IN	5	O
aggravation	aggravation	NOUN	NN	5	O
of	of	ADP	IN	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
of	of	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
akinesia	akinesia	NOUN	NN	5	B-Disease
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
cessation	cessation	NOUN	NN	5	O
in	in	ADP	IN	5	O
14	14	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Tiapride	tiapride	NOUN	NN	7	B-Chemical
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
levodopa	levodopa	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
early	early	ADJ	JJ	9	O
morning	morning	NOUN	NN	5	O
of	of	ADP	IN	5	O
"	"	PUNCT	``	5	O
off	off	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
period	period	NOUN	NN	5	O
"	"	PUNCT	''	5	O
segmental	segmental	ADJ	JJ	5	O
dystonia	dystonia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
fail	fail	VERB	VBP	5	O
to	to	PART	TO	5	O
support	support	VERB	VB	5	O
the	the	DET	DT	5	O
notion	notion	NOUN	NN	9	O
that	that	ADP	IN	5	O
levodopa	levodopa	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
are	be	VERB	VBP	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
overstimulation	overstimulation	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
separate	separate	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Quinidine	quinidine	NOUN	NN	0	B-Chemical
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
quinidine	quinidine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
SGOT	SGOT	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
lactic	lactic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
dehydrogenase	dehydrogenase	NOUN	NN	1	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
alkaline	alkaline	NOUN	NN	0	O
phosphatase	phosphatase	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
active	active	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Discontinuance	discontinuance	NOUN	NN	5	O
of	of	ADP	IN	5	O
quinidine	quinidine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
normalization	normalization	NOUN	NN	5	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
challenge	challenge	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
quinidine	quinidine	NOUN	NN	0	B-Chemical
caused	cause	VERB	VBD	9	O
clinical	clinical	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
abrupt	abrupt	ADJ	JJ	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
SGOT	SGOT	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
alkaline	alkaline	NOUN	NN	0	O
phosphatase	phosphatase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
lactic	lactic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
dehydrogenase	dehydrogenase	NOUN	NN	1	O
values	value	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
concluded	conclude	VERB	VBD	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
quinidine	quinidine	NOUN	NN	0	B-Chemical
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
believe	believe	VERB	VBP	5	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
reported	report	VERB	VBD	9	O
with	with	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
documentation	documentation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
also	also	ADV	RB	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
after	after	ADP	IN	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
reversible	reversible	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Arterial	arterial	ADJ	JJ	5	O
thromboembolism	thromboembolism	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
systemic	systemic	ADJ	JJ	9	O
heparin	heparin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
complication	complication	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Arterial	arterial	ADJ	JJ	5	O
thromboembolism	thromboembolism	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
recognized	recognize	VERB	VBN	9	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
heparin	heparin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Characteristic	characteristic	ADJ	JJ	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
entity	entity	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
arterial	arterial	ADJ	JJ	5	B-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
platelet	platelet	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
fibrin	fibrin	NOUN	NN	0	O
thrombi	thrombi	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
distal	distal	ADJ	JJ	9	O
ischemia	ischemia	NOUN	NN	9	B-Disease
occurring	occur	VERB	VBG	9	O
four	four	NUM	CD	9	O
to	to	PART	TO	5	O
twenty	twenty	NUM	CD	5	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
preceded	precede	VERB	VBN	9	O
by	by	ADP	IN	9	O
profound	profound	ADJ	JJ	9	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
platelet	platelet	NOUN	NN	9	O
counts	count	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
to	to	ADP	IN	5	O
40	40	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
per	per	ADP	IN	9	O
cubic	cubic	ADJ	JJ	5	O
millimeter	millimeter	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinically	clinically	ADV	RB	5	O
apparent	apparent	ADJ	JJ	9	O
occlusion	occlusion	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
preceded	precede	VERB	VBN	9	O
by	by	ADP	IN	9	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
musculoskeletal	musculoskeletal	ADJ	JJ	5	I-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
that	that	DET	WDT	5	O
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
in	in	ADP	IN	5	O
origin	origin	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
might	may	VERB	MD	9	O
serve	serve	VERB	VB	5	O
to	to	PART	TO	5	O
warn	warn	VERB	VB	5	O
the	the	DET	DT	5	O
clinician	clinician	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
phenomena	phenomenon	NOUN	NNS	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
recent	recent	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
common	common	ADJ	JJ	5	O
factor	factor	NOUN	NN	9	O
relating	relate	VERB	VBG	5	O
thromboembolism	thromboembolism	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
platelet	platelet	NOUN	NN	9	B-Disease
aggregation	aggregation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Appropriate	appropriate	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
consists	consist	VERB	VBZ	5	O
of	of	ADP	IN	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
with	with	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
warfarin	warfarin	NOUN	NN	5	I-Chemical
if	if	ADP	IN	5	O
necessary	necessary	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Vascular	vascular	NOUN	NN	9	O
procedures	procedure	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
performed	perform	VERB	VBN	9	O
as	as	ADP	IN	5	O
indicated	indicate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Pharmacology	pharmacology	NOUN	NN	2	O
of	of	ADP	IN	5	O
GYKI	GYKI	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
41	41	NUM	CD	7	I-Chemical
099	099	NUM	CD	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
chlorpropanol	chlorpropanol	NOUN	NN	_	B-Chemical
,	,	PUNCT	,	9	O
Tobanum	Tobanum	PROPN	NNP	_	B-Chemical
)	)	PUNCT	-RRB-	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
potent	potent	ADJ	JJ	3	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
antagonist	antagonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
compound	compound	NOUN	NN	0	O
GYKI	GYKI	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
41	41	NUM	CD	7	I-Chemical
099	099	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
times	time	NOUN	NNS	5	O
more	more	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
than	than	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Its	-PRON-	DET	PRP$	5	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
effectiveness	effectiveness	NOUN	NN	5	O
surpasses	surpass	VERB	VBZ	5	O
that	that	ADP	IN	5	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
pindolol	pindolol	NOUN	NN	0	B-Chemical
inhibiting	inhibit	VERB	VBG	3	O
the	the	DET	DT	5	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
cats	cat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

GYKI	GYKI	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
41	41	NUM	CD	7	I-Chemical
900	900	NUM	CD	9	I-Chemical
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
negligible	negligible	ADJ	JJ	9	O
cardiodepressant	cardiodepressant	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
;	;	PUNCT	:	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
cardioselective	cardioselective	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
compound	compound	NOUN	NN	0	O
shows	show	VERB	VBZ	9	O
a	a	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
long	long	ADJ	JJ	5	O
lasting	last	VERB	VBG	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
prolonged	prolonged	ADJ	JJ	9	O
elimination	elimination	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
radioactivity	radioactivity	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
14C	14c	NUM	CD	0	B-Chemical
-	-	SYM	SYM	7	I-Chemical
41	41	NUM	CD	7	I-Chemical
099	099	NUM	CD	7	I-Chemical
to	to	PART	TO	5	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
half	half	ADJ	JJ	5	O
life	life	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
unlabeled	unlabeled	ADJ	JJ	0	O
substance	substance	NOUN	NN	5	O
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
10	10	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
to	to	ADP	IN	5	O
bendrofluazide	bendrofluazide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
propranolol	propranolol	VERB	VB	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Report	Report	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Medical	Medical	PROPN	NNP	2	O
Research	Research	PROPN	NNP	2	O
Council	Council	PROPN	NNP	2	O
Working	Working	PROPN	NNP	5	O
Party	Party	PROPN	NNP	5	O
on	on	ADP	IN	5	O
Mild	Mild	PROPN	NNP	9	O
to	to	ADP	IN	5	O
Moderate	Moderate	PROPN	NNP	7	O
Hypertension	Hypertension	PROPN	NNP	7	B-Disease
.	.	PUNCT	.	9	O

Participants	participant	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Medical	Medical	PROPN	NNP	2	O
Research	Research	PROPN	NNP	2	O
Council	Council	PROPN	NNP	2	O
treatment	treatment	NOUN	NN	9	O
trial	trial	NOUN	NN	5	O
for	for	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
randomly	randomly	ADV	RB	5	O
allocated	allocate	VERB	VBN	5	O
to	to	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
bendrofluazide	bendrofluazide	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
for	for	ADP	IN	5	O
either	either	DET	DT	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
trial	trial	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

23	23	NUM	CD	7	O
582	582	NUM	CD	7	O
patient	patient	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
observation	observation	NOUN	NN	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
completed	complete	VERB	VBN	5	O
so	so	ADV	RB	5	O
far	far	ADV	RB	5	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
684	684	NUM	CD	7	O
on	on	ADP	IN	5	O
active	active	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
898	898	NUM	CD	7	O
on	on	ADP	IN	5	O
placebos	placebo	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
an	an	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
bendrofluazide	bendrofluazide	ADP	IN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
impotence	impotence	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
impotence	impotence	NOUN	NN	5	B-Disease
also	also	ADV	RB	9	O
occurred	occur	VERB	VBD	9	O
more	more	ADV	RBR	5	O
frequently	frequently	ADV	RB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
taking	take	VERB	VBG	5	O
placebos	placebos	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
significantly	significantly	ADV	RB	9	O
linked	link	VERB	VBD	9	O
with	with	ADP	IN	5	O
active	active	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
include	include	VERB	VBP	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
glucose	glucose	NOUN	NN	0	I-Disease
tolerance	tolerance	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
women	woman	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
gout	gout	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
men	man	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
bendrofluazide	bendrofluazide	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Raynaud	Raynaud	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
phenomenon	phenomenon	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
dyspnoea	dyspnoea	VERB	VB	5	B-Disease
in	in	ADP	IN	5	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
women	woman	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
corneal	corneal	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
occurred	occur	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
serum	serum	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
fell	fall	VERB	VBD	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
urea	urea	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
uric	uric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
levels	level	NOUN	NNS	3	O
rose	rise	VERB	VBD	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
women	woman	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
bendrofluazide	bendrofluazide	ADV	RB	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
serum	serum	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
uric	uric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
levels	level	NOUN	NNS	3	O
rose	rise	VERB	VBD	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
sexes	sex	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
urea	urea	ADJ	JJ	0	B-Chemical
level	level	NOUN	NN	9	O
rose	rise	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

Serotonergic	serotonergic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
benzodiazepines	benzodiazepine	NOUN	NNS	5	B-Chemical
and	and	CCONJ	CC	5	O
baclofen	baclofen	NOUN	NN	0	B-Chemical
block	block	NOUN	NN	9	O
muscimol	muscimol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myoclonic	myoclonic	ADJ	JJ	5	B-Disease
jerks	jerk	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
strain	strain	NOUN	NN	1	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
male	male	ADJ	JJ	9	O
Swiss	swiss	ADJ	JJ	2	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
muscimol	muscimol	NOUN	NN	0	B-Chemical
produced	produce	VERB	VBD	9	O
myoclonic	myoclonic	ADJ	JJ	5	B-Disease
jerks	jerk	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
dose	dose	NOUN	NN	9	O
induced	induce	VERB	VBD	3	O
this	this	DET	DT	5	O
response	response	NOUN	NN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mice	mouse	NOUN	NNS	3	O
tested	test	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
peak	peak	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
of	of	ADP	IN	5	O
73	73	NUM	CD	7	O
jerks	jerk	NOUN	NNS	5	O
per	per	ADP	IN	9	O
min	min	NOUN	NN	0	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
27	27	NUM	CD	7	O
and	and	CCONJ	CC	5	O
45	45	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Increasing	increase	VERB	VBG	9	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
levels	level	NOUN	NNS	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxytryptophan	hydroxytryptophan	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
80	80	NUM	CD	9	O
-	-	SYM	SYM	7	O
160	160	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
decarboxylase	decarboxylase	NOUN	NN	1	O
inhibitor	inhibitor	NOUN	NN	3	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
muscimol	muscimol	NOUN	NN	0	B-Chemical
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
experiment	experiment	NOUN	NN	9	O
l	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
80	80	NUM	CD	9	O
-	-	SYM	SYM	7	O
160	160	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
without	without	ADP	IN	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
212	212	NUM	CD	7	I-Chemical
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
response	response	NOUN	NN	9	O
of	of	ADP	IN	5	O
muscimol	muscimol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
benzodiazepines	benzodiazepine	NOUN	NNS	5	B-Chemical
,	,	PUNCT	,	9	O
clonazepam	clonazepam	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
several	several	ADJ	JJ	9	O
fold	fold	ADV	RB	9	O
more	more	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
than	than	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
blocking	block	VERB	VBG	3	O
the	the	DET	DT	5	O
myoclonic	myoclonic	ADJ	JJ	5	B-Disease
jerks	jerk	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
baclofen	baclofen	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
proved	prove	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
antagonist	antagonist	NOUN	NN	3	O
of	of	ADP	IN	5	O
muscimol	muscimol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
its	-PRON-	DET	PRP$	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
isomer	isomer	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
lacked	lack	VERB	VBD	9	O
this	this	DET	DT	5	O
property	property	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Considering	consider	VERB	VBG	9	O
the	the	DET	DT	5	O
fact	fact	NOUN	NN	9	O
that	that	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	SYM	SYM	7	I-Chemical
HTP	HTP	PROPN	NNP	5	I-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
benzodiazepines	benzodiazepine	NOUN	NNS	5	B-Chemical
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
beneficial	beneficial	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
muscimol	muscimol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
satisfactory	satisfactory	ADJ	JJ	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
prove	prove	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
new	new	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
treatments	treatment	NOUN	NNS	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
condition	condition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
indicated	indicate	VERB	VBD	9	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
of	of	ADP	IN	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
212	212	NUM	CD	7	I-Chemical
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
baclofen	baclofen	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
adrenergic	adrenergic	NOUN	NN	9	I-Chemical
blocking	block	VERB	VBG	3	I-Chemical
drugs	drug	NOUN	NNS	5	I-Chemical
and	and	CCONJ	CC	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ischaemic	ischaemic	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
developed	develop	VERB	VBD	5	O
profound	profound	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
during	during	ADP	IN	5	O
combined	combine	VERB	VBN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
adrenergic	adrenergic	NOUN	NN	9	I-Chemical
blocking	block	VERB	VBG	3	I-Chemical
drugs	drug	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
picture	picture	NOUN	NN	5	O
resolved	resolve	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
with	with	ADP	IN	5	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
combined	combine	VERB	VBN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Baseline	Baseline	PROPN	NNP	9	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	O
catheterisation	catheterisation	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
nuclear	nuclear	ADJ	JJ	3	O
angiography	angiography	NOUN	NN	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
only	only	ADV	RB	9	O
mildly	mildly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Simultaneously	simultaneously	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
adrenergic	adrenergic	NOUN	NN	9	I-Chemical
blocking	block	VERB	VBG	3	I-Chemical
drugs	drug	NOUN	NNS	5	I-Chemical
and	and	CCONJ	CC	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
profound	profound	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
interactions	interaction	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
should	should	VERB	MD	5	O
only	only	ADV	RB	9	O
be	be	VERB	VB	5	O
administered	administer	VERB	VBN	9	O
with	with	ADP	IN	5	O
great	great	ADJ	JJ	5	O
caution	caution	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Comparison	Comparison	PROPN	NNP	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effectiveness	effectiveness	NOUN	NN	5	O
of	of	ADP	IN	5	O
ranitidine	ranitidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
inhibiting	inhibit	VERB	VBG	3	O
acid	acid	NOUN	NN	0	O
secretion	secretion	NOUN	NN	3	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
gastric	gastric	ADJ	JJ	9	O
hypersecretory	hypersecretory	ADJ	JJ	5	O
states	state	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
H2	H2	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
histamine	histamine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
ranitidine	ranitidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
for	for	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
abilities	ability	NOUN	NNS	5	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
gastric	gastric	ADJ	JJ	9	O
acid	acid	NOUN	NN	0	O
hypersecretion	hypersecretion	NOUN	NN	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
basis	basis	NOUN	NN	5	O
in	in	ADP	IN	5	O
22	22	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
gastric	gastric	ADJ	JJ	9	O
acid	acid	NOUN	NN	0	O
hypersecretory	hypersecretory	ADJ	JJ	5	O
states	state	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Nineteen	nineteen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
Zollinger	Zollinger	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Ellison	Ellison	PROPN	NNP	6	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
systemic	systemic	ADJ	JJ	9	B-Disease
mastocytosis	mastocytosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
idiopathic	idiopathic	ADJ	JJ	5	O
hypersecretion	hypersecretion	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
ranitidine	ranitidine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
anticholinergic	anticholinergic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
close	close	ADJ	JJ	5	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
daily	daily	ADJ	JJ	5	O
maintenance	maintenance	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
drug	drug	NOUN	NN	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
acid	acid	NOUN	NN	0	O
secretion	secretion	NOUN	NN	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
ranitidine	ranitidine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
threefold	threefold	ADV	RB	9	O
more	more	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
than	than	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
both	both	DET	DT	9	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
inhibition	inhibition	NOUN	NN	3	O
studies	study	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
maintenance	maintenance	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
needed	need	VERB	VBN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
ranitidine	ranitidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
g	g	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Sixty	sixty	NUM	CD	5	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
males	male	NOUN	NNS	9	O
developed	develop	VERB	VBD	5	O
breast	breast	NOUN	NN	3	O
changes	change	NOUN	NNS	9	O
or	or	CCONJ	CC	5	O
impotence	impotence	NOUN	NN	5	B-Disease
while	while	ADP	IN	9	O
taking	take	VERB	VBG	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
cases	case	NOUN	NNS	5	O
these	these	DET	DT	5	O
changes	change	NOUN	NNS	9	O
disappeared	disappear	VERB	VBD	9	O
when	when	ADV	WRB	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
replaced	replace	VERB	VBN	9	O
by	by	ADP	IN	9	O
ranitidine	ranitidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
one	one	NUM	CD	5	O
to	to	PART	TO	5	O
60	60	NUM	CD	9	O
months	month	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
median	median	NOUN	NN	9	O
,	,	PUNCT	,	9	O
11	11	NUM	CD	7	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
ranitidine	ranitidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
two	two	NUM	CD	5	O
to	to	PART	TO	5	O
31	31	NUM	CD	7	O
months	month	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
median	median	NOUN	NN	9	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
or	or	CCONJ	CC	5	I-Disease
hematologic	hematologic	ADJ	JJ	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	O
alterations	alteration	NOUN	NNS	9	O
of	of	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
gastrin	gastrin	NOUN	NN	3	O
concentrations	concentration	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
ranitidine	ranitidine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
than	than	ADP	IN	5	O
seen	see	VERB	VBN	9	O
with	with	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
can	can	VERB	MD	5	O
adequately	adequately	ADV	RB	5	O
inhibit	inhibit	VERB	VB	3	O
acid	acid	NOUN	NN	0	O
secretion	secretion	NOUN	NN	3	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
gastric	gastric	ADJ	JJ	9	O
hypersecretory	hypersecretory	ADJ	JJ	5	O
states	state	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
are	be	VERB	VBP	5	O
safe	safe	ADJ	JJ	5	O
at	at	ADP	IN	9	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
ranitidine	ranitidine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
threefold	threefold	ADV	RB	9	O
more	more	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
cause	cause	VERB	VB	5	O
the	the	DET	DT	5	O
antiandrogen	antiandrogen	ADJ	JJ	0	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
frequently	frequently	ADV	RB	5	O
seen	see	VERB	VBN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Epileptogenic	epileptogenic	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
of	of	ADP	IN	5	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
clinical	clinical	ADJ	JJ	5	O
interpretation	interpretation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
EEG	EEG	PROPN	NNP	5	O
changes	change	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
single	single	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
to	to	PART	TO	5	O
enflurane	enflurane	VERB	VB	0	B-Chemical
anesthesia	anesthesia	NOUN	NN	5	O
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
administered	administer	VERB	VBD	9	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
donor	donor	NOUN	NN	9	O
nephrectomy	nephrectomy	NOUN	NN	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
unexpected	unexpected	ADJ	JJ	9	O
partial	partial	ADJ	JJ	9	O
motor	motor	NOUN	NN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Until	until	ADP	IN	5	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
correctly	correctly	ADV	RB	5	O
identified	identify	VERB	VBN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
inappropriately	inappropriately	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
anticonvulsants	anticonvulsant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
other	other	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
suffered	suffer	VERB	VBD	5	O
from	from	ADP	IN	9	O
partial	partial	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
complex	complex	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
generalized	generalized	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
uncontrolled	uncontrolle	VERB	VBN	5	O
by	by	ADP	IN	9	O
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Epileptic	epileptic	ADJ	JJ	5	B-Disease
foci	foci	NOUN	NN	9	O
delineated	delineate	VERB	VBD	5	O
and	and	CCONJ	CC	5	O
activated	activate	VERB	VBN	3	O
by	by	ADP	IN	9	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
surgically	surgically	ADV	RB	5	O
ablated	ablate	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
now	now	ADV	RB	5	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
exposures	exposure	NOUN	NNS	5	O
to	to	PART	TO	5	O
enflurane	enflurane	VERB	VB	0	B-Chemical
have	have	VERB	VB	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
disclosed	disclose	VERB	VBN	9	O
to	to	PART	TO	5	O
avoid	avoid	VERB	VB	5	O
mistakes	mistake	NOUN	NNS	5	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
interpretation	interpretation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
EEG	EEG	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
prove	prove	VERB	VB	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
safe	safe	ADJ	JJ	5	O
fast	fast	ADJ	JJ	5	O
acting	act	VERB	VBG	9	O
activator	activator	NOUN	NN	3	O
of	of	ADP	IN	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
foci	foci	NOUN	NN	9	O
during	during	ADP	IN	5	O
corticography	corticography	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
depth	depth	NOUN	NN	5	O
electrode	electrode	NOUN	NN	5	O
intraoperative	intraoperative	ADJ	JJ	5	O
recordings	recording	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Development	development	NOUN	NN	2	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
female	female	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
daily	daily	ADJ	JJ	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ISO	ISO	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
was	be	VERB	VBD	9	O
established	establish	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
tissue	tissue	NOUN	NN	9	O
mass	mass	NOUN	NN	9	O
,	,	PUNCT	,	9	O
RNA	RNA	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
DNA	dna	NOUN	NN	9	O
content	content	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
hydroxyproline	hydroxyproline	NOUN	NN	0	B-Chemical
content	content	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Heart	heart	NOUN	NN	2	O
weight	weight	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
44	44	NUM	CD	7	O
%	%	NOUN	NN	9	O
after	after	ADP	IN	9	O
8	8	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
half	half	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Ventricular	ventricular	ADJ	JJ	5	O
RNA	RNA	PROPN	NNP	9	O
content	content	NOUN	NN	9	O
was	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
after	after	ADP	IN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
reached	reach	VERB	VBD	9	O
a	a	DET	DT	5	O
maximal	maximal	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
following	follow	VERB	VBG	9	O
8	8	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
half	half	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
for	for	ADP	IN	5	O
RNA	rna	NOUN	NN	9	O
accumulation	accumulation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
content	content	NOUN	NN	9	O
of	of	ADP	IN	5	O
hydroxyproline	hydroxyproline	NOUN	NN	0	B-Chemical
remained	remain	VERB	VBD	9	O
stable	stable	ADJ	JJ	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
increased	increase	VERB	VBD	9	O
46	46	NUM	CD	7	O
%	%	NOUN	NN	9	O
after	after	ADP	IN	9	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ventricular	ventricular	ADJ	JJ	5	O
DNA	DNA	PROPN	NNP	9	O
content	content	NOUN	NN	9	O
was	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
hypertrophic	hypertrophic	ADJ	JJ	3	B-Disease
growth	growth	NOUN	NN	3	O
but	but	CCONJ	CC	9	O
increased	increase	VERB	VBD	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
steady	steady	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
state	state	NOUN	NN	5	O
level	level	NOUN	NN	9	O
19	19	NUM	CD	7	O
%	%	NOUN	NN	9	O
above	above	ADP	IN	9	O
the	the	DET	DT	5	O
controls	control	NOUN	NNS	9	O
after	after	ADP	IN	9	O
8	8	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Intraventricular	intraventricular	ADJ	JJ	7	O
pressures	pressure	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
coronary	coronary	ADJ	JJ	5	O
flow	flow	NOUN	NN	5	O
measures	measure	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
for	for	ADP	IN	5	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
experimental	experimental	ADJ	JJ	5	O
animals	animal	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
developed	developed	ADJ	JJ	5	O
hypertrophy	hypertrophy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
dP	dP	PROPN	NNP	5	O
/	/	PUNCT	NFP	9	O
dt	dt	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ISO	ISO	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
hearts	heart	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
slightly	slightly	ADV	RB	9	O
but	but	CCONJ	CC	9	O
significantly	significantly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
elevated	elevate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
adaptive	adaptive	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
ISO	ISO	PROPN	NNP	0	B-Chemical
shows	show	VERB	VBZ	9	O
an	an	DET	DT	5	O
early	early	ADJ	JJ	9	O
hypertrophic	hypertrophic	ADJ	JJ	3	B-Disease
phase	phase	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
substantial	substantial	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
RNA	RNA	PROPN	NNP	9	O
content	content	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
mass	mass	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
DNA	dna	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
prolonged	prolong	VERB	VBN	9	O
stimulation	stimulation	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
-	-	SYM	SYM	7	O
12	12	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
represent	represent	VERB	VB	9	O
a	a	DET	DT	5	O
complex	complex	ADJ	JJ	9	O
integration	integration	NOUN	NN	5	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
cellular	cellular	ADJ	JJ	3	O
hypertrophy	hypertrophy	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
hyperplasia	hyperplasia	NOUN	NN	9	B-Disease
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Multiple	multiple	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
penicillamine	penicillamine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Skin	skin	NOUN	NN	9	B-Disease
rashes	rash	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
systemic	systemic	ADJ	JJ	9	B-Disease
lupus	lupus	NOUN	NN	9	I-Disease
erythematosus	erythematosus	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
polymyositis	polymyositis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
myasthenia	myasthenia	ADJ	JJ	9	B-Disease
gravis	gravi	NOUN	NNS	2	I-Disease
have	have	VERB	VBP	5	O
all	all	ADV	RB	5	O
been	be	VERB	VBN	9	O
recorded	record	VERB	VBN	5	O
as	as	ADP	IN	5	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
penicillamine	penicillamine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
all	all	DET	DT	5	O
5	5	NUM	CD	9	O
is	be	VERB	VBZ	5	O
now	now	ADV	RB	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
skin	skin	NOUN	NN	5	B-Disease
lesion	lesion	NOUN	NN	5	I-Disease
resembled	resemble	VERB	VBD	9	O
elastosis	elastosis	NOUN	NN	5	B-Disease
perforans	perforan	NOUN	NNS	4	I-Disease
serpiginosa	serpiginosa	NOUN	NN	4	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Wilson	Wilson	PROPN	NNP	6	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
penicillamine	penicillamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Obsolete	obsolete	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
dangerous	dangerous	ADJ	JJ	5	O
antacid	antacid	ADJ	JJ	5	O
preparations	preparation	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
hypercalcaemia	hypercalcaemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
of	of	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
nephrolithiasis	nephrolithiasis	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
regularly	regularly	ADV	RB	5	O
consumed	consume	VERB	VBN	5	O
large	large	ADJ	JJ	5	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
carbon	carbon	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ate	ate	NOUN	NN	5	I-Chemical
-	-	PUNCT	HYPH	7	O
sodium	sodium	NOUN	NN	0	B-Chemical
bicarbonate	bicarbonate	NOUN	NN	0	I-Chemical
powders	powder	NOUN	NNS	0	O
for	for	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
20	20	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
powders	powder	NOUN	NNS	0	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
obtained	obtain	VERB	VBN	9	O
from	from	ADP	IN	9	O
pharmacists	pharmacist	NOUN	NNS	5	O
unknown	unknown	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
medical	medical	ADJ	JJ	5	O
practitioners	practitioner	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
preparations	preparation	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
problems	problem	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
such	such	ADJ	JJ	5	O
powders	powder	NOUN	NNS	0	O
should	should	VERB	MD	5	O
no	no	ADV	RB	9	O
longer	longer	ADV	RB	5	O
be	be	VERB	VB	5	O
freely	freely	ADV	RB	5	O
obtainable	obtainable	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
left	left	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
sided	sided	ADJ	JJ	5	O
Wilms	Wilms	PROPN	NNPS	9	B-Disease
tumor	tumor	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Wilms	Wilms	PROPN	NNPS	9	B-Disease
tumor	tumor	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
kidney	kidney	NOUN	NN	9	O
experienced	experience	VERB	VBD	5	O
severe	severe	ADJ	JJ	5	O
anthracycline	anthracycline	ADJ	JJ	9	B-Chemical
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
irradiation	irradiation	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
tumor	tumor	NOUN	NN	3	B-Disease
bed	bed	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
conventional	conventional	ADJ	JJ	5	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
attributed	attribute	VERB	VBN	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
fact	fact	NOUN	NN	9	O
that	that	ADP	IN	5	O
radiation	radiation	NOUN	NN	9	O
fields	field	NOUN	NNS	5	O
for	for	ADP	IN	5	O
left	left	ADJ	JJ	5	O
Wilms	Wilms	PROPN	NNPS	9	B-Disease
tumor	tumor	NOUN	NN	3	I-Disease
include	include	VERB	VBP	5	O
the	the	DET	DT	5	O
lower	low	ADJ	JJR	9	O
portion	portion	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
irradiation	irradiation	NOUN	NN	9	O
on	on	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
that	that	ADP	IN	5	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
dosage	dosage	NOUN	NN	9	O
be	be	VERB	VB	5	O
sharply	sharply	ADV	RB	9	O
restricted	restrict	VERB	VBN	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Wilms	Wilms	PROPN	NNPS	9	B-Disease
tumor	tumor	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
kidney	kidney	NOUN	NN	9	O
who	who	PRON	WP	5	O
receive	receive	VERB	VBP	5	O
postoperative	postoperative	ADJ	JJ	5	O
irradiation	irradiation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
calcitonin	calcitonin	NOUN	NN	3	O
on	on	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
system	system	NOUN	NN	5	O
:	:	PUNCT	:	9	O
behavioral	behavioral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
biochemical	biochemical	ADJ	JJ	9	O
data	datum	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
human	human	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
salmon	salmon	NOUN	NN	4	O
calcitonin	calcitonin	NOUN	NN	3	O
on	on	ADP	IN	5	O
biochemical	biochemical	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
behavioral	behavioral	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
system	system	NOUN	NN	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Calcitonin	calcitonin	ADJ	JJ	0	O
injection	injection	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
potentiation	potentiation	NOUN	NN	3	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
calcitonin	calcitonin	NOUN	NN	3	O
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
nigral	nigral	ADJ	JJ	3	O
GAD	GAD	PROPN	NNP	9	O
activity	activity	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
DA	DA	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
DOPAC	DOPAC	PROPN	NNP	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
GAD	GAD	PROPN	NNP	9	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
in	in	ADP	IN	5	O
view	view	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
calcitonin	calcitonin	NOUN	NN	3	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
striatonigral	striatonigral	ADJ	JJ	3	O
GABAergic	GABAergic	PROPN	NNP	3	O
pathway	pathway	ADV	RB	3	O
mediating	mediate	VERB	VBG	9	O
the	the	DET	DT	5	O
DA	DA	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
behavioral	behavioral	ADJ	JJ	5	O
messages	message	NOUN	NNS	5	O
of	of	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
origin	origin	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Naloxazone	naloxazone	NOUN	NN	_	B-Chemical
pretreatment	pretreatment	ADJ	JJ	0	O
modifies	modifie	NOUN	NNS	9	O
cardiorespiratory	cardiorespiratory	NOUN	NN	5	O
,	,	PUNCT	,	9	O
temperature	temperature	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Behavioral	behavioral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
cardiorespiratory	cardiorespiratory	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
lethal	lethal	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
naloxazone	naloxazone	NOUN	NN	_	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
antagonist	antagonist	NOUN	NN	3	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
affinity	affinity	NOUN	NN	0	O
mu	mu	NOUN	NNS	9	O
1	1	NUM	CD	9	O
opioid	opioid	ADJ	JJ	5	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
with	with	ADP	IN	5	O
naloxazone	naloxazone	NOUN	NN	_	B-Chemical
significantly	significantly	ADV	RB	9	O
blocked	block	VERB	VBN	3	O
morphine	morphine	NOUN	NN	0	B-Chemical
analgesia	analgesia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hypothermia	hypothermia	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
which	which	DET	WDT	5	O
completely	completely	ADV	RB	9	O
eliminated	eliminate	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
affinity	affinity	NOUN	NN	0	O
binding	bind	VERB	VBG	1	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
membranes	membrane	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
naloxazone	naloxazone	NOUN	NN	_	B-Chemical
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
depression	depression	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
affected	affected	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
subpopulations	subpopulation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mu	mu	NOUN	NNS	9	O
receptors	receptor	NOUN	NNS	3	O
may	may	VERB	MD	5	O
mediate	mediate	VERB	VB	3	O
selective	selective	ADJ	JJ	9	O
behavioral	behavioral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
cardiorespiratory	cardiorespiratory	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Modification	modification	NOUN	NN	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
action	action	NOUN	NN	5	O
by	by	ADP	IN	9	O
hyperammonemia	hyperammonemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
with	with	ADP	IN	5	O
ammonium	ammonium	NOUN	NN	0	B-Chemical
acetate	acetate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NH4Ac	NH4Ac	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	PROPN	NNP	0	O
s	s	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
approximately	approximately	ADV	RB	9	O
doubled	double	VERB	VBD	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
mice	mouse	NOUN	NNS	3	O
remained	remain	VERB	VBD	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
hot	hot	ADJ	JJ	5	O
surface	surface	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
similarly	similarly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
muscular	muscular	ADJ	JJ	5	O
incoordination	incoordination	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
NH4Ac	NH4Ac	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
alone	alone	ADV	RB	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
hyperammonemia	hyperammonemia	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
capable	capable	ADJ	JJ	9	O
of	of	ADP	IN	5	O
altering	alter	VERB	VBG	9	O
drug	drug	NOUN	NN	5	O
action	action	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
along	along	PART	RP	9	O
with	with	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
metabolism	metabolism	NOUN	NN	9	O
in	in	ADP	IN	5	O
enhanced	enhance	VERB	VBN	3	O
drug	drug	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Experiments	experiment	NOUN	NNS	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catecholamine	catecholamine	NOUN	NN	9	B-Chemical
release	release	NOUN	NN	9	O
from	from	ADP	IN	9	O
bovine	bovine	ADJ	JJ	9	O
adrenal	adrenal	ADJ	JJ	9	O
medulla	medulla	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
depressed	depressed	ADJ	JJ	5	O
as	as	ADV	RB	5	O
much	much	ADJ	JJ	5	O
as	as	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
by	by	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
mM	mM	PROPN	NNP	0	O
NH4Ac	NH4Ac	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
KCl	KCl	NOUN	NNS	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
contractions	contraction	NOUN	NNS	5	O
of	of	ADP	IN	5	O
guinea	guinea	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
pig	pig	NOUN	NN	9	O
ileum	ileum	NOUN	NN	9	O
were	be	VERB	VBD	9	O
inhibited	inhibit	VERB	VBN	3	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
by	by	ADP	IN	9	O
5	5	NUM	CD	9	O
mM	mM	PROPN	NNP	0	O
NH4Ac	NH4Ac	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Addition	addition	NOUN	NN	0	O
of	of	ADP	IN	5	O
excess	excess	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
reversed	reverse	VERB	VBD	9	O
the	the	DET	DT	5	O
depression	depression	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
tissues	tissue	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
independent	independent	ADJ	JJ	9	O
catecholamine	catecholamine	NOUN	NN	9	B-Chemical
release	release	NOUN	NN	9	O
by	by	ADP	IN	9	O
acetaldehyde	acetaldehyde	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
NH4Ac	NH4Ac	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
ammonia	ammonia	NOUN	NN	0	B-Chemical
blocks	block	NOUN	NNS	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
channels	channel	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Parallels	parallel	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
NH4Ac	NH4Ac	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blocker	blocker	NOUN	NN	0	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
support	support	NOUN	NN	5	O
this	this	DET	DT	5	O
concept	concept	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
NH4Ac	NH4Ac	PROPN	NNP	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
enhanced	enhance	VERB	VBD	3	O
morphine	morphine	NOUN	NN	0	B-Chemical
analgesia	analgesia	NOUN	NN	5	B-Disease
-	-	PUNCT	,	7	O
and	and	CCONJ	CC	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
muscular	muscular	ADJ	JJ	5	O
incoordination	incoordination	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
antagonized	antagonize	VERB	VBN	3	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
motor	motor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
neither	neither	CCONJ	CC	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
nor	nor	CCONJ	CC	9	O
NH4Ac	NH4Ac	PROPN	NNP	0	B-Chemical
affected	affect	VERB	VBD	9	O
the	the	DET	DT	5	O
convulsant	convulsant	ADJ	JJ	0	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
metrazol	metrazol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
hyperammonemia	hyperammonemia	NOUN	NN	5	B-Disease
exerts	exert	VERB	VBZ	9	O
a	a	DET	DT	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blocking	block	VERB	VBG	3	O
action	action	NOUN	NN	5	O
which	which	DET	WDT	5	O
enhances	enhance	VERB	VBZ	3	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
depressants	depressant	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
certain	certain	ADJ	JJ	5	O
opioid	opioid	NOUN	NN	5	O
analgesics	analgesic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Levodopa	Levodopa	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
thalamotomy	thalamotomy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Levodopa	Levodopa	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
limbs	limb	NOUN	NNS	5	O
in	in	ADP	IN	5	O
thirteen	thirteen	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Parkinsonism	Parkinsonism	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
choreic	choreic	NOUN	NN	5	O
,	,	PUNCT	,	9	O
ballistic	ballistic	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
dystonic	dystonic	ADJ	JJ	5	B-Disease
in	in	ADP	IN	5	O
type	type	NOUN	NN	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
alleviated	alleviate	VERB	VBN	9	O
almost	almost	ADV	RB	9	O
completely	completely	ADV	RB	9	O
by	by	ADP	IN	9	O
stereotaxic	stereotaxic	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
microelectrode	microelectrode	NOUN	NN	5	O
technique	technique	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
ventralis	ventralis	NOUN	NN	4	O
oralis	oralis	ADP	IN	4	O
anterior	anterior	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
posterior	posterior	ADJ	JJ	5	O
nuclei	nucleus	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
thalamus	thalamus	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
much	much	ADV	RB	5	O
less	less	ADJ	JJR	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
ventralis	ventralis	NOUN	NN	4	O
intermedius	intermedius	NOUN	NN	4	O
nucleus	nucleus	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
by	by	ADP	IN	9	O
thalamic	thalamic	ADJ	JJ	5	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
routine	routine	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
Parkinsonism	Parkinsonism	PROPN	NNP	5	B-Disease
is	be	VERB	VBZ	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
urothelial	urothelial	ADJ	JJ	3	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
by	by	ADP	IN	9	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
mercaptoethane	mercaptoethane	NOUN	NN	0	I-Chemical
sulphonate	sulphonate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
MESNA	MESNA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
inoperable	inoperable	ADJ	JJ	5	O
lung	lung	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
thiol	thiol	NOUN	NN	0	B-Chemical
compound	compound	NOUN	NN	0	O
sodium	sodium	NOUN	NN	0	B-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
mercaptoethane	mercaptoethane	NOUN	NN	0	I-Chemical
sulphonate	sulphonate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
MESNA	MESNA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
against	against	ADP	IN	9	O
urothelial	urothelial	ADJ	JJ	3	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
IF	IF	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
45	45	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
inoperable	inoperable	ADJ	JJ	5	O
lung	lung	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
under	under	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
IF	IF	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
2250	2250	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
polychemotherapy	polychemotherapy	NOUN	NN	5	O
regimen	regimen	NOUN	NN	5	O
repeated	repeat	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
cycle	cycle	NOUN	NN	9	O
.	.	PUNCT	.	9	O

MESNA	MESNA	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
orally	orally	ADV	RB	0	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
IF	IF	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
840	840	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
each	each	DET	DT	5	O
administered	administer	VERB	VBD	9	O
at	at	ADP	IN	9	O
0	0	NUM	CD	7	O
hr	hr	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
=	=	ADP	IN	7	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
IF	IF	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
hr	hr	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
hr	hr	NOUN	NN	0	O
p	p	X	XX	7	O
.	.	PUNCT	.	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O

Out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
88	88	NUM	CD	7	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
observed	observe	VERB	VBD	9	O
10	10	NUM	CD	9	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
microscopic	microscopic	ADJ	JJ	9	O
haematuria	haematuria	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
gross	gross	ADJ	JJ	5	O
haematuria	haematuria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
45	45	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
under	under	ADP	IN	9	O
protection	protection	NOUN	NN	9	O
with	with	ADP	IN	5	O
MESNA	MESNA	PROPN	NNP	0	B-Chemical
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
5	5	NUM	CD	9	O
complete	complete	ADJ	JJ	9	O
remissions	remission	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
9	9	NUM	CD	7	O
partial	partial	ADJ	JJ	9	O
remissions	remission	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
total	total	ADJ	JJ	9	O
31	31	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
further	further	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
25	25	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
under	under	ADP	IN	9	O
polychemotherapy	polychemotherapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
IF	IF	PROPN	NNP	9	B-Chemical
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
conventional	conventional	ADJ	JJ	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
measures	measure	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
raised	raise	VERB	VBN	9	O
fluid	fluid	ADJ	JJ	5	O
intake	intake	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
forced	force	VERB	VBN	5	O
diuresis	diuresis	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
group	group	NOUN	NN	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
complete	complete	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
partial	partial	ADJ	JJ	9	O
remissions	remission	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
total	total	ADJ	JJ	9	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
nearly	nearly	ADV	RB	9	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
either	either	CCONJ	CC	9	O
gross	gross	ADJ	JJ	5	O
haematuria	haematuria	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
irritation	irritation	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
cystitis	cystitis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
pollakisuria	pollakisuria	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
appreciable	appreciable	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
MESNA	MESNA	PROPN	NNP	0	B-Chemical
series	series	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
conventional	conventional	ADJ	JJ	5	O
prophylaxis	prophylaxis	NOUN	NN	5	O
series	series	NOUN	NN	5	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
either	either	CCONJ	CC	9	O
haematological	haematological	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
systemic	systemic	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cytostatic	cytostatic	ADJ	JJ	3	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
support	support	VERB	VBP	5	O
the	the	DET	DT	5	O
view	view	NOUN	NN	5	O
that	that	ADP	IN	5	O
MESNA	MESNA	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
orally	orally	ADV	RB	0	O
in	in	ADP	IN	5	O
conjunction	conjunction	NOUN	NN	9	O
with	with	ADP	IN	5	O
combined	combine	VERB	VBN	9	O
cytostatic	cytostatic	ADJ	JJ	3	O
regimens	regimen	NOUN	NNS	5	O
which	which	DET	WDT	5	O
include	include	VERB	VBP	5	O
IF	if	ADP	IN	9	B-Chemical
,	,	PUNCT	,	9	O
simplifies	simplify	VERB	VBZ	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
provides	provide	VERB	VBZ	5	O
optimum	optimum	ADJ	JJ	9	O
protection	protection	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
urinary	urinary	ADJ	JJ	9	O
epithelium	epithelium	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Protection	protection	NOUN	NN	2	O
with	with	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
MESNA	MESNA	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
particularly	particularly	ADV	RB	5	O
suitable	suitable	ADJ	JJ	5	O
for	for	ADP	IN	5	O
outpatients	outpatient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Myoclonic	myoclonic	ADJ	JJ	7	B-Disease
,	,	PUNCT	,	9	I-Disease
atonic	atonic	ADJ	JJ	5	I-Disease
,	,	PUNCT	,	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
absence	absence	NOUN	NN	3	I-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
following	follow	VERB	VBG	9	O
institution	institution	NOUN	NN	5	O
of	of	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
children	child	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
aged	age	VERB	VBN	9	O
3	3	NUM	CD	9	O
to	to	ADP	IN	5	O
11	11	NUM	CD	7	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
aberrant	aberrant	ADJ	JJ	3	O
reaction	reaction	NOUN	NN	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
myoclonic	myoclonic	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	I-Disease
atypical	atypical	ADJ	JJ	5	I-Disease
absence	absence	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	I-Disease
/	/	SYM	SYM	9	I-Disease
or	or	CCONJ	CC	5	I-Disease
atonic	atonic	ADJ	JJ	5	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
minor	minor	ADJ	JJ	9	I-Disease
motor	motor	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
within	within	ADP	IN	9	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
the	the	DET	DT	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
children	child	NOUN	NNS	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
former	former	ADJ	JJ	5	O
state	state	NOUN	NN	5	O
very	very	ADV	RB	5	O
quickly	quickly	ADV	RB	5	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
had	have	VERB	VBD	9	O
the	the	DET	DT	5	O
minor	minor	ADJ	JJ	9	O
motor	motor	NOUN	NN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
resolve	resolve	VERB	VBP	5	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
one	one	PRON	PRP	5	O
had	have	VERB	VBD	9	O
the	the	DET	DT	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
persist	persist	VERB	VB	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
child	child	NOUN	NN	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
the	the	DET	DT	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
persisted	persist	VERB	VBD	9	O
was	be	VERB	VBD	9	O
later	later	ADV	RB	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
ceroid	ceroid	ADJ	JJ	3	B-Disease
lipofuscinosis	lipofuscinosis	NOUN	NN	2	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
children	child	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
doing	do	VERB	VBG	5	O
well	well	ADV	RB	9	O
on	on	ADP	IN	5	O
other	other	ADJ	JJ	5	O
anticonvulsants	anticonvulsant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
synthetase	synthetase	NOUN	NN	1	O
inhibitors	inhibitor	NOUN	NNS	3	O
on	on	ADP	IN	5	O
experimentally	experimentally	ADV	RB	9	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
of	of	ADP	IN	5	O
prostaglandins	prostaglandin	NOUN	NNS	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PGs	pg	NOUN	NNS	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
seizure	seizure	VERB	VB	5	B-Disease
induction	induction	NOUN	NN	3	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
six	six	NUM	CD	9	O
PG	pg	NOUN	NN	9	O
synthetase	synthetase	NOUN	NN	1	O
inhibitors	inhibitor	NOUN	NNS	3	O
on	on	ADP	IN	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
flurothyl	flurothyl	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
pentetrazol	pentetrazol	ADP	IN	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
PTZ	PTZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
electroshock	electroshock	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
bicuculline	bicuculline	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Ibuprofen	Ibuprofen	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
mefenamic	mefenamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
meclofenamic	meclofenamic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
latency	latency	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
onset	onset	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
flurothyl	flurothyl	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
PTZ	ptz	NOUN	NN	0	B-Chemical
models	model	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
electroshock	electroshock	NOUN	NN	5	O
,	,	PUNCT	,	9	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
bicuculline	bicuculline	NOUN	NN	0	B-Chemical
models	model	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pretreatment	pretreatment	ADJ	JJ	0	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
PGs	pg	NOUN	NNS	9	B-Chemical
are	be	VERB	VBP	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
s	s	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
underlying	underlie	VERB	VBG	5	O
fluorthyl	fluorthyl	NOUN	NN	_	B-Chemical
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
PTZ	ptz	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
electroshock	electroshock	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
bicuculline	bicuculline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
ammonia	ammonia	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
predict	predict	VERB	VB	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
valproic	valproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Valproic	Valproic	PROPN	NNP	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
VPA	VPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
24	24	NUM	CD	9	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
already	already	ADV	RB	5	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
standardized	standardized	ADJ	JJ	5	O
loading	loading	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
venous	venous	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
was	be	VERB	VBD	9	O
sampled	sample	VERB	VBN	5	O
at	at	ADP	IN	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Ammonia	Ammonia	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
NH3	NH3	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
drowsiness	drowsiness	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
symptom	symptom	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
VPA	VPA	PROPN	NNP	9	B-Chemical
plasma	plasma	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
measuring	measure	VERB	VBG	9	O
VPA	VPA	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
NH3	NH3	PROPN	NNP	0	B-Chemical
content	content	NOUN	NN	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
possible	possible	ADJ	JJ	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
higher	high	ADJ	JJR	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
obtundation	obtundation	NOUN	NN	5	O
when	when	ADV	WRB	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
is	be	VERB	VBZ	5	O
given	give	VERB	VBN	5	O
chronically	chronically	ADV	RB	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
existing	existing	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
aminonucleoside	aminonucleoside	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Proteinuria	Proteinuria	PROPN	NNP	7	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
captopril	captopril	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
reproducing	reproduce	VERB	VBG	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	B-Disease
abnormality	abnormality	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
SHR	SHR	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
for	for	ADP	IN	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
aggravate	aggravate	VERB	VB	9	O
proteinuria	proteinuria	X	FW	9	B-Disease
pre	pre	VERB	VBN	9	O
-	-	ADJ	JJ	7	O
existing	exist	VERB	VBG	5	O
in	in	ADP	IN	5	O
SHR	SHR	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
,	,	PUNCT	,	9	O
captopril	captopril	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
potentiate	potentiate	VERB	VB	3	O
or	or	CCONJ	CC	5	O
facilitate	facilitate	VERB	VB	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
massive	massive	ADJ	JJ	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
invoked	invoke	VERB	VBN	5	O
by	by	ADP	IN	9	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
in	in	ADP	IN	5	O
SHR	SHR	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Captopril	Captopril	PROPN	NNP	0	B-Chemical
had	have	VERB	VBD	9	O
little	little	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
no	no	DET	DT	9	O
demonstrable	demonstrable	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
electrolyte	electrolyte	NOUN	NN	0	O
concentrations	concentration	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
urine	urine	NOUN	NN	9	O
,	,	PUNCT	,	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
endogenous	endogenous	ADJ	JJ	3	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
food	food	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
water	water	NOUN	NN	0	O
consumption	consumption	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
ketone	ketone	VERB	VBD	0	B-Chemical
bodies	body	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
consistently	consistently	ADV	RB	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
urine	urine	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
several	several	ADJ	JJ	9	O
lethalities	lethality	NOUN	NNS	3	O
occurred	occur	VERB	VBD	9	O
during	during	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	O
dosing	dosing	NOUN	NN	9	O
of	of	ADP	IN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
SHR	SHR	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Complete	complete	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
block	block	NOUN	NN	9	I-Disease
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
trazodone	trazodone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
starting	starting	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
trazodone	trazodone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBN	5	O
complete	complete	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
block	block	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
case	case	NOUN	NN	5	O
illustrates	illustrate	VERB	VBZ	5	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
despite	despite	ADP	IN	9	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
earlier	early	ADJ	JJR	9	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
trazodone	trazodone	NOUN	NN	0	B-Chemical
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
conduction	conduction	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
severe	severe	ADJ	JJ	5	O
in	in	ADP	IN	5	O
individuals	individual	NOUN	NNS	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
conduction	conduction	NOUN	NN	5	O
delay	delay	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
neurologically	neurologically	ADV	RB	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
impaired	impair	VERB	VBN	9	I-Disease
child	child	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
child	child	NOUN	NN	5	O
with	with	ADP	IN	5	O
known	know	VERB	VBN	9	O
neurologic	neurologic	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
soon	soon	ADV	RB	5	O
after	after	ADP	IN	9	O
starting	start	VERB	VBG	9	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Known	known	ADJ	JJ	9	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
movement	movement	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
eliminated	eliminate	VERB	VBN	9	O
after	after	ADP	IN	9	O
evaluation	evaluation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
repeat	repeat	NOUN	NN	9	O
challenge	challenge	NOUN	NN	9	O
with	with	ADP	IN	5	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
recurred	recur	VERB	VBD	5	O
.	.	PUNCT	.	9	O

Phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
added	add	VERB	VBN	0	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
list	list	NOUN	NN	5	O
of	of	ADP	IN	5	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
movement	movement	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
amine	amine	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
on	on	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
catatonia	catatonia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
pinealectomized	pinealectomized	ADJ	JJ	3	O
or	or	CCONJ	CC	5	O
hypophysectomized	hypophysectomize	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
clarify	clarify	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
catecholamines	catecholamine	NOUN	NNS	9	B-Chemical
and	and	CCONJ	CC	5	O
pineal	pineal	ADJ	JJ	5	O
idolamines	idolamine	NOUN	NNS	_	O
on	on	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
catatonia	catatonia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
intact	intact	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
pinealectomized	pinealectomized	ADJ	JJ	3	O
or	or	CCONJ	CC	5	O
hypophysectomized	hypophysectomize	VERB	VBN	3	O
chick	chick	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
pinealectomized	pinealectomized	ADJ	JJ	3	O
chick	chick	NOUN	NN	9	O
,	,	PUNCT	,	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
catatonia	catatonia	ADJ	JJ	5	B-Disease
(	(	PUNCT	-LRB-	9	O
DOC	DOC	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pineal	pineal	ADJ	JJ	5	O
indolamines	indolamine	NOUN	NNS	0	O
exhibited	exhibit	VERB	VBD	9	O
mixed	mixed	ADJ	JJ	9	O
actions	action	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Serotonin	Serotonin	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
acetyl	acetyl	NOUN	NN	0	I-Chemical
serotonin	serotonin	NOUN	NN	9	I-Chemical
which	which	DET	WDT	5	O
augmented	augment	VERB	VBD	9	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
DOC	DOC	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
do	do	VERB	VB	5	O
so	so	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pineal	pineal	ADJ	JJ	5	O
gland	gland	NOUN	NN	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
potentiated	potentiate	VERB	VBD	3	O
the	the	DET	DT	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
DOC	DOC	PROPN	NNP	0	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
intact	intact	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
pinealectomized	pinealectomized	ADJ	JJ	3	O
chick	chick	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Ketamine	Ketamine	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hypophysectomized	hypophysectomized	ADJ	JJ	3	O
chick	chick	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
circadian	circadian	ADJ	JJ	9	O
rhythm	rhythm	NOUN	NN	5	O
noted	note	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
intact	intact	ADJ	JJ	9	O
chick	chick	NOUN	NN	9	O
was	be	VERB	VBD	9	O
absent	absent	ADJ	JJ	9	O
;	;	PUNCT	:	9	O
furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
augment	augment	VERB	VB	9	O
the	the	DET	DT	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
DOC	DOC	PROPN	NNP	0	O
whereas	whereas	ADP	IN	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
continued	continue	VERB	VBD	9	O
to	to	PART	TO	5	O
do	do	VERB	VB	5	O
so	so	ADV	RB	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
demonstrate	demonstrate	VERB	VB	9	O
a	a	DET	DT	5	O
species	species	NOUN	NN	4	O
difference	difference	NOUN	NN	9	O
regarding	regard	VERB	VBG	5	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
amines	amine	NOUN	NNS	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
pineal	pineal	NOUN	NN	5	O
in	in	ADP	IN	5	O
spite	spite	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
immature	immature	ADJ	JJ	3	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
young	young	ADJ	JJ	5	O
chick	chick	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
intact	intact	ADJ	JJ	9	O
barrier	barrier	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pituitary	pituitary	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
augmentation	augmentation	NOUN	NN	9	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
DOC	DOC	PROPN	NNP	0	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
melatonin	melatonin	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
act	act	VERB	VB	9	O
on	on	ADP	IN	5	O
systems	system	NOUN	NNS	5	O
more	more	ADV	RBR	5	O
closely	closely	ADV	RB	9	O
involved	involved	ADJ	JJ	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
catatonia	catatonia	NOUN	NN	5	B-Disease
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
directly	directly	ADV	RB	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
pituitary	pituitary	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Heparin	Heparin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Sixty	sixty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
disorder	disorder	NOUN	NN	5	O
include	include	VERB	VBP	5	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
more	more	ADV	RBR	5	O
frequently	frequently	ADV	RB	5	O
,	,	PUNCT	,	9	O
thromboembolic	thromboembolic	ADJ	JJ	5	B-Disease
events	event	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
heparin	heparin	ADV	RB	0	B-Chemical
.	.	PUNCT	.	9	O

Laboratory	laboratory	NOUN	NN	2	O
testing	testing	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
revealed	reveal	VERB	VBN	9	O
a	a	DET	DT	5	B-Disease
falling	fall	VERB	VBG	5	I-Disease
platelet	platelet	NOUN	NN	9	I-Disease
count	count	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
increased	increase	VERB	VBN	9	O
resistance	resistance	NOUN	NN	9	O
to	to	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
aggregation	aggregation	NOUN	NN	9	O
of	of	ADP	IN	5	O
platelets	platelet	NOUN	NNS	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
plasma	plasma	NOUN	NN	9	O
when	when	ADV	WRB	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
added	add	VERB	VBN	0	O
.	.	PUNCT	.	9	O

Immunologic	immunologic	ADJ	JJ	9	O
testing	testing	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
demonstrated	demonstrate	VERB	VBN	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
platelet	platelet	NOUN	NN	9	O
membrane	membrane	NOUN	NN	9	O
antibody	antibody	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
20	20	NUM	CD	9	O
deaths	death	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
52	52	NUM	CD	7	O
hemorrhagic	hemorrhagic	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
thromboembolic	thromboembolic	ADJ	JJ	5	I-Disease
complications	complication	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
21	21	NUM	CD	7	O
surgical	surgical	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
to	to	PART	TO	5	O
manage	manage	VERB	VB	5	O
the	the	DET	DT	5	O
complications	complication	NOUN	NNS	5	O
confirm	confirm	VERB	VBP	9	O
the	the	DET	DT	5	O
seriousness	seriousness	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
disorder	disorder	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Specific	specific	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
identified	identify	VERB	VBN	9	O
;	;	PUNCT	:	9	O
therefore	therefore	ADV	RB	5	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
heparin	heparin	ADV	RB	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
monitored	monitor	VERB	VBN	9	O
.	.	PUNCT	.	9	O

If	if	ADP	IN	5	O
the	the	DET	DT	5	O
platelet	platelet	NOUN	NN	9	O
count	count	NOUN	NN	9	O
falls	fall	VERB	VBZ	5	O
to	to	ADP	IN	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
/	/	SYM	SYM	9	O
mm3	mm3	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
receiving	receive	VERB	VBG	9	O
heparin	heparin	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
platelet	platelet	VERB	VB	9	B-Disease
aggregation	aggregation	NOUN	NN	9	I-Disease
testing	testing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
plasma	plasma	NOUN	NN	9	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
indicated	indicate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Management	management	NOUN	NN	5	O
consists	consist	VERB	VBZ	5	O
of	of	ADP	IN	5	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
platelet	platelet	VERB	VB	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
aggregating	aggregating	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
alternate	alternate	ADJ	JJ	9	O
forms	form	NOUN	NNS	9	O
of	of	ADP	IN	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
when	when	ADV	WRB	5	O
indicated	indicate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
from	from	ADP	IN	9	O
diatrizoate	diatrizoate	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
chelating	chelate	VERB	VBG	0	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
Renografin	Renografin	PROPN	NNP	0	B-Chemical
76	76	NUM	CD	7	I-Chemical
%	%	NOUN	NN	9	I-Chemical
was	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
Hypaque	Hypaque	PROPN	NNP	0	B-Chemical
76	76	NUM	CD	7	I-Chemical
%	%	NOUN	NN	9	I-Chemical
by	by	ADP	IN	9	O
selective	selective	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
of	of	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Renografin	Renografin	PROPN	NNP	0	B-Chemical
contains	contain	VERB	VBZ	9	O
the	the	DET	DT	5	O
chelating	chelate	VERB	VBG	0	O
agents	agent	NOUN	NNS	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
citrate	citrate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
disodium	disodium	NOUN	NN	0	B-Chemical
edetate	edetate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
Hypaque	Hypaque	PROPN	NNP	0	B-Chemical
contains	contain	VERB	VBZ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
disodium	disodium	NOUN	NN	0	I-Chemical
edetate	edetate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
citrate	citrate	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
often	often	ADV	RB	5	O
with	with	ADP	IN	5	O
Renografin	Renografin	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
chelating	chelate	VERB	VBG	0	O
agents	agent	NOUN	NNS	5	O
contribute	contribute	VERB	VBP	9	O
to	to	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	O
angiography	angiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Amiodarone	Amiodarone	PROPN	NNP	7	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
154	154	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
sustained	sustain	VERB	VBN	5	O
,	,	PUNCT	,	9	O
symptomatic	symptomatic	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
VT	VT	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
118	118	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
36	36	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
refractory	refractory	ADJ	JJ	9	O
to	to	ADP	IN	5	O
conventional	conventional	ADJ	JJ	5	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
loading	loading	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
maintenance	maintenance	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
600	600	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Sixty	sixty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
continued	continue	VERB	VBD	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptomatic	symptomatic	ADJ	JJ	5	O
VT	VT	PROPN	NNP	9	B-Disease
or	or	CCONJ	CC	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
VF	VF	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
to	to	PART	TO	5	O
52	52	NUM	CD	7	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
standard	standard	ADJ	JJ	5	O
deviation	deviation	NOUN	NN	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
nonfatal	nonfatal	ADJ	JJ	5	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
VT	VT	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
successfully	successfully	ADV	RB	5	O
managed	manage	VERB	VBN	5	O
by	by	ADP	IN	9	O
continuing	continue	VERB	VBG	5	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
dose	dose	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
conventional	conventional	ADJ	JJ	5	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
reactions	reaction	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
51	51	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Adverse	Adverse	PROPN	NNP	5	O
effects	effect	NOUN	NNS	9	O
forced	force	VERB	VBD	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
41	41	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
symptomatic	symptomatic	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
tremor	tremor	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
ataxia	ataxia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
anorexia	anorexia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
visual	visual	ADJ	JJ	5	B-Disease
halos	halos	NOUN	NN	0	I-Disease
or	or	CCONJ	CC	5	I-Disease
blurring	blurring	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
thyroid	thyroid	NOUN	NN	9	B-Disease
function	function	NOUN	NN	9	I-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
interstitial	interstitial	ADJ	JJ	9	I-Disease
infiltrates	infiltrate	NOUN	NNS	9	I-Disease
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
large	large	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
highly	highly	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
VT	VT	PROPN	NNP	9	B-Disease
or	or	CCONJ	CC	5	O
VF	VF	PROPN	NNP	5	B-Disease
refractory	refractory	NOUN	NN	9	O
to	to	ADP	IN	5	O
conventional	conventional	ADJ	JJ	5	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
causes	cause	VERB	VBZ	9	O
significant	significant	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
adjusted	adjust	VERB	VBN	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
VT	VT	PROPN	NNP	9	B-Disease
or	or	CCONJ	CC	5	O
VF	VF	PROPN	NNP	5	B-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
successfully	successfully	ADV	RB	5	O
managed	manage	VERB	VBN	5	O
with	with	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Why	why	ADV	WRB	5	O
may	may	VERB	MD	5	O
epsilon	epsilon	VERB	VB	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminocaproic	aminocaproic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
EACA	EACA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
induce	induce	VERB	VB	3	O
myopathy	myopathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
?	?	PUNCT	.	5	O

Report	Report	PROPN	NNP	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
literature	literature	NOUN	NN	5	O
review	review	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
necrotizing	necrotize	VERB	VBG	5	B-Disease
myopathy	myopathy	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
short	short	ADJ	JJ	5	O
epsilon	epsilon	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminocaproic	aminocaproic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
EACA	EACA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
72	72	NUM	CD	9	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
subarachnoid	subarachnoid	ADJ	JJ	5	B-Disease
haemorrhage	haemorrhage	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SAH	SAH	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Pathogenetic	pathogenetic	ADJ	JJ	5	O
hypotheses	hypothesis	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Cerebral	cerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
phenylpropanolamine	phenylpropanolamine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Phenylpropanolamine	Phenylpropanolamine	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
PPA	PPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
that	that	DET	WDT	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
including	include	VERB	VBG	9	O
stroke	stroke	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
often	often	ADV	RB	5	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
diet	diet	NOUN	NN	9	O
preparations	preparation	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
"	"	PUNCT	``	5	O
look	look	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
alike	alike	ADV	RB	5	O
"	"	PUNCT	''	5	O
pills	pill	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
PPA	PPA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	PART	TO	5	O
stroke	stroke	VERB	VB	5	B-Disease
in	in	ADP	IN	5	O
normotensive	normotensive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
administered	administer	VERB	VBD	9	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
times	time	NOUN	NNS	5	O
the	the	DET	DT	5	O
allowed	allow	VERB	VBN	9	O
human	human	ADJ	JJ	3	O
dose	dose	NOUN	NN	9	O
calculated	calculate	VERB	VBN	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
per	per	ADP	IN	9	O
weight	weight	NOUN	NN	9	O
basis	basis	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
two	two	NUM	CD	5	O
times	time	NOUN	NNS	5	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
five	five	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Subarachnoid	Subarachnoid	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
cerebral	cerebral	ADJ	JJ	5	I-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
18	18	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
single	single	ADJ	JJ	9	O
PPA	PPA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
same	same	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
lead	lead	NOUN	NN	5	O
to	to	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
normotensive	normotensive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
PPA	PPA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
previously	previously	ADV	RB	9	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
animals	animal	NOUN	NNS	9	O
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
allowed	allow	VERB	VBN	9	O
dosage	dosage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
elevation	elevation	NOUN	NN	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
contributing	contribute	VERB	VBG	9	O
factor	factor	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	B-Disease
papillary	papillary	ADJ	JJ	5	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
naproxen	naproxen	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
31	31	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
previously	previously	ADV	RB	9	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
fenoprofen	fenoprofen	ADJ	JJ	0	B-Chemical
calcium	calcium	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
salicylates	salicylate	NOUN	NNS	0	B-Chemical
and	and	CCONJ	CC	5	O
gold	gold	NOUN	NN	0	B-Chemical
salts	salt	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
developed	develop	VERB	VBD	5	O
renal	renal	ADJ	JJ	9	B-Disease
papillary	papillary	ADJ	JJ	5	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
RPN	RPN	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
institution	institution	NOUN	NN	5	O
of	of	ADP	IN	5	O
naproxen	naproxen	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
factor	factor	NOUN	NN	9	O
predisposing	predispose	VERB	VBG	5	O
to	to	ADP	IN	5	O
RPN	RPN	PROPN	NNP	5	B-Disease
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
discovered	discover	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Sulindac	Sulindac	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
substituted	substitute	VERB	VBN	0	O
for	for	ADP	IN	5	O
naproxen	naproxen	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
further	further	ADV	RB	9	O
adverse	adverse	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
next	next	ADJ	JJ	9	O
12	12	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
review	review	VERB	VBP	5	O
previous	previous	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
linking	link	VERB	VBG	9	O
RPN	RPN	PROPN	NNP	5	B-Disease
to	to	ADP	IN	5	O
antiinflammatory	antiinflammatory	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
discuss	discuss	VERB	VB	5	O
possible	possible	ADJ	JJ	5	O
advantages	advantage	NOUN	NNS	5	O
of	of	ADP	IN	5	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
experienced	experience	VERB	VBN	5	O
renal	renal	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
from	from	ADP	IN	9	O
other	other	ADJ	JJ	5	O
antiinflammatory	antiinflammatory	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Nephrotoxic	nephrotoxic	ADJ	JJ	0	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
aminoglycoside	aminoglycoside	ADJ	JJ	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
reabsorption	reabsorption	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
accumulation	accumulation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
quantify	quantify	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
kanamycin	kanamycin	NOUN	NN	1	B-Chemical
and	and	CCONJ	CC	5	O
netilmicin	netilmicin	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
reabsorption	reabsorption	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
accumulation	accumulation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	PART	TO	5	O
rats	rat	NOUN	NNS	9	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
or	or	CCONJ	CC	5	O
21	21	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Scanning	scan	VERB	VBG	0	O
electron	electron	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glomerular	glomerular	ADJ	JJ	5	O
endothelia	endothelia	NOUN	NN	3	O
,	,	PUNCT	,	9	O
urinary	urinary	ADJ	JJ	9	O
measurements	measurement	NOUN	NNS	5	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
endogenous	endogenous	ADJ	JJ	3	O
lysozyme	lysozyme	NOUN	NN	0	O
,	,	PUNCT	,	9	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
acetyl	acetyl	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
D	d	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glucosaminidase	glucosaminidase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
NAG	NAG	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
clearance	clearance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
accumulation	accumulation	NOUN	NN	9	O
experiments	experiment	NOUN	NNS	9	O
after	after	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
egg	egg	NOUN	NN	4	O
-	-	PUNCT	HYPH	7	O
white	white	ADJ	JJ	9	O
lysozyme	lysozyme	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
measurements	measurement	NOUN	NNS	5	O
of	of	ADP	IN	5	O
inulin	inulin	ADJ	JJ	0	O
clearance	clearance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
GFR	GFR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Gentamicin	Gentamicin	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
diameter	diameter	NOUN	NN	9	O
,	,	PUNCT	,	9	O
density	density	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
shape	shape	NOUN	NN	5	O
of	of	ADP	IN	5	O
endothelial	endothelial	ADJ	JJ	3	O
fenestrae	fenestrae	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Kanamycin	Kanamycin	PROPN	NNP	1	B-Chemical
and	and	CCONJ	CC	5	O
netilmicin	netilmicin	NOUN	NN	0	B-Chemical
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
three	three	NUM	CD	9	O
aminoglycosides	aminoglycoside	NOUN	NNS	9	B-Chemical
decreased	decrease	VERB	VBD	9	O
GFR	GFR	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
urinary	urinary	ADJ	JJ	9	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
kanamycin	kanamycin	NOUN	NN	1	B-Chemical
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
reabsorption	reabsorption	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
lysozyme	lysozyme	NOUN	NN	0	O
after	after	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
egg	egg	NOUN	NN	4	O
-	-	PUNCT	HYPH	7	O
white	white	ADJ	JJ	9	O
lysozyme	lysozyme	NOUN	NN	0	O
netilmicin	netilmicin	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Daily	daily	ADJ	JJ	5	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
total	total	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
endogenous	endogenous	ADJ	JJ	3	O
lysozyme	lysozyme	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
NAG	NAG	PROPN	NNP	0	O
increased	increase	VERB	VBD	9	O
only	only	ADV	RB	9	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
kanamycin	kanamycin	NOUN	NN	1	B-Chemical
and	and	CCONJ	CC	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
aminoglycosides	aminoglycoside	NOUN	NNS	9	B-Chemical
may	may	VERB	MD	5	O
act	act	VERB	VB	9	O
as	as	ADP	IN	5	O
nephrotoxicants	nephrotoxicant	NOUN	NNS	5	O
at	at	ADP	IN	9	O
glomerular	glomerular	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
tubular	tubular	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
inducing	induce	VERB	VBG	3	O
impairment	impairment	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
reabsorption	reabsorption	NOUN	NN	0	I-Disease
and	and	CCONJ	CC	5	O
accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
proteins	protein	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

Induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
obstructive	obstructive	ADJ	JJ	5	B-Disease
sleep	sleep	NOUN	NN	5	I-Disease
apnea	apnea	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
woman	woman	NOUN	NN	5	O
by	by	ADP	IN	9	O
exogenous	exogenous	ADJ	JJ	3	O
androgen	androgen	NOUN	NN	3	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
documented	document	VERB	VBD	9	O
airway	airway	NOUN	NN	5	O
occlusion	occlusion	NOUN	NN	5	O
during	during	ADP	IN	5	O
sleep	sleep	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
abnormally	abnormally	ADV	RB	9	O
high	high	ADJ	JJ	9	O
supraglottic	supraglottic	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
while	while	ADP	IN	9	O
awake	awake	ADJ	JJ	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
54	54	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
yr	yr	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
physical	physical	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
obstructive	obstructive	ADJ	JJ	5	I-Disease
sleep	sleep	NOUN	NN	5	I-Disease
apnea	apnea	NOUN	NN	5	I-Disease
while	while	ADP	IN	9	O
being	be	VERB	VBG	5	O
administered	administer	VERB	VBN	9	O
exogenous	exogenous	ADJ	JJ	3	O
androgens	androgen	NOUN	NNS	9	B-Chemical
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
the	the	DET	DT	5	O
androgens	androgen	NOUN	NNS	9	B-Chemical
were	be	VERB	VBD	9	O
withdrawn	withdraw	VERB	VBN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
physical	physical	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
sleep	sleep	NOUN	NN	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
supraglottic	supraglottic	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
all	all	DET	DT	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
rechallenge	rechallenge	NOUN	NN	3	O
with	with	ADP	IN	5	O
androgen	androgen	NOUN	NN	3	B-Chemical
produced	produce	VERB	VBD	9	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
obstructive	obstructive	ADJ	JJ	5	B-Disease
sleep	sleep	NOUN	NN	5	I-Disease
apnea	apnea	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
abated	abate	VERB	VBD	5	O
upon	upon	ADP	IN	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hormone	hormone	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
favored	favor	VERB	VBN	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
androgens	androgen	NOUN	NNS	9	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
sleep	sleep	NOUN	NN	5	B-Disease
apnea	apnea	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
report	report	NOUN	NN	5	O
provides	provide	VERB	VBZ	5	O
direct	direct	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
role	role	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Structural	structural	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	O
measurements	measurement	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
androgens	androgen	VERB	VBZ	9	B-Chemical
exert	exert	VERB	VBP	9	O
a	a	DET	DT	5	O
permissive	permissive	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
necessary	necessary	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
structural	structural	ADJ	JJ	9	O
configuration	configuration	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
oropharynx	oropharynx	NOUN	NN	5	O
that	that	DET	WDT	5	O
predisposes	predispose	NOUN	NNS	9	O
to	to	ADP	IN	5	O
obstruction	obstruction	NOUN	NN	5	O
during	during	ADP	IN	5	O
sleep	sleep	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Development	development	NOUN	NN	2	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
obstructive	obstructive	ADJ	JJ	5	B-Disease
sleep	sleep	NOUN	NN	5	I-Disease
apnea	apnea	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
androgen	androgen	NOUN	NN	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cardiotoxic	Cardiotoxic	PROPN	NNP	0	B-Disease
and	and	CCONJ	CC	5	O
possible	possible	ADJ	JJ	5	O
leukemogenic	leukemogenic	ADJ	JJ	3	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
in	in	ADP	IN	5	O
nonhuman	nonhuman	NOUN	NN	5	O
primates	primate	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

10	10	NUM	CD	9	O
monkeys	monkey	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
macaques	macaque	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
by	by	ADP	IN	9	O
monthly	monthly	ADJ	JJ	5	O
intravenous	intravenous	ADJ	JJ	0	O
injections	injection	NOUN	NNS	9	O
at	at	ADP	IN	9	O
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

8	8	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
10	10	NUM	CD	9	O
monkeys	monkey	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
average	average	ADJ	JJ	5	O
cumulative	cumulative	ADJ	JJ	5	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
310	310	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
well	well	ADV	RB	9	O
below	below	ADP	IN	9	O
that	that	DET	DT	5	O
considered	consider	VERB	VBD	5	O
the	the	DET	DT	5	O
safe	safe	ADJ	JJ	5	O
upper	upper	ADJ	JJ	9	O
limit	limit	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
550	550	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Histologically	histologically	ADV	RB	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
resembled	resemble	VERB	VBD	9	O
those	those	DET	DT	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
human	human	ADJ	JJ	3	O
anthracycline	anthracycline	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
10	10	NUM	CD	9	O
monkeys	monkey	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	B-Disease
myeloblastic	myeloblastic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
after	after	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
324	324	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
10th	10th	ADJ	JJ	9	O
monkey	monkey	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
alive	alive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
well	well	ADV	RB	9	O
26	26	NUM	CD	7	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
cardiotoxin	cardiotoxin	NOUN	NN	3	O
in	in	ADP	IN	5	O
monkeys	monkey	NOUN	NNS	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	DET	DT	5	O
leukemia	leukemia	NOUN	NN	3	B-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
consequence	consequence	NOUN	NN	5	O
of	of	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Tricuspid	tricuspid	ADJ	JJ	7	B-Disease
valve	valve	NOUN	NN	5	I-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
carbonate	carbonate	NOUN	NN	0	I-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
newborn	newborn	ADJ	JJ	9	O
infant	infant	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
newborn	newborn	ADJ	JJ	9	O
with	with	ADP	IN	5	O
massive	massive	ADJ	JJ	9	O
tricuspid	tricuspid	ADJ	JJ	5	B-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
atrial	atrial	ADJ	JJ	5	B-Disease
flutter	flutter	ADV	RB	5	I-Disease
,	,	PUNCT	,	9	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
to	to	PART	TO	5	O
initially	initially	ADV	RB	9	O
manifest	manifest	VERB	VB	5	O
tricuspid	tricuspid	ADJ	JJ	5	B-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
flutter	flutter	ADV	RB	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
11th	11th	ADJ	JJ	9	O
described	describe	VERB	VBN	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
among	among	ADP	IN	5	O
infants	infant	NOUN	NNS	5	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
compounds	compound	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
trimester	trimester	NOUN	NN	5	O
of	of	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sixty	sixty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
infants	infant	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
tricuspid	tricuspid	ADJ	JJ	5	O
valve	valve	NOUN	NN	5	O
involvement	involvement	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lithium	Lithium	PROPN	NNP	0	B-Chemical
carbonate	carbonate	NOUN	NN	0	I-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
factor	factor	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
increasing	increase	VERB	VBG	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
congenital	congenital	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
when	when	ADV	WRB	5	O
taken	take	VERB	VBN	5	O
during	during	ADP	IN	5	O
early	early	ADJ	JJ	9	O
pregnancy	pregnancy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
causes	cause	VERB	VBZ	9	O
neurologic	neurologic	ADJ	JJ	5	B-Disease
depression	depression	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
cyanosis	cyanosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrhythmia	arrhythmia	NOUN	NN	5	I-Disease
when	when	ADV	WRB	5	O
consumed	consume	VERB	VBN	5	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
delivery	delivery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
compound	compound	NOUN	NN	0	O
aniracetam	aniracetam	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
Ro	Ro	PROPN	NNP	0	B-Chemical
13	13	NUM	CD	7	I-Chemical
-	-	SYM	SYM	7	I-Chemical
5057	5057	NUM	CD	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
upon	upon	ADP	IN	9	O
impaired	impaired	ADJ	JJ	9	B-Disease
learning	learning	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rodents	rodent	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
aniracetam	aniracetam	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
Ro	Ro	PROPN	NNP	0	B-Chemical
13	13	NUM	CD	7	I-Chemical
-	-	SYM	SYM	7	I-Chemical
5057	5057	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
anisoyl	anisoyl	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pyrrolidinone	pyrrolidinone	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
on	on	ADP	IN	5	O
various	various	ADJ	JJ	9	O
forms	form	NOUN	NNS	9	O
of	of	ADP	IN	5	O
experimentally	experimentally	ADV	RB	9	O
impaired	impair	VERB	VBN	9	B-Disease
cognitive	cognitive	ADJ	JJ	5	I-Disease
functions	function	NOUN	NNS	9	I-Disease
(	(	PUNCT	-LRB-	9	O
learning	learning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
memory	memory	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
rodents	rodent	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
produced	produce	VERB	VBD	9	O
the	the	DET	DT	5	O
following	following	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
almost	almost	ADV	RB	9	O
complete	complete	ADJ	JJ	9	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
incapacity	incapacity	NOUN	NN	5	O
to	to	PART	TO	5	O
learn	learn	VERB	VB	5	O
a	a	DET	DT	5	O
discrete	discrete	ADJ	JJ	5	O
escape	escape	NOUN	NN	5	O
response	response	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
exposed	expose	VERB	VBN	9	O
to	to	PART	TO	5	O
sublethal	sublethal	ADJ	JJ	9	O
hypercapnia	hypercapnia	NOUN	NN	5	B-Disease
immediately	immediately	ADV	RB	9	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
acquisition	acquisition	NOUN	NN	5	O
session	session	NOUN	NN	5	O
;	;	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
partial	partial	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
rats	rat	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
complete	complete	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
mice	mouse	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
amnesia	amnesia	NOUN	NN	5	B-Disease
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
;	;	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
complete	complete	ADJ	JJ	9	O
protection	protection	NOUN	NN	9	O
against	against	ADP	IN	9	O
amnesia	amnesia	NOUN	NN	5	B-Disease
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
submitted	submit	VERB	VBN	9	O
to	to	ADP	IN	5	O
electroconvulsive	electroconvulsive	ADJ	JJ	5	O
shock	shock	NOUN	NN	9	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
avoidance	avoidance	NOUN	NN	5	O
acquisition	acquisition	NOUN	NN	5	O
;	;	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
retention	retention	NOUN	NN	9	O
-	-	PUNCT	:	7	O
or	or	CCONJ	CC	5	O
retrieval	retrieval	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
deficit	deficit	NOUN	NN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
mice	mouse	NOUN	NNS	3	O
by	by	ADP	IN	9	O
chloramphenicol	chloramphenicol	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
cycloheximide	cycloheximide	NOUN	NN	3	B-Chemical
administered	administer	VERB	VBN	9	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
acquisition	acquisition	NOUN	NN	5	O
;	;	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
5	5	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
reversal	reversal	NOUN	NN	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
as	as	ADV	RB	5	O
late	late	ADV	RB	9	O
as	as	ADP	IN	5	O
1	1	NUM	CD	9	O
h	h	NOUN	NN	0	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
retention	retention	NOUN	NN	9	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
deficit	deficit	NOUN	NN	5	O
in	in	ADP	IN	5	O
retention	retention	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
retrieval	retrieval	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
cycloheximide	cycloheximide	NOUN	NN	3	B-Chemical
injected	inject	VERB	VBD	3	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
previously	previously	ADV	RB	9	O
;	;	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
6	6	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
deficit	deficit	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
retrieval	retrieval	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
active	active	ADJ	JJ	9	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
by	by	ADP	IN	9	O
subconvulsant	subconvulsant	ADJ	JJ	0	O
electroshock	electroshock	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
hypercapnia	hypercapnia	NOUN	NN	5	B-Disease
applied	apply	VERB	VBN	5	O
immediately	immediately	ADV	RB	9	O
before	before	ADP	IN	9	O
retrieval	retrieval	NOUN	NN	5	O
testing	testing	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
acquisition	acquisition	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
improvements	improvement	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
normalizations	normalization	NOUN	NNS	5	O
of	of	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
cognitive	cognitive	ADJ	JJ	5	I-Disease
functions	function	NOUN	NNS	9	I-Disease
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
at	at	ADP	IN	9	O
oral	oral	ADJ	JJ	9	O
aniracetam	aniracetam	NOUN	NN	9	B-Chemical
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Generally	generally	ADV	RB	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
curves	curve	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
bell	bell	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
shaped	shape	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
underlying	underlie	VERB	VBG	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
aniracetam	aniracetam	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
'	'	PUNCT	``	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
window	window	NOUN	NN	5	O
'	'	PUNCT	''	9	O
are	be	VERB	VBP	5	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Piracetam	piracetam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
another	another	DET	DT	9	O
pyrrolidinone	pyrrolidinone	NOUN	NN	0	B-Chemical
derivative	derivative	NOUN	NN	0	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
active	active	ADJ	JJ	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
of	of	ADP	IN	5	O
nine	nine	NUM	CD	9	O
tests	test	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
about	about	ADV	RB	5	O
one	one	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
tenth	tenth	NOUN	NN	5	O
the	the	DET	DT	5	O
potency	potency	NOUN	NN	9	O
of	of	ADP	IN	5	O
aniracetam	aniracetam	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
aniracetam	aniracetam	NOUN	NN	9	B-Chemical
improves	improve	VERB	VBZ	5	O
cognitive	cognitive	ADJ	JJ	5	O
functions	function	NOUN	NNS	9	O
which	which	DET	WDT	5	O
are	be	VERB	VBP	5	O
impaired	impair	VERB	VBN	9	O
by	by	ADP	IN	9	O
different	different	ADJ	JJ	9	O
procedure	procedure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
different	different	ADJ	JJ	9	O
phases	phase	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
learning	learning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
memory	memory	NOUN	NN	5	O
process	process	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
on	on	ADP	IN	5	O
gross	gross	ADJ	JJ	5	O
behavioural	behavioural	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
eserine	eserine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
cats	cat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
injected	inject	VERB	VBN	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
cerebral	cerebral	ADJ	JJ	5	O
ventricles	ventricle	NOUN	NNS	5	O
of	of	ADP	IN	5	O
group	group	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
housed	house	VERB	VBN	9	O
unanaesthetized	unanaesthetized	ADJ	JJ	5	O
cats	cat	NOUN	NNS	9	O
upon	upon	ADP	IN	9	O
vocalization	vocalization	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
rage	rage	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hissing	hiss	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
snarling	snarling	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
fighting	fighting	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
attack	attack	NOUN	NN	5	O
with	with	ADP	IN	5	O
paws	paw	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
claws	claw	NOUN	NNS	4	O
,	,	PUNCT	,	9	O
defense	defense	NOUN	NN	5	O
with	with	ADP	IN	5	O
paws	paw	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
claws	claw	NOUN	NNS	4	O
and	and	CCONJ	CC	5	O
biting	biting	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
mydriasis	mydriasis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
tremor	tremor	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
clonic	clonic	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
tonic	tonic	NOUN	NN	5	I-Disease
convulsions	convulsion	NOUN	NNS	5	I-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
eserine	eserine	NOUN	NN	0	B-Chemical
injected	inject	VERB	VBN	3	O
similarly	similarly	ADV	RB	9	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Calcium	calcium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
depressed	depress	VERB	VBN	5	O
or	or	CCONJ	CC	5	O
almost	almost	ADV	RB	9	O
completely	completely	ADV	RB	9	O
abolished	abolish	VERB	VBD	3	O
the	the	DET	DT	5	O
vocalization	vocalization	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
fighting	fighting	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
eserine	eserine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
mydriasis	mydriasis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
tremor	tremor	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
clonic	clonic	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
tonic	tonic	NOUN	NN	5	I-Disease
convulsions	convulsion	NOUN	NNS	5	I-Disease
evoked	evoke	VERB	VBN	5	O
by	by	ADP	IN	9	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
eserine	eserine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
changed	change	VERB	VBN	9	O
by	by	ADP	IN	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
apparent	apparent	ADJ	JJ	9	O
that	that	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
can	can	VERB	MD	5	O
"	"	PUNCT	``	5	O
dissociate	dissociate	VERB	VB	9	O
"	"	PUNCT	''	5	O
vocalization	vocalization	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
fighting	fighting	NOUN	NN	5	O
from	from	ADP	IN	9	O
autonomic	autonomic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
motor	motor	NOUN	NN	5	O
phenomena	phenomenon	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
mydriasis	mydriasis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
tremor	tremor	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
clonic	clonic	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
tonic	tonic	NOUN	NN	5	I-Disease
convulsions	convulsion	NOUN	NNS	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
eserine	eserine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Calcium	calcium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
vocalization	vocalization	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
fighting	fighting	NOUN	NN	5	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
eserine	eserine	NOUN	NN	0	B-Chemical
most	most	ADV	RBS	9	O
probably	probably	ADV	RB	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
nonspecific	nonspecific	ADJ	JJ	3	O
stabilizing	stabilize	VERB	VBG	9	O
action	action	NOUN	NN	5	O
on	on	ADP	IN	5	O
central	central	ADJ	JJ	5	O
muscarinic	muscarinic	ADJ	JJ	3	O
cholinoceptive	cholinoceptive	ADJ	JJ	3	O
sites	site	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
further	further	ADV	RB	9	O
support	support	VERB	VBP	5	O
the	the	DET	DT	5	O
view	view	NOUN	NN	5	O
that	that	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
ions	ion	NOUN	NNS	0	O
in	in	ADP	IN	5	O
excess	excess	NOUN	NN	9	O
have	have	VERB	VBP	5	O
an	an	DET	DT	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
action	action	NOUN	NN	5	O
also	also	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thiazide	thiazide	NOUN	NN	7	B-Chemical
diuretics	diuretic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Thiazide	thiazide	NOUN	NN	7	B-Chemical
diuretics	diuretic	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
widely	widely	ADV	RB	5	O
accepted	accept	VERB	VBN	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
cornerstone	cornerstone	NOUN	NN	5	O
of	of	ADP	IN	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
programs	program	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Hypokalemia	Hypokalemia	PROPN	NNP	7	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
commonly	commonly	ADV	RB	5	O
encountered	encounter	VERB	VBN	5	O
metabolic	metabolic	ADJ	JJ	9	O
consequence	consequence	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	NOUN	NN	5	O
thiazide	thiazide	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
treated	treat	VERB	VBD	3	O
38	38	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
low	low	ADJ	JJ	9	O
renin	renin	NOUN	NN	9	O
,	,	PUNCT	,	9	O
16	16	NUM	CD	9	O
normal	normal	ADJ	JJ	9	O
renin	renin	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
moderate	moderate	ADJ	JJ	9	O
diastolic	diastolic	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
hydrochlorothiazide	hydrochlorothiazide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
HCTC	HCTC	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
administered	administer	VERB	VBD	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
twice	twice	ADV	RB	9	O
daily	daily	ADJ	JJ	5	O
schedule	schedule	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Initial	initial	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
at	at	ADP	IN	9	O
monthly	monthly	ADJ	JJ	5	O
intervals	interval	NOUN	NNS	5	O
to	to	ADP	IN	5	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
until	until	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
normalized	normalize	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
K	K	PROPN	NNP	9	B-Chemical
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
period	period	NOUN	NN	5	O
was	be	VERB	VBD	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mEq	meq	NOUN	NN	0	O
/	/	SYM	SYM	9	O
l	l	NOUN	NN	0	O
an	an	DET	DT	5	O
on	on	ADP	IN	5	O
50	50	NUM	CD	0	O
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
150	150	NUM	CD	0	O
and	and	CCONJ	CC	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
daily	daily	ADJ	JJ	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
mEq	meq	NOUN	NN	0	O
/	/	SYM	SYM	9	O
l	l	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Corresponding	correspond	VERB	VBG	9	O
figures	figure	NOUN	NNS	5	O
for	for	ADP	IN	5	O
whole	whole	ADJ	JJ	9	O
body	body	NOUN	NN	5	O
K	K	PROPN	NNP	9	B-Chemical
were	be	VERB	VBD	9	O
4107	4107	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
208	208	NUM	CD	7	O
,	,	PUNCT	,	9	O
3722	3722	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
319	319	NUM	CD	7	O
,	,	PUNCT	,	9	O
3628	3628	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
257	257	NUM	CD	7	O
,	,	PUNCT	,	9	O
3551	3551	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
336	336	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
3269	3269	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
380	380	NUM	CD	9	O
mEq	meq	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
we	-PRON-	PRON	PRP	5	O
observed	observe	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
PVC	PVC	PROPN	NNP	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
during	during	ADP	IN	5	O
rest	rest	NOUN	NN	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
during	during	ADP	IN	5	O
static	static	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
dynamic	dynamic	ADJ	JJ	5	O
exercise	exercise	NOUN	NN	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
rest	rest	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
observed	observe	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
08	08	NUM	CD	7	O
PVC	pvc	NOUN	NN	5	O
beats	beat	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
+	+	X	XX	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SEM	sem	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
static	static	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
dynamic	dynamic	ADJ	JJ	5	O
exercise	exercise	NOUN	NN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
06	06	NUM	CD	7	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
15	15	NUM	CD	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Corresponding	correspond	VERB	VBG	9	O
figures	figure	NOUN	NNS	5	O
during	during	ADP	IN	5	O
HCTZ	HCTZ	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
were	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
4	4	NUM	CD	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
PVC	PVC	PROPN	NNP	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
correlated	correlate	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
K	K	PROPN	NNP	9	B-Chemical
+	+	CCONJ	CC	9	O
observed	observe	VERB	VBD	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
72	72	NUM	CD	9	O
,	,	PUNCT	,	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
thiazide	thiazide	NOUN	NN	5	B-Chemical
diuretics	diuretic	NOUN	NNS	5	O
cause	cause	VERB	VBP	5	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
depletion	depletion	NOUN	NN	3	O
of	of	ADP	IN	5	O
body	body	NOUN	NN	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
more	more	ADV	RBR	5	O
profound	profound	ADJ	JJ	9	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
greater	great	ADJ	JJR	5	O
the	the	DET	DT	5	O
propensity	propensity	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
PVC	PVC	PROPN	NNP	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Circulating	circulate	VERB	VBG	3	O
lysosomal	lysosomal	ADJ	JJ	3	O
enzymes	enzyme	NOUN	NNS	1	O
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lysosomal	lysosomal	ADJ	JJ	3	O
enzymes	enzyme	NOUN	NNS	1	O
acid	acid	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
neutral	neutral	ADJ	JJ	5	O
protease	protease	NOUN	NN	0	O
,	,	PUNCT	,	9	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
acetylglucosaminidase	acetylglucosaminidase	NOUN	NN	1	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
acid	acid	NOUN	NN	0	O
phosphatase	phosphatase	NOUN	NN	0	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Acid	acid	ADJ	JJ	0	O
protease	protease	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
cathepsin	cathepsin	NOUN	NN	3	O
D	D	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
about	about	ADP	IN	5	O
tenfold	tenfold	ADV	RB	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
died	die	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
nearly	nearly	ADV	RB	9	O
fourfold	fourfold	VERB	VBN	9	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
who	who	PRON	WP	5	O
survived	survive	VERB	VBD	9	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
activities	activity	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
equally	equally	ADV	RB	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
viral	viral	ADJ	JJ	9	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
whether	whether	ADP	IN	9	O
or	or	CCONJ	CC	5	O
not	not	ADV	RB	5	O
they	-PRON-	PRON	PRP	5	O
survived	survive	VERB	VBD	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
correlation	correlation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
between	between	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
acid	acid	ADJ	JJ	0	O
protease	protease	NOUN	NN	0	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
prothrombin	prothrombin	NOUN	NN	9	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
cathepsin	cathepsin	NOUN	NN	3	O
D	d	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
sustained	sustain	VERB	VBN	5	O
over	over	ADP	IN	5	O
several	several	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
aspartate	aspartate	NOUN	NN	1	B-Chemical
aminotransferase	aminotransferase	NOUN	NN	7	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
sharp	sharp	ADJ	JJ	5	O
early	early	ADJ	JJ	9	O
peak	peak	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
a	a	DET	DT	5	O
fall	fall	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Circulating	circulate	VERB	VBG	3	O
lysosomal	lysosomal	ADJ	JJ	3	O
proteases	protease	NOUN	NNS	9	O
can	can	VERB	MD	5	O
damage	damage	VERB	VB	9	O
other	other	ADJ	JJ	5	O
organs	organ	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
measurement	measurement	NOUN	NN	5	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
activity	activity	NOUN	NN	9	O
may	may	VERB	MD	5	O
therefore	therefore	ADV	RB	5	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
added	add	VERB	VBN	0	O
value	value	NOUN	NN	9	O
in	in	ADP	IN	5	O
assessing	assess	VERB	VBG	5	O
prognosis	prognosis	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
condition	condition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hepatic	hepatic	ADJ	JJ	9	B-Disease
veno	veno	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
occlusive	occlusive	ADJ	JJ	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
thioguanine	thioguanine	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Clinically	clinically	ADV	RB	5	O
reversible	reversible	ADJ	JJ	9	O
veno	veno	NOUN	NNS	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
occlusive	occlusive	ADJ	JJ	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
developed	develop	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
23	23	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
lymphocytic	lymphocytic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
after	after	ADP	IN	9	O
10	10	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
maintenance	maintenance	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
thioguanine	thioguanine	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Serial	serial	ADJ	JJ	9	O
liver	liver	NOUN	NN	9	O
biopsies	biopsy	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
intense	intense	ADJ	JJ	9	O
sinusoidal	sinusoidal	NOUN	NN	5	O
engorgement	engorgement	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
this	this	DET	DT	5	O
disease	disease	NOUN	NN	5	O
was	be	VERB	VBD	9	O
clinically	clinically	ADV	RB	5	O
reversible	reversible	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
some	some	DET	DT	5	O
subintimal	subintimal	ADJ	JJ	5	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
terminal	terminal	ADJ	JJ	9	O
hepatic	hepatic	ADJ	JJ	9	O
veins	vein	NOUN	NNS	5	O
persisted	persist	VERB	VBD	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
presented	present	VERB	VBD	5	O
a	a	DET	DT	5	O
unique	unique	ADJ	JJ	9	O
opportunity	opportunity	NOUN	NN	5	O
to	to	PART	TO	5	O
observe	observe	VERB	VB	9	O
the	the	DET	DT	5	O
histologic	histologic	ADJ	JJ	9	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
clinically	clinically	ADV	RB	5	O
reversible	reversible	ADJ	JJ	9	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
veno	veno	NOUN	NNS	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
occlusive	occlusive	ADJ	JJ	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
over	over	ADP	IN	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
veno	veno	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
occlusive	occlusive	ADJ	JJ	5	O
related	relate	VERB	VBN	9	O
solely	solely	ADV	RB	9	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
thioguanine	thioguanine	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Chlorpropamide	chlorpropamide	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
65	65	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
adult	adult	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
onset	onset	NOUN	NN	5	I-Disease
diabetes	diabete	NOUN	NNS	5	I-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
chlorpropamide	chlorpropamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Diabenese	Diabenese	PROPN	NNP	_	B-Chemical
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	B-Disease
optic	optic	ADJ	JJ	5	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
resolved	resolve	VERB	VBD	9	O
with	with	ADP	IN	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
chlorpropamide	chlorpropamide	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Visual	visual	ADJ	JJ	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
occurs	occur	VERB	VBZ	9	O
in	in	ADP	IN	5	O
diabetics	diabetic	NOUN	NNS	5	B-Disease
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
reasons	reason	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
accurate	accurate	ADJ	JJ	5	O
diagnosis	diagnosis	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
necessary	necessary	ADJ	JJ	5	O
to	to	PART	TO	5	O
institute	institute	VERB	VB	5	O
appropriate	appropriate	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
optic	optic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
visual	visual	ADJ	JJ	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
diabetics	diabetic	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Plasma	plasma	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
urinary	urinary	ADJ	JJ	9	O
lipids	lipid	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
lipoproteins	lipoprotein	NOUN	NNS	0	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
by	by	ADP	IN	9	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
ascertain	ascertain	VERB	VB	9	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
alterations	alteration	NOUN	NNS	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
lipoproteins	lipoprotein	NOUN	NNS	0	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
were	be	VERB	VBD	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
per	per	X	FW	9	O
se	se	X	FW	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
in	in	ADP	IN	5	O
part	part	NOUN	NN	9	O
,	,	PUNCT	,	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
aminonucleoside	aminonucleoside	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
urinary	urinary	ADJ	JJ	9	O
lipoproteins	lipoprotein	NOUN	NNS	0	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
subsequent	subsequent	ADJ	JJ	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
massive	massive	ADJ	JJ	9	O
albuminuria	albuminuria	NOUN	NN	9	B-Disease
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
6	6	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
course	course	NOUN	NN	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
two	two	NUM	CD	5	O
stages	stage	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
stage	stage	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
day	day	NOUN	NN	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
stage	stage	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
day	day	NOUN	NN	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
stage	stage	NOUN	NN	9	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
fatty	fatty	ADJ	JJ	0	B-Chemical
acids	acid	NOUN	NNS	0	I-Chemical
,	,	PUNCT	,	9	O
triacylglycerol	triacylglycerol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
VLDL	vldl	NOUN	NN	0	O
decreased	decrease	VERB	VBD	9	O
while	while	ADP	IN	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
phospholipid	phospholipid	ADJ	JJ	0	O
,	,	PUNCT	,	9	O
cholesteryl	cholesteryl	NOUN	NN	0	B-Chemical
esters	ester	NOUN	NNS	0	I-Chemical
and	and	CCONJ	CC	5	O
HDL	HDL	PROPN	NNP	9	O
remained	remain	VERB	VBD	9	O
constant	constant	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Plasma	plasma	NOUN	NN	0	O
apolipoprotein	apolipoprotein	NOUN	NN	9	O
A	A	PROPN	NNP	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
increase	increase	VERB	VB	9	O
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
increase	increase	NOUN	NN	9	O
at	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
beginning	beginning	NOUN	NN	5	O
of	of	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
stage	stage	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
day	day	NOUN	NN	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
albumin	albumin	NOUN	NN	0	O
dropped	drop	VERB	VBD	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
very	very	ADV	RB	5	O
low	low	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
apolipoprotein	apolipoprotein	NOUN	NN	9	O
A	A	PROPN	NNP	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
increased	increase	VERB	VBD	9	O
abruptly	abruptly	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
-	-	ADV	RB	7	O
fold	fold	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
continued	continue	VERB	VBD	9	O
to	to	PART	TO	5	O
rise	rise	VERB	VB	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
less	less	ADV	RBR	5	O
steeply	steeply	ADV	RB	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
HDL	HDL	PROPN	NNP	9	O
followed	follow	VERB	VBD	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
VLDL	VLDL	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
LDL	LDL	PROPN	NNP	0	O
increased	increase	VERB	VBD	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
later	later	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
day	day	NOUN	NN	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Plasma	plasma	NOUN	NN	0	O
apolipoprotein	apolipoprotein	NOUN	NN	9	O
A	A	PROPN	NNP	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
not	not	ADV	RB	5	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
HDL	HDL	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
063	063	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
210	210	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
also	also	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
LDL	LDL	PROPN	NNP	0	O
density	density	NOUN	NN	9	O
class	class	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
025	025	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
050	050	NUM	CD	2	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
stage	stage	NOUN	NN	9	O
lipoproteinuria	lipoproteinuria	NOUN	NN	_	O
was	be	VERB	VBD	9	O
negligible	negligible	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
stage	stage	NOUN	NN	9	O
the	the	DET	DT	5	O
urinary	urinary	ADJ	JJ	9	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
lipoproteins	lipoprotein	NOUN	NNS	0	O
consisted	consist	VERB	VBN	5	O
mainly	mainly	ADV	RB	9	O
of	of	ADP	IN	5	O
HDL	HDL	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
observations	observation	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
puromycin	puromycin	VERB	VBN	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
alters	alter	NOUN	NNS	9	O
plasma	plasma	VERB	VBP	9	O
lipoproteins	lipoprotein	NOUN	NNS	0	O
by	by	ADP	IN	9	O
lowering	lower	VERB	VBG	9	O
VLDL	VLDL	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
increasing	increase	VERB	VBG	9	O
HDL	HDL	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
likely	likely	ADJ	JJ	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
striking	striking	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
HDL	HDL	PROPN	NNP	9	O
found	find	VERB	VBD	9	O
in	in	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
on	on	ADP	IN	5	O
HDL	HDL	PROPN	NNP	9	O
metabolism	metabolism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Fatal	fatal	ADJ	JJ	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
following	follow	VERB	VBG	9	O
topical	topical	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
ophthalmic	ophthalmic	ADJ	JJ	5	O
chloramphenicol	chloramphenicol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
73	73	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
died	die	VERB	VBD	9	O
of	of	ADP	IN	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
two	two	NUM	CD	5	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
undergoing	undergo	VERB	VBG	9	O
cataract	cataract	ADJ	JJ	5	B-Disease
extraction	extraction	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
beginning	begin	VERB	VBG	5	O
topical	topical	ADJ	JJ	0	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
chloramphenicol	chloramphenicol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
pancytopenia	pancytopenia	NOUN	NN	5	B-Disease
began	begin	VERB	VBD	5	O
within	within	ADP	IN	9	O
one	one	NUM	CD	5	O
month	month	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
idiosyncratic	idiosyncratic	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
to	to	PART	TO	5	O
chloramphenicol	chloramphenicol	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
topical	topical	ADJ	JJ	0	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
chloramphenicol	chloramphenicol	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
ocular	ocular	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
reversible	reversible	ADJ	JJ	9	O
bone	bone	NOUN	NN	5	B-Disease
marrow	marrow	NOUN	NN	3	I-Disease
hypoplasia	hypoplasia	NOUN	NN	5	I-Disease
have	have	VERB	VBP	5	O
also	also	ADV	RB	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Any	any	DET	DT	5	O
other	other	ADJ	JJ	5	O
suspected	suspect	VERB	VBN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ocular	ocular	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
topically	topically	ADV	RB	0	O
applied	apply	VERB	VBN	5	O
chloramphenicol	chloramphenicol	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
reported	report	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
National	National	PROPN	NNP	2	O
Registry	Registry	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Drug	Drug	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
Induced	Induced	PROPN	NNP	9	O
Ocular	Ocular	PROPN	NNP	5	O
Side	Side	PROPN	NNP	5	O
Effects	Effects	PROPN	NNPS	9	O
,	,	PUNCT	,	9	O
Oregon	Oregon	PROPN	NNP	2	O
Health	Health	PROPN	NNP	2	O
Sciences	Sciences	PROPN	NNPS	2	O
University	University	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Portland	Portland	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
OR	or	CCONJ	CC	9	O
97201	97201	NUM	CD	2	O
.	.	PUNCT	.	9	O

Midazolam	Midazolam	PROPN	NNP	0	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
thiopentone	thiopentone	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
induction	induction	NOUN	NN	3	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
premedicated	premedicate	VERB	VBN	0	O
with	with	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
+	+	CCONJ	CC	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
nitrazepam	nitrazepam	NOUN	NN	0	B-Chemical
the	the	DET	DT	5	O
evening	evening	NOUN	NN	5	O
before	before	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
sleep	sleep	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
inducing	induce	VERB	VBG	3	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
was	be	VERB	VBD	9	O
clearly	clearly	ADV	RB	9	O
slower	slow	ADJ	JJR	9	O
in	in	ADP	IN	5	O
onset	onset	NOUN	NN	5	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
thiopentone	thiopentone	NOUN	NN	0	B-Chemical
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
67	67	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
Somewhat	somewhat	ADV	RB	5	O
fewer	few	ADJ	JJR	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
local	local	ADJ	JJ	5	O
sequelae	sequelae	NOUN	NN	5	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
apnoea	apnoea	NOUN	NN	5	B-Disease
occurred	occur	VERB	VBD	9	O
less	less	ADV	RBR	5	O
often	often	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
it	-PRON-	PRON	PRP	5	O
lasted	last	VERB	VBD	5	O
longer	longer	ADV	RBR	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
whole	whole	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
thiopentone	thiopentone	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
apparent	apparent	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
consequences	consequence	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Midazolam	Midazolam	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
alternative	alternative	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
for	for	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Extrapyramidal	extrapyramidal	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
oral	oral	ADJ	JJ	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
explanatory	explanatory	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
characteristics	characteristic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
EPS	EPS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
98	98	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
parkinsonism	parkinsonism	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
at	at	ADP	IN	9	O
higher	high	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
younger	young	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Prophylactic	prophylactic	ADJ	JJ	5	O
antiparkinsonian	antiparkinsonian	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
was	be	VERB	VBD	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
younger	young	ADJ	JJR	5	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
medications	medication	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
young	young	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
old	old	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
after	after	ADP	IN	9	O
parkinsonism	parkinsonism	NOUN	NN	5	B-Disease
developed	develop	VERB	VBD	5	O
.	.	PUNCT	.	9	O

Akathisia	Akathisia	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
controlled	control	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
benzodiazepine	benzodiazepine	NOUN	NN	5	B-Chemical
lorazepam	lorazepam	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
14	14	NUM	CD	7	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
16	16	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
prophylactic	prophylactic	ADJ	JJ	5	O
antiparkinsonians	antiparkinsonian	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
ineffective	ineffective	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
points	point	NOUN	NNS	5	O
to	to	ADP	IN	5	O
patient	patient	ADJ	JJ	5	O
characteristics	characteristic	NOUN	NNS	5	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
significance	significance	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
EPS	EPS	PROPN	NNP	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Deaths	death	NOUN	NNS	5	O
from	from	ADP	IN	9	O
local	local	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
convulsant	convulsant	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
CD50	CD50	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
median	median	NOUN	NN	9	O
lethal	lethal	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
LD50	LD50	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
representative	representative	ADJ	JJ	9	O
local	local	ADJ	JJ	5	O
anesthetics	anesthetic	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
threat	threat	NOUN	NN	5	O
to	to	ADP	IN	5	O
life	life	NOUN	NN	5	O
of	of	ADP	IN	5	O
local	local	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
CD50	CD50	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
LD50	LD50	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
57	57	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
and	and	CCONJ	CC	5	O
58	58	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
for	for	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
111	111	NUM	CD	7	O
.	.	NOUN	NN	9	O
0	0	NUM	CD	7	O
and	and	CCONJ	CC	5	O
133	133	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
for	for	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
243	243	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
266	266	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
for	for	ADP	IN	5	O
chloroprocaine	chloroprocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
given	give	VERB	VBN	5	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
,	,	PUNCT	,	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
thus	thus	ADV	RB	9	O
was	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
about	about	ADV	RB	5	O
twice	twice	DET	PDT	9	O
as	as	ADV	RB	5	O
toxic	toxic	ADJ	JJ	0	O
as	as	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
four	four	NUM	CD	9	O
times	time	NOUN	NNS	5	O
as	as	ADV	RB	5	O
toxic	toxic	ADJ	JJ	0	O
as	as	ADP	IN	5	O
chloroprocaine	chloroprocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Convulsions	convulsion	NOUN	NNS	7	B-Disease
always	always	ADV	RB	5	O
preceded	precede	VERB	VBD	9	O
death	death	NOUN	NN	9	O
,	,	PUNCT	,	9	O
except	except	ADP	IN	9	O
after	after	ADP	IN	9	O
precipitous	precipitous	ADJ	JJ	5	O
cardiopulmonary	cardiopulmonary	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
from	from	ADP	IN	9	O
extreme	extreme	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
CD50	CD50	PROPN	NNP	3	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
local	local	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
causing	cause	VERB	VBG	9	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
fatal	fatal	ADJ	JJ	5	O
in	in	ADP	IN	5	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
57	57	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
chloroprocaine	chloroprocaine	NOUN	NN	5	B-Chemical
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
narrow	narrow	ADJ	JJ	5	O
gap	gap	NOUN	NN	5	O
between	between	ADP	IN	5	O
convulsant	convulsant	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
lethal	lethal	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
local	local	ADJ	JJ	5	O
anesthetics	anesthetic	NOUN	NNS	5	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
untreated	untreated	ADJ	JJ	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
present	present	VERB	VBP	9	O
much	much	ADV	RB	5	O
more	more	ADJ	JJR	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
threat	threat	NOUN	NN	5	O
to	to	ADP	IN	5	O
life	life	NOUN	NN	5	O
than	than	ADP	IN	5	O
heretofore	heretofore	ADV	RB	5	O
appreciated	appreciate	VERB	VBN	5	O
.	.	PUNCT	.	9	O

REM	rem	NOUN	NN	5	B-Disease
sleep	sleep	NOUN	NN	5	I-Disease
deprivation	deprivation	NOUN	NN	9	I-Disease
changes	change	VERB	VBZ	9	O
behavioral	behavioral	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
catecholaminergic	catecholaminergic	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
serotonergic	serotonergic	ADJ	JJ	5	O
receptor	receptor	NOUN	NN	3	O
activation	activation	NOUN	NN	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
REM	rem	NOUN	NN	5	B-Disease
sleep	sleep	NOUN	NN	5	I-Disease
deprivation	deprivation	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
REMD	REMD	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
aggressiveness	aggressiveness	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
quipazine	quipazine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
head	head	NOUN	NN	5	B-Disease
twitches	twitch	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
eight	eight	NUM	CD	9	O
hr	hr	NOUN	NN	0	O
of	of	ADP	IN	5	O
REMD	REMD	PROPN	NNP	5	B-Disease
increased	increase	VERB	VBD	9	O
apomorphine	apomorphine	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
aggressiveness	aggressiveness	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
completing	complete	VERB	VBG	5	O
of	of	ADP	IN	5	O
REMD	REMD	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
96	96	NUM	CD	9	O
hr	hr	NOUN	NNS	0	O
after	after	ADP	IN	9	O
completing	complete	VERB	VBG	5	O
of	of	ADP	IN	5	O
REMD	REMD	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
quipazine	quipazine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
head	head	NOUN	NN	5	B-Disease
twitches	twitch	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
similarity	similarity	NOUN	NN	5	O
to	to	ADP	IN	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
antidepressive	antidepressive	ADJ	JJ	5	O
treatments	treatment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Fatal	fatal	ADJ	JJ	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
indomethacin	indomethacin	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
lymphocyte	lymphocyte	ADJ	JJ	3	O
transformation	transformation	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
indomethacin	indomethacin	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
observations	observation	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
its	-PRON-	DET	PRP$	9	O
role	role	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
definitely	definitely	ADV	RB	5	O
established	establish	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
no	no	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
other	other	ADJ	JJ	5	O
than	than	ADP	IN	5	O
allopurinol	allopurinol	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
indomethacin	indomethacin	ADV	RB	0	B-Chemical
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Indomethacin	Indomethacin	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
first	first	ADV	RB	9	O
given	give	VERB	VBN	5	O
four	four	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
positive	positive	ADJ	JJ	9	O
lymphocyte	lymphocyte	ADJ	JJ	3	O
transformation	transformation	NOUN	NN	9	O
test	test	NOUN	NN	5	O
with	with	ADP	IN	5	O
indomethacin	indomethacin	ADV	RB	0	B-Chemical
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
further	further	ADV	RB	9	O
substantiates	substantiate	VERB	VBZ	9	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
causing	cause	VERB	VBG	9	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
susceptible	susceptible	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Fortunately	fortunately	ADV	RB	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
very	very	ADV	RB	5	O
rare	rare	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Dose	dose	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
structure	structure	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
function	function	NOUN	NN	9	O
relationships	relationship	NOUN	NNS	5	O
in	in	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
CM	CM	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
anticancer	anticancer	NOUN	NN	0	O
drug	drug	NOUN	NN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DXR	DXR	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
Adriamycin	Adriamycin	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
provides	provide	VERB	VBZ	5	O
a	a	DET	DT	5	O
unique	unique	ADJ	JJ	9	O
opportunity	opportunity	NOUN	NN	5	O
to	to	PART	TO	5	O
analyze	analyze	VERB	VB	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
structure	structure	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
function	function	NOUN	NN	9	O
relationships	relationship	NOUN	NNS	5	O
during	during	ADP	IN	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
measured	measure	VERB	VBD	9	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
morphologic	morphologic	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
by	by	ADP	IN	9	O
ultrastructural	ultrastructural	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
of	of	ADP	IN	5	O
endomyocardial	endomyocardial	ADJ	JJ	5	O
biopsy	biopsy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
performance	performance	NOUN	NN	5	O
abnormally	abnormally	ADV	RB	9	O
by	by	ADP	IN	9	O
right	right	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
catheterization	catheterization	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
DXR	DXR	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Morphologic	morphologic	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
was	be	VERB	VBD	9	O
variable	variable	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
proportional	proportional	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
cumulative	cumulative	ADJ	JJ	5	O
DXR	dxr	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
between	between	ADP	IN	5	O
100	100	NUM	CD	0	O
and	and	CCONJ	CC	5	O
600	600	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
.	.	PUNCT	.	9	O

Performance	performance	NOUN	NN	5	O
abnormalities	abnormality	NOUN	NNS	9	O
correlated	correlate	VERB	VBD	9	O
weakly	weakly	ADV	RB	9	O
with	with	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
exhibited	exhibit	VERB	VBD	9	O
a	a	DET	DT	5	O
curvilinear	curvilinear	NOUN	NN	5	O
relationship	relationship	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
"	"	PUNCT	``	5	O
threshold	threshold	NOUN	NN	5	O
"	"	PUNCT	''	5	O
for	for	ADP	IN	5	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Catheterization	catheterization	NOUN	NN	5	O
abnormalities	abnormality	NOUN	NNS	9	O
correlated	correlate	VERB	VBD	9	O
well	well	ADV	RB	9	O
with	with	ADP	IN	5	O
morphologic	morphologic	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
57	57	NUM	CD	7	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
78	78	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
subgroup	subgroup	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
exercise	exercise	NOUN	NN	5	O
hemodynamics	hemodynamic	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
this	this	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
also	also	ADV	RB	9	O
exhibited	exhibit	VERB	VBD	9	O
a	a	DET	DT	5	O
curvilinear	curvilinear	NOUN	NN	5	O
,	,	PUNCT	,	9	O
threshold	threshold	NOUN	NN	5	O
configuration	configuration	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
DXR	DXR	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
CM	CM	PROPN	NNP	9	B-Disease
myocardial	myocardial	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
proportional	proportional	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
cytotoxic	cytotoxic	NOUN	NN	3	O
insult	insult	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
DXR	dxr	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
while	while	ADP	IN	9	O
myocardial	myocardial	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
preserved	preserve	VERB	VBN	9	O
until	until	ADP	IN	5	O
a	a	DET	DT	5	O
critical	critical	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
damage	damage	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
reached	reach	VERB	VBN	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
which	which	DET	WDT	5	O
myocardial	myocardial	ADJ	JJ	9	O
performance	performance	NOUN	NN	5	O
deteriorates	deteriorate	VERB	VBZ	5	O
rapidly	rapidly	ADV	RB	9	O
.	.	PUNCT	.	9	O

Massive	massive	ADJ	JJ	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
fulminant	fulminant	ADJ	JJ	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
overdose	overdose	ADJ	JJ	0	B-Disease
:	:	PUNCT	:	9	O
possible	possible	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
cranial	cranial	ADJ	JJ	5	O
decompression	decompression	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cerebral	cerebral	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
complicate	complicate	VERB	VB	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Response	response	NOUN	NN	5	O
to	to	ADP	IN	5	O
conventional	conventional	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
disappointing	disappointing	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
unresponsive	unresponsive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
conventional	conventional	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cranial	cranial	ADJ	JJ	5	O
decompression	decompression	NOUN	NN	5	O
was	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
justification	justification	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
further	further	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
cranial	cranial	ADJ	JJ	5	O
decompression	decompression	NOUN	NN	5	O
in	in	ADP	IN	5	O
such	such	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Subjective	subjective	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Various	various	ADJ	JJ	9	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
male	male	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
received	receive	VERB	VBN	9	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
longterm	longterm	ADJ	JJ	5	O
basis	basis	NOUN	NN	5	O
have	have	VERB	VBP	5	O
increased	increase	VERB	VBN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
luteinizing	luteinize	VERB	VBG	0	O
hormone	hormone	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
LH	LH	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
links	link	NOUN	NNS	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
sexual	sexual	ADJ	JJ	5	O
behavior	behavior	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
LH	LH	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
without	without	ADP	IN	9	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
of	of	ADP	IN	5	O
similar	similar	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
functional	functional	ADJ	JJ	9	O
capacity	capacity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
age	age	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
-	-	SYM	SYM	7	O
40	40	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
selected	select	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
rheumatic	rheumatic	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
subjective	subjective	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
behavior	behavior	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
parameters	parameter	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
desire	desire	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sexual	sexual	ADJ	JJ	5	O
excitement	excitement	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
relations	relation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Personal	personal	ADJ	JJ	5	O
interviews	interview	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
questionnaire	questionnaire	NOUN	NN	5	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
behavior	behavior	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
support	support	VERB	VBP	5	O
the	the	DET	DT	5	O
reports	report	NOUN	NNS	9	O
concerning	concern	VERB	VBG	5	O
digoxin	digoxin	NOUN	NN	0	B-Chemical
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
LH	LH	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
means	mean	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Tests	test	NOUN	NNS	5	O
used	use	VERB	VBD	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
behavior	behavior	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
sexual	sexual	ADJ	JJ	5	I-Disease
desire	desire	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
sexual	sexual	ADJ	JJ	5	O
excitement	excitement	NOUN	NN	5	O
phase	phase	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
erection	erection	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
relations	relation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Endometrial	endometrial	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
after	after	ADP	IN	9	O
Hodgkin	Hodgkin	PROPN	NNP	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
childhood	childhood	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
34	34	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
metastic	metastic	ADJ	JJ	3	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
after	after	ADP	IN	9	O
Hodgkin	Hodgkin	PROPN	NNP	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
childhood	childhood	NOUN	NN	5	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
abdominal	abdominal	ADJ	JJ	5	O
irradiation	irradiation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
Hodgkin	Hodgkin	PROPN	NNP	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
received	receive	VERB	VBD	9	O
exogenous	exogenous	ADJ	JJ	3	O
estrogens	estrogen	NOUN	NNS	9	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
menopausal	menopausal	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Young	young	ADJ	JJ	6	O
women	woman	NOUN	NNS	5	O
on	on	ADP	IN	5	O
replacement	replacement	NOUN	NN	9	O
estrogens	estrogen	VERB	VBZ	9	B-Chemical
for	for	ADP	IN	5	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
cancer	cancer	NOUN	NN	3	B-Disease
therapy	therapy	NOUN	NN	5	O
may	may	VERB	MD	5	O
also	also	ADV	RB	9	O
have	have	VERB	VB	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
examined	examine	VERB	VBN	9	O
periodically	periodically	ADV	RB	5	O
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Interim	interim	ADJ	JJ	5	O
report	report	NOUN	NN	5	O
on	on	ADP	IN	5	O
fifty	fifty	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
report	report	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Creatinine	creatinine	ADJ	JJ	7	B-Chemical
clearance	clearance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
maximum	maximum	ADJ	JJ	5	O
urinary	urinary	ADJ	JJ	9	O
osmolality	osmolality	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
24	24	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
urine	urine	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
50	50	NUM	CD	0	O
affectively	affectively	ADV	RB	5	O
ill	ill	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
on	on	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
norms	norm	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
values	value	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
tests	test	NOUN	NNS	5	O
from	from	ADP	IN	9	O
screening	screen	VERB	VBG	5	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
available	available	ADJ	JJ	5	O
for	for	ADP	IN	5	O
most	most	ADJ	JJS	9	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
for	for	ADP	IN	5	O
any	any	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
during	during	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Low	low	ADJ	JJ	9	O
clearance	clearance	NOUN	NN	9	O
values	value	NOUN	NNS	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
several	several	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
accounted	account	VERB	VBN	5	O
for	for	ADP	IN	5	O
by	by	ADP	IN	9	O
their	-PRON-	DET	PRP$	5	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
lithium	lithium	ADJ	JJ	0	B-Chemical
values	value	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Urinary	urinary	ADJ	JJ	9	O
concentration	concentration	NOUN	NN	0	O
defect	defect	NOUN	NN	9	O
appeared	appear	VERB	VBD	9	O
frequent	frequent	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
impairment	impairment	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
difficult	difficult	ADJ	JJ	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
uncertainty	uncertainty	NOUN	NN	5	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
norms	norm	NOUN	NNS	5	O
applicable	applicable	ADJ	JJ	5	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
defect	defect	NOUN	NN	9	O
appeared	appear	VERB	VBD	9	O
reversible	reversible	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
in	in	ADP	IN	5	O
part	part	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Polyuria	Polyuria	NOUN	NNS	7	B-Disease
above	above	ADP	IN	9	O
3	3	NUM	CD	9	O
litres	litre	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
attempt	attempt	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
made	make	VERB	VBN	5	O
to	to	PART	TO	5	O
draw	draw	VERB	VB	5	O
practical	practical	ADJ	JJ	5	O
conclusions	conclusion	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
preliminary	preliminary	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Nephrotoxicity	nephrotoxicity	NOUN	NN	0	B-Disease
of	of	ADP	IN	5	O
cyclosporin	cyclosporin	NOUN	NN	0	B-Chemical
A	A	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
FK506	fk506	NOUN	NN	3	B-Chemical
:	:	PUNCT	:	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
calcineurin	calcineurin	NOUN	NN	3	O
phosphatase	phosphatase	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Cyclosporin	Cyclosporin	PROPN	NNP	0	B-Chemical
A	A	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
CsA	csa	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Fujimycine	Fujimycine	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
FK506	fk506	NOUN	NN	3	B-Chemical
;	;	PUNCT	:	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
the	the	DET	DT	5	O
related	related	ADJ	JJ	9	O
macrolide	macrolide	NOUN	NN	9	B-Chemical
immunosuppressant	immunosuppressant	NOUN	NN	9	O
rapamycin	rapamycin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
degenerative	degenerative	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
proximal	proximal	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	O
epithelium	epithelium	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hypertrophy	hypertrophy	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
juxtaglomerular	juxtaglomerular	ADJ	JJ	3	O
apparatus	apparatus	NOUN	NN	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
FK506	fk506	NOUN	NN	3	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Cyclophilin	Cyclophilin	PROPN	NNP	1	O
A	A	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
FK506	fk506	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
binding	bind	VERB	VBG	1	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
intracytoplasmic	intracytoplasmic	ADJ	JJ	3	O
receptors	receptor	NOUN	NNS	3	O
for	for	ADP	IN	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
FK506	FK506	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
each	each	DET	DT	5	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
extract	extract	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
immunoreactive	immunoreactive	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
enzymatically	enzymatically	ADV	RB	0	O
active	active	ADJ	JJ	9	O
calcineurin	calcineurin	NOUN	NN	3	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
inhibited	inhibit	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
immunosuppressants	immunosuppressant	NOUN	NNS	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
FK506	FK506	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
by	by	ADP	IN	9	O
rapamycin	rapamycin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
specific	specific	ADJ	JJ	9	O
immunophilin	immunophilin	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
calcineurin	calcineurin	NOUN	NN	3	O
complexes	complex	NOUN	NNS	9	O
formed	form	VERB	VBN	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
FK506	FK506	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
rapamycin	rapamycin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
FK506	FK506	PROPN	NNP	3	B-Chemical
is	be	VERB	VBZ	5	O
likely	likely	ADV	RB	5	O
mediated	mediate	VERB	VBN	3	O
through	through	ADP	IN	9	O
binding	bind	VERB	VBG	1	O
to	to	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
immunophilin	immunophilin	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
inhibiting	inhibit	VERB	VBG	3	O
calcineurin	calcineurin	NOUN	NN	3	O
phosphatase	phosphatase	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Carboplatin	Carboplatin	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
to	to	PART	TO	5	O
adult	adult	VERB	VB	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
4	4	NUM	CD	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
girl	girl	NOUN	NN	5	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
parameningeal	parameningeal	ADJ	JJ	5	O
embryonal	embryonal	ADJ	JJ	3	B-Disease
rhabdomyosarcoma	rhabdomyosarcoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
developed	develop	VERB	VBD	5	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
slow	slow	ADJ	JJ	5	O
partial	partial	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
contributing	contributing	NOUN	NN	9	O
factors	factor	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
on	on	ADP	IN	5	O
combined	combined	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
prostacyclin	prostacyclin	NOUN	NN	0	B-Chemical
analogue	analogue	NOUN	NN	0	O
beraprost	beraprost	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
phosphodiesterase	phosphodiesterase	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
cilostazol	cilostazol	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
various	various	ADJ	JJ	9	O
oral	oral	ADJ	JJ	9	O
antiplatelets	antiplatelet	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
prostacyclin	prostacyclin	NOUN	NN	0	B-Chemical
analogue	analogue	NOUN	NN	0	O
beraprost	beraprost	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
BPT	BPT	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
phosphodiesterase	phosphodiesterase	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
cilostazol	cilostazol	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
CLZ	CLZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
untoward	untoward	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
synergistic	synergistic	ADJ	JJ	9	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
intracellular	intracellular	ADJ	JJ	3	O
cAMP	cAMP	PROPN	NNP	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
cyclic	cyclic	NOUN	NN	0	B-Chemical
adenosine	adenosine	NOUN	NN	0	I-Chemical
3	3	NUM	CD	9	I-Chemical
'	'	PUNCT	''	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
'	'	PUNCT	''	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
monophosphate	monophosphate	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Thereby	thereby	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
combined	combined	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
agents	agent	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
attempted	attempt	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Twelve	twelve	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assigned	assign	VERB	VBN	5	O
to	to	PART	TO	5	O
take	take	VERB	VB	5	O
BPT	BPT	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
CLZ	CLZ	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
following	following	ADJ	JJ	9	O
schedule	schedule	NOUN	NN	5	O
;	;	PUNCT	:	9	O
BPT	bpt	ADV	RB	0	B-Chemical
:	:	PUNCT	:	9	O
40	40	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
at	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
120	120	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
t	t	NOUN	NN	5	O
.	.	PUNCT	.	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O
from	from	ADP	IN	9	O
day	day	NOUN	NN	9	O
7	7	NUM	CD	9	O
to	to	ADP	IN	5	O
14	14	NUM	CD	7	O
,	,	PUNCT	,	9	O
CLZ	CLZ	PROPN	NNP	0	B-Chemical
:	:	PUNCT	:	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
t	t	NOUN	NN	5	O
.	.	PUNCT	.	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O
from	from	ADP	IN	9	O
day	day	NOUN	NN	9	O
3	3	NUM	CD	9	O
to	to	ADP	IN	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
various	various	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
intervals	interval	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
physical	physical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	O
collection	collection	NOUN	NN	5	O
for	for	ADP	IN	5	O
ex	ex	NOUN	NN	9	O
vivo	vivo	NOUN	NNS	3	O
platelet	platelet	NOUN	NN	9	B-Disease
aggregation	aggregation	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
determination	determination	NOUN	NN	9	O
of	of	ADP	IN	5	O
intraplatelet	intraplatelet	NOUN	NN	3	O
cAMP	cAMP	PROPN	NNP	3	B-Chemical
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Throughout	throughout	ADP	IN	5	O
the	the	DET	DT	5	O
observation	observation	NOUN	NN	9	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
alteration	alteration	NOUN	NN	9	O
in	in	ADP	IN	5	O
vital	vital	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Seven	seven	NUM	CD	9	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
headache	headache	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
short	short	ADJ	JJ	5	O
duration	duration	NOUN	NN	5	O
accompanying	accompany	VERB	VBG	5	O
facial	facial	ADJ	JJ	5	B-Disease
flush	flush	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
and	and	CCONJ	CC	5	O
nausea	nausea	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
after	after	ADP	IN	9	O
ingestion	ingestion	NOUN	NN	9	O
of	of	ADP	IN	5	O
CLZ	CLZ	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
probably	probably	ADV	RB	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
vasodilating	vasodilating	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
of	of	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
degree	degree	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
special	special	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
required	require	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Intraplatelet	Intraplatelet	PROPN	NNP	9	O
cAMP	cAMP	PROPN	NNP	3	B-Chemical
content	content	NOUN	NN	9	O
was	be	VERB	VBD	9	O
gradually	gradually	ADV	RB	9	O
but	but	CCONJ	CC	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
to	to	ADP	IN	5	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
84	84	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
59	59	NUM	CD	7	O
pmol	pmol	NOUN	NN	0	O
per	per	ADP	IN	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
platelets	platelet	NOUN	NNS	3	O
at	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
14	14	NUM	CD	7	O
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
value	value	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
87	87	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
pmol	pmol	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
platelet	platelet	NOUN	NN	9	O
aggregability	aggregability	NOUN	NN	0	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
suppressed	suppress	VERB	VBN	3	O
at	at	ADP	IN	9	O
various	various	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
intervals	interval	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
additive	additive	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
synergistic	synergistic	ADJ	JJ	9	O
inhibitory	inhibitory	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
combined	combined	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
combined	combined	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
BPT	BPT	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
CLZ	CLZ	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
safe	safe	ADJ	JJ	5	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
though	though	ADP	IN	9	O
the	the	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
combined	combined	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
yet	yet	ADV	RB	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
elucidated	elucidate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Pravastatin	pravastatin	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
myopathy	myopathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Report	Report	PROPN	NNP	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
inflammatory	inflammatory	ADJ	JJ	3	B-Disease
myopathy	myopathy	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
pravastatin	pravastatin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
hydrophilic	hydrophilic	ADJ	JJ	0	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hydroxy	hydroxy	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
methylglutaril	methylglutaril	ADJ	JJ	_	O
coenzyme	coenzyme	NOUN	NN	0	O
A	a	DET	DT	9	O
reductase	reductase	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
69	69	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
was	be	VERB	VBD	9	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
non	non	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
insulin	insulin	ADJ	JJ	3	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
dependent	dependent	ADJ	JJ	9	I-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
assumed	assume	VERB	VBD	5	O
pravastatin	pravastatin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
hypercholesterolemia	hypercholesterolemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
myopathy	myopathy	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lower	low	ADJ	JJR	9	O
limbs	limb	NOUN	NNS	5	O
which	which	DET	WDT	5	O
resolved	resolve	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
pravastatin	pravastatin	ADJ	JJ	0	B-Chemical
discontinuation	discontinuation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
previously	previously	ADV	RB	9	O
unknown	unknown	ADJ	JJ	9	O
hypothyroidism	hypothyroidism	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
probably	probably	ADV	RB	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
autoimmune	autoimmune	ADJ	JJ	3	B-Disease
thyroiditis	thyroiditis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
evidenced	evidence	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Muscle	muscle	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
left	leave	VERB	VBN	5	O
gastrocnemius	gastrocnemius	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
perimysial	perimysial	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
endomysial	endomysial	ADJ	JJ	3	O
inflammatory	inflammatory	ADJ	JJ	3	O
infiltrate	infiltrate	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
CD4	CD4	PROPN	NNP	3	O
+	+	SYM	SYM	9	O
lymphocytes	lymphocyte	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	O
myopathy	myopathy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
pravastatin	pravastatin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
myopathy	myopathy	NOUN	NN	9	B-Disease
could	could	VERB	MD	9	O
represent	represent	VERB	VB	9	O
a	a	DET	DT	5	O
distinct	distinct	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
inflammatory	inflammatory	ADJ	JJ	3	O
entity	entity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
ammonia	ammonia	ADJ	JJ	0	B-Chemical
coma	coma	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
by	by	ADP	IN	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	PROPN	NNP	0	I-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Ammonia	ammonia	ADJ	JJ	0	B-Chemical
coma	coma	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
produced	produce	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
within	within	ADP	IN	9	O
10	10	NUM	CD	9	O
to	to	PART	TO	5	O
15	15	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
intraperitonealinjection	intraperitonealinjection	NOUN	NN	0	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
mmol	mmol	NOUN	NN	0	O
NH4CL	NH4CL	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
coma	coma	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
prevented	prevent	VERB	VBN	9	O
with	with	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
68	68	NUM	CD	7	O
mmol	mmol	NOUN	NN	0	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
given	give	VERB	VBN	5	O
by	by	ADP	IN	9	O
gastric	gastric	ADJ	JJ	9	O
intubation	intubation	NOUN	NN	5	O
15	15	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
ammonium	ammonium	NOUN	NN	0	B-Chemical
salt	salt	NOUN	NN	0	I-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	PROPN	NNP	0	I-Chemical
was	be	VERB	VBD	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
ammonia	ammonia	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
ammonia	ammonia	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
urea	urea	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

Intraventricular	intraventricular	ADJ	JJ	7	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
sufficient	sufficient	ADJ	JJ	9	O
to	to	PART	TO	5	O
raise	raise	VERB	VB	9	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
extent	extent	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
prevent	prevent	VERB	VB	5	O
the	the	DET	DT	5	O
ammonia	ammonia	NOUN	NN	0	B-Chemical
coma	coma	NOUN	NN	5	B-Disease
nor	nor	CCONJ	CC	9	O
affect	affect	VERB	VBP	9	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
ammonia	ammonia	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Bilateral	bilateral	ADJ	JJ	5	O
nephrectomy	nephrectomy	NOUN	NN	5	O
eliminated	eliminate	VERB	VBD	9	O
the	the	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
on	on	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
ammonia	ammonia	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
ammonia	ammonia	ADJ	JJ	0	B-Chemical
coma	coma	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
prevented	prevent	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
ammonia	ammonia	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
ammonia	ammonia	ADJ	JJ	0	B-Chemical
coma	coma	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
accounted	account	VERB	VBN	5	O
for	for	ADP	IN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
central	central	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
provide	provide	VERB	VBP	5	O
a	a	DET	DT	5	O
reasonable	reasonable	ADJ	JJ	5	O
explanation	explanation	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
encephalopathic	encephalopathic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Etoposide	etoposide	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
after	after	ADP	IN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
containing	contain	VERB	VBG	0	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
causal	causal	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Halogenated	halogenated	ADJ	JJ	0	O
anesthetics	anesthetic	NOUN	NNS	5	O
form	form	NOUN	NN	9	O
liver	liver	NOUN	NN	9	O
adducts	adduct	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
antigens	antigen	VERB	VBZ	3	O
that	that	ADP	IN	5	O
cross	cross	NOUN	NN	5	O
-	-	NOUN	NN	7	O
react	react	NOUN	NN	9	O
with	with	ADP	IN	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
antibodies	antibody	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
halogenated	halogenated	ADJ	JJ	0	O
anesthetics	anesthetic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
allergic	allergic	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
both	both	CCONJ	CC	9	O
alone	alone	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
following	follow	VERB	VBG	9	O
previous	previous	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Halothane	halothane	NOUN	NN	0	B-Chemical
hepatitis	hepatitis	NOUN	NN	9	B-Disease
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
involve	involve	VERB	VB	5	O
an	an	DET	DT	5	O
aberrant	aberrant	ADJ	JJ	3	O
immune	immune	ADJ	JJ	3	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
antibody	antibody	NOUN	NN	3	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
protein	protein	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
bound	bind	VERB	VBN	9	O
biotransformation	biotransformation	NOUN	NN	0	O
product	product	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
trifluoroacetyl	trifluoroacetyl	NOUN	NN	0	B-Chemical
adduct	adduct	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
detected	detect	VERB	VBN	9	O
on	on	ADP	IN	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
hepatitis	hepatitis	NOUN	NN	9	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
reactivity	reactivity	NOUN	NN	9	O
between	between	ADP	IN	5	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
isoflurane	isoflurane	VERB	VB	0	B-Chemical
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
halothane	halothane	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
subcellular	subcellular	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
lobular	lobular	ADJ	JJ	5	O
production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
neoantigens	neoantigen	NOUN	NNS	3	O
recognized	recognize	VERB	VBN	9	O
by	by	ADP	IN	9	O
halothane	halothane	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
antibodies	antibody	NOUN	NNS	3	O
following	follow	VERB	VBG	9	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
biochemical	biochemical	ADJ	JJ	9	O
nature	nature	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
neoantigens	neoantigen	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
animal	animal	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Enflurane	Enflurane	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
neoantigens	neoantigen	NOUN	NNS	3	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
microsomal	microsomal	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
cytosolic	cytosolic	ADJ	JJ	3	O
fraction	fraction	NOUN	NN	9	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
homogenates	homogenate	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
centrilobular	centrilobular	ADJ	JJ	5	O
region	region	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
liver	liver	NOUN	NN	9	O
,	,	PUNCT	,	9	O
biochemical	biochemical	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
detected	detect	VERB	VBD	9	O
fluorinated	fluorinate	VERB	VBN	0	O
liver	liver	NOUN	NN	9	O
adducts	adduct	NOUN	NNS	0	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
up	up	ADV	RB	5	O
to	to	PART	TO	5	O
20	20	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
fold	fold	VERB	VB	9	O
greater	great	ADJ	JJR	5	O
in	in	ADP	IN	5	O
guinea	guinea	NOUN	NN	9	O
pigs	pig	NOUN	NNS	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
supports	support	VERB	VBZ	9	O
and	and	CCONJ	CC	5	O
extends	extend	VERB	VBZ	9	O
previous	previous	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
could	could	VERB	MD	9	O
produce	produce	VERB	VB	9	O
a	a	DET	DT	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
condition	condition	NOUN	NN	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
hepatitis	hepatitis	NOUN	NN	9	B-Disease
either	either	CCONJ	CC	9	O
alone	alone	ADV	RB	9	O
or	or	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
to	to	PART	TO	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
guinea	guinea	NOUN	NN	9	O
pig	pig	NOUN	NN	9	O
would	would	VERB	MD	5	O
appear	appear	VERB	VB	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
further	further	ADJ	JJ	9	O
investigations	investigation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
immunological	immunological	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
these	these	DET	DT	5	O
antigens	antigen	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Cholinergic	Cholinergic	PROPN	NNP	3	O
toxicity	toxicity	NOUN	NN	9	B-Disease
resulting	result	VERB	VBG	9	O
from	from	ADP	IN	9	O
ocular	ocular	ADJ	JJ	5	O
instillation	instillation	NOUN	NN	0	O
of	of	ADP	IN	5	O
echothiophate	echothiophate	ADJ	JJ	0	B-Chemical
iodide	iodide	ADJ	JJ	0	I-Chemical
eye	eye	NOUN	NN	5	O
drops	drop	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
cholinergic	cholinergic	NOUN	NN	3	O
syndrome	syndrome	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
echothiophate	echothiophate	ADJ	JJ	0	B-Chemical
iodide	iodide	ADJ	JJ	0	I-Chemical
ophthalmic	ophthalmic	ADJ	JJ	5	O
drops	drop	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
profound	profound	ADJ	JJ	9	O
muscle	muscle	NOUN	NN	9	B-Disease
weakness	weakness	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
initially	initially	ADV	RB	9	O
given	give	VERB	VBN	5	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
myasthenia	myasthenia	ADJ	JJ	9	B-Disease
gravis	gravi	NOUN	NNS	2	I-Disease
.	.	PUNCT	.	9	O

Red	red	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cell	cell	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
serum	serum	ADJ	JJ	9	O
cholinesterase	cholinesterase	NOUN	NN	0	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
severely	severely	ADV	RB	9	O
depressed	depressed	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
resolved	resolve	VERB	VBD	9	O
spontaneously	spontaneously	ADV	RB	5	O
following	follow	VERB	VBG	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
eye	eye	NOUN	NN	5	O
drops	drop	VERB	VBZ	0	O
.	.	PUNCT	.	9	O

Seizure	seizure	VERB	VB	5	B-Disease
after	after	ADP	IN	9	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
pediatric	pediatric	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Flumazenil	Flumazenil	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
benzodiazepine	benzodiazepine	ADJ	JJ	5	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
reverse	reverse	VERB	VB	9	O
sedation	sedation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
depression	depression	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
benzodiazepines	benzodiazepine	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

Seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
have	have	VERB	VBP	5	O
complicated	complicate	VERB	VBN	5	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Overdose	Overdose	PROPN	NNP	7	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
coingested	coingeste	VERB	VBN	9	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressants	antidepressant	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Little	little	ADJ	JJ	9	O
information	information	NOUN	NN	5	O
exists	exist	VERB	VBZ	9	O
concerning	concern	VERB	VBG	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
generalized	generalize	VERB	VBN	5	O
tonic	tonic	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
clonic	clonic	NOUN	NN	5	I-Disease
seizure	seizure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
pediatric	pediatric	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
flumazenil	flumazenil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Phase	Phase	PROPN	NNP	9	O
I	-PRON-	PRON	PRP	9	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
13	13	NUM	CD	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
cis	cis	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
retinoic	retinoic	NOUN	NN	3	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
neuroblastoma	neuroblastoma	NOUN	NN	3	B-Disease
following	follow	VERB	VBG	9	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
neuroblastoma	neuroblastoma	ADJ	JJ	3	B-Disease
cell	cell	NOUN	NN	3	O
lines	line	NOUN	NNS	3	O
with	with	ADP	IN	5	O
13	13	NUM	CD	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
cis	cis	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
retinoic	retinoic	NOUN	NN	3	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
cis	cis	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
RA	ra	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
sustained	sustained	ADJ	JJ	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
proliferation	proliferation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
cis	cis	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
RA	RA	PROPN	NNP	9	I-Chemical
has	have	VERB	VBZ	9	O
demonstrated	demonstrate	VERB	VBN	9	O
clinical	clinical	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
in	in	ADP	IN	5	O
neuroblastoma	neuroblastoma	ADJ	JJ	3	B-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
relapse	relapse	NOUN	NN	5	O
after	after	ADP	IN	9	O
cytotoxic	cytotoxic	NOUN	NN	3	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
phase	phase	NOUN	NN	5	O
I	-PRON-	PRON	PRP	9	O
trial	trial	NOUN	NN	5	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
maximal	maximal	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
tolerated	tolerate	VERB	VBN	9	O
dosage	dosage	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
MTD	MTD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pharmacokinetics	pharmacokinetic	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cis	cis	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
RA	RA	PROPN	NNP	9	I-Chemical
administered	administer	VERB	VBD	9	O
on	on	ADP	IN	5	O
an	an	DET	DT	5	O
intermittent	intermittent	ADJ	JJ	5	O
schedule	schedule	NOUN	NN	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
neuroblastoma	neuroblastoma	NOUN	NN	3	B-Disease
following	follow	VERB	VBG	9	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
BMT	BMT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Fifty	fifty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
assessable	assessable	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
to	to	PART	TO	5	O
12	12	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
cis	cis	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
RA	RA	PROPN	NNP	9	I-Chemical
administered	administer	VERB	VBD	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
equally	equally	ADV	RB	9	O
divided	divide	VERB	VBN	5	O
doses	dose	NOUN	NNS	0	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
rest	rest	NOUN	NN	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
12	12	NUM	CD	9	O
courses	course	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
escalated	escalate	VERB	VBN	5	O
from	from	ADP	IN	9	O
100	100	NUM	CD	0	O
to	to	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
until	until	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
DLT	DLT	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
single	single	ADJ	JJ	9	O
intrapatient	intrapatient	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
escalation	escalation	NOUN	NN	5	O
was	be	VERB	VBD	9	O
permitted	permit	VERB	VBN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
MTD	MTD	PROPN	NNP	9	O
of	of	ADP	IN	5	O
cis	cis	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
RA	ra	NOUN	NN	9	I-Chemical
was	be	VERB	VBD	9	O
160	160	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Dose	dose	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
of	of	ADP	IN	5	O
nine	nine	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
included	include	VERB	VBN	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
rash	rash	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
anemia	anemia	NOUN	NN	9	B-Disease
/	/	SYM	SYM	9	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
/	/	SYM	SYM	9	O
emesis	emesis	NOUN	NN	5	B-Disease
/	/	SYM	SYM	9	O
rash	rash	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
resolved	resolve	VERB	VBD	9	O
after	after	ADP	IN	9	O
cis	cis	ADV	RB	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
RA	RA	PROPN	NNP	9	I-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
complete	complete	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
marrow	marrow	NOUN	NN	3	O
metastases	metastasis	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
peak	peak	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
trough	trough	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
MTD	MTD	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
during	during	ADP	IN	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
DLT	DLT	PROPN	NNP	5	O
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
10	10	NUM	CD	9	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
MTD	MTD	PROPN	NNP	9	O
of	of	ADP	IN	5	O
cis	cis	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
RA	ra	NOUN	NN	9	I-Chemical
given	give	VERB	VBN	5	O
on	on	ADP	IN	5	O
this	this	DET	DT	5	O
intermittent	intermittent	ADJ	JJ	5	O
schedule	schedule	NOUN	NN	5	O
was	be	VERB	VBD	9	O
160	160	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
effective	effective	ADJ	JJ	5	O
against	against	ADP	IN	9	O
neuroblastoma	neuroblastoma	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
were	be	VERB	VBD	9	O
achieved	achieve	VERB	VBN	5	O
at	at	ADP	IN	9	O
this	this	DET	DT	5	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
DLT	DLT	PROPN	NNP	5	O
included	include	VERB	VBD	5	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
predicted	predict	VERB	VBN	9	O
by	by	ADP	IN	9	O
serum	serum	ADJ	JJ	9	O
cis	cis	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
RA	ra	NOUN	NN	9	I-Chemical
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Monitoring	monitoring	NOUN	NN	5	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
cis	cis	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
RA	ra	NOUN	NN	9	I-Chemical
levels	level	NOUN	NNS	3	O
is	be	VERB	VBZ	5	O
indicated	indicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
future	future	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Time	time	NOUN	NN	9	O
dependence	dependence	NOUN	NN	5	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
oxypurines	oxypurine	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
nucleosides	nucleoside	NOUN	NNS	0	B-Chemical
during	during	ADP	IN	5	O
incomplete	incomplete	ADJ	JJ	9	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Incomplete	incomplete	ADJ	JJ	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
by	by	ADP	IN	9	O
bilaterally	bilaterally	ADV	RB	5	O
clamping	clamp	VERB	VBG	5	O
the	the	DET	DT	5	O
common	common	ADJ	JJ	5	O
carotid	carotid	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Peripheral	peripheral	ADJ	JJ	9	O
venous	venous	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
withdrawn	withdraw	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
femoral	femoral	ADJ	JJ	5	O
vein	vein	NOUN	NN	5	O
four	four	NUM	CD	9	O
times	time	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
once	once	ADV	RB	5	O
every	every	DET	DT	5	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
before	before	ADP	IN	9	O
ischemia	ischemia	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
time	time	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
ischemia	ischemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Plasma	plasma	NOUN	NN	0	O
extracts	extract	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
highly	highly	ADV	RB	9	O
sensitive	sensitive	ADJ	JJ	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
performance	performance	NOUN	NN	5	O
liquid	liquid	NOUN	NN	0	O
chromatographic	chromatographic	ADJ	JJ	0	O
method	method	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
determination	determination	NOUN	NN	9	O
of	of	ADP	IN	5	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
oxypurines	oxypurine	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
nucleosides	nucleoside	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
ischemia	ischemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
oxypurines	oxypurine	NOUN	NNS	0	B-Chemical
and	and	CCONJ	CC	5	O
nucleosides	nucleoside	NOUN	NNS	0	B-Chemical
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
minimal	minimal	ADJ	JJ	9	O
amount	amount	NOUN	NN	9	O
at	at	ADP	IN	9	O
zero	zero	NUM	CD	5	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
058	058	NUM	CD	7	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
liter	liter	NOUN	NN	0	O
plasma	plasma	NOUN	NN	9	O
;	;	PUNCT	:	9	O
SD	sd	NOUN	NN	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
015	015	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBN	9	O
after	after	ADP	IN	9	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
of	of	ADP	IN	5	O
ischemia	ischemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
fivefold	fivefold	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
after	after	ADP	IN	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
of	of	ADP	IN	5	O
carotid	carotid	ADJ	JJ	5	O
occlusion	occlusion	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
298	298	NUM	CD	7	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
liter	liter	NOUN	NN	0	O
plasma	plasma	NOUN	NN	9	O
;	;	PUNCT	:	9	O
SD	sd	NOUN	NN	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
078	078	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
plasma	plasma	NOUN	NN	9	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
recorded	record	VERB	VBN	5	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
other	other	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
receiving	receive	VERB	VBG	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
b	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O
w	w	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cyclooxygenase	cyclooxygenase	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
acetylsalicylate	acetylsalicylate	NOUN	NN	0	B-Chemical
intravenously	intravenously	ADV	RB	0	O
immediately	immediately	ADV	RB	9	O
before	before	ADP	IN	9	O
ischemia	ischemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
receiving	receive	VERB	VBG	9	O
650	650	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
b	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O
w	w	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
drug	drug	NOUN	NN	5	O
nitroprusside	nitroprusside	ADV	RB	0	B-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
flow	flow	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
103	103	NUM	CD	7	O
microliters	microliter	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
intravenously	intravenously	ADV	RB	0	O
during	during	ADP	IN	5	O
ischemia	ischemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
determination	determination	NOUN	NN	9	O
of	of	ADP	IN	5	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
oxypurines	oxypurine	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
nucleosides	nucleoside	NOUN	NNS	0	B-Chemical
in	in	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
monitor	monitor	VERB	VB	5	O
the	the	DET	DT	5	O
metabolic	metabolic	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
of	of	ADP	IN	5	O
tissues	tissue	NOUN	NNS	9	O
occurring	occur	VERB	VBG	9	O
during	during	ADP	IN	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
phenomena	phenomenon	NOUN	NNS	5	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Acute	acute	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
adriamycin	adriamycin	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
loaded	load	VERB	VBN	0	O
cyanoacrylate	cyanoacrylate	NOUN	NN	0	B-Chemical
nanoparticles	nanoparticle	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
loaded	load	VERB	VBN	0	O
nanoparticle	nanoparticle	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
DXNP	DXNP	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
renal	renal	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
explored	explore	VERB	VBN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
normal	normal	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
glomerulonephritis	glomerulonephritis	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
free	free	ADJ	JJ	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DX	DX	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
died	die	VERB	VBD	9	O
within	within	ADP	IN	9	O
one	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
all	all	DET	DT	5	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
having	have	VERB	VBG	5	O
received	receive	VERB	VBN	9	O
free	free	ADJ	JJ	9	O
NP	NP	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
DXNP	DXNP	PROPN	NNP	_	O
survived	survive	VERB	VBD	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
3	3	NUM	CD	9	O
times	time	NOUN	NNS	5	O
higher	high	ADJ	JJR	9	O
proteinuria	proteinuria	NOUN	NNS	9	B-Disease
appeared	appear	VERB	VBD	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
DXNP	DXNP	PROPN	NNP	_	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
DX	DX	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Free	Free	PROPN	NNP	9	O
NP	NP	PROPN	NNP	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
provoke	provoke	VERB	VB	9	O
any	any	DET	DT	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
hr	hr	INTJ	UH	0	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
injection	injection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
DXNP	DXNP	PROPN	NNP	_	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
times	time	NOUN	NNS	5	O
more	more	ADV	RBR	5	O
concentrated	concentrated	ADJ	JJ	0	O
in	in	ADP	IN	5	O
kidneys	kidney	NOUN	NNS	9	O
than	than	ADP	IN	5	O
free	free	ADJ	JJ	9	O
DX	DX	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
025	025	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
immune	immune	ADJ	JJ	3	O
experimental	experimental	ADJ	JJ	5	O
glomerulonephritis	glomerulonephritis	ADJ	JJ	3	B-Disease
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
DX	DX	PROPN	NNP	9	B-Chemical
died	die	VERB	VBD	9	O
within	within	ADP	IN	9	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
DXNP	DXNP	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
NP	NP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
untreated	untreated	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
all	all	DET	DT	5	O
survived	survive	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Proteinuria	Proteinuria	PROPN	NNP	7	B-Disease
appeared	appear	VERB	VBD	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
series	series	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
times	time	NOUN	NNS	5	O
more	more	ADV	RBR	5	O
intense	intense	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
prolonged	prolong	VERB	VBN	9	O
after	after	ADP	IN	9	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
400	400	NUM	CD	0	O
-	-	SYM	SYM	7	O
700	700	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
DXNP	DXNP	PROPN	NNP	_	O
and	and	CCONJ	CC	5	O
DX	DX	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
unloaded	unloaded	ADJ	JJ	9	O
NP	NP	PROPN	NNP	9	O
behaved	behave	VERB	VBN	9	O
as	as	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
DXNP	DXNP	PROPN	NNP	_	O
killed	kill	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
animals	animal	NOUN	NNS	9	O
than	than	ADP	IN	5	O
free	free	ADJ	JJ	9	O
DX	DX	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
despite	despite	ADP	IN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
enhanced	enhance	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
former	former	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
effects	effect	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
better	well	ADJ	JJR	5	O
survival	survival	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
nephrosis	nephrosis	NOUN	NN	0	B-Disease
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
most	most	ADV	RBS	9	O
probably	probably	ADV	RB	9	O
related	related	ADJ	JJ	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
enhanced	enhanced	ADJ	JJ	3	O
capture	capture	NOUN	NN	5	O
of	of	ADP	IN	5	O
DXNP	DXNP	PROPN	NNP	_	O
by	by	ADP	IN	9	O
cells	cell	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mononuclear	mononuclear	NOUN	NN	3	O
phagocyte	phagocyte	NOUN	NN	3	O
system	system	NOUN	NN	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
mesangial	mesangial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Prostaglandin	Prostaglandin	PROPN	NNP	0	B-Chemical
E2	E2	PROPN	NNP	3	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
bladder	bladder	NOUN	NN	9	B-Disease
hyperactivity	hyperactivity	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
conscious	conscious	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
tachykinins	tachykinin	NOUN	NNS	3	B-Chemical
?	?	PUNCT	.	5	O

In	in	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
conscious	conscious	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
investigated	investigate	VERB	VBN	9	O
by	by	ADP	IN	9	O
continuous	continuous	ADJ	JJ	5	O
cystometry	cystometry	NOUN	NN	5	O
,	,	PUNCT	,	9	O
intravesically	intravesically	ADV	RB	0	O
instilled	instill	VERB	VBN	9	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
PG	PG	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
E2	E2	PROPN	NNP	3	I-Chemical
facilitated	facilitate	VERB	VBD	5	O
micturition	micturition	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
basal	basal	ADJ	JJ	3	O
intravesical	intravesical	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
attenuated	attenuate	VERB	VBN	3	O
by	by	ADP	IN	9	O
both	both	DET	DT	9	O
the	the	DET	DT	5	O
NK1	NK1	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
selective	selective	ADJ	JJ	9	O
antagonist	antagonist	NOUN	NN	3	O
RP	RP	PROPN	NNP	9	B-Chemical
67	67	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	I-Chemical
580	580	NUM	CD	9	I-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
NK2	NK2	PROPN	NNPS	3	O
receptor	receptor	VERB	VBP	3	O
selective	selective	ADJ	JJ	9	O
antagonist	antagonist	NOUN	NN	3	O
SR	SR	PROPN	NNP	9	B-Chemical
48	48	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
968	968	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
intra	intra	ADJ	JJ	5	O
-	-	NOUN	NN	7	O
arterially	arterially	ADV	RB	0	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
NK1	NK1	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
NK2	NK2	PROPN	NNP	3	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Intra	Intra	PROPN	NNP	5	O
-	-	PUNCT	:	7	O
arterially	arterially	ADV	RB	0	O
given	give	VERB	VBN	5	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
distinct	distinct	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
before	before	ADP	IN	9	O
initiating	initiate	VERB	VBG	9	O
a	a	DET	DT	5	O
micturition	micturition	NOUN	NN	5	O
reflex	reflex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
PG	PG	PROPN	NNP	9	B-Chemical
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
contractant	contractant	NOUN	NN	0	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
detrusor	detrusor	NOUN	NN	5	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
intra	intra	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
arterial	arterial	ADJ	JJ	5	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
could	could	VERB	MD	9	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
intra	intra	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
arterial	arterial	ADJ	JJ	5	O
RP	RP	PROPN	NNP	9	B-Chemical
67	67	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	I-Chemical
580	580	NUM	CD	9	I-Chemical
or	or	CCONJ	CC	5	O
SR	SR	PROPN	NNP	9	B-Chemical
48	48	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
968	968	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
opens	open	VERB	VBZ	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
micturition	micturition	NOUN	NN	5	O
reflex	reflex	NOUN	NN	5	O
elicited	elicit	VERB	VBN	9	O
by	by	ADP	IN	9	O
intra	intra	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
arterial	arterial	ADJ	JJ	5	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
was	be	VERB	VBD	9	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
pathways	pathway	NOUN	NNS	9	O
other	other	ADJ	JJ	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
reflex	reflex	NOUN	NN	5	O
initiated	initiate	VERB	VBD	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
PG	PG	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
intravesically	intravesically	ADV	RB	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
thus	thus	ADV	RB	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
intra	intra	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
arterial	arterial	ADJ	JJ	5	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
near	near	ADP	IN	9	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
initiate	initiate	VERB	VB	9	O
micturition	micturition	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
rat	rat	NOUN	NN	3	O
chiefly	chiefly	ADV	RB	9	O
by	by	ADP	IN	9	O
directly	directly	ADV	RB	9	O
contracting	contract	VERB	VBG	5	O
the	the	DET	DT	5	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
detrusor	detrusor	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
intravesically	intravesically	ADV	RB	0	O
,	,	PUNCT	,	9	O
PGE2	PGE2	PROPN	NNP	3	B-Chemical
may	may	VERB	MD	5	O
stimulate	stimulate	VERB	VB	3	O
micturition	micturition	NOUN	NN	5	O
by	by	ADP	IN	9	O
releasing	release	VERB	VBG	9	O
tachykinins	tachykinin	NOUN	NNS	3	B-Chemical
from	from	ADP	IN	9	O
nerves	nerve	NOUN	NNS	5	O
in	in	ADP	IN	5	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
immediately	immediately	ADV	RB	9	O
below	below	ADP	IN	9	O
the	the	DET	DT	5	O
urothelium	urothelium	NOUN	NN	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
tachykinins	tachykinin	NOUN	NNS	3	B-Chemical
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
turn	turn	NOUN	NN	9	O
,	,	PUNCT	,	9	O
initiate	initiate	VERB	VBP	9	O
a	a	DET	DT	5	O
micturition	micturition	NOUN	NN	5	O
reflex	reflex	NOUN	NN	5	O
by	by	ADP	IN	9	O
stimulating	stimulate	VERB	VBG	9	O
NK1	NK1	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
NK2	NK2	PROPN	NNP	3	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Prostanoids	prostanoid	NOUN	NNS	0	B-Chemical
may	may	VERB	MD	5	O
,	,	PUNCT	,	9	O
via	via	ADP	IN	9	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
tachykinins	tachykinin	NOUN	NNS	3	B-Chemical
,	,	PUNCT	,	9	O
contribute	contribute	VERB	VBP	9	O
to	to	ADP	IN	5	O
both	both	DET	DT	9	O
urge	urge	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
bladder	bladder	NOUN	NN	9	B-Disease
hyperactivity	hyperactivity	NOUN	NN	5	I-Disease
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
conditions	condition	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lower	low	ADJ	JJR	9	O
urinary	urinary	ADJ	JJ	9	O
tract	tract	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Refractory	refractory	ADJ	JJ	5	O
cardiogenic	cardiogenic	ADJ	JJ	5	B-Disease
shock	shock	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
complete	complete	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
block	block	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
SR	sr	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
seventy	seventy	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
eight	eight	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
complete	complete	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
block	block	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
refractory	refractory	NOUN	NN	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
two	two	NUM	CD	5	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
sustained	sustained	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
concomitant	concomitant	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
continued	continue	VERB	VBD	9	O
to	to	PART	TO	5	O
remain	remain	VERB	VB	9	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
with	with	ADP	IN	5	O
complete	complete	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
block	block	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
with	with	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	O
uses	use	NOUN	NNS	5	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
atropine	atropine	NOUN	NN	0	B-Chemical
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
pressor	pressor	NOUN	NN	5	O
agents	agent	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
shortly	shortly	ADV	RB	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
calcium	calcium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
refractory	refractory	ADJ	JJ	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
complete	complete	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
block	block	NOUN	NN	9	I-Disease
resolved	resolve	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
misoprostol	misoprostol	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
indomethacin	indomethacin	ADV	RB	0	B-Chemical
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
protective	protective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
misoprostol	misoprostol	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
hospitalized	hospitalize	VERB	VBN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
indomethacin	indomethacin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
hospitalized	hospitalize	VERB	VBD	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
65	65	NUM	CD	7	O
years	year	NOUN	NNS	5	O
old	old	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
who	who	PRON	WP	5	O
required	require	VERB	VBD	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
antiinflammatory	antiinflammatory	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
NSAID	NSAID	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
either	either	CCONJ	CC	9	O
indomethacin	indomethacin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Group	Group	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
indomethacin	indomethacin	VERB	VBD	0	B-Chemical
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
plus	plus	CCONJ	CC	9	O
misoprostol	misoprostol	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Group	Group	PROPN	NNP	9	O
B	B	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Laboratory	laboratory	NOUN	NN	2	O
variables	variable	NOUN	NNS	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
serum	serum	ADJ	JJ	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
blood	blood	NOUN	NN	9	B-Chemical
urea	urea	ADJ	JJ	0	I-Chemical
nitrogen	nitrogen	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
BUN	BUN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
electrolytes	electrolyte	NOUN	NNS	0	O
]	]	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
before	before	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
every	every	DET	DT	5	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
until	until	ADP	IN	5	O
termination	termination	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
6	6	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Response	response	NOUN	NN	5	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
visual	visual	ADJ	JJ	5	O
analog	analog	NOUN	NN	0	O
scale	scale	NOUN	NN	5	O
for	for	ADP	IN	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
completed	complete	VERB	VBD	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
22	22	NUM	CD	7	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
B	B	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

BUN	BUN	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
>	>	X	XX	0	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
54	54	NUM	CD	7	O
and	and	CCONJ	CC	5	O
45	45	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
only	only	ADV	RB	9	O
20	20	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
B	B	PROPN	NNP	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Potassium	potassium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
K	K	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
increment	increment	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mEq	meq	NOUN	NN	0	O
/	/	SYM	SYM	9	O
l	l	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
in	in	ADP	IN	5	O
only	only	ADV	RB	9	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
B	B	PROPN	NNP	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
increments	increment	NOUN	NNS	9	O
in	in	ADP	IN	5	O
BUN	BUN	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
K	K	PROPN	NNP	9	B-Chemical
were	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
63	63	NUM	CD	7	O
,	,	PUNCT	,	9	O
80	80	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
42	42	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
B	B	PROPN	NNP	9	O
patients	patient	NOUN	NNS	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
Response	response	NOUN	NN	5	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Hospitalized	hospitalize	VERB	VBN	7	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
indomethacin	indomethacin	ADV	RB	0	B-Chemical
related	relate	VERB	VBN	9	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Addition	addition	NOUN	NN	0	O
of	of	ADP	IN	5	O
misoprostol	misoprostol	NOUN	NN	5	B-Chemical
can	can	VERB	MD	5	O
minimize	minimize	VERB	VB	5	O
this	this	DET	DT	5	O
renal	renal	ADJ	JJ	9	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
without	without	ADP	IN	9	O
affecting	affect	VERB	VBG	9	O
pain	pain	NOUN	NN	5	B-Disease
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cognitive	cognitive	ADJ	JJ	5	B-Disease
deterioration	deterioration	NOUN	NN	5	I-Disease
from	from	ADP	IN	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
abuse	abuse	NOUN	NN	5	O
of	of	ADP	IN	5	O
dextromethorphan	dextromethorphan	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Dextromethorphan	Dextromethorphan	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DM	DM	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
dextrorotatory	dextrorotatory	ADJ	JJ	0	O
isomer	isomer	NOUN	NN	0	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxy	hydroxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
N	n	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylmorphinan	methylmorphinan	NOUN	NN	_	I-Chemical
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
ingredient	ingredient	NOUN	NN	0	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
widely	widely	ADV	RB	5	O
available	available	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
over	over	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
the	the	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
counter	counter	NOUN	NN	5	O
antitussives	antitussive	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Initial	initial	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
Bornstein	Bornstein	PROPN	NNP	6	O
1968	1968	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
possessed	possess	VERB	VBD	9	O
no	no	DET	DT	9	O
respiratory	respiratory	ADJ	JJ	5	O
suppressant	suppressant	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
addiction	addiction	NOUN	NN	5	O
liability	liability	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Subsequently	subsequently	ADV	RB	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
several	several	ADJ	JJ	9	O
articles	article	NOUN	NNS	5	O
reporting	report	VERB	VBG	5	O
abuse	abuse	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
have	have	VERB	VBP	5	O
appeared	appear	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
ranging	range	VERB	VBG	9	O
from	from	ADP	IN	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
restlessness	restlessness	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
insomnia	insomnia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
ataxia	ataxia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
slurred	slur	VERB	VBN	5	O
speech	speech	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
nystagmus	nystagmus	ADJ	JJ	5	B-Disease
to	to	ADP	IN	5	O
mood	mood	NOUN	NN	5	O
changes	change	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
perceptual	perceptual	ADJ	JJ	5	O
alterations	alteration	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
inattention	inattention	NOUN	NN	5	O
,	,	PUNCT	,	9	O
disorientation	disorientation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
aggressive	aggressive	ADJ	JJ	5	B-Disease
behavior	behavior	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
Rammer	rammer	NOUN	NN	2	O
et	et	PROPN	NNP	6	O
al	al	PROPN	NNP	6	O
1988	1988	NUM	CD	2	O
;	;	PUNCT	:	9	O
Katona	Katona	PROPN	NNP	6	O
and	and	CCONJ	CC	5	O
Watson	Watson	PROPN	NNP	6	O
1986	1986	NUM	CD	2	O
;	;	PUNCT	:	9	O
Isbell	Isbell	PROPN	NNP	6	O
and	and	CCONJ	CC	5	O
Fraser	Fraser	PROPN	NNP	6	O
1953	1953	NUM	CD	2	O
;	;	PUNCT	:	9	O
Devlin	Devlin	PROPN	NNP	6	O
et	et	X	FW	6	O
al	al	PROPN	NNP	6	O
1985	1985	NUM	CD	2	O
;	;	PUNCT	:	9	O
McCarthy	McCarthy	PROPN	NNP	6	O
1971	1971	NUM	CD	2	O
;	;	PUNCT	:	9	O
Dodds	Dodds	PROPN	NNP	6	O
and	and	CCONJ	CC	5	O
Revai	Revai	PROPN	NNP	9	O
1967	1967	NUM	CD	2	O
;	;	PUNCT	:	9	O
Degkwitz	Degkwitz	PROPN	NNP	2	O
1964	1964	NUM	CD	2	O
;	;	PUNCT	:	9	O
Hildebrand	Hildebrand	PROPN	NNP	6	O
et	et	PROPN	NNP	6	O
al	al	PROPN	NNP	6	O
1989	1989	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
have	have	VERB	VBP	5	O
also	also	ADV	RB	9	O
been	be	VERB	VBN	9	O
two	two	NUM	CD	5	O
reported	report	VERB	VBN	9	O
fatalities	fatality	NOUN	NNS	5	O
from	from	ADP	IN	9	O
DM	DM	PROPN	NNP	9	B-Chemical
overdoses	overdose	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
Fleming	fleme	VERB	VBG	6	O
1986	1986	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
no	no	DET	DT	9	O
reports	report	NOUN	NNS	9	O
describing	describe	VERB	VBG	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
abuse	abuse	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
describes	describe	VERB	VBZ	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
deterioration	deterioration	NOUN	NN	5	I-Disease
resulting	result	VERB	VBG	9	O
from	from	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
DM	DM	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
supply	supply	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
demand	demand	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
volumetric	volumetric	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
metabolic	metabolic	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
digitalis	digitalis	NOUN	NN	9	B-Chemical
glycosides	glycoside	NOUN	NNS	0	I-Chemical
on	on	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
supply	supply	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
demand	demand	NOUN	NN	5	O
are	be	VERB	VBP	5	O
of	of	ADP	IN	5	O
particular	particular	ADJ	JJ	5	O
interest	interest	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
obstructive	obstructive	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
measured	measure	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
assessed	assess	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
015	015	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
volumetric	volumetric	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
metabolic	metabolic	ADJ	JJ	9	O
parameters	parameter	NOUN	NNS	5	O
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
chronic	chronic	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
without	without	ADP	IN	9	O
clinical	clinical	ADJ	JJ	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
the	the	DET	DT	5	O
protocol	protocol	NOUN	NN	9	O
was	be	VERB	VBD	9	O
long	long	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
involved	involved	ADJ	JJ	9	O
interventions	intervention	NOUN	NNS	5	O
which	which	DET	WDT	5	O
might	may	VERB	MD	9	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
determinations	determination	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
studied	study	VERB	VBD	9	O
in	in	ADP	IN	5	O
nine	nine	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
using	use	VERB	VBG	9	O
an	an	DET	DT	5	O
identical	identical	ADJ	JJ	9	O
protocol	protocol	NOUN	NN	9	O
except	except	ADP	IN	9	O
that	that	DET	DT	5	O
ouabain	ouabain	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
was	be	VERB	VBD	9	O
omitted	omit	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Left	leave	VERB	VBN	9	O
ventricular	ventricular	ADJ	JJ	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
fell	fall	VERB	VBD	5	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
patient	patient	NOUN	NN	5	O
given	give	VERB	VBN	5	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
though	though	ADP	IN	9	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
initially	initially	ADV	RB	9	O
elevated	elevate	VERB	VBN	9	O
in	in	ADP	IN	5	O
only	only	ADV	RB	9	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Left	leave	VERB	VBN	9	O
ventricular	ventricular	ADJ	JJ	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
fell	fall	VERB	VBD	5	O
from	from	ADP	IN	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SE	se	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
fell	fall	VERB	VBD	5	O
from	from	ADP	IN	9	O
100	100	NUM	CD	0	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
17	17	NUM	CD	7	O
to	to	PART	TO	5	O
82	82	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
was	be	VERB	VBD	9	O
completed	complete	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
velocity	velocity	NOUN	NN	5	O
of	of	ADP	IN	5	O
contractile	contractile	ADJ	JJ	9	O
element	element	NOUN	NN	9	O
shortening	shortening	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
68	68	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
11	11	NUM	CD	7	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
s	s	NOUN	NN	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
18	18	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
21	21	NUM	CD	7	O
muscle	muscle	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
lengths	length	NOUN	NNS	9	O
/	/	SYM	SYM	9	O
s	s	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
contractility	contractility	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
parameters	parameter	NOUN	NNS	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
ouabain	ouabain	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
this	this	DET	DT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ouabain	ouabain	ADJ	JJ	0	B-Chemical
patients	patient	NOUN	NNS	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
left	leave	VERB	VBD	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
end	end	NOUN	NN	9	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
diastolic	diastolic	ADJ	JJ	5	I-Disease
volume	volume	NOUN	NN	9	I-Disease
falls	fall	VERB	VBZ	5	I-Disease
after	after	ADP	IN	9	O
ouabain	ouabain	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
even	even	ADV	RB	5	O
when	when	ADV	WRB	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
initially	initially	ADV	RB	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Though	though	ADP	IN	5	O
this	this	DET	DT	5	O
fall	fall	NOUN	NN	5	O
would	would	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
wall	wall	NOUN	NN	5	O
tension	tension	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
therefore	therefore	ADV	RB	5	O
,	,	PUNCT	,	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
sufficient	sufficient	ADJ	JJ	9	O
magnitude	magnitude	NOUN	NN	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
a	a	DET	DT	5	O
net	net	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Nevertheless	nevertheless	ADV	RB	9	O
,	,	PUNCT	,	9	O
compensatory	compensatory	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
prevent	prevent	VERB	VBP	5	O
a	a	DET	DT	5	O
deterioration	deterioration	NOUN	NN	5	O
of	of	ADP	IN	5	O
resting	rest	VERB	VBG	5	O
myocardial	myocardial	ADJ	JJ	9	O
metabolism	metabolism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ocular	ocular	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
perfusion	perfusion	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
cultured	culture	VERB	VBN	3	O
human	human	ADJ	JJ	3	O
eyes	eye	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Glucocorticoid	Glucocorticoid	PROPN	NNP	9	O
administration	administration	NOUN	NN	9	O
can	can	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
ocular	ocular	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
corticosteroid	corticosteroid	ADJ	JJ	5	B-Disease
glaucoma	glaucoma	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
subset	subset	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
population	population	NOUN	NN	5	O
through	through	ADP	IN	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
aqueous	aqueous	ADJ	JJ	0	O
humor	humor	NOUN	NN	5	O
outflow	outflow	ADJ	JJ	5	O
facility	facility	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
glucocorticoid	glucocorticoid	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
can	can	VERB	MD	5	O
directly	directly	ADV	RB	9	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
outflow	outflow	ADJ	JJ	5	O
facility	facility	NOUN	NN	5	O
of	of	ADP	IN	5	O
isolated	isolated	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
perfusion	perfusion	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
cultured	culture	VERB	VBN	3	O
human	human	ADJ	JJ	3	O
eyes	eye	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
anterior	anterior	ADJ	JJ	5	O
segments	segment	NOUN	NNS	9	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
donor	donor	NOUN	NN	9	O
eyes	eye	NOUN	NNS	5	O
from	from	ADP	IN	9	O
regional	regional	ADJ	JJ	5	O
eye	eye	NOUN	NN	5	O
banks	bank	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
placed	place	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
constant	constant	ADJ	JJ	9	O
flow	flow	NOUN	NN	5	O
,	,	PUNCT	,	9	O
variable	variable	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
perfusion	perfusion	NOUN	NN	5	O
culture	culture	NOUN	NN	9	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Paired	pair	VERB	VBN	9	O
eyes	eye	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
perfused	perfuse	VERB	VBN	0	O
in	in	ADP	IN	5	O
serum	serum	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
media	medium	NOUN	NNS	9	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
M	m	NOUN	NN	9	O
dexamethasone	dexamethasone	ADJ	JJ	0	B-Chemical
for	for	ADP	IN	5	O
12	12	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Intraocular	intraocular	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
daily	daily	ADV	RB	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
incubation	incubation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
eyes	eye	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
morphologically	morphologically	ADV	RB	4	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
light	light	ADJ	JJ	9	O
microscopy	microscopy	NOUN	NN	9	O
,	,	PUNCT	,	9	O
transmission	transmission	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
scanning	scan	VERB	VBG	5	O
electron	electron	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
scanning	scan	VERB	VBG	5	O
laser	laser	ADJ	JJ	5	O
confocal	confocal	ADJ	JJ	3	O
microscopy	microscopy	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
intraocular	intraocular	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
developed	develop	VERB	VBN	5	O
in	in	ADP	IN	5	O
13	13	NUM	CD	7	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
44	44	NUM	CD	7	O
pairs	pair	NOUN	NNS	9	O
of	of	ADP	IN	5	O
eyes	eye	NOUN	NNS	5	O
perfused	perfuse	VERB	VBN	0	O
with	with	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
average	average	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
rise	rise	NOUN	NN	9	O
of	of	ADP	IN	5	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
after	after	ADP	IN	9	O
12	12	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
contralateral	contralateral	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
eyes	eye	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
receive	receive	VERB	VB	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
maintained	maintain	VERB	VBD	9	O
a	a	DET	DT	5	O
stable	stable	ADJ	JJ	9	O
intraocular	intraocular	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
outflow	outflow	NOUN	NN	5	O
pathway	pathway	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
untreated	untreated	ADJ	JJ	3	O
eyes	eye	NOUN	NNS	5	O
appeared	appear	VERB	VBD	9	O
morphologically	morphologically	ADV	RB	4	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treated	ADJ	JJ	3	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
eyes	eye	NOUN	NNS	5	I-Disease
had	have	VERB	VBD	9	O
thickened	thicken	VERB	VBN	5	O
trabecular	trabecular	ADJ	JJ	5	O
beams	beam	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
intertrabecular	intertrabecular	ADJ	JJ	5	O
spaces	space	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
thickened	thicken	VERB	VBD	5	O
juxtacanalicular	juxtacanalicular	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
,	,	PUNCT	,	9	O
activated	activate	VERB	VBD	3	O
trabecular	trabecular	ADJ	JJ	5	O
meshwork	meshwork	NOUN	NN	5	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
amorphogranular	amorphogranular	ADJ	JJ	_	O
extracellular	extracellular	ADJ	JJ	9	O
material	material	NOUN	NN	5	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
juxtacanalicular	juxtacanalicular	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
beneath	beneath	ADP	IN	5	O
the	the	DET	DT	5	O
endothelial	endothelial	ADJ	JJ	3	O
lining	lining	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
canal	canal	NOUN	NN	5	O
of	of	ADP	IN	5	O
Schlemm	Schlemm	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
nonresponder	nonresponder	NOUN	NN	9	O
eyes	eye	NOUN	NNS	5	O
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
morphologically	morphologically	ADV	RB	4	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
untreated	untreated	ADJ	JJ	3	O
eyes	eye	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
several	several	ADJ	JJ	9	O
subtle	subtle	ADJ	JJ	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
morphologic	morphologic	NOUN	NN	9	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
evident	evident	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Dexamethasone	dexamethasone	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
isolated	isolated	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
perfusion	perfusion	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
cultured	culture	VERB	VBN	3	O
human	human	ADJ	JJ	3	O
eyes	eye	NOUN	NNS	5	O
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
generation	generation	NOUN	NN	9	O
of	of	ADP	IN	5	O
ocular	ocular	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
eyes	eye	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Steroid	Steroid	PROPN	NNP	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
morphologic	morphologic	NOUN	NN	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
trabecular	trabecular	ADJ	JJ	5	O
meshwork	meshwork	NOUN	NN	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
reported	report	VERB	VBN	9	O
for	for	ADP	IN	5	O
corticosteroid	corticosteroid	ADJ	JJ	5	B-Disease
glaucoma	glaucoma	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
open	open	ADJ	JJ	5	B-Disease
angle	angle	NOUN	NN	5	I-Disease
glaucoma	glaucoma	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
system	system	NOUN	NN	5	O
may	may	VERB	MD	5	O
provide	provide	VERB	VB	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
model	model	NOUN	NN	5	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
pathogenic	pathogenic	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
steroid	steroid	NOUN	NN	9	B-Disease
glaucoma	glaucoma	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
primary	primary	ADJ	JJ	9	B-Disease
open	open	ADJ	JJ	5	I-Disease
angle	angle	NOUN	NN	5	I-Disease
glaucoma	glaucoma	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Auditory	auditory	NOUN	NN	5	O
disturbance	disturbance	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
interscalene	interscalene	ADJ	JJ	5	O
brachial	brachial	ADJ	JJ	5	O
plexus	plexus	NOUN	NN	9	O
block	block	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
performed	perform	VERB	VBD	9	O
an	an	DET	DT	5	O
audiometric	audiometric	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
20	20	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
surgery	surgery	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
shoulder	shoulder	NOUN	NN	5	O
region	region	NOUN	NN	9	O
under	under	ADP	IN	9	O
an	an	DET	DT	5	O
interscalene	interscalene	ADJ	JJ	5	O
brachial	brachial	ADJ	JJ	5	O
plexus	plexus	NOUN	NN	9	O
block	block	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
IBPB	IBPB	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Bupivacaine	Bupivacaine	PROPN	NNP	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
with	with	ADP	IN	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hr	hr	NOUN	NN	0	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
audiometric	audiometric	ADJ	JJ	5	O
threshold	threshold	NOUN	NN	5	O
measurements	measurement	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
-	-	SYM	SYM	7	O
18	18	NUM	CD	7	O
kHz	khz	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
before	before	ADP	IN	9	O
IBPB	IBPB	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
operation	operation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
hearing	hear	VERB	VBG	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
side	side	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
block	block	NOUN	NN	9	O
was	be	VERB	VBD	9	O
demonstrated	demonstrate	VERB	VBN	9	O
after	after	ADP	IN	9	O
operation	operation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
measurements	measurement	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
frequencies	frequency	NOUN	NNS	9	O
at	at	ADP	IN	9	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
impairment	impairment	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
varied	varied	ADJ	JJ	9	O
between	between	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
only	only	ADV	RB	9	O
low	low	ADJ	JJ	9	O
frequencies	frequency	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
kHz	khz	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
involved	involve	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
threshold	threshold	NOUN	NN	5	O
was	be	VERB	VBD	9	O
35	35	NUM	CD	9	O
dB	db	NUM	CD	5	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
kHz	khz	NOUN	NN	5	O
measured	measure	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
hearing	hear	VERB	VBG	5	O
threshold	threshold	NOUN	NN	5	O
changes	change	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
dB	db	NUM	CD	5	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
kHz	khz	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
opposite	opposite	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
also	also	ADV	RB	9	O
.	.	PUNCT	.	9	O

IBPB	IBPB	PROPN	NNP	1	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
transient	transient	ADJ	JJ	9	O
auditory	auditory	NOUN	NN	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ipsilateral	ipsilateral	ADJ	JJ	5	O
ear	ear	NOUN	NN	5	O
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
via	via	ADP	IN	9	O
an	an	DET	DT	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
innervation	innervation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
butyl	butyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
deoxynojirimycin	deoxynojirimycin	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
SC	SC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
48334	48334	NUM	CD	_	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
1	1	NUM	CD	9	I-Disease
infection	infection	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
200	200	NUM	CD	0	O
-	-	SYM	SYM	7	O
500	500	NUM	CD	0	O
CD4	CD4	PROPN	NNPS	3	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
mm3	mm3	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomized	ADJ	JJ	5	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
butyl	butyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
deoxynojirimycin	deoxynojirimycin	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
SC	SC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
48334	48334	NUM	CD	_	I-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
an	an	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glucosidase	glucosidase	NOUN	NN	0	O
I	-PRON-	PRON	PRP	9	O
inhibitor	inhibitor	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
versus	versus	ADP	IN	9	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
200	200	NUM	CD	0	O
to	to	PART	TO	5	O
500	500	NUM	CD	0	O
CD4	cd4	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
mm3	mm3	NOUN	NNS	9	O
who	who	PRON	WP	5	O
tolerated	tolerate	VERB	VBD	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
received	receive	VERB	VBD	9	O
SC	SC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
48334	48334	NUM	CD	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
1000	1000	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
every	every	DET	DT	5	O
8	8	NUM	CD	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
zidovudine	zidovudine	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
every	every	DET	DT	5	O
8	8	NUM	CD	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Sixty	sixty	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
58	58	NUM	CD	7	O
,	,	PUNCT	,	9	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
38	38	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
discontinued	discontinue	VERB	VBN	5	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
15	15	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
SC	SC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
48334	48334	NUM	CD	_	I-Chemical
steady	steady	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
state	state	NOUN	NN	5	O
trough	trough	NOUN	NN	9	O
level	level	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
99	99	NUM	CD	7	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
below	below	ADP	IN	9	O
the	the	DET	DT	5	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
inhibitory	inhibitory	ADJ	JJ	3	O
concentration	concentration	NOUN	NN	0	O
for	for	ADP	IN	5	O
human	human	ADJ	JJ	3	O
immunodeficiency	immunodeficiency	NOUN	NN	9	B-Disease
virus	virus	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HIV	HIV	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
CD4	CD4	PROPN	NNP	3	O
cells	cell	NOUN	NNS	3	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
4	4	NUM	CD	9	O
was	be	VERB	VBD	9	O
73	73	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
mm3	mm3	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
52	52	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
mm3	mm3	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
36	36	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
CD4	CD4	PROPN	NNP	3	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
groups	group	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
63	63	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
mm3	mm3	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
mm3	mm3	NOUN	NN	9	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
8	8	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
mm3	mm3	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
45	45	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
cells	cell	NOUN	NNS	3	O
/	/	SYM	SYM	9	O
mm3	mm3	NOUN	NN	9	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
16	16	NUM	CD	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
suppression	suppression	NOUN	NN	9	O
of	of	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	O
p24	p24	NOUN	NN	3	O
antigenemia	antigenemia	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
groups	group	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
six	six	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
4	4	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	X	XX	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
five	five	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
45	45	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
24	24	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
08	08	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Diarrhea	diarrhea	NOUN	NN	7	B-Disease
,	,	PUNCT	,	9	O
flatulence	flatulence	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
abdominal	abdominal	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
weight	weight	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
were	be	VERB	VBD	9	O
common	common	ADJ	JJ	5	O
for	for	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Prolonged	prolong	VERB	VBN	9	O
paralysis	paralysis	NOUN	NN	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
nondepolarizing	nondepolarize	VERB	VBG	5	B-Chemical
neuromuscular	neuromuscular	ADJ	JJ	5	I-Chemical
blocking	block	VERB	VBG	3	I-Chemical
agents	agent	NOUN	NNS	5	I-Chemical
and	and	CCONJ	CC	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
nondepolarizing	nondepolarize	VERB	VBG	5	B-Chemical
neuromuscular	neuromuscular	ADJ	JJ	5	I-Chemical
blocking	block	VERB	VBG	3	I-Chemical
agents	agent	NOUN	NNS	5	I-Chemical
(	(	PUNCT	-LRB-	9	O
ND	ND	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NMBA	NMBA	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
recently	recently	ADV	RB	9	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
prolonged	prolonged	ADJ	JJ	9	O
muscle	muscle	NOUN	NN	9	B-Disease
weakness	weakness	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
site	site	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lesion	lesion	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
predisposing	predispose	VERB	VBG	5	O
factors	factor	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
age	age	NOUN	NN	5	O
37	37	NUM	CD	9	O
-	-	SYM	SYM	7	O
52	52	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
prolonged	prolong	VERB	VBN	9	O
weakness	weakness	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
ND	ND	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NMBAs	nmba	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
also	also	ADV	RB	9	O
received	receive	VERB	VBD	9	O
intravenous	intravenous	ADJ	JJ	0	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
but	but	CCONJ	CC	9	O
hepatic	hepatic	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
impaired	impair	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
had	have	VERB	VBD	9	O
acidosis	acidosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Electrophysiologic	electrophysiologic	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
low	low	ADJ	JJ	9	O
amplitude	amplitude	NOUN	NN	5	O
compound	compound	NOUN	NN	0	O
motor	motor	NOUN	NN	5	O
action	action	NOUN	NN	5	O
potentials	potential	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
normal	normal	ADJ	JJ	9	O
sensory	sensory	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
fibrillations	fibrillation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Repetitive	repetitive	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
Hz	Hz	PROPN	NNP	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
decremental	decremental	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
vecuronium	vecuronium	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
patient	patient	ADJ	JJ	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
discontinued	discontinue	VERB	VBN	5	O
was	be	VERB	VBD	9	O
172	172	NUM	CD	7	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
muscle	muscle	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
thick	thick	ADJ	JJ	9	I-Disease
,	,	PUNCT	,	9	I-Disease
myosin	myosin	ADJ	JJ	3	I-Disease
filaments	filament	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
weakness	weakness	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
pathology	pathology	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	I-Disease
both	both	CCONJ	CC	9	I-Disease
the	the	DET	DT	5	I-Disease
neuromuscular	neuromuscular	ADJ	JJ	5	I-Disease
junction	junction	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
most	most	ADV	RBS	9	O
likely	likely	ADV	RB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
ND	ND	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NMBA	NMBA	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
muscle	muscle	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
most	most	ADV	RBS	9	O
likely	likely	ADV	RB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Hepatic	hepatic	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
acidosis	acidosis	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
contributing	contribute	VERB	VBG	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Failure	failure	NOUN	NN	5	O
of	of	ADP	IN	5	O
ancrod	ancrod	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
arterial	arterial	ADJ	JJ	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
morbidity	morbidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
remain	remain	VERB	VBP	9	O
high	high	ADJ	JJ	9	O
despite	despite	ADP	IN	9	O
numerous	numerous	ADJ	JJ	9	O
empirical	empirical	ADJ	JJ	5	O
therapies	therapy	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ancrod	Ancrod	PROPN	NNP	3	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
successfully	successfully	ADV	RB	5	O
for	for	ADP	IN	5	O
prophylaxis	prophylaxis	NOUN	NN	5	O
against	against	ADP	IN	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
heparin	heparin	ADJ	JJ	0	B-Chemical
induced	induce	VERB	VBN	3	O
platelet	platelet	NOUN	NN	9	B-Disease
aggregation	aggregation	NOUN	NN	9	I-Disease
who	who	PRON	WP	5	O
require	require	VERB	VBP	5	O
brief	brief	ADJ	JJ	5	O
reexposure	reexposure	NOUN	NN	3	O
to	to	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
its	-PRON-	DET	PRP$	9	O
success	success	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
developed	develop	VERB	VBN	5	O
the	the	DET	DT	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
syndrome	syndrome	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
well	well	ADV	RB	9	O
defined	define	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
failure	failure	NOUN	NN	5	O
of	of	ADP	IN	5	O
ancrod	ancrod	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Water	water	NOUN	NN	0	B-Disease
intoxication	intoxication	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
oxytocin	oxytocin	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
during	during	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
abortion	abortion	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
water	water	NOUN	NN	0	B-Disease
intoxication	intoxication	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
connection	connection	NOUN	NN	5	O
with	with	ADP	IN	5	O
oxytocin	oxytocin	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
during	during	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
abortions	abortion	NOUN	NNS	5	B-Disease
are	be	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
water	water	NOUN	NN	0	B-Disease
intoxication	intoxication	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
discussed	discuss	VERB	VBN	5	O
in	in	ADP	IN	5	O
regard	regard	NOUN	NN	5	O
to	to	ADP	IN	5	O
these	these	DET	DT	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Oxytocin	oxytocin	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
during	during	ADP	IN	5	O
midtrimester	midtrimester	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
abortions	abortion	NOUN	NNS	5	B-Disease
is	be	VERB	VBZ	5	O
advocated	advocate	VERB	VBN	5	O
only	only	ADV	RB	9	O
if	if	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
under	under	ADP	IN	9	O
careful	careful	ADJ	JJ	5	O
observations	observation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
alert	alert	ADJ	JJ	5	O
nursing	nursing	NOUN	NN	5	O
staff	staff	NOUN	NN	5	O
,	,	PUNCT	,	9	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
water	water	NOUN	NN	0	B-Disease
intoxication	intoxication	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
instructed	instruct	VERB	VBN	5	O
to	to	PART	TO	5	O
watch	watch	VERB	VB	5	O
the	the	DET	DT	5	O
diuresis	diuresis	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
report	report	VERB	VB	5	O
such	such	ADJ	JJ	5	O
early	early	ADJ	JJ	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
as	as	ADP	IN	5	O
asthenia	asthenia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
muscular	muscular	ADJ	JJ	5	O
irritability	irritability	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
headaches	headache	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
oxytocin	oxytocin	NOUN	NN	5	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
given	give	VERB	VBN	5	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
Ringers	ringer	NOUN	NNS	0	O
lactate	lactate	VERB	VBP	0	B-Chemical
or	or	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
alternately	alternately	ADV	RB	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
Ringers	ringer	NOUN	NNS	0	O
lactate	lactate	VERB	VBP	0	B-Chemical
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
5	5	NUM	CD	9	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
dextrose	dextrose	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
water	water	NOUN	NN	0	O
solutions	solution	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
urinary	urinary	ADJ	JJ	9	O
output	output	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
monitored	monitor	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
oxytocin	oxytocin	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
discontinued	discontinue	VERB	VBD	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
electrolytes	electrolyte	NOUN	NNS	0	O
checked	check	VERB	VBD	9	O
if	if	ADP	IN	5	O
the	the	DET	DT	5	O
urinary	urinary	ADJ	JJ	9	O
output	output	NOUN	NN	5	O
decreases	decrease	VERB	VBZ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
oxytocin	oxytocin	NOUN	NN	5	B-Chemical
should	should	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
excess	excess	NOUN	NN	9	O
of	of	ADP	IN	5	O
36	36	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

If	if	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
aborted	abort	VERB	VBN	5	O
by	by	ADP	IN	9	O
then	then	ADV	RB	9	O
the	the	DET	DT	5	O
oxytocin	oxytocin	NOUN	NN	5	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
discontinued	discontinue	VERB	VBN	5	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
to	to	PART	TO	5	O
12	12	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
perform	perform	VERB	VB	5	O
electrolyte	electrolyte	NOUN	NN	0	O
determinations	determination	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
correct	correct	VERB	VB	5	O
any	any	DET	DT	5	O
electrolyte	electrolyte	NOUN	NN	0	O
imbalance	imbalance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Light	light	ADJ	JJ	9	O
chain	chain	NOUN	NN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
cellular	cellular	ADJ	JJ	3	O
mediated	mediate	VERB	VBN	3	O
immunity	immunity	NOUN	NN	3	O
in	in	ADP	IN	5	O
rifampin	rifampin	NOUN	NN	0	B-Chemical
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
tuberculosis	tuberculosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Light	light	ADJ	JJ	9	O
chain	chain	NOUN	NN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
9	9	NUM	CD	7	O
of	of	ADP	IN	5	O
17	17	NUM	CD	7	O
tuberculosis	tuberculosis	NOUN	NN	9	B-Disease
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
rifampin	rifampin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Concomitant	concomitant	ADJ	JJ	9	O
assay	assay	NOUN	NN	3	O
of	of	ADP	IN	5	O
cellular	cellular	ADJ	JJ	3	O
mediated	mediate	VERB	VBN	3	O
immunity	immunity	NOUN	NN	3	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
using	use	VERB	VBG	9	O
skin	skin	NOUN	NN	5	O
test	test	NOUN	NN	5	O
antigen	antigen	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
lymphokine	lymphokine	NOUN	NN	3	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
test	test	NOUN	NN	5	O
provided	provide	VERB	VBD	9	O
results	result	NOUN	NNS	9	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
different	different	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Response	response	NOUN	NN	5	O
to	to	ADP	IN	5	O
Varidase	Varidase	PROPN	NNP	0	O
skin	skin	NOUN	NN	5	O
test	test	NOUN	NN	5	O
antigen	antigen	NOUN	NN	3	O
was	be	VERB	VBD	9	O
negative	negative	ADJ	JJ	9	O
for	for	ADP	IN	5	O
all	all	DET	DT	5	O
eight	eight	NUM	CD	9	O
tuberculosis	tuberculosis	NOUN	NN	9	B-Disease
patients	patient	NOUN	NNS	5	O
tested	test	VERB	VBN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
there	there	ADV	EX	5	O
occurred	occur	VERB	VBD	9	O
a	a	DET	DT	5	O
hyper	hyper	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
responsiveness	responsiveness	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lymphocytes	lymphocyte	NOUN	NNS	3	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
to	to	PART	TO	5	O
phytomitogen	phytomitogen	VERB	VB	9	O
(	(	PUNCT	-LRB-	9	O
PHA	PHA	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
P	P	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
of	of	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
seven	seven	NUM	CD	9	O
other	other	ADJ	JJ	5	O
tuberculous	tuberculous	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
last	last	ADJ	JJ	5	O
finding	finding	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
testing	testing	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
endogenous	endogenous	ADJ	JJ	3	O
serum	serum	NOUN	NN	9	O
binding	bind	VERB	VBG	1	O
of	of	ADP	IN	5	O
rifampin	rifampin	NOUN	NN	0	B-Chemical
which	which	DET	WDT	5	O
could	could	VERB	MD	9	O
have	have	VERB	VB	5	O
inhibited	inhibit	VERB	VBN	3	O
mitogen	mitogen	NOUN	NN	3	O
activity	activity	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
lymphocyte	lymphocyte	NOUN	NN	3	O
.	.	PUNCT	.	9	O

KF17837	kf17837	NOUN	NN	9	B-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
selective	selective	ADJ	JJ	9	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
A2A	A2A	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
with	with	ADP	IN	5	O
anticataleptic	anticataleptic	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

KF17837	KF17837	PROPN	NNP	9	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
selective	selective	ADJ	JJ	9	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
A2A	A2A	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
KF17837	KF17837	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
significantly	significantly	ADV	RB	9	O
ameliorated	ameliorate	VERB	VBD	9	O
the	the	DET	DT	5	O
cataleptic	cataleptic	ADJ	JJ	5	B-Disease
responses	response	NOUN	NNS	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
intracerebroventricular	intracerebroventricular	ADJ	JJ	3	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
A2A	A2A	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
CGS	CGS	PROPN	NNP	9	B-Chemical
21680	21680	NUM	CD	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

KF17837	KF17837	PROPN	NNP	9	B-Chemical
also	also	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
anticataleptic	anticataleptic	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
exhibited	exhibit	VERB	VBN	9	O
dose	dose	NOUN	NN	9	O
dependently	dependently	ADV	RB	3	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
from	from	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
625	625	NUM	CD	7	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
KF17837	KF17837	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
625	625	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
potentiated	potentiate	VERB	VBD	3	O
the	the	DET	DT	5	O
anticataleptic	anticataleptic	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
subthreshold	subthreshold	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroxyphenylalanine	dihydroxyphenylalanine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DOPA	DOPA	PROPN	NNP	0	I-Chemical
;	;	PUNCT	:	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
plus	plus	CCONJ	CC	9	O
benserazide	benserazide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
KF17837	KF17837	PROPN	NNP	9	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
centrally	centrally	ADV	RB	5	O
active	active	ADJ	JJ	9	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
A2A	A2A	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
nigrostriatal	nigrostriatal	ADJ	JJ	3	O
pathway	pathway	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
potentiated	potentiate	VERB	VBN	3	O
by	by	ADP	IN	9	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
A2A	A2A	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
KF17837	KF17837	PROPN	NNP	9	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
parkinsonism	parkinsonism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
nondopaminergic	nondopaminergic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
on	on	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
MPTP	MPTP	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
monkeys	monkey	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
monkeys	monkey	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
rendered	render	VERB	VBN	9	O
parkinsonian	parkinsonian	ADV	RB	5	B-Disease
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
toxin	toxin	NOUN	NN	1	O
MPTP	MPTP	PROPN	NNP	3	B-Chemical
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
chronically	chronically	ADV	RB	9	O
with	with	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DOPA	DOPA	PROPN	NNP	0	I-Chemical
/	/	SYM	SYM	9	I-Chemical
benserazide	benserazide	VERB	VB	0	I-Chemical
50	50	NUM	CD	0	O
/	/	SYM	SYM	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
given	give	VERB	VBN	5	O
orally	orally	ADV	RB	0	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
dose	dose	NOUN	NN	9	O
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
striking	striking	ADJ	JJ	9	O
antiparkinsonian	antiparkinsonian	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
all	all	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
manifested	manifest	VERB	VBD	9	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
agents	agent	NOUN	NNS	5	O
acting	act	VERB	VBG	9	O
primarily	primarily	ADV	RB	9	O
on	on	ADP	IN	5	O
neurotransmitters	neurotransmitter	NOUN	NNS	9	O
other	other	ADJ	JJ	5	O
than	than	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DOPA	DOPA	PROPN	NNP	0	I-Chemical
to	to	PART	TO	5	O
see	see	VERB	VB	9	O
if	if	ADP	IN	5	O
the	the	DET	DT	5	O
dyskinetic	dyskinetic	ADJ	JJ	5	B-Disease
movements	movement	NOUN	NNS	5	O
would	would	VERB	MD	5	O
be	be	VERB	VB	5	O
modified	modify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Several	several	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
physostigmine	physostigmine	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
methysergide	methysergide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
-	-	SYM	SYM	7	I-Chemical
MDOT	mdot	NOUN	NN	5	I-Chemical
,	,	PUNCT	,	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
,	,	PUNCT	,	9	O
markedly	markedly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
dyskinetic	dyskinetic	ADJ	JJ	5	B-Disease
movements	movement	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
cost	cost	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
return	return	NOUN	NN	5	O
of	of	ADP	IN	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
symptomatology	symptomatology	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
meperidine	meperidine	NOUN	NN	0	B-Chemical
reduced	reduce	VERB	VBD	9	O
predominantly	predominantly	ADV	RB	9	O
the	the	DET	DT	5	O
dyskinetic	dyskinetic	ADJ	JJ	5	B-Disease
movements	movement	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Baclofen	Baclofen	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
monkey	monkey	NOUN	NN	9	O
against	against	ADP	IN	9	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
dystonic	dystonic	ADJ	JJ	5	B-Disease
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Atropine	Atropine	PROPN	NNP	0	B-Chemical
converted	convert	VERB	VBD	9	O
the	the	DET	DT	5	O
dystonic	dystonic	ADJ	JJ	5	B-Disease
movements	movement	NOUN	NNS	5	O
into	into	ADP	IN	9	O
chorea	chorea	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Hallucinations	hallucination	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Hallucinations	hallucination	NOUN	NNS	5	B-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
symptom	symptom	NOUN	NN	5	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
are	be	VERB	VBP	5	O
a	a	DET	DT	5	O
known	know	VERB	VBN	9	O
but	but	CCONJ	CC	9	O
poorly	poorly	ADV	RB	9	O
described	describe	VERB	VBN	9	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Most	Most	ADJ	JJS	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hallucinations	hallucination	NOUN	NNS	5	B-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
changes	change	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
interviewed	interview	VERB	VBD	5	O
six	six	NUM	CD	9	O
persons	person	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hallucinations	hallucination	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
clear	clear	ADJ	JJ	9	O
sensorium	sensorium	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplant	transplant	NOUN	NN	9	O
procedure	procedure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Hallucinations	hallucination	NOUN	NNS	5	B-Disease
occurred	occur	VERB	VBD	9	O
only	only	ADV	RB	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
eyes	eye	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
closed	closed	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
but	but	ADP	IN	9	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
as	as	ADP	IN	5	O
disturbing	disturbing	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
frightening	frightening	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Underreporting	underreporte	VERB	VBG	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
hallucinations	hallucination	NOUN	NNS	5	B-Disease
by	by	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
likely	likely	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Hallucinations	hallucination	NOUN	NNS	5	B-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
sole	sole	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
first	first	ADJ	JJ	9	O
manifestation	manifestation	NOUN	NN	5	O
of	of	ADP	IN	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
dose	dose	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
infusion	infusion	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
related	relate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinician	clinician	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
alerted	alert	VERB	VBN	5	O
for	for	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hallucinations	hallucination	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
occur	occur	VERB	VB	5	O
without	without	ADP	IN	9	O
other	other	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

"	"	PUNCT	``	5	O
Eyes	eye	NOUN	NNS	5	O
-	-	PUNCT	HYPH	7	O
closed	close	VERB	VBN	5	O
"	"	PUNCT	``	5	O
hallucinatory	hallucinatory	ADJ	JJ	5	B-Disease
experiences	experience	NOUN	NNS	5	O
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
feature	feature	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
presentation	presentation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
anxious	anxious	ADJ	JJ	5	O
about	about	ADP	IN	5	O
this	this	DET	DT	5	O
experience	experience	NOUN	NN	5	O
respond	respond	NOUN	NN	5	O
well	well	ADV	RB	9	O
to	to	PART	TO	5	O
support	support	VERB	VB	5	O
and	and	CCONJ	CC	5	O
education	education	NOUN	NN	5	O
about	about	ADP	IN	5	O
this	this	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Optimal	optimal	ADJ	JJ	5	O
pharmacologic	pharmacologic	NOUN	NN	9	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
disturbed	disturb	VERB	VBN	5	O
patients	patient	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

If	if	ADP	IN	5	O
agitation	agitation	NOUN	NN	5	B-Disease
becomes	become	VERB	VBZ	5	O
marked	mark	VERB	VBN	9	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
potency	potency	NOUN	NN	9	O
neuroleptics	neuroleptic	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
effective	effective	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Photodistributed	photodistribute	VERB	VBN	_	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
facial	facial	ADJ	JJ	5	O
telangiectasia	telangiectasia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
starting	start	VERB	VBG	9	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Adalat	Adalat	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
photodistributed	photodistribute	VERB	VBN	5	O
facial	facial	ADJ	JJ	5	O
telangiectasia	telangiectasia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
became	become	VERB	VBD	9	O
more	more	ADV	RBR	5	O
noticeable	noticeable	ADJ	JJ	9	O
with	with	ADP	IN	5	O
time	time	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neither	neither	DET	DT	9	O
patient	patient	NOUN	NN	5	O
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
photosensitivity	photosensitivity	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
flushing	flushing	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
reported	report	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
cosmetic	cosmetic	ADJ	JJ	5	O
improvement	improvement	NOUN	NN	5	O
after	after	ADP	IN	9	O
discontinuing	discontinue	VERB	VBG	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
commenced	commence	VERB	VBD	5	O
the	the	DET	DT	5	O
closely	closely	ADV	RB	9	O
related	related	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
telangiectasia	telangiectasia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
photodistribution	photodistribution	NOUN	NN	_	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
telangiectasia	telangiectasia	NOUN	NN	9	B-Disease
suggests	suggest	VERB	VBZ	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
/	/	SYM	SYM	9	O
light	light	ADJ	JJ	9	O
interaction	interaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Penicillamine	penicillamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rapidly	rapidly	ADV	RB	9	O
progressive	progressive	ADJ	JJ	5	O
glomerulonephritis	glomerulonephritis	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
67	67	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
presented	present	VERB	VBD	5	O
rapidly	rapidly	ADV	RB	9	O
progressive	progressive	ADJ	JJ	5	O
glomerulonephritis	glomerulonephritis	ADJ	JJ	3	B-Disease
(	(	PUNCT	-LRB-	9	O
RPGN	RPGN	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
5	5	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
250	250	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Light	light	ADJ	JJ	9	O
microscopy	microscopy	NOUN	NN	9	O
study	study	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
severe	severe	ADJ	JJ	5	O
glomerulonephritis	glomerulonephritis	ADJ	JJ	3	B-Disease
with	with	ADP	IN	5	O
crescent	crescent	ADJ	JJ	5	O
formation	formation	NOUN	NN	9	O
in	in	ADP	IN	5	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glomeruli	glomeruli	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
infiltration	infiltration	NOUN	NN	3	O
of	of	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
wall	wall	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
arteriole	arteriole	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Immunofluorescence	immunofluorescence	NOUN	NN	3	O
revealed	reveal	VERB	VBD	9	O
scanty	scanty	NUM	CD	9	O
granular	granular	NOUN	NN	9	O
IgG	igg	NOUN	NN	3	O
,	,	PUNCT	,	9	O
IgA	IgA	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
C3	C3	PROPN	NNP	9	O
deposits	deposit	NOUN	NNS	9	O
along	along	ADP	IN	9	O
the	the	DET	DT	5	O
capillary	capillary	ADJ	JJ	0	O
walls	wall	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
mesangium	mesangium	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
pulse	pulse	NOUN	NN	5	O
,	,	PUNCT	,	9	O
plasmapheresis	plasmapheresis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
antiplatelet	antiplatelet	NOUN	NN	5	B-Chemical
agents	agent	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
complete	complete	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
achieved	achieve	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
new	new	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
RPGN	RPGN	PROPN	NNP	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
D	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
emphasizes	emphasize	VERB	VBZ	5	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
frequent	frequent	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
sediment	sediment	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
proteinuria	proteinuria	VERB	VB	9	B-Disease
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
prompt	prompt	ADJ	JJ	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
vigorous	vigorous	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
measures	measure	NOUN	NNS	5	O
could	could	VERB	MD	9	O
allow	allow	VERB	VB	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
good	good	ADJ	JJ	5	O
prognosis	prognosis	NOUN	NN	5	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
polymyositis	polymyositis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
primary	primary	ADJ	JJ	9	B-Disease
biliary	biliary	ADJ	JJ	5	I-Disease
cirrhosis	cirrhosis	NOUN	NN	5	I-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
D	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
many	many	ADJ	JJ	5	O
rheumatologic	rheumatologic	NOUN	NN	5	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
limits	limit	VERB	VBZ	5	O
its	-PRON-	DET	PRP$	9	O
usefulness	usefulness	NOUN	NN	5	O
in	in	ADP	IN	5	O
many	many	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Polymyositis	Polymyositis	PROPN	NNP	7	B-Disease
/	/	SYM	SYM	9	O
dermatomyositis	dermatomyositis	NOUN	NN	5	B-Disease
can	can	VERB	MD	5	O
develop	develop	VERB	VB	5	O
as	as	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
autoimmune	autoimmune	ADJ	JJ	3	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
its	-PRON-	DET	PRP$	9	O
exact	exact	ADJ	JJ	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
remains	remain	VERB	VBZ	9	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
primary	primary	ADJ	JJ	9	B-Disease
biliary	biliary	ADJ	JJ	5	I-Disease
cirrhosis	cirrhosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
polymyositis	polymyositis	NOUN	NN	9	B-Disease
while	while	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
described	describe	VERB	VBD	9	O
the	the	DET	DT	5	O
special	special	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
followed	follow	VERB	VBN	9	O
carefully	carefully	ADV	RB	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
autoimmune	autoimmune	ADJ	JJ	3	O
complications	complication	NOUN	NNS	5	O
like	like	ADP	IN	9	O
polymyositis	polymyositis	NOUN	NN	9	B-Disease
/	/	SYM	SYM	9	O
dermatomyositis	dermatomyositis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Hyperalgesia	hyperalgesia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
terminal	terminal	ADJ	JJ	9	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
intravenous	intravenous	ADJ	JJ	0	O
morphine	morphine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
terminal	terminal	ADJ	JJ	9	O
stages	stage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
disease	disease	NOUN	NN	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
morphine	morphine	NOUN	NN	0	B-Chemical
developed	develop	VERB	VBD	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
cases	case	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
retrospectively	retrospectively	ADV	RB	5	O
sampled	sample	VERB	VBN	5	O
from	from	ADP	IN	9	O
three	three	NUM	CD	9	O
different	different	ADJ	JJ	9	O
hospitals	hospital	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Copenhagen	Copenhagen	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
universal	universal	ADJ	JJ	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
hyperesthesia	hyperesthesia	NOUN	NN	5	B-Disease
which	which	DET	WDT	5	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
a	a	DET	DT	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
existing	exist	VERB	VBG	5	O
neuralgia	neuralgia	NOUN	NN	5	B-Disease
increased	increase	VERB	VBD	9	O
to	to	ADP	IN	5	O
excruciating	excruciate	VERB	VBG	5	O
intensity	intensity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
cases	case	NOUN	NNS	5	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
occurred	occur	VERB	VBD	9	O
simultaneously	simultaneously	ADV	RB	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
only	only	ADJ	JJ	9	O
few	few	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
descriptions	description	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
/	/	SYM	SYM	9	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
available	available	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
experimental	experimental	ADJ	JJ	5	O
support	support	NOUN	NN	5	O
from	from	ADP	IN	9	O
animal	animal	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
indicates	indicate	VERB	VBZ	9	O
that	that	DET	DT	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
metabolites	metabolite	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
causative	causative	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
observed	observed	ADJ	JJ	9	O
behavioural	behavioural	ADJ	JJ	5	O
syndrome	syndrome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
proposals	proposal	NOUN	NNS	5	O
given	give	VERB	VBN	5	O
suggesting	suggest	VERB	VBG	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
more	more	ADV	RBR	5	O
efficacious	efficacious	ADJ	JJ	5	O
opioids	opioid	NOUN	NNS	5	O
with	with	ADP	IN	5	O
less	less	ADJ	JJR	5	O
excitatory	excitatory	ADJ	JJ	5	O
potency	potency	NOUN	NN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
situations	situation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Liposomal	Liposomal	PROPN	NNP	0	O
daunorubicin	daunorubicin	VERB	VBP	0	B-Chemical
in	in	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
Kaposi	Kaposi	PROPN	NNPS	9	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
sarcoma	sarcoma	NOUN	NN	9	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
randomized	randomized	ADJ	JJ	5	O
Phase	Phase	PROPN	NNP	9	O
II	II	PROPN	NNP	9	O
clinical	clinical	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
liposomal	liposomal	ADJ	JJ	0	O
daunorubicin	daunorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DaunoXome	DaunoXome	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
related	relate	VERB	VBD	9	O
Kaposi	Kaposi	PROPN	NNP	9	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
sarcoma	sarcoma	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Eleven	eleven	NUM	CD	9	O
homosexual	homosexual	ADJ	JJ	5	O
men	man	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
Kaposi	Kaposi	PROPN	NNPS	9	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
sarcoma	sarcoma	NOUN	NN	9	I-Disease
were	be	VERB	VBD	9	O
entered	enter	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
size	size	NOUN	NN	9	O
,	,	PUNCT	,	9	O
colour	colour	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
associated	associate	VERB	VBN	9	O
oedema	oedema	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
selected	select	VERB	VBN	9	O
'	'	PART	POS	9	O
target	target	NOUN	NN	9	O
'	'	PUNCT	''	9	O
lesions	lesion	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
biochemical	biochemical	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
haematological	haematological	ADJ	JJ	5	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Ten	ten	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
achieved	achieve	VERB	VBN	5	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
,	,	PUNCT	,	9	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
two	two	NUM	CD	5	O
subsequently	subsequently	ADV	RB	9	O
relapsed	relapse	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Stabilization	stabilization	NOUN	NN	9	O
of	of	ADP	IN	5	O
Kaposi	Kaposi	PROPN	NNP	9	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
sarcoma	sarcoma	NOUN	NN	9	I-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
six	six	NUM	CD	9	O
,	,	PUNCT	,	9	O
maintained	maintain	VERB	VBN	9	O
until	until	ADP	IN	5	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
trial	trial	NOUN	NN	5	O
period	period	NOUN	NN	5	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
generally	generally	ADV	RB	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
few	few	ADJ	JJ	5	O
mild	mild	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
problem	problem	NOUN	NN	5	O
encountered	encounter	VERB	VBD	5	O
was	be	VERB	VBD	9	O
haematological	haematological	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
three	three	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
experiencing	experience	VERB	VBG	5	O
severe	severe	ADJ	JJ	5	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
neutrophil	neutrophil	NOUN	NN	3	O
count	count	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
l	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
small	small	ADJ	JJ	9	O
patient	patient	ADJ	JJ	5	O
sample	sample	NOUN	NN	9	O
,	,	PUNCT	,	9	O
liposomal	liposomal	ADJ	JJ	0	O
daunorubicin	daunorubicin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
agent	agent	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
Kaposi	Kaposi	PROPN	NNP	9	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
sarcoma	sarcoma	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
vincristine	vincristine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Non	Non	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Hodgkin	Hodgkin	PROPN	NNP	5	I-Disease
'	'	PUNCT	''	9	I-Disease
s	s	VERB	VBZ	9	I-Disease
Lymphoma	Lymphoma	PROPN	NNP	2	I-Disease
treated	treat	VERB	VBD	3	O
with	with	ADP	IN	5	O
vincristine	vincristine	NOUN	NN	0	B-Chemical
between	between	ADP	IN	5	O
1984	1984	NUM	CD	2	O
and	and	CCONJ	CC	5	O
1990	1990	NUM	CD	2	O
(	(	PUNCT	-LRB-	9	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
in	in	ADP	IN	5	O
18	18	NUM	CD	7	O
-	-	SYM	SYM	7	O
24	24	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
term	term	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
vincristine	vincristine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
interviewed	interview	VERB	VBN	5	O
with	with	ADP	IN	5	O
emphasis	emphasis	NOUN	NN	5	O
on	on	ADP	IN	5	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Physical	physical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
quantitative	quantitative	ADJ	JJ	9	O
sensory	sensory	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
with	with	ADP	IN	5	O
determination	determination	NOUN	NN	9	O
of	of	ADP	IN	5	O
vibratory	vibratory	NOUN	NN	5	O
perception	perception	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
thermal	thermal	ADJ	JJ	9	O
discrimination	discrimination	NOUN	NN	5	O
thresholds	threshold	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
,	,	PUNCT	,	9	O
four	four	NUM	CD	9	O
to	to	PART	TO	5	O
77	77	NUM	CD	7	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
median	median	ADJ	JJ	9	O
34	34	NUM	CD	7	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
vincristine	vincristine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
seven	seven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
reported	report	VERB	VBD	9	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
13	13	NUM	CD	7	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
27	27	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
symptoms	symptom	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
still	still	ADV	RB	5	O
present	present	ADJ	JJ	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
examination	examination	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
sensory	sensory	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
predominated	predominate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
14	14	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
symptoms	symptom	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
past	past	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Symptoms	symptom	NOUN	NNS	5	O
persisted	persist	VERB	VBD	9	O
maximally	maximally	ADV	RB	9	O
40	40	NUM	CD	9	O
months	month	NOUN	NNS	5	O
since	since	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
age	age	NOUN	NN	5	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
complaints	complaint	NOUN	NNS	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
examination	examination	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Normal	normal	ADJ	JJ	9	O
reflexes	reflex	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
third	third	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Neuropathic	neuropathic	ADJ	JJ	5	O
complaints	complaint	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
very	very	ADV	RB	5	O
troublesome	troublesome	ADJ	JJ	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
term	term	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
above	above	ADV	RB	9	O
mentioned	mention	VERB	VBN	5	O
vincristine	vincristine	ADJ	JJ	0	B-Chemical
dose	dose	NOUN	NN	9	O
schedule	schedule	NOUN	NN	5	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
vincristine	vincristine	ADJ	JJ	0	B-Chemical
neuropathy	neuropathy	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
reversible	reversible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
great	great	ADJ	JJ	5	O
deal	deal	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
prognosis	prognosis	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
fairly	fairly	ADV	RB	5	O
good	good	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Hepatic	hepatic	ADJ	JJ	9	O
adenomas	adenoma	NOUN	NNS	9	B-Disease
and	and	CCONJ	CC	5	O
focal	focal	ADJ	JJ	5	B-Disease
nodular	nodular	ADJ	JJ	5	I-Disease
hyperplasia	hyperplasia	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
on	on	ADP	IN	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
:	:	PUNCT	:	9	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
adenoma	adenoma	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
focal	focal	ADJ	JJ	5	B-Disease
nodular	nodular	ADJ	JJ	5	I-Disease
hyperplasia	hyperplasia	NOUN	NN	9	I-Disease
presumably	presumably	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Special	special	ADJ	JJ	2	O
reference	reference	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
made	make	VERB	VBN	5	O
to	to	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
clinical	clinical	ADJ	JJ	5	O
presentation	presentation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
totally	totally	ADV	RB	9	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
of	of	ADP	IN	5	O
little	little	ADJ	JJ	9	O
diagnostic	diagnostic	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
valuable	valuable	ADJ	JJ	5	O
information	information	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
obtained	obtain	VERB	VBN	9	O
from	from	ADP	IN	9	O
both	both	DET	DT	9	O
liver	liver	NOUN	NN	9	O
scanning	scanning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
hepatic	hepatic	ADJ	JJ	9	O
angiography	angiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Histologic	histologic	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
similarities	similarity	NOUN	NNS	9	O
between	between	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
adenoma	adenoma	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
focal	focal	ADJ	JJ	5	B-Disease
nodular	nodular	ADJ	JJ	5	I-Disease
hyperplasia	hyperplasia	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
decarboxylase	decarboxylase	NOUN	NN	1	O
mRNA	mRNA	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
situ	situ	ADJ	JJ	9	O
hybridization	hybridization	NOUN	NN	9	O
methods	method	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
glutamic	glutamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
decarboxylase	decarboxylase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
GAD	GAD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
mRNA	mRNA	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
neurons	neuron	NOUN	NNS	3	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
hilus	hilus	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
are	be	VERB	VBP	5	O
vulnerable	vulnerable	ADJ	JJ	5	O
to	to	PART	TO	5	O
seizure	seizure	VERB	VB	5	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
damage	damage	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
with	with	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
formation	formation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
histologically	histologically	ADV	RB	9	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
week	week	NOUN	NN	9	O
intervals	interval	NOUN	NNS	5	O
after	after	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
situ	situ	ADJ	JJ	9	O
hybridization	hybridization	NOUN	NN	9	O
histochemistry	histochemistry	NOUN	NN	9	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
digoxigenin	digoxigenin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
labeled	label	VERB	VBN	3	O
GAD	GAD	PROPN	NNP	9	O
cRNA	cRNA	PROPN	NNP	0	O
probe	probe	NOUN	NN	9	O
,	,	PUNCT	,	9	O
demonstrated	demonstrate	VERB	VBD	9	O
a	a	DET	DT	5	O
substantial	substantial	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
GAD	GAD	PROPN	NNP	9	O
mRNA	mRNA	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hilus	hilus	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
at	at	ADP	IN	9	O
all	all	DET	DT	5	O
time	time	NOUN	NN	5	O
intervals	interval	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Additional	additional	ADJ	JJ	9	O
neuronanatomical	neuronanatomical	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
cresyl	cresyl	NOUN	NN	0	B-Chemical
violet	violet	NOUN	NN	0	I-Chemical
staining	staining	NOUN	NN	3	O
,	,	PUNCT	,	9	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
degeneration	degeneration	NOUN	NN	9	I-Disease
methods	method	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
histochemical	histochemical	ADJ	JJ	9	O
localization	localization	NOUN	NN	3	O
of	of	ADP	IN	5	O
glial	glial	ADJ	JJ	3	O
fibrillary	fibrillary	ADJ	JJ	3	O
acidic	acidic	ADJ	JJ	0	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
GAD	GAD	PROPN	NNP	9	O
mRNA	mRNA	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
neurons	neuron	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
loss	loss	NOUN	NN	9	I-Disease
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
GAD	GAD	PROPN	NNP	9	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
GAD	GAD	PROPN	NNP	9	O
mRNA	mRNA	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hilus	hilus	NOUN	NN	3	O
contrasted	contrast	VERB	VBN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
preservation	preservation	NOUN	NN	9	O
of	of	ADP	IN	5	O
labeled	label	VERB	VBN	3	O
putative	putative	ADJ	JJ	1	O
basket	basket	NOUN	NN	5	O
cells	cell	NOUN	NNS	3	O
along	along	ADP	IN	9	O
the	the	DET	DT	5	O
inner	inner	ADJ	JJ	9	O
margin	margin	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
granule	granule	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
layer	layer	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Quantitative	quantitative	ADJ	JJ	9	O
analyses	analyse	VERB	VBZ	9	O
of	of	ADP	IN	5	O
labeled	label	VERB	VBN	3	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
regions	region	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
week	week	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
GAD	GAD	PROPN	NNP	9	O
mRNA	mRNA	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hilus	hilus	NOUN	NN	3	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
layer	layer	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
granule	granule	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
layer	layer	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
included	include	VERB	VBD	5	O
labeled	label	VERB	VBN	3	O
neurons	neuron	NOUN	NNS	3	O
along	along	ADP	IN	9	O
the	the	DET	DT	5	O
lower	low	ADJ	JJR	9	O
margin	margin	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
granule	granule	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
layer	layer	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
subpopulation	subpopulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
GAD	GAD	PROPN	NNP	9	O
mRNA	mRNA	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
neurons	neuron	NOUN	NNS	3	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
selectively	selectively	ADV	RB	3	O
vulnerable	vulnerable	ADJ	JJ	5	O
to	to	ADP	IN	5	O
seizure	seizure	VERB	VB	5	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
differential	differential	ADJ	JJ	9	O
vulnerability	vulnerability	NOUN	NN	5	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
another	another	DET	DT	9	O
indication	indication	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
heterogeneity	heterogeneity	NOUN	NN	9	O
of	of	ADP	IN	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
neurons	neuron	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
deliberate	deliberate	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
labetalol	labetalol	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
neuropsychological	neuropsychological	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
deliberate	deliberate	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
function	function	NOUN	NN	9	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
neuropsychological	neuropsychological	ADJ	JJ	5	O
tests	test	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
41	41	NUM	CD	7	O
adult	adult	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
anaesthetized	anaesthetize	VERB	VBN	0	O
for	for	ADP	IN	5	O
middle	middle	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
ear	ear	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
with	with	ADP	IN	5	O
deliberate	deliberate	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
labetalol	labetalol	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Seventeen	seventeen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
served	serve	VERB	VBD	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
77	77	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
mmHg	mmhg	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
kPa	kpa	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
before	before	ADP	IN	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
mmHg	mmhg	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
kPa	kpa	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
86	86	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
mmHg	mmhg	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
kPa	kpa	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
psychological	psychological	ADJ	JJ	5	O
tests	test	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
:	:	PUNCT	:	9	O
four	four	NUM	CD	9	O
subtests	subtest	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Wechsler	Wechsler	PROPN	NNP	5	O
Adult	Adult	PROPN	NNP	9	O
Intelligence	Intelligence	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
similarities	similarity	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
digit	digit	NOUN	NN	5	O
span	span	NOUN	NN	9	O
,	,	PUNCT	,	9	O
vocabulary	vocabulary	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
digit	digit	NOUN	NN	5	O
symbol	symbol	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
Trail	Trail	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Making	Making	PROPN	NNP	5	O
tests	test	NOUN	NNS	5	O
A	a	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
B	B	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
Zung	Zung	PROPN	NNP	5	O
tests	test	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
rating	rate	VERB	VBG	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
scale	scale	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
rating	rate	VERB	VBG	5	O
depression	depression	NOUN	NN	5	B-Disease
scale	scale	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
part	part	NOUN	NN	9	O
memory	memory	NOUN	NN	5	O
test	test	NOUN	NN	5	O
battery	battery	NOUN	NN	5	O
with	with	ADP	IN	5	O
immediate	immediate	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
delayed	delay	VERB	VBN	9	O
recall	recall	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
tests	test	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
preoperatively	preoperatively	ADV	RB	5	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
postoperatively	postoperatively	ADV	RB	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
groups	group	NOUN	NNS	9	O
in	in	ADP	IN	5	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
tests	test	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
from	from	ADP	IN	9	O
preoperative	preoperative	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
to	to	PART	TO	5	O
postoperative	postoperative	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
labetalol	labetalol	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
harmful	harmful	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
mental	mental	ADJ	JJ	5	O
functions	function	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
normotensive	normotensive	ADJ	JJ	9	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Apparent	apparent	ADJ	JJ	9	O
cure	cure	NOUN	NN	5	O
of	of	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
by	by	ADP	IN	9	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
sustained	sustained	ADJ	JJ	5	O
remissions	remission	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
possible	possible	ADJ	JJ	5	O
cure	cure	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
erosive	erosive	ADJ	JJ	5	O
rheumatoid	rheumatoid	NOUN	NN	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
RA	RA	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
by	by	ADP	IN	9	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
BMT	BMT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

BMT	BMT	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
severe	severe	ADJ	JJ	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
gold	gold	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
D	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
8	8	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
years	year	NOUN	NNS	5	O
since	since	ADP	IN	9	O
the	the	DET	DT	5	O
transplants	transplant	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
representing	represent	VERB	VBG	9	O
8	8	NUM	CD	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
years	year	NOUN	NNS	5	O
since	since	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
RA	RA	PROPN	NNP	9	B-Disease
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
case	case	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
completely	completely	ADV	RB	9	O
quiescent	quiescent	ADJ	JJ	3	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
short	short	ADJ	JJ	5	O
term	term	NOUN	NN	5	O
remission	remission	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
RA	RA	PROPN	NNP	9	B-Disease
following	follow	VERB	VBG	9	O
BMT	BMT	PROPN	NNP	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
cases	case	NOUN	NNS	5	O
for	for	ADP	IN	5	O
which	which	DET	WDT	5	O
prolonged	prolong	VERB	VBN	9	O
followup	followup	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
available	available	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
experience	experience	NOUN	NN	5	O
raises	raise	VERB	VBZ	9	O
the	the	DET	DT	5	O
question	question	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
BMT	BMT	PROPN	NNP	9	O
itself	-PRON-	PRON	PRP	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
option	option	NOUN	NN	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
uncontrolled	uncontrolled	ADJ	JJ	5	O
destructive	destructive	ADJ	JJ	5	O
synovitis	synovitis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Seizures	seizure	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
combined	combined	ADJ	JJ	9	O
levomepromazine	levomepromazine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
fluvoxamine	fluvoxamine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
combined	combine	VERB	VBN	9	O
levomepromazine	levomepromazine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
fluvoxamine	fluvoxamine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
seems	seem	VERB	VBZ	5	O
that	that	ADP	IN	5	O
combined	combine	VERB	VBN	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
fluvoxamine	fluvoxamine	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
phenothiazines	phenothiazine	NOUN	NNS	0	B-Chemical
may	may	VERB	MD	5	O
possess	possess	VERB	VB	9	O
proconvulsive	proconvulsive	ADJ	JJ	3	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
:	:	PUNCT	:	9	O
pentamidine	pentamidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
polymorphic	polymorphic	ADJ	JJ	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
revisited	revisit	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Pentamidine	pentamidine	ADJ	JJ	0	B-Chemical
isethionate	isethionate	NOUN	NN	0	I-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachyarrhythmias	tachyarrhythmia	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
article	article	NOUN	NN	6	O
reports	report	VERB	VBZ	9	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
reviews	review	VERB	VBZ	5	O
all	all	DET	DT	5	O
reported	report	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
to	to	ADP	IN	5	O
date	date	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pentamidine	pentamidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
torsade	torsade	NOUN	NN	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
serum	serum	VERB	VB	9	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
hypomagnesemia	hypomagnesemia	NOUN	NN	5	B-Disease
may	may	VERB	MD	5	O
synergistically	synergistically	ADV	RB	9	O
induce	induce	VERB	VB	3	O
torsade	torsade	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Torsade	Torsade	PROPN	NNP	2	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
an	an	DET	DT	5	O
average	average	NOUN	NN	5	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
pentamidine	pentamidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
acute	acute	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
pentamidine	pentamidine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Torsade	Torsade	PROPN	NNP	2	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
treated	treat	VERB	VBN	3	O
when	when	ADV	WRB	5	O
recognized	recognize	VERB	VBN	9	O
early	early	ADV	RB	9	O
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
without	without	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
pentamidine	pentamidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
QTc	qtc	ADJ	JJ	5	B-Disease
interval	interval	ADJ	JJ	5	I-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
observed	observe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
early	early	ADJ	JJ	9	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
supplementation	supplementation	NOUN	NN	0	O
is	be	VERB	VBZ	5	O
advocated	advocate	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Efficacy	efficacy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
3390	3390	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
moderate	moderate	ADJ	JJ	9	O
hypercholesterolemia	hypercholesterolemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
moderate	moderate	ADJ	JJ	9	O
hypercholesterolemia	hypercholesterolemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
Expanded	Expanded	PROPN	NNP	5	O
Clinical	Clinical	PROPN	NNP	5	O
Evaluation	Evaluation	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Lovastatin	Lovastatin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
EXCEL	EXCEL	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
Study	Study	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
diet	diet	NOUN	NN	9	O
-	-	PUNCT	,	7	O
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
participants	participant	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
placebo	placebo	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
or	or	CCONJ	CC	5	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
once	once	ADV	RB	5	O
daily	daily	ADV	RB	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
20	20	NUM	CD	9	O
or	or	CCONJ	CC	5	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
twice	twice	ADV	RB	9	O
daily	daily	ADJ	JJ	5	O
for	for	ADP	IN	5	O
48	48	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

SETTING	set	VERB	VBG	2	O
:	:	PUNCT	:	9	O
Ambulatory	ambulatory	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
recruited	recruit	VERB	VBN	9	O
by	by	ADP	IN	9	O
362	362	NUM	CD	7	O
participating	participate	VERB	VBG	5	O
centers	center	NOUN	NNS	5	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
States	States	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Women	Women	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
3390	3390	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
cohort	cohort	NOUN	NN	9	O
of	of	ADP	IN	5	O
8245	8245	NUM	CD	7	O
volunteers	volunteer	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

MEASUREMENTS	measurement	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Plasma	plasma	VERB	VB	0	O
total	total	NOUN	NN	9	O
,	,	PUNCT	,	9	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
density	density	NOUN	NN	9	O
lipoprotein	lipoprotein	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
LDL	LDL	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
density	density	NOUN	NN	9	O
lipoprotein	lipoprotein	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HDL	HDL	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
triglycerides	triglyceride	NOUN	NNS	9	B-Chemical
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
monitored	monitor	VERB	VBD	9	O
periodically	periodically	ADV	RB	5	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Among	among	ADP	IN	9	O
women	woman	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
to	to	PART	TO	5	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
produced	produce	VERB	VBN	9	O
sustained	sustained	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
48	48	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
changes	change	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
LDL	LDL	PROPN	NNP	0	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
triglycerides	triglyceride	NOUN	NNS	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
18	18	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
HDL	HDL	PROPN	NNP	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Depending	depend	VERB	VBG	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
from	from	ADP	IN	9	O
82	82	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
women	woman	NOUN	NNS	5	O
achieved	achieve	VERB	VBD	5	O
the	the	DET	DT	5	O
National	National	PROPN	NNP	2	O
Cholesterol	Cholesterol	PROPN	NNP	7	B-Chemical
Education	Education	PROPN	NNP	2	O
Program	Program	PROPN	NNP	2	O
goal	goal	NOUN	NN	5	O
of	of	ADP	IN	5	O
LDL	LDL	PROPN	NNP	0	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
14	14	NUM	CD	7	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
160	160	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
87	87	NUM	CD	7	O
%	%	NOUN	NN	9	O
achieved	achieve	VERB	VBD	5	O
the	the	DET	DT	5	O
goal	goal	NOUN	NN	5	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
36	36	NUM	CD	9	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
130	130	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Successive	successive	ADJ	JJ	5	O
transaminase	transaminase	NOUN	NN	0	O
elevations	elevation	VERB	VBZ	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
the	the	DET	DT	5	O
upper	upper	ADJ	JJ	9	O
limit	limit	NOUN	NN	5	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
dependent	dependent	ADJ	JJ	9	O
above	above	ADP	IN	9	O
the	the	DET	DT	5	O
20	20	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Myopathy	Myopathy	PROPN	NNP	7	B-Disease
,	,	PUNCT	,	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	O
symptoms	symptom	NOUN	NNS	5	O
with	with	ADP	IN	5	O
creatine	creatine	NOUN	NN	0	B-Chemical
kinase	kinase	NOUN	NN	3	O
elevations	elevation	NOUN	NNS	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
10	10	NUM	CD	9	O
times	time	NOUN	NNS	5	O
the	the	DET	DT	5	O
upper	upper	ADJ	JJ	9	O
limit	limit	NOUN	NN	5	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
rare	rare	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
recommended	recommend	VERB	VBN	5	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Estrogen	estrogen	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
replacement	replacement	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
either	either	CCONJ	CC	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
profile	profile	NOUN	NN	9	O
of	of	ADP	IN	5	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Lovastatin	Lovastatin	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
highly	highly	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
generally	generally	ADV	RB	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
as	as	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
hypercholesterolemia	hypercholesterolemia	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Tetany	tetany	NOUN	NN	2	B-Disease
and	and	CCONJ	CC	5	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
surreptitious	surreptitious	ADJ	JJ	5	O
furosemide	furosemide	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
importance	importance	NOUN	NN	5	O
of	of	ADP	IN	5	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
supplementation	supplementation	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Diuretics	diuretic	NOUN	NNS	7	O
may	may	VERB	MD	5	O
induce	induce	VERB	VB	3	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hypocalcemia	hypocalcemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hypomagnesemia	hypomagnesemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
severe	severe	ADJ	JJ	5	O
hypokalemia	hypokalemia	NOUN	NNS	5	B-Disease
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
muscle	muscle	NOUN	NN	9	B-Disease
weakness	weakness	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
severe	severe	ADJ	JJ	5	O
hypomagnesemia	hypomagnesemia	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	B-Disease
spasms	spasm	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
tetany	tetany	NOUN	NN	5	B-Disease
which	which	DET	WDT	5	O
cannot	cannot	NOUN	NN	5	O
be	be	VERB	VB	5	O
corrected	correct	VERB	VBN	5	O
by	by	ADP	IN	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
supplementation	supplementation	NOUN	NN	0	O
alone	alone	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Surreptitious	surreptitious	ADJ	JJ	9	O
diuretic	diuretic	ADJ	JJ	5	O
ingestion	ingestion	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
mainly	mainly	ADV	RB	9	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
concerned	concerned	ADJ	JJ	5	O
that	that	ADP	IN	5	O
they	-PRON-	PRON	PRP	5	O
are	be	VERB	VBP	5	O
obese	obese	ADJ	JJ	9	B-Disease
or	or	CCONJ	CC	5	O
edematous	edematous	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

Symptomatic	symptomatic	ADJ	JJ	5	O
hypokalemia	hypokalemia	NOUN	NN	5	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
such	such	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
hypocalcemia	hypocalcemia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
depletion	depletion	NOUN	NN	3	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ciprofloxacin	Ciprofloxacin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Nephrotoxicity	nephrotoxicity	NOUN	NN	0	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
ciprofloxacin	ciprofloxacin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
uncommon	uncommon	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
followed	follow	VERB	VBD	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
ciprofloxacin	ciprofloxacin	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
15	15	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
are	be	VERB	VBP	5	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
than	than	ADP	IN	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
characteristic	characteristic	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
abnormal	abnormal	ADJ	JJ	9	O
laboratory	laboratory	NOUN	NN	9	O
findings	finding	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
frequently	frequently	ADV	RB	5	O
present	present	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Allergic	allergic	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
believed	believe	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
pathological	pathological	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
process	process	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Definitive	definitive	ADJ	JJ	2	O
diagnosis	diagnosis	NOUN	NN	5	O
requires	require	VERB	VBZ	5	O
performance	performance	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
biopsy	biopsy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
always	always	ADV	RB	5	O
feasible	feasible	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
that	that	DET	WDT	5	O
followed	follow	VERB	VBD	9	O
the	the	DET	DT	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
offending	offend	VERB	VBG	5	O
antibiotic	antibiotic	NOUN	NN	5	O
supports	support	VERB	VBZ	9	O
the	the	DET	DT	5	O
presumptive	presumptive	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
ciprofloxacin	ciprofloxacin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Venous	venous	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
of	of	ADP	IN	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
versus	versus	ADP	IN	9	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
some	some	DET	DT	5	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
suggested	suggest	VERB	VBN	9	O
fewer	few	ADJ	JJR	5	O
venous	venous	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
are	be	VERB	VBP	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
than	than	ADP	IN	5	O
with	with	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
endoscopic	endoscopic	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
variable	variable	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
well	well	ADV	RB	9	O
documented	document	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
prospectively	prospectively	ADV	RB	5	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
after	after	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
122	122	NUM	CD	7	O
consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
colonoscopy	colonoscopy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
esophagogastroduodenoscopy	esophagogastroduodenoscopy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Overall	overall	ADV	RB	9	O
,	,	PUNCT	,	9	O
venous	venous	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
with	with	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
of	of	ADP	IN	5	O
62	62	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
with	with	ADP	IN	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
of	of	ADP	IN	5	O
60	60	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
palpable	palpable	ADJ	JJ	5	O
venous	venous	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
23	23	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
of	of	ADP	IN	5	O
62	62	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
60	60	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Pain	pain	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
site	site	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
of	of	ADP	IN	5	O
62	62	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
of	of	ADP	IN	5	O
60	60	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Swelling	swell	VERB	VBG	0	B-Disease
and	and	CCONJ	CC	5	O
warmth	warmth	NOUN	NN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
site	site	NOUN	NN	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Smoking	smoking	NOUN	NN	7	O
,	,	PUNCT	,	9	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
drug	drug	NOUN	NN	5	O
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
intravenous	intravenous	ADJ	JJ	0	O
catheter	catheter	NOUN	NN	5	O
site	site	NOUN	NN	9	O
,	,	PUNCT	,	9	O
dwell	dwell	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
needle	needle	NOUN	NN	5	O
,	,	PUNCT	,	9	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Clarithromycin	Clarithromycin	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
visual	visual	ADJ	JJ	5	B-Disease
hallucinations	hallucination	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
on	on	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
ambulatory	ambulatory	ADJ	JJ	5	O
peritoneal	peritoneal	ADJ	JJ	3	O
dialysis	dialysis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Visual	visual	ADJ	JJ	5	B-Disease
hallucinations	hallucination	NOUN	NNS	5	I-Disease
are	be	VERB	VBP	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
not	not	ADV	RB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
uremia	uremia	ADJ	JJ	5	B-Disease
per	per	ADP	IN	9	O
se	se	X	FW	9	O
.	.	PUNCT	.	9	O

Unreported	unreported	ADJ	JJ	7	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
visual	visual	ADJ	JJ	5	B-Disease
hallucinations	hallucination	NOUN	NNS	5	I-Disease
occurring	occur	VERB	VBG	9	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
new	new	ADJ	JJ	5	O
macrolide	macrolide	NOUN	NN	9	B-Chemical
antibiotic	antibiotic	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
clarithromycin	clarithromycin	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
such	such	DET	PDT	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
maintained	maintain	VERB	VBN	9	O
on	on	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
ambulatory	ambulatory	ADJ	JJ	5	O
peritoneal	peritoneal	ADJ	JJ	3	O
dialysis	dialysis	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CAPD	CAPD	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
relatively	relatively	ADV	RB	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
clarithromycin	clarithromycin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
face	face	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
functionally	functionally	ADV	RB	9	O
anephric	anephric	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
underlying	underlie	VERB	VBG	5	O
aluminum	aluminum	NOUN	NN	0	B-Chemical
intoxication	intoxication	NOUN	NN	9	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
facilitated	facilitate	VERB	VBN	5	O
the	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
important	important	ADJ	JJ	9	O
to	to	PART	TO	5	O
understand	understand	VERB	VB	5	O
the	the	DET	DT	5	O
pharmacokinetics	pharmacokinetic	NOUN	NNS	9	O
of	of	ADP	IN	5	O
medications	medication	NOUN	NNS	5	O
in	in	ADP	IN	5	O
face	face	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
interactions	interaction	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
how	how	ADV	WRB	5	O
these	these	DET	DT	5	O
factors	factor	NOUN	NNS	9	O
should	should	VERB	MD	5	O
help	help	VERB	VB	5	O
guide	guide	VERB	VB	5	O
medication	medication	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
peroxisomes	peroxisome	NOUN	NNS	9	O
in	in	ADP	IN	5	O
preneoplastic	preneoplastic	ADJ	JJ	3	O
liver	liver	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
hepatoma	hepatoma	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
benzene	benzene	NOUN	NN	0	I-Chemical
hexachloride	hexachloride	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Peroxisomes	peroxisome	NOUN	NNS	0	O
in	in	ADP	IN	5	O
hepatomas	hepatomas	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
hyperplastic	hyperplastic	ADJ	JJ	3	O
preneoplastic	preneoplastic	ADJ	JJ	3	O
liver	liver	NOUN	NN	9	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
by	by	ADP	IN	9	O
500	500	NUM	CD	0	O
ppm	ppm	NOUN	NNS	0	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
benzene	benzene	NOUN	NN	0	I-Chemical
hexachloride	hexachloride	NOUN	NNS	0	I-Chemical
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
histochemically	histochemically	ADV	RB	3	O
and	and	CCONJ	CC	5	O
electron	electron	VERB	VB	0	O
microscopically	microscopically	ADV	RB	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
most	most	ADJ	JJS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hepatomas	hepatomas	NOUN	NN	3	B-Disease
were	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
differentiated	differentiate	VERB	VBN	3	O
tumors	tumor	NOUN	NNS	3	B-Disease
and	and	CCONJ	CC	5	O
contained	contain	VERB	VBD	9	O
a	a	DET	DT	5	O
considerable	considerable	ADJ	JJ	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
peroxisomes	peroxisome	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
tumor	tumor	NOUN	NN	3	B-Disease
cells	cell	NOUN	NNS	3	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
respond	respond	VERB	VB	5	O
to	to	ADP	IN	5	O
ethyl	ethyl	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chlorophenoxyisobutyrate	chlorophenoxyisobutyrate	NOUN	NN	0	I-Chemical
with	with	ADP	IN	5	O
proliferation	proliferation	NOUN	NN	3	O
of	of	ADP	IN	5	O
peroxisomes	peroxisome	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
16th	16th	ADJ	JJ	5	O
week	week	NOUN	NN	9	O
of	of	ADP	IN	5	O
carcinogen	carcinogen	NOUN	NN	0	O
feeding	feeding	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hyperplastic	hyperplastic	ADJ	JJ	3	O
nodules	nodule	NOUN	NNS	9	O
appeared	appear	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
advanced	advance	VERB	VBD	5	O
to	to	ADP	IN	5	O
further	further	ADJ	JJ	9	O
stages	stage	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
majority	majority	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
nodules	nodule	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
considerable	considerable	ADJ	JJ	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
peroxisomes	peroxisome	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
inductive	inductive	ADJ	JJ	5	O
proliferation	proliferation	NOUN	NN	3	O
of	of	ADP	IN	5	O
peroxisomes	peroxisome	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Within	within	ADP	IN	9	O
the	the	DET	DT	5	O
nodules	nodule	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
foci	foci	NOUN	NN	9	O
of	of	ADP	IN	5	O
proliferation	proliferation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cells	cell	NOUN	NNS	3	O
that	that	DET	WDT	5	O
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
inducibility	inducibility	NOUN	NN	3	O
of	of	ADP	IN	5	O
proliferation	proliferation	NOUN	NN	3	O
of	of	ADP	IN	5	O
peroxisomes	peroxisome	NOUN	NNS	9	O
appeared	appear	VERB	VBD	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
cells	cell	NOUN	NNS	3	O
proliferated	proliferate	VERB	VBD	3	O
further	further	ADV	RB	9	O
,	,	PUNCT	,	9	O
replacing	replace	VERB	VBG	9	O
the	the	DET	DT	5	O
most	most	ADJ	JJS	9	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
nodules	nodule	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
process	process	NOUN	NN	5	O
hepatomas	hepatomas	NOUN	NN	3	B-Disease
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
formed	form	VERB	VBN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
abnormal	abnormal	ADJ	JJ	9	O
matrical	matrical	ADJ	JJ	5	O
inclusions	inclusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
peroxisomes	peroxisome	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
formed	form	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cells	cell	NOUN	NNS	3	O
of	of	ADP	IN	5	O
hyperplastic	hyperplastic	ADJ	JJ	3	O
nodules	nodule	NOUN	NNS	9	O
by	by	ADP	IN	9	O
ethyl	ethyl	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chlorophenoxyisobutyrate	chlorophenoxyisobutyrate	NOUN	NN	0	I-Chemical
unlike	unlike	ADP	IN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Contribution	contribution	NOUN	NN	6	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
to	to	PART	TO	5	O
salt	salt	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
sensitivity	sensitivity	NOUN	NN	9	O
in	in	ADP	IN	5	O
lifetime	lifetime	NOUN	NN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
test	test	VERB	VB	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	WDT	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
lifetime	lifetime	NOUN	NN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
SHR	SHR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
contributes	contribute	VERB	VBZ	9	O
importantly	importantly	ADV	RB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
dietary	dietary	ADJ	JJ	5	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
supplementation	supplementation	NOUN	NN	0	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Male	male	ADJ	JJ	7	O
SHR	SHR	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
aged	age	VERB	VBN	9	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
that	that	DET	WDT	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
from	from	ADP	IN	9	O
conception	conception	NOUN	NN	5	O
onward	onward	ADV	RB	9	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
captopril	captopril	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
vehicle	vehicle	NOUN	NN	3	O
remained	remain	VERB	VBD	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
basal	basal	NOUN	NN	3	O
sodium	sodium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
diet	diet	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
fed	feed	VERB	VBN	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
diet	diet	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
ganglionic	ganglionic	ADJ	JJ	3	O
blockade	blockade	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Lifetime	lifetime	NOUN	NN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
significantly	significantly	ADV	RB	9	O
lowered	lower	VERB	VBD	9	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ganglionic	ganglionic	ADJ	JJ	3	O
blocker	blocker	NOUN	NN	0	O
hexamethonium	hexamethonium	NOUN	NN	0	B-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
decline	decline	NOUN	NN	9	O
in	in	ADP	IN	5	O
MAP	MAP	PROPN	NNP	9	O
that	that	DET	WDT	5	O
eliminated	eliminate	VERB	VBD	9	O
the	the	DET	DT	5	O
dietary	dietary	ADJ	JJ	5	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
increase	increase	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
MAP	MAP	PROPN	NNP	9	I-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
alpha2	alpha2	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
adrenergic	adrenergic	NOUN	NN	9	I-Chemical
receptor	receptor	NOUN	NN	3	I-Chemical
agonist	agonist	NOUN	NN	3	I-Chemical
clonidine	clonidine	NOUN	NN	0	B-Chemical
also	also	ADV	RB	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
MAP	MAP	PROPN	NNP	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
SHR	SHR	PROPN	NNP	9	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
fed	feed	VERB	VBN	9	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
basal	basal	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
diet	diet	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
both	both	DET	DT	9	O
lifetime	lifetime	NOUN	NN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
control	control	VERB	VB	9	O
SHR	SHR	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
contributes	contribute	NOUN	NNS	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
pressor	pressor	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
diet	diet	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Angioedema	Angioedema	PROPN	NNP	5	B-Disease
associated	associate	VERB	VBD	9	O
with	with	ADP	IN	5	O
droperidol	droperidol	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Angioedema	Angioedema	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
also	also	ADV	RB	9	O
known	know	VERB	VBN	9	O
as	as	ADP	IN	5	O
angioneurotic	angioneurotic	ADJ	JJ	2	B-Disease
edema	edema	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
Quincke	Quincke	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
demarcated	demarcate	VERB	VBN	5	O
,	,	PUNCT	,	9	O
localized	localize	VERB	VBN	9	O
edema	edema	NOUN	NN	5	B-Disease
involving	involve	VERB	VBG	5	O
the	the	DET	DT	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
tissues	tissue	NOUN	NNS	9	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
upper	upper	ADJ	JJ	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
airway	airway	NOUN	NN	5	I-Disease
obstruction	obstruction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
previously	previously	ADV	RB	9	O
healthy	healthy	ADJ	JJ	5	O
19	19	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
known	know	VERB	VBN	9	O
drug	drug	NOUN	NN	5	B-Disease
allergies	allergy	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
angioedema	angioedema	VERB	VBP	5	B-Disease
with	with	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
tongue	tongue	NOUN	NN	5	B-Disease
swelling	swell	VERB	VBG	5	I-Disease
and	and	CCONJ	CC	5	O
protrusion	protrusion	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
within	within	ADP	IN	9	O
10	10	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
IV	iv	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
droperidol	droperidol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Late	late	ADJ	JJ	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
malignant	malignant	ADJ	JJ	3	O
bone	bone	NOUN	NN	5	B-Disease
tumor	tumor	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
survivors	survivor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
malignant	malignant	ADJ	JJ	3	O
bone	bone	NOUN	NN	5	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
Rosen	Rosen	PROPN	NNP	6	B-Chemical
'	'	PART	POS	9	I-Chemical
s	s	NOUN	NN	9	I-Chemical
T5	t5	NOUN	NN	9	I-Chemical
or	or	CCONJ	CC	5	I-Chemical
T10	t10	NOUN	NN	9	I-Chemical
protocol	protocol	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
including	include	VERB	VBG	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
age	age	NOUN	NN	5	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
45	45	NUM	CD	9	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
median	median	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
median	median	NOUN	NN	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
following	follow	VERB	VBG	9	O
completion	completion	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cumulative	cumulative	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
225	225	NUM	CD	9	O
-	-	SYM	SYM	7	O
550	550	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
(	(	PUNCT	-LRB-	9	O
median	median	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
360	360	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
evaluation	evaluation	NOUN	NN	5	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
,	,	PUNCT	,	9	O
physical	physical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
,	,	PUNCT	,	9	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ECG	ECG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
signal	signal	NOUN	NN	9	O
averaged	average	VERB	VBN	5	O
ECG	ECG	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
ambulatory	ambulatory	NOUN	NN	5	O
ECG	ECG	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
echocardiography	echocardiography	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
radionuclide	radionuclide	VERB	VB	5	O
angiography	angiography	ADV	RB	5	O
.	.	PUNCT	.	9	O

Eighteen	eighteen	NUM	CD	9	O
of	of	ADP	IN	5	O
31	31	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
58	58	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
having	have	VERB	VBG	5	O
one	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
abnormalities	abnormality	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
late	late	ADJ	JJ	9	O
potentials	potential	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
complex	complex	ADJ	JJ	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
dilation	dilation	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
shortening	shorten	VERB	VBG	9	O
fraction	fraction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
increased	increase	VERB	VBD	9	O
with	with	ADP	IN	5	O
length	length	NOUN	NN	9	O
of	of	ADP	IN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
correlation	correlation	NOUN	NN	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
demonstrated	demonstrate	VERB	VBN	9	O
between	between	ADP	IN	5	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
,	,	PUNCT	,	9	O
except	except	ADP	IN	9	O
for	for	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
variability	variability	NOUN	NN	5	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
adjusted	adjust	VERB	VBN	9	O
to	to	ADP	IN	5	O
body	body	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
area	area	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
posterior	posterior	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
thickness	thickness	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
LVPW	LVPW	PROPN	NNP	7	O
index	index	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
high	high	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
increases	increase	NOUN	NNS	9	O
with	with	ADP	IN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
,	,	PUNCT	,	9	O
irrespective	irrespective	ADV	RB	9	O
of	of	ADP	IN	5	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Life	life	NOUN	NN	2	O
-	-	PUNCT	HYPH	7	O
long	long	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
warranted	warrant	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
study	study	NOUN	NN	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
variability	variability	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
LVPW	LVPW	PROPN	NNP	7	O
index	index	NOUN	NN	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
sensitive	sensitive	ADJ	JJ	9	O
indicators	indicator	NOUN	NNS	5	O
for	for	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
elevations	elevation	NOUN	NNS	9	O
with	with	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
men	man	NOUN	NNS	5	O
with	with	ADP	IN	5	O
borderline	borderline	NOUN	NN	9	O
systemic	systemic	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
vasoconstrictive	vasoconstrictive	ADJ	JJ	5	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
enhanced	enhance	VERB	VBN	3	O
in	in	ADP	IN	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
persons	person	NOUN	NNS	5	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
demonstrated	demonstrate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
was	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
48	48	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
men	man	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
aged	age	VERB	VBN	9	O
20	20	NUM	CD	9	O
to	to	PART	TO	5	O
35	35	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
selected	select	VERB	VBN	9	O
after	after	ADP	IN	9	O
screening	screen	VERB	VBG	5	O
on	on	ADP	IN	5	O
2	2	NUM	CD	9	O
separate	separate	ADJ	JJ	9	O
occasions	occasion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Borderline	Borderline	PROPN	NNP	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
men	man	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
24	24	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
selected	select	VERB	VBN	9	O
with	with	ADP	IN	5	O
screening	screen	VERB	VBG	5	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BP	BP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
140	140	NUM	CD	9	O
to	to	PART	TO	5	O
160	160	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
diastolic	diastolic	ADJ	JJ	5	O
BP	BP	PROPN	NNP	9	O
90	90	NUM	CD	9	O
to	to	PART	TO	5	O
99	99	NUM	CD	7	O
mm	mm	NOUN	NNS	9	O
Hg	Hg	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

Low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
24	24	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
reported	report	VERB	VBD	9	O
no	no	DET	DT	9	O
parental	parental	ADJ	JJ	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
screening	screen	VERB	VBG	5	O
BP	BP	PROPN	NNP	9	O
<	<	X	XX	0	O
130	130	NUM	CD	9	O
/	/	SYM	SYM	9	O
85	85	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

Participants	participant	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
tested	test	VERB	VBN	9	O
on	on	ADP	IN	5	O
2	2	NUM	CD	9	O
occasions	occasion	NOUN	NNS	5	O
after	after	ADP	IN	9	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
abstinence	abstinence	NOUN	NN	5	O
from	from	ADP	IN	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
protocols	protocol	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
this	this	DET	DT	5	O
required	require	VERB	VBD	9	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
laboratory	laboratory	NOUN	NN	9	O
visits	visit	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Caffeine	caffeine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
diastolic	diastolic	ADJ	JJ	5	O
BP	BP	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
times	time	NOUN	NNS	5	O
larger	large	ADJ	JJR	5	O
in	in	ADP	IN	5	O
borderline	borderline	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
8	8	NUM	CD	9	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
+	+	X	XX	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
attributable	attributable	ADJ	JJ	9	O
to	to	PART	TO	5	O
larger	large	ADJ	JJR	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
impedance	impedance	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
derived	derive	VERB	VBN	9	O
measures	measure	NOUN	NNS	5	O
of	of	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
135	135	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
+	+	CCONJ	CC	9	O
45	45	NUM	CD	9	O
dynes	dyne	NOUN	NNS	0	O
.	.	PUNCT	.	9	O
s	s	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
cm	cm	NOUN	NNS	9	O
-	-	PUNCT	:	7	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
004	004	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
consistent	consistent	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
reached	reach	VERB	VBN	9	O
significance	significance	NOUN	NN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
protocols	protocol	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
borderline	borderline	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
diastolic	diastolic	ADJ	JJ	5	O
BP	BP	PROPN	NNP	9	O
changes	change	NOUN	NNS	9	O
exceeded	exceed	VERB	VBD	9	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
control	control	NOUN	NN	9	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
96	96	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Consequently	consequently	ADV	RB	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
all	all	DET	DT	5	O
participants	participant	NOUN	NNS	5	O
exhibited	exhibit	VERB	VBD	9	O
normotensive	normotensive	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
resting	rest	VERB	VBG	5	O
predrug	predrug	NOUN	NN	5	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
33	33	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
borderline	borderline	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
achieved	achieve	VERB	VBN	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
BP	BP	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
after	after	ADP	IN	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
ingestion	ingestion	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
borderline	borderline	NOUN	NN	9	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
men	man	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
exaggerated	exaggerated	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
:	:	PUNCT	:	9	O
selective	selective	ADJ	JJ	9	O
for	for	ADP	IN	5	O
diastolic	diastolic	ADJ	JJ	5	O
BP	BP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
greater	great	ADJ	JJR	5	O
vasoconstriction	vasoconstriction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
replicated	replicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
protocols	protocol	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
representative	representative	NOUN	NN	9	O
of	of	ADP	IN	5	O
nearly	nearly	ADV	RB	9	O
all	all	DET	DT	5	O
borderline	borderline	NOUN	NN	9	O
hypertensives	hypertensive	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suspect	suspect	VERB	VBP	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
for	for	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
stabilize	stabilize	VERB	VB	9	O
high	high	ADJ	JJ	9	O
resistance	resistance	NOUN	NN	9	O
states	state	NOUN	NNS	5	O
in	in	ADP	IN	5	O
susceptible	susceptible	ADJ	JJ	9	O
persons	person	NOUN	NNS	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
may	may	VERB	MD	5	O
facilitate	facilitate	VERB	VB	5	O
their	-PRON-	DET	PRP$	5	O
disease	disease	NOUN	NN	5	O
progression	progression	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
hinder	hind	ADJ	JJR	5	O
accurate	accurate	ADJ	JJ	5	O
diagnosis	diagnosis	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Absence	absence	NOUN	NN	9	O
of	of	ADP	IN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
sertraline	sertraline	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
sensitization	sensitization	NOUN	NN	9	O
of	of	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
study	study	NOUN	NN	9	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
alone	alone	ADV	RB	9	O
and	and	CCONJ	CC	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
plus	plus	CCONJ	CC	9	O
sertraline	sertraline	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
psychomotor	psychomotor	NOUN	NN	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
24	24	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
All	all	DET	DT	9	O
subjects	subject	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
placebo	placebo	NOUN	NN	9	O
on	on	ADP	IN	5	O
Day	day	NOUN	NN	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
on	on	ADP	IN	5	O
Days	day	NOUN	NNS	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
Days	day	NOUN	NNS	9	O
9	9	NUM	CD	7	O
to	to	ADP	IN	5	O
25	25	NUM	CD	9	O
,	,	PUNCT	,	9	O
subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
either	either	DET	DT	9	O
sertraline	sertraline	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
sertraline	sertraline	NOUN	NN	5	B-Chemical
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
titrated	titrate	VERB	VBN	0	O
from	from	ADP	IN	9	O
50	50	NUM	CD	0	O
to	to	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
from	from	ADP	IN	9	O
Days	Days	PROPN	NNP	9	O
9	9	NUM	CD	7	O
to	to	ADP	IN	5	O
16	16	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
remained	remain	VERB	VBD	9	O
at	at	ADP	IN	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
final	final	ADJ	JJ	9	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cognitive	cognitive	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
testing	testing	NOUN	NN	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
before	before	ADP	IN	9	O
dosing	dose	VERB	VBG	9	O
and	and	CCONJ	CC	5	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
period	period	NOUN	NN	5	O
after	after	ADP	IN	9	O
dosing	dose	VERB	VBG	9	O
on	on	ADP	IN	5	O
Days	Days	PROPN	NNP	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Impairment	impairment	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
cognitive	cognitive	ADJ	JJ	5	I-Disease
function	function	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
6	6	NUM	CD	9	O
to	to	PART	TO	5	O
8	8	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
Day	day	NOUN	NN	9	O
2	2	NUM	CD	9	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
evident	evident	ADJ	JJ	9	O
23	23	NUM	CD	7	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
dosing	dose	VERB	VBG	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
again	again	ADV	RB	9	O
25	25	NUM	CD	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
greater	great	ADJ	JJR	5	O
impairment	impairment	NOUN	NN	5	O
with	with	ADP	IN	5	O
earlier	early	ADJ	JJR	9	O
onset	onset	NOUN	NN	5	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
several	several	ADJ	JJ	9	O
tests	test	NOUN	NNS	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
indication	indication	NOUN	NN	5	O
that	that	ADP	IN	5	O
sertraline	sertraline	NOUN	NN	5	B-Chemical
exacerbated	exacerbate	VERB	VBD	9	O
the	the	DET	DT	5	O
impairment	impairment	NOUN	NN	5	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
since	since	ADP	IN	9	O
an	an	DET	DT	5	O
equivalent	equivalent	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
also	also	ADV	RB	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
on	on	ADP	IN	5	O
sertraline	sertraline	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
on	on	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
withdrew	withdraw	VERB	VBD	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Ten	ten	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
group	group	NOUN	NN	9	O
reported	report	VERB	VBD	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
profiles	profile	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sertraline	sertraline	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Haloperidol	Haloperidol	PROPN	NNP	7	B-Chemical
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
clear	clear	ADJ	JJ	9	O
profile	profile	NOUN	NN	9	O
of	of	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
worsened	worsen	VERB	VBN	5	O
by	by	ADP	IN	9	O
concomitant	concomitant	ADJ	JJ	9	O
sertraline	sertraline	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Coexistence	coexistence	NOUN	NN	5	O
of	of	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
venous	venous	ADJ	JJ	5	I-Disease
sinus	sinus	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
internal	internal	ADJ	JJ	5	I-Disease
carotid	carotid	ADJ	JJ	5	I-Disease
artery	artery	NOUN	NN	5	I-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
exogenous	exogenous	ADJ	JJ	3	O
sex	sex	NOUN	NN	5	O
hormones	hormone	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
forty	forty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
premenopausal	premenopausal	NOUN	NN	5	O
woman	woman	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
headache	headache	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
left	leave	VERB	VBD	5	O
hemiparesis	hemiparesis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
seizure	seizure	VERB	VB	5	B-Disease
two	two	NUM	CD	5	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
parenteral	parenteral	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
progesterone	progesterone	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

Diabetes	diabetes	NOUN	NN	7	B-Disease
mellitus	mellitus	PROPN	NNP	9	I-Disease
(	(	PUNCT	-LRB-	9	O
DM	DM	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
during	during	ADP	IN	5	O
admission	admission	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Computed	compute	VERB	VBN	5	O
tomography	tomography	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
infarct	infarct	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
frontal	frontal	ADJ	JJ	5	O
lobe	lobe	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
density	density	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
superior	superior	ADJ	JJ	5	O
sagittal	sagittal	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
SSS	SSS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Left	leave	VERB	VBN	9	O
carotid	carotid	ADJ	JJ	5	O
angiography	angiography	NOUN	NN	5	O
found	find	VERB	VBD	9	O
occlusion	occlusion	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
left	left	ADJ	JJ	5	I-Disease
internal	internal	ADJ	JJ	5	I-Disease
carotid	carotid	ADJ	JJ	5	I-Disease
artery	artery	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ICA	ICA	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Right	right	ADJ	JJ	9	O
carotid	carotid	ADJ	JJ	5	O
angiograms	angiogram	NOUN	NNS	5	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
show	show	VERB	VB	9	O
the	the	DET	DT	5	O
SSS	SSS	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
inferior	inferior	ADJ	JJ	5	O
sagittal	sagittal	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
,	,	PUNCT	,	9	O
suggestive	suggestive	NOUN	NN	9	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
sinus	sinus	NOUN	NN	5	I-Disease
thrombosis	thrombosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Coexistence	coexistence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
the	the	DET	DT	5	I-Disease
venous	venous	ADJ	JJ	5	I-Disease
sinus	sinus	NOUN	NN	5	I-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
infrequently	infrequently	ADV	RB	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
postulate	postulate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
and	and	CCONJ	CC	5	O
progesterone	progesterone	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
DM	DM	PROPN	NNP	9	B-Disease
increased	increase	VERB	VBD	9	O
vascular	vascular	ADJ	JJ	5	O
thrombogenicity	thrombogenicity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
provided	provide	VERB	VBD	9	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
denominator	denominator	NOUN	NN	5	O
for	for	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
both	both	CCONJ	CC	9	I-Disease
the	the	DET	DT	5	I-Disease
ICA	ICA	PROPN	NNP	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
the	the	DET	DT	5	I-Disease
venous	venous	ADJ	JJ	5	I-Disease
sinus	sinus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Chemotherapy	chemotherapy	NOUN	NN	9	O
of	of	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
inoperable	inoperable	ADJ	JJ	5	O
non	non	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
small	small	ADJ	JJ	9	I-Disease
cell	cell	NOUN	NN	3	I-Disease
lung	lung	NOUN	NN	9	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
with	with	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Paclitaxel	Paclitaxel	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Taxol	Taxol	PROPN	NNP	0	B-Chemical
;	;	PUNCT	:	9	O
Bristol	Bristol	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Myers	Myers	PROPN	NNP	6	O
Squibb	Squibb	PROPN	NNP	2	O
Company	Company	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Princeton	Princeton	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
NJ	NJ	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
demonstrated	demonstrate	VERB	VBN	9	O
significant	significant	ADJ	JJ	9	O
antineoplastic	antineoplastic	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
against	against	ADP	IN	9	O
different	different	ADJ	JJ	9	O
tumor	tumor	NOUN	NN	3	B-Disease
types	type	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
notably	notably	ADV	RB	9	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
breast	breast	NOUN	NN	3	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
trials	trial	NOUN	NNS	5	O
of	of	ADP	IN	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
infusions	infusion	NOUN	NNS	9	O
in	in	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
naive	naive	ADJ	JJ	3	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
stage	stage	NOUN	NN	9	O
IIIB	IIIB	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
IV	IV	PROPN	NNP	9	O
non	non	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
small	small	ADJ	JJ	9	I-Disease
cell	cell	NOUN	NN	3	I-Disease
lung	lung	NOUN	NN	9	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
NSCLC	NSCLC	PROPN	NNP	3	B-Disease
)	)	PUNCT	-RRB-	9	O
reported	report	VERB	VBD	9	O
response	response	NOUN	NN	9	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Leukopenia	Leukopenia	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
limiting	limit	VERB	VBG	9	O
:	:	PUNCT	:	9	O
as	as	ADV	RB	5	O
many	many	ADJ	JJ	5	O
as	as	ADP	IN	5	O
62	62	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
grade	grade	NOUN	NN	9	O
4	4	NUM	CD	9	O
leukopenia	leukopenia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
trial	trial	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
inoperable	inoperable	ADJ	JJ	5	O
stage	stage	NOUN	NN	9	O
IIIB	IIIB	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
IV	IV	PROPN	NNP	9	O
NSCLC	NSCLC	PROPN	NNP	3	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
58	58	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBD	3	O
(	(	PUNCT	-LRB-	9	O
41	41	NUM	CD	7	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
17	17	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
median	median	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
59	59	NUM	CD	7	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
age	age	NOUN	NN	5	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
25	25	NUM	CD	9	O
to	to	PART	TO	5	O
75	75	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
performance	performance	NOUN	NN	5	O
status	status	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
through	through	ADP	IN	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O

Most	Most	ADJ	JJS	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
72	72	NUM	CD	9	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
stage	stage	NOUN	NN	9	O
IV	IV	PROPN	NNP	9	O
NSCLC	NSCLC	PROPN	NNP	3	B-Disease
.	.	PUNCT	.	9	O

Paclitaxel	Paclitaxel	PROPN	NNP	0	B-Chemical
225	225	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
was	be	VERB	VBD	9	O
infused	infuse	VERB	VBN	9	O
over	over	ADP	IN	5	O
3	3	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
every	every	DET	DT	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
with	with	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
premedication	premedication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
50	50	NUM	CD	0	O
patients	patient	NOUN	NNS	5	O
evaluable	evaluable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
partial	partial	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
26	26	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
52	52	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
had	have	VERB	VBD	9	O
disease	disease	NOUN	NN	5	O
progression	progression	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Hematologic	hematologic	ADJ	JJ	7	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
mild	mild	ADJ	JJ	9	O
:	:	PUNCT	:	9	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBN	5	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
or	or	CCONJ	CC	5	O
4	4	NUM	CD	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
29	29	NUM	CD	7	O
%	%	NOUN	NN	9	O
had	have	VERB	VBD	9	O
grade	grade	NOUN	NN	9	O
1	1	NUM	CD	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O

Grade	Grade	PROPN	NNP	9	O
1	1	NUM	CD	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
polyneuropathy	polyneuropathy	NOUN	NN	5	B-Disease
affected	affect	VERB	VBN	9	O
56	56	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
while	while	ADP	IN	9	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
experienced	experience	VERB	VBD	5	O
severe	severe	ADJ	JJ	5	O
polyneuropathy	polyneuropathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
grade	grade	NOUN	NN	9	O
1	1	NUM	CD	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
myalgia	myalgia	NOUN	NN	5	B-Disease
/	/	SYM	SYM	9	O
arthralgia	arthralgia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
63	63	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
only	only	ADV	RB	9	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
experienced	experienced	ADJ	JJ	5	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
or	or	CCONJ	CC	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O

Nausea	nausea	NOUN	NN	7	B-Disease
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
infrequent	infrequent	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
14	14	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
experiencing	experience	VERB	VBG	5	O
grade	grade	NOUN	NN	9	O
1	1	NUM	CD	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
only	only	ADV	RB	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
experiencing	experience	VERB	VBG	5	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
or	or	CCONJ	CC	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O

Paclitaxel	Paclitaxel	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
thus	thus	ADV	RB	9	O
an	an	DET	DT	5	O
active	active	ADJ	JJ	9	O
single	single	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
infusion	infusion	NOUN	NN	0	O
proving	prove	VERB	VBG	9	O
comparably	comparably	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
infusion	infusion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
superior	superior	ADJ	JJ	5	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
hematologic	hematologic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
nonhematologic	nonhematologic	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
phase	phase	VERB	VB	5	O
II	II	PROPN	NNP	9	O
studies	study	NOUN	NNS	9	O
with	with	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
active	active	ADJ	JJ	9	O
against	against	ADP	IN	9	O
NSCLC	NSCLC	PROPN	NNP	3	B-Disease
are	be	VERB	VBP	5	O
indicated	indicate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
phase	phase	VERB	VB	5	O
III	III	PROPN	NNP	9	O
studies	study	NOUN	NNS	9	O
comparing	compare	VERB	VBG	9	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
remain	remain	VERB	VBP	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
completed	complete	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Paclitaxel	Paclitaxel	PROPN	NNP	0	B-Chemical
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
phase	phase	NOUN	NN	5	O
I	-PRON-	PRON	PRP	9	O
study	study	VERB	VBP	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
tolerated	tolerate	VERB	VBN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Taxol	Taxol	PROPN	NNP	0	B-Chemical
;	;	PUNCT	:	9	O
Bristol	Bristol	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Myers	Myers	PROPN	NNP	6	O
Squibb	Squibb	PROPN	NNP	2	O
Company	Company	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Princeton	Princeton	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
NJ	NJ	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
given	give	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
infusion	infusion	NOUN	NN	0	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
administered	administer	VERB	VBN	9	O
every	every	DET	DT	5	O
21	21	NUM	CD	7	O
days	day	NOUN	NNS	9	O
to	to	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
doses	dose	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
escalated	escalate	VERB	VBN	5	O
as	as	ADP	IN	5	O
follows	follow	VERB	VBZ	9	O
:	:	PUNCT	:	9	O
level	level	NOUN	NN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
135	135	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
;	;	PUNCT	:	9	O
level	level	NOUN	NN	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
160	160	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
;	;	PUNCT	:	9	O
level	level	NOUN	NN	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
185	185	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
level	level	NOUN	NN	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
210	210	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
fixed	fix	VERB	VBN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
levels	level	NOUN	NNS	3	O
1	1	NUM	CD	9	O
through	through	ADP	IN	9	O
4	4	NUM	CD	9	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
to	to	PART	TO	5	O
achieve	achieve	VERB	VB	5	O
an	an	DET	DT	5	O
area	area	NOUN	NN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
curve	curve	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
AUC	AUC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
Calvert	Calvert	PROPN	NNP	6	O
formula	formula	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
levels	level	NOUN	NNS	3	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
the	the	DET	DT	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
targeted	target	VERB	VBN	9	O
at	at	ADP	IN	9	O
AUCs	auc	NOUN	NNS	5	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
fixed	fix	VERB	VBN	9	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
185	185	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
date	date	NOUN	NN	5	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
previously	previously	ADV	RB	9	O
untreated	untreated	ADJ	JJ	3	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
all	all	ADV	RB	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
good	good	ADJ	JJ	5	O
performance	performance	NOUN	NN	5	O
status	status	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Eastern	Eastern	PROPN	NNP	4	O
Cooperative	Cooperative	PROPN	NNP	2	O
Oncology	Oncology	PROPN	NNP	2	O
Group	Group	PROPN	NNP	9	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
entered	enter	VERB	VBN	5	O
into	into	ADP	IN	9	O
this	this	DET	DT	5	O
ongoing	ongoing	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
was	be	VERB	VBD	9	O
myelosuppression	myelosuppression	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
leukopenia	leukopenia	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
granulocytopenia	granulocytopenia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Neurotoxicity	neurotoxicity	NOUN	NN	0	B-Disease
was	be	VERB	VBD	9	O
largely	largely	ADV	RB	9	O
moderate	moderate	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

So	so	ADV	RB	9	O
far	far	ADV	RB	5	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
evaluable	evaluable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
response	response	NOUN	NN	9	O
;	;	PUNCT	:	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
,	,	PUNCT	,	9	O
eight	eight	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
57	57	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
objective	objective	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
complete	complete	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
partial	partial	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
disease	disease	NOUN	NN	5	O
stabilized	stabilize	VERB	VBD	9	O
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
disease	disease	NOUN	NN	5	O
progression	progression	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
185	185	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
administered	administer	VERB	VBD	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
infusion	infusion	NOUN	NN	0	O
followed	follow	VERB	VBD	9	O
immediately	immediately	ADV	RB	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
AUC	AUC	PROPN	NNP	9	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
administered	administer	VERB	VBN	9	O
safely	safely	ADV	RB	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
21	21	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
schedule	schedule	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
outpatient	outpatient	NOUN	NN	5	O
setting	setting	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
recommended	recommend	VERB	VBN	5	O
dose	dose	NOUN	NN	9	O
for	for	ADP	IN	5	O
phase	phase	NOUN	NN	5	O
III	iii	NUM	CD	9	O
studies	study	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
paclitaxel	paclitaxel	VERB	VBN	0	B-Chemical
185	185	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
and	and	CCONJ	CC	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
AUC	AUC	PROPN	NNP	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
steroid	steroid	NOUN	NN	9	B-Chemical
administration	administration	NOUN	NN	9	O
on	on	ADP	IN	5	O
ventilatory	ventilatory	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	O
muscles	muscle	NOUN	NNS	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Occasional	occasional	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
that	that	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
myopathy	myopathy	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
occur	occur	VERB	VB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
massive	massive	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
myopathy	myopathy	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
poorly	poorly	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
male	male	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
daily	daily	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
C	c	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
M	M	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
triamcinolone	triamcinolone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
T	t	NOUN	NN	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
d	d	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Nutritional	nutritional	ADJ	JJ	9	O
intake	intake	NOUN	NN	5	O
,	,	PUNCT	,	9	O
measured	measure	VERB	VBN	9	O
daily	daily	ADV	RB	5	O
in	in	ADP	IN	5	O
15	15	NUM	CD	9	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
food	food	NOUN	NN	5	I-Disease
intake	intake	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
50	50	NUM	CD	0	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
79	79	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
M	M	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
T	T	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
loss	loss	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
body	body	NOUN	NN	5	I-Disease
weight	weight	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
45	45	NUM	CD	9	O
remaining	remain	VERB	VBG	9	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
diaphragm	diaphragm	NOUN	NN	5	O
contractility	contractility	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
histopathologic	histopathologic	ADJ	JJ	9	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
several	several	ADJ	JJ	9	O
muscles	muscle	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Weights	weight	NOUN	NNS	5	O
of	of	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	O
muscles	muscle	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
similarly	similarly	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
after	after	ADP	IN	9	O
steroid	steroid	NOUN	NN	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Maximal	maximal	ADJ	JJ	9	O
twitches	twitch	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
diaphragm	diaphragm	NOUN	NN	5	O
were	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
C	c	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
653	653	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
174	174	NUM	CD	7	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
cm	cm	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
M	M	PROPN	NNP	9	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
837	837	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
171	171	NUM	CD	7	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
cm	cm	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
T	t	NOUN	NN	3	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
765	765	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
145	145	NUM	CD	7	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
cm	cm	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
NS	NS	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Half	half	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
relaxation	relaxation	NOUN	NN	5	O
time	time	NOUN	NN	5	O
was	be	VERB	VBD	9	O
prolonged	prolong	VERB	VBN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
steroid	steroid	NOUN	NN	9	B-Chemical
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
time	time	NOUN	NN	5	O
to	to	PART	TO	5	O
peak	peak	VERB	VB	9	O
tension	tension	NOUN	NN	5	O
was	be	VERB	VBD	9	O
longer	long	ADJ	JJR	5	O
with	with	ADP	IN	5	O
M	M	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
tetanic	tetanic	ADJ	JJ	5	B-Disease
tensions	tension	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Steroid	Steroid	PROPN	NNP	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
also	also	ADV	RB	9	O
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
leftward	leftward	NOUN	NN	5	O
shift	shift	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
force	force	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
frequency	frequency	NOUN	NN	5	O
curve	curve	NOUN	NN	9	O
at	at	ADP	IN	9	O
25	25	NUM	CD	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
Hz	Hz	PROPN	NNPS	5	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

ATPase	ATPase	PROPN	NNP	1	O
staining	staining	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
diaphragm	diaphragm	NOUN	NN	5	O
,	,	PUNCT	,	9	O
scalenus	scalenus	ADJ	JJ	5	O
medius	medius	NOUN	NN	4	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
gastrocnemius	gastrocnemius	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
type	type	NOUN	NN	9	O
IIb	IIb	NOUN	NNS	9	O
fiber	fiber	NOUN	NN	5	O
atrophy	atrophy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
groups	group	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
diaphragmatic	diaphragmatic	ADJ	JJ	5	O
type	type	NOUN	NN	9	O
IIa	IIa	NOUN	NNS	9	O
atrophy	atrophy	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
T	T	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
histologic	histologic	ADJ	JJ	9	O
examinations	examination	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
muscular	muscular	ADJ	JJ	5	O
pattern	pattern	NOUN	NN	9	O
with	with	ADP	IN	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
pair	pair	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
fed	fed	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PF	PF	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
18	18	NUM	CD	7	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
C	c	NOUN	NN	9	O
,	,	PUNCT	,	9	O
T	T	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
PF	PF	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	B-Disease
atrophy	atrophy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
considerably	considerably	ADV	RB	9	O
less	less	ADV	RBR	5	O
pronounced	pronounce	VERB	VBN	9	O
in	in	ADP	IN	5	O
PF	PF	PROPN	NNP	9	O
animals	animal	NOUN	NNS	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
T	t	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
massive	massive	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
induced	induce	VERB	VBD	3	O
severe	severe	ADJ	JJ	5	O
respiratory	respiratory	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
limb	limb	NOUN	NN	5	O
muscle	muscle	NOUN	NN	9	O
wasting	wasting	NOUN	NN	5	O
;	;	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
both	both	DET	DT	9	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
induced	induce	VERB	VBD	3	O
predominantly	predominantly	ADV	RB	9	O
type	type	NOUN	NN	9	O
IIb	IIb	NOUN	NNS	9	O
atrophy	atrophy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
expected	expect	VERB	VBN	9	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
diaphragm	diaphragm	NOUN	NN	5	O
contractile	contractile	NOUN	NN	9	O
properties	property	NOUN	NNS	9	O
;	;	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
neither	neither	CCONJ	CC	9	O
steroid	steroid	NOUN	NN	9	B-Chemical
caused	cause	VERB	VBD	9	O
muscle	muscle	NOUN	NN	9	O
necrosis	necrosis	NOUN	NN	9	B-Disease
;	;	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
type	type	NOUN	NN	9	O
IIb	IIb	NOUN	NNS	9	O
atrophy	atrophy	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
acute	acute	ADJ	JJ	9	O
nutritional	nutritional	ADJ	JJ	5	O
deprivation	deprivation	NOUN	NN	9	O
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

Continuous	continuous	ADJ	JJ	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
ifosfamide	ifosfamide	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Hemorrhagic	hemorrhagic	ADJ	JJ	9	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
potential	potential	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
that	that	DET	WDT	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
administering	administer	VERB	VBG	9	O
mesna	mesna	NOUN	NN	0	B-Chemical
along	along	ADP	IN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
cytotoxic	cytotoxic	NOUN	NN	3	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Mesna	Mesna	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
generally	generally	ADV	RB	5	O
administered	administer	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
intravenous	intravenous	ADJ	JJ	0	O
route	route	NOUN	NN	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
experience	experience	NOUN	NN	5	O
with	with	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
delivery	delivery	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
increased	increase	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
continuous	continuous	ADJ	JJ	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
the	the	DET	DT	5	O
advantage	advantage	NOUN	NN	5	O
of	of	ADP	IN	5	O
not	not	ADV	RB	5	O
requiring	require	VERB	VBG	5	O
intravenous	intravenous	ADJ	JJ	0	O
access	access	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
delivery	delivery	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
neutralizing	neutralize	VERB	VBG	3	O
agent	agent	NOUN	NN	9	O
will	will	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
inadequate	inadequate	ADJ	JJ	5	O
urinary	urinary	ADJ	JJ	9	O
mesna	mesna	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
taking	take	VERB	VBG	5	O
oral	oral	ADJ	JJ	9	O
mesna	mesna	NOUN	NN	0	B-Chemical
who	who	PRON	WP	5	O
experiences	experience	VERB	VBZ	5	O
severe	severe	ADJ	JJ	5	O
ifosfamide	ifosfamide	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
emesis	emesis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
unable	unable	ADJ	JJ	9	O
to	to	PART	TO	5	O
absorb	absorb	VERB	VB	0	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Limited	limited	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
experience	experience	NOUN	NN	5	O
with	with	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
mesna	mesna	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
safe	safe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
practical	practical	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
economic	economic	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
delivery	delivery	NOUN	NN	5	O
that	that	DET	WDT	5	O
permits	permit	VERB	VBZ	5	O
ifosfamide	ifosfamide	ADJ	JJ	0	B-Chemical
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
administered	administer	VERB	VBN	9	O
successfully	successfully	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
outpatient	outpatient	NOUN	NN	5	O
setting	setting	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Leg	Leg	PROPN	NNP	2	B-Disease
and	and	CCONJ	CC	5	I-Disease
back	back	ADJ	JJ	5	I-Disease
pain	pain	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
involving	involve	VERB	VBG	5	O
hyperbaric	hyperbaric	ADJ	JJ	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
lignocaine	lignocaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Fifty	fifty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
aged	age	VERB	VBN	9	O
27	27	NUM	CD	7	O
-	-	SYM	SYM	7	O
90	90	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
lignocaine	lignocaine	NOUN	NN	0	B-Chemical
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
solution	solution	NOUN	NN	0	O
for	for	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Thirteen	thirteen	NUM	CD	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
experienced	experience	VERB	VBD	5	O
pain	pain	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
legs	leg	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
/	/	SYM	SYM	9	I-Disease
or	or	CCONJ	CC	5	I-Disease
back	back	ADV	RB	5	I-Disease
after	after	ADP	IN	9	O
recovery	recovery	NOUN	NN	9	O
from	from	ADP	IN	9	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
affected	affect	VERB	VBN	9	O
were	be	VERB	VBD	9	O
younger	young	ADJ	JJR	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
site	site	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dural	dural	ADJ	JJ	5	O
puncture	puncture	NOUN	NN	5	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
individuals	individual	NOUN	NNS	5	O
without	without	ADP	IN	9	O
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
38	38	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
seven	seven	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
41	41	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
without	without	ADP	IN	9	O
pain	pain	NOUN	NN	5	B-Disease
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
intake	intake	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
contributing	contribute	VERB	VBG	9	O
factor	factor	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Leg	Leg	PROPN	NNP	2	B-Disease
and	and	CCONJ	CC	5	I-Disease
/	/	SYM	SYM	9	I-Disease
or	or	CCONJ	CC	5	I-Disease
back	back	ADJ	JJ	5	I-Disease
pain	pain	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
hyperbaric	hyperbaric	ADJ	JJ	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
lignocaine	lignocaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
cholinesterase	cholinesterase	NOUN	NN	0	O
in	in	ADP	IN	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
apnoea	apnoea	ADV	RB	5	B-Disease
.	.	PUNCT	.	9	O

Fifteen	fifteen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
demonstrating	demonstrate	VERB	VBG	9	O
unexpected	unexpected	ADJ	JJ	9	O
prolonged	prolong	VERB	VBN	9	O
apnoea	apnoea	ADV	RB	5	B-Disease
lasting	last	VERB	VBG	5	O
several	several	ADJ	JJ	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
preparation	preparation	NOUN	NN	9	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
serum	serum	NOUN	NN	9	O
cholinesterase	cholinesterase	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Adequate	adequate	ADJ	JJ	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
respiration	respiration	NOUN	NN	9	O
was	be	VERB	VBD	9	O
re	re	VERB	VBN	5	O
-	-	VERB	VBN	7	O
established	establish	VERB	VBN	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
average	average	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
ten	ten	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
biochemical	biochemical	ADJ	JJ	9	O
genetic	genetic	ADJ	JJ	5	O
examinations	examination	NOUN	NNS	5	O
confirmed	confirm	VERB	VBD	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
atypical	atypical	ADJ	JJ	5	O
serum	serum	ADJ	JJ	9	O
cholinesterase	cholinesterase	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
none	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
usual	usual	ADJ	JJ	5	O
variants	variant	NOUN	NNS	1	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
therefore	therefore	ADV	RB	5	O
supposed	suppose	VERB	VBN	5	O
that	that	ADP	IN	5	O
other	other	ADJ	JJ	5	O
unknown	unknown	ADJ	JJ	9	O
variants	variant	NOUN	NNS	1	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
cholinesterase	cholinesterase	NOUN	NN	0	O
exist	exist	VERB	VBP	9	O
which	which	DET	WDT	5	O
cannot	cannot	NOUN	NN	5	O
hydrolyze	hydrolyze	ADJ	JJ	0	O
succinylcholine	succinylcholine	ADJ	JJ	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
cholinesterase	cholinesterase	NOUN	NN	0	O
in	in	ADP	IN	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
apnoea	apnoea	NOUN	NN	5	B-Disease
provided	provide	VERB	VBD	9	O
considerable	considerable	ADJ	JJ	5	O
relief	relief	NOUN	NN	5	O
to	to	ADP	IN	5	O
both	both	CCONJ	CC	9	O
patient	patient	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
anaesthetist	anaesthetist	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
sulfation	sulfation	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
7alpha	7alpha	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hydroxylation	hydroxylation	NOUN	NN	0	O
of	of	ADP	IN	5	O
deoxycholic	deoxycholic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
ethinyl	ethinyl	ADJ	JJ	0	B-Chemical
estradiol	estradiol	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Deoxycholic	deoxycholic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
conjugation	conjugation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
transport	transport	NOUN	NN	9	O
capacity	capacity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
metabolism	metabolism	NOUN	NN	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ethinyl	ethinyl	VERB	VB	0	B-Chemical
estradiol	estradiol	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
capacity	capacity	NOUN	NN	9	O
to	to	PART	TO	5	O
transport	transport	VERB	VB	9	O
deoxycholic	deoxycholic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
than	than	ADP	IN	5	O
taurodeoxycholic	taurodeoxycholic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
both	both	DET	DT	9	O
were	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
by	by	ADP	IN	9	O
ethinyl	ethinyl	ADJ	JJ	0	B-Chemical
estradiol	estradiol	NOUN	NN	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	O
24	24	NUM	CD	9	O
-	-	SYM	SYM	7	O
14C	14c	NUM	CD	0	O
]	]	PUNCT	-RRB-	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
deoxycholate	deoxycholate	ADJ	JJ	0	I-Chemical
infusion	infusion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
[	[	PUNCT	-LRB-	9	O
14C	14c	NUM	CD	0	O
]	]	PUNCT	-RRB-	9	O
biliary	biliary	ADJ	JJ	5	O
bile	bile	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
secretion	secretion	NOUN	NN	3	O
increased	increase	VERB	VBD	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
bile	bile	NOUN	NN	0	O
flow	flow	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
in	in	ADP	IN	5	O
either	either	DET	DT	9	O
control	control	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
ethinyl	ethinyl	VERB	VB	0	B-Chemical
estradiol	estradiol	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Ethinyl	ethinyl	VERB	VB	7	B-Chemical
estradiol	estradiol	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
excreted	excrete	VERB	VBD	0	O
significantly	significantly	ADV	RB	9	O
less	less	ADJ	JJR	5	O
14C	14c	NUM	CD	0	O
as	as	ADP	IN	5	O
taurocholic	taurocholic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
than	than	ADP	IN	5	O
did	do	VERB	VBD	9	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
impairment	impairment	NOUN	NN	5	O
of	of	ADP	IN	5	O
7alpha	7alpha	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hydroxylation	hydroxylation	NOUN	NN	0	O
of	of	ADP	IN	5	O
taurodeoxycholic	taurodeoxycholic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Ethinyl	ethinyl	VERB	VB	7	B-Chemical
estradiol	estradiol	NOUN	NN	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
impair	impair	VERB	VB	9	O
conjugation	conjugation	NOUN	NN	0	O
of	of	ADP	IN	5	O
deoxycholic	deoxycholic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
sulfation	sulfation	NOUN	NN	0	O
of	of	ADP	IN	5	O
taurodeoxycholic	taurodeoxycholic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
to	to	ADP	IN	5	O
nearly	nearly	ADV	RB	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
poorer	poor	ADJ	JJR	5	O
tolerance	tolerance	NOUN	NN	9	O
for	for	ADP	IN	5	O
deoxycholic	deoxycholic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
than	than	ADP	IN	5	O
do	do	VERB	VB	5	O
certain	certain	ADJ	JJ	5	O
other	other	ADJ	JJ	5	O
species	specie	NOUN	NNS	4	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
converts	convert	NOUN	NNS	0	O
deoxycholic	deoxycholic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
poor	poor	ADJ	JJ	5	O
choleretic	choleretic	NOUN	NN	0	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
taurocholic	taurocholic	VERB	VB	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
good	good	ADJ	JJ	5	O
choleretic	choleretic	NOUN	NN	0	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
this	this	DET	DT	5	O
conversion	conversion	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
impaired	impair	VERB	VBN	9	O
with	with	ADP	IN	5	O
ethinyl	ethinyl	ADJ	JJ	0	B-Chemical
estradiol	estradiol	NOUN	NNS	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
sulfation	sulfation	NOUN	NN	0	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
alternate	alternate	ADJ	JJ	9	O
pathway	pathway	NOUN	NN	3	O
for	for	ADP	IN	5	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
harmful	harmful	ADJ	JJ	5	O
bile	bile	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Influence	influence	NOUN	NN	9	O
of	of	ADP	IN	5	O
diet	diet	NOUN	NN	9	O
free	free	ADJ	JJ	9	O
of	of	ADP	IN	5	O
NAD	NAD	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
precursors	precursor	NOUN	NNS	3	O
on	on	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
demonstrated	demonstrate	VERB	VBD	9	O
the	the	DET	DT	5	O
hepatoprotective	hepatoprotective	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nicotinic	nicotinic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
amide	amide	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
poly	poly	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
ADP	ADP	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ribose	ribose	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
polymerase	polymerase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
PARP	PARP	PROPN	NNP	3	O
;	;	PUNCT	:	9	O
EC	EC	PROPN	NNP	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
30	30	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
AAP	AAP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
AAP	AAP	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
liver	liver	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
involves	involve	VERB	VBZ	5	O
a	a	DET	DT	5	O
step	step	NOUN	NN	9	O
which	which	DET	WDT	5	O
depends	depend	VERB	VBZ	5	O
on	on	ADP	IN	5	O
adenoribosylation	adenoribosylation	NOUN	NN	_	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
investigates	investigate	VERB	VBZ	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
diet	diet	NOUN	NN	9	O
free	free	ADJ	JJ	9	O
of	of	ADP	IN	5	O
precursors	precursor	NOUN	NNS	3	O
of	of	ADP	IN	5	O
NAD	NAD	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
substrate	substrate	NOUN	NN	0	O
on	on	ADP	IN	5	O
which	which	DET	WDT	5	O
PARP	PARP	PROPN	NNP	3	O
acts	act	VERB	VBZ	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
female	female	ADJ	JJ	9	O
NMRI	nmri	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
AAP	AAP	PROPN	NNP	9	B-Chemical
hepatitis	hepatitis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
evaluates	evaluate	VERB	VBZ	5	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
simultaneous	simultaneous	ADJ	JJ	5	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	B-Disease
injuries	injury	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
quantified	quantify	VERB	VBN	9	O
as	as	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
oxaloacetate	oxaloacetate	NOUN	NN	0	B-Chemical
transaminase	transaminase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
GOT	GOT	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
glutamate	glutamate	VERB	VB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
pyruvate	pyruvate	NOUN	NN	0	B-Chemical
transaminase	transaminase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
GPT	GPT	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
AAP	AAP	PROPN	NNP	9	B-Chemical
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
117	117	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
fold	fold	ADJ	JJ	9	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
transaminase	transaminase	NOUN	NN	0	O
activities	activity	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
kept	keep	VERB	VBN	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
laboratory	laboratory	NOUN	NN	9	O
diet	diet	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
exacerbated	exacerbate	VERB	VBN	9	O
by	by	ADP	IN	9	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
inhibited	inhibit	VERB	VBN	3	O
by	by	ADP	IN	9	O
nicotinic	nicotinic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
amide	amide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NAA	NAA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
fed	feed	VERB	VBD	9	O
a	a	DET	DT	5	O
diet	diet	NOUN	NN	9	O
free	free	ADJ	JJ	9	O
of	of	ADP	IN	5	O
precursors	precursor	NOUN	NNS	3	O
of	of	ADP	IN	5	O
NAD	NAD	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
these	these	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
minor	minor	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
of	of	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
transaminase	transaminase	NOUN	NN	0	O
activities	activity	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
AAP	AAP	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
unlike	unlike	ADP	IN	9	O
the	the	DET	DT	5	O
exacerbation	exacerbation	NOUN	NN	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
diet	diet	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
inhibited	inhibit	VERB	VBN	3	O
by	by	ADP	IN	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
by	by	ADP	IN	9	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
further	further	ADJ	JJ	9	O
64	64	NUM	CD	7	O
%	%	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
NAA	NAA	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
AAP	aap	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
provide	provide	VERB	VBP	5	O
evidence	evidence	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
AAP	AAP	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
exacerbation	exacerbation	NOUN	NN	5	O
by	by	ADP	IN	9	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
either	either	CCONJ	CC	9	O
be	be	VERB	VB	5	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
product	product	NOUN	NN	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
PARP	PARP	PROPN	NNP	3	O
by	by	ADP	IN	9	O
NAA	NAA	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
by	by	ADP	IN	9	O
dietary	dietary	ADJ	JJ	5	O
depletion	depletion	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
enzyme	enzyme	ADJ	JJ	0	O
'	'	PUNCT	``	9	O
s	s	PART	POS	9	O
substrate	substrate	NOUN	NN	0	O
NAD	NAD	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
see	see	VERB	VBP	9	O
the	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
NAA	NAA	PROPN	NNP	0	B-Chemical
as	as	ADP	IN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
combinational	combinational	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
pharmaceutical	pharmaceutical	ADJ	JJ	5	O
preparations	preparation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
avoid	avoid	VERB	VB	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
analgesic	analgesic	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Nightmares	nightmare	NOUN	NNS	7	O
and	and	CCONJ	CC	5	O
hallucinations	hallucination	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
intake	intake	NOUN	NN	5	O
of	of	ADP	IN	5	O
tramadol	tramadol	NOUN	NN	0	B-Chemical
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
antidepressants	antidepressant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Tramadol	tramadol	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
weak	weak	ADJ	JJ	9	O
opioid	opioid	NOUN	NN	5	O
with	with	ADP	IN	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
adrenergic	adrenergic	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
serotonergic	serotonergic	NOUN	NN	5	O
neurotransmission	neurotransmission	NOUN	NN	5	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
cancer	cancer	NOUN	NN	3	B-Disease
pain	pain	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
chronic	chronic	VERB	VB	5	O
non	non	ADJ	JJ	9	O
malignant	malignant	ADJ	JJ	3	O
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
initiated	initiate	VERB	VBN	9	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
paroxetine	paroxetine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
dosulepine	dosulepine	NOUN	NN	_	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
tetraparetic	tetraparetic	ADJ	JJ	5	B-Disease
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Fifty	fifty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
hallucinations	hallucination	NOUN	NNS	5	B-Disease
that	that	DET	WDT	5	O
only	only	ADV	RB	9	O
stopped	stop	VERB	VBD	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
psycho	psycho	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
active	active	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
tramadol	tramadol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
questions	question	VERB	VBZ	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
killers	killer	NOUN	NNS	5	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
psycho	psycho	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
active	active	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
non	non	ADJ	JJ	9	O
malignant	malignant	ADJ	JJ	3	O
pain	pain	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
if	if	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
under	under	ADP	IN	9	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminopyridine	aminopyridine	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
on	on	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Hypotension	hypotension	NOUN	NN	7	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
contributor	contributor	NOUN	NN	9	O
to	to	ADP	IN	5	O
mortality	mortality	NOUN	NN	5	O
in	in	ADP	IN	5	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressant	antidepressant	ADJ	JJ	5	O
overdose	overdose	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

Recent	recent	ADJ	JJ	9	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressants	antidepressant	NOUN	NNS	5	O
inhibit	inhibit	VERB	VBP	3	O
calcium	calcium	NOUN	NN	0	B-Chemical
influx	influx	NOUN	NN	9	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
tissues	tissue	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
addressed	address	VERB	VBD	5	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockade	blockade	NOUN	NN	3	O
in	in	ADP	IN	5	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressant	antidepressant	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
interventions	intervention	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
that	that	DET	WDT	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
with	with	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blocker	blocker	NOUN	NN	0	O
overdose	overdose	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

CaCl2	CaCl2	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminopyridine	aminopyridine	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Anesthetized	anesthetized	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
the	the	DET	DT	5	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressant	antidepressant	NOUN	NN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
IP	IP	PROPN	NNP	9	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
QRS	QRS	PROPN	NNP	5	O
prolongation	prolongation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Fifteen	fifteen	ADJ	JJ	9	O
min	min	NOUN	NN	0	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
animals	animal	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
CaCl2	CaCl2	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
NaHCO3	nahco3	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
saline	saline	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
experiment	experiment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressant	antidepressant	NOUN	NN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
IP	IP	PROPN	NNP	9	O
followed	follow	VERB	VBD	9	O
in	in	ADP	IN	5	O
15	15	NUM	CD	9	O
min	min	NOUN	NN	0	O
by	by	ADP	IN	9	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminopyridine	aminopyridine	NOUN	NN	0	I-Chemical
or	or	CCONJ	CC	5	O
saline	saline	NOUN	NN	0	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
NaHCO3	nahco3	NOUN	NN	0	B-Chemical
briefly	briefly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
reversed	reverse	VERB	VBN	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
QRS	QRS	PROPN	NNP	5	O
prolongation	prolongation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CaCl2	CaCl2	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminopyridine	aminopyridine	NOUN	NN	0	I-Chemical
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
004	004	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
CaCl2	CaCl2	PROPN	NNP	0	B-Chemical
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
CaCl2	CaCl2	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminopyridine	aminopyridine	NOUN	NN	0	I-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
reverse	reverse	VERB	VB	9	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressant	antidepressant	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CaCl2	cacl2	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
may	may	VERB	MD	5	O
possibly	possibly	ADV	RB	9	O
worsen	worsen	VERB	VB	5	O
both	both	CCONJ	CC	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
central	central	ADJ	JJ	5	I-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
support	support	VERB	VB	5	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
for	for	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
inhibition	inhibition	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressant	antidepressant	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Valsartan	Valsartan	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
II	ii	NUM	CD	9	I-Chemical
antagonist	antagonist	NOUN	NN	3	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
essential	essential	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
comparative	comparative	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
against	against	ADP	IN	9	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
II	ii	NOUN	NN	9	I-Chemical
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
valsartan	valsartan	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
reference	reference	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
One	one	NUM	CD	5	O
hundred	hundred	NUM	CD	5	O
sixty	sixty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
eight	eight	NUM	CD	9	O
adult	adult	NOUN	NN	9	O
outpatients	outpatient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
to	to	PART	TO	5	O
moderate	moderate	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
allocated	allocate	VERB	VBN	5	O
in	in	ADP	IN	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
fashion	fashion	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
number	number	NOUN	NN	9	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
valsartan	valsartan	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
whose	whose	DET	WP$	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
remained	remain	VERB	VBD	9	O
uncontrolled	uncontrolled	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
added	add	VERB	VBN	0	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
at	at	ADP	IN	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
efficacy	efficacy	NOUN	NN	9	O
variable	variable	NOUN	NN	5	O
was	be	VERB	VBD	9	O
change	change	NOUN	NN	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
in	in	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
sitting	sit	VERB	VBG	5	O
diastolic	diastolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
at	at	ADP	IN	9	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Secondary	secondary	ADJ	JJ	9	O
variables	variable	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
sitting	sit	VERB	VBG	5	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
responder	responder	NOUN	NN	9	O
rates	rate	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Both	both	CCONJ	CC	9	O
valsartan	valsartan	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
effective	effective	ADJ	JJ	5	O
at	at	ADP	IN	9	O
lowering	lower	VERB	VBG	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
at	at	ADP	IN	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Similar	similar	ADJ	JJ	9	O
decreases	decrease	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
groups	group	NOUN	NNS	9	O
for	for	ADP	IN	5	O
any	any	DET	DT	5	O
variable	variable	NOUN	NN	5	O
analyzed	analyze	VERB	VBN	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
variable	variable	NOUN	NN	5	O
the	the	DET	DT	5	O
difference	difference	NOUN	NN	9	O
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
in	in	ADP	IN	5	O
favor	favor	NOUN	NN	9	O
of	of	ADP	IN	5	O
valsartan	valsartan	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	X	XX	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
68	68	NUM	CD	7	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Responder	responder	NOUN	NN	9	O
rates	rate	NOUN	NNS	5	O
at	at	ADP	IN	9	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
66	66	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
valsartan	valsartan	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
60	60	NUM	CD	9	O
.	.	NOUN	NNS	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
39	39	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
treatments	treatment	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
dependent	dependent	ADJ	JJ	9	O
edema	edema	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
somewhat	somewhat	ADV	RB	5	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
valsartan	valsartan	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
valsartan	valsartan	ADJ	JJ	0	B-Chemical
plus	plus	CCONJ	CC	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
valsartan	valsartan	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
as	as	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
as	as	ADP	IN	5	O
amlodipine	amlodipine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
to	to	PART	TO	5	O
moderate	moderate	VERB	VB	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
also	also	ADV	RB	9	O
show	show	VERB	VBP	9	O
valsartan	valsartan	ADJ	JJ	0	B-Chemical
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
suggest	suggest	VERB	VB	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
characteristic	characteristic	ADJ	JJ	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
comparator	comparator	NOUN	NN	5	O
class	class	NOUN	NN	9	O
,	,	PUNCT	,	9	O
dihydropyridine	dihydropyridine	NOUN	NN	0	B-Chemical
calcium	calcium	NOUN	NN	0	B-Chemical
antagonists	antagonist	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
measure	measure	NOUN	NN	5	O
of	of	ADP	IN	5	O
pupillary	pupillary	ADJ	JJ	5	B-Disease
oscillation	oscillation	NOUN	NN	5	I-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
marker	marker	NOUN	NN	3	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
paranoia	paranoia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
paranoia	paranoia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
CIP	CIP	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
remains	remain	VERB	VBZ	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
idiopathic	idiopathic	ADJ	JJ	5	O
paranoia	paranoia	NOUN	NN	5	B-Disease
for	for	ADP	IN	5	O
which	which	DET	WDT	5	O
no	no	DET	DT	9	O
psychophysiologic	psychophysiologic	ADJ	JJ	5	O
marker	marker	NOUN	NN	3	O
has	have	VERB	VBZ	9	O
yet	yet	ADV	RB	9	O
emerged	emerge	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Measures	measure	NOUN	NNS	5	O
of	of	ADP	IN	5	O
pupillary	pupillary	ADJ	JJ	5	B-Disease
oscillation	oscillation	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
significantly	significantly	ADV	RB	9	O
distinguish	distinguish	VERB	VB	9	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
abstinent	abstinent	ADJ	JJ	5	O
crack	crack	NOUN	NN	5	B-Chemical
cocaine	cocaine	NOUN	NN	5	I-Chemical
abusers	abuser	NOUN	NNS	5	O
endorsing	endorse	VERB	VBG	5	O
past	past	ADP	IN	5	O
CIP	CIP	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
32	32	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
another	another	DET	DT	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
crack	crack	NOUN	NN	5	B-Chemical
addicts	addict	NOUN	NNS	5	O
who	who	PRON	WP	5	O
denied	deny	VERB	VBD	5	O
past	past	ADP	IN	5	O
CIP	CIP	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
29	29	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Serotonin	serotonin	ADP	IN	0	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
from	from	ADP	IN	9	O
venlafaxine	venlafaxine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
tranylcypromine	tranylcypromine	NOUN	NN	0	B-Chemical
interaction	interaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Excessive	excessive	ADJ	JJ	9	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
5HT1A	5ht1a	NUM	CD	3	O
receptors	receptor	NOUN	NNS	3	O
causes	cause	VERB	VBZ	9	O
a	a	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
of	of	ADP	IN	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
excess	excess	NOUN	NN	9	O
that	that	DET	WDT	5	O
consists	consist	VERB	VBZ	5	O
of	of	ADP	IN	5	O
shivering	shivering	NOUN	NN	5	O
,	,	PUNCT	,	9	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
salivation	salivation	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
confusion	confusion	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
agitation	agitation	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hyperthermia	hyperthermia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
a	a	DET	DT	5	O
monoamine	monoamine	NOUN	NN	0	O
oxidase	oxidase	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
MAOI	MAOI	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Venlafaxine	Venlafaxine	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
antidepressant	antidepressant	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
that	that	DET	WDT	5	O
inhibits	inhibit	VERB	VBZ	3	O
the	the	DET	DT	5	O
reuptake	reuptake	NOUN	NN	0	O
of	of	ADP	IN	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
venlafaxine	venlafaxine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
MAOI	maoi	ADJ	JJ	0	O
interaction	interaction	NOUN	NN	9	O
that	that	DET	WDT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
serotonin	serotonin	NOUN	NN	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
23	23	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
y	y	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	NOUN	NN	9	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
taking	take	VERB	VBG	5	O
tranylcypromine	tranylcypromine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
depression	depression	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
well	well	ADV	RB	9	O
until	until	ADP	IN	5	O
the	the	DET	DT	5	O
morning	morning	NOUN	NN	5	O
of	of	ADP	IN	5	O
presentation	presentation	NOUN	NN	5	O
when	when	ADV	WRB	5	O
he	-PRON-	PRON	PRP	5	O
took	take	VERB	VBD	5	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
tab	tab	NOUN	NN	5	O
of	of	ADP	IN	5	O
venlafaxine	venlafaxine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Within	within	ADP	IN	9	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
he	-PRON-	PRON	PRP	5	O
became	become	VERB	VBD	9	O
confused	confused	ADJ	JJ	4	O
with	with	ADP	IN	5	O
jerking	jerk	VERB	VBG	5	O
movements	movement	NOUN	NNS	5	O
of	of	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
extremities	extremity	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
tremors	tremor	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
brought	bring	VERB	VBN	5	O
directly	directly	ADV	RB	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
where	where	ADV	WRB	5	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
agitated	agitate	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
confused	confuse	VERB	VBN	4	O
with	with	ADP	IN	5	O
shivering	shivering	NOUN	NN	5	O
,	,	PUNCT	,	9	O
myoclonic	myoclonic	ADJ	JJ	5	B-Disease
jerks	jerk	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
rigidity	rigidity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
salivation	salivation	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
diaphoresis	diaphoresis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

His	-PRON-	DET	PRP$	9	O
pupils	pupil	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
7	7	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
sluggishly	sluggishly	ADV	RB	5	O
reactive	reactive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
light	light	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Vital	vital	ADJ	JJ	2	O
signs	sign	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
:	:	PUNCT	:	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
120	120	NUM	CD	9	O
/	/	SYM	SYM	9	O
67	67	NUM	CD	7	O
mm	mm	NOUN	NNS	9	O
Hg	Hg	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
127	127	NUM	CD	7	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respiratory	respiratory	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
28	28	NUM	CD	7	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
temperature	temperature	NOUN	NN	0	O
97	97	NUM	CD	7	O
F	f	NOUN	NN	7	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
180	180	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
he	-PRON-	PRON	PRP	5	O
remained	remain	VERB	VBD	9	O
tremulous	tremulous	ADJ	JJ	5	O
with	with	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
clenched	clench	VERB	VBN	5	O
jaws	jaw	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
intubated	intubate	VERB	VBN	5	O
for	for	ADP	IN	5	O
airway	airway	NOUN	NN	5	O
protection	protection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
hypoventilation	hypoventilation	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
paralyzed	paralyzed	ADJ	JJ	5	B-Disease
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

His	-PRON-	DET	PRP$	9	O
subsequent	subsequent	ADJ	JJ	9	O
course	course	NOUN	NN	5	O
was	be	VERB	VBD	9	O
remarkable	remarkable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
immune	immune	ADJ	JJ	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
which	which	DET	WDT	5	O
resolved	resolve	VERB	VBD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
maximal	maximal	ADJ	JJ	9	O
temperature	temperature	NOUN	NN	0	O
was	be	VERB	VBD	9	O
101	101	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
F	F	PROPN	NNP	7	O
and	and	CCONJ	CC	5	O
his	-PRON-	DET	PRP$	5	O
CPK	CPK	PROPN	NNP	9	O
remained	remain	VERB	VBD	9	O
<	<	X	XX	0	O
500	500	NUM	CD	0	O
units	unit	NOUN	NNS	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

His	-PRON-	DET	PRP$	9	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
normalized	normalize	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
transferred	transfer	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
psychiatry	psychiatry	NOUN	NN	5	O
ward	ward	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
survived	survive	VERB	VBD	9	O
without	without	ADP	IN	9	O
sequelae	sequelae	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
aggressive	aggressive	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
neuromuscular	neuromuscular	ADJ	JJ	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Cyclophosphamide	Cyclophosphamide	PROPN	NNP	0	B-Chemical
associated	associate	VERB	VBD	9	O
bladder	bladder	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
-	-	PUNCT	,	7	O
-	-	PUNCT	:	7	O
a	a	DET	DT	5	O
highly	highly	ADV	RB	9	O
aggressive	aggressive	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
:	:	PUNCT	:	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
gained	gain	VERB	VBD	5	O
knowledge	knowledge	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
etiology	etiology	NOUN	NN	9	O
,	,	PUNCT	,	9	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
associated	associate	VERB	VBD	9	O
urothelial	urothelial	ADJ	JJ	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
records	record	NOUN	NNS	5	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
age	age	NOUN	NN	5	O
55	55	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
associated	associate	VERB	VBN	9	O
bladder	bladder	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
were	be	VERB	VBD	9	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
All	all	DET	DT	9	O
tumors	tumor	NOUN	NNS	3	B-Disease
were	be	VERB	VBD	9	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
or	or	CCONJ	CC	5	O
4	4	NUM	CD	9	O
transitional	transitional	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
initially	initially	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
endoscopic	endoscopic	ADJ	JJ	5	O
resection	resection	NOUN	NN	5	O
alone	alone	ADV	RB	9	O
only	only	ADV	RB	9	O
1	1	NUM	CD	9	O
is	be	VERB	VBZ	5	O
alive	alive	ADJ	JJ	9	O
without	without	ADP	IN	9	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
6	6	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
early	early	ADJ	JJ	9	O
cystectomy	cystectomy	NOUN	NN	5	O
4	4	NUM	CD	9	O
were	be	VERB	VBD	9	O
alive	alive	ADJ	JJ	9	O
at	at	ADP	IN	9	O
24	24	NUM	CD	9	O
to	to	PART	TO	5	O
111	111	NUM	CD	7	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
extensive	extensive	ADJ	JJ	5	O
cancer	cancer	NOUN	NN	3	B-Disease
underwent	undergo	VERB	VBD	5	O
partial	partial	ADJ	JJ	9	O
cystectomy	cystectomy	NOUN	NN	5	O
for	for	ADP	IN	5	O
palliation	palliation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
died	die	VERB	VBD	9	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
associated	associate	VERB	VBN	9	O
bladder	bladder	NOUN	NN	9	B-Disease
tumor	tumor	NOUN	NN	3	I-Disease
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
aggressive	aggressive	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
survival	survival	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
possible	possible	ADJ	JJ	5	O
when	when	ADV	WRB	5	O
radical	radical	ADJ	JJ	0	O
cystectomy	cystectomy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
performed	perform	VERB	VBN	9	O
for	for	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
with	with	ADP	IN	5	O
any	any	DET	DT	5	O
sign	sign	NOUN	NN	5	O
of	of	ADP	IN	5	O
invasion	invasion	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
high	high	ADJ	JJ	9	O
grade	grade	NOUN	NN	9	O
disease	disease	NOUN	NN	5	O
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
when	when	ADV	WRB	5	O
noninvasive	noninvasive	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
phase	phase	NOUN	NN	5	O
I	-PRON-	PRON	PRP	9	O
clinical	clinical	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
antipurine	antipurine	NOUN	NN	0	B-Chemical
antifolate	antifolate	NOUN	NN	0	O
lometrexol	lometrexol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DDATHF	DDATHF	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
given	give	VERB	VBN	5	O
with	with	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
folic	folic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Lometrexol	Lometrexol	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
antifolate	antifolate	NOUN	NN	0	O
which	which	DET	WDT	5	O
inhibits	inhibit	VERB	VBZ	3	O
glycinamide	glycinamide	ADJ	JJ	0	B-Chemical
ribonucleotide	ribonucleotide	NOUN	NN	1	I-Chemical
formyltransferase	formyltransferase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
GARFT	GARFT	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
enzyme	enzyme	ADJ	JJ	0	O
essential	essential	NOUN	NN	9	O
for	for	ADP	IN	5	O
de	de	X	FW	2	O
novo	novo	X	FW	9	O
purine	purine	ADJ	JJ	0	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Extensive	extensive	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
limited	limited	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
lometrexol	lometrexol	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
activity	activity	NOUN	NN	9	O
against	against	ADP	IN	9	O
tumours	tumour	NOUN	NNS	3	B-Disease
which	which	DET	WDT	5	O
are	be	VERB	VBP	5	O
refractory	refractory	ADJ	JJ	9	O
to	to	ADP	IN	5	O
other	other	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
notably	notably	ADV	RB	9	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
lometrexol	lometrexol	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
curtailed	curtail	VERB	VBN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
cumulative	cumulative	ADJ	JJ	5	O
antiproliferative	antiproliferative	ADJ	JJ	3	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Preclinical	preclinical	ADJ	JJ	9	O
murine	murine	NOUN	NN	3	O
studies	study	NOUN	NNS	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
lometrexol	lometrexol	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
folic	folic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
bolus	bolus	NOUN	NN	0	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
observation	observation	NOUN	NN	9	O
prompted	prompt	VERB	VBD	9	O
a	a	DET	DT	5	O
Phase	Phase	PROPN	NNP	9	O
I	-PRON-	PRON	PRP	9	O
clinical	clinical	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
lometrexol	lometrexol	NOUN	NN	0	B-Chemical
given	give	VERB	VBN	5	O
with	with	ADP	IN	5	O
folic	folic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
supplementation	supplementation	NOUN	NN	0	O
which	which	DET	WDT	5	O
has	have	VERB	VBZ	9	O
confirmed	confirm	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
lometrexol	lometrexol	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
markedly	markedly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
folic	folic	ADJ	JJ	0	B-Chemical
acid	acid	ADJ	JJ	0	I-Chemical
supplementation	supplementation	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Thrombocytopenia	thrombocytopenia	NOUN	NN	7	B-Disease
and	and	CCONJ	CC	5	O
mucositis	mucositis	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
clear	clear	ADJ	JJ	9	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
folate	folate	ADJ	JJ	9	B-Chemical
elevation	elevation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Associated	associated	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
lometrexol	lometrexol	ADJ	JJ	0	B-Chemical
plasma	plasma	NOUN	NN	9	O
pharmacokinetics	pharmacokinetic	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
altered	alter	VERB	VBN	9	O
by	by	ADP	IN	9	O
folic	folic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
administration	administration	NOUN	NN	9	O
indicating	indicate	VERB	VBG	9	O
that	that	DET	DT	5	O
supplementation	supplementation	NOUN	NN	0	O
is	be	VERB	VBZ	5	O
unlikely	unlikely	ADJ	JJ	9	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
by	by	ADP	IN	9	O
enhancing	enhance	VERB	VBG	9	O
lometrexol	lometrexol	ADJ	JJ	0	B-Chemical
plasma	plasma	NOUN	NN	9	O
clearance	clearance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
work	work	NOUN	NN	5	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
report	report	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
identified	identify	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
a	a	DET	DT	5	O
clinically	clinically	ADV	RB	5	O
acceptable	acceptable	ADJ	JJ	5	O
schedule	schedule	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
GARFT	GARFT	PROPN	NNP	0	O
inhibitor	inhibitor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
information	information	NOUN	NN	5	O
will	will	VERB	MD	5	O
facilitate	facilitate	VERB	VB	5	O
the	the	DET	DT	5	O
future	future	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
class	class	NOUN	NN	9	O
of	of	ADP	IN	5	O
compounds	compound	NOUN	NNS	0	O
in	in	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Fatal	fatal	ADJ	JJ	5	O
excited	excited	ADJ	JJ	0	O
delirium	delirium	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
:	:	PUNCT	:	9	O
epidemiologic	epidemiologic	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
provide	provide	VERB	VBP	5	O
new	new	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
an	an	DET	DT	5	O
outbreak	outbreak	NOUN	NN	5	O
of	of	ADP	IN	5	O
deaths	death	NOUN	NNS	5	O
from	from	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
excited	excited	ADJ	JJ	0	O
delirium	delirium	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
EDDs	EDDs	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
Dade	Dade	PROPN	NNP	2	O
County	County	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Florida	Florida	PROPN	NNP	4	O
between	between	ADP	IN	5	O
1979	1979	NUM	CD	2	O
and	and	CCONJ	CC	5	O
1990	1990	NUM	CD	2	O
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
a	a	DET	DT	5	O
registry	registry	NOUN	NN	5	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
deaths	death	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Dade	Dade	PROPN	NNP	2	O
County	County	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Florida	Florida	PROPN	NNP	4	O
,	,	PUNCT	,	9	O
from	from	ADP	IN	9	O
1969	1969	NUM	CD	2	O
-	-	SYM	SYM	7	O
1990	1990	NUM	CD	2	O
,	,	PUNCT	,	9	O
58	58	NUM	CD	7	O
EDDs	edd	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
125	125	NUM	CD	9	O
victims	victim	NOUN	NNS	5	O
of	of	ADP	IN	5	O
accidental	accidental	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
without	without	ADP	IN	9	O
excited	excited	ADJ	JJ	0	O
delirium	delirium	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
EDDs	edd	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
frequently	frequently	ADV	RB	5	O
black	black	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
male	male	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
younger	young	ADJ	JJR	5	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
body	body	NOUN	NN	5	O
mass	mass	NOUN	NN	9	O
index	index	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
died	die	VERB	VBN	9	O
in	in	ADP	IN	5	O
police	police	NOUN	NN	5	O
custody	custody	NOUN	NN	5	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
received	receive	VERB	VBN	9	O
medical	medical	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
immediately	immediately	ADV	RB	9	O
before	before	ADP	IN	9	O
death	death	NOUN	NN	9	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
survived	survive	VERB	VBN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
longer	long	ADJ	JJR	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
developed	develop	VERB	VBN	5	O
hyperthermia	hyperthermia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
died	die	VERB	VBN	9	O
in	in	ADP	IN	5	O
summer	summer	NOUN	NN	4	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

EDDs	EDDs	PROPN	NNP	5	B-Disease
had	have	VERB	VBD	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
benzoylecgonine	benzoylecgonine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
autopsy	autopsy	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
for	for	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
epidemiologic	epidemiologic	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
most	most	ADV	RBS	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	WDT	5	O
chronic	chronic	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
disrupts	disrupt	NOUN	NNS	9	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
coupled	couple	VERB	VBN	9	O
with	with	ADP	IN	5	O
recent	recent	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
precipitate	precipitate	VERB	VB	0	O
agitation	agitation	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
delirium	delirium	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
aberrant	aberrant	ADJ	JJ	3	O
thermoregulation	thermoregulation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sudden	sudden	ADJ	JJ	5	B-Disease
death	death	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Pemoline	Pemoline	PROPN	NNP	7	B-Chemical
induced	induce	VERB	VBD	3	O
acute	acute	ADJ	JJ	9	O
choreoathetosis	choreoathetosis	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Pemoline	Pemoline	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
oxazolidine	oxazolidine	NOUN	NN	0	B-Chemical
derivative	derivative	NOUN	NN	0	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
structurally	structurally	ADV	RB	9	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
amphetamines	amphetamine	NOUN	NNS	5	B-Chemical
and	and	CCONJ	CC	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
attention	attention	NOUN	NN	5	B-Disease
deficit	deficit	NOUN	NN	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Pemoline	Pemoline	PROPN	NNP	7	B-Chemical
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
commonly	commonly	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
movement	movement	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
case	case	NOUN	NN	5	O
describes	describe	VERB	VBZ	5	O
two	two	NUM	CD	5	O
children	child	NOUN	NNS	5	O
acutely	acutely	ADV	RB	9	O
poisoned	poison	VERB	VBD	5	O
with	with	ADP	IN	5	O
pemoline	pemoline	NOUN	NN	5	B-Chemical
who	who	PRON	WP	5	O
experienced	experience	VERB	VBD	5	O
profound	profound	ADJ	JJ	9	O
choreoathetosis	choreoathetosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
REPORT	REPORT	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	NOUN	NN	9	O
,	,	PUNCT	,	9	O
identical	identical	ADJ	JJ	9	O
twin	twin	ADJ	JJ	5	O
siblings	sibling	NOUN	NNS	5	O
presented	present	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
after	after	ADP	IN	9	O
found	find	VERB	VBD	9	O
playing	play	VERB	VBG	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
an	an	DET	DT	5	O
empty	empty	ADJ	JJ	3	O
bottle	bottle	NOUN	NN	5	O
of	of	ADP	IN	5	O
pemoline	pemoline	NOUN	NN	5	B-Chemical
originally	originally	ADV	RB	9	O
containing	contain	VERB	VBG	0	O
59	59	NUM	CD	7	O
tablets	tablet	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
children	child	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
significant	significant	ADJ	JJ	9	O
for	for	ADP	IN	5	O
attention	attention	NOUN	NN	5	B-Disease
deficit	deficit	NOUN	NN	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
previously	previously	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
methylphenidate	methylphenidate	NOUN	NN	5	B-Chemical
without	without	ADP	IN	9	O
success	success	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
their	-PRON-	DET	PRP$	5	O
first	first	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
pemoline	pemoline	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
choreoathetoid	choreoathetoid	ADJ	JJ	5	B-Disease
movements	movement	NOUN	NNS	5	O
began	begin	VERB	VBD	5	O
45	45	NUM	CD	9	O
min	min	NOUN	NN	0	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
ingestion	ingestion	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
children	child	NOUN	NNS	5	O
gave	give	VERB	VBD	9	O
no	no	DET	DT	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
movement	movement	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
family	family	NOUN	NN	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
movement	movement	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
children	child	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	O
decontamination	decontamination	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
benzodiazepines	benzodiazepine	NOUN	NNS	5	B-Chemical
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
attempt	attempt	NOUN	NN	5	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
the	the	DET	DT	5	O
choreoathetoid	choreoathetoid	ADJ	JJ	5	B-Disease
movements	movement	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
children	child	NOUN	NNS	5	O
continued	continue	VERB	VBD	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
choreoathetosis	choreoathetosis	NOUN	NN	5	B-Disease
for	for	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
eight	eight	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
admission	admission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
children	child	NOUN	NNS	5	O
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
at	at	ADP	IN	9	O
their	-PRON-	DET	PRP$	5	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
discharged	discharge	VERB	VBN	5	O
home	home	ADV	RB	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Pemoline	Pemoline	PROPN	NNP	7	B-Chemical
associated	associate	VERB	VBN	9	O
movement	movement	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
rarely	rarely	ADV	RB	5	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
toxicology	toxicology	NOUN	NN	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
choreoathetoid	choreoathetoid	ADJ	JJ	5	B-Disease
movements	movement	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
presenting	present	VERB	VBG	5	O
after	after	ADP	IN	9	O
pemoline	pemoline	NOUN	NN	5	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
myopic	myopic	ADJ	JJ	5	O
excimer	excimer	ADJ	JJ	0	O
laser	laser	NOUN	NN	5	O
photorefractive	photorefractive	ADJ	JJ	5	O
keratectomy	keratectomy	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
electrophysiologic	electrophysiologic	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
retina	retina	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
optic	optic	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
by	by	ADP	IN	9	O
electrophysiologic	electrophysiologic	ADJ	JJ	5	O
testing	test	VERB	VBG	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
photorefractive	photorefractive	ADJ	JJ	5	O
keratectomy	keratectomy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PRK	PRK	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
retina	retina	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
optic	optic	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
.	.	PUNCT	.	9	O

SETTING	setting	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Eye	Eye	PROPN	NNP	2	O
Clinic	Clinic	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
S	S	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Salvatore	Salvatore	PROPN	NNP	6	O
Hospital	Hospital	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
L	L	PROPN	NNP	0	O
'	'	PUNCT	``	9	O
Aquila	Aquila	PROPN	NNP	4	O
University	University	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Italy	Italy	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Standard	standard	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
electroretinograms	electroretinogram	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ERGs	ERGs	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
standard	standard	ADJ	JJ	5	O
pattern	pattern	NOUN	NN	9	O
visual	visual	ADJ	JJ	5	O
evoked	evoke	VERB	VBN	5	O
potentials	potential	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
VEPs	VEPs	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
in	in	ADP	IN	5	O
25	25	NUM	CD	9	O
eyes	eye	NOUN	NNS	5	O
of	of	ADP	IN	5	O
25	25	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
myopic	myopic	ADJ	JJ	5	O
PRK	PRK	PROPN	NNP	1	O
for	for	ADP	IN	5	O
an	an	DET	DT	5	O
attempted	attempt	VERB	VBN	5	O
correction	correction	NOUN	NN	5	O
between	between	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
00	00	PUNCT	NFP	7	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
00	00	PUNCT	NFP	7	O
diopters	diopter	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
D	D	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
00	00	PUNCT	NFP	7	O
D	d	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Testing	Testing	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
preoperatively	preoperatively	ADV	RB	5	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
18	18	NUM	CD	7	O
months	month	NOUN	NNS	5	O
postoperatively	postoperatively	ADV	RB	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
contralateral	contralateral	ADJ	JJ	5	O
eyes	eye	NOUN	NNS	5	O
served	serve	VERB	VBD	9	O
as	as	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBD	5	O
steroid	steroid	ADV	RB	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
elevated	elevated	ADJ	JJ	9	B-Disease
intraocular	intraocular	ADJ	JJ	5	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
IOP	IOP	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
that	that	DET	WDT	5	O
resolved	resolve	VERB	VBD	9	O
after	after	ADP	IN	9	O
corticosteroid	corticosteroid	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
No	no	DET	DT	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
between	between	ADP	IN	5	O
treated	treat	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
eyes	eye	NOUN	NNS	5	O
nor	nor	CCONJ	CC	9	O
between	between	ADP	IN	5	O
treated	treated	ADJ	JJ	3	O
eyes	eye	NOUN	NNS	5	O
preoperatively	preoperatively	ADV	RB	5	O
and	and	CCONJ	CC	5	O
postoperatively	postoperatively	ADV	RB	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Myopic	myopic	ADJ	JJ	5	O
excimer	excimer	NOUN	NN	0	O
laser	laser	NOUN	NN	5	O
PRK	PRK	PROPN	NNP	1	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
seem	seem	VERB	VB	5	O
to	to	PART	TO	5	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
posterior	posterior	ADJ	JJ	5	O
segment	segment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
transient	transient	ADJ	JJ	9	O
steroid	steroid	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
IOP	IOP	PROPN	NNP	5	B-Disease
rise	rise	NOUN	NN	9	I-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
seem	seem	VERB	VB	5	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
functional	functional	ADJ	JJ	9	O
impairment	impairment	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neutrophil	neutrophil	NOUN	NN	9	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
hydrogen	hydrogen	NOUN	NN	0	B-Chemical
peroxide	peroxide	NOUN	NN	0	I-Chemical
production	production	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Defects	defect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
hydrogen	hydrogen	NOUN	NN	0	B-Chemical
peroxide	peroxide	NOUN	NN	0	I-Chemical
production	production	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
bacterial	bacterial	ADJ	JJ	9	B-Disease
infections	infection	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ALF	ALF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
radical	radical	ADJ	JJ	0	O
production	production	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ALF	ALF	PROPN	NNP	9	B-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
was	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Neutrophils	neutrophil	NOUN	NNS	9	O
from	from	ADP	IN	9	O
14	14	NUM	CD	7	O
ALF	ALF	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
stimulated	stimulate	VERB	VBN	3	O
via	via	ADP	IN	9	O
the	the	DET	DT	5	O
complement	complement	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
using	use	VERB	VBG	9	O
zymosan	zymosan	NOUN	NN	3	O
opsonized	opsonize	VERB	VBN	3	O
with	with	ADP	IN	5	O
ALF	ALF	PROPN	NNP	9	B-Disease
or	or	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
serum	serum	ADV	RB	9	O
.	.	PUNCT	.	9	O

Superoxide	Superoxide	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
hydrogen	hydrogen	NOUN	NN	0	B-Chemical
peroxide	peroxide	NOUN	NN	0	I-Chemical
production	production	NOUN	NN	9	O
by	by	ADP	IN	9	O
ALF	ALF	PROPN	NNP	9	B-Disease
neutrophils	neutrophil	NOUN	NNS	3	O
stimulated	stimulate	VERB	VBN	3	O
with	with	ADP	IN	5	O
zymosan	zymosan	NOUN	NN	3	O
opsonized	opsonize	VERB	VBN	3	O
with	with	ADP	IN	5	O
ALF	ALF	PROPN	NNP	9	B-Disease
serum	serum	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
defect	defect	NOUN	NN	9	O
persisted	persist	VERB	VBD	9	O
when	when	ADV	WRB	5	O
zymosan	zymosan	NOUN	NN	3	O
opsonized	opsonize	VERB	VBN	3	O
by	by	ADP	IN	9	O
control	control	NOUN	NN	9	O
serum	serum	NOUN	NN	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Superoxide	Superoxide	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
hydrogen	hydrogen	NOUN	NN	0	B-Chemical
peroxide	peroxide	NOUN	NN	0	I-Chemical
production	production	NOUN	NN	9	O
in	in	ADP	IN	5	O
neutrophils	neutrophil	NOUN	NNS	3	O
stimulated	stimulate	VERB	VBN	3	O
with	with	ADP	IN	5	O
formyl	formyl	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methionyl	methionyl	NOUN	NN	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
leucyl	leucyl	NOUN	NN	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phenylalanine	phenylalanine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
fMLP	fMLP	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
further	further	ADJ	JJ	9	O
18	18	NUM	CD	7	O
ALF	ALF	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
unaffected	unaffected	ADJ	JJ	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
control	control	NOUN	NN	9	O
neutrophils	neutrophil	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Serum	Serum	PROPN	NNP	9	O
C3	C3	PROPN	NNP	9	O
complement	complement	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
ALF	ALF	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0005	0005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
a	a	DET	DT	5	O
neutrophil	neutrophil	NOUN	NN	3	O
defect	defect	NOUN	NN	9	O
in	in	ADP	IN	5	O
ALF	ALF	PROPN	NNP	9	B-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
paracetamol	paracetamol	ADJ	JJ	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
,	,	PUNCT	,	9	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
complement	complement	NOUN	NN	9	O
dependent	dependent	ADJ	JJ	9	O
but	but	CCONJ	CC	9	O
independent	independent	ADJ	JJ	9	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
complement	complement	NOUN	NN	9	O
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
connected	connect	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
complement	complement	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Cholesteryl	cholesteryl	NOUN	NN	0	B-Chemical
hemisuccinate	hemisuccinate	ADJ	JJ	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
protects	protect	VERB	VBZ	3	O
rodents	rodent	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
,	,	PUNCT	,	9	O
carbon	carbon	NOUN	NN	0	B-Chemical
tetrachloride	tetrachloride	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
chloroform	chloroform	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
galactosamine	galactosamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
stabilizer	stabilizer	NOUN	NN	0	O
/	/	SYM	SYM	9	O
rigidifier	rigidifier	NOUN	NN	9	O
of	of	ADP	IN	5	O
membranes	membrane	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
cholesteryl	cholesteryl	NOUN	NN	0	B-Chemical
hemisuccinate	hemisuccinate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
tris	tris	NOUN	NN	0	B-Chemical
salt	salt	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CS	CS	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
also	also	ADV	RB	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
protect	protect	VERB	VB	9	O
rats	rat	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
hepatotoxic	hepatotoxic	ADJ	JJ	0	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
carbon	carbon	NOUN	NN	0	B-Chemical
tetrachloride	tetrachloride	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CCl4	CCl4	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
further	further	VERB	VB	9	O
our	-PRON-	DET	PRP$	5	O
understanding	understanding	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
CS	CS	PROPN	NNP	9	B-Chemical
cytoprotection	cytoprotection	NOUN	NN	3	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
examined	examine	VERB	VBD	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
mice	mouse	NOUN	NNS	3	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
abilities	ability	NOUN	NNS	5	O
of	of	ADP	IN	5	O
CS	CS	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
hydrolyzable	hydrolyzable	ADJ	JJ	0	O
ether	ether	ADJ	JJ	0	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
CS	CS	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
cholesteryloxybutyric	cholesteryloxybutyric	NOUN	NN	_	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
tris	tris	NOUN	NN	0	B-Chemical
salt	salt	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CSE	CSE	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
against	against	ADP	IN	9	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
carbon	carbon	NOUN	NN	0	B-Chemical
tetrachloride	tetrachloride	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
chloroform	chloroform	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
galactosamine	galactosamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
CS	CS	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
protection	protection	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
selective	selective	ADJ	JJ	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
particular	particular	ADJ	JJ	5	O
species	specie	NOUN	NNS	4	O
,	,	PUNCT	,	9	O
organ	organ	NOUN	NN	5	O
system	system	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
toxic	toxic	ADJ	JJ	0	O
chemical	chemical	NOUN	NN	0	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
24	24	NUM	CD	9	O
-	-	SYM	SYM	7	O
h	h	NOUN	NN	0	O
pretreatment	pretreatment	NOUN	NN	0	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
CS	CS	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
100mg	100mg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
protection	protection	NOUN	NN	9	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
hepatotoxic	hepatotoxic	ADJ	JJ	0	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
CCl4	CCl4	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
CHCl3	CHCl3	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
galactosamine	galactosamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
lethal	lethal	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
and	and	CCONJ	CC	5	O
presumably	presumably	ADV	RB	9	O
cardiotoxic	cardiotoxic	ADJ	JJ	5	B-Disease
)	)	PUNCT	-RRB-	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Maximal	Maximal	PROPN	NNP	9	O
CS	CS	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
protection	protection	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
animals	animal	NOUN	NNS	9	O
pretreated	pretreate	VERB	VBD	3	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
insult	insult	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
CS	CS	PROPN	NNP	9	B-Chemical
intervenes	intervene	NOUN	NNS	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
critical	critical	ADJ	JJ	9	O
cellular	cellular	ADJ	JJ	3	O
event	event	NOUN	NN	5	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
common	common	ADJ	JJ	5	O
pathway	pathway	NOUN	NN	3	O
to	to	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	O
cell	cell	NOUN	NN	3	O
death	death	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
CS	CS	PROPN	NNP	9	B-Chemical
protection	protection	NOUN	NN	9	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
appear	appear	VERB	VB	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
dependent	dependent	ADJ	JJ	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
chemical	chemical	ADJ	JJ	0	O
bioactivation	bioactivation	NOUN	NN	0	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
reactive	reactive	ADJ	JJ	9	O
intermediate	intermediate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
in	in	ADP	IN	5	O
light	light	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
protection	protection	NOUN	NN	9	O
observed	observe	VERB	VBN	9	O
against	against	ADP	IN	9	O
galactosamine	galactosamine	ADJ	JJ	0	B-Chemical
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
presented	present	VERB	VBN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
not	not	ADV	RB	5	O
exclude	exclude	VERB	VB	9	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
CS	CS	PROPN	NNP	9	B-Chemical
administration	administration	NOUN	NN	9	O
inhibits	inhibit	VERB	VBZ	3	O
chemical	chemical	NOUN	NN	0	O
bioactivation	bioactivation	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
findings	finding	NOUN	NNS	9	O
do	do	VERB	VBP	5	O
suggest	suggest	VERB	VB	9	O
that	that	ADP	IN	5	O
CS	CS	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
protection	protection	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
dependent	dependent	ADJ	JJ	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
intact	intact	ADJ	JJ	9	O
anionic	anionic	ADJ	JJ	0	O
CS	CS	PROPN	NNP	9	B-Chemical
molecule	molecule	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
hydrolyzable	hydrolyzable	ADJ	JJ	0	O
CSE	CSE	PROPN	NNP	3	B-Chemical
was	be	VERB	VBD	9	O
as	as	ADV	RB	5	O
protective	protective	ADJ	JJ	9	O
as	as	ADP	IN	5	O
CS	CS	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
whose	whose	DET	WP$	9	O
mechanism	mechanism	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
yet	yet	ADV	RB	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
defined	define	VERB	VBN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
murine	murine	ADJ	JJ	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
adenomyosis	adenomyosis	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
adenomyosis	adenomyosis	NOUN	NN	5	B-Disease
induction	induction	NOUN	NN	3	O
in	in	ADP	IN	5	O
Wistar	Wistar	PROPN	NNP	9	O
albino	albino	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
castrated	castrate	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
noncastrated	noncastrated	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
caused	cause	VERB	VBD	9	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
effects	effect	NOUN	NNS	9	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
adenomyosis	adenomyosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Fluoxetine	Fluoxetine	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
Wistar	Wistar	PROPN	NNP	9	O
Albino	Albino	PROPN	NNP	2	O
rats	rat	NOUN	NNS	9	O
for	for	ADP	IN	5	O
98	98	NUM	CD	7	O
days	day	NOUN	NNS	9	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
consisting	consist	VERB	VBG	9	O
of	of	ADP	IN	5	O
castrated	castrate	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
noncastrated	noncastrated	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
castrated	castrate	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
noncastrated	noncastrated	ADJ	JJ	3	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Prolactin	prolactin	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
uteri	uteri	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
removed	remove	VERB	VBN	9	O
for	for	ADP	IN	5	O
histopathological	histopathological	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
98	98	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

SETTING	setting	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Marmara	Marmara	PROPN	NNP	2	O
University	University	PROPN	NNP	2	O
School	School	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Medicine	Medicine	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Department	Department	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Histology	Histology	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
Embryology	Embryology	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Zeynep	Zeynep	PROPN	NNP	6	O
Kamil	Kamil	PROPN	NNP	6	O
Women	Women	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Children	Children	PROPN	NNP	5	O
'	'	PART	POS	9	O
s	s	PROPN	NNP	9	O
Hospital	Hospital	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

MAIN	MAIN	PROPN	NNP	2	O
OUTCOME	OUTCOME	PROPN	NNP	2	O
MEASURES	MEASURES	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Serum	serum	ADJ	JJ	9	O
prolactin	prolactin	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
uterine	uterine	ADJ	JJ	5	O
histopathology	histopathology	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
prolactin	prolactin	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
castrated	castrate	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
noncastrated	noncastrated	ADJ	JJ	3	O
groups	group	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
respective	respective	ADJ	JJ	9	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Histological	histological	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
11	11	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
adenomyosis	adenomyosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
noncastrated	noncastrated	ADJ	JJ	3	O
group	group	NOUN	NN	9	O
receiving	receive	VERB	VBG	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
high	high	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
prolactin	prolactin	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
cause	cause	VERB	VBP	5	O
degeneration	degeneration	NOUN	NN	9	O
of	of	ADP	IN	5	O
myometrial	myometrial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
ovarian	ovarian	ADJ	JJ	9	O
steroids	steroid	NOUN	NNS	9	B-Chemical
that	that	DET	WDT	5	O
results	result	VERB	VBZ	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
myometrial	myometrial	ADJ	JJ	3	O
invasion	invasion	NOUN	NN	3	O
by	by	ADP	IN	9	O
endometrial	endometrial	ADJ	JJ	9	O
stroma	stroma	NOUN	NN	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
invasion	invasion	NOUN	NN	3	O
eventually	eventually	ADV	RB	5	O
progresses	progress	VERB	VBZ	5	O
to	to	PART	TO	5	O
adenomyosis	adenomyosis	VERB	VB	5	B-Disease
.	.	PUNCT	.	9	O

Postinfarction	postinfarction	NOUN	NN	7	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
septal	septal	ADJ	JJ	5	I-Disease
defect	defect	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
postinfarction	postinfarction	NOUN	NN	3	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
septal	septal	ADJ	JJ	5	I-Disease
rupture	rupture	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
are	be	VERB	VBP	5	O
presented	present	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
favourable	favourable	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
cases	case	NOUN	NNS	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
possible	possible	ADJ	JJ	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
postinfarction	postinfarction	NOUN	NN	3	O
septal	septal	ADJ	JJ	5	B-Disease
rupture	rupture	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Neuroactive	neuroactive	ADJ	JJ	7	O
steroids	steroid	NOUN	NNS	9	B-Chemical
protect	protect	VERB	VBP	9	O
against	against	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
kainic	kainic	VERB	VB	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
limbic	limbic	NOUN	NN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Several	several	ADJ	JJ	9	O
structurally	structurally	ADV	RB	9	O
related	relate	VERB	VBN	9	O
metabolites	metabolite	NOUN	NNS	0	O
of	of	ADP	IN	5	O
progesterone	progesterone	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	B-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxy	hydroxy	NOUN	NN	0	I-Chemical
pregnane	pregnane	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
20	20	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ones	one	NOUN	NNS	5	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
deoxycorticosterone	deoxycorticosterone	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	B-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxy	hydroxy	NOUN	NN	0	I-Chemical
pregnane	pregnane	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
21	21	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
diol	diol	NOUN	NNS	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
20	20	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ones	one	NOUN	NNS	5	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
3	3	NUM	CD	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
epimers	epimer	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
for	for	ADP	IN	5	O
protective	protective	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
against	against	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
kainic	kainic	VERB	VB	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
(	(	PUNCT	-LRB-	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Steroids	steroid	NOUN	NNS	0	B-Chemical
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hydroxy	hydroxy	NOUN	NN	0	O
group	group	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
position	position	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
H	h	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
configurations	configuration	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
highly	highly	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
protecting	protect	VERB	VBG	9	O
against	against	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
416	416	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
s	s	X	XX	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
induced	induce	VERB	VBN	3	O
limbic	limbic	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ED50	ED50	PROPN	NNP	0	O
values	value	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
corresponding	correspond	VERB	VBG	9	O
epimers	epimer	NOUN	NNS	0	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hydroxy	hydroxy	NOUN	NN	0	O
group	group	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
position	position	NOUN	NN	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
less	less	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
ED50	ED50	PROPN	NNP	0	O
values	value	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
-	-	SYM	SYM	7	O
63	63	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
neuroactive	neuroactive	ADJ	JJ	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
were	be	VERB	VBD	9	O
considerably	considerably	ADV	RB	9	O
less	less	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
benzodiazepine	benzodiazepine	NOUN	NN	5	B-Chemical
clonazepam	clonazepam	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
protecting	protect	VERB	VBG	9	O
against	against	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
steroids	steroid	NOUN	NNS	9	B-Chemical
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
alpha	alpha	NOUN	NN	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
configuration	configuration	NOUN	NN	5	O
had	have	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
protective	protective	ADJ	JJ	9	O
index	index	NOUN	NN	5	O
values	value	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
TD50	TD50	PROPN	NNP	0	O
for	for	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
impairment	impairment	NOUN	NN	5	O
divided	divide	VERB	VBN	5	O
by	by	ADP	IN	9	O
ED50	ED50	PROPN	NNP	0	O
for	for	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
protection	protection	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
clonazepam	clonazepam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
some	some	DET	DT	5	O
neuroactive	neuroactive	ADJ	JJ	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
lower	low	ADJ	JJR	9	O
relative	relative	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Steroids	steroid	NOUN	NNS	0	B-Chemical
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
alpha	alpha	NOUN	NN	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
5	5	NUM	CD	9	O
beta	beta	NOUN	NN	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
configurations	configuration	NOUN	NNS	5	O
also	also	ADV	RB	9	O
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
delay	delay	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
limbic	limbic	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
kainic	kainic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
32	32	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
s	s	X	XX	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
completely	completely	ADV	RB	9	O
protect	protect	VERB	VB	9	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
1	1	NUM	CD	9	O
hr	hr	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
complete	complete	ADJ	JJ	9	O
protection	protection	NOUN	NN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
kainic	kainic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
limbic	limbic	NOUN	NN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
also	also	ADV	RB	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
delay	delay	NOUN	NN	5	O
in	in	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
257	257	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
s	s	X	XX	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
induced	induce	VERB	VBN	3	O
lethality	lethality	NOUN	NN	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
completely	completely	ADV	RB	9	O
protect	protect	VERB	VB	9	O
against	against	ADP	IN	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
seizures	seizure	NOUN	NNS	5	B-Disease
or	or	CCONJ	CC	5	O
lethality	lethality	NOUN	NN	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
neuroactive	neuroactive	ADJ	JJ	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
are	be	VERB	VBP	5	O
highly	highly	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
protecting	protect	VERB	VBG	9	O
against	against	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
kainic	kainic	VERB	VB	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
utility	utility	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
some	some	DET	DT	5	O
forms	form	NOUN	NNS	9	O
of	of	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Hepatic	hepatic	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
extrahepatic	extrahepatic	ADJ	JJ	5	O
angiotensinogen	angiotensinogen	NOUN	NN	3	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
concentration	concentration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
renin	renin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
system	system	NOUN	NN	5	O
proteins	protein	NOUN	NNS	1	O
are	be	VERB	VBP	5	O
altered	alter	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
NS	NS	PROPN	NNP	7	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
work	work	NOUN	NN	5	O
the	the	DET	DT	5	O
messenger	messenger	NOUN	NN	9	O
ribonucleic	ribonucleic	NOUN	NN	0	O
acid	acid	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
mRNA	mRNA	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
angiotensinogen	angiotensinogen	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
Ao	Ao	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
slot	slot	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
blot	blot	NOUN	NN	3	O
hybridization	hybridization	NOUN	NN	9	O
technique	technique	NOUN	NN	5	O
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
extrahepatic	extrahepatic	ADJ	JJ	5	O
tissues	tissue	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
kidney	kidney	NOUN	NN	9	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	O
,	,	PUNCT	,	9	O
brain	brain	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
adrenal	adrenal	ADJ	JJ	9	O
gland	gland	NOUN	NN	9	O
from	from	ADP	IN	9	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pair	pair	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
fed	fed	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PF	PF	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

NS	NS	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
amino	amino	NOUN	NN	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nucleoside	nucleoside	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
a	a	DET	DT	5	O
great	great	ADJ	JJ	5	O
urinary	urinary	ADJ	JJ	9	O
excretion	excretion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
half	half	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
normal	normal	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
Ao	Ao	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
6	6	NUM	CD	9	O
after	after	ADP	IN	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
injection	injection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
NS	NS	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
clearly	clearly	ADV	RB	9	O
established	establish	VERB	VBN	9	O
,	,	PUNCT	,	9	O
hepatic	hepatic	ADJ	JJ	9	O
Ao	Ao	PROPN	NNP	9	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
Ao	Ao	PROPN	NNP	9	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
in	in	ADP	IN	5	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
extrahepatic	extrahepatic	ADJ	JJ	5	O
tissues	tissue	NOUN	NNS	9	O
studied	study	VERB	VBD	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
nor	nor	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
its	-PRON-	DET	PRP$	9	O
hepatic	hepatic	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
at	at	ADP	IN	9	O
days	day	NOUN	NNS	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
7	7	NUM	CD	9	O
after	after	ADP	IN	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
hepatic	hepatic	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
extrahepatic	extrahepatic	ADJ	JJ	5	O
Ao	Ao	PROPN	NNP	9	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
unaltered	unaltered	ADJ	JJ	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
NS	NS	PROPN	NNP	7	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Neuroleptic	neuroleptic	ADJ	JJ	2	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Neuroleptic	neuroleptic	ADJ	JJ	2	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
thought	think	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D2	d2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
blockade	blockade	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
basal	basal	ADJ	JJ	3	O
ganglia	ganglion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Risperidone	Risperidone	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
benzisoxazole	benzisoxazole	NOUN	NN	0	B-Chemical
derivative	derivative	ADJ	JJ	0	O
antipsychotic	antipsychotic	NOUN	NN	5	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
high	high	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HT2	ht2	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
blockade	blockade	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
D2	d2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
blockade	blockade	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
ratio	ratio	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
believed	believe	VERB	VBN	5	O
to	to	PART	TO	5	O
impart	impart	VERB	VB	5	O
the	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
low	low	ADJ	JJ	9	O
dosages	dosage	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
this	this	DET	DT	5	O
low	low	ADJ	JJ	9	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
thought	think	VERB	VBN	5	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
might	may	VERB	MD	9	O
also	also	ADV	RB	9	O
be	be	VERB	VB	5	O
lowered	lower	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
73	73	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
monotherapy	monotherapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
reversed	reverse	VERB	VBD	9	O
after	after	ADP	IN	9	O
discontinuing	discontinue	VERB	VBG	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
starting	start	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
dantrolene	dantrolene	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
appears	appear	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
protection	protection	NOUN	NN	9	O
from	from	ADP	IN	9	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
ensure	ensure	VERB	VB	5	O
protection	protection	NOUN	NN	9	O
from	from	ADP	IN	9	O
neuroleptic	neuroleptic	ADJ	JJ	5	B-Disease
malignant	malignant	ADJ	JJ	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
attenuating	attenuate	VERB	VBG	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
carteolol	carteolol	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
that	that	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
antagonists	antagonist	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
akathisia	akathisia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
that	that	DET	WDT	5	O
occur	occur	VERB	VBP	5	O
during	during	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Neuroleptic	neuroleptic	ADJ	JJ	2	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
suitable	suitable	ADJ	JJ	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
predicting	predict	VERB	VBG	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
akathisia	akathisia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
considered	consider	VERB	VBN	5	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
test	test	NOUN	NN	5	O
for	for	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
akathisia	akathisia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
carteolol	carteolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
behaviorally	behaviorally	ADV	RB	5	O
studied	study	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
biperiden	biperiden	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
muscarinic	muscarinic	ADJ	JJ	3	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Carteolol	Carteolol	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
biperiden	biperiden	ADV	RB	5	B-Chemical
,	,	PUNCT	,	9	O
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
carteolol	carteolol	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
almost	almost	ADV	RB	9	O
comparable	comparable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
weaker	weak	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
biperiden	biperiden	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Carteolol	Carteolol	PROPN	NNP	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
evoke	evoke	VERB	VB	5	O
postsynaptic	postsynaptic	ADJ	JJ	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
stimulating	stimulate	VERB	VBG	9	O
behavioral	behavioral	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
stereotypy	stereotypy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
hyperlocomotion	hyperlocomotion	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Carteolol	Carteolol	PROPN	NNP	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
antagonize	antagonize	VERB	VB	3	O
the	the	DET	DT	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
stereotypy	stereotypy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
carteolol	carteolol	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
evoke	evoke	VERB	VB	5	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
HT1A	ht1a	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
stimulating	stimulate	VERB	VBG	9	O
behavioral	behavioral	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
flat	flat	ADJ	JJ	5	O
body	body	NOUN	NN	5	O
posture	posture	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
forepaw	forepaw	ADV	RB	5	O
treading	tread	VERB	VBG	4	O
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
inhibit	inhibit	VERB	VB	3	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxytryptophan	hydroxytryptophan	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
head	head	NOUN	NN	5	O
twitch	twitch	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
carteolol	carteolol	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
inhibit	inhibit	VERB	VB	3	O
physostigmine	physostigmine	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
lethality	lethality	NOUN	NN	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
strongly	strongly	ADV	RB	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
carteolol	carteolol	NOUN	NN	0	B-Chemical
improves	improve	VERB	VBZ	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
via	via	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
antagonistic	antagonistic	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
expected	expect	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
akathisia	akathisia	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	O
attenuating	attenuate	VERB	VBG	9	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
postsynaptic	postsynaptic	ADJ	JJ	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonistic	antagonistic	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Granulosa	Granulosa	PROPN	NNP	3	B-Disease
cell	cell	NOUN	NN	3	I-Disease
tumor	tumor	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
ovary	ovary	ADJ	JJ	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
antecedent	antecedent	NOUN	NN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Increased	increase	VERB	VBN	9	O
attention	attention	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
focused	focus	VERB	VBN	5	O
recently	recently	ADV	RB	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
estrogenic	estrogenic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Review	review	NOUN	NN	2	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
reveals	reveal	VERB	VBZ	9	O
an	an	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
gynecologic	gynecologic	ADJ	JJ	5	O
tumors	tumor	NOUN	NNS	3	B-Disease
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
52	52	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
postmenopausal	postmenopausal	NOUN	NN	5	O
woman	woman	NOUN	NN	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
stage	stage	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
breast	breast	NOUN	NN	3	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
aspartate	aspartate	NOUN	NN	1	B-Chemical
transaminase	transaminase	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
alanine	alanine	NOUN	NN	1	B-Chemical
transaminase	transaminase	NOUN	NN	0	O
levels	level	NOUN	NNS	3	O
increase	increase	VERB	VBP	9	O
markedly	markedly	ADV	RB	9	O
after	after	ADP	IN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
an	an	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
17	17	NUM	CD	7	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
elevated	elevated	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
transaminases	transaminase	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
stage	stage	NOUN	NN	9	O
Ic	Ic	PROPN	NNP	9	O
granulosa	granulosa	NOUN	NN	3	B-Disease
cell	cell	NOUN	NN	3	I-Disease
tumor	tumor	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
ovary	ovary	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
liver	liver	NOUN	NN	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
at	at	ADP	IN	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
granulosa	granulosa	NOUN	NN	3	B-Disease
cell	cell	NOUN	NN	3	I-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
metabolism	metabolism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lifetime	lifetime	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
azidothymidine	azidothymidine	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
produces	produce	VERB	VBZ	9	O
myelodysplasia	myelodysplasia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

AZT	AZT	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
induced	induce	VERB	VBN	3	O
a	a	DET	DT	5	O
macrocytic	macrocytic	ADJ	JJ	3	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
long	long	ADJ	JJ	5	O
term	term	NOUN	NN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
generally	generally	ADV	RB	5	O
assumed	assume	VERB	VBN	5	O
that	that	ADP	IN	5	O
DNA	dna	NOUN	NN	9	O
elongation	elongation	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
stopped	stop	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
insertion	insertion	NOUN	NN	1	O
of	of	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
chain	chain	NOUN	NN	9	O
in	in	ADP	IN	5	O
place	place	NOUN	NN	5	O
of	of	ADP	IN	5	O
thymidine	thymidine	NOUN	NN	0	B-Chemical
thus	thus	ADV	RB	9	O
preventing	prevent	VERB	VBG	9	O
the	the	DET	DT	5	O
phosphate	phosphate	ADJ	JJ	0	B-Chemical
hydroxyl	hydroxyl	NOUN	NN	0	O
linkages	linkage	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
therefore	therefore	ADV	RB	5	O
suppresses	suppress	VERB	VBZ	3	O
hemopoietic	hemopoietic	ADJ	JJ	3	O
progenitor	progenitor	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
early	early	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
of	of	ADP	IN	5	O
differentiation	differentiation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

CBA	CBA	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
Ca	ca	NOUN	NN	0	O
male	male	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
started	start	VERB	VBD	5	O
on	on	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
H2O	H2O	PROPN	NNP	0	O
at	at	ADP	IN	9	O
84	84	NUM	CD	7	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
kept	keep	VERB	VBD	9	O
on	on	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
for	for	ADP	IN	5	O
687	687	NUM	CD	7	O
days	day	NOUN	NNS	9	O
when	when	ADV	WRB	5	O
dosage	dosage	NOUN	NN	9	O
reduced	reduce	VERB	VBN	9	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
H2O	H2O	PROPN	NNP	0	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
another	another	DET	DT	9	O
group	group	NOUN	NN	9	O
removed	remove	VERB	VBD	9	O
from	from	ADP	IN	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
to	to	PART	TO	5	O
see	see	VERB	VB	9	O
recovery	recovery	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
third	third	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
on	on	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
687	687	NUM	CD	7	O
days	day	NOUN	NNS	9	O
mice	mouse	NOUN	NNS	3	O
that	that	DET	WDT	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
on	on	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
had	have	VERB	VBD	9	O
average	average	ADJ	JJ	5	O
platelet	platelet	NOUN	NN	9	O
counts	count	NOUN	NNS	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Histological	histological	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
on	on	ADP	IN	5	O
9	9	NUM	CD	7	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
such	such	ADJ	JJ	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
showed	show	VERB	VBD	9	O
changes	change	NOUN	NNS	9	O
compatible	compatible	ADJ	JJ	5	O
with	with	ADP	IN	5	O
myelodysplastic	myelodysplastic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MDS	MDS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
histological	histological	ADJ	JJ	9	O
patterns	pattern	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hypocellular	hypocellular	ADJ	JJ	5	O
myelodysplasia	myelodysplasia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hypersegmented	hypersegmented	ADJ	JJ	3	O
myelodysplastic	myelodysplastic	ADJ	JJ	5	B-Disease
granulocytosis	granulocytosis	NOUN	NN	3	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hypercellular	hypercellular	ADJ	JJ	5	O
marrow	marrow	NOUN	NN	3	O
with	with	ADP	IN	5	O
abnormal	abnormal	ADJ	JJ	9	O
megakaryocytes	megakaryocyte	NOUN	NNS	3	O
with	with	ADP	IN	5	O
bizarre	bizarre	ADJ	JJ	5	O
nuclei	nucleus	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
megakaryocytic	megakaryocytic	ADJ	JJ	3	O
myelosis	myelosis	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
hyperplastic	hyperplastic	ADJ	JJ	3	B-Disease
marrow	marrow	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
dysmyelopoiesis	dysmyelopoiesis	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
hypocellular	hypocellular	ADJ	JJ	5	B-Disease
marrow	marrow	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
myelodysplasia	myelodysplasia	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
dyserythropoiesis	dyserythropoiesis	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
hemosiderosis	hemosiderosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
hypocellular	hypocellular	ADJ	JJ	5	B-Disease
marrow	marrow	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Above	above	ADP	IN	9	O
mentioned	mention	VERB	VBD	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
incorporation	incorporation	NOUN	NN	0	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
induced	induce	VERB	VBN	3	O
an	an	DET	DT	5	O
ineffective	ineffective	ADJ	JJ	9	O
hemopoiesis	hemopoiesis	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
primitive	primitive	ADJ	JJ	5	O
hemopoietic	hemopoietic	ADJ	JJ	3	O
progenitor	progenitor	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
seen	see	VERB	VBN	9	O
commonly	commonly	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
myelodysplastic	myelodysplastic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Biphasic	biphasic	ADJ	JJ	0	O
response	response	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
SA	SA	PROPN	NNP	9	O
node	node	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dog	dog	NOUN	NN	5	O
heart	heart	NOUN	NN	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
to	to	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
SA	SA	PROPN	NNP	9	O
node	node	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dog	dog	NOUN	NN	5	O
heart	heart	NOUN	NN	5	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
perfusion	perfusion	NOUN	NN	5	O
technique	technique	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
SA	SA	PROPN	NNP	9	O
node	node	NOUN	NN	5	O
artery	artery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
from	from	ADP	IN	9	O
100	100	NUM	CD	0	O
microgram	microgram	NOUN	NN	0	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
artery	artery	NOUN	NN	5	O
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
depression	depression	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
SA	SA	PROPN	NNP	9	O
nodal	nodal	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
action	action	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
depression	depression	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
sudden	sudden	ADJ	JJ	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
stimulatory	stimulatory	ADJ	JJ	3	O
phase	phase	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Bilateral	bilateral	ADJ	JJ	5	O
vagotomy	vagotomy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
sympathectomy	sympathectomy	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
prior	prior	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
ganglion	ganglion	NOUN	NN	5	O
blocker	blocker	NOUN	NN	0	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
inhibit	inhibit	VERB	VB	3	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
abolished	abolish	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
reserpinized	reserpinize	VERB	VBN	3	O
dogs	dog	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
prior	prior	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocking	block	VERB	VBG	3	O
agent	agent	NOUN	NN	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
SA	SA	PROPN	NNP	9	O
node	node	NOUN	NN	5	O
artery	artery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
may	may	VERB	MD	5	O
indicate	indicate	VERB	VB	9	O
that	that	ADP	IN	5	O
an	an	DET	DT	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
adrenergic	adrenergic	NOUN	NN	9	O
mechanism	mechanism	NOUN	NN	9	O
plays	play	VERB	VBZ	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
excitatory	excitatory	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
injected	inject	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
SA	SA	PROPN	NNP	9	O
node	node	NOUN	NN	5	O
artery	artery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Over	over	ADP	IN	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
vascular	vascular	ADJ	JJ	5	O
endothelial	endothelial	ADJ	JJ	3	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
receptor	receptor	NOUN	NN	3	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rat	rat	NOUN	NN	3	O
pituitary	pituitary	ADJ	JJ	3	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
may	may	VERB	MD	5	O
mediate	mediate	VERB	VB	3	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
initiated	initiate	VERB	VBN	9	O
tumor	tumor	NOUN	NN	3	B-Disease
angiogenesis	angiogenesis	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Estrogens	Estrogens	PROPN	NNP	5	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
several	several	ADJ	JJ	9	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
animal	animal	NOUN	NN	5	O
cancers	cancer	NOUN	NNS	9	B-Disease
,	,	PUNCT	,	9	O
can	can	VERB	MD	5	O
induce	induce	VERB	VB	3	O
tumor	tumor	NOUN	NN	3	B-Disease
angiogenesis	angiogenesis	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pituitary	pituitary	NOUN	NN	3	O
of	of	ADP	IN	5	O
Fischer	Fischer	PROPN	NNP	6	O
344	344	NUM	CD	7	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanistic	mechanistic	ADJ	JJ	9	O
details	detail	NOUN	NNS	5	O
of	of	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
angiogenesis	angiogenesis	NOUN	NN	3	O
induction	induction	NOUN	NN	3	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
carcinogenesis	carcinogenesis	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
still	still	ADV	RB	5	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
elucidate	elucidate	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
angiogenesis	angiogenesis	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pituitary	pituitary	NOUN	NN	3	O
of	of	ADP	IN	5	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
density	density	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
vessels	vessel	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
analysed	analyse	VERB	VBN	9	O
using	use	VERB	VBG	9	O
factor	factor	NOUN	NN	9	O
VIII	viii	NUM	CD	9	O
related	relate	VERB	VBN	9	O
antigen	antigen	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
FVIIIRAg	FVIIIRAg	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
vascular	vascular	ADJ	JJ	5	O
endothelial	endothelial	ADJ	JJ	3	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
/	/	SYM	SYM	9	O
vascular	vascular	NOUN	NN	5	O
permeability	permeability	NOUN	NN	0	O
factor	factor	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
VEGF	VEGF	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
VPF	VPF	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
by	by	ADP	IN	9	O
Western	western	ADJ	JJ	3	O
blot	blot	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
immunohistochemical	immunohistochemical	ADJ	JJ	3	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
VEGF	VEGF	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
VEGFR	VEGFR	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
Flk	Flk	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
KDR	KDR	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
examined	examine	VERB	VBN	9	O
by	by	ADP	IN	9	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
17beta	17beta	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
estradiol	estradiol	NOUN	NNS	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
E2	E2	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
induces	induce	VERB	VBZ	3	O
neovascularization	neovascularization	NOUN	NN	3	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
growth	growth	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
enlargement	enlargement	NOUN	NN	5	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
vessels	vessel	NOUN	NNS	5	O
after	after	ADP	IN	9	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
tumor	tumor	NOUN	NN	3	B-Disease
angiogenic	angiogenic	ADJ	JJ	3	O
potential	potential	NOUN	NN	9	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
elevated	elevated	ADJ	JJ	9	O
VEGF	VEGF	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
VPF	VPF	PROPN	NNP	3	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
E2	E2	PROPN	NNP	3	B-Chemical
exposed	expose	VERB	VBN	9	O
pituitary	pituitary	NOUN	NN	3	O
of	of	ADP	IN	5	O
ovariectomized	ovariectomized	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
OVEX	OVEX	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

VEGF	VEGF	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
VPF	VPF	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
FVIIIRAg	FVIIIRAg	NOUN	NNS	9	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
endothelial	endothelial	ADJ	JJ	3	O
specific	specific	ADJ	JJ	9	O
lectin	lectin	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
UEA1	UEA1	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
binding	bind	VERB	VBG	1	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
VEGF	VEGF	PROPN	NNP	3	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
initially	initially	ADV	RB	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
blood	blood	NOUN	NN	9	O
vessels	vessel	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
endothelial	endothelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
15	15	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
E2	E2	PROPN	NNP	3	B-Chemical
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
VEGF	VEGF	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
VPF	VPF	PROPN	NNP	3	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
endothelial	endothelial	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
population	population	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sharply	sharply	ADV	RB	9	O
declined	decline	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
restricted	restrict	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
vessels	vessel	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
endothelial	endothelial	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
derived	derive	VERB	VBN	9	O
VEGF	VEGF	PROPN	NNP	3	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
clear	clear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
immunohistochemical	immunohistochemical	ADJ	JJ	3	O
studies	study	NOUN	NNS	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
VEGFR	VEGFR	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
flk	flk	VERB	VBN	1	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
KDR	KDR	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
expression	expression	NOUN	NN	3	O
was	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
significantly	significantly	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
endothelial	endothelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
of	of	ADP	IN	5	O
microblood	microblood	NOUN	NN	9	O
vessels	vessel	NOUN	NNS	5	O
after	after	ADP	IN	9	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
E2	E2	PROPN	NNP	3	B-Chemical
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
over	over	ADP	IN	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
VEGF	VEGF	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
receptor	receptor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
VEGFR	VEGFR	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
may	may	VERB	MD	5	O
play	play	VERB	VB	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
step	step	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
induced	induce	VERB	VBN	3	O
tumor	tumor	NOUN	NN	3	B-Disease
angiogenesis	angiogenesis	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
pituitary	pituitary	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Persistent	persistent	ADJ	JJ	9	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
severe	severe	ADJ	JJ	5	O
hypernatraemic	hypernatraemic	ADJ	JJ	9	O
dehydration	dehydration	NOUN	NN	9	B-Disease
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
head	head	NOUN	NN	5	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Ten	ten	NUM	CD	9	O
years	year	NOUN	NNS	5	O
previously	previously	ADV	RB	9	O
he	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
diagnosed	diagnose	VERB	VBN	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
discontinued	discontinue	VERB	VBN	5	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
remained	remain	VERB	VBD	9	O
thirsty	thirsty	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
polyuric	polyuric	ADJ	JJ	5	B-Disease
despite	despite	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
investigations	investigation	NOUN	NNS	9	O
on	on	ADP	IN	5	O
admission	admission	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
him	-PRON-	PRON	PRP	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
normal	normal	ADJ	JJ	9	O
osmoregulated	osmoregulate	VERB	VBN	1	O
thirst	thirst	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
vasopressin	vasopressin	NOUN	NN	9	B-Chemical
secretion	secretion	NOUN	NN	3	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
clear	clear	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Lithium	Lithium	PROPN	NNP	0	B-Chemical
induced	induce	VERB	VBD	3	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
considered	consider	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
reversible	reversible	ADJ	JJ	9	O
on	on	ADP	IN	5	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
polyuria	polyuria	NOUN	NN	5	B-Disease
persisted	persist	VERB	VBD	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
for	for	ADP	IN	5	O
ten	ten	NUM	CD	9	O
years	year	NOUN	NNS	5	O
after	after	ADP	IN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
discuss	discuss	VERB	VBP	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
implications	implication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrogenic	nephrogenic	ADJ	JJ	5	B-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
NIK	NIK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
247	247	NUM	CD	7	I-Chemical
on	on	ADP	IN	5	O
cholinesterase	cholinesterase	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
NIK	NIK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
247	247	NUM	CD	7	I-Chemical
on	on	ADP	IN	5	O
cholinesterase	cholinesterase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
movement	movement	NOUN	NN	5	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
known	know	VERB	VBN	9	O
cholinesterase	cholinesterase	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
tacrine	tacrine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
E	e	NOUN	NN	9	B-Chemical
-	-	NOUN	NN	7	I-Chemical
2020	2020	NUM	CD	5	I-Chemical
.	.	PUNCT	.	9	O

NIK	NIK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
247	247	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
tacrine	tacrine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
E	e	NOUN	NN	9	B-Chemical
-	-	NOUN	NN	7	I-Chemical
2020	2020	NUM	CD	5	I-Chemical
all	all	DET	DT	5	O
strongly	strongly	ADV	RB	9	O
inhibited	inhibited	ADJ	JJ	3	O
acetylcholinesterase	acetylcholinesterase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
AChE	AChE	PROPN	NNPS	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
human	human	ADJ	JJ	3	O
red	red	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
IC50s	ic50s	X	FW	3	O
=	=	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
M	m	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
NIK	NIK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
247	247	NUM	CD	7	I-Chemical
and	and	CCONJ	CC	5	O
tacrine	tacrine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
E	e	NOUN	NN	9	B-Chemical
-	-	NOUN	NN	7	I-Chemical
2020	2020	NUM	CD	5	I-Chemical
,	,	PUNCT	,	9	O
strongly	strongly	ADV	RB	9	O
inhibited	inhibited	ADJ	JJ	3	O
butyrylcholinestrase	butyrylcholinestrase	NOUN	NN	_	O
(	(	PUNCT	-LRB-	9	O
BuChE	BuChE	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
human	human	ADJ	JJ	3	O
serum	serum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
three	three	NUM	CD	9	O
drugs	drug	NOUN	NNS	5	O
produced	produce	VERB	VBD	9	O
mixed	mixed	ADJ	JJ	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
AChE	AChE	PROPN	NNPS	0	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
NIK	NIK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
247	247	NUM	CD	7	I-Chemical
on	on	ADP	IN	5	O
AChE	AChE	PROPN	NNPS	0	O
was	be	VERB	VBD	9	O
reversible	reversible	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
compounds	compound	NOUN	NNS	0	O
at	at	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	INTJ	UH	9	O
.	.	PUNCT	.	9	O
significantly	significantly	ADV	RB	9	O
improved	improve	VERB	VBD	5	O
the	the	DET	DT	5	O
amnesia	amnesia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
s	s	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
performing	perform	VERB	VBG	5	O
a	a	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
task	task	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
three	three	NUM	CD	9	O
compounds	compound	NOUN	NNS	0	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
decrease	decrease	VERB	VB	9	O
spontaneous	spontaneous	ADJ	JJ	5	O
movement	movement	NOUN	NN	5	O
by	by	ADP	IN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
NIK	NIK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
247	247	NUM	CD	7	I-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
improves	improve	VERB	VBZ	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
but	but	CCONJ	CC	9	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
spontaneous	spontaneous	ADJ	JJ	5	O
movement	movement	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
NIK	NIK	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
247	247	NUM	CD	7	I-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Potential	potential	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D1	d1	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
A	a	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
86929	86929	NUM	CD	_	I-Chemical
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
primed	primed	ADJ	JJ	3	O
monkeys	monkey	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
utility	utility	NOUN	NN	5	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
DA	DA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
D1	d1	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
agonists	agonist	VERB	VBZ	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	pd	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
DA	DA	PROPN	NNP	9	B-Chemical
D1	d1	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
agonists	agonist	VERB	VBZ	3	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
SKF	SKF	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
82958	82958	PROPN	NNP	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chloro	chloro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
7	7	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
8	8	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroxy	dihydroxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
allyl	allyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phenyl	phenyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tetrahydro	tetrahydro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1H	1h	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
benzaze	benzaze	NOUN	NN	_	I-Chemical
pine	pine	NOUN	NN	4	I-Chemical
hydrobromide	hydrobromide	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
A	a	DET	DT	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
77636	77636	NUM	CD	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
[	[	PUNCT	-LRB-	9	B-Chemical
1R	1r	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
3S	3s	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
'	'	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
admantyl	admantyl	NOUN	NN	_	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminomethyl	aminomethyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydro	dihydro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5	5	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
6	6	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroxy	dihydroxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1H	1h	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
benzo	benzo	NOUN	NN	0	I-Chemical
pyran	pyran	NOUN	NN	0	I-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
seems	seem	VERB	VBZ	5	O
limited	limited	ADJ	JJ	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
too	too	ADV	RB	5	O
short	short	ADJ	JJ	5	O
for	for	ADP	IN	5	O
SKF	SKF	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
82958	82958	PROPN	NNP	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
1	1	NUM	CD	9	O
hr	hr	INTJ	UH	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
too	too	ADV	RB	5	O
long	long	ADJ	JJ	5	O
for	for	ADP	IN	5	O
A	a	DET	DT	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
77636	77636	NUM	CD	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
20	20	NUM	CD	9	O
hr	hr	NOUN	NN	0	O
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
behavioral	behavioral	ADJ	JJ	5	O
tolerance	tolerance	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
therefore	therefore	ADV	RB	5	O
conducted	conduct	VERB	VBD	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
acute	acute	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
1	1	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phenyl	phenyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
6	6	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tetrahydropyridine	tetrahydropyridine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
MPTP	MPTP	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
cynomolgus	cynomolgus	ADJ	JJ	9	O
monkeys	monkey	NOUN	NNS	5	O
primed	prime	VERB	VBN	3	O
to	to	PART	TO	5	O
exhibit	exhibit	VERB	VB	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
locomotor	locomotor	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
dyskinetic	dyskinetic	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
challenge	challenge	NOUN	NN	9	O
with	with	ADP	IN	5	O
four	four	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
A	A	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
86929	86929	NUM	CD	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
[	[	PUNCT	-LRB-	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
5aR	5ar	NUM	CD	0	I-Chemical
,	,	PUNCT	,	9	I-Chemical
11bS	11bs	NUM	CD	7	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
5a	5a	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
6	6	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
7	7	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
11b	11b	NOUN	NNS	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hexahydro	hexahydro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
propyl	propyl	NUM	CD	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
thia	thia	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
+	+	CCONJ	CC	9	I-Chemical
+	+	X	XX	9	I-Chemical
+	+	CCONJ	CC	9	I-Chemical
azacyclopent	azacyclopent	ADJ	JJ	_	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ena	ena	NOUN	NN	1	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
c	c	NOUN	NN	9	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
phenathrene	phenathrene	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
10	10	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
diol	diol	NOUN	NNS	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
full	full	ADJ	JJ	5	O
DA	DA	PROPN	NNP	9	B-Chemical
D1	D1	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
intermediate	intermediate	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Levodopa	Levodopa	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
DA	DA	PROPN	NNP	9	B-Chemical
D2	D2	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
LY	LY	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
171555	171555	NUM	CD	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
[	[	PUNCT	-LRB-	9	B-Chemical
4aR	4ar	NUM	CD	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
trans	trans	NOUN	NN	9	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4a	4a	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
6	6	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
7	7	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
8	8	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
8a	8a	NUM	CD	0	I-Chemical
,	,	PUNCT	,	9	I-Chemical
9	9	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
o	o	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydro	dihydro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5n	5n	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
propyl	propyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2H	2h	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pyrazo	pyrazo	NOUN	NN	_	I-Chemical
lo	lo	PROPN	NNP	2	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
quinoline	quinoline	NOUN	NN	0	I-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
A	A	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
86929	86929	NUM	CD	_	I-Chemical
was	be	VERB	VBD	9	O
as	as	ADV	RB	5	O
efficacious	efficacious	ADJ	JJ	5	O
in	in	ADP	IN	5	O
alleviating	alleviate	VERB	VBG	5	O
MPTP	MPTP	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
parkinsonism	parkinsonism	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
and	and	CCONJ	CC	5	O
LY	LY	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
171555	171555	NUM	CD	0	I-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
reproduce	reproduce	VERB	VB	5	O
the	the	DET	DT	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
than	than	ADP	IN	5	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
LY	LY	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
171555	171555	NUM	CD	0	I-Chemical
or	or	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
challenge	challenge	NOUN	NN	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
.	.	PUNCT	.	9	O

Selective	selective	ADJ	JJ	9	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
DA	DA	PROPN	NNP	9	B-Chemical
D1	d1	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
may	may	VERB	MD	5	O
provide	provide	VERB	VB	5	O
better	well	ADJ	JJR	5	O
integration	integration	NOUN	NN	5	O
of	of	ADP	IN	5	O
neural	neural	ADJ	JJ	5	O
inputs	input	NOUN	NNS	5	O
transmitted	transmit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
internal	internal	ADJ	JJ	5	O
segment	segment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
globus	globus	NOUN	NN	5	O
pallidus	pallidus	NOUN	NN	4	O
(	(	PUNCT	-LRB-	9	O
referred	refer	VERB	VBN	5	O
to	to	ADP	IN	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
basal	basal	ADJ	JJ	3	O
ganglia	ganglia	NOUN	NN	5	O
output	output	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
and	and	CCONJ	CC	5	O
selective	selective	ADJ	JJ	9	O
DA	DA	PROPN	NNP	9	B-Chemical
D2	d2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Potent	potent	ADJ	JJ	0	O
DA	DA	PROPN	NNP	9	B-Chemical
D1	d1	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
agents	agent	NOUN	NNS	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
intermediate	intermediate	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
efficacy	efficacy	NOUN	NN	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
A	A	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
86929	86929	NUM	CD	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
approximately	approximately	ADV	RB	9	O
4	4	NUM	CD	9	O
hr	hr	INTJ	UH	0	O
at	at	ADP	IN	9	O
higher	high	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
tested	test	VERB	VBN	9	O
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
potential	potential	ADJ	JJ	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
tools	tool	NOUN	NNS	5	O
in	in	ADP	IN	5	O
PD	pd	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
merit	merit	NOUN	NN	5	O
further	further	ADJ	JJ	9	O
attention	attention	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neuropeptide	Neuropeptide	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
Y	Y	PROPN	NNP	9	O
immunoreactivity	immunoreactivity	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
temporal	temporal	ADJ	JJ	5	B-Disease
lobe	lobe	NOUN	NN	5	I-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Neuropeptide	Neuropeptide	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
Y	Y	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
NPY	NPY	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
expressed	express	VERB	VBN	3	O
by	by	ADP	IN	9	O
granule	granule	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
mossy	mossy	NOUN	NN	5	O
fibres	fibre	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
during	during	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
temporal	temporal	ADJ	JJ	5	B-Disease
lobe	lobe	NOUN	NN	5	I-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TLE	tle	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
expression	expression	NOUN	NN	3	O
may	may	VERB	MD	5	O
represent	represent	VERB	VB	9	O
an	an	DET	DT	5	O
endogenous	endogenous	ADJ	JJ	3	O
damping	damping	NOUN	NN	5	O
mechanism	mechanism	NOUN	NN	9	O
since	since	ADP	IN	9	O
NPY	NPY	PROPN	NNP	3	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
block	block	VERB	VB	9	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
events	event	NOUN	NNS	5	O
following	follow	VERB	VBG	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
frequency	frequency	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
in	in	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
slices	slice	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PILO	PILO	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
spontaneous	spontaneous	ADJ	JJ	5	O
recurrent	recurrent	NOUN	NN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
related	related	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
peroxidase	peroxidase	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
antiperoxidase	antiperoxidase	NOUN	NN	0	O
immunostaining	immunostaining	NOUN	NN	3	O
for	for	ADP	IN	5	O
NPY	NPY	PROPN	NNP	3	O
in	in	ADP	IN	5	O
several	several	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
regions	region	NOUN	NNS	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PILO	PILO	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
injected	inject	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
NPY	NPY	PROPN	NNP	3	O
immunoreactivity	immunoreactivity	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
region	region	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mossy	mossy	NOUN	NN	5	O
fibre	fibre	NOUN	NN	0	O
terminals	terminal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
inner	inner	ADJ	JJ	9	O
molecular	molecular	ADJ	JJ	9	O
layer	layer	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
within	within	ADP	IN	9	O
presumed	presume	VERB	VBN	9	O
granule	granule	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

NPY	npy	NOUN	NN	3	O
immunoreactivity	immunoreactivity	NOUN	NN	3	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
dramatically	dramatically	ADV	RB	9	O
changed	change	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
entorhinal	entorhinal	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
amygdala	amygdala	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
sensorimotor	sensorimotor	NOUN	NN	5	O
areas	area	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
PILO	PILO	PROPN	NNP	3	B-Chemical
injected	inject	VERB	VBD	3	O
animals	animal	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
NPY	npy	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
immunoreactive	immunoreactive	ADJ	JJ	3	O
interneurons	interneuron	NOUN	NNS	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
NPY	NPY	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
granule	granule	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
mossy	mossy	NOUN	NN	5	O
fibres	fibre	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
vulnerable	vulnerable	ADJ	JJ	5	O
NPY	NPY	PROPN	NNP	3	O
neurons	neuron	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PILO	PILO	PROPN	NNP	3	B-Chemical
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
TLE	TLE	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
significance	significance	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
changed	change	VERB	VBN	9	O
synthesis	synthesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
NPY	NPY	PROPN	NNP	3	O
remains	remain	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Posteroventral	posteroventral	ADJ	JJ	9	O
medial	medial	ADJ	JJ	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
in	in	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Posteroventral	posteroventral	ADJ	JJ	9	O
medial	medial	ADJ	JJ	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
sometimes	sometimes	ADV	RB	5	O
produces	produce	VERB	VBZ	9	O
striking	strike	VERB	VBG	9	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
studies	study	NOUN	NNS	9	O
to	to	ADP	IN	5	O
date	date	NOUN	NN	5	O
have	have	VERB	VBP	5	O
involved	involve	VERB	VBN	9	O
small	small	ADJ	JJ	9	O
numbers	number	NOUN	NNS	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Forty	forty	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
underwent	undergo	VERB	VBD	5	O
serial	serial	NOUN	NN	9	O
,	,	PUNCT	,	9	O
detailed	detailed	ADJ	JJ	5	O
assessments	assessment	NOUN	NNS	5	O
both	both	DET	DT	9	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
"	"	PUNCT	``	5	O
off	off	ADP	IN	5	O
"	"	PUNCT	''	5	O
period	period	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
while	while	ADP	IN	9	O
taking	take	VERB	VBG	5	O
their	-PRON-	DET	PRP$	5	O
optimal	optimal	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
regimens	regimen	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
"	"	PUNCT	``	5	O
on	on	ADP	IN	5	O
"	"	PUNCT	``	5	O
period	period	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
preoperatively	preoperatively	ADV	RB	5	O
and	and	CCONJ	CC	5	O
39	39	NUM	CD	7	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
at	at	ADP	IN	9	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
27	27	NUM	CD	7	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
examined	examine	VERB	VBN	9	O
at	at	ADP	IN	9	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	O
at	at	ADP	IN	9	O
two	two	NUM	CD	5	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
percent	percent	NOUN	NN	5	O
improvements	improvement	NOUN	NNS	5	O
at	at	ADP	IN	9	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
as	as	ADP	IN	5	O
follows	follow	VERB	VBZ	9	O
:	:	PUNCT	:	9	O
off	off	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
period	period	NOUN	NN	5	O
score	score	NOUN	NN	5	O
for	for	ADP	IN	5	O
overall	overall	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
28	28	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
19	19	NUM	CD	7	O
to	to	PART	TO	5	O
38	38	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
most	most	ADJ	JJS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
contralateral	contralateral	ADJ	JJ	5	O
limbs	limb	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
off	off	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
period	period	NOUN	NN	5	O
score	score	NOUN	NN	5	O
for	for	ADP	IN	5	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
living	living	NOUN	NN	5	O
,	,	PUNCT	,	9	O
29	29	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
19	19	NUM	CD	7	O
to	to	PART	TO	5	O
39	39	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
on	on	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
period	period	NOUN	NN	5	O
score	score	NOUN	NN	5	O
for	for	ADP	IN	5	O
contralateral	contralateral	ADJ	JJ	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
82	82	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
72	72	NUM	CD	9	O
to	to	PART	TO	5	O
91	91	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
period	period	NOUN	NN	5	O
score	score	NOUN	NN	5	O
for	for	ADP	IN	5	O
ipsilateral	ipsilateral	ADJ	JJ	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
44	44	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
29	29	NUM	CD	7	O
to	to	PART	TO	5	O
59	59	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
improvements	improvement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
scores	score	NOUN	NNS	5	O
for	for	ADP	IN	5	O
off	off	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
period	period	NOUN	NN	5	O
parkinsonism	parkinsonism	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
contralateral	contralateral	ADJ	JJ	5	O
bradykinesia	bradykinesia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
sustained	sustain	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
examined	examine	VERB	VBN	9	O
at	at	ADP	IN	9	O
two	two	NUM	CD	5	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
ipsilateral	ipsilateral	ADJ	JJ	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
lost	lose	VERB	VBN	9	O
after	after	ADP	IN	9	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
improvements	improvement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
postural	postural	ADJ	JJ	5	O
stability	stability	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
gait	gait	VERB	VB	5	O
lasted	last	VERB	VBD	5	O
only	only	ADV	RB	9	O
three	three	NUM	CD	9	O
to	to	PART	TO	5	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Approximately	approximately	ADV	RB	9	O
half	half	DET	PDT	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
dependent	dependent	ADJ	JJ	9	O
on	on	ADP	IN	5	O
assistance	assistance	NOUN	NN	6	O
in	in	ADP	IN	5	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
living	live	VERB	VBG	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
off	off	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
before	before	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
became	become	VERB	VBD	9	O
independent	independent	ADJ	JJ	9	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
surgery	surgery	NOUN	NN	5	O
were	be	VERB	VBD	9	O
generally	generally	ADV	RB	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
late	late	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
stage	stage	NOUN	NN	9	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
pallidotomy	pallidotomy	NOUN	NN	5	O
significantly	significantly	ADV	RB	9	O
reduces	reduce	VERB	VBZ	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
off	off	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
period	period	NOUN	NN	5	O
disability	disability	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Much	much	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
benefit	benefit	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
sustained	sustain	VERB	VBN	5	O
at	at	ADP	IN	9	O
two	two	NUM	CD	5	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
some	some	DET	DT	5	O
improvements	improvement	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
those	those	DET	DT	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
ipsilateral	ipsilateral	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
axial	axial	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
wane	wane	NOUN	NN	5	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
on	on	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
period	period	NOUN	NN	5	O
symptoms	symptom	NOUN	NNS	5	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
resistant	resistant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
respond	respond	VERB	VB	5	O
to	to	ADP	IN	5	O
pallidotomy	pallidotomy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Clarithromycin	Clarithromycin	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Clarithromycin	Clarithromycin	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
relatively	relatively	ADV	RB	5	O
new	new	ADJ	JJ	5	O
macrolide	macrolide	NOUN	NN	9	B-Chemical
antibiotic	antibiotic	NOUN	NN	5	O
that	that	DET	WDT	5	O
offers	offer	VERB	VBZ	5	O
twice	twice	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
daily	daily	ADV	RB	5	O
dosing	dosing	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
differs	differ	VERB	VBZ	9	O
from	from	ADP	IN	9	O
erythromycin	erythromycin	ADV	RB	0	B-Chemical
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
methylation	methylation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hydroxyl	hydroxyl	NOUN	NN	0	O
group	group	NOUN	NN	9	O
at	at	ADP	IN	9	O
position	position	NOUN	NN	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
profile	profile	NOUN	NN	9	O
of	of	ADP	IN	5	O
erythromycin	erythromycin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
established	establish	VERB	VBN	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
gastroenteritis	gastroenteritis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
interactions	interaction	NOUN	NNS	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
subject	subject	ADJ	JJ	5	O
to	to	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
mixed	mixed	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
function	function	NOUN	NN	9	O
oxidase	oxidase	NOUN	NN	0	O
metabolism	metabolism	NOUN	NN	9	O
,	,	PUNCT	,	9	O
experience	experience	NOUN	NN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
newer	new	ADJ	JJR	5	O
macrolides	macrolide	NOUN	NNS	0	B-Chemical
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
being	be	VERB	VBG	5	O
recorded	record	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
demonstrated	demonstrate	VERB	VBN	9	O
after	after	ADP	IN	9	O
both	both	CCONJ	CC	9	O
intravenous	intravenous	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
erythromycin	erythromycin	NOUN	NN	0	B-Chemical
but	but	CCONJ	CC	9	O
has	have	VERB	VBZ	9	O
never	never	ADV	RB	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
newer	new	ADJ	JJR	5	O
macrolides	macrolide	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
dysrhythmias	dysrhythmia	NOUN	NNS	5	I-Disease
that	that	DET	WDT	5	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
six	six	NUM	CD	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
clarithromycin	clarithromycin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dysrhythmias	dysrhythmia	NOUN	NNS	5	B-Disease
resolved	resolve	VERB	VBD	9	O
after	after	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
glyceryl	glyceryl	NOUN	NN	0	B-Chemical
trinitrate	trinitrate	NOUN	NN	0	I-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
sphincter	sphincter	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
Oddi	Oddi	PROPN	NNP	5	I-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
evoked	evoke	VERB	VBN	5	O
by	by	ADP	IN	9	O
prostigmine	prostigmine	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
morphine	morphine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
glyceryl	glyceryl	NOUN	NN	0	B-Chemical
trinitrate	trinitrate	NOUN	NN	0	I-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
prostigmine	prostigmine	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
sphincter	sphincter	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
Oddi	Oddi	PROPN	NNP	5	I-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
nine	nine	NUM	CD	9	O
female	female	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
sphincter	sphincter	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
Oddi	Oddi	PROPN	NNP	5	I-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Sphincter	sphincter	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
Oddi	Oddi	PROPN	NNP	5	I-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
prostigmine	prostigmine	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
morphine	morphine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
prostigmine	prostigmine	NOUN	NN	0	B-Chemical
intramuscularly	intramuscularly	ADV	RB	0	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
mg	mg	NUM	CD	0	O
morphine	morphine	NOUN	NN	0	B-Chemical
subcutaneously	subcutaneously	ADV	RB	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
visualized	visualize	VERB	VBN	9	O
by	by	ADP	IN	9	O
quantitative	quantitative	ADJ	JJ	9	O
hepatobiliary	hepatobiliary	ADJ	JJ	5	O
scintigraphy	scintigraphy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
procedure	procedure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
repeated	repeat	VERB	VBN	5	O
during	during	ADP	IN	5	O
glyceryl	glyceryl	NOUN	NN	0	B-Chemical
trinitrate	trinitrate	NOUN	NN	0	I-Chemical
infusion	infusion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
Nitrolingual	Nitrolingual	PROPN	NNP	0	B-Chemical
1	1	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
for	for	ADP	IN	5	O
120	120	NUM	CD	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Prostigmine	prostigmine	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	O
morphine	morphine	NOUN	NN	0	B-Chemical
provocation	provocation	NOUN	NN	5	O
caused	cause	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
to	to	PART	TO	5	O
peak	peak	VERB	VB	9	O
activity	activity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Tmax	Tmax	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
hepatic	hepatic	ADJ	JJ	9	O
hilum	hilum	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
HH	HH	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
34	34	NUM	CD	7	O
.	.	PUNCT	.	9	O
33	33	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
22	22	NUM	CD	7	O
.	.	PUNCT	.	9	O
77	77	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
26	26	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
common	common	ADJ	JJ	5	O
bile	bile	NOUN	NN	0	O
duct	duct	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CBD	CBD	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
60	60	NUM	CD	9	O
.	.	PUNCT	.	9	O
44	44	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
99	99	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
40	40	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
88	88	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
half	half	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
excretion	excretion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
T1	T1	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
parenchyma	parenchyma	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
LP	LP	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
120	120	NUM	CD	9	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
27	27	NUM	CD	7	O
.	.	PUNCT	.	9	O
37	37	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
19	19	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
HH	HH	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
117	117	NUM	CD	7	O
.	.	PUNCT	.	9	O
61	61	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
71	71	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
31	31	NUM	CD	7	O
.	.	PUNCT	.	9	O
85	85	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
99	99	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
CBD	CBD	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
158	158	NUM	CD	7	O
.	.	PUNCT	.	9	O
11	11	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
18	18	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
40	40	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
24	24	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
spasm	spasm	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sphincter	sphincter	NOUN	NN	5	O
of	of	ADP	IN	5	O
Oddi	Oddi	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Glyceryl	glyceryl	NOUN	NN	0	B-Chemical
trinitrate	trinitrate	NOUN	NN	0	I-Chemical
infusion	infusion	NOUN	NN	0	O
completely	completely	ADV	RB	9	O
normalized	normalize	VERB	VBD	9	O
the	the	DET	DT	5	O
prostigmine	prostigmine	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
quantitative	quantitative	ADJ	JJ	9	O
parameters	parameter	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
TmaX	TmaX	NOUN	NNS	_	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
LP	LP	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
33	33	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
13	13	NUM	CD	7	O
;	;	PUNCT	:	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
HH	HH	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
88	88	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
48	48	NUM	CD	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
CBD	CBD	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
36	36	NUM	CD	9	O
.	.	PUNCT	.	9	O
22	22	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
92	92	NUM	CD	7	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
T1	T1	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
LP	LP	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
28	28	NUM	CD	7	O
.	.	PUNCT	.	9	O
21	21	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
83	83	NUM	CD	7	O
;	;	PUNCT	:	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
HH	HH	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
42	42	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
10	10	NUM	CD	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
CBD	CBD	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
41	41	NUM	CD	7	O
.	.	PUNCT	.	9	O
66	66	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
33	33	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
sphincter	sphincter	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
relaxing	relax	VERB	VBG	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
glyceryl	glyceryl	NOUN	NN	0	B-Chemical
trinitrate	trinitrate	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
provide	provide	VERB	VBP	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effectiveness	effectiveness	NOUN	NN	5	O
of	of	ADP	IN	5	O
glyceryl	glyceryl	NOUN	NN	0	B-Chemical
trinitrate	trinitrate	NOUN	NN	0	I-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
sphincter	sphincter	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
Oddi	Oddi	PROPN	NNP	5	I-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
glyceryl	glyceryl	NOUN	NN	0	B-Chemical
trinitrate	trinitrate	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
overcome	overcome	VERB	VB	5	O
even	even	ADV	RB	5	O
the	the	DET	DT	5	O
drastic	drastic	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
relevance	relevance	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
sphincter	sphincter	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
Oddi	Oddi	PROPN	NNP	5	I-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Immunopathology	immunopathology	NOUN	NN	2	O
of	of	ADP	IN	5	O
penicillamine	penicillamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
developed	develop	VERB	VBD	5	O
heavy	heavy	ADJ	JJ	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
five	five	NUM	CD	9	O
to	to	PART	TO	5	O
12	12	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Light	light	ADJ	JJ	9	O
microscopy	microscopy	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
biopsy	biopsy	NOUN	NN	5	O
samples	sample	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
minimal	minimal	ADJ	JJ	9	O
glomerular	glomerular	ADJ	JJ	5	O
capillary	capillary	ADJ	JJ	0	O
wall	wall	NOUN	NN	5	O
thickening	thickening	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mesangial	mesangial	NOUN	NN	3	O
matrix	matrix	NOUN	NN	5	O
increase	increase	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
no	no	DET	DT	9	O
departure	departure	NOUN	NN	5	O
from	from	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Electron	Electron	PROPN	NNP	0	O
microscopy	microscopy	NOUN	NN	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
revealed	reveal	VERB	VBD	9	O
subepithelial	subepithelial	ADJ	JJ	5	O
electron	electron	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
dense	dense	ADJ	JJ	5	O
deposits	deposit	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
fusion	fusion	NOUN	NN	1	O
of	of	ADP	IN	5	O
epithelial	epithelial	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
foot	foot	NOUN	NN	5	O
processes	process	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
mesangial	mesangial	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Immunofluorescence	immunofluorescence	NOUN	NN	3	O
microscopy	microscopy	NOUN	NN	9	O
demonstrated	demonstrate	VERB	VBD	9	O
granular	granular	ADJ	JJ	9	O
capillary	capillary	ADJ	JJ	0	O
wall	wall	NOUN	NN	5	O
deposits	deposit	NOUN	NNS	9	O
of	of	ADP	IN	5	O
IgG	igg	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
C3	c3	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
early	early	ADJ	JJ	9	O
membranous	membranous	ADJ	JJ	9	B-Disease
glomerulonephritis	glomerulonephritis	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
differences	difference	NOUN	NNS	9	O
being	be	VERB	VBG	5	O
observed	observe	VERB	VBN	9	O
however	however	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
staining	staining	NOUN	NN	3	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
complement	complement	NOUN	NN	9	O
components	component	NOUN	NNS	5	O
C1q	c1q	VERB	VB	3	O
and	and	CCONJ	CC	5	O
C4	C4	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
tentatively	tentatively	ADV	RB	4	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
complement	complement	NOUN	NN	9	O
was	be	VERB	VBD	9	O
activated	activate	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
classical	classical	ADJ	JJ	9	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Experimental	experimental	ADJ	JJ	9	O
cranial	cranial	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
elicited	elicit	VERB	VBN	9	O
by	by	ADP	IN	9	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
PET	PET	PROPN	NNP	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
positron	positron	NOUN	NN	5	O
emission	emission	NOUN	NN	0	O
tomography	tomography	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PET	PET	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
study	study	VERB	VBP	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
shown	show	VERB	VBN	9	O
recently	recently	ADV	RB	9	O
that	that	ADP	IN	5	O
in	in	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	O
aura	aura	NOUN	NN	5	O
certain	certain	ADJ	JJ	5	O
areas	area	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
stem	stem	NOUN	NN	3	O
were	be	VERB	VBD	9	O
activated	activate	VERB	VBN	3	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
headache	headache	NOUN	NN	5	B-Disease
state	state	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
headache	headache	NOUN	NN	5	B-Disease
free	free	ADJ	JJ	9	O
interval	interval	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
brain	brain	NOUN	NN	5	O
stem	stem	NOUN	NN	3	O
activation	activation	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
inherent	inherent	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
attack	attack	NOUN	NN	5	O
itself	-PRON-	PRON	PRP	9	O
and	and	CCONJ	CC	5	O
represents	represent	VERB	VBZ	9	O
the	the	DET	DT	5	O
so	so	ADV	RB	5	O
called	call	VERB	VBN	5	O
'	'	PUNCT	``	9	O
migraine	migraine	ADJ	JJ	5	B-Disease
generator	generator	NOUN	NN	5	O
'	'	PUNCT	''	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
test	test	VERB	VB	5	O
this	this	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
performed	perform	VERB	VBD	9	O
an	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
seven	seven	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
positioning	positioning	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PET	PET	PROPN	NNP	5	O
scanner	scanner	NOUN	NN	5	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
small	small	ADJ	JJ	9	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
subcutaneously	subcutaneously	ADV	RB	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
forehead	forehead	NOUN	NN	5	O
to	to	PART	TO	5	O
evoke	evoke	VERB	VB	5	O
a	a	DET	DT	5	O
burning	burn	VERB	VBG	5	O
painful	painful	ADJ	JJ	5	B-Disease
sensation	sensation	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
division	division	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
trigeminal	trigeminal	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Increases	increase	NOUN	NNS	9	O
of	of	ADP	IN	5	O
regional	regional	ADJ	JJ	5	O
cerebral	cerebral	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
rCBF	rCBF	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
bilaterally	bilaterally	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
insula	insula	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
anterior	anterior	ADJ	JJ	5	O
cingulate	cingulate	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
cavernous	cavernous	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
cerebellum	cerebellum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
stereotactic	stereotactic	ADJ	JJ	5	O
space	space	NOUN	NN	5	O
limits	limit	NOUN	NNS	5	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
above	above	ADV	RB	9	O
mentioned	mention	VERB	VBN	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
study	study	NOUN	NN	9	O
no	no	DET	DT	9	O
brain	brain	NOUN	NN	5	O
stem	stem	NOUN	NN	3	O
activation	activation	NOUN	NN	3	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
pain	pain	NOUN	NN	5	B-Disease
state	state	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
pain	pain	NOUN	NN	5	B-Disease
free	free	ADJ	JJ	9	O
state	state	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
activation	activation	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
region	region	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cavernous	cavernous	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
structure	structure	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
trigeminal	trigeminal	ADJ	JJ	5	O
transmitted	transmit	VERB	VBN	5	O
pain	pain	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
such	such	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
headache	headache	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
was	be	VERB	VBD	9	O
suggested	suggest	VERB	VBN	9	O
for	for	ADP	IN	5	O
cluster	cluster	NOUN	NN	9	B-Disease
headache	headache	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Value	value	NOUN	NN	5	O
of	of	ADP	IN	5	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
arthralgia	arthralgia	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
myalgia	myalgia	NOUN	NN	5	B-Disease
syndrome	syndrome	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
iron	iron	NOUN	NN	0	B-Chemical
dextran	dextran	NOUN	NN	0	I-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
blind	blind	ADJ	JJ	5	O
randomized	randomize	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
infusion	infusion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
TDI	TDI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
iron	iron	NOUN	NN	0	B-Chemical
dextran	dextran	NOUN	NN	0	I-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
well	well	ADV	RB	9	O
documented	document	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
arthralgia	arthralgia	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
myalgia	myalgia	NOUN	NN	5	B-Disease
syndrome	syndrome	NOUN	NN	5	O
develops	develop	VERB	VBZ	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
MP	MP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
prevents	prevent	VERB	VBZ	9	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sixty	sixty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
34	34	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
31	31	NUM	CD	7	O
men	man	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
ages	age	NOUN	NNS	5	O
36	36	NUM	CD	9	O
to	to	PART	TO	5	O
80	80	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
received	receive	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
TDI	TDI	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
125	125	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
MP	mp	VERB	VB	9	B-Chemical
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
saline	saline	NOUN	NN	0	O
after	after	ADP	IN	9	O
TDI	TDI	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
125	125	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
MP	mp	VERB	VB	9	B-Chemical
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
TDI	TDI	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
for	for	ADP	IN	5	O
72	72	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
reactions	reaction	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
graded	grade	VERB	VBN	5	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
severity	severity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Fifty	fifty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
eight	eight	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
group	group	NOUN	NN	9	O
1	1	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
33	33	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
group	group	NOUN	NN	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
group	group	NOUN	NN	9	O
3	3	NUM	CD	9	O
had	have	VERB	VBD	9	O
reactions	reaction	NOUN	NNS	9	O
to	to	ADP	IN	5	O
TDI	TDI	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
reactions	reaction	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
minimal	minimal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
mild	mild	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
moderate	moderate	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
as	as	ADP	IN	5	O
follows	follow	VERB	VBZ	9	O
:	:	PUNCT	:	9	O
group	group	NOUN	NN	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
;	;	PUNCT	:	9	O
group	group	NOUN	NN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
;	;	PUNCT	:	9	O
group	group	NOUN	NN	9	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
sided	sided	ADJ	JJ	5	O
Fisher	Fisher	PROPN	NNP	9	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
exact	exact	ADJ	JJ	5	O
test	test	NOUN	NN	5	O
using	use	VERB	VBG	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
intervals	interval	NOUN	NNS	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
approximation	approximation	NOUN	NN	5	O
of	of	ADP	IN	5	O
Woolf	Woolf	PROPN	NNP	6	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
MP	MP	PROPN	NNP	9	B-Chemical
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
TDI	TDI	PROPN	NNP	5	O
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
arthralgia	arthralgia	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
myalgia	myalgia	NOUN	NN	5	B-Disease
syndrome	syndrome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
125	125	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
MP	MP	PROPN	NNP	9	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
given	give	VERB	VBN	5	O
routinely	routinely	ADV	RB	9	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
TDI	TDI	PROPN	NNP	5	O
of	of	ADP	IN	5	O
iron	iron	NOUN	NN	0	B-Chemical
dextran	dextran	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Prolongation	prolongation	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
QT	QT	PROPN	NNP	5	I-Disease
interval	interval	NOUN	NN	5	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
interaction	interaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cisapride	Cisapride	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
cytochrome	cytochrome	ADJ	JJ	0	O
P450	P450	PROPN	NNP	1	O
3A4	3a4	NUM	CD	0	O
(	(	PUNCT	-LRB-	9	O
CYP3A4	CYP3A4	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
substrate	substrate	NOUN	NN	0	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
widely	widely	ADV	RB	5	O
prescribed	prescribe	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
motility	motility	NOUN	NN	9	I-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Prolongation	prolongation	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
QT	QT	PROPN	NNP	5	I-Disease
interval	interval	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sudden	sudden	ADJ	JJ	5	B-Disease
cardiac	cardiac	ADJ	JJ	5	I-Disease
death	death	NOUN	NN	9	I-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
after	after	ADP	IN	9	O
concomitant	concomitant	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
with	with	ADP	IN	5	O
erythromycin	erythromycin	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
azole	azole	NOUN	NN	0	B-Chemical
antifungal	antifungal	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
CYP3A4	cyp3a4	NOUN	NN	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
possible	possible	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
interaction	interaction	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
45	45	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
taking	take	VERB	VBG	5	O
cisapride	cisapride	ADV	RB	0	B-Chemical
for	for	ADP	IN	5	O
gastroesophageal	gastroesophageal	NOUN	NN	5	B-Disease
reflux	reflux	NOUN	NN	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
agent	agent	NOUN	NN	9	O
that	that	DET	WDT	5	O
has	have	VERB	VBZ	9	O
inhibitory	inhibitory	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
CYP3A4	CYP3A4	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
in	in	ADP	IN	5	O
near	near	ADP	IN	9	O
syncope	syncope	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
QT	QT	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
interval	interval	ADJ	JJ	5	I-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
discontinuing	discontinue	VERB	VBG	5	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
recur	recur	VERB	VB	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	DET	DT	5	O
caution	caution	NOUN	NN	5	O
be	be	VERB	VB	5	O
taken	take	VERB	VBN	5	O
when	when	ADV	WRB	5	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
prescribed	prescribe	VERB	VBN	5	O
with	with	ADP	IN	5	O
any	any	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
CYP3A4	cyp3a4	NOUN	NN	3	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

Cortical	cortical	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
overactivation	overactivation	NOUN	NN	3	O
in	in	ADP	IN	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
peak	peak	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
studied	study	VERB	VBN	9	O
the	the	DET	DT	5	O
regional	regional	ADJ	JJ	5	O
cerebral	cerebral	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
rCBF	rCBF	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
changes	change	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
execution	execution	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
finger	finger	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
thumb	thumb	NOUN	NN	5	O
opposition	opposition	NOUN	NN	5	O
motor	motor	NOUN	NN	5	O
task	task	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
supplementary	supplementary	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
primary	primary	ADJ	JJ	9	O
motor	motor	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	ADJ	JJ	0	I-Chemical
medication	medication	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
one	one	NOUN	NN	5	O
without	without	ADP	IN	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
induced	induced	ADJ	JJ	3	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
23	23	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
with	with	ADP	IN	5	O
moderate	moderate	ADJ	JJ	9	O
peak	peak	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
15	15	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
14	14	NUM	CD	7	O
normal	normal	ADJ	JJ	9	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Single	single	ADJ	JJ	9	O
photon	photon	NOUN	NN	5	O
emission	emission	NOUN	NN	0	O
tomography	tomography	NOUN	NN	5	O
with	with	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
133Xe	133xe	NUM	CD	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
measure	measure	VERB	VB	5	O
the	the	DET	DT	5	O
rCBF	rCBF	PROPN	NNP	5	O
changes	change	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dyskinetic	dyskinetic	ADJ	JJ	5	B-Disease
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
exhibited	exhibit	VERB	VBD	9	O
a	a	DET	DT	5	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
response	response	NOUN	NN	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
subjects	subject	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
dyskinetic	dyskinetic	ADJ	JJ	5	B-Disease
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
overactivation	overactivation	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
supplementary	supplementary	ADJ	JJ	5	O
motor	motor	NOUN	NN	5	O
area	area	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
ipsi	ipsi	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
contralateral	contralateral	ADJ	JJ	5	O
primary	primary	ADJ	JJ	9	O
motor	motor	NOUN	NN	5	O
areas	area	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
compatible	compatible	ADJ	JJ	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
an	an	DET	DT	5	O
hyperkinetic	hyperkinetic	ADJ	JJ	5	B-Disease
abnormal	abnormal	ADJ	JJ	9	B-Disease
involuntary	involuntary	ADJ	JJ	5	I-Disease
movement	movement	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
like	like	ADP	IN	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
peak	peak	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
disinhibition	disinhibition	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
associated	associated	ADJ	JJ	9	O
motor	motor	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
excessive	excessive	ADJ	JJ	5	O
outflow	outflow	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pallidothalamocortical	pallidothalamocortical	ADJ	JJ	_	O
motor	motor	NOUN	NN	5	O
loop	loop	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
levofloxacin	levofloxacin	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
bacterial	bacterial	ADJ	JJ	9	O
sinusitis	sinusitis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
levofloxacin	levofloxacin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
orally	orally	ADV	RB	0	O
once	once	ADV	RB	5	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
to	to	PART	TO	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
treating	treat	VERB	VBG	5	O
adult	adult	NOUN	NN	9	O
outpatients	outpatient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
bacterial	bacterial	ADJ	JJ	9	O
sinusitis	sinusitis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
329	329	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
enrolled	enrol	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
at	at	ADP	IN	9	O
24	24	NUM	CD	9	O
centers	center	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
pre	pre	ADJ	JJ	9	O
-	-	NOUN	NN	7	O
therapy	therapy	ADJ	JJ	5	O
Gram	Gram	PROPN	NNP	9	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
stain	stain	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
culture	culture	NOUN	NN	9	O
of	of	ADP	IN	5	O
sinus	sinus	NOUN	NN	5	O
exudate	exudate	NOUN	NN	9	O
obtained	obtain	VERB	VBN	9	O
by	by	ADP	IN	9	O
antral	antral	ADJ	JJ	5	O
puncture	puncture	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
nasal	nasal	NOUN	NN	5	O
endoscopy	endoscopy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
sinus	sinus	NOUN	NN	5	O
radiograph	radiograph	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
computed	compute	VERB	VBN	5	O
tomography	tomography	NOUN	NN	5	O
results	result	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Microbiologic	Microbiologic	PROPN	NNP	5	O
cure	cure	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
presumed	presume	VERB	VBN	9	O
plus	plus	CCONJ	CC	9	O
documented	document	VERB	VBN	9	O
eradication	eradication	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
therapy	therapy	ADJ	JJ	5	O
pathogen	pathogen	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
s	s	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
pathogens	pathogen	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
Haemophilus	Haemophilus	PROPN	NNP	4	O
influenzae	influenzae	NOUN	NNS	4	O
,	,	PUNCT	,	9	O
Streptococcus	Streptococcus	PROPN	NNP	4	O
pneumoniae	pneumoniae	NOUN	NN	4	O
,	,	PUNCT	,	9	O
Staphylococcus	Staphylococcus	PROPN	NNP	4	O
aureus	aureus	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Moraxella	Moraxella	PROPN	NNP	4	O
catarrhalis	catarrhalis	VERB	VBP	1	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
300	300	NUM	CD	0	O
clinically	clinically	ADV	RB	5	O
evaluable	evaluable	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
175	175	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
58	58	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
cured	cure	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
90	90	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
improved	improve	VERB	VBN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
therapy	therapy	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
success	success	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
88	88	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
clinically	clinically	ADV	RB	5	O
failed	fail	VERB	VBD	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
microbiologic	microbiologic	ADJ	JJ	5	O
eradication	eradication	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
presumed	presume	VERB	VBN	9	O
plus	plus	CCONJ	CC	9	O
documented	document	VERB	VBN	9	O
)	)	PUNCT	-RRB-	9	O
among	among	ADP	IN	5	O
138	138	NUM	CD	7	O
microbiologically	microbiologically	ADV	RB	5	O
evaluable	evaluable	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
92	92	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Microbiologic	Microbiologic	PROPN	NNP	5	O
eradication	eradication	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
presumed	presume	VERB	VBN	9	O
plus	plus	CCONJ	CC	9	O
documented	document	VERB	VBN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
pathogens	pathogen	NOUN	NNS	5	O
ranged	range	VERB	VBD	9	O
from	from	ADP	IN	9	O
93	93	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
M	M	PROPN	NNP	9	O
.	.	PROPN	NNP	9	O
catarrhalis	catarrhalis	NOUN	NN	1	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
100	100	NUM	CD	0	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
S	S	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
pneumoniae	pneumoniae	PROPN	NNP	4	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
therapy	therapy	ADJ	JJ	5	O
visit	visit	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
but	but	ADP	IN	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
265	265	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
cured	cure	VERB	VBN	5	O
or	or	CCONJ	CC	5	O
improved	improve	VERB	VBN	5	O
at	at	ADP	IN	9	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
therapy	therapy	NOUN	NN	5	O
returned	return	VERB	VBD	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
visit	visit	NOUN	NN	5	O
;	;	PUNCT	:	9	O
243	243	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
92	92	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
remained	remain	VERB	VBD	9	O
well	well	ADV	RB	9	O
4	4	NUM	CD	9	O
to	to	PART	TO	5	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
therapy	therapy	NOUN	NN	5	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
21	21	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
relapse	relapse	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
considered	consider	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
levofloxacin	levofloxacin	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
by	by	ADP	IN	9	O
29	29	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
diarrhea	diarrhea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
flatulence	flatulence	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
nausea	nausea	NOUN	NN	5	B-Disease
;	;	PUNCT	:	9	O
most	most	ADJ	JJS	9	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
mild	mild	ADJ	JJ	9	O
to	to	PART	TO	5	O
moderate	moderate	VERB	VB	9	O
in	in	ADP	IN	5	O
severity	severity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
levofloxacin	levofloxacin	ADJ	JJ	0	B-Chemical
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
once	once	ADV	RB	5	O
daily	daily	ADV	RB	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
safe	safe	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
bacterial	bacterial	ADJ	JJ	9	O
sinusitis	sinusitis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Iatrogenic	iatrogenic	ADJ	JJ	5	O
risks	risk	NOUN	NNS	5	O
of	of	ADP	IN	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
large	large	ADJ	JJ	5	O
French	french	ADJ	JJ	2	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

F	F	PROPN	NNP	7	O
d	d	NOUN	NN	9	O
ration	ration	NOUN	NN	9	O
Nationale	Nationale	PROPN	NNP	2	O
des	des	PROPN	NNP	2	O
Centres	Centres	PROPN	NNP	2	O
de	de	PROPN	NNP	2	O
Lutte	Lutte	PROPN	NNP	2	O
Contre	Contre	PROPN	NNP	2	O
le	le	VERB	VBD	2	O
Cancer	Cancer	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
FNCLCC	FNCLCC	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
proposed	propose	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
its	-PRON-	DET	PRP$	9	O
endometrial	endometrial	ADJ	JJ	9	O
iatrogenic	iatrogenic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
carefully	carefully	ADV	RB	5	O
examined	examine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
investigated	investigate	VERB	VBN	9	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
use	use	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
treatments	treatment	NOUN	NNS	9	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cases	case	NOUN	NNS	9	O
of	of	ADP	IN	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
diagnosed	diagnose	VERB	VBN	5	O
after	after	ADP	IN	9	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
135	135	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
467	467	NUM	CD	7	O
controls	control	NOUN	NNS	9	O
matched	match	VERB	VBN	9	O
for	for	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
year	year	NOUN	NN	5	O
of	of	ADP	IN	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
hospital	hospital	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
survival	survival	NOUN	NN	9	O
time	time	NOUN	NN	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
intact	intact	ADJ	JJ	9	O
uterus	uterus	NOUN	NN	9	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
diagnosed	diagnose	VERB	VBN	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
not	not	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
crude	crude	ADJ	JJ	0	O
relative	relative	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Univariate	univariate	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
adjusted	adjust	VERB	VBN	9	O
analyses	analysis	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
increased	increase	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
length	length	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
received	receive	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
irrespective	irrespective	ADV	RB	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
undergone	undergo	VERB	VBN	5	O
pelvic	pelvic	ADJ	JJ	5	O
radiotherapy	radiotherapy	NOUN	NN	5	O
also	also	ADV	RB	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
risk	risk	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
crude	crude	ADJ	JJ	0	O
relative	relative	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
adjusting	adjust	VERB	VBG	5	O
for	for	ADP	IN	5	O
confounding	confound	VERB	VBG	5	O
factors	factor	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
for	for	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
users	user	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0012	0012	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
all	all	DET	DT	5	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
pelvic	pelvic	ADJ	JJ	5	O
radiotherapy	radiotherapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
012	012	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
had	have	VERB	VBD	9	O
more	more	ADV	RBR	5	O
advanced	advanced	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
poorer	poor	ADJ	JJR	5	O
prognosis	prognosis	NOUN	NN	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
not	not	ADV	RB	5	O
received	receive	VERB	VBN	9	O
this	this	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
causal	causal	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
in	in	ADP	IN	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
when	when	ADV	WRB	5	O
used	use	VERB	VBN	5	O
as	as	ADV	RB	5	O
currently	currently	ADV	RB	5	O
proposed	propose	VERB	VBN	5	O
for	for	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
prevention	prevention	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pelvic	pelvic	ADJ	JJ	5	O
radiotherapy	radiotherapy	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
iatrogenic	iatrogenic	ADJ	JJ	5	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Endometrial	endometrial	ADJ	JJ	9	B-Disease
cancers	cancer	NOUN	NNS	9	I-Disease
diagnosed	diagnose	VERB	VBN	5	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
have	have	VERB	VBP	5	O
poorer	poor	ADJ	JJR	5	O
prognosis	prognosis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
receive	receive	VERB	VBP	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
offered	offer	VERB	VBN	5	O
gynaecological	gynaecological	ADJ	JJ	5	O
surveillance	surveillance	NOUN	NN	5	O
during	during	ADP	IN	5	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
benefit	benefit	NOUN	NN	5	O
ratio	ratio	NOUN	NN	9	O
of	of	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
preventive	preventive	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
is	be	VERB	VBZ	5	O
clearly	clearly	ADV	RB	9	O
warranted	warrant	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Contribution	contribution	NOUN	NN	6	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glycine	glycine	NOUN	NN	0	B-Chemical
site	site	NOUN	NN	9	O
of	of	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
rostral	rostral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
intermediate	intermediate	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
caudal	caudal	ADJ	JJ	5	O
parts	part	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	O
tone	tone	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
contribution	contribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glycine	glycine	NOUN	NN	0	B-Chemical
site	site	NOUN	NN	9	O
of	of	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	O
tone	tone	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Muscle	muscle	NOUN	NN	9	O
tone	tone	NOUN	NN	5	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
combined	combined	ADJ	JJ	9	O
mechanoand	mechanoand	NOUN	NN	_	O
electromyographic	electromyographic	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
measured	measure	VERB	VBD	9	O
simultaneously	simultaneously	ADV	RB	5	O
the	the	DET	DT	5	O
muscle	muscle	NOUN	NN	9	O
resistance	resistance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
MMG	MMG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
'	'	PUNCT	``	9	O
s	s	PART	POS	9	O
hind	hind	NOUN	NN	4	O
foot	foot	NOUN	NN	5	O
to	to	ADP	IN	5	O
passive	passive	ADJ	JJ	5	O
extension	extension	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
flexion	flexion	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ankle	ankle	NOUN	NN	5	O
joint	joint	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
electromyographic	electromyographic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
EMG	EMG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
antagonistic	antagonistic	ADJ	JJ	9	O
muscles	muscle	NOUN	NNS	5	O
of	of	ADP	IN	5	O
that	that	DET	DT	5	O
joint	joint	NOUN	NN	5	O
:	:	PUNCT	:	9	O
gastrocnemius	gastrocnemius	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tibialis	tibialis	NOUN	NN	4	O
anterior	anterior	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

5	5	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
7	7	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dichlorokynurenic	dichlorokynurenic	ADJ	JJ	9	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
7	7	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DCKA	DCKA	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
glycine	glycine	NOUN	NN	0	B-Chemical
site	site	NOUN	NN	9	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
injected	inject	VERB	VBN	3	O
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
bilaterally	bilaterally	ADV	RB	5	O
,	,	PUNCT	,	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
rostral	rostral	ADJ	JJ	5	O
region	region	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
muscle	muscle	NOUN	NN	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MMG	MMG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
enhanced	enhance	VERB	VBN	3	O
electromyographic	electromyographic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
EMG	EMG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

5	5	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
7	7	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DCKA	DCKA	PROPN	NNP	0	I-Chemical
injected	inject	VERB	VBD	3	O
bilaterally	bilaterally	ADV	RB	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microl	microl	NOUN	NN	0	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
intermediate	intermediate	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
caudal	caudal	ADJ	JJ	5	O
region	region	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
not	not	ADV	RB	5	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
muscle	muscle	NOUN	NN	9	O
tone	tone	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	DET	DT	5	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glycine	glycine	NOUN	NN	0	B-Chemical
site	site	NOUN	NN	9	O
of	of	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rostral	rostral	ADJ	JJ	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
mainly	mainly	ADV	RB	9	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
antiparkinsonian	antiparkinsonian	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Carboplatin	carboplatin	ADJ	JJ	0	B-Chemical
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
striking	striking	ADJ	JJ	9	O
of	of	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
advantages	advantage	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
CBDCA	CBDCA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
over	over	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
CDDP	CDDP	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
its	-PRON-	DET	PRP$	9	O
markedly	markedly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
CBDCA	cbdca	NOUN	NN	0	B-Chemical
higher	high	ADJ	JJR	9	O
-	-	PUNCT	HYPH	7	O
intensity	intensity	NOUN	NN	5	O
schedules	schedule	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
drugs	drug	NOUN	NNS	5	O
in	in	ADP	IN	5	O
polychemotherapy	polychemotherapy	NOUN	NN	5	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
some	some	DET	DT	5	O
concern	concern	NOUN	NN	5	O
about	about	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
safety	safety	NOUN	NN	5	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
different	different	ADJ	JJ	9	O
schedules	schedule	NOUN	NNS	5	O
of	of	ADP	IN	5	O
CBDCA	CBDCA	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
twice	twice	DET	PDT	9	O
a	a	DET	DT	5	O
week	week	NOUN	NN	9	O
for	for	ADP	IN	5	O
nine	nine	NUM	CD	9	O
times	time	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Neurotoxicity	Neurotoxicity	PROPN	NNP	0	B-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
for	for	ADP	IN	5	O
behavioral	behavioral	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
tail	tail	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
flick	flick	NOUN	NN	5	O
test	test	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
neurophysiological	neurophysiological	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
nerve	nerve	NOUN	NN	5	O
conduction	conduction	NOUN	NN	5	O
velocity	velocity	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
tail	tail	NOUN	NN	9	O
nerve	nerve	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
morphological	morphological	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
morphometrical	morphometrical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
analytical	analytical	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
CBDCA	cbdca	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
induced	induce	VERB	VBD	3	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neurotoxicity	neurotoxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Pain	pain	NOUN	NN	5	B-Disease
perception	perception	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
nerve	nerve	NOUN	NN	5	O
conduction	conduction	NOUN	NN	5	O
velocity	velocity	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
tail	tail	NOUN	NN	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
impaired	impair	VERB	VBN	9	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dorsal	dorsal	ADJ	JJ	5	O
root	root	NOUN	NN	5	O
ganglia	ganglia	VERB	VBZ	5	O
sensory	sensory	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
lesser	less	ADJ	JJR	9	O
extent	extent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
satellite	satellite	NOUN	NN	5	O
cells	cell	NOUN	NNS	3	O
showed	show	VERB	VBD	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
as	as	ADP	IN	5	O
those	those	DET	DT	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
CDDP	CDDP	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
mainly	mainly	ADV	RB	9	O
affecting	affect	VERB	VBG	9	O
the	the	DET	DT	5	O
nucleus	nucleus	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
nucleolus	nucleolus	NOUN	NN	9	O
of	of	ADP	IN	5	O
ganglionic	ganglionic	ADJ	JJ	3	O
sensory	sensory	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
significant	significant	ADJ	JJ	9	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
platinum	platinum	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dorsal	dorsal	ADJ	JJ	5	O
root	root	NOUN	NN	5	O
ganglia	ganglion	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
kidney	kidney	NOUN	NN	9	O
after	after	ADP	IN	9	O
CBDCA	CBDCA	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
CBDCA	cbdca	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
pathological	pathological	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
it	-PRON-	PRON	PRP	5	O
induces	induce	VERB	VBZ	3	O
are	be	VERB	VBP	5	O
so	so	ADV	RB	5	O
closely	closely	ADV	RB	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
CDDP	CDDP	PROPN	NNP	3	B-Chemical
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
probable	probable	ADJ	JJ	9	O
that	that	ADP	IN	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
drugs	drug	NOUN	NNS	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
mechanism	mechanism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
model	model	NOUN	NN	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
alone	alone	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
to	to	PART	TO	5	O
explore	explore	VERB	VB	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
CBDCA	CBDCA	PROPN	NNP	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
postcibal	postcibal	ADJ	JJ	_	O
small	small	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
bowel	bowel	NOUN	NN	5	O
motor	motor	NOUN	NN	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
irritable	irritable	ADJ	JJ	5	B-Disease
bowel	bowel	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Irritable	irritable	ADJ	JJ	7	B-Disease
bowel	bowel	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
abdominal	abdominal	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
discomfort	discomfort	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
disordered	disordered	ADJ	JJ	5	B-Disease
gastrointestinal	gastrointestinal	ADJ	JJ	9	I-Disease
motility	motility	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
aim	aim	NOUN	NN	5	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
prokinetic	prokinetic	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
postprandial	postprandial	ADJ	JJ	5	O
jejunal	jejunal	ADJ	JJ	9	O
motility	motility	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
irritable	irritable	ADJ	JJ	5	B-Disease
bowel	bowel	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
IBS	IBS	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

METHODS	METHODS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
IBS	IBS	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
constipation	constipation	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
predominant	predominant	NOUN	NN	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
17	17	NUM	CD	7	O
;	;	PUNCT	:	9	O
diarrhoea	diarrhoea	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
predominant	predominant	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
21	21	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
underwent	undergo	VERB	VBD	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
h	h	DET	DT	0	O
ambulatory	ambulatory	ADJ	JJ	5	O
jejunal	jejunal	ADJ	JJ	9	O
manometry	manometry	NOUN	NN	5	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
12	12	NUM	CD	9	O
week	week	NOUN	NN	9	O
'	'	PUNCT	''	9	O
s	s	PUNCT	LS	9	O
treatment	treatment	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
daily	daily	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
19	19	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
19	19	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
]	]	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
diarrhoea	diarrhoea	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
predominant	predominant	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
contraction	contraction	NOUN	NN	9	O
characteristics	characteristic	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
cisapride	cisapride	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
diarrhoea	diarrhoea	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
predominant	predominant	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
contraction	contraction	NOUN	NN	9	O
amplitude	amplitude	NOUN	NN	5	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
(	(	PUNCT	-LRB-	9	O
29	29	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
versus	versus	ADP	IN	9	O
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
versus	versus	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
pretreatment	pretreatment	NOUN	NN	0	O
,	,	PUNCT	,	9	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
contraction	contraction	NOUN	NN	9	O
duration	duration	NOUN	NN	5	O
longer	longer	ADV	RBR	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
versus	versus	ADP	IN	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
sec	sec	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
versus	versus	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
pretreatment	pretreatment	NOUN	NN	0	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
sec	sec	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
contraction	contraction	NOUN	NN	9	O
frequency	frequency	NOUN	NN	5	O
lower	lower	ADV	RBR	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
versus	versus	ADP	IN	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
cont	cont	NOUN	NN	3	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
min	min	INTJ	UH	0	O
,	,	PUNCT	,	9	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
versus	versus	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
pretreatment	pretreatment	NOUN	NN	0	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
cont	cont	NOUN	NN	3	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
]	]	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
jejunal	jejunal	ADJ	JJ	9	O
motility	motility	NOUN	NN	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
constipation	constipation	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
predominant	predominant	ADJ	JJ	9	O
IBS	IBS	PROPN	NNP	5	B-Disease
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Symptoms	symptom	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
visual	visual	ADJ	JJ	5	O
analogue	analogue	NOUN	NN	0	O
scale	scale	NOUN	NN	5	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Symptom	symptom	NOUN	NN	5	O
scores	score	NOUN	NNS	5	O
relating	relate	VERB	VBG	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
constipation	constipation	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
constipation	constipation	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
predominant	predominant	ADJ	JJ	9	O
IBS	IBS	PROPN	NNP	5	B-Disease
patients	patient	NOUN	NNS	5	O
[	[	PUNCT	-LRB-	9	O
score	score	NOUN	NN	5	O
,	,	PUNCT	,	9	O
54	54	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
versus	versus	ADP	IN	9	O
67	67	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
14	14	NUM	CD	7	O
mm	mm	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
versus	versus	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
pretreatment	pretreatment	NOUN	NN	0	O
,	,	PUNCT	,	9	O
62	62	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
19	19	NUM	CD	7	O
mm	mm	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Diarrhoea	diarrhoea	NOUN	NN	7	B-Disease
-	-	PUNCT	HYPH	7	O
predominant	predominant	ADJ	JJ	9	O
IBS	IBS	PROPN	NNP	5	B-Disease
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
pain	pain	NOUN	NN	5	B-Disease
score	score	NOUN	NN	5	O
after	after	ADP	IN	9	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
score	score	NOUN	NN	5	O
,	,	PUNCT	,	9	O
55	55	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
15	15	NUM	CD	9	O
versus	versus	ADP	IN	9	O
34	34	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
versus	versus	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
pretreatment	pretreatment	NOUN	NN	0	O
,	,	PUNCT	,	9	O
67	67	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
19	19	NUM	CD	7	O
mm	mm	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Cisapride	cisapride	NOUN	NN	0	B-Chemical
affects	affect	VERB	VBZ	9	O
jejunal	jejunal	ADJ	JJ	9	O
contraction	contraction	NOUN	NN	9	O
characteristics	characteristic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
some	some	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
in	in	ADP	IN	5	O
IBS	IBS	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Prevention	prevention	NOUN	NN	2	O
of	of	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
with	with	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
:	:	PUNCT	:	9	O
preliminary	preliminary	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
Italian	Italian	PROPN	NNP	5	O
randomised	randomise	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
among	among	ADP	IN	5	O
hysterectomised	hysterectomise	VERB	VBN	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Italian	italian	ADJ	JJ	5	O
Tamoxifen	Tamoxifen	PROPN	NNP	0	B-Chemical
Prevention	Prevention	PROPN	NNP	2	O
Study	Study	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Tamoxifen	tamoxifen	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
candidate	candidate	ADJ	JJ	9	O
chemopreventive	chemopreventive	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
in	in	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
did	do	VERB	VBD	9	O
a	a	DET	DT	5	O
trial	trial	NOUN	NN	5	O
in	in	ADP	IN	5	O
hysterectomised	hysterectomise	VERB	VBN	5	O
women	woman	NOUN	NNS	5	O
of	of	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
chemopreventive	chemopreventive	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
October	October	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
1992	1992	NUM	CD	2	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
started	start	VERB	VBD	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
randomised	randomise	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mainly	mainly	ADV	RB	9	O
in	in	ADP	IN	5	O
Italy	Italy	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
who	who	PRON	WP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
had	have	VERB	VBN	9	O
a	a	DET	DT	5	O
hysterectomy	hysterectomy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Women	woman	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomised	randomise	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
orally	orally	ADV	RB	0	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
original	original	ADJ	JJ	5	O
plan	plan	NOUN	NN	5	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
follow	follow	VERB	VB	5	O
the	the	DET	DT	5	O
intervention	intervention	NOUN	NN	5	O
phase	phase	NOUN	NN	5	O
by	by	ADP	IN	9	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
'	'	PART	POS	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
June	June	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
1997	1997	NUM	CD	2	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
trialists	trialist	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
data	data	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
monitoring	monitor	VERB	VBG	5	O
committee	committee	NOUN	NN	2	O
decided	decide	VERB	VBD	5	O
to	to	PART	TO	5	O
end	end	VERB	VB	9	O
recruitment	recruitment	NOUN	NN	9	O
primarily	primarily	ADV	RB	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
dropping	drop	VERB	VBG	5	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Recruitment	recruitment	NOUN	NN	5	O
ended	end	VERB	VBD	5	O
on	on	ADP	IN	5	O
July	July	PROPN	NNP	2	O
11	11	NUM	CD	7	O
,	,	PUNCT	,	9	O
1997	1997	NUM	CD	2	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
will	will	VERB	MD	5	O
continue	continue	VERB	VB	5	O
as	as	ADP	IN	5	O
planned	plan	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
endpoints	endpoint	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
and	and	CCONJ	CC	5	O
deaths	death	NOUN	NNS	5	O
from	from	ADP	IN	9	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
preliminary	preliminary	ADJ	JJ	9	O
interim	interim	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
intention	intention	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
treat	treat	NOUN	NN	5	O
.	.	PUNCT	.	9	O

FINDINGS	finding	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
5408	5408	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomised	randomise	VERB	VBN	5	O
;	;	PUNCT	:	9	O
participating	participate	VERB	VBG	5	O
women	woman	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
median	median	ADJ	JJ	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
46	46	NUM	CD	7	O
months	month	NOUN	NNS	5	O
for	for	ADP	IN	5	O
major	major	ADJ	JJ	9	O
endpoints	endpoint	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

41	41	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
occurred	occur	VERB	VBD	9	O
so	so	ADV	RB	5	O
far	far	ADV	RB	5	O
;	;	PUNCT	:	9	O
there	there	ADV	EX	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
no	no	DET	DT	9	O
deaths	death	NOUN	NNS	5	O
from	from	ADP	IN	9	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
frequency	frequency	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
19	19	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
arms	arm	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
among	among	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
who	who	PRON	WP	5	O
also	also	ADV	RB	9	O
used	use	VERB	VBD	5	O
hormone	hormone	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
replacement	replacement	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
trial	trial	NOUN	NN	5	O
:	:	PUNCT	:	9	O
among	among	ADP	IN	5	O
390	390	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
on	on	ADP	IN	5	O
such	such	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
allocated	allocate	VERB	VBN	5	O
to	to	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
eight	eight	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
among	among	ADP	IN	5	O
362	362	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
allocated	allocate	VERB	VBN	5	O
to	to	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
vascular	vascular	ADJ	JJ	5	B-Disease
events	event	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
hypertriglyceridaemia	hypertriglyceridaemia	NOUN	NN	5	B-Disease
among	among	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
on	on	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

INTERPRETATION	interpretation	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Although	although	ADP	IN	9	O
this	this	DET	DT	5	O
preliminary	preliminary	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
low	low	ADJ	JJ	9	O
power	power	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
cohort	cohort	NOUN	NN	9	O
of	of	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
at	at	ADP	IN	9	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
normal	normal	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
postulated	postulated	ADJ	JJ	9	O
protective	protective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
yet	yet	ADV	RB	9	O
apparent	apparent	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Women	woman	NOUN	NNS	5	O
using	use	VERB	VBG	9	O
hormone	hormone	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
replacement	replacement	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
benefited	benefit	VERB	VBN	5	O
from	from	ADP	IN	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
deaths	death	NOUN	NNS	5	O
from	from	ADP	IN	9	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
recorded	record	VERB	VBN	5	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
essential	essential	ADJ	JJ	9	O
to	to	PART	TO	5	O
continue	continue	VERB	VB	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
to	to	PART	TO	5	O
quantify	quantify	VERB	VB	9	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
risks	risk	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
benefits	benefit	NOUN	NNS	5	O
of	of	ADP	IN	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Epileptogenic	epileptogenic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
folic	folic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
induces	induce	NOUN	NNS	3	O
SLE	SLE	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
folic	folic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
folic	folic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
multivitamin	multivitamin	NOUN	NN	5	O
supplementation	supplementation	NOUN	NN	0	O
in	in	ADP	IN	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
women	woman	NOUN	NNS	5	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
structural	structural	ADJ	JJ	9	O
birth	birth	NOUN	NN	5	B-Disease
defects	defect	NOUN	NNS	9	I-Disease
and	and	CCONJ	CC	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

STUDY	STUDY	PROPN	NNP	2	O
DESIGN	DESIGN	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
First	first	ADV	RB	9	O
a	a	DET	DT	5	O
randomised	randomise	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
,	,	PUNCT	,	9	O
later	later	ADV	RB	9	O
periconception	periconception	NOUN	NN	5	O
care	care	NOUN	NN	5	O
including	include	VERB	VBG	9	O
in	in	ADP	IN	5	O
total	total	ADJ	JJ	9	O
12225	12225	NUM	CD	7	O
females	female	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Of	of	ADP	IN	9	O
60	60	NUM	CD	9	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
periconceptional	periconceptional	ADJ	JJ	5	O
folic	folic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
multivitamin	multivitamin	NOUN	NN	5	O
supplementation	supplementation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
one	one	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
periconception	periconception	NOUN	NN	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
woman	woman	NOUN	NN	5	O
delivered	deliver	VERB	VBD	5	O
a	a	DET	DT	5	O
newborn	newborn	NOUN	NN	9	O
with	with	ADP	IN	5	O
cleft	cleft	ADJ	JJ	5	B-Disease
lip	lip	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
palate	palate	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Another	another	DET	DT	5	O
patient	patient	NOUN	NN	5	O
exhibited	exhibit	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
cluster	cluster	NOUN	NN	9	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
periconception	periconception	NOUN	NN	5	O
period	period	NOUN	NN	5	O
using	use	VERB	VBG	9	O
another	another	DET	DT	9	O
multivitamin	multivitamin	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
22	22	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
woman	woman	NOUN	NN	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
continuously	continuously	ADV	RB	5	O
by	by	ADP	IN	9	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
folic	folic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
multivitamin	multivitamin	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
20th	20th	ADJ	JJ	5	O
week	week	NOUN	NN	9	O
of	of	ADP	IN	5	O
gestation	gestation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
later	later	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	B-Disease
lupus	lupus	NOUN	NN	9	I-Disease
erythematodes	erythematode	NOUN	NNS	2	I-Disease
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
pregnancy	pregnancy	NOUN	NN	5	O
ended	end	VERB	VBD	5	O
with	with	ADP	IN	5	O
stillbirth	stillbirth	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
pregnant	pregnant	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
autoimmune	autoimmune	NOUN	NN	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
probably	probably	ADV	RB	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
lupus	lupus	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
could	could	VERB	MD	9	O
damage	damage	VERB	VB	9	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
,	,	PUNCT	,	9	O
therefore	therefore	ADV	RB	5	O
the	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
folic	folic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
triggered	trigger	VERB	VBD	9	O
a	a	DET	DT	5	O
cluster	cluster	NOUN	NN	9	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Physiological	physiological	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
folic	folic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
both	both	DET	DT	9	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
60	60	NUM	CD	9	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
women	woman	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
all	all	ADV	RB	5	O
without	without	ADP	IN	9	O
any	any	DET	DT	5	O
autoimmune	autoimmune	ADJ	JJ	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Stroke	stroke	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
association	association	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
with	with	ADP	IN	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
stroke	stroke	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
based	base	VERB	VBN	5	O
almost	almost	ADV	RB	9	O
solely	solely	ADV	RB	9	O
on	on	ADP	IN	5	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
case	case	NOUN	NN	5	O
series	series	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
limited	limited	ADJ	JJ	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
epidemiologic	epidemiologic	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
stroke	stroke	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
done	do	VERB	VBN	9	O
in	in	ADP	IN	5	O
settings	setting	NOUN	NNS	5	O
that	that	DET	WDT	5	O
serve	serve	VERB	VBP	5	O
mostly	mostly	ADV	RB	9	O
the	the	DET	DT	5	O
poor	poor	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
minorities	minority	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
defined	define	VERB	VBN	5	O
population	population	NOUN	NN	5	O
comprising	comprise	VERB	VBG	9	O
members	member	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Kaiser	Kaiser	PROPN	NNP	6	O
Permanente	Permanente	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Northern	Northern	PROPN	NNP	4	O
and	and	CCONJ	CC	5	O
Southern	Southern	PROPN	NNP	4	O
California	California	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
attempted	attempt	VERB	VBD	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
all	all	DET	DT	5	O
incident	incident	NOUN	NN	5	O
strokes	stroke	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
ages	age	VERB	VBZ	5	O
15	15	NUM	CD	9	O
-	-	SYM	SYM	7	O
44	44	NUM	CD	7	O
years	year	NOUN	NNS	5	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
period	period	NOUN	NN	5	O
using	use	VERB	VBG	9	O
hospital	hospital	NOUN	NN	5	O
admission	admission	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
discharge	discharge	NOUN	NN	5	O
records	record	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
logs	log	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
payment	payment	NOUN	NN	5	O
requests	request	NOUN	NNS	5	O
for	for	ADP	IN	5	O
out	out	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
of	of	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
plan	plan	NOUN	NN	5	O
hospitalizations	hospitalization	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
selected	select	VERB	VBD	9	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
matched	match	VERB	VBN	9	O
on	on	ADP	IN	5	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
facility	facility	NOUN	NN	5	O
of	of	ADP	IN	5	O
usual	usual	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
random	random	ADJ	JJ	5	O
from	from	ADP	IN	9	O
healthy	healthy	ADJ	JJ	5	O
members	member	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
health	health	NOUN	NN	5	O
plan	plan	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
obtained	obtain	VERB	VBD	9	O
information	information	NOUN	NN	5	O
in	in	ADP	IN	5	O
face	face	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
face	face	NOUN	NN	5	O
interviews	interview	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
347	347	NUM	CD	7	O
confirmed	confirm	VERB	VBN	9	O
stroke	stroke	NOUN	NN	5	B-Disease
cases	case	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
021	021	NUM	CD	7	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
univariate	univariate	ADJ	JJ	5	O
matched	match	VERB	VBN	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
for	for	ADP	IN	5	O
stroke	stroke	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
admitted	admit	VERB	VBD	5	O
to	to	ADP	IN	5	O
using	use	VERB	VBG	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
=	=	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
further	further	ADJ	JJ	9	O
adjustment	adjustment	NOUN	NN	5	O
for	for	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
confounders	confounder	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
reported	report	VERB	VBD	9	O
using	use	VERB	VBG	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
-	-	SYM	SYM	7	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
strong	strong	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
stroke	stroke	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
socioeconomically	socioeconomically	ADV	RB	5	O
heterogeneous	heterogeneous	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
insured	insure	VERB	VBN	5	O
urban	urban	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
subsequent	subsequent	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
rifampicin	rifampicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
reported	report	VERB	VBN	9	O
earlier	earlier	ADV	RBR	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
clinical	clinical	ADJ	JJ	5	O
presentation	presentation	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
made	make	VERB	VBN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
year	year	NOUN	NN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
six	six	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
earlier	earlier	ADV	RBR	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
transient	transient	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
intermittent	intermittent	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
rifampicin	rifampicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
stage	stage	NOUN	NN	9	O
of	of	ADP	IN	5	O
olig	olig	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
anuria	anuria	NOUN	NN	5	B-Disease
lasted	last	VERB	VBD	5	O
for	for	ADP	IN	5	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
five	five	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
hemodialysis	hemodialysis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
died	die	VERB	VBD	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
unrelated	unrelated	ADJ	JJ	9	O
causes	cause	NOUN	NNS	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
re	re	VERB	VBD	5	O
-	-	ADJ	JJ	7	O
examined	examine	VERB	VBN	9	O
were	be	VERB	VBD	9	O
clinically	clinically	ADV	RB	5	O
cured	cure	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Pathologic	pathologic	NOUN	NN	9	O
findings	finding	NOUN	NNS	9	O
by	by	ADP	IN	9	O
light	light	ADJ	JJ	9	O
microscopy	microscopy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
immunofluorescence	immunofluorescence	NOUN	NN	3	O
at	at	ADP	IN	9	O
biopsy	biopsy	NOUN	NN	5	O
were	be	VERB	VBD	9	O
scarce	scarce	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Nothing	Nothing	NOUN	NN	5	O
abnormal	abnormal	ADJ	JJ	9	O
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
by	by	ADP	IN	9	O
electron	electron	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
studied	study	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
three	three	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
the	the	DET	DT	5	O
excretion	excretion	NOUN	NN	0	O
at	at	ADP	IN	9	O
131I	131i	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
hippuran	hippuran	NOUN	NN	9	O
renography	renography	NOUN	NN	5	O
was	be	VERB	VBD	9	O
slightly	slightly	ADV	RB	9	O
slowed	slow	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
histologically	histologically	ADV	RB	9	O
appeared	appear	VERB	VBD	9	O
toxic	toxic	ADJ	JJ	0	O
,	,	PUNCT	,	9	O
evidence	evidence	NOUN	NN	9	O
suggestive	suggestive	ADJ	JJ	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
immunological	immunological	ADJ	JJ	9	O
mechanism	mechanism	NOUN	NN	9	O
cannot	cannot	NOUN	NN	5	O
be	be	VERB	VB	5	O
excluded	exclude	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
synthetic	synthetic	ADJ	JJ	0	O
anthracycline	anthracycline	ADJ	JJ	9	B-Chemical
derivative	derivative	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
SM	SM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5887	5887	NUM	CD	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
beagle	beagle	NOUN	NN	0	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	O
cardiotoxic	cardiotoxic	ADJ	JJ	5	B-Disease
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
SM	SM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5887	5887	NUM	CD	7	I-Chemical
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
deteriorating	deteriorate	VERB	VBG	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
SM	sm	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5887	5887	NUM	CD	7	I-Chemical
on	on	ADP	IN	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
grade	grade	NOUN	NN	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
induced	induced	ADJ	JJ	3	O
by	by	ADP	IN	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
beagle	beagle	NOUN	NN	0	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
beagle	beagle	VERB	VB	0	O
dogs	dog	NOUN	NNS	5	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
sex	sex	NOUN	NN	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
intravenously	intravenously	ADV	RB	0	O
once	once	ADV	RB	5	O
every	every	DET	DT	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
either	either	CCONJ	CC	9	O
a	a	DET	DT	5	O
sublethal	sublethal	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
SM	sm	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5887	5887	NUM	CD	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
experiment	experiment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
terminated	terminate	VERB	VBN	9	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
ninth	ninth	ADJ	JJ	9	O
dosing	dosing	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
which	which	DET	WDT	5	O
received	receive	VERB	VBD	9	O
over	over	ADP	IN	5	O
six	six	NUM	CD	9	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
demonstrated	demonstrate	VERB	VBD	9	O
the	the	DET	DT	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ECG	ECG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
changes	change	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
grade	grade	NOUN	NN	9	O
histopathological	histopathological	ADJ	JJ	9	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
animals	animal	NOUN	NNS	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
terminally	terminally	ADV	RB	3	O
sacrificed	sacrifice	VERB	VBN	3	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
SM	SM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5887	5887	NUM	CD	7	I-Chemical
administration	administration	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
show	show	VERB	VB	9	O
any	any	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
ECG	ECG	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
histopathological	histopathological	ADJ	JJ	9	O
examinations	examination	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
examine	examine	VERB	VB	9	O
a	a	DET	DT	5	O
possibly	possibly	ADV	RB	9	O
deteriorating	deteriorate	VERB	VBG	5	O
cardiotoxic	cardiotoxic	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
SM	sm	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5887	5887	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
grade	grade	NOUN	NN	9	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
by	by	ADP	IN	9	O
four	four	NUM	CD	9	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Nine	nine	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
dogs	dog	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
four	four	NUM	CD	9	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
SM	sm	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5887	5887	NUM	CD	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
once	once	ADV	RB	5	O
every	every	DET	DT	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
grade	grade	NOUN	NN	9	O
cardiotoxic	cardiotoxic	NOUN	NN	5	B-Disease
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
enhanced	enhance	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
contrary	contrary	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
SM	SM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5887	5887	NUM	CD	7	I-Chemical
treatment	treatment	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
progress	progress	VERB	VB	5	O
the	the	DET	DT	5	O
grade	grade	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
SM	SM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5887	5887	PROPN	NNP	7	I-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
any	any	DET	DT	5	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
deteriorating	deteriorate	VERB	VBG	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
valvular	valvular	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
among	among	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
fenfluramine	fenfluramine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
dexfenfluramine	dexfenfluramine	NOUN	NN	5	B-Chemical
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
echocardiography	echocardiography	NOUN	NN	5	O
before	before	ADP	IN	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Because	because	ADP	IN	9	O
uncontrolled	uncontrolled	ADJ	JJ	5	O
echocardiographic	echocardiographic	ADJ	JJ	5	O
surveys	survey	NOUN	NNS	5	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
38	38	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
fenfluramine	fenfluramine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
dexfenfluramine	dexfenfluramine	NOUN	NN	5	B-Chemical
had	have	VERB	VBD	9	O
valvular	valvular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
withdrawn	withdraw	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
market	market	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
new	new	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
worsening	worsen	VERB	VBG	5	O
valvular	valvular	ADJ	JJ	5	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
among	among	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
fenfluramine	fenfluramine	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
dexfenfluramine	dexfenfluramine	NOUN	NN	5	B-Chemical
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
echocardiography	echocardiography	NOUN	NN	5	O
before	before	ADP	IN	9	O
they	-PRON-	PRON	PRP	5	O
began	begin	VERB	VBD	5	O
to	to	PART	TO	5	O
take	take	VERB	VB	5	O
these	these	DET	DT	5	O
medications	medication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Cohort	cohort	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

SETTING	set	VERB	VBG	2	O
:	:	PUNCT	:	9	O
Academic	academic	ADJ	JJ	2	O
primary	primary	ADJ	JJ	9	O
care	care	NOUN	NN	5	O
practices	practice	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
46	46	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
used	use	VERB	VBD	5	O
fenfluramine	fenfluramine	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
dexfenfluramine	dexfenfluramine	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
echocardiograms	echocardiogram	NOUN	NNS	5	O
obtained	obtain	VERB	VBN	9	O
before	before	ADP	IN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

MEASUREMENTS	measurement	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
echocardiography	echocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
outcome	outcome	NOUN	NN	5	O
was	be	VERB	VBD	9	O
new	new	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
worsening	worsen	VERB	VBG	5	O
valvulopathy	valvulopathy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
either	either	CCONJ	CC	9	O
aortic	aortic	ADJ	JJ	9	B-Disease
or	or	CCONJ	CC	5	I-Disease
mitral	mitral	ADJ	JJ	5	I-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
one	one	NUM	CD	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
severity	severity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
disease	disease	NOUN	NN	5	O
that	that	DET	WDT	5	O
met	meet	VERB	VBD	5	O
U	u	PRON	PRP	9	O
.	.	PUNCT	.	9	O
S	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Food	food	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
Drug	Drug	PROPN	NNP	5	O
Administration	Administration	PROPN	NNP	2	O
criteria	criterion	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
mild	mild	ADJ	JJ	9	O
aortic	aortic	ADJ	JJ	9	B-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
moderate	moderate	ADJ	JJ	9	O
mitral	mitral	ADJ	JJ	5	B-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
receiving	receive	VERB	VBG	9	O
fenfluramine	fenfluramine	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
phentermine	phentermine	NOUN	NN	5	B-Chemical
developed	develop	VERB	VBD	5	O
valvular	valvular	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
had	have	VERB	VBD	9	O
baseline	baseline	NOUN	NN	5	O
bicuspid	bicuspid	ADP	IN	5	B-Disease
aortic	aortic	ADJ	JJ	9	I-Disease
valve	valve	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
mild	mild	ADJ	JJ	9	O
aortic	aortic	ADJ	JJ	9	B-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
progressed	progress	VERB	VBD	9	O
to	to	ADP	IN	5	O
moderate	moderate	ADJ	JJ	9	O
regurgitation	regurgitation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
new	new	ADJ	JJ	5	O
moderate	moderate	ADJ	JJ	9	O
aortic	aortic	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
diet	diet	NOUN	NN	9	O
medications	medication	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
valvular	valvular	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
reported	report	VERB	VBD	9	O
previously	previously	ADV	RB	9	O
.	.	PUNCT	.	9	O

Therapeutic	therapeutic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
monitoring	monitoring	NOUN	NN	5	O
of	of	ADP	IN	5	O
tobramycin	tobramycin	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
once	once	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
daily	daily	ADV	RB	5	O
versus	versus	ADP	IN	9	O
twice	twice	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
daily	daily	ADJ	JJ	5	O
dosage	dosage	NOUN	NN	9	O
schedules	schedule	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
dosage	dosage	NOUN	NN	9	O
regimen	regiman	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
once	once	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
daily	daily	ADV	RB	5	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
twice	twice	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
daily	daily	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
tobramicyn	tobramicyn	NOUN	NN	_	B-Chemical
on	on	ADP	IN	5	O
steady	steady	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
state	state	NOUN	NN	5	O
serum	serum	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
tobramycin	tobramycin	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
randomised	randomise	VERB	VBN	5	O
to	to	ADP	IN	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Group	Group	PROPN	NNP	9	O
OD	OD	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
22	22	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
once	once	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
tobramycin	tobramycin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
group	group	NOUN	NN	9	O
TD	TD	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
21	21	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
divided	divide	VERB	VBD	5	O
into	into	ADP	IN	9	O
two	two	NUM	CD	5	O
doses	dose	NOUN	NNS	0	O
daily	daily	ADV	RB	5	O
.	.	PUNCT	.	9	O

Tobramycin	Tobramycin	PROPN	NNP	0	B-Chemical
serum	serum	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
peak	peak	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
trough	trough	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
enzyme	enzyme	ADJ	JJ	0	O
multiplied	multiply	VERB	VBN	5	O
immunoassay	immunoassay	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
auditory	auditory	NOUN	NN	5	O
functions	function	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
before	before	ADV	RB	9	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
and	and	CCONJ	CC	5	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Trough	Trough	PROPN	NNP	4	O
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
<	<	X	XX	0	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Peak	peak	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
>	>	X	XX	0	O
6	6	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
in	in	ADP	IN	5	O
100	100	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
OD	OD	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
67	67	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
TD	TD	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
peak	peak	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
:	:	PUNCT	:	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
00	00	PUNCT	NFP	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
89	89	NUM	CD	7	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
in	in	ADP	IN	5	O
OD	OD	PROPN	NNP	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
53	53	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
45	45	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
in	in	ADP	IN	5	O
TD	TD	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pharmacokinetics	pharmacokinetic	NOUN	NNS	9	O
parameters	parameter	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
:	:	PUNCT	:	9	O
Ke	Ke	PROPN	NNP	6	O
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
15	15	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
/	/	SYM	SYM	9	O
h	h	NOUN	NN	0	O
in	in	ADP	IN	5	O
OD	OD	PROPN	NNP	9	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
.	.	PUNCT	.	9	O
24	24	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
06	06	NUM	CD	7	O
/	/	SYM	SYM	9	O
h	h	NOUN	NN	0	O
in	in	ADP	IN	5	O
TD	TD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
t1	t1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
95	95	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
41	41	NUM	CD	7	O
h	h	NOUN	NN	0	O
in	in	ADP	IN	5	O
OD	OD	PROPN	NNP	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
3	3	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
07	07	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
71	71	NUM	CD	7	O
h	h	NOUN	NN	0	O
in	in	ADP	IN	5	O
TD	TD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
Vd	Vd	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
11	11	NUM	CD	7	O
l	l	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
in	in	ADP	IN	5	O
OD	OD	PROPN	NNP	9	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
.	.	PUNCT	.	9	O
33	33	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
09	09	NUM	CD	7	O
l	l	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
in	in	ADP	IN	5	O
TD	TD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
Cl	Cl	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
86	86	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
29	29	NUM	CD	7	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
in	in	ADP	IN	5	O
OD	OD	PROPN	NNP	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
28	28	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
33	33	NUM	CD	7	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
in	in	ADP	IN	5	O
TD	TD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
73	73	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
OD	OD	PROPN	NNP	9	O
versus	versus	ADP	IN	9	O
57	57	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
TD	TD	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
TD	TD	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
decreased	decrease	VERB	VBN	9	B-Disease
auditory	auditory	NOUN	NN	5	I-Disease
function	function	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
one	one	PRON	PRP	5	O
presented	present	VERB	VBD	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
auditory	auditory	ADJ	JJ	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
30	30	NUM	CD	9	O
dB	db	NOUN	NN	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
OD	OD	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
decreased	decrease	VERB	VBD	9	B-Disease
auditory	auditory	NOUN	NN	5	I-Disease
function	function	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
small	small	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
once	once	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
daily	daily	ADJ	JJ	5	O
dosing	dosing	ADJ	JJ	9	O
regimen	regiman	NOUN	NNS	5	O
of	of	ADP	IN	5	O
tobramycin	tobramycin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
as	as	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
as	as	ADP	IN	5	O
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
more	more	ADJ	JJR	5	O
and	and	CCONJ	CC	5	O
possibly	possibly	ADV	RB	9	O
less	less	ADV	RBR	5	O
toxic	toxic	ADJ	JJ	0	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
twice	twice	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
daily	daily	ADJ	JJ	5	O
regimen	regimen	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
peak	peak	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
determination	determination	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
necessary	necessary	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
trough	trough	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
monitored	monitor	VERB	VBN	9	O
to	to	PART	TO	5	O
ensure	ensure	VERB	VB	5	O
levels	level	NOUN	NNS	3	O
below	below	ADP	IN	9	O
2	2	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Enhanced	enhanced	ADJ	JJ	9	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
antagonists	antagonist	NOUN	NNS	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
increase	increase	NOUN	NN	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
vasodilators	vasodilator	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
change	change	VERB	VB	9	O
the	the	DET	DT	5	O
accompanying	accompanying	ADJ	JJ	5	O
reflex	reflex	ADJ	JJ	5	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
to	to	ADP	IN	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	O
synthesis	synthesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminobutyric	aminobutyric	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
enhancement	enhancement	NOUN	NN	9	O
by	by	ADP	IN	9	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
antagonists	antagonist	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
anaesthetised	anaesthetise	VERB	VBN	5	O
with	with	ADP	IN	5	O
chloralose	chloralose	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
urethane	urethane	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Isoniazid	Isoniazid	PROPN	NNP	0	B-Chemical
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
pindolol	pindolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
labetalol	labetalol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
atenolol	atenolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
after	after	ADP	IN	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
after	after	ADP	IN	9	O
hexamethonium	hexamethonium	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Enhancement	enhancement	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
methylatropine	methylatropine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
previously	previously	ADV	RB	9	O
vagotomised	vagotomise	VERB	VBN	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
compatible	compatible	ADJ	JJ	5	O
with	with	ADP	IN	5	O
interference	interference	NOUN	NN	9	O
by	by	ADP	IN	9	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
GABAergic	GABAergic	PROPN	NNP	3	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
parasympathetic	parasympathetic	ADJ	JJ	5	O
tone	tone	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
interference	interference	NOUN	NN	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
exerted	exert	VERB	VBN	9	O
centrally	centrally	ADV	RB	5	O
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
nucleus	nucleus	NOUN	NN	9	O
ambiguus	ambiguus	NOUN	NN	4	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
peripherally	peripherally	ADV	RB	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
sinus	sinus	NOUN	NN	5	O
node	node	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Structural	structural	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
functional	functional	ADJ	JJ	9	I-Disease
impairment	impairment	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	I-Disease
mitochondria	mitochondria	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
:	:	PUNCT	:	9	O
suppression	suppression	NOUN	NN	9	O
of	of	ADP	IN	5	O
cytochrome	cytochrome	DET	PDT	0	O
c	c	DET	DT	9	O
oxidase	oxidase	NOUN	NN	0	O
II	II	PROPN	NNP	9	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
chemotherapy	chemotherapy	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
limited	limit	VERB	VBN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
cumulative	cumulative	ADJ	JJ	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Earlier	early	ADJ	JJR	9	O
observations	observation	NOUN	NNS	9	O
that	that	DET	WDT	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
interacts	interact	VERB	VBZ	1	O
with	with	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
cytochrome	cytochrome	DET	PDT	0	O
c	c	DET	DT	9	O
oxidase	oxidase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
COX	COX	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
suppresses	suppress	VERB	VBZ	3	O
its	-PRON-	DET	PRP$	9	O
enzyme	enzyme	ADJ	JJ	0	O
activity	activity	NOUN	NN	9	O
led	lead	VERB	VBD	9	O
us	-PRON-	PRON	PRP	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
action	action	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
functions	function	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
morphology	morphology	NOUN	NN	9	O
in	in	ADP	IN	5	O
Balb	Balb	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
c	c	PROPN	NNP	9	O
mice	mouse	NOUN	NNS	3	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
for	for	ADP	IN	5	O
several	several	ADJ	JJ	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
various	various	ADJ	JJ	9	O
times	time	NOUN	NNS	5	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
for	for	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
functions	function	NOUN	NNS	9	O
by	by	ADP	IN	9	O
electrocardiography	electrocardiography	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
tissue	tissue	NOUN	NN	9	O
damage	damage	NOUN	NN	9	O
by	by	ADP	IN	9	O
electron	electron	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
parallel	parallel	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
RNA	RNA	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
extracted	extract	VERB	VBN	9	O
from	from	ADP	IN	9	O
samples	sample	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dissected	dissect	VERB	VBN	9	O
heart	heart	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
analyzed	analyze	VERB	VBN	9	O
by	by	ADP	IN	9	O
Northern	northern	ADJ	JJ	4	O
blot	blot	NOUN	NN	3	O
hybridization	hybridization	NOUN	NN	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
steady	steady	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
state	state	NOUN	NN	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
RNA	RNA	PROPN	NNP	9	O
transcripts	transcript	NOUN	NNS	1	O
encoded	encode	VERB	VBN	1	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
COXII	COXII	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
COXIII	COXIII	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
COXIV	coxiv	ADJ	JJ	3	O
genes	gene	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
samples	sample	NOUN	NNS	9	O
obtained	obtain	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
for	for	ADP	IN	5	O
comparative	comparative	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
indicated	indicate	VERB	VBD	9	O
that	that	ADP	IN	5	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
caused	cause	VERB	VBD	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
extension	extension	NOUN	NN	9	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	O
depolarization	depolarization	NOUN	NN	9	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
tQRS	tQRS	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
failure	failure	NOUN	NN	5	O
of	of	ADP	IN	5	O
QRS	QRS	PROPN	NNP	5	O
at	at	ADP	IN	9	O
high	high	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
14	14	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
mitochondria	mitochondria	NOUN	NN	3	O
underwent	underwent	NOUN	NN	5	O
swelling	swell	VERB	VBG	5	B-Disease
,	,	PUNCT	,	9	O
fusion	fusion	NOUN	NN	1	O
,	,	PUNCT	,	9	O
dissolution	dissolution	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
cristae	cristae	NOUN	NN	9	O
after	after	ADP	IN	9	O
several	several	ADJ	JJ	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
abnormalities	abnormality	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mitochondria	mitochondria	NOUN	NN	3	O
of	of	ADP	IN	5	O
liver	liver	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
genes	gene	NOUN	NNS	1	O
of	of	ADP	IN	5	O
COX	COX	PROPN	NNP	9	O
enzyme	enzyme	NOUN	NN	0	O
examined	examine	VERB	VBD	9	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
COXII	COXII	PROPN	NNP	1	O
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
was	be	VERB	VBD	9	O
suppressed	suppress	VERB	VBN	3	O
by	by	ADP	IN	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mainly	mainly	ADV	RB	9	O
after	after	ADP	IN	9	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
heart	heart	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Knowing	know	VERB	VBG	5	O
that	that	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
mitochondria	mitochondria	NOUN	NN	3	O
represent	represent	VERB	VBP	9	O
almost	almost	ADV	RB	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
muscle	muscle	NOUN	NN	9	O
by	by	ADP	IN	9	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
deteriorating	deteriorate	VERB	VBG	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
on	on	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
involve	involve	VERB	VBP	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
structural	structural	ADJ	JJ	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
functional	functional	ADJ	JJ	9	I-Disease
impairment	impairment	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

